U.S. patent application number 11/212443 was filed with the patent office on 2005-12-29 for meningococcal antigens.
This patent application is currently assigned to Chiron Corporation. Invention is credited to Grandi, Guido, Masignani, Vega, Pizza, Mariagrazia, Rappuoli, Rino, Scarlato, Vincenzo.
Application Number | 20050287165 11/212443 |
Document ID | / |
Family ID | 27269171 |
Filed Date | 2005-12-29 |
United States Patent
Application |
20050287165 |
Kind Code |
A1 |
Scarlato, Vincenzo ; et
al. |
December 29, 2005 |
Meningococcal antigens
Abstract
The invention provides proteins from Neisseria meningitidis
(strains A & B), including amino acid sequences, the
corresponding nucleotide sequences, expression data, and
serological data. The proteins are useful antigens for vaccines,
immunogenic compositions, and/or diagnostics.
Inventors: |
Scarlato, Vincenzo; (Siena,
IT) ; Masignani, Vega; (Siena, IT) ; Rappuoli,
Rino; (Siena, IT) ; Pizza, Mariagrazia;
(Siena, IT) ; Grandi, Guido; (Siena, IT) |
Correspondence
Address: |
MORRISON & FOERSTER LLP
425 MARKET STREET
SAN FRANCISCO
CA
94105-2482
US
|
Assignee: |
Chiron Corporation
Emeryville
CA
|
Family ID: |
27269171 |
Appl. No.: |
11/212443 |
Filed: |
August 24, 2005 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
11212443 |
Aug 24, 2005 |
|
|
|
10695499 |
Oct 28, 2003 |
|
|
|
10695499 |
Oct 28, 2003 |
|
|
|
09302626 |
Apr 30, 1999 |
|
|
|
6709660 |
|
|
|
|
09302626 |
Apr 30, 1999 |
|
|
|
PCT/IB99/00103 |
Jan 14, 1999 |
|
|
|
Current U.S.
Class: |
424/190.1 ;
435/252.3; 435/320.1; 435/6.15; 435/69.3; 530/350; 530/388.4;
536/23.7 |
Current CPC
Class: |
A61P 31/04 20180101;
C07K 14/22 20130101; A61K 39/00 20130101 |
Class at
Publication: |
424/190.1 ;
435/006; 435/069.3; 435/252.3; 435/320.1; 536/023.7; 530/350;
530/388.4 |
International
Class: |
C12Q 001/68; C07H
021/04; A61K 039/02 |
Foreign Application Data
Date |
Code |
Application Number |
Oct 9, 1998 |
GB |
9822143.5 |
Sep 1, 1998 |
GB |
9819015.0 |
Jan 14, 1998 |
GB |
9800760.2 |
Claims
1-17. (canceled)
18. An isolated polypeptide comprising a member selected from the
group consisting of (a) the amino acid sequence of SEQ ID NO: 4;
and (b) an immunogenic fragment of at least 15 contiguous amino
acids of SEQ ID NO: 4, wherein the immunogenic fragment, when
administered to a subject in a suitable composition which can
include an adjuvant, or a suitable carrier coupled to the
polypeptide, induces an antibody or T-cell meditated immune
response that recognizes the isolated polypeptide SEQ ID NO: 4.
19. The isolated polypeptide of claim 18, wherein the polypeptide
is according to (a).
20. The isolated polypeptide of claim 18, wherein the polypeptide
is according to (b).
21. The isolated polypeptide of claim 18, wherein the immunogenic
fragment of (b) comprises at least 20 contiguous amino acids of SEQ
ID NO:4; wherein the immunogenic fragment, when administered to a
subject in a suitable composition which can include an adjuvant, or
a suitable carrier coupled to the polypeptide, induces an antibody
or T-cell meditated immune response that recognizes the polypeptide
SEQ ID NO: 4.
22. The isolated polypeptide of claim 18, wherein the isolated
polypeptide consists of SEQ ID NO: 4.
23. A fusion protein comprising the isolated polypeptide of claim
18.
24. An immunogenic composition comprising the polypeptide of claim
18, and a pharmaceutically acceptable carrier.
25. The isolated polypeptide of claim 18, wherein the isolated
polypeptide is a recombinant polypeptide.
26. The isolated polypeptide of claim 19, wherein the isolated
polypeptide is a recombinant polypeptide.
27. The isolated polypeptide of claim 20, wherein the isolated
polypeptide is a recombinant polypeptide.
28. An immunogenic composition comprising the isolated polypeptide
of claim 19.
29. An immunogenic composition comprising the isolated polypeptide
of claim 20.
30. A fusion protein comprising the isolated polypeptide of claim
19.
31. A fusion protein comprising the isolated polypeptide of claim
20.
Description
[0001] This application is a continuation-in-part of international
patent application PCT/IB99/00103, filed Jan. 14, 1999, from which
priority is claimed under 35 U.S.C. .sctn. 119.
[0002] This invention relates to antigens from the bacterium
Neisseria meningitidis.
BACKGROUND
[0003] Neisseria meningitidis is a non-motile, gram negative
diplococcus human pathogen. It colonises the pharynx, causing
meningitis and, occasionally, septicaemia in the absence of
meningitis. It is closely related to N. gonorrhoeae, although one
feature that clearly differentiates meningococcus from gonococcus
is the presence of a polysaccharide capsule that is present in all
pathogenic meningococci.
[0004] N. meningitidis causes both endemic and epidemic disease. In
the United States the attack rate is 0.6-1 per 100,000 persons per
year, and it can be much greater during outbreaks (see Lieberman el
al. (1996) Safety and Immunogenicity of a Serogroups A/C Neisseria
meningitidis Oligosaccharide-Protein Conjugate Vaccine in Young
Children. JAMA 275(19):1499-1503; Schuchat et al (1997) Bacterial
Meningitis in the United States in 1995. N Engl J Med
337(14):970-976). In developing countries, endemic disease rates
are much higher and during epidemics incidence rates can reach 500
cases per 100,000 persons per year. Mortality is extremely high, at
10-20% in the United States, and much higher in developing
countries. Following the introduction of the conjugate vaccine
against Haemophilus influenzae, N. meningitidis is the major cause
of bacterial meningitis at all ages in the United States (Schuchat
et al (1997) supra).
[0005] Based on the organism's capsular polysaccharide, 12
serogroups of N. meningitidis have been identified. Group A is the
pathogen most often implicated in epidemic disease in sub-Saharan
Africa. Serogroups B and C are responsible for the vast majority of
cases in the United States and in most developed countries.
Serogroups W135 and Y are responsible for the rest of the cases in
the United States and developed countries. The meningococcal
vaccine currently in use is a tetravalent polysaccharide vaccine
composed of serogroups A, C, Y and W135. Although efficacious in
adolescents and adults, it induces a poor immune response and short
duration of protection, and cannot be used in infants [eg.
Morbidity and Mortality weekly report, Vol. 46, No. RR-5 (1997)].
This is because polysaccharides are T-cell independent antigens
that induce a weak immune response that cannot be boosted by
repeated immunization. Following the success of the vaccination
against H. influenzae, conjugate vaccines against serogroups A and
C have been developed and are at the final stage of clinical
testing (Zollinger W D "New and Improved Vaccines Against
Meningococcal Disease" in: New Generation Vaccines, supra, pp.
469-488; Lieberman et al (1996) supra; Costantino et al (1992)
Development and phase I clinical testing of a conjugate vaccine
against meningococcus A and C. Vaccine 10:691-698).
[0006] Meningococcus B remains a problem, however. This serotype
currently is responsible for approximately 50% of total meningitis
in the United States, Europe, and South America. The polysaccharide
approach cannot be used because the menB capsular polysaccharide is
a polymer of .alpha.(2-8)-linked N-acetyl neuraminic acid that is
also present in mammalian tissue. This results in tolerance to the
antigen; indeed, if an immune response were elicited, it would be
anti-self, and therefore undesirable. In order to avoid induction
of autoimmunity and to induce a protective immune response, the
capsular polysaccharide has, for instance, been chemically modified
substituting the N-acetyl groups with N-propionyl groups, leaving
the specific antigenicity unaltered (Romero & Outschoorn (1994)
Current status of Meningococcal group B vaccine candidates:
capsular or non-capsular? Clin Microbiol Rev 7(4):559-575).
[0007] Alternative approaches to menB vaccines have used complex
mixtures of outer membrane proteins (OMPs), containing either the
OMPs alone, or OMPs enriched in porins, or deleted of the class 4
OMPs that are believed to induce antibodies that block bactericidal
activity. This approach produces vaccines that are not well
characterized. They are able to protect against the homologous
strain, but are not effective at large where there are many
antigenic variants of the outer membrane proteins. To overcome the
antigenic variability, multivalent vaccines containing up to nine
different porins have been constructed (eg. Poolman J T (1992)
Development of a meningococcal vaccine. Infect. Agents Dis.
4:13-28). Additional proteins to be used in outer membrane vaccines
have been the opa and opc proteins, but none of these approaches
have been able to overcome the antigenic variability (eg.
Ala'Aldeen & Borriello (1996) The meningococcal
transferrin-binding proteins 1 and 2 are both surface exposed and
generate bactericidal antibodies capable of killing homologous and
heterologous strains. Vaccine 14(1):49-53).
[0008] A certain amount of sequence data is available for
meningococcal and gonococcal genes and proteins (eg. EP-A-0467714,
WO96/29412), but this is by no means complete. The provision of
further sequences could provide an opportunity to identify secreted
or surface-exposed proteins that are presumed targets for the
immune system and which are not antigenically variable. For
instance, some of the identified proteins could be components of
efficacious vaccines against meningococcus B, some could be
components of vaccines against all meningococcal serotypes, and
others could be components of vaccines against all pathogenic
Neisseriae.
[0009] The Invention
[0010] The invention provides proteins comprising the N.
meningitidis amino acid sequences disclosed in the examples.
[0011] It also provides proteins comprising sequences homologous
(ie. having sequence identity) to the N. meningitidis amino acid
sequences disclosed in the examples. Depending on the particular
sequence, the degree of sequence identity is preferably greater
than 50% (eg. 60%, 70%, 80%, 90%, 95%, 99% or more). These
homologous proteins include mutants and allelic variants of the
sequences disclosed in the examples. Typically, 50% identity or
more between two proteins is considered to be an indication of
functional equivalence. Identity between the proteins is preferably
determined by the Smith-Waterman homology search algorithm as
implemented in the MPSRCH program (Oxford Molecular), using an
affine gap search with parameters gap open penalty=12 and gap
extension penalty=1.
[0012] The invention further provides proteins comprising fragments
of the N. meningitidis amino acid sequences disclosed in the
examples. The fragments should comprise at least n consecutive
amino acids from the sequences and, depending on the particular
sequence, n is 7 or more (eg. 8, 10, 12, 14, 16, 18, 20 or more).
Preferably the fragments comprise an epitope from the sequence.
[0013] The proteins of the invention can, of course, be prepared by
various means (eg. recombinant expression, purification from cell
culture, chemical synthesis etc.) and in various forms (eg. native,
fusions etc.). They are preferably prepared in substantially pure
form (ie. substantially free from other N. meningitidis or host
cell proteins).
[0014] According to a further aspect, the invention provides
antibodies which bind to these proteins. These may be polyclonal or
monoclonal and may be produced by any suitable means.
[0015] According to a further aspect, the invention provides
nucleic acid comprising the N. meningitidis nucleotide sequences
disclosed in the examples. In addition, the invention provides
nucleic acid comprising sequences homologous (ie. having sequence
identity) to the N. meningitidis nucleotide sequences disclosed in
the examples.
[0016] Furthermore, the invention provides nucleic acid which can
hybridise to the N. meningitidis nucleic acid disclosed in the
examples, preferably under "high stringency" conditions (eg.
65.degree. C. in a 0.1.times.SSC, 0.5% SDS solution).
[0017] Nucleic acid comprising fragments of these sequences are
also provided. These should comprise at least n consecutive
nucleotides from the N. meningitidis sequences and, depending on
the particular sequence, n is 10 or more (eg 12, 14, 15, 18, 20,
25, 30, 35, 40 or more).
[0018] According to a further aspect, the invention provides
nucleic acid encoding the proteins and protein fragments of the
invention.
[0019] It should also be appreciated that the invention provides
nucleic acid comprising sequences complementary to those described
above (eg. for antisense or probing purposes).
[0020] Nucleic acid according to the invention can, of course, be
prepared in many ways (eg. by chemical synthesis, from genomic or
cDNA libraries, from the organism itself etc.) and can take various
forms (eg. single stranded, double stranded, vectors, probes
etc.).
[0021] In addition, the term "nucleic acid" includes DNA and RNA,
and also their analogues, such as those containing modified
backbones, and also peptide nucleic acids (PNA) etc.
[0022] According to a further aspect, the invention provides
vectors comprising nucleotide sequences of the invention (eg.
expression vectors) and host cells transformed with such
vectors.
[0023] According to a further aspect, the invention provides
compositions comprising protein, antibody, and/or nucleic acid
according to the invention. These compositions may be suitable as
vaccines, for instance, or as diagnostic reagents, or as
immunogenic compositions.
[0024] The invention also provides nucleic acid, protein, or
antibody according to the invention for use as medicaments (eg. as
vaccines) or as diagnostic reagents. It also provides the use of
nucleic acid, protein, or antibody according to the invention in
the manufacture of: (i) a medicament for treating or preventing
infection due to Neisserial bacteria; (ii) a diagnostic reagent for
detecting the presence of Neisserial bacteria or of antibodies
raised against Neisserial bacteria; and/or (iii) a reagent which
can raise antibodies against Neisserial bacteria Said Neisserial
bacteria may be any species or strain (such as N. gonorrhoeae) but
are preferably N. meningitidis, especially strain A, strain B or
strain C.
[0025] The invention also provides a method of treating a patient,
comprising administering to the patient a therapeutically effective
amount of nucleic acid, protein, and/or antibody according to the
invention.
[0026] According to further aspects, the invention provides various
processes.
[0027] A process for producing proteins of the invention is
provided, comprising the step of culturing a host cell according to
the invention under conditions which induce protein expression.
[0028] A process for producing protein or nucleic acid of the
invention is provided, wherein the protein or nucleic acid is
synthesised in part or in whole using chemical means.
[0029] A process for detecting polynucleotides of the invention is
provided, comprising the steps of: (a) contacting a nucleic probe
according to the invention with a biological sample under
hybridizing conditions to form duplexes; and (b) detecting said
duplexes.
[0030] A process for detecting proteins of the invention is
provided, comprising the steps of: (a) contacting an antibody
according to the invention with a biological sample under
conditions suitable for the formation of an antibody-antigen
complexes; and (b) detecting said complexes.
[0031] Unlike the sequences disclosed in PCT/IB98/01665, the
sequences disclosed in the present application are believed not to
have any significant homologs in N. gonorrhoeae. Accordingly, the
sequences of the present invention also find use in the preparation
of reagents for distinguishing between N. meningitidis and N.
gonorrhoeae.
[0032] A summary of standard techniques and procedures which may be
employed in order to perform the invention (eg. to utilise the
disclosed sequences for vaccination or diagnostic purposes)
follows. This summary is not a limitation on the invention but,
rather, gives examples that may be used, but are not required.
[0033] General
[0034] The practice of the present invention will employ, unless
otherwise indicated, conventional techniques of molecular biology,
microbiology, recombinant DNA, and immunology, which are within the
skill of the art. Such techniques are explained fully in the
literature eg. Sambrook Molecular Cloning; A Laboratory Manual,
Second Edition (1989); DNA Cloning, Volumes I and ii (D. N Glover
ed. 1985); Oligonucleotide Synthesis (M. J. Gait ed, 1984); Nucleic
Acid Hybridization (B. D. Hames & S. J. Higgins eds. 1984);
Transcription and Translation (B. D. Hames & S. J. Higgins eds.
1984); Animal Cell Culture (R. I. Freshney ed. 1986); Immobilized
Cells and Enzymes (IRL Press, 1986); B. Perbal, A Practical Guide
to Molecular Cloning (1984); the Methods in Enzymology series
(Academic Press, Inc.), especially volumes 154 & 155; Gene
Transfer Vectors for Mammalian Cells (J. H. Miller and M. P. Calos
eds. 1987, Cold Spring Harbor Laboratory); Mayer and Walker, eds.
(1987), Immunochemical Methods in Cell and Molecular Biology
(Academic Press, London); Scopes, (1987) Protein Purification:
Principles and Practice, Second Edition (Springer-Verlag, N.Y.),
and Handbook of Experimental Immunology, Volumes I-IV (D. M. Weir
and C. C. Blackwell eds 1986).
[0035] Standard abbreviations for nucleotides and amino acids are
used in this specification.
[0036] All publications, patents, and patent applications cited
herein are incorporated in full by reference. In particular, the
contents of UK patent applications 9800760.2, 9819015.0 and
9822143.5 are incorporated herein.
[0037] Definitions
[0038] A composition containing X is "substantially free of" Y when
at least 85% by weight of the total X+Y in the composition is X.
Preferably, X comprises at least about 90% by weight of the total
of X+Y in the composition, more preferably at least about 95% or
even 99% by weight.
[0039] The term "comprising" means "including" as well as
"consisting" eg. a composition "comprising" X may consist
exclusively of X or may include something additional to X, such as
X+Y.
[0040] A "conserved" Neisseria amino acid fragment or protein is
one that is present in a particular Neisserial protein in at least
x % of Neisseria. The value of x may be 50% or more, e.g., 66%,
75%, 80%, 90%, 95% or even 100% (i.e. the amino acid is found in
the protein in question in all Neisseria). In order to determine
whether an animo acid is "conserved" in a particular Neisserial
protein, it is necessary to compare that amino acid residue in the
sequences of the protein in question from a plurality of different
Neisseria (a reference population). The reference population may
include a number of different Neisseria species or may include a
single species. The reference population may include a number of
different serogroups of a particular species or a single serogroup.
A preferred reference population consists of the 5 most common
Neisseria.
[0041] The term "heterologous" refers to two biological components
that are not found together in nature. The components may be host
cells, genes, or regulatory regions, such as promoters. Although
the heterologous components are not found together in nature, they
can function together, as when a promoter heterologous to a gene is
operably linked to the gene. Another example is where a Neisserial
sequence is heterologous to a mouse host cell. A further examples
would be two epitopes from the same or different proteins which
have been assembled in a single protein in an arrangement not found
in nature.
[0042] An "origin of replication" is a polynucleotide sequence that
initiates and regulates replication of polynucleotides, such as an
expression vector. The origin of replication behaves as an
autonomous unit of polynucleotide replication within a cell,
capable of replication under its own control. An origin of
replication may be needed for a vector to replicate in a particular
host cell. With certain origins of replication, an expression
vector can be reproduced at a high copy number in the presence of
the appropriate proteins within the cell. Examples of origins are
the autonomously replicating sequences, which are effective in
yeast; and the viral T-antigen, effective in COS-7 cells.
[0043] A "mutant" sequence is defined as DNA, RNA or amino acid
sequence differing from but having sequence identity with the
native or disclosed sequence. Depending on the particular sequence,
the degree of sequence identity between the native or disclosed
sequence and the mutant sequence is preferably greater than 50%
(eg. 60%, 70%, 80%, 90%, 95%, 99% or more, calculated using the
Smith-Waterman algorithm as described above). As used herein, an
"allelic variant" of a nucleic acid molecule, or region, for which
nucleic acid sequence is provided herein is a nucleic acid
molecule, or region, that occurs essentially at the same locus in
the genome of another or second isolate, and that, due to natural
variation caused by, for example, mutation or recombination, has a
similar but not identical nucleic acid sequence. A coding region
allelic variant typically encodes a protein having similar activity
to that of the protein encoded by the gene to which it is being
compared. An allelic variant can also comprise an alteration in the
5' or 3' untranslated regions of the gene, such as in regulatory
control regions (eg. see U.S. Pat. No. 5,753,235).
[0044] Expression Systems
[0045] The Neisserial nucleotide sequences can be expressed in a
variety of different expression systems; for example those used
with mammalian cells, baculoviruses, plants, bacteria, and
yeast.
[0046] i. Mammalian Systems
[0047] Mammalian expression systems are known in the art. A
mammalian promoter is any DNA sequence capable of binding mammalian
RNA polymerase and initiating the downstream (3') transcription of
a coding sequence (eg. structural gene) into mRNA. A promoter will
have a transcription initiating region, which is usually placed
proximal to the 5' end of the coding sequence, and a TATA box,
usually located 25-30 base pairs (bp) upstream of the transcription
initiation site. The TATA box is thought to direct RNA polymerase
II to begin RNA synthesis at the correct site. A mammalian promoter
will also contain an upstream promoter element, usually located
within 100 to 200 bp upstream of the TATA box. An upstream promoter
element determines the rate at which transcription is initiated and
can act in either orientation [Sambrook et al. (1989) "Expression
of Cloned Genes in Mammalian Cells." In Molecular Cloning: A
Laboratory Manual, 2nd ed.]
[0048] Mammalian viral genes are often highly expressed and have a
broad host range; therefore sequences encoding mammalian viral
genes provide particularly useful promoter sequences. Examples
include the SV40 early promoter, mouse mammary tumor virus LTR
promoter, adenovirus major late promoter (Ad MLP), and herpes
simplex virus promoter. In addition, sequences derived from
non-viral genes, such as the murine metallotheionein gene, also
provide useful promoter sequences. Expression may be either
constitutive or regulated (inducible), depending on the promoter
can be induced with glucocorticoid in hormone-responsive cells.
[0049] The presence of an enhancer element (enhancer), combined
with the promoter elements described above, will usually increase
expression levels. An enhancer is a regulatory DNA sequence that
can stimulate transcription up to 1000-fold when linked to
homologous or heterologous promoters, with synthesis beginning at
the normal RNA start site. Enhancers are also active when they are
placed upstream or downstream from the transcription initiation
site, in either normal or flipped orientation, or at a distance of
more than 1000 nucleotides from the promoter [Maniatis et al.
(1987) Science 236:1237; Alberts et al. (1989) Molecular Biology of
the Cell, 2nd ed.]. Enhancer elements derived from viruses may be
particularly useful, because they usually have a broader host
range. Examples include the SV40 early gene enhancer [Dijkema et al
(1985) EMBO J. 4:761] and the enhancer/promoters derived from the
long terminal repeat (LTR) of the Rous Sarcoma Virus [Gorman et al.
(1982b) Proc. Natl. Acad. Sci. 79:6777] and from human
cytomegalovirus [Boshart et al. (1985) Cell 41:521]. Additionally,
some enhancers are regulatable and become active only in the
presence of an inducer, such as a hormone or metal ion
[Sassone-Corsi and Borelli (1986) Trends Genet. 2:215; Maniatis et
al. (1987) Science 236:1237].
[0050] A DNA molecule may be expressed intracellularly in mammalian
cells. A promoter sequence may be directly linked with the DNA
molecule, in which case the first amino acid at the N-terminus of
the recombinant protein will always be a methionine, which is
encoded by the ATG start codon. If desired, the N-terminus may be
cleaved from the protein by in vitro incubation with cyanogen
bromide.
[0051] Alternatively, foreign proteins can also be secreted from
the cell into the growth media by creating chimeric DNA molecules
that encode a fusion protein comprised of a leader sequence
fragment that provides for secretion of the foreign protein in
mammalian cells. Preferably, there are processing sites encoded
between the leader fragment and the foreign gene that can be
cleaved either in vivo or in vitro. The leader sequence fragment
usually encodes a signal peptide comprised of hydrophobic amino
acids which direct the secretion of the protein from the cell. The
adenovirus triparite leader is an example of a leader sequence that
provides for secretion of a foreign protein in mammalian cells.
[0052] Usually, transcription termination and polyadenylation
sequences recognized by mammalian cells are regulatory regions
located 3' to the translation stop codon and thus, together with
the promoter elements, flank the coding sequence. The 3' terminus
of the mature mRNA is formed by site-specific post-transcriptional
cleavage and polyadenylation [Birnstiel et al. (1985) Cell 41:349;
Proudfoot and Whitelaw (1988) "Termination and 3' end processing of
eukaryotic RNA. In Transcription and splicing (ed. B. D. Hames and
D. M. Glover); Proudfoot (1989) Trends Biochem. Sci. 14:105]. These
sequences direct the transcription of an mRNA which can be
translated into the polypeptide encoded by the DNA. Examples of
transcription terminater/polyadenylation signals include those
derived from SV40 [Sambrook et al (1989) "Expression of cloned
genes in cultured mammalian cells." In Molecular Cloning: A
Laboratory Manual].
[0053] Usually, the above described components, comprising a
promoter, polyadenylation signal, and transcription termination
sequence are put together into expression constructs. Enhancers;
introns with functional splice donor and acceptor sites, and leader
sequences may also be included in an expression construct, if
desired. Expression constructs are often maintained in a replicon,
such as an extrachromosomal element (eg. plasmids) capable of
stable maintenance in a host, such as mammalian cells or bacteria.
Mammalian replication systems include those derived from animal
viruses, which require trans-acting factors to replicate. For
example, plasmids containing the replication systems of
papovaviruses, such as SV40 [Gluzman (1981) Cell 23:175] or
polyomavirus, replicate to extremely high copy number in the
presence of the appropriate viral T antigen. Additional examples of
mammalian replicons include those derived from bovine
papillomavirus and Epstein-Barr virus. Additionally, the replicon
may have two replicaton systems, thus allowing it to be maintained,
for example, in mammalian cells for expression and in a prokaryotic
host for cloning and amplification. Examples of such
mammalian-bacteria shuttle vectors include pMT2 [Kaufman et al.
(1989) Mol. Cell. Biol. 9:946] and pHEBO [Shimizu et al. (1986)
Mol. Cell. Biol. 6:1074].
[0054] The transformation procedure used depends upon the host to
be transformed. Methods for introduction of heterologous
polynucleotides into mammalian cells are known in the art and
include dextran-mediated transfection, calcium phosphate
precipitation, polybrene mediated transfection, protoplast fusion,
electroporation, encapsulation of the polynucleotide(s) in
liposomes, and direct microinjection of the DNA into nuclei.
[0055] Mammalian cell lines available as hosts for expression are
known in the art and include many immortalized cell lines available
from the American Type Culture Collection (ATCC), including but not
limited to, Chinese hamster ovary (CHO) cells, HeLa cells, baby
hamster kidney (BHK) cells, monkey kidney cells (COS), human
hepatocellular carcinoma cells (eg. Hep G2), and a number of other
cell lines.
[0056] ii. Baculovirus Systems
[0057] The polynucleotide encoding the protein can also be inserted
into a suitable insect expression vector, and is operably linked to
the control elements within that vector. Vector construction
employs techniques which are known in the art. Generally, the
components of the expression system include a transfer vector,
usually a bacterial plasmid, which contains both a fragment of the
baculovirus genome, and a convenient restriction site for insertion
of the heterologous gene or genes to be expressed; a wild type
baculovirus with a sequence homologous to the baculovirus-specific
fragment in the transfer vector (this allows for the homologous
recombination of the heterologous gene in to the baculovirus
genome); and appropriate insect host cells and growth media.
[0058] After inserting the DNA sequence encoding the protein into
the transfer vector, the vector and the wild type viral genome are
transfected into an insect host cell where the vector and viral
genome are allowed to recombine. The packaged recombinant-virus is
expressed and recombinant plaques are identified and purified.
Materials and methods for baculovirus/insect cell expression
systems are commercially available in kit form from, inter alia,
Invitrogen, San Diego Calif. ("MaxBac" kit). These techniques are
generally known to those skilled in the art and fully described in
Summers and Smith, Texas Agricultural Experiment Station Bulletin
No. 1555 (1987) (hereinafter "Summers and Smith").
[0059] Prior to inserting the DNA sequence encoding the protein
into the baculovirus genome, the above described components,
comprising a promoter, leader (if desired), coding sequence of
interest, and transcription termination sequence, are usually
assembled into an intermediate transplacement construct (transfer
vector). This construct may contain a single gene and operably
linked regulatory elements; multiple genes, each with its owned set
of operably linked regulatory elements; or multiple genes,
regulated by the same set of regulatory elements. Intermediate
transplacement constructs are often maintained in a replicon, such
as an extrachromosomal element (eg. plasmids) capable of stable
maintenance in a host, such as a bacterium. The replicon will have
a replication system, thus allowing it to be maintained in a
suitable host for cloning and amplification.
[0060] Currently, the most commonly used transfer vector for
introducing foreign genes into AcNPV is pAc373. Many other vectors,
known to those of skill in the art, have also been designed. These
include, for example, pVL985 (which alters the polyhedrin start
codon from ATG to ATT, and which introduces a BamHI cloning site 32
basepairs downstream from the ATT; see Luckow and Summers, Virology
(1989) 17:31.
[0061] The plasmid usually also contains the polyhedrin
polyadenylation signal (Miller et al. (1988) Ann. Rev. Microbiol.,
42:177) and a prokaryotic ampicillin-resistance (amp) gene and
origin of replication for selection and propagation in E. coli.
[0062] Baculovirus transfer vectors usually contain a baculovirus
promoter. A baculovirus promoter is any DNA sequence capable of
binding a baculovirus RNA polymerase and initiating the downstream
(5' to 3) transcription of a coding sequence (eg. structural gene)
into mRNA. A promoter will have a transcription initiation region
which is usually placed proximal to the 5' end of the coding
sequence. This transcription initiation region usually includes an
RNA polymerase binding site and a transcription initiation site. A
baculovirus transfer vector may also have a second domain called an
enhancer, which, if present, is usually distal to the structural
gene. Expression may be either regulated or constitutive.
[0063] Structural genes, abundantly transcribed at late times in a
viral infection cycle, provide particularly useful promoter
sequences. Examples include sequences derived from the gene
encoding the viral polyhedron protein, Friesen et al., (1986) "The
Regulation of Baculovirus Gene Expression," in: The Molecular
Biology of Baculoviruses (ed. Walter Doerfler); EPO Publ. Nos. 127
839 and 155 476; and the gene encoding the p10 protein, Vlak et
al., (1988), J. Gen. Virol. 69:765.
[0064] DNA encoding suitable signal sequences can be derived from
genes for secreted insect or baculovirus proteins, such as the
baculovirus polyhedrin gene (Carbonell et al. (1988) Gene, 73:409).
Alternatively, since the signals for mammalian cell
posttranslational modifications (such as signal peptide cleavage,
proteolytic cleavage, and phosphorylation) appear to be recognized
by insect cells, and the signals required for secretion and nuclear
accumulation also appear to be conserved between the invertebrate
cells and vertebrate cells, leaders of non-insect origin, such as
those derived from genes encoding human .alpha.-interferon, Maeda
et al., (1985), Nature 315:592; human gastrin-releasing peptide,
Lebacq-Verheyden et al., (1988), Molec. Cell. Biol. 8:3129; human
IL-2, Smith et al., (1985) Proc. Nat'l Acad. Sci. USA, 82:8404;
mouse IL-3, (Miyajima et al., (1987) Gene 58:273; and human
glucocerebrosidase, Martin et al. (1988) DNA, 7:99, can also be
used to provide for secretion in insects.
[0065] A recombinant polypeptide or polyprotein may be expressed
intracellularly or, if it is expressed with the proper regulatory
sequences, it can be secreted. Good intracellular expression of
nonfused foreign proteins usually requires heterologous genes that
ideally have a short leader sequence containing suitable
translation initiation signals preceding an ATG start signal. If
desired, methionine at the N-terminus may be cleaved from the
mature protein by in vitro incubation with cyanogen bromide.
[0066] Alternatively, recombinant polyproteins or proteins which
are not naturally secreted can be secreted from the insect cell by
creating chimeric DNA molecules that encode a fusion protein
comprised of a leader sequence fragment that provides for secretion
of the foreign protein in insects. The leader sequence fragment
usually encodes a signal peptide comprised of hydrophobic amino
acids which direct the translocation of the protein into the
endoplasmic reticulum.
[0067] After insertion of the DNA sequence and/or the gene encoding
the expression product precursor of the protein, an insect cell
host is co-transformed with the heterologous DNA of the transfer
vector and the genomic DNA of wild type baculovirus--usually by
co-transfection. The promoter and transcription termination
sequence of the construct will usually comprise a 2-5 kb section of
the baculovirus genome. Methods for introducing heterologous DNA
into the desired site in the baculovirus virus are known in the art
(See Summers and Smith supra; Ju et al. (1987); Smith et al., Mol.
Cell. Biol. (1983) 3:2156; and Luckow and Summers (1989)). For
example, the insertion can be into a gene such as the polyhedrin
gene, by homologous double crossover recombination; insertion can
also be into a restriction enzyme site engineered into the desired
baculovirus gene. Miller et al., (1989), Bioessays 4:91 The DNA
sequence, when cloned in place of the polyhedrin gene in the
expression vector, is flanked both 5' and 3' by polyhedrin-specific
sequences and is positioned downstream of the polyhedrin
promoter.
[0068] The newly formed baculovirus expression vector is
subsequently packaged into an infectious recombinant baculovirus.
Homologous recombination occurs at low frequency (between about 1%
and about 5%); thus, the majority of the virus produced after
cotransfection is still wild-type virus. Therefore, a method is
necessary to identify recombinant viruses. An advantage of the
expression system is a visual screen allowing recombinant viruses
to be distinguished. The polyhedrin protein, which is produced by
the native virus, is produced at very high levels in the nuclei of
infected cells at late times after viral infection. Accumulated
polyhedrin protein forms occlusion bodies that also contain
embedded particles. These occlusion bodies, up to 15 .mu.m in size,
are highly refractile, giving them a bright shiny appearance that
is readily visualized under the light microscope. Cells infected
with recombinant viruses lack occlusion bodies. To distinguish
recombinant virus from wild-type virus, the transfection
supernatant is plaqued onto a monolayer of insect cells by
techniques known to those skilled in the art. Namely, the plaques
are screened under the light microscope for the presence
(indicative of wild-type virus) or absence (indicative of
recombinant virus) of occlusion bodies. "Current Protocols in
Microbiology" Vol. 2 (Ausubel et al. eds) at 16.8 (Supp. 10, 1990);
Summers and Smith, supra; Miller et al. (1989).
[0069] Recombinant baculovirus expression vectors have been
developed for infection into several insect cells. For example,
recombinant baculoviruses have been developed for, inter alia:
Aedes aegypti, Autographa californica, Bombyx mori, Drosophila
melanogaster, Spodoptera frugiperda, and Trichoplusia ni (WO
89/046699; Carbonell et al., (1985) J. Virol. 56:153; Wright (1986)
Nature 321:718; Smith et al., (1983) Mol. Cell. Biol. 3:2156; and
see generally, Fraser, et al. (1989) In Vitro Cell. Dev. Biol.
25:225).
[0070] Cells and cell culture media are commercially available for
both direct and fusion expression of heterologous polypeptides in a
baculovirus/expression system; cell culture technology is generally
known to those skilled in the art. See, eg. Summers and Smith
supra.
[0071] The modified insect cells may then be grown in an
appropriate nutrient medium, which allows for stable maintenance of
the plasmid(s) present in the modified insect host. Where the
expression product gene is under inducible control, the host may be
grown to high density, and expression induced. Alternatively, where
expression is constitutive, the product will be continuously
expressed into the medium and the nutrient medium must be
continuously circulated, while removing the product of interest and
augmenting depleted nutrients. The product may be purified by such
techniques as chromatography, eg. HPLC, affinity chromatography,
ion exchange chromatography, etc.; electrophoresis; density
gradient centrifugation; solvent extraction, or the like. As
appropriate, the product may be further purified, as required, so
as to remove substantially any insect proteins which are also
secreted in the medium or result from lysis of insect cells, so as
to provide a product which is at least substantially free of host
debris, eg. proteins, lipids and polysaccharides.
[0072] In order to obtain protein expression, recombinant host
cells derived from the transformants are incubated under conditions
which allow expression of the recombinant protein encoding
sequence. These conditions will vary, dependent upon the host cell
selected. However, the conditions are readily ascertainable to
those of ordinary skill in the art, based upon what is known in the
art.
[0073] iii. Plant Systems
[0074] There are many plant cell culture and whole plant genetic
expression systems known in the art. Exemplary plant cellular
genetic expression systems include those described in patents, such
as: U.S. Pat. No. 5,693,506; U.S. Pat. No. 5,659,122; and U.S. Pat.
No. 5,608,143. Additional examples of genetic expression in plant
cell culture has been described by Zenk, Phytochemistry
30:3861-3863 (1991). Descriptions of plant protein signal peptides
may be found in addition to the references described above in
Vaulcombe et al., Mol. Gen. Genet. 209:33-40 (1987); Chandler et
al., Plant Molecular Biology 3:407-418 (1984); Rogers, J. Biol.
Chem. 260:3731-3738 (1985); Rothstein et al., Gene 55:353-356
(1987); Whittier et al., Nucleic Acids Research 15:2515-2535
(1987); Wirsel et al., Molecular Microbiology 3:3-14 (1989); Yu et
al., Gene 122:247-253 (1992). A description of the regulation of
plant gene expression by the phytohormone, gibberellic acid and
secreted enzymes induced by gibberellic acid can be found in R. L.
Jones and J. MacMillin, Gibberellins: in: Advanced Plant
Physiology, Malcolm B. Wilkins, ed., 1984 Pitman Publishing
Limited, London, pp. 21-52. References that describe other
metabolically-regulated genes: Sheen, Plant Cell, 2:1027-1038
(1990); Maas et al., EMBO J. 9:3447-3452 (1990); Benkel and Hickey,
Proc. Natl. Acad. Sci 84:1337-1339 (1987)
[0075] Typically, using techniques known in the art, a desired
polynucleotide sequence is inserted into an expression cassette
comprising genetic regulatory elements designed for operation in
plants. The expression cassette is inserted into a desired
expression vector with companion sequences upstream and downstream
from the expression cassette suitable for expression in a plant
host. The companion sequences will be of plasmid or viral origin
and provide necessary characteristics to the vector to permit the
vectors to move DNA from an original cloning host, such as
bacteria, to the desired plant host. The basic bacterial/plant
vector construct will preferably provide a broad host range
prokaryote replication origin; a prokaryote selectable marker, and,
for Agrobacterium transformations, T DNA sequences for
Agrobacterium-mediated transfer to plant chromosomes. Where the
heterologous gene is not readily amenable to detection, the
construct will preferably also have a selectable marker gene
suitable for determining if a plant cell has been transformed. A
general review of suitable markers, for example for the members of
the grass family, is found in Wilmink and Dons, 1993, Plant Mol.
Biol. Reptr, 11(2):165-185.
[0076] Sequences suitable for permitting integration of the
heterologous sequence into the plant genome are also recommended.
These might include transposon sequences and the like for
homologous recombination as well as Ti sequences which permit
random insertion of a heterologous expression cassette into a plant
genome. Suitable prokaryote selectable markers include resistance
toward antibiotics such as ampicillin or tetracycline. Other DNA
sequences encoding additional functions may also be present in the
vector, as is known in the art.
[0077] The nucleic acid molecules of the subject invention may be
included into an expression cassette for expression of the
protein(s) of interest. Usually, there will be only one expression
cassette, although two or more are feasible. The recombinant
expression cassette will contain in addition to the heterologous
protein encoding sequence the following elements, a promoter
region, plant 5' untranslated sequences, initiation codon depending
upon whether or not the structural gene comes equipped with one,
and a transcription and translation termination sequence. Unique
restriction enzyme sites at the 5' and 3' ends of the cassette
allow for easy insertion into a pre-existing vector.
[0078] A heterologous coding sequence may be for any protein
relating to the present invention. The sequence encoding the
protein of interest will encode a signal peptide which allows
processing and translocation of the protein, as appropriate, and
will usually lack any sequence which might result in the binding of
the desired protein of the invention to a membrane. Since, for the
most part, the transcriptional initiation region will be for a gene
which is expressed and translocated during germination, by
employing the signal peptide which provides for translocation, one
may also provide for translocation of the protein of interest. In
this way, the protein(s) of interest will be translocated from the
cells in which they are expressed and may be efficiently harvested.
Typically secretion in seeds are across the aleurone or scutellar
epithelium layer into the endosperm of the seed. While it is not
required that the protein be secreted from the cells in which the
protein is produced, this facilitates the isolation and
purification of the recombinant protein.
[0079] Since the ultimate expression of the desired gene product
will be in a eucaryotic cell it is desirable to determine whether
any portion of the cloned gene contains sequences which will be
processed out as introns by the host's splicosome machinery. If so,
site-directed mutagenesis of the "intron" region may be conducted
to prevent losing a portion of the genetic message as a false
intron code, Reed and Maniatis, Cell 41:95-105, 1985.
[0080] The vector can be microinjected directly into plant cells by
use of micropipettes to mechanically transfer the recombinant DNA.
Crossway, Mol. Gen. Genet, 202:179-185, 1985. The genetic material
may also be transferred into the plant cell by using polyethylene
glycol, Krens, et al., Nature, 296, 72-74, 1982. Another method of
introduction of nucleic acid segments is high velocity ballistic
penetration by small particles with the nucleic acid either within
the matrix of small beads or particles, or on the surface, Klein,
et al., Nature, 327, 70-73, 1987 and Knudsen and Muller, 1991,
Planta, 185:330-336 teaching particle bombardment of barley
endosperm to create transgenic barley. Yet another method of
introduction would be fusion of protoplasts with other entities,
either minicells, cells, lysosomes or other fusible lipid-surfaced
bodies, Fraley, et al., Proc. Natl. Acad. Sci. USA, 79, 1859-1863,
1982.
[0081] The vector may also be introduced into the plant cells by
electroporation. (Fromm et al., Proc. Natl Acad. Sci. USA 82:5824,
1985). In this technique, plant protoplasts are electroporated in
the presence of plasmids containing the gene construct. Electrical
impulses of high field strength reversibly permeabilize
biomembranes allowing the introduction of the plasmids.
Electroporated plant protoplasts reform the cell wall, divide, and
form plant callus.
[0082] All plants from which protoplasts can be isolated and
cultured to give whole regenerated plants can be transformed by the
present invention so that whole plants are recovered which contain
the transferred gene. It is known that practically all plants can
be regenerated from cultured cells or tissues, including but not
limited to all major species of sugarcane, sugar beet, cotton,
fruit and other trees, legumes and vegetables. Some suitable plants
include, for example, species from the genera Fragaria, Lotus,
Medicago, Onobrychis, Trifolium, Trigonella, Vigna, Citrus, Linum,
Geranium, Manihot, Daucus, Arabidopsis, Brassica, Raphanus,
Sinapis, Atropa, Capsicum, Datura, Hyoscyamus, Lycopersion,
Nicotiana, Solanum, Petunia, Digitalis, Majorana, Cichorium,
Helianthus, Lactuca, Bromus, Asparagus, Antirrhinum, Hererocallis,
Nemesia, Pelargonium, Panicum, Pennisetum, Ranunculus, Senecio,
Salpiglossis, Cucumis, Browaalia, Glycine, Lolium, Zea, Triticum,
Sorghum, and Datura.
[0083] Means for regeneration vary from species to species of
plants, but generally a suspension of transformed protoplasts
containing copies of the heterologous gene is first provided.
Callus tissue is formed and shoots may be induced from callus and
subsequently rooted. Alternatively, embryo formation can be induced
from the protoplast suspension. These embryos germinate as natural
embryos to form plants. The culture media will generally contain
various amino acids and hormones, such as auxin and cytokinins. It
is also advantageous to add glutamic acid and proline to the
medium, especially for such species as corn and alfalfa. Shoots and
roots normally develop simultaneously. Efficient regeneration will
depend on the medium, on the genotype, and on the history of the
culture. If these three variables are controlled, then regeneration
is fully reproducible and repeatable.
[0084] In some plant cell culture systems, the desired protein of
the invention may be excreted or alternatively, the protein may be
extracted from the whole plant. Where the desired protein of the
invention is secreted into the medium, it may be collected.
Alternatively, the embryos and embryoless-half seeds or other plant
tissue may be mechanically disrupted to release any secreted
protein between cells and tissues. The mixture may be suspended in
a buffer solution to retrieve soluble proteins. Conventional
protein isolation and purification methods will be then used to
purify the recombinant protein. Parameters of time, temperature pH,
oxygen, and volumes will be adjusted through routine methods to
optimize expression and recovery of heterologous protein.
[0085] iv. Bacterial Systems
[0086] Bacterial expression techniques are known in the art. A
bacterial promoter is any DNA sequence capable of binding bacterial
RNA polymerase and initiating the downstream (3') transcription of
a coding sequence (eg. structural gene) into mRNA. A promoter will
have a transcription initiation region which is usually placed
proximal to the 5' end of the coding sequence. This transcription
initiation region usually includes an RNA polymerase binding site
and a transcription initiation site. A bacterial promoter may also
have a second domain called an operator, that may overlap an
adjacent RNA polymerase binding site at which RNA synthesis begins.
The operator permits negative regulated (inducible) transcription,
as a gene repressor protein may bind the operator and thereby
inhibit transcription of a specific gene. Constitutive expression
may occur in the absence of negative regulatory elements, such as
the operator. In addition, positive regulation may be achieved by a
gene activator protein binding sequence, which, if present is
usually proximal (5') to the RNA polymerase binding sequence. An
example of a gene activator protein is the catabolite activator
protein (CAP), which helps initiate transcription of the lac operon
in Escherichia coli (E. coli) [Raibaud et al. (1984) Annu. Rev.
Genet. 18:173]. Regulated expression may therefore be either
positive or negative, thereby either enhancing or reducing
transcription.
[0087] Sequences encoding metabolic pathway enzymes provide
particularly useful promoter sequences. Examples include promoter
sequences derived from sugar metabolizing enzymes, such as
galactose, lactose (lac) [Chang et al. (1977) Nature 198:1056], and
maltose. Additional examples include promoter sequences derived
from biosynthetic enzymes such as tryptophan (trp) [Goeddel et al.
(1980) Nuc. Acids Res. 8:4057; Yelverton et al. (1981) Nucl. Acids
Res. 9:731; U.S. Pat. No. 4,738,921; EP-A-0036776 and
EP-A-0121775]. The g-laotamase (bla) promoter system [Weissmann
(1981) "The cloning of interferon and other mistates." In
Interferon 3 (ed I. Gresser)], bacteriophage lambda PL [Shimatake
et al. (1981) Nature 292:128] and T5 [U.S. Pat. No. 4,689,406]
promoter systems also provide useful promoter sequences.
[0088] In addition, synthetic promoters which do not occur in
nature also function as bacterial promoters. For example,
transcription activation sequences of one bacterial or
bacteriophage promoter may be joined with the operon sequences of
another bacterial or bacteriophage promoter, creating a synthetic
hybrid promoter [U.S. Pat. No. 4,551,433]. For example, the tac
promoter is a hybrid trp-lac promoter comprised of both trp
promoter and lac operon sequences that is regulated by the lac
repressor [Amann et al. (1983) Gene 25:167; de Boer et al. (1983)
Proc. Natl. Acad. Sci. 80:21]. Furthermore, a bacterial promoter
can include naturally occurring promoters of non-bacterial origin
that have the ability to bind bacterial RNA polymerase and initiate
transcription. A naturally occurring promoter of non-bacterial
origin can also be coupled with a compatible RNA polymerase to
produce high levels of expression of some genes in prokaryotes. The
bacteriophage T7 RNA polymerase/promoter system is an example of a
coupled promoter system [Studier et al. (1986) J. Mol. Biol.
189:113; Tabor et al. (1985) Proc Natl. Acad. Sci. 82:1074]. In
addition, a hybrid promoter can also be comprised of a
bacteriophage promoter and an E. coli operator region (EPO-A-0 267
851).
[0089] In addition to a functioning promoter sequence, an efficient
ribosome binding site is also useful for the expression of foreign
genes in prokaryotes. In E. coli, the ribosome binding site is
called the Shine-Dalgarno (SD) sequence and includes an initiation
codon (ATG) and a sequence 3-9 nucleotides in length located 3-11
nucleotides upstream of the initiation codon [Shine et al. (1975)
Nature 254:34). The SD sequence is thought to promote binding of
mRNA to the ribosome by the pairing of bases between the SD
sequence and the 3' and of E. coli 16S rRNA [Steitz et al. (1979)
"Genetic signals and nucleotide sequences in messenger RNA." In
Biological Regulation and Development: Gene Expression (ed. R. F.
Goldberger)]. To express eukaryotic genes and prokaryotic genes
with weak ribosome-binding site [Sambrook et al. (1989) "Expression
of cloned genes in Escherichia coli." In Molecular Cloning: A
Laboratory Manual].
[0090] A DNA molecule may be expressed intracellularly. A promoter
sequence may be directly linked with the DNA molecule, in which
case the first amino acid at the N-terminus will always be a
methionine, which is encoded by the ATG start codon. If desired,
methionine at the N-terminus may be cleaved from the protein by in
vitro incubation with cyanogen bromide or by either in vivo on in
vitro incubation with a bacterial methionine N-terminal peptidase
(EPO-A-0 219 237).
[0091] Fusion proteins provide an alternative to direct expression.
Usually, a DNA sequence encoding the N-terminal portion of an
endogenous bacterial protein, or other stable protein, is fused to
the 5' end of heterologous coding sequences. Upon expression, this
construct will provide a fusion of the two amino acid sequences.
For example, the bacteriophage lambda cell gene can be linked at
the 5' terminus of a foreign gene and expressed in bacteria The
resulting fusion protein preferably retains a site for a processing
enzyme (factor Xa) to cleave the bacteriophage protein from the
foreign gene [Nagai et al. (1984) Nature 309:810]. Fusion proteins
can also be made with sequences from the lacZ [Jia et al. (1987)
Gene 60:197], trpE (Allen et al. (1987) J. Biotechnol. 5:93; Makoff
et al. (1989) J. Gen. Microbiol. 135:11], and Chey [EP-A-0 324 647]
genes. The DNA sequence at the junction of the two amino acid
sequences may or may not encode a cleavable site. Another example
is a ubiquitin fusion protein. Such a fusion protein is made with
the ubiquitin region that preferably retains a site for a
processing enzyme (eg. ubiquitin specific processing-protease) to
cleave the ubiquitin from the foreign protein. Through this method,
native foreign protein can be isolated [Miller et al. (1989)
Bio/Technology 7:698].
[0092] Alternatively, foreign proteins can also be secreted from
the cell by creating chimeric DNA molecules that encode a fusion
protein comprised of a signal peptide sequence fragment that
provides for secretion of the foreign protein in bacteria [U.S.
Pat. No. 4,336,336]. The signal sequence fragment usually encodes a
signal peptide comprised of hydrophobic amino acids which direct
the secretion of the protein from the cell. The protein is either
secreted into the growth media (gram-positive bacteria) or into the
periplasmic space, located between the inner and outer membrane of
the cell (gram-negative bacteria). Preferably there are processing
sites, which can be cleaved either in vivo or in vitro encoded
between the signal peptide fragment and the foreign gene.
[0093] DNA encoding suitable signal sequences can be derived from
genes for secreted bacterial proteins, such as the E. coli outer
membrane protein gene (ompA) [Masui et al. (1983), in: Experimental
Manipulation of Gene Expression; Ghrayeb et al. (1984) EMBO J.
3:2437] and the E. coli alkaline phosphatase signal sequence (phoA)
[Oka et al. (1985) Proc. Natl. Acad. Sci. 82:7212]. As an
additional example, the signal sequence of the alpha-amylase gene
from various Bacillus strains can be used to secrete heterologous
proteins from B. subtilis [Palva et al. (1982) Proc. Natl. Acad.
Sci. USA 79:5582; EP-A-0 244 042].
[0094] Usually, transcription termination sequences recognized by
bacteria are regulatory regions located 3' to the translation stop
codon, and thus together with the promoter flank the coding
sequence. These sequences direct the transcription of an mRNA which
can be translated into the polypeptide encoded by the DNA.
Transcription termination sequences frequently include DNA
sequences of about 50 nucleotides capable of forming stem loop
structures that aid in terminating transcription. Examples include
transcription termination sequences derived from genes with strong
promoters, such as the trip gene in E. coli as well as other
biosynthetic genes.
[0095] Usually, the above described components, comprising a
promoter, signal sequence (if desired), coding sequence of
interest, and transcription termination sequence, are put together
into expression constructs. Expression constructs are often
maintained in a replicon, such as an extrachromosomal element (eg.
plasmids) capable of stable maintenance in a host, such as bacteria
The replicon will have a replication system, thus allowing it to be
maintained in a prokaryotic host either for expression or for
cloning and amplification. In addition, a replicon may be either a
high or low copy number plasmid. A high copy number plasmid will
generally have a copy number ranging from about 5 to about 200, and
usually about 10 to about 150. A host containing a high copy number
plasmid will preferably contain at least about 10, and more
preferably at least about 20 plasmids. Either a high or low copy
number vector may be selected, depending upon the effect of the
vector and the foreign protein on the host.
[0096] Alternatively, the expression constructs can be integrated
into the bacterial genome with an integrating vector. Integrating
vectors usually contain at least one sequence homologous to the
bacterial chromosome that allows the vector to integrate.
Integrations appear to result from recombinations between
homologous DNA in the vector and the bacterial chromosome. For
example, integrating vectors constructed with DNA from various
Bacillus strains integrate into the Bacillus chromosome (EP-A-0 127
328). Integrating vectors may also be comprised of bacteriophage or
transposon sequences.
[0097] Usually, extrachromosomal and integrating expression
constructs may contain selectable markers to allow for the
selection of bacterial strains that have been transformed.
Selectable markers can be expressed in the bacterial host and may
include genes which render bacteria resistant to drugs such as
ampicillin, chloramphenicol, erythromycin, kanamycin (neomycin),
and tetracycline [Davies et al. (1978) Annu. Rev. Microbiol.
32:469]. Selectable markers may also include biosynthetic genes,
such as those in the histidine, tryptophan, and leucine
biosynthetic pathways.
[0098] Alternatively, some of the above described components can be
put together in transformation vectors. Transformation vectors are
usually comprised of a selectable market that is either maintained
in a replicon or developed into an integrating vector, as described
above.
[0099] Expression and transformation vectors, either
extra-chromosomal replicons or integrating vectors, have been
developed for transformation into many bacteria For example,
expression vectors have been developed for, inter alia, the
following bacteria: Bacillus subtilis [Palva et al. (1982) Proc.
Natl. Acad. Sci. USA 79:5582; EP-A-0 036 259 and EP-A-0 063 953; WO
84/04541], Escherichia coli [Shimatake et al. (1981) Nature
292:128; Amann et al. (1985) Gene 40:183; Studier et al. (1986) J.
Mol. Biol. 189:113; EP-A-0 036 776, EP-A-0 136 829 and EP-A-0 136
907], Streptococcus cremoris [Powell et al. (1988) Appl. Environ.
Microbiol. 54:655]; Streptococcus lividans [Powell et al. (1988)
Appl. Environ. Microbiol. 54:655], Streptomyces lividans [U.S. Pat.
No. 4,745,056].
[0100] Methods of introducing exogenous DNA into bacterial hosts
are well-known in the art, and usually include either the
transformation of bacteria treated with CaCl.sub.2 or other agents,
such as divalent cations and DMSO. DNA can also be introduced into
bacterial cells by electroporation. Transformation procedures
usually vary with the bacterial species to be transformed. See eg.
[Masson et al. (1989) FEMS Microbiol. Lett. 60:273; Palva et al.
(1982) Proc. Natl. Acad. Sci USA 79:5582; EP-A-0 036 259 and EP-A-0
063 953; WO 84/04541, Bacillus], [Miller et al. (1988) Proc. Natl.
Acad. Sci. 85:856; Wang et al. (1990) J. Bacteriol. 172:949,
Campylobacter], [Cohen et al. (1973) Proc. Natl. Acad. Sci.
69:2110; Dower et al. (1988) Nucleic Acids Res. 16:6127; Kushner
(1978) "An improved method for transformation of Escherichia coli
with ColE1-derived plasmids. In Genetic Engineering: Proceedings of
the International Symposium on Genetic Engineering (eds. H. W.
Boyer and S. Nicosia); Mandel et al. (1970) J. Mol. Biol. 53:159;
Taketo (1988) Biochim Biophys. Acta 949:318; Escherichia], [Chassy
et al. (1987) FEMS Microbiol. Lett. 44:173 Lactobacillus]; [Fiedler
et al. (1988) Anal. Biochem 170:38, Pseudomonas]; [Augustin et al.
(1990) FEMS Microbiol. Lett. 66:203, Staphylococcus], [Barany et
al. (1980) J. Bacteriol. 144:698; Harlander (1987) "Transformation
of Streptococcus lactis by electroporation, in: Streptococcal
Genetics (ed. J. Ferretti and R. Curtiss III); Perry et al. (1981)
Infect Immun. 32:1295; Powell et al. (1988) Appl. Environ.
Microbiol. 54:655; Somkuti et al. (1987) Proc. 4th Evr. Cong.
Biotechnology 1:412, Streptococcus].
[0101] v. Yeast Expression
[0102] Yeast expression systems are also known to one of ordinary
skill in the art. A yeast promoter is any DNA sequence capable of
binding yeast RNA polymerase and initiating the downstream (3')
transcription of a coding sequence (eg. structural gene) into mRNA.
A promoter will have a transcription initiation region which is
usually placed proximal to the 5' end of the coding sequence. This
transcription initiation region usually includes an RNA polymerase
binding site (the "TATA Box") and a transcription initiation site.
A yeast promoter may also have a second domain called an upstream
activator sequence (UAS), which, if present, is usually distal to
the structural gene. The UAS permits regulated (inducible)
expression. Constitutive expression occurs in the absence of a UAS.
Regulated expression may be either positive or negative, thereby
either enhancing or reducing transcription.
[0103] Yeast is a fermenting organism with an active metabolic
pathway, therefore sequences encoding enzymes in the metabolic
pathway provide particularly useful promoter sequences. Examples
include alcohol dehydrogenase (ADH) (EP-A-0 284 044), enolase,
glucokinase, glucose-6-phosphate isomerase,
glyceraldehyde-3-phosphate-dehydrogenase (GAP or GAPDH),
hexokinase, phosphofructokinase, 3-phosphoglycerate mutase, and
pyruvate kinase (PyK) (EPO-A-0 329 203). The yeast PHO5 gene,
encoding acid phosphatase, also provides useful promoter sequences
[Myanohara et al. (1983) Proc. Natl. Acad. Sci. USA 80:1].
[0104] In addition, synthetic promoters which do not occur in
nature also function as yeast promoters. For example, UAS sequences
of one yeast promoter may be joined with the transcription
activation region of another yeast promoter, creating a synthetic
hybrid promoter. Examples of such hybrid promoters include the ADH
regulatory sequence linked to the GAP transcription activation
region (U.S. Pat. Nos. 4,876,197 and 4,880,734). Other examples of
hybrid promoters include promoters which consist of the regulatory
sequences of either the ADH2, GAL4, GAL10, OR PHO5 genes, combined
with the transcriptional activation region of a glycolytic enzyme
gene such as GAP or PyK (EP-A-0 164 556). Furthermore, a yeast
promoter can include naturally occurring promoters of non-yeast
origin that have the ability to bind yeast RNA polymerase and
initiate transcription. Examples of such promoters include, inter
alia, [Cohen et al. (1980) Proc. Natl. Acad. Sci. USA 77:1078;
Henikoff et al. (1981) Nature 283:835; Hollenberg et al. (1981)
Curr. Topics Microbiol. Immunol. 96:119; Hollenberg et al. (1979)
"The Expression of Bacterial Antibiotic Resistance Genes in the
Yeast Saccharomyces cerevisiae," in: Plasmids of Medical,
Environmental and Commercial Importance (eds. K. N. Timmis and A.
Puhler); Mercerau-Puigalon et al. (1980) Gene 11:163; Panthier et
al. (1980) Curr. Genet. 2:109;].
[0105] A DNA molecule may be expressed intracellularly in yeast. A
promoter sequence may be directly linked with the DNA molecule, in
which case the first amino acid at the N-terminus of the
recombinant protein will always be a methionine, which is encoded
by the ATG start codon. If desired, methionine at the N-terminus
may be cleaved from the protein by in vitro incubation with
cyanogen bromide.
[0106] Fusion proteins provide an alternative for yeast expression
systems, as well as in mammalian, baculovirus, and bacterial
expression systems. Usually, a DNA sequence encoding the N-terminal
portion of an endogenous yeast protein, or other stable protein, is
fused to the 5' end of heterologous coding sequences. Upon
expression, this construct will provide a fusion of the two amino
acid sequences. For example, the yeast or human superoxide
dismutase (SOD) gene, can be linked at the 5' terminus of a foreign
gene and expressed in yeast. The DNA sequence at the junction of
the two amino acid sequences may or may not encode a cleavable
site. See eg. EP-A-0 196 056. Another example is a ubiquitin fusion
protein. Such a fusion protein is made with the ubiquitin region
that preferably retains a site for a processing enzyme (eg.
ubiquitin-specific processing protease) to cleave the ubiquitin
from the foreign protein. Through this method, therefore, native
foreign protein can be isolated (eg. WO88/024066).
[0107] Alternatively, foreign proteins can also be secreted from
the cell into the growth media by creating chimeric DNA molecules
that encode a fusion protein comprised of a leader sequence
fragment that provide for secretion in yeast of the foreign
protein. Preferably, there are processing sites encoded between the
leader fragment and the foreign gene that can be cleaved either in
vivo or in vitro. The leader sequence fragment usually encodes a
signal peptide comprised of hydrophobic amino acids which direct
the secretion of the protein from the cell.
[0108] DNA encoding suitable signal sequences can be derived from
genes for secreted yeast proteins, such as the yeast invertase gene
(EP-A-0 012 873; JPO. 62,096,086) and the A-factor gene (U.S. Pat.
No. 4,588,684). Alternatively, leaders of non-yeast origin, such as
an interferon leader, exist that also provide for secretion in
yeast (EP-A-0 060 057).
[0109] A preferred class of secretion leaders are those that employ
a fragment of the yeast alpha-factor gene, which contains both a
"pre" signal sequence, and a "pro" region. The types of
alpha-factor fragments that can be employed include the full-length
pre-pro alpha factor leader (about 83 amino acid residues) as well
as truncated alpha-factor leaders (usually about 25 to about 50
amino acid residues) (U.S. Pat. Nos. 4,546,083 and 4,870,008;
EP-A-0 324 274). Additional leaders employing an alpha-factor
leader fragment that provides for secretion include hybrid
alpha-factor leaders made with a presequence of a first yeast, but
a pro-region from a second yeast alphafactor. (eg. see WO
89/02463.)
[0110] Usually, transcription termination sequences recognized by
yeast are regulatory regions located 3' to the translation stop
codon, and thus together with the promoter flank the coding
sequence. These sequences direct the transcription of an mRNA which
can be translated into the polypeptide encoded by the DNA. Examples
of transcription terminator sequence and other yeast-recognized
termination sequences, such as those coding for glycolytic
enzymes.
[0111] Usually, the above described components, comprising a
promoter, leader (if desired), coding sequence of interest, and
transcription termination sequence, are put together into
expression constructs. Expression constructs are often maintained
in a replicon, such as an extrachromosomal element (eg. plasmids)
capable of stable maintenance in a host, such as yeast or bacteria.
The replicon may have two replication systems, thus allowing it to
be maintained, for example, in yeast for expression and in a
prokaryotic host for cloning and amplification. Examples of such
yeast-bacteria shuttle vectors include YEp24 [Botstein et al.
(1979) Gene 8:17-24], pCl/1 [Brake et al. (1984) Proc. Natl. Acad.
Sci USA 81:4642-4646], and YRp17 [Stinchcomb et al. (1982) J. Mol.
Biol. 158:157]. In addition, a replicon may be either a high or low
copy number plasmid. A high copy number plasmid will generally have
a copy number ranging from about 5 to about 200, and usually about
10 to about 150. A host containing a high copy number plasmid will
preferably have at least about 10, and more preferably at least
about 20. Enter a high or low copy number vector may be selected,
depending upon the effect of the vector and the foreign protein on
the host. See eg. Brake et al., supra.
[0112] Alternatively, the expression constructs can be integrated
into the yeast genome with an integrating vector. Integrating
vectors usually contain at least one sequence homologous to a yeast
chromosome that allows the vector to integrate, and preferably
contain two homologous sequences flanking the expression construct.
Integrations appear to result from recombinations between
homologous DNA in the vector and the yeast chromosome [Orr-Weaver
et al. (1983) Methods in Enzymol. 101:228-245]. An integrating
vector may be directed to a specific locus in yeast by selecting
the appropriate homologous sequence for inclusion in the vector.
See Orr-Weaver et al., supra. One or more expression construct may
integrate, possibly affecting levels of recombinant protein
produced [Rine et al. (1983) Proc. Natl. Acad. Sci. USA 80:6750].
The chromosomal sequences included in the vector can occur either
as a single segment in the vector, which results in the integration
of the entire vector, or two segments homologous to adjacent
segments in the chromosome and flanking the expression construct in
the vector, which can result in the stable integration of only the
expression construct.
[0113] Usually, extrachromosomal and integrating expression
constructs may contain selectable markers to allow for the
selection of yeast strains that have been transformed. Selectable
markers may include biosynthetic genes that can be expressed in the
yeast host, such as ADE2, HIS4, LEU2, TRP1, and ALG7, and the G418
resistance gene, which confer resistance in yeast cells to
tunicamycin and G418, respectively. In addition, a suitable
selectable marker may also provide yeast with the ability to grow
in the presence of toxic compounds, such as metal. For example, the
presence of CUP1 allows yeast to grow in the presence of copper
ions [Butt et al. (1987) Microbiol, Rev. 51:351].
[0114] Alternatively, some of the above described components can be
put together into transformation vectors. Transformation vectors
are usually comprised of a selectable marker that is either
maintained in a replicon or developed into an integrating vector,
as described above.
[0115] Expression and transformation vectors, either
extrachromosomal replicons or integrating vectors, have been
developed for transformation into many yeasts. For example,
expression vectors have been developed for, inter alia, the
following yeasts: Candida albicans [Kurtz, et al. (1986) Mol. Cell.
Biol. 6:142], Candida maltosa [Kunze, et al. (1985) J. Basic
Microbiol. 25:141]. Hansenula polymorpha [Gleeson, et al. (1986) J.
Gen. Microbiol. 132:3459; Roggenkamp et al. (1986) Mol. Gen. Genet.
202:302], Kluyveromyces fragilis [Das, et al. (1984) J. Bacteriol.
158:1165], Kluyveromyces lactis [De Louvencourt et al. (1983) J.
Bacteriol. 154:737; Van den Berg et al. (1990) Bio/Technology
8:135], Pichia guillerimondii [Kunze et al. (1985) J. Basic
Microbiol. 25:141], Pichia pastoris [Cregg, et al. (1985) Mol.
Cell. Biol. 5:3376; U.S. Pat. Nos. 4,837,148 and 4,929,555],
Saccharomyces cerevisiae [Hinnen et al. (1978) Proc. Natl. Acad.
Sci. USA 75:1929; Ito et al. (1983) J. Bacteriol. 153:163],
Schizosaccharomyces pombe [Beach and Nurse (1981) Nature 300:706],
and Yarrowia lipolytica [Davidow, et al. (1985) Curr. Genet.
10:380471 Gaillardin, et al (1985) Curr. Genet. 10:49].
[0116] Methods of introducing exogenous DNA into yeast hosts are
well-known in the art, and usually include either the
transformation of spheroplasts or of intact yeast cells treated
with alkali cations. Transformation procedures usually vary with
the yeast species to be transformed. See eg. [Kurtz et al. (1986)
Mol. Cell. Biol. 6:142; Kunze et al. (1985) J. Basic Microbiol.
25:141; Candida]; [Gleeson et al. (1986) J. Gen. Microbiol.
132:3459; Roggenkamp et al. (1986) Mol. Gen. Genet. 202:302;
Hansenula]; [Das et al. (1984) J. Bacteriol. 158:1165; De
Louvencourt et al. (1983) J. Bacteriol. 154:1165; Van den Berg et
al. (1990) Bio/Technology 8:135; Kluyveromyces]; [Cregg et al.
(1985) Mol. Cell. Biol. 5:3376; Kunze et al. (1985) J. Basic
Microbiol. 25:141; U.S. Pat. Nos. 4,837,148 and 4,929,555; Pichia];
[Hinnen et al. (1978) Proc. Natl. Acad. Sci. USA 75;1929; Ito et
al. (1983) J. Bacteriol. 153:163 Saccharomyces]; [Beach and Nurse
(1981) Nature 300:706; Schizosaccharomyces]; [Davidow et al. (1985)
Curr. Genet. 10:39; Gaillardin et al. (1985) Curr. Genet. 10:49;
Yarrowia].
[0117] Antibodies
[0118] As used herein, the term "antibody" refers to a polypeptide
or group of polypeptides composed of at least one antibody
combining site. An "antibody combining site" is the
three-dimensional binding space with an internal surface shape and
charge distribution complementary to the features of an epitope of
an antigen, which allows a binding of the antibody with the
antigen. "Antibody" includes, for example, vertebrate antibodies,
hybrid antibodies, chimeric antibodies, humanised antibodies,
altered antibodies, univalent antibodies, Fab proteins, and single
domain antibodies. Antibodies against the proteins of the invention
are useful for affinity chromatography, immunoassays, and
distinguishing/identifying Neisserial proteins.
[0119] Antibodies to the proteins of the invention, both polyclonal
and monoclonal, may be prepared by conventional methods. In
general, the protein is first used to immunize a suitable animal,
preferably a mouse, rat, rabbit or goat. Rabbits and goats are
preferred for the preparation of polyclonal sera due to the volume
of serum obtainable, and the availability of labeled anti-rabbit
and anti-goat antibodies. Immunization is generally performed by
mixing or emulsifying the protein in saline, preferably in an
adjuvant such as Freund's complete adjuvant, and injecting the
mixture or emulsion parenterally (generally subcutaneously or
intramuscularly). A dose of 50-200 .mu.g/injection is typically
sufficient. Immunization is generally boosted 2-6 weeks later with
one or more injections of the protein in saline, preferably using
Freund's incomplete adjuvant. One may alternatively generate
antibodies by in vitro immunization using methods known in the adt,
which for the purposes of this invention is considered equivalent
to in vivo immunization. Polyclonal antisera is obtained by
bleeding the immunized animal into a glass or plastic container,
incubating the blood at 25.degree. C. for one hour, followed by
incubating at 4.degree. C. for 2-18 hours. The serum is recovered
by centrifugation (eg. 1,000 g for 10 minutes). About 20-50 ml per
bleed may be obtained from rabbits.
[0120] Monoclonal antibodies are prepared using the standard method
of Kohler & Milstein [Nature (1975) 256:495-96], or a
modification thereof. Typically, a mouse or rat is immunized as
described above. However, rather than bleeding the animal to
extract serum, the spleen (and optionally several large lymph
nodes) is removed and dissociated into single cells. If desired,
the spleen cells may be screened (after removal of nonspecifically
adherent cells) by applying a cell suspension to a plate or well
coated with the protein antigen. B-cells expressing membrane-bound
immunoglobulin specific for the antigen bind to the plate, and are
not rinsed away with the rest of the suspension. Resulting B-cells,
or all dissociated spleen cells, are then induced to fuse with
myeloma cells to form hybridomas, and are cultured in a selective
medium (eg. hypoxanthine, aminopterin, thymidine medium, "HAT").
The resulting hybridomas are plated by limiting dilution, and are
assayed for the production of antibodies which bind specifically to
the immunizing antigen (and which do not bind to unrelated
antigens). The selected MAb-secreting hybridomas are then cultured
either in vitro (eg. in tissue culture bottles or hollow fiber
reactors), or in vivo (as ascites in mice).
[0121] If desired, the antibodies (whether polyclonal or
monoclonal) may be labeled using conventional techniques. Suitable
labels include fluorophores, chromophores, radioactive atoms
(particularly .sup.32P and .sup.125I), electron-dense reagents,
enzymes, and ligands having specific binding partners. Enzymes are
typically detected by their activity. For example, horseradish
peroxidase is usually detected by its ability to convert
3,3',5,5'-tetramethylbenzidine (TMB) to a blue pigment,
quantifiable with a spectrophotometer. "Specific binding partner"
refers to a protein capable of binding a ligand molecule with high
specificity, as for example in the case of an antigen and a
monoclonal antibody specific therefor. Other specific binding
partners include biotin and avidin or streptavidin, IgG and protein
A, and the numerous receptor-ligand couples known in the art. It
should be understood that the above description is not meant to
categorize the various labels into distinct classes, as the same
label may serve in several different modes. For example, .sup.125I
may serve as a radioactive label or as an electron-dense reagent.
HRP may serve as enzyme or as antigen for a MAb. Further, one may
combine various labels for desired effect. For example, MAbs and
avidin also require labels in the practice of this invention: thus,
one might label a MAb with biotin, and detect its presence with
avidin labeled with .sup.125I, or with an anti-biotin MAb labeled
with HRP. Other permutations and possibilities will be readily
apparent to those of ordinary skill in the art, and are considered
as equivalents within the scope of the instant invention.
[0122] Pharmaceutical Compositions
[0123] Pharmaceutical compositions can comprise either
polypeptides, antibodies, or nucleic acid of the invention. The
pharmaceutical compositions will comprise a therapeutically
effective amount of either polypeptides, antibodies, or
polynucleotides of the claimed invention.
[0124] The term "therapeutically effective amount" as used herein
refers to an amount of a therapeutic agent to treat, ameliorate, or
prevent a desired disease or condition, or to exhibit a detectable
therapeutic or preventative effect. The effect can be detected by,
for example, chemical markers or antigen levels. Therapeutic
effects also include reduction in physical symptoms, such as
decreased body temperature. The precise effective amount for a
subject will depend upon the subject's size and health, the nature
and extent of the condition, and the therapeutics or combination of
therapeutics selected for administration. Thus, it is not useful to
specify an exact effective amount in advance. However, the
effective amount for a given situation can be determined by routine
experimentation and is within the judgement of the clinician.
[0125] For purposes of the present invention, an effective dose
will be from about 0.01 mg/kg to 50 mg/kg or 0.05 mg/kg to about 10
mg/kg of the DNA constructs in the individual to which it is
administered.
[0126] A pharmaceutical composition can also contain a
pharmaceutically acceptable carrier. The term "pharmaceutically
acceptable carrier" refers to a carrier for administration of a
therapeutic agent, such as antibodies or a polypeptide, genes, and
other therapeutic agents. The term refers to any pharmaceutical
carrier that does not itself induce the production of antibodies
harmful to the individual receiving the composition, and which may
be administered without undue toxicity. Suitable carriers may be
large, slowly metabolized macromolecules such as proteins,
polysaccharides, polylactic acids, polyglycolic acids, polymeric
amino acids, amino acid copolymers, and inactive virus particles.
Such carriers are well known to those of ordinary skill in the
art.
[0127] Pharmaceutically acceptable salts can be used therein, for
example, mineral acid salts such as hydrochlorides, hydrobromides,
phosphates, sulfates, and the like; and the salts of organic acids
such as acetates, propionates, malonates, benzoates, and the like.
A thorough discussion of pharmaceutically acceptable excipients is
available in Remington's Pharmaceutical Sciences (Mack Pub. Co.,
N.J. 1991).
[0128] Pharmaceutically acceptable carriers in therapeutic
compositions may contain liquids such as water, saline, glycerol
and ethanol. Additionally, auxiliary substances, such as wetting or
emulsifying agents, pH buffering substances, and the like, may be
present in such vehicles. Typically, the therapeutic compositions
are prepared as injectables, either as liquid solutions or
suspensions; solid forms suitable for solution in, or suspension
in, liquid vehicles prior to injection may also be prepared.
Liposomes are included within the definition of a pharmaceutically
acceptable carrier.
[0129] Delivery Methods
[0130] Once formulated, the compositions of the invention can be
administered directly to the subject. The subjects to be treated
can be animals; in particular, human subjects can be treated.
[0131] Direct delivery of the compositions will generally be
accomplished by injection, either subcutaneously,
intraperitoneally, intravenously or intramuscularly or delivered to
the interstitial space of a tissue. The compositions can also be
administered into a lesion. Other modes of administration include
oral and pulmonary administration, suppositories, and transdermal
or transcutaneous applications (eg. see WO98/20734), needles, and
gene guns or hyposprays. Dosage treatment may be a single dose
schedule or a multiple dose schedule.
[0132] Vaccines
[0133] Vaccines according to the invention may either be
prophylactic (ie. to prevent infection) or therapeutic (ie. to
treat disease after infection).
[0134] Such vaccines comprise immunising antigen(s), immunogen(s),
polypeptide(s), protein(s) or nucleic acid, usually in combination
with "pharmaceutically acceptable carriers," which include any
carrier that does not itself induce the production of antibodies
harmful to the individual receiving the composition. Suitable
carriers are typically large, slowly metabolized macromolecules
such as proteins, polysaccharides, polylactic acids, polyglycolic
acids, polymeric amino acids, amino acid copolymers, lipid
aggregates (such as oil droplets or liposomes), and inactive virus
particles. Such carriers are well known to those of ordinary skill
in the art. Additionally, these carriers may function as
immunostimulating agents ("adjuvants"). Furthermore, the antigen or
immunogen may be conjugated to a bacterial toxoid, such as a toxoid
from diphtheria, tetanus, cholera, H. pylori, etc. pathogens.
[0135] Preferred adjuvants to enhance effectiveness of the
composition include, but are not limited to: (1) aluminum salts
(alum), such as aluminum hydroxide, aluminum phosphate, aluminum
sulfate, etc; (2) oil-in-water emulsion formulations (with or
without other specific immunostimulating agents such as muramyl
peptides (see below) or bacterial cell wall components), such as
for example (a) MF59.TM. (WO 90/14837; Chapter 10 in Vaccine
design: the subunit and adjuvant approach, eds. Powell &
Newman, Plenum Press 1995), containing 5% Squalene, 0.5% Tween 80,
and 0.5% Span 85 (optionally containing various amounts of MTP-PE
(see below), although not required) formulated into submicron
particles using a microfluidizer such as Model 110Y microfluidizer
(Microfluidics, Newton, Mass.), (b) SAF, containing 10% Squalane,
0.4% Tween 80, 5% pluronic-blocked polymer L121, and thr-MDP (see
below) either microfluidized into a submicron emulsion or vortexed
to generate a larger particle size emulsion, and (c) Ribi.TM.
adjuvant system (RAS), (Ribi Immunochem, Hamilton, Mont.)
containing 2% Squalene, 0.2% Tween 80, and one or more bacterial
cell wall components from the group consisting of
monophosphorylipid A (MPL), trehalose dimycolate (TDM), and cell
wall skeleton (CWS), preferably MPL+CWS (Detox.TM.); (3) saponin
adjuvants, such as Stimulon.TM. (Cambridge Bioscience, Worcester,
Mass.) may be used or particles generated therefrom such as ISCOMs
(immunostimulating complexes); (4) Complete Freund's Adjuvant (CFA)
and Incomplete Freund's Adjuvant (IFA); (5) cytokines, such as
interleukins (eg. IL-1, IL-2, IL-4, IL-5, IL-6, IL-7, IL-12, etc.),
interferons (eg. gamma interferon), macrophage colony stimulating
factor (M-CSF), tumor necrosis factor (TNF), etc; and (6) other
substances that act as immunostimulating agents to enhance the
effectiveness of the composition. Alum and MF59.TM. are
preferred.
[0136] As mentioned above, muramyl peptides include, but are not
limited to, N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP),
N-acetyl-normuramyl-L-alanyl-D-isoglutamine (nor-MDP),
N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1'-2'-dipalmitoyl-s-
n-glycero-3-hydroxyphosphoryloxy)ethylamine (MTP-PE), etc.
[0137] The immunogenic compositions (eg. the immunising
antigen/immunogen/polypeptide/protein/nucleic acid,
pharmaceutically acceptable carrier, and adjuvant) typically will
contain diluents, such as water, saline, glycerol, ethanol, etc.
Additionally, auxiliary substances, such as wetting or emulsifying
agents, pH buffering substances, and the like, may be present in
such vehicles.
[0138] Typically, the immunogenic compositions are prepared as
injectables, either as liquid solutions or suspensions; solid forms
suitable for solution in, or suspension in, liquid vehicles prior
to injection may also be prepared. The preparation also may be
emulsified or encapsulated in liposomes for enhanced adjuvant
effect, as discussed above under pharmaceutically acceptable
carriers.
[0139] Immunogenic compositions used as vaccines comprise an
immunologically effective amount of the antigenic or immunogenic
polypeptides, as well as any other of the above-mentioned
components, as needed. By "immunologically effective amount", it is
meant that the administration of that amount to an individual,
either in a single dose or as part of a series, is effective for
treatment or prevention. This amount varies depending upon the
health and physical condition of the individual to be treated, the
taxonomic group of individual to be treated (eg. nonhuman primate,
primate, etc.), the capacity of the individual's immune system to
synthesize antibodies, the degree of protection desired, the
formulation of the vaccine, the treating doctors assessment of the
medical situation, and other relevant factors. It is expected that
the amount will fall in a relatively broad range that can be
determined through routine trials.
[0140] The immunogenic compositions are conventionally administered
parenterally, eg. by injection, either subcutaneously,
intramuscularly, or transdermally/transcutaneously (eg.
WO98/20734). Additional formulations suitable for other modes of
administration include oral and pulmonary formulations,
suppositories, and transdermal applications. Dosage treatment may
be a single dose schedule or a multiple dose schedule. The vaccine
may be administered in conjunction with other immunoregulatory
agents.
[0141] As an alternative to protein-based vaccines, DNA vaccination
may be employed [eg. Robinson & Torres (1997) Seminars in
Immunology 9:271-283; Donnelly et al. (1997) Annu Rev Immunol
15:617-648; see later herein].
[0142] Gene Delivery Vehicles
[0143] Gene therapy vehicles for delivery of constructs including a
coding sequence of a therapeutic of the invention, to be delivered
to the mammal for expression in the mammal, can be administered
either locally or systemically. These constructs can utilize viral
or non-viral vector approaches in in vivo or ex vivo modality.
Expression of such coding sequence can be induced using endogenous
mammalian or heterologous promoters. Expression of the coding
sequence in vivo can be either constitutive or regulated.
[0144] The invention includes gene delivery vehicles capable of
expressing the contemplated nucleic acid sequences. The gene
delivery vehicle is preferably a viral vector and, more preferably,
a retroviral, adenoviral, adeno-associated viral (AAV), herpes
viral, or alphavirus vector. The viral vector can also be an
astrovirus, coronavirus, orthomyxovirus, papovavirus,
paramyxovirus, parvovirus, picomavirus, poxvirus, or togavirus
viral vector. See generally, Jolly (1994) Cancer Gene Therapy
1:51-64; Kimura (1994) Human Gene Therapy 5:845-852; Connelly
(1995) Human Gene Therapy 6:185-193; and Kaplitt (1994) Nature
Genetics 6:148-153.
[0145] Retroviral vectors are well known in the art and we
contemplate that any retroviral gene therapy vector is employable
in the invention, including B, C and D type retroviruses,
xenotropic retroviruses (for example, NZB-X1, NZB-X2 and NZB9-1
(see O'Neill (1985) J. Virol. 53:160) polytropic retrovirus eg. MCF
and MCF-MLV (see Kelly (1983) J. Virol. 45:291), spumaviruses and
lentiviruses. See RNA Tumor Viruses, Second Edition, Cold Spring
Harbor Laboratory, 1985.
[0146] Portions of the retroviral gene therapy vector may be
derived from different retroviruses. For example, retrovector LTRs
may be derived from a Murine Sarcoma Virus, a tRNA binding site
from a Rous Sarcoma Virus, a packaging signal from a Murine
Leukemia Virus, and an origin of second strand synthesis from an
Avian Leukosis Virus.
[0147] These recombinant retroviral vectors may be used to generate
transduction competent retroviral vector particles by introducing
them into appropriate packaging cell lines (see U.S. Pat. No.
5,591,624). Retrovirus vectors can be constructed for site-specific
integration into host cell DNA by incorporation of a chimeric
integrase enzyme into the retroviral particle (see WO96/37626). It
is preferable that the recombinant viral vector is a replication
defective recombinant virus.
[0148] Packaging cell lines suitable for use with the
above-described retrovirus vectors are well known in the art, are
readily prepared (see WO95/30763 and WO92/05266), and can be used
to create producer cell lines (also termed vector cell lines or
"VCLs") for the production of recombinant vector particles.
Preferably, the packaging cell lines are made from human parent
cells (eg. HT1080 cells) or mink parent cell lines, which
eliminates inactivation in human serum.
[0149] Preferred retroviruses for the construction of retroviral
gene therapy vectors include Avian Leukosis Virus, Bovine Leukemia,
Virus, Murine Leukemia Virus, Mink-Cell Focus-Inducing Virus,
Murine Sarcoma Virus, Reticuloendotheliosis Virus and Rous Sarcoma
Virus. Particularly preferred Murine Leukemia Viruses include 4070A
and 1504A (Hartley and Rowe (1976) J Virol 19:19-25), Abelson (ATCC
No. VR-999), Friend (ATCC No. VR-245), Graffi, Gross (ATCC Nol
VR-590), Kirsten, Harvey Sarcoma Virus and Rauscher (ATCC No.
VR-998) and Moloney Murine Leukemia Virus (ATCC No. VR-190). Such
retroviruses may be obtained from depositories or collections such
as the American Type Culture Collection ("ATCC") in Rockville, Md.
or isolated from known sources using commonly available
techniques.
[0150] Exemplary known retroviral gene therapy vectors employable
in this invention include those described in patent applications
GB2200651, EP0415731, EP0345242, EP0334301, WO89/02468; WO89/05349,
WO89/09271, WO90/02806, WO90/07936, WO94/03622, WO93/25698,
WO93/25234, WO93/11230, WO93/10218, WO91/02805, WO91/02825,
WO95/07994, U.S. Pat. No. 5,219,740, U.S. Pat. No. 4,405,712, U.S.
Pat. No. 4,861,719, U.S. Pat. No. 4,980,289, U.S. Pat. No.
4,777,127, U.S. Pat. No. 5,591,624. See also Vile (1993) Cancer Res
53:3860-3864; Vile (1993) Cancer Res 53:962-967; Rain (1993) Cancer
Res 53 (1993) 83-88; Takamiya (1992) J Neurosci Res 33:493-503;
Baba (1993) J Neurosurg 79:729-735; Mann (1983) Cell 33:153; Cane
(1984) Proc Natl Acad Sci 81:6349; and Miller (1990) Human Gene
Therapy 1.
[0151] Human adenoviral gene therapy vectors are also known in the
art and employable in this invention. See, for example, Berkner
(1988) Biotechniques 6:616 and Rosenfeld (1991) Science 252:431,
and WO93/07283, WO93/06223, and WO93/07282. Exemplary known
adenoviral gene therapy vectors employable in this invention
include those described in the above referenced documents and in
WO94/12649, WO93/03769, WO93/19191, WO94/28938, WO95/11984,
WO95/00655, WO95/27071, WO95/29993, WO95/34671, WO96/05320,
WO94/08026, WO94/11506, WO93/06223, WO94/24299, WO95/14102,
WO95/24297, WO95/02697, WO94/28152, WO94/24299, WO95/09241,
WO95/25807, WO95/05835, WO94/18922 and WO95/09654. Alternatively,
administration of DNA linked to killed adenovirus as described in
Curiel (1992) Hum. Gene Ther. 3:147-154 may be employed. The gene
delivery vehicles of the invention also include adenovirus
associated virus (AAV) vectors. Leading and preferred examples of
such vectors for use in this invention are the AAV-2 based vectors
disclosed in Srivastava, WO93/09239. Most preferred AAV vectors
comprise the two AAV inverted terminal repeats in which the native
D-sequences are modified by substitution of nucleotides, such that
at least 5 native nucleotides and up to 18 native nucleotides,
preferably at least 10 native nucleotides up to 18 native
nucleotides, most preferably 10 native nucleotides are retained and
the remaining nucleotides of the D-sequence are deleted or replaced
with non-native nucleotides. The native D-sequences of the AAV
inverted terminal repeats are sequences of 20 consecutive
nucleotides in each AAV inverted terminal repeat (ie. there is one
sequence at each end) which are not involved in HP formation. The
non-native replacement nucleotide may be any nucleotide other than
the nucleotide found in the native D-sequence in the same position.
Other employable exemplary AAV vectors are pWP-19, pWN-1, both of
which are disclosed in Nahreini (1993) Gene 124:257-262. Another
example of such an AAV vector is psub201 (see Samulski (1987) J.
Virol. 61:3096). Another exemplary AAV vector is the Double-D ITR
vector. Construction of the Double-D ITR vector is disclosed in
U.S. Pat. No. 5,478,745. Still other vectors are those disclosed in
Carter U.S. Pat. No. 4,797,368 and Muzyczka U.S. Pat. No.
5,139,941, Chartejee U.S. Pat. No. 5,474,935, and Kotin
WO94/288157. Yet a further example of an AAV vector employable in
this invention is SSV9AFABTKneo, which contains the AFP enhancer
and albumin promoter and directs expression predominantly in the
liver. Its structure and construction are disclosed in Su (1996)
Human Gene Therapy 7:463-470. Additional AAV gene therapy vectors
are described in U.S. Pat. No. 5,354,678, U.S. Pat. No. 5,173,414,
U.S. Pat. No. 5,139,941, and U.S. Pat. No. 5,252,479.
[0152] The gene therapy vectors of the invention also include
herpes vectors. Leading and preferred examples are herpes simplex
virus vectors containing a sequence encoding a thymidine kinase
polypeptide such as those disclosed in U.S. Pat. No. 5,288,641 and
EP0176170 (Roizman). Additional exemplary herpes simplex virus
vectors include HFEM/ICP6-LacZ disclosed in WO95/04139 (Wistar
Institute), pHSVlac described in Geller (1988) Science
241:1667-1669 and in WO90/09441 and WO92/07945, HSV Us3::pgC-lacZ
described in Fink (1992) Human Gene Therapy 3:11-19 and HSV 7134, 2
RH 105 and GAL4 described in EP 0453242 (Breakefield), and those
deposited with the ATCC as accession numbers ATCC VR-977 and ATCC
VR-260.
[0153] Also contemplated are alpha virus gene therapy vectors that
can be employed in this invention. Preferred alpha virus vectors
are Sindbis viruses vectors. Togaviruses, Semliki Forest virus
(ATCC VR-67; ATCC VR-1247), Middleberg virus (ATCC VR-370), Ross
River virus (ATCC VR-373; ATCC VR-1246), Venezuelan equine
encephalitis virus (ATCC VR923; ATCC VR-1250; ATCC VR-1249; ATCC
VR-532), and those described in U.S. Pat. Nos. 5,091,309,
5,217,879, and WO92/10578. More particularly, those alpha virus
vectors described in U.S. Ser. No. 08/405,627, filed Mar. 15, 1995,
WO94/21792, WO92/10578, WO95/07994, U.S. Pat. No. 5,091,309 and
U.S. Pat. No. 5,217,879 are employable. Such alpha viruses may be
obtained from depositories or collections such as the ATCC in
Rockville, Md. or isolated from known sources using commonly
available techniques. Preferably, alphavirus vectors with reduced
cytotoxicity are used (see U.S. Ser. No. 08/679,640).
[0154] DNA vector systems such as eukaryotic layered expression
systems are also useful for expressing the nucleic acids of the
invention. See WO95/07994 for a detailed description of eukaryotic
layered expression systems. Preferably, the eukaryotic layered
expression systems of the invention are derived from alphavirus
vectors and most preferably from Sindbis viral vectors.
[0155] Other viral vectors suitable for use in the present
invention include those derived from poliovirus, for example ATCC
VR-58 and those described in Evans, Nature 339 (1989) 385 and Sabin
(1973) J. Biol. Standardization 1:115; rhinovirus, for example ATCC
VR-1110 and those described in Arnold (1990) J Cell Biochem L401;
pox viruses such as canary pox virus or vaccinia virus, for example
ATCC VR-111 and ATCC VR-2010 and those described in Fisher-Hoch
(1989) Proc Natl Acad Sci 86:317; Flexner (1989) Ann NY Acad Sci
569:86, Flexner (1990) Vaccine 8:17; in U.S. Pat. No. 4,603,112 and
U.S. Pat. No. 4,769,330 and WO89/01973; SV40 virus, for example
ATCC VR-305 and those described in Mulligan (1979) Nature 277:108
and Madzak (1992) J Gen Virol 73:1533; influenza virus, for example
ATCC VR-797 and recombinant influenza viruses made employing
reverse genetics techniques as described in U.S. Pat. No. 5,166,057
and in Enami (1990) Proc Nail Acad Sci 87:3802-3805; Enami &
Palese (1991) J Virol 65:2711-2713 and Luytjes (1989) Cell 59:110,
(see also McMichael (1983) NEJ Med 309:13, and Yap (1978) Nature
273:238 and Nature (1979) 277:108); human immunodeficiency virus as
described in EP-0386882 and in Buchschacher (1992) J. Virol.
66:2731; measles virus, for example ATCC VR-67 and VR-1247 and
those described in EP-0440219; Aura virus, for example ATCC VR-368;
Bebaru virus, for example ATCC VR-600 and ATCC VR-1240; Cabassou
virus, for example ATCC VR-922; Chikungunya virus, for example ATCC
VR-64 and ATCC VR-1241; Fort Morgan Virus, for example ATCC VR-924;
Getah virus, for example ATCC VR-369 and ATCC VR-1243; Kyzylagach
virus, for example ATCC VR-927; Mayaro virus, for example ATCC
VR-66; Mucambo virus, for example ATCC VR-580 and ATCC VR-1244;
Ndumu virus, for example ATCC VR-371; Pixuna virus, for example
ATCC VR-372 and ATCC VR-1245; Tonate virus, for example ATCC
VR-925; Triniti virus, for example ATCC VR-469; Una virus, for
example ATCC VR-374; Whataroa virus, for example ATCC VR-926;
Y-62-33 virus, for example ATCC VR-375; O'Nyong virus, Eastern
encephalitis virus, for example ATCC VR-65 and ATCC VR-1242;
Western encephalitis virus, for example ATCC VR-70, ATCC VR-1251,
ATCC VR-622 and ATCC VR-1252; and coronavirus, for example ATCC
VR-740 and those described in Hamre (1966) Proc Soc Exp Biol Med
121:190.
[0156] Delivery of the compositions of this invention into cells is
not limited to the above mentioned viral vectors. Other delivery
methods and media may be employed such as, for example, nucleic
acid expression vectors, polycationic condensed DNA linked or
unlinked to killed adenovirus alone, for example see U.S. Ser. No.
08/366,787, filed Dec. 30, 1994 and Curiel (1992) Hum Gene Ther
3:147-154 ligand linked DNA, for example see Wu (1989) J Biol Chem
264:16985-16987, eucaryotic cell delivery vehicles cells, for
example see U.S. Ser. No. 08/240,030, filed May 9, 1994, and U.S.
Ser. No. 08/404,796, deposition of photopolymerized hydrogel
materials, hand-held gene transfer particle gun, as described in
U.S. Pat. No. 5,149,655, ionizing radiation as described in U.S.
Pat. No. 5,206,152 and in WO92/11033, nucleic charge neutralization
or fusion with cell membranes. Additional approaches are described
in Philip (1994) Mol Cell Biol 14:2411-2418 and in Woffendin (1994)
Proc Natl Acad Sci 91:1581-1585.
[0157] Particle mediated gene transfer may be employed, for example
see U.S. Ser. No. 60/023,867. Briefly, the sequence can be inserted
into conventional vectors that contain conventional control
sequences for high level expression, and then incubated with
synthetic gene transfer molecules such as polymeric DNA-binding
cations like polylysine, protamine, and albumin, linked to cell
targeting ligands such as asialoorosomucoid, as described in Wu
& Wu (1987) J. Biol. Chem. 262:4429-4432, insulin as described
in Hucked (1990) Biochem Pharmacol 40:253-263, galactose as
described in Plank (1992) Bioconjugate Chem 3:533-539, lactose or
transferrin.
[0158] Naked DNA may also be employed. Exemplary naked DNA
introduction methods are described in WO 90/11092 and U.S. Pat. No.
5,580,859. Uptake efficiency may be improved using biodegradable
latex beads. DNA coated latex beads are efficiently transported
into cells after endocytosis initiation by the beads. The method
may be improved further by treatment of the beads to increase
hydrophobicity and thereby facilitate disruption of the endosome
and release of the DNA into the cytoplasm.
[0159] Liposomes that can act as gene delivery vehicles are
described in U.S. Pat. No. 5,422,120, WO95/13796, WO94/23697,
WO91/14445 and EP-524,968. As described in U.S. S No. 60/023,867,
on non-viral delivery, the nucleic acid sequences encoding a
polypeptide can be inserted into conventional vectors that contain
conventional control sequences for high level expression, and then
be incubated with synthetic gene transfer molecules such as
polymeric DNA-binding cations like polylysine, protamine, and
albumin, linked to cell targeting ligands such as
asialoorosomucoid, insulin, galactose, lactose, or transferrin.
Other delivery systems include the use of liposomes to encapsulate
DNA comprising the gene under the control of a variety of
tissue-specific or ubiquitously-active promoters. Further non-viral
delivery suitable for use includes mechanical delivery systems such
as the approach described in Woffendin et al (1994) Proc. Natl.
Acad. Sci. USA 91(24):11581-11585. Moreover, the coding sequence
and the product of expression of such can be delivered through
deposition of photopolymerized hydrogel materials. Other
conventional methods for gene delivery that can be used for
delivery of the coding sequence include, for example, use of
hand-held gene transfer particle gun, as described in U.S. Pat. No.
5,149,655; use of ionizing radiation for activating transferred
gene, as described in U.S. Pat. No. 5,206,152 and WO92/11033
[0160] Exemplary liposome and polycationic gene delivery vehicles
are those described in U.S. Pat. Nos. 5,422,120 and 4,762,915; in
WO 95/13796; WO94/23697, and WO91/14445; in EP-0524968; and in
Stryer, Biochemistry, pages 236-240 (1975) W.H. Freeman, San
Francisco; Szoka (1980) Biochem Biophys Acta 600:1; Bayer (1979)
Biochem Biophys Acta 550:464; Rivnay (1987) Meth Enzymol 149:119;
Wang (1987) Proc Natl Acad Sci 84:7851; Plant (1989) Anal Biochem
176:420.
[0161] A polynucleotide composition can comprises therapeutically
effective amount of a gene therapy vehicle, as the term is defined
above. For purposes of the present invention, an effective dose
will be from about 0.01 mg/kg to 50 mg/kg or 0.05 mg/kg to about 10
mg/kg of the DNA constructs in the individual to which it is
administered.
[0162] Delivery Methods
[0163] Once formulated, the polynucleotide compositions of the
invention can be administered (1) directly to the subject; (2)
delivered ex vivo, to cells derived from the subject; or (3) in
vitro for expression of recombinant proteins. The subjects to be
treated can be mammals or birds. Also, human subjects can be
treated.
[0164] Direct delivery of the compositions will generally be
accomplished by injection, either subcutaneously,
intraperitoneally, intravenously or intramuscularly or delivered to
the interstitial space of a tissue. The compositions can also be
administered into a lesion. Other modes of administration include
oral and pulmonary administration, suppositories, and transdermal
or transcutaneous applications (eg. see WO98/20734), needles, and
gene guns or hyposprays. Dosage treatment may be a single dose
schedule or a multiple dose schedule.
[0165] Methods for the ex vivo delivery and reimplantation of
transformed cells into a subject are known in the art and described
in eg. WO93/14778. Examples of cells useful in ex vivo applications
include, for example, stem cells, particularly hematopoetic, lymph
cells, macrophages, dendritic cells, or tumor cells.
[0166] Generally, delivery of nucleic acids for both ex vivo and in
vitro applications can be accomplished by the following procedures,
for example, dextran-mediated transfection, calcium phosphate
precipitation, polybrene mediated transfection, protoplast fusion,
electroporation, encapsulation of the polynucleotide(s) in
liposomes, and direct microinjection of the DNA into nuclei, all
well known in the art.
[0167] Polynucleotide and Polypeptide Pharmaceutical
Compositions
[0168] In addition to the pharmaceutically acceptable carriers and
salts described above, the following additional agents can be used
with polynucleotide and/or polypeptide compositions.
[0169] A. Polypeptides
[0170] One example are polypeptides which include, without
limitation: asioloorosomucoid (ASOR); transferrin;
asialoglycoproteins; antibodies; antibody fragments; ferritin;
interleukins; interferons, granulocyte, macrophage colony
stimulating factor (GM-CSF), granulocyte colony stimulating factor
(G-CSF), macrophage colony stimulating factor (M-CSF), stem cell
factor and erythropoietin. Viral antigens, such as envelope
proteins, can also be used. Also, proteins from other invasive
organisms, such as the 17 amino acid peptide from the
circumsporozoite protein of plasmodium falciparum known as RII.
[0171] B. Hormones, Vitamins, etc.
[0172] Other groups that can be included are, for example:
hormones, steroids, androgens, estrogens, thyroid hormone, or
vitamins, folic acid.
[0173] C. Polyalkylenes, Polysaccharides, etc.
[0174] Also, polyalkylene glycol can be included with the desired
polynucleotides/polypeptides. In a preferred embodiment, the
polyalkylene glycol is polyethlylene glycol. In addition, mono-,
di-, or polysaccharides can be included. In a preferred embodiment
of this aspect, the polysaccharide is dextran or DEAE-dextran.
Also, chitosan and poly(lactide-co-glycolide)
[0175] D. Lipids, and Liposomes
[0176] The desired polynucleotide/polypeptide can also be
encapsulated in lipids or packaged in liposomes prior to delivery
to the subject or to cells derived therefrom.
[0177] Lipid encapsulation is generally accomplished using
liposomes which are able to stably bind or entrap and retain
nucleic acid. The ratio of condensed polynucleotide to lipid
preparation can vary but will generally be around 1:1 (mg
DNA:micromoles lipid), or more of lipid. For a review of the use of
liposomes as carriers for delivery of nucleic acids, see, Hug and
Sleight (1991) Biochim. Biophys. Acta. 1097:1-17; Straubinger
(1983) Meth. Enzymol. 101:512-527.
[0178] Liposomal preparations for use in the present invention
include cationic (positively charged), anionic (negatively charged)
and neutral preparations. Cationic liposomes have been shown to
mediate intracellular delivery of plasmid DNA (Felgner (1987) Proc.
Natl. Acad. Sci. USA 84:7413-7416); mRNA (Malone (1989) Proc. Natl.
Acad. Sci. USA 86:6077-6081); and purified transcription factors
(Debs (1990) J. Biol. Chem. 265:10189-10192), in functional
form.
[0179] Cationic liposomes are readily available. For example,
N[1-2,3-dioleyloxy)propyl]-N,N,N-triethylammonium (DOTMA) liposomes
are available under the trademark Lipofectin, from GIBCO BRL, Grand
Island, N.Y. (See, also, Felgner supra). Other commercially
available liposomes include transfectace (DDAB/DOPE) and DOTAP/DOPE
(Boerhinger). Other cationic liposomes can be prepared from readily
available materials using techniques well known in the art. See,
eg. Szoka (1978) Proc. Nail. Acad. Sci. USA 75:41944198; WO90/11092
for a description of the synthesis of DOTAP
(1,2-bis(oleoyloxy)-3-(trimethylammonio)propane) liposomes.
[0180] Similarly, anionic and neutral liposomes are readily
available, such as from Avanti Polar Lipids (Birmingham, Ala.), or
can be easily prepared using readily available materials. Such
materials include phosphatidyl choline, cholesterol, phosphatidyl
ethanolamine, dioleoylphosphatidyl choline (DOPC),
dioleoylphosphatidyl glycerol (DOPG), dioleoylphoshatidyl
ethanolamine (DOPE), among others. These materials can also be
mixed with the DOTMA and DOTAP starting materials in appropriate
ratios. Methods for making liposomes using these materials are well
known in the art.
[0181] The liposomes can comprise multilammelar vesicles (MLVs),
small unilamellar vesicles (SUVs), or large unilamellar vesicles
(LUVs). The various liposome-nucleic acid complexes are prepared
using methods known in the art See eg. Straubinger (1983) Meth.
Immunol. 101:512-527; Szoka (1978) Proc. Natl. Acad. Sci. USA
75:4194-4198; Papahadjopoulos (1975) Biochim. Biophys. Acta
394:483; Wilson (1979) Cell 17:77); Deamer & Bangham (1976)
Biochim. Biophys. Acia 443:629; Ostro (1977) Biochem. Biophys. Res.
Commun. 76:836; Fraley (1979) Proc. Natl. Acad. Sci. USA 76:3348);
Enoch & Strittmatter (1979) Proc. Natl. Acad. Sci. USA 76:145;
Fraley (1980) J. Biol. Chem. (1980) 255:10431; Szoka &
Papahadjopoulos (1978) Proc. Natl. Acad. Sci. USA 75:145; and
Schaefer-Ridder (1982) Science 215:166.
[0182] E. Lipoproteins
[0183] In addition, lipoproteins can be included with the
polynucleotide/polypeptide to be delivered. Examples of
lipoproteins to be utilized include: chylomicrons, HDL, DL, LDL,
and VLDL. Mutants, fragments, or fusions of these proteins can also
be used. Also, modifications of naturally occurring lipoproteins
can be used, such as acetylated LDL. These lipoproteins can target
the delivery of polynucleotides to cells expressing lipoprotein
receptors. Preferably, if lipoproteins are including with the
polynucleotide to be delivered, no other targeting ligand is
included in the composition.
[0184] Naturally occurring lipoproteins comprise a lipid and a
protein portion. The protein portion are known as apoproteins. At
the present, apoproteins A, B, C, D, and E have been isolated and
identified. At least two of these contain several proteins,
designated by Roman numerals, AI, AII, AIV; CI, CII, CIII.
[0185] A lipoprotein can comprise more than one apoprotein. For
example, naturally occurring chylomicrons comprises of A, B, C, and
E, over time these lipoproteins lose A and acquire C and E
apoproteins. VLDL comprises A, B, C, and E apoproteins, LDL
comprises apoprotein B; and HDL comprises apoproteins A, C, and
E.
[0186] The amino acid of these apoproteins are known and are
described in, for example, Breslow (1985) Annu Rev. Biochem 54:699;
Law (1986) Adv. Exp Med. Biol. 151:162; Chen (1986) J Biol Chem
261:12918; Kane (1980) Proc Natl Acad Sci USA 77:2465; and Utermann
(1984) Hum Genet 65:232.
[0187] Lipoproteins contain a variety of lipids including,
triglycerides, cholesterol (free and esters), and phospholipids.
The composition of the lipids varies in naturally occurring
lipoproteins. For example, chylomicrons comprise mainly
triglycerides. A more detailed description of the lipid content of
naturally occurring lipoproteins can be found, for example, in
Meth. Enzymol. 128 (1986). The composition of the lipids are chosen
to aid in conformation of the apoprotein for receptor binding
activity. The composition of lipids can also be chosen to
facilitate hydrophobic interaction and association with the
polynucleotide binding molecule.
[0188] Naturally occurring lipoproteins can be isolated from serum
by ultracentrifugation, for instance. Such methods are described in
Meth. Enzymol. (supra); Pitas (1980) J. Biochem. 255:5454-5460 and
Mahey (1979) J. Clin. Invest 64:743-750. Lipoproteins can also be
produced by in vitro or recombinant methods by expression of the
apoprotein genes in a desired host cell. See, for example, Atkinson
(1986) Annu Rev Biophys Chem 15:403 and Radding (1958) Biochim
Biophys Acia 30: 443. Lipoproteins can also be purchased from
commercial suppliers, such as Biomedical Techniologies, Inc.,
Stoughton, Mass., USA. Further description of lipoproteins can be
found in Zuckermann et al. PCT/US97/14465.
[0189] F. Polycationic Agents
[0190] Polycationic agents can be included, with or without
lipoprotein, in a composition with the desired
polynucleotide/polypeptide to be delivered.
[0191] Polycationic agents, typically, exhibit a net positive
charge at physiological relevant pH and are capable of neutralizing
the electrical charge of nucleic acids to facilitate delivery to a
desired location. These agents have both in vitro, ex vivo, and in
vivo applications. Polycationic agents can be used to deliver
nucleic acids to a living subject either intramuscularly,
subcutaneously, etc.
[0192] The following are examples of useful polypeptides as
polycationic agents: polylysine, polyarginine, polyornithine, and
protamine. Other examples include histones, protamines, human serum
albumin, DNA binding proteins, non-histone chromosomal proteins,
coat proteins from DNA viruses, such as (X174, transcriptional
factors also contain domains that bind DNA and therefore may be
useful as nucleic aid condensing agents. Briefly, transcriptional
factors such as C/CEBP, c-jun, c-fos, AP-1, AP-2, AP-3, CPF,
Prot-1, Sp-1, Oct-1, Oct-2, CREP, and TFIID contain basic domains
that bind DNA sequences.
[0193] Organic polycationic agents include: spermine, spermidine,
and purtrescine.
[0194] The dimensions and of the physical properties of a
polycationic agent can be extrapolated from the list above, to
construct other polypeptide polycationic agents or to produce
synthetic polycationic agents.
[0195] Synthetic polycationic agents which are useful include, for
example, DEAE-dextran, polybrene. Lipofectin.TM., and
lipofectAMINE.TM. are monomers that form polycationic complexes
when combined with polynucleotides/polypeptides.
[0196] Immunodiagnostic Assays
[0197] Neisserial antigens of the invention can be used in
immunoassays to detect antibody levels (or, conversely,
anti-Neisserial antibodies can be used to detect antigen levels).
Immunoassays based on well defined, recombinant antigens can be
developed to replace invasive diagnostics methods. Antibodies to
Neisserial proteins within biological samples, including for
example, blood or serum samples, can be detected. Design of the
immunoassays is subject to a great deal of variation, and a variety
of these are known in the art. Protocols for the immunoassay may be
based, for example, upon competition, or direct reaction, or
sandwich type assays. Protocols may also, for example, use solid
supports, or may be by immunoprecipitation. Most assays involve the
use of labeled antibody or polypeptide; the labels may be, for
example, fluorescent, chemiluminescent, radioactive, or dye
molecules. Assays which amplify the signals from the probe are also
known; examples of which are assays which utilize biotin and
avidin, and enzyme-labeled and mediated immunoassays, such as ELISA
assays.
[0198] Kits suitable for immunodiagnosis and containing the
appropriate labeled reagents are constructed by packaging the
appropriate materials, including the compositions of the invention,
in suitable containers, along with the remaining reagents and
materials (for example, suitable buffers, salt solutions, etc.)
required for the conduct of the assay, as well as suitable set of
assay instructions.
[0199] Nucleic Acid Hybridisation
[0200] "Hybridization" refers to the association of two nucleic
acid sequences to one another by hydrogen bonding. Typically, one
sequence will be fixed to a solid support and the other will be
free in solution. Then, the two sequences will be placed in contact
with one another under conditions that favor hydrogen bonding.
Factors that affect this bonding include: the type and volume of
solvent; reaction temperature; time of hybridization; agitation;
agents to block the non-specific attachment of the liquid phase
sequence to the solid support (Denhardt's reagent or BLOTTO);
concentration of the sequences; use of compounds to increase the
rate of association of sequences (dextran sulfate or polyethylene
glycol); and the stringency of the washing conditions following
hybridization. See Sambrook et al. [supra] Volume 2, chapter 9,
pages 9.47 to 9.57.
[0201] "Stringency" refers to conditions in a hybridization
reaction that favor association of very similar sequences over
sequences that differ. For example, the combination of temperature
and salt concentration should be chosen that is approximately 120
to 200.degree. C. below the calculated Tm of the hybrid under
study. The temperature and salt conditions can often be determined
empirically in preliminary experiments in which samples of genomic
DNA immobilized on filters are hybridized to the sequence of
interest and then washed under conditions of different
stringencies. See Sambrook et al. at page 9.50.
[0202] Variables to consider when performing, for example, a
Southern blot are (1) the complexity of the DNA being blotted and
(2) the homology between the probe and the sequences being
detected. The total amount of the fragment(s) to be studied can
vary a magnitude of 10, from 0.1 to 1 g for a plasmid or phage
digest to 10.sup.-9 to 10.sup.-8 g for a single copy gene in a
highly complex eukaryotic genome. For lower complexity
polynucleotides, substantially shorter blotting, hybridization, and
exposure times, a smaller amount of starting polynucleotides, and
lower specific activity of probes can be used. For example, a
single-copy yeast gene can be detected with an exposure time of
only 1 hour starting with 1 .mu.g of yeast DNA, blotting for two
hours, and hybridizing for 4-8 hours with a probe of 10.sup.8
cpm/.mu.g. For a single-copy mammalian gene a conservative approach
would start with 10 .mu.g of DNA, blot overnight, and hybridize
overnight in the presence of 10% dextran sulfate using a probe of
greater than 10.sup.8 cpm/.mu.g, resulting in an exposure time of
24 hours.
[0203] Several factors can affect the melting temperature (Tm) of a
DNA-DNA hybrid between the probe and the fragment of interest, and
consequently, the appropriate conditions for hybridization and
washing. In many cases the probe is not 100% homologous to the
fragment. Other commonly encountered variables include the length
and total G+C content of the hybridizing sequences and the ionic
strength and formamide content of the hybridization buffer. The
effects of all of these factors can be approximated by a single
equation:
Tm--81+16.6(log.sub.10 Ci)+0.4[% (G+C)]-0.6(%
formamide)-600/n-1.5(% mismatch).
[0204] where Ci is the salt concentration (monovalent ions) and n
is the length of the hybrid in base pairs (slightly modified from
Meinkoth & Wahl (1984) Anal. Biochem. 138: 267-284).
[0205] In designing a hybridization experiment, some factors
affecting nucleic acid hybridization can be conveniently altered.
The temperature of the hybridization and washes and the salt
concentration during the washes are the simplest to adjust. As the
temperature of the hybridization increases (ie. stringency), it
becomes less likely for hybridization to occur between strands that
are nonhomologous, and as a result, background decreases. If the
radiolabeled probe is not completely homologous with the
immobilized fragment (as is frequently the case in gene family and
interspecies hybridization experiments), the hybridization
temperature must be reduced, and background will increase. The
temperature of the washes affects the intensity of the hybridizing
band and the degree of background in a similar manner. The
stringency of the washes is also increased with decreasing salt
concentrations.
[0206] In general, convenient hybridization temperatures in the
presence of 50% formamide are 42.degree. C. for a probe with is 95%
to 100% homologous to the target fragment, 37.degree. C. for 90% to
95% homology, and 32.degree. C. for 85% to 90% homology. For lower
homologies, formamide content should be lowered and temperature
adjusted accordingly, using the equation above. If the homology
between the probe and the target fragment are not known, the
simplest approach is to start with both hybridization and wash
conditions which are nonstringent. If non-specific bands or high
background are observed after autoradiography, the filter can be
washed at high stringency and reexposed. If the time required for
exposure makes this approach impractical, several hybridization
and/or washing stringencies should be tested in parallel.
[0207] Nucleic Acid Probe Assays
[0208] Methods such as PCR, branched DNA probe assays, or blotting
techniques utilizing nucleic acid probes according to the invention
can determine the presence of cDNA or mRNA. A probe is said to
"hybridize" with a sequence of the invention if it can form a
duplex or double stranded complex, which is stable enough to be
detected.
[0209] The nucleic acid probes will hybridize to the Neisserial
nucleotide sequences of the invention (including both sense and
antisense strands). Though many different nucleotide sequences will
encode the amino acid sequence, the native Neisserial sequence is
preferred because it is the actual sequence present in cells. mRNA
represents a coding sequence and so a probe should be complementary
to the coding sequence; single-stranded cDNA is complementary to
mRNA, and so a cDNA probe should be complementary to the non-coding
sequence.
[0210] The probe sequence need not be identical to the Neisserial
sequence (or its complement)--some variation in the sequence and
length can lead to increased assay sensitivity if the nucleic acid
probe can form a duplex with target nucleotides, which can be
detected. Also, the nucleic acid probe can include additional
nucleotides to stabilize the formed duplex. Additional Neisserial
sequence may also be helpful as a label to detect the formed
duplex. For example, a non-complementary nucleotide sequence may be
attached to the 5' end of the probe, with the remainder of the
probe sequence being complementary to a Neisserial sequence.
Alternatively, non-complementary bases or longer sequences can be
interspersed into the probe, provided that the probe sequence has
sufficient complementarity with the a Neisserial sequence in order
to hybridize therewith and thereby form a duplex which can be
detected.
[0211] The exact length and sequence of the probe will depend on
the hybridization conditions, such as temperature, salt condition
and the like. For example, for diagnostic applications, depending
on the complexity of the analyte sequence, the nucleic acid probe
typically contains at least 10-20 nucleotides, preferably 15-25,
and more preferably at least 30 nucleotides, although it may be
shorter than this. Short primers generally require cooler
temperatures to form sufficiently stable hybrid complexes with the
template.
[0212] Probes may be produced by synthetic procedures, such as the
triester method of Matteucci et al. [J. Am. Chem. Soc. (1981)
103:3185], or according to Urdea et al. [Proc. Natl. Acad. Sci. USA
(1983) 80: 7461], or using commercially available automated
oligonucleotide synthesizers.
[0213] The chemical nature of the probe can be selected according
to preference. For certain applications, DNA or RNA are
appropriate. For other applications, modifications may be
incorporated eg. backbone modifications, such as phosphorothioates
or methylphosphonates, can be used to increase in vivo half-life,
alter RNA affinity, increase nuclease resistance etc. [eg. see
Agrawal & Iyer (1995) Curr Opin Biotechnol 6:12-19; Agrawal
(1996) TIBTECH 14:376-387]; analogues such as peptide nucleic acids
may also be used [eg. see Corey (1997) TIBTECH 15:224-229; Buchardt
et al. (1993) TIBTECH 11:384-386].
[0214] Alternatively, the polymerase chain reaction (PCR) is
another well-known means for detecting small amounts of target
nucleic acids. The assay is described in: Mullis et al. [Meth.
Enzymol. (1987) 155: 335-350]; U.S. Pat. Nos. 4,683,195 and
4,683,202. Two "primer" nucleotides hybridize with the target
nucleic acids and are used to prime the reaction. The primers can
comprise sequence that does not hybridize to the sequence of the
amplification target (or its complement) to aid with duplex
stability or, for example, to incorporate a convenient restriction
site. Typically, such sequence will flank the desired Neisserial
sequence.
[0215] A thermostable polymerase creases copies of target nucleic
acids from the primers using the original target nucleic acids as a
template. After a threshold amount of target nucleic acids are
generated by the polymerase, they can be detected by more
traditional methods, such as Southern blots. When using the
Southern blot method, the labelled probe will hybridize to the
Neisserial sequence (or its complement).
[0216] Also, mRNA or cDNA can be detected by traditional blotting
techniques described in Sambrook et al [supra]. mRNA, or cDNA
generated from mRNA using a polymerase enzyme, can be purified and
separated using gel electrophoresis. The nucleic acids on the gel
are then blotted onto a solid support, such as nitrocellulose. The
solid support is exposed to a labelled probe and then washed to
remove any unhybridized probe. Next, the duplexes containing the
labeled probe are detected. Typically, the probe is labelled with a
radioactive moiety.
BRIEF DESCRIPTION OF THE DRAWINGS
[0217] FIGS. 1-7 show biochemical data and sequence analysis
pertaining to Examples 1, 2, 3, 7, 13, 16 and 19, respectively,
with ORFs 40, 38, 44, 52, 114, 41 and 124. M1 and M2 are molecular
weight markers. Arrows indicate the position of the main
recombinant product or, in Western blots, the position of the main
N. meningitidis immunoreactive band. TP indicates N. meningitidis
total protein extract; OMV indicates N. meningitidis outer membrane
vesicle preparation. In bactericidal assay results: a diamond
(.diamond-solid.) shows preimmune data; a triangle
(.tangle-solidup.) shows GST control data; a circle
(.circle-solid.) shows data with recombinant N. meningitidis
protein. Computer analyses show a hydrophilicity plot (upper), an
antigenic index plot (middle), and an AMPHI analysis (lower). The
AMPHI program has been used to predict T-cell epitopes [Gao et al.
(1989) J. Immunol. 143:3007; Roberts et al. (1996) AIDS Res Hum
Retrovir 12:593; Quakyi et al. (1992) Scand J Immunol suppl. 11:9)
and is available in the Protean package of DNASTAR, Inc. (1228
South Park Street, Madison, Wis. 53715 USA).
[0218] FIG. 8 shows an alignment comparison of amino acid sequences
for ORF 40 for several strains of Neisseria. Dark shading indicates
regions of homology, and gray shading indicates the conservation of
amino acids with similar characteristics. The Figure demonstrates a
high degree of conservation among the various strains, further
confirming its utility as an antigen for both vaccines and
diagnostics.
EXAMPLES
[0219] The examples describe nucleic acid sequences which have been
identified in N. meningitidis, along with their putative
translation products. Not all of the nucleic acid sequences are
complete ie. they encode less than the full-length wild-type
protein. It is believed at present that none of the DNA sequences
described herein have significant homologs in N. gonorrhoeae.
[0220] The examples are generally in the following format:
[0221] a nucleotide sequence which has been identified in N.
meningitidis (strain B)
[0222] the putative translation product of this sequence
[0223] a computer analysis of the translation product based on
database comparisons
[0224] a corresponding gene and protein sequence identified in N.
meningitidis (strain A)
[0225] a description of the characteristics of the proteins which
indicates that they might be suitably antigenic
[0226] results of biochemical analysis (expression, purification,
ELISA, FACS etc.)
[0227] The examples typically include details of sequence homology
between species and strains. Proteins that are similar in sequence
are generally similar in both structure and function, and the
homology often indicates a common evolutionary origin. Comparison
with sequences of proteins of known function is widely used as a
guide for the assignment of putative protein function to a new
sequence and has proved particularly useful in whole-genome
analyses.
[0228] Sequence comparisons were performed at NCBI
(http://www.ncbi.nlm.ni- h.gov) using the algorithms BLAST, BLAST2,
BLASTn, BLASTp, tBLASTn, BLASTx, & tBLASTx [eg. see also
Altschul et al. (1997) Gapped BLAST and PSI-BLAST: a new generation
of protein database search programs. Nucleic Acids Research
25:2289-3402]. Searches were performed against the following
databases: non-redundant GenBank+EMBL+DDBJ+PDB sequences and
non-redundant GenBank CDS translations+PDB+SwissProt+SPupdate+PIR
sequences.
[0229] Dots within nucleotide sequences (eg. position 288 in
Example 12) represent nucleotides which have been arbitrarily
introduced in order to maintain a reading frame. In the same way,
double-underlined nucleotides were removed. Lower case letters (eg.
position 589 in Example 12) represent ambiguities which arose
during alignment of independent sequencing reactions (some of the
nucleotide sequences in the examples are derived from combining the
results of two or more experiments).
[0230] Nucleotide sequences were scanned in all six reading frames
to predict the presence of hydrophobic domains using an algorithm
based on the statistical studies of Esposti et al. [Critical
evaluation of the hydropathy of membrane proteins (1990) Eur J
Biochem 190:207-219]. These domains represent potential
transmembrane regions or hydrophobic leader sequences.
[0231] Open reading frames were predicted from fragmented
nucleotide sequences using the program ORFFINDER (NCBI).
[0232] Underlined amino acid sequences indicate possible
transmembrane domains or leader sequences in the ORFs, as predicted
by the PSORT algorithm (http://www.psort.nibb.ac.jp). Functional
domains were also predicted using the MOTIFS program (GCG Wisconsin
& PROSITE).
[0233] Various tests can be used to assess the in vivo
immunogenicity of the proteins identified in the examples. For
example, the proteins can be expressed recombinantly and used to
screen patient sera by immunoblot A positive reaction between the
protein and patient serum indicates that the patient has previously
mounted an immune response to the protein in question ie. the
protein is an immunogen. This method can also be used to identify
immunodominant proteins.
[0234] The recombinant protein can also be conveniently used to
prepare antibodies eg. in a mouse. These can be used for direct
confirmation that a protein is located on the cell-surface.
Labelled antibody (eg. fluorescent labelling for FACS) can be
incubated with intact bacteria and the presence of label on the
bacterial surface confirms the location of the protein.
[0235] In particular, the following methods (A) to (S) were used to
express, purify and biochemically characterise the proteins of the
invention:
[0236] A) Chromosomal DNA Preparation
[0237] N. meningitidis strain 2996 was grown to exponential phase
in 100 ml of GC medium, harvested by centrifugation, and
resuspended in 5 ml buffer (20% Sucrose, 50 mM Tris-HCl, 50 mM
EDTA, pH8). After 10 minutes incubation on ice, the bacteria were
lysed by adding 10 ml lysis solution (50 mM NaCl, 1% Na-Sarkosyl,
50 .mu.g/ml Proteinase K), and the suspension was incubated at
37.degree. C. for 2 hours. Two phenol extractions (equilibrated to
pH 8) and one ChCl.sub.3/isoamylalcohol (24:1) extraction were
performed. DNA was precipitated by addition of 0.3M sodium acetate
and 2 volumes ethanol, and was collected by centrifugation. The
pellet was washed once with 70% ethanol and redissolved in 4 ml
buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8). The DNA concentration was
measured by reading the OD at 260 nm.
[0238] B) Oligonucleotide Design
[0239] Synthetic oligonucleotide primers were designed on the basis
of the coding sequence of each ORF, using (a) the meningococcus B
sequence when available, or (b) the gonococcus/meningococcus A
sequence, adapted to the codon preference usage of meningococcus as
necessary. Any predicted signal peptides were omitted, by deducing
the 5'-end amplification primer sequence immediately downstream
from the predicted leader sequence.
[0240] The 5' primers included two restriction enzyme recognition
sites (BamHI-NdeI, BamHI-NheI, or EcoRI-NheI, depending on the
gene's own restriction pattern); the 3' primers included a XhoI
restriction site. This procedure was established in order to direct
the cloning of each amplification product (corresponding to each
ORF) into two different expression systems: pGEX-KG (using either
BamHI-XhoI or EcoRI-XhoI), and pET21b+ (using either NdeI-XhoI or
NheI-XhoI).
1 5'end primer tail: CGCGGATCCCATATG (BamHI-NdeI) CGCGGATCCGCTAGC
(BamHI-NheI) CCGGAATTCTAGCTAGC (EcoRI-NheI) 3'-end primer tail:
CCCGCTCGAG (XhoI)
[0241] As well as containing the restriction enzyme recognition
sequences, the primers included nucleotides which hybridised to the
sequence to be amplified. The number of hybridizing nucleotides
depended on the melting temperature of the whole primer, and was
determined for each primer using the formulae:
T.sub.m=4 (G+C)+2 (A+T) (tail excluded)
T.sub.m=64.9+0.41 (% GC)-600/N (whole primer)
[0242] The average melting temperature of the selected oligos were
65-70.degree. C. for the whole oligo and 50-55.degree. C. for the
hybridising region alone.
[0243] Table I shows the forward and reverse primers used for each
amplification. Oligos were synthesized by a Perkin Elmer 394
DNA/RNA Synthesizer, eluted from the columns in 2 ml NH.sub.4OH,
and deprotected by 5 hours incubation at 56.degree. C. The oligos
were precipitated by addition of 0.3M Na-Acetate and 2 volumes
ethanol. The samples were then centrifuged and the pellets
resuspended in either 100 .mu.l or 1 ml of water. OD.sub.260 was
determined using a Perkin Elmer Lambda Bio spectrophotometer and
the concentration was determined and adjusted to 2-10
pmol/.mu.l.
2TABLE I PCR primers ORF Primer Sequence Restriction sites ORF 38
Forward CGCGGATCCCATATG-TCGCCGCAA- AATTCCGA BamHI-NdeI <SEQ ID
112> Reverse CCCGCTCGAG-TTTTGCCGCGTTAAAAGC XhoI <SEQ ID
113> ORF 40 Forward CGCGGATCCCATATG-ACCGTGAAGACCGCC BamHI-NdeI
<SEQ ID 114> Reverse CCCGCTCGAG-CCACTGATAACCGACAGA XhoI
<SEQ ID 115> ORF 41 Forward
CGCGGATCCCATATG-TATTTGAAACAGCTCCAAG BamHI-NdeI <SEQ ID 116>
Reverse CCCGCTCGAG-TTCTGGGTGAATGTTA XhoI <SEQ ID 117> ORF 44
Forward GCGGATCCCATATG-GGCACGGACAACCCC BamHI-NdeI <SEQ ID
118> Reverse CCCGCTCGAG-ACGTGGGGAACAGTCT XhoI <SEQ ID 119>
ORF 51 Forward GCGGATCCCATATG-AAAAATATTCAAGTAGTTGC BamHI-NdeI
<SEQ ID 120> Reverse CCCGCTCGAG-AAGTTTGATTAAACCCG XhoI
<SEQ ID 121> ORF 52 Forward CGCGGATCCCATATG-TGCCAACCGCAATCCG
BamHI-NdeI <SEQ ID 122> Reverse CCCGCTCGAG-TTTTTCCAGCTCCGGCA
XhoI <SEQ ID 123> ORF 56 Forward
GCGGATCCCATATG-GTTATCGGAATATTACTCG BamHI-NdeI <SEQ ID 124>
Reverse CCCGCTCGAG-GGCTGCAGAAGCTGG XhoI <SEQ ID 125> ORF 69
Forward CGCGGATCCCATATG-CGGACGTGGTTGGTTTT BamHI-NdeI <SEQ ID
126> Reverse CCCGCTCGAG-ATATCTTCCGTTTTTTTCAC XhoI <SEQ ID
127> ORF 82 Forward CGCGGATCCGCTAGC-GTAAATTTATTATTTTTAGAA
BamHI-NheI <SEQ ID 128> Reverse CCCGCTCGAG-TCCAACTCATTGAAGTA
XhoI <SEQ ID 129> ORF 114 Forward
CGCGGATCCCATATG-AATAAAGGTTTACATCGCAT BamHI-NheI <SEQ ID 130>
Reverse CCCGCTCGAG-AATCGCTGCACCGGCT XhoI <SEQ ID 131> ORF 124
Forward CGCGGATCCCATATG-ACTGCCTTTTCGAC- A BamHI-NheI <SEQ ID
132> Reverse CCCGCTCGAG-GCGTGAAGCGTCAGGA XhoI <SEQ ID
133>
[0244] C) Amplification
[0245] The standard PCR protocol was as follows: 50-200 ng of
genomic DNA were used as a template in the presence of 20-40 .mu.M
of each oligo, 400-8004M dNTs solution, 1.times.PCR buffer
(including 1.5 mM MgCl.sub.2), 2.5 units TaqI DNA polymerase (using
Perkin-Elmer AmpliTaQ, GIBCO Platinum, Pwo DNA polymerase, or
Tahara Shuzo Taq polymerase).
[0246] In some cases, PCR was optimised by the addition of 10 .mu.l
DMSO or 50 .mu.l 2M betaine.
[0247] After a hot start (adding the polymerase during a
preliminary 3 minute incubation of the whole mix at 95.degree. C.),
each sample underwent a double-step amplification: the first 5
cycles were performed using as the hybridization temperature the
one of the oligos excluding the restriction enzymes tail, followed
by 30 cycles performed according to the hybridization temperature
of the whole length oligos. The cycles were followed by a final 10
minute extension step at 72.degree. C.
[0248] The standard cycles were as follows:
3 Denaturation Hybridisation Elongation First 5 cycles 30 seconds
30 seconds 30-60 seconds 95.degree. C. 50-55.degree. C. 72.degree.
C. Last 30 cycles 30 seconds 30 seconds 30-60 seconds 95.degree. C.
65-70.degree. C. 72.degree. C.
[0249] The elongation time varied according to the length of the
ORF to be amplified.
[0250] The amplifications were performed using either a 9600 or a
2400 Perkin Elmer GeneAmp PCR System. To check the results,
{fraction (1/10)} of the amplification volume was loaded onto a
1-1.5% agarose gel and the size of each amplified fragment compared
with a DNA molecular weight marker.
[0251] The amplified DNA was either loaded directly on a 1% agarose
gel or first precipitated with ethanol and resuspended in a
suitable volume to be loaded on a 1% agarose gel. The DNA fragment
corresponding to the right size band was then eluted and purified
from gel, using the Qiagen Gel Extraction Kit, following the
instructions of the manufacturer. The final volume of the DNA
fragment was 30 .mu.l or 500 of either water or 10 mM Tris, pH
8.5.
[0252] D) Digestion of PCR Fragments
[0253] The purified DNA corresponding to the amplified fragment was
split into 2 aliquots and double-digested with:
[0254] NdeI/XhoI or NheI/XhoI for cloning into pET-21b+ and further
expression of the protein as a C-terminus His-tag fusion
[0255] BamHI/XhoI or EcoRI/XhoI for cloning into pGEX-KG and
further expression of the protein as N-terminus GST fusion.
[0256] EcoRI/PstI, EcoRI/SalI, SalI/PstI for cloning into pGex-His
and further expression of the protein as N-terminus His-tag
fusion
[0257] Each purified DNA fragment was incubated (37.degree. C. for
3 hours to overnight) with 20 units of each restriction enzyme (New
England Biolabs) in a either 30 or 40 .mu.l final volume in the
presence of the appropriate buffer. The digestion product was then
purified using the QIAquick PCR purification kit, following the
manufacturer's instructions, and eluted in a final volume of 30 or
50 .mu.l of either water or 10 mM Tris-HCl, pH 8.5. The final DNA
concentration was determined by 1% agarose gel electrophoresis in
the presence of titrated molecular weight marker.
[0258] E) Digestion of the Cloning Vectors (pET22B, pGEX-KG,
pTRC-His A, and pGex-His)
[0259] 10 .mu.g plasmid was double-digested with 50 units of each
restriction enzyme in 200 .mu.l reaction volume in the presence of
appropriate buffer by overnight incubation at 37.degree. C. After
loading the whole digestion on a 1% agarose gel, the band
corresponding to the digested vector was purified from the gel
using the Qiagen QIAquick-Gel Extraction Kit and the DNA was eluted
in 50 .mu.l of 10 mM Tris-HCl, pH 8.5. The DNA concentration was
evaluated by measuring OD.sub.260 of the sample, and adjusted to 50
.mu.g/.mu.l. 1 .mu.l of plasmid was used for each cloning
procedure.
[0260] The vector pGEX-His is a modified pGEX-2T vector carrying a
region encoding six histidine residues upstream to the thrombin
cleavage site and containing the multiple cloning site of the
vector pTRC99 (Pharmacia).
[0261] F) Cloning
[0262] The fragments corresponding to each ORF, previously digested
and purified, were ligated in both pET22b and pGEX-KG. In a final
volume of 20 .mu.l, a molar ratio of 3:1 fragment/vector was
ligated using 0.5 .mu.l of NEB T4 DNA ligase (400 units/.mu.l), in
the presence of the buffer supplied by the manufacturer. The
reaction was incubated at room temperature for 3 hours. In some
experiments, ligation was performed using the Boehringer "Rapid
Ligation Kit", following the manufacturer's instructions.
[0263] In order to introduce the recombinant plasmid in a suitable
strain, 100 .mu.l E. coli DH5 competent cells were incubated with
the ligase reaction solution for 40 minutes on ice, then at
37.degree. C. for 3 minutes, then, after adding 800 .mu.l LB broth,
again at 37.degree. C. for 20 minutes. The cells were then
centrifuged at maximum speed in an Eppendorf microfuge and
resuspended in approximately 200 .mu.l of the supernatant. The
suspension was then plated on LB ampicillin (100 mg/ml).
[0264] The screening of the recombinant clones was performed by
growing 5 randomly-chosen colonies overnight at 37.degree. C. in
either 2 ml (pGEX or pTC clones) or 5 ml (pET clones) LB broth+100
.mu.g/ml ampicillin. The cells were then pelletted and the DNA
extracted using the Qiagen QIAprep Spin Miniprep Kit, following the
manufacturer's instructions, to a final volume of 30 .mu.l. 5 .mu.l
of each individual miniprep (approximately 1 g) were digested with
either NdeI/XhoI or BamHI/XhoI and the whole digestion loaded onto
a 1-1.5% agarose gel (depending on the expected insert size), in
parallel with the molecular weight marker (1 Kb DNA Ladder, GIBCO).
The screening of the positive clones was made on the base of the
correct insert size.
[0265] G) Expression
[0266] Each ORF cloned into the expression vector was transformed
into the strain suitable for expression of the recombinant protein
product. 1 .mu.l of each construct was used to transform 30 .mu.l
of E. coli BL21 (pGEX vector), E. coli TOP 10 (pTRC vector) or E.
coli BL21-DE3 (pET vector), as described above. In the case of the
pGEX-His vector, the same E. coli strain (W3110) was used for
initial cloning and expression. Single recombinant colonies were
inoculated into 2 ml LB+Amp (100 .mu.g/ml), incubated at 37.degree.
C. overnight, then diluted 1:30 in 20 ml of LB+Amp (100 .mu.g/ml)
in 100 ml flasks, making sure that the OD.sub.600 ranged between
0.1 and 0.15. The flasks were incubated at 30.degree. C. into
gyratory water bath shakers until OD indicated exponential growth
suitable for induction of expression (0.4-0.8 OD for pET and pTRC
vectors; 0.8-1 OD for pGEX and pGEX-His vectors). For the pET, pTRC
and pGEX-His vectors, the protein expression was induced by
addition of 1 mM IPTG, whereas in the case of pGEX system the final
concentration of IPTG was 0.2 mM. After 3 hours incubation at
30.degree. C., the final concentration of the sample was checked by
OD. In order to check expression, 1 ml of each sample was removed,
centrifuged in a microfuge, the pellet resuspended in PBS, and
analysed by 12% SDS-PAGE with Coomassie Blue staining. The whole
sample was centrifuged at 6000 g and the pellet resuspended in PBS
for further use.
[0267] H) GST-Fusion Proteins Large-Scale Purification.
[0268] A single colony was grown overnight at 37.degree. C. on
LB+Amp agar plate. The bacteria were inoculated into 20 ml of
LB+Amp liquid culture in a water bath shaker and grown overnight.
Bacteria were diluted 1:30 into 600 ml of fresh medium and allowed
to grow at the optimal temperature (20-37.degree. C.) to OD.sub.550
0.8-1. Protein expression was induced with 0.2 mM IPTG followed by
three hours incubation. The culture was centrifuged at 800 rpm at
4.degree. C. The supernatant was discarded and the bacterial pellet
was resuspended in 7.5 ml cold PBS. The cells were disrupted by
sonication on ice for 30 sec at 40 W using a Branson sonifier B-15,
frozen and thawed twice and centrifuged again. The supernatant was
collected and mixed with 150 .mu.l Glutatione-Sepharose 4B resin
(Pharmacia) (previously washed with PBS) and incubated at room
temperature for 30 minutes. The sample was centrifuged at 700 g for
5 minutes at 4.degree. C. The resin was washed twice with 10 ml
cold PBS for 10 minutes, resuspended in 1 ml cold PBS, and loaded
on a disposable column. The resin was washed twice with 2 ml cold
PBS until the flow-through reached OD.sub.280 of 0.02-0.06. The
GST-fusion protein was eluted by addition of 70011 cold Glutathione
elution buffer (10 mM reduced glutathione, 50 mM Tris-HCl) and
fractions collected until the OD.sub.280 was 0.1. 21 .mu.l of each
fraction were loaded on a 12% SDS gel using either Biorad SDS-PAGE
Molecular weight standard broad range (M1) (200, 116.25, 97.4,
66.2, 45, 31, 21.5, 14.4, 6.5 kDa) or Amersham Rainbow Marker (M2)
(220, 66, 46, 30, 21.5, 14.3 kDa) as standards. As the MW of GST is
26 kDa, this value must be added to the MW of each GST-fusion
protein.
[0269] I) His-Fusion Solubility Analysis
[0270] To analyse the solubility of the His-fusion expression
products, pellets of 3 ml cultures were resuspended in buffer M1
[500 .mu.l PBS pH 7.2]. 25 .mu.l lysozyme (10 mg/ml) was added and
the bacteria were incubated for 15 min at 4.degree. C. The pellets
were sonicated for 30 sec at 40 W using a Branson sonifier B-15,
frozen and thawed twice and then separated again into pellet and
supernatant by a centrifugation step. The supernatant was collected
and the pellet was resuspended in buffer M2 [8M urea, 0.5M NaCl, 20
mM imidazole and 0.1M NaH.sub.2 PO.sub.4] and incubated for 3 to 4
hours at 4.degree. C. After centrifugation, the supernatant was
collected and the pellet was resuspended in buffer M3 [6M
guanidinium-HCl, 0.5M NaCl, 20 mM imidazole and 0.1M
NaH.sub.2PO.sub.4] overnight at 4.degree. C. The supernatants from
all steps were analysed by SDS-PAGE.
[0271] J) His-Fusion Large-Scale Purification.
[0272] A single colony was grown overnight at 37.degree. C. on a
LB+Amp agar plate. The bacteria were inoculated into 20 ml of
LB+Amp liquid culture and incubated overnight in a water bath
shaker. Bacteria were diluted 1:30 into 600 ml fresh medium and
allowed to grow at the optimal temperature (20-37.degree. C.) to
OD.sub.550 0.6-0.8. Protein expression was induced by addition of 1
mM IPTG and the culture further incubated for three hours. The
culture was centrifuged at 8000 rpm at 4.degree. C., the
supernatant was discarded and the bacterial pellet was resuspended
in 7.5 ml of either (i) cold buffer A (300 mM NaCl, 50 mM phosphate
buffer, 10 mM imidazole, pH 8) for soluble proteins or (ii) buffer
B (urea 8M, 10 mM Tris-HCl, 100 mM phosphate buffer, pH 8.8) for
insoluble proteins.
[0273] The cells were disrupted by sonication on ice for 30 sec at
40 W using a Branson sonifier B-15, frozen and thawed two times and
centrifuged again.
[0274] For insoluble proteins, the supernatant was stored at
-20.degree. C., while the pellets were resuspended in 2 ml buffer C
(6M guanidine hydrochloride, 100 mM phosphate buffer, 10 mM
Tris-HCl, pH 7.5) and treated in a homogenizer for 10 cycles. The
product was centrifuged at 13000 rpm for 40 minutes.
[0275] Supernatants were collected and mixed with 150 .mu.l
Ni.sup.2+-resin (Pharmacia) (previously washed with either buffer A
or buffer B, as appropriate) and incubated at room temperature with
gentle agitation for 30 minutes. The sample was centrifuged at 700
g for 5 minutes at 4.degree. C. The resin was washed twice with 10
ml buffer A or B for 10 minutes, resuspended in 1 ml buffer A or B
and loaded on a disposable column. The resin was washed at either
(i) 4.degree. C. with 2 ml cold buffer A or (ii) room temperature
with 2 ml buffer B, until the flow-through reached OD.sub.280 of
0.02-0.06.
[0276] The resin was washed with either (i) 2 ml cold 20 mM
imidazole buffer (300 mM NaCl, 50 mM phosphate buffer, 20 mM
imidazole, pH 8) or (ii) buffer D (urea 8M, 10 mM Tris-HCl, 100 mM
phosphate buffer, pH 6.3) until the flow-through reached the
O.D.sub.280 of 0.02-0.06. The His-fusion protein was eluted by
addition of 700 .mu.l of either (i) cold elution buffer A (300 mM
NaCl, 50 mM phosphate buffer, 250 mM imidazole, pH 8) or (ii)
elution buffer B (urea 8M, 10 mM Tris-HCl, 100 mM phosphate buffer,
pH 4.5) and fractions collected until the O.D.sub.280 was 0.1. 21
.mu.l of each fraction were loaded on a 12% SDS gel.
[0277] K) His-Fusion Proteins Renaturation
[0278] 10% glycerol was added to the denatured proteins. The
proteins were then diluted to 20 .mu.g/ml using dialysis buffer I
(10% glycerol, 0.5M arginine, 50 mM phosphate buffer, 5 mM reduced
glutathione, 0.5 mM oxidised glutathione, 2M urea, pH 8.8) and
dialysed against the same buffer at 4.degree. C. for 12-14 hours.
The protein was further dialysed against dialysis buffer II (10%
glycerol, 0.5M arginine, 50 mM phosphate buffer, 5 mM reduced
glutathione, 0.5 mM oxidised glutathione, pH 8.8) for 12-14 hours
at 4.degree. C. Protein concentration was evaluated using the
formula:
Protein (mg/ml)=(1.55.times.OD.sub.280)-(0.76.times.OD.sub.260)
[0279] L) His-Fusion Large-Scale Purification
[0280] 500 ml of bacterial cultures were induced and the fusion
proteins were obtained soluble in buffer M1, M2 or M3 using the
procedure described above. The crude extract of the bacteria was
loaded onto a Ni-NTA superflow column (Qiagen) equilibrated with
buffer M1, M2 or M3 depending on the solubilization buffer of the
fusion proteins. Unbound material was eluted by washing the column
with the same buffer. The specific protein was eluted with the
corresponding buffer containing 500 mM imidazole and dialysed
against the corresponding buffer without imidazole. After each run
the columns were sanitized by washing with at least two column
volumes of 0.5 M sodium hydroxide and reequilibrated before the
next use.
[0281] M) Mice Immunisations
[0282] 20 .mu.g of each purified protein were used to immunise mice
intraperitoneally. In the case of ORF 44, CD1 mice were immunised
with Al(OH).sub.3 as adjuvant on days 1, 21 and 42, and immune
response was monitored in samples taken on day 56. For ORF 40, CD1
mice were immunised using Freund's adjuvant, rather than
Al(OH).sub.3, and the same immunisation protocol was used, except
that the immune response was measured on day 42, rather than 56.
Similarly, for ORF 38, CD1 mice were immunised with Freund's
adjuvant, but the immune response was measured on day 49.
[0283] N) ELISA Assay (Sera Analysis)
[0284] The acapsulated MenB M7 strain was plated on chocolate agar
plates and incubated overnight at 37.degree. C. Bacterial colonies
were collected from the agar plates using a sterile dracon swab and
inoculated into 7 ml of Mueller-Hinton Broth (Difco) containing
0.25% Glucose. Bacterial growth was monitored every 30 minutes by
following OD.sub.620. The bacteria were let to grow until the OD
reached the value of 0.3-0.4. The culture was centrifuged for 10
minutes at 10000 rpm. The supernatant was discarded and bacteria
were washed once with PBS, resuspended in PBS containing 0.025%
formaldehyde, and incubated for 2 hours at room temperature and
then overnight at 4.degree. C. with stirring. 100 .mu.l bacterial
cells were added to each well of a 96 well Greiner plate and
incubated overnight at 4.degree. C. The wells were then washed
three times with PBT washing buffer (0.1% Tween-20 in PBS). 200
.mu.l of saturation buffer (2.7% Polyvinylpyrrolidone 10 in water)
was added to each well and the plates incubated for 2 hours at
37.degree. C. Wells were washed three times with PBT. 200 .mu.l of
diluted sera (Dilution buffer: 1% BSA, 0.1% Tween-20, 0.1%
NaN.sub.3 in PBS) were added to each well and the plates incubated
for 90 minutes at 37.degree. C. Wells were washed three times with
PBT. 100 .mu.l of HRP-conjugated rabbit anti-mouse (Dako) serum
diluted 1:2000 in dilution buffer were added to each well and the
plates were incubated for 90 minutes at 37.degree. C. Wells were
washed three times with PBT buffer. 100 .mu.l of substrate buffer
for HRP (25 ml of citrate buffer pH5, 10 mg of O-phenildiamine and
10 .mu.l of H.sub.2O) were added to each well and the plates were
left at room temperature for 20 minutes. 100 .mu.l H.sub.2SO.sub.4
was added to each well and OD.sub.490 was followed. The ELISA was
considered positive when OD.sub.490 was 2.5 times the respective
pre-immune sera.
[0285] O) FACScan Bacteria Binding Assay Procedure.
[0286] The acapsulated MenB M7 strain was plated on chocolate agar
plates and incubated overnight at 37.degree. C. Bacterial colonies
were collected from the agar plates using a sterile dracon swab and
inoculated into 4 tubes containing 8 ml each Mueller-Hinton Broth
(Difco) containing 0.25% glucose. Bacterial growth was monitored
every 30 minutes by following OD.sub.620. The bacteria were let to
grow until the OD reached the value of 0.35-0.5. The culture was
centrifuged for 10 minutes at 4000 rpm. The supernatant was
discarded and the pellet was resuspended in blocking buffer (1%
BSA, 0.4% NaN.sub.3) and centrifuged for 5 minutes at 4000 rpm.
Cells were resuspended in blocking buffer to reach OD.sub.620 of
0.07. 100 .mu.l bacterial cells were added to each well of a Costar
96 well plate. 100 .mu.l of diluted (1:200) sera (in blocking
buffer) were added to each well and plates incubated for 2 hours at
4.degree. C. Cells were centrifuged for 5 minutes at 4000 rpm, the
supernatant aspirated and cells washed by addition of 200
.mu.l/well of blocking buffer in each well. 100 .mu.l of
R-Phicoerytin conjugated F(ab).sub.2 goat anti-mouse, diluted
1:100, was added to each well and plates incubated for 1 hour at
4.degree. C. Cells were spun down by centrifugation at 4000 rpm for
5 minutes and washed by addition of 200 .mu.l/well of blocking
buffer. The supernatant was aspirated and cells resuspended in 200
.mu.l/well of PBS, 0.25% formaldehyde. Samples were transferred to
FACScan tubes and read. The condition for FACScan setting were: FL1
on, FL2 and FL3 off; FSC-H threshold: 92; FSC PMT Voltage: E 02;
SSC PMT: 474; Amp. Gains 7.1; FL-2 PMT: 539; compensation values:
0.
[0287] P) OMV Preparations
[0288] Bacteria were grown overnight on 5 GC plates, harvested with
a loop and resuspended in 10 ml 20 mM Tris-HCl. Heat inactivation
was performed at 56.degree. C. for 30 minutes and the bacteria
disrupted by sonication for 10 minutes on ice (50% duty cycle, 50%
output). Unbroken cells were removed by centrifugation at 5000 g
for 10 minutes and the total cell envelope fraction recovered by
centrifugation at 50000 g at 4.degree. C. for 75 minutes. To
extract cytoplasmic membrane proteins from the crude outer
membranes, the whole fraction was resuspended in 2% sarkosyl
(Sigma) and incubated at room temperature for 20 minutes. The
suspension was centrifuged at 10000 g for 10 minutes to remove
aggregates, and the supernatant further ultracentrifuged at 50000 g
for 75 minutes to pellet the outer membranes. The outer membranes
were resuspended in 10 mM Tris-HCl, pH8 and the protein
concentration measured by the Bio-Rad Protein assay, using BSA as a
standard.
[0289] Q) Whole Extracts Preparation
[0290] Bacteria were grown overnight on a GC plate, harvested with
a loop and resuspended in 1 ml of 20 mM Tris-HCl. Heat inactivation
was performed at 56.degree. C. for 30 minutes.
[0291] R) Western Blotting
[0292] Purified proteins (500 ng/lane), outer membrane vesicles (5
.mu.g) and total cell extracts (25 .mu.g) derived from MenB strain
2996 were loaded on 15% SDS-PAGE and transferred to a
nitrocellulose membrane. The transfer was performed for 2 hours at
150 mA at 4.degree. C., in transferring buffer (0.3% Tris base,
1.44% glycine, 20% methanol). The membrane was saturated by
overnight incubation at 4.degree. C. in saturation buffer (10%
skimmed milk, 0.1% Triton X100 in PBS). The membrane was washed
twice with washing buffer (3% skimmed milk, 0.1% Triton X100 in
PBS) and incubated for 2 hours at 37.degree. C. with mice sera
diluted 1:200 in washing buffer. The membrane was washed twice and
incubated for 90 minutes with a 1:2000 dilution of horseradish
peroxidase labelled anti-mouse Ig. The membrane was washed twice
with 0.1% Triton X100 in PBS and developed with the Opti-4CN
Substrate Kit (Bio-Rad). The reaction was stopped by adding
water.
[0293] S) Bactericidal Assay
[0294] MC58 strain was grown overnight at 37.degree. C. on
chocolate agar plates. 5-7 colonies were collected and used to
inoculate 7 ml Mueller-Hinton broth. The suspension was incubated
at 37.degree. C. on a nutator and let to grow until OD.sub.620 was
0.5-0.8. The culture was aliquoted into sterile 1.5 ml Eppendorf
tubes and centrifuged for 20 minutes at maximum speed in a
microfuge. The pellet was washed once in Gey's buffer (Gibco) and
resuspended in the same buffer to an OD.sub.620 of 0.5, diluted
1:20000 in Gey's buffer and stored at 25.degree. C.
[0295] 50 .mu.l of Gey's buffer/1% BSA was added to each well of a
96-well tissue culture plate. 25 .mu.l of diluted mice sera (1:100
in Gey's buffer/0.2% BSA) were added to each well and the plate
incubated at 4.degree. C. 25 .mu.l of the previously described
bacterial suspension were added to each well. 25 .mu.l of either
heat-inactivated (56.degree. C. waterbath for 30 minutes) or normal
baby rabbit complement were added to each well. Immediately after
the addition of the baby rabbit complement, 22 .mu.l of each
sample/well were plated on Mueller-Hinton agar plates (time 0). The
96-well plate was incubated for 1 hour at 37.degree. C. with
rotation and then 22 .mu.l of each sample/well were plated on
Mueller-Hinton agar plates (time 1). After overnight incubation the
colonies corresponding to time 0 and time 1 hour were counted.
[0296] Table II gives a summary of the cloning, expression and
purification results.
4TABLE II Cloning, expression and purification His-fusion
GST-fusion ORF PCR/cloning expression expression Purification orf
38 + + + His-fusion orf 40 + + + His-fusion orf 41 + n.d. n.d. orf
44 + + + His-fusion orf 51 + n.d. n.d. orf 52 + n.d. + GST-fusion
orf 56 + n.d. n.d. orf 69 + n.d. n.d. orf 82 + n.d. n.d. orf 114 +
n.d. + GST-fusion orf 124 + n.d. n.d.
Example 1
[0297] The following partial DNA sequence was identified in N.
meningitidis <SEQ ID 1>:
5 1 ACACTGTTGT TTGCAACGGT TCAGGCAAGT GCTAACCAAT GAAGAGCAAG 51
AAGAAGATTT ATATTTAGAC CCCGTACAAC GCACTGTTGC CGTGTTGATA 101
GTCAATTCCG ATAAAGAAGG CACGGGAGAA AAAGAAAAAG TAGAAGAAAA 151
TTCAGATTGG GCAGTATATT TCAACGAGAA AGGAGTACTA ACAGCCAGAG 201
AAATCACCyT CAAAGCCGGC GACAACCTGA AAATCAAACA AAACGGCACA 251
AACTTCACCT ACTCGCTGAA AAALGACCTC ACAGATCTGA CCAGTGTTGG 301
AACTGAAAAA TTATCGTTTA GCGCAAACGG CAATAAAGTC AACATCACAA 351
GCGACACCAA AGGCTTGAAT TTTGCGAAAG AAACGGCTGG sACGAACGgC 401
GACACCACGG TTCATCTGAA CGGTATTGGT TCGACTTTGA CCGATACGCT 451
GCTGAATACC GGAGCGACCA CAAACGTAAC CAACGACAAC GTTACCGATG 501
ACGAGAAAAA ACGTGCGGCA AGCGTTAAAG ACGTATTAAA CGCTGGCTGG 551
AACATTAAAG GCGTTAAACC CGGTACAACA GCTTCCGATA ACGTTGATTT 601
CGTCCGCACT TACGACACAG TCGAGTTCTT GAGCGCAGAT ACGAAAACAA 651
CGACTGTTAA TGTGGAAAGC AAAGACAACG GCAAGAAAAC CGAAGTTAAA 701
ATCGGTGCGA AGACTTCTGT TATTAAAGAA AAAGAC...
[0298] This corresponds to the amino acid sequence <SEQ ID 2;
ORF40>:
6 1 ..TLLFATVQAS ANQEEQEEDL YLDPVQRTVA VLIVNSDKEG TGEKEKVEEN 51
SDWAVYFNEK GVLTAREITX KAGDNLKIKQ NGTNFTYSLK KDLTDLTSVG 101
TEKLSFSANG NKVNITSDTK GLNFAKETAG TNGDTTVHLN GIGSTLTDTL 151
LNTGATTNVT NDNVTDDEKK RAASVKDVLN AGWNIKGVKP GTTASDNVDF 201
VRTYDTVEFL SADTKTITVN VESKDNGKKT EVKIGAXTSV IKEKD...
[0299] Further work revealed the complete DNA sequence <SEQ ID
3>:
7 1 ATGAACAAAA TATACCGCAT CATTTGGAAT AGTGCCCTCA ATGCCTGGGT 51
CGTCGTATCC GAGCTCACAC GCAACCACAC CAAACGCGCC TCCGCAACCG 101
TGAAGACCGC CGTATTGGCG ACACTGTTGT TTGCAACGGT TCAGGCAAGT 151
GCTAACAATG AAGAGCAAGA AGAAGATTTA TATTTAGACC CCGTACAACG 201
CACTGTTGCC GTGTTGATAG TCAATTCCGA TAAAGAAGGC ACGGGAGAAA 251
AAGAAAAAGT AGAAGAAAAT TCAGATTGGG CAGTATATTT CAACGAGAAA 301
GGAGTACTAA CAGCCAGAGA AATCACCCTC AAAGCCGGCG ACAACCTGAA 351
AATCAAACAA AACGGCACAA ACTTCACCTA CTCGCTGAAA AAAGACCTCA 401
CAGATCTGAC CAGTGTTGGA ACTGAAAAAT TATCGTTTAG CGCAAACGGC 451
AATAAAGTCA ACATCACAAG CGACACCAAA GGCTTGAATT TTGCGAAAGA 501
AACGGCTGGG ACGAACGGCG ACACCACGGT TCATCTGAAC GGTATTGGTT 551
CGACTTTGAC CGATACGCTG CTGAATACCG GAGCGACCAC AAACGTAACC 601
AACGACAACG TTACCGATGA CGAGAAAAAA CGTGCGGCAA GCGTTAAAGA 651
CGTATTAAAC GCTGGCTGGA ACATTAAAGG CGTTAAACCC GGTACAACAG 701
CTTCCGATAA CGTTGATTTC GTCCGCACTT ACGACACAGT CGAGTTCTTG 751
AGCGCAGATA CGAAAACAAC GACTGTTAAT GTGGAAAGCA AAGACAACGG 801
CAAGAAAACC GAAGTTAAAA TCGGTGCGAA GACTTCTGTT ATTAAAGAAA 851
AAGACGGTAA GTTGGTTACT GGTAAAGACA AAGGCGAGAA TGGTTCTTCT 901
ACAGACGAAG GCGAAGGCTT AGTGACTGCA AAAGAAGTGA TTGATGCAGT 951
AAACAAGGCT GGTTGGAGAA TGAAAACAAC AACCGCTAAT GGTCAAACAG 1001
GTCAAGCTGA CAAGTTTGAA ACCGTTACAT CAGGCACAAA TGTAACCTTT 1051
GCTAGTGGTA AAGGTACAAC TGCGACTGTA AGTAAAGATG ATCAAGGCAA 1101
CATCACTGTT ATGTATGATG TAAATGTCGG CGATGCCCTA AACGTCAATC 1151
AGCTGCAAAA CAGCGGTTGG AATTTGGATT CCAAAGCGGT TGCAGGTTCT 1201
TCGGGCAAAG TCATCAGCGG CAATGTTTCG CCGAGCAAGG GAAAGATGGA 1251
TGAAACCGTC AACATTAATG CCGGCAACAA CATCGAGATT ACCCGCAACG 1301
GTAAAAATAT CGACATCGCC ACTTCGATGA CCCCGCAGTT TTCCAGCGTT 1351
TCGCTCGGCG CGGGGGCGGA TGCGCCCACT TTGAGCGTGG ATGGGGACGC 1401
ATTGAATGTC GGCAGCAAGA AGGACAACAA ACCCGTCCGC ATTACCAATG 1451
TCGCCCCGGG CGTTAAAGAG GGGGATGTTA CAAACGTCGC ACAACTTAAA 1501
GGCGTGGCGC AAAACTTGAA CAACCGCATC GACAATGTGG ACGGCAACGC 1551
GCGTGCGGGC ATCGCCCAAG CGATTGCAAC CGCAGGTCTG GTTCAGGCGT 1601
ATTTGCCCGG CAAGAGTATG ATGGCGATCG GCGGCGGCAC TTATCGCGGC 1651
GAAGCCGGTT ACGCCATCGG CTACTCCAGT ATTTCCGACG GCGGAAATTG 1701
GATTATCAAA GGCACGGCTT CCGGCAATTC GCGCGGCCAT TTCGGTGCTT 1751
CCGCATCTGT CGGTTATCAG TGGTAA
[0300] This corresponds to the amino acid sequence <SEQ ID 4;
ORF40-1>:
8 1 MNKIYRIIWN SALNAWVVVS ELTRNHTKRA SATVKTAVLA TLLFATVQAS 51
ANNEEQEEDL YLDFVQRTVA VLIVNSDKEG TGEKEKVEEN SDWAVYFNEK 101
GVLTAREITL KAGDNLKIKQ NGTNFTYSLK KDLTDLTSVG TEKLSFSMIG 151
NKVNITSDTK GLNFAKETAG TNGDTTVHLN GIGSTLTDTL LNTGATTNVT 201
NDNVTDDEKK RAASVKDVLN AGWNIKGVKP GTTASDNVDF VRTYDTVEFL 251
SADTKTTTVN VESKDNGKKT EVKIGAKTSV IKEKDGKLVT GKDKGENGSS 301
TDEGEGLVTA KEVIDAYNKA GWRMKTTTAN GQTGQADKFE TVTSGTNVTF 351
ASGKGTTATV SKDDQGNITV NYDVNVGDAL NVNQLQNSGW NLDSKAVAGS 401
SGKVISGNVS PSKGKMDETV NINAGNNIEI TRNGKNIDIA TSHTPQFSSV 451
SLGAGADAPT LSVDGDALNV GSKKDNKPVR ITNVAPGVKE GOVTNVAQLK 501
GVAQNLNNRI DNVDGNARAG ZAQAIATAGL VQAYLPGKSM MAIGGGTYRG 551
EAGYAIGYSS ISDGGNWIIK GTASGNSRGH FGASASVGYQ W*
[0301] Further work identified the corresponding gene in strain A
of N. meningitidis <SEQ ID 5>:
9 1 ATGAACAAAA TATACCGCAT CATTTGGAAT AGTGCCCTCA ATGCCTGNGT 51
CGCCGTATCC GAGCTCACAC GCAACCACAC CAAACGCGCC TCCGCAACCG 101
TGAAGACCGC CGTATTGGCG ACACTGTTGT TTGCAACGGT TCAGGCGAAT 151
GCTACCGATG AAGATGAAGA AGAAGAGTTA GAATCCGTAC AACGCTCTGT 201
CGTAGGGAGC ATTCAAGCCA GTATGGAAGG CAGCGGCGAA TTGGAAACGA 251
TATCATTATC AATGACTAAC GACAGCAAGG AATTTGTAGA CCCATACATA 301
GTAGTTACCC TCAAAGCCGG CGACAACCTG AAAATCAAAC AAAACACCAA 351
TGAAAACACC AATGCCAGTA GCTTCACCTA CTCGCTGAAA AAAGACCTCA 401
CAGGCCTGAT CAATGTTGAN ACTGAAAAAT TATCGTTTGG CGCAAACGGC 451
AAGAAAGTCA ACATCATAAG CGACACCAAA GGCTTGAATT TCGCGAAAGA 501
AACGGCTGGG ACGAACGGCG ACACCACGGT TCATCTGAAC GGTATCGGTT 551
CGACTTTGAC CGATACGCTT GCGGGTTCTT CTGCTTCTCA CGTTGATGCG 601
GGTAACCNAA GTACACATTA CACTCGTGCA GCAAGTATTA AGGATGTGTT 651
GAATGCGGGT TGGAATATTA AGGGTGTTAA ANNNGGCTCA ACAACTGGTC 701
AATCAGAAAA TGTCGATTTC GTCCGCACTT ACGACACAGT CGAGTTCTTG 751
AGCGCAGATA CGNAAACAAC GACNGTTAAT GTGGAAAGCA AAGACAACGG 801
CAAGAGAACC GAAGTTAAAA TCGGTGCGAA GACTTCTGTT ATTAAAGAAA 851
AAGACGGTAA GTTGGTTACT GGTAAAGGCA AAGGCGAGAA TGGTTCTTCT 901
ACAGACGAAG GCGAAGGCTT AGTGACTGCA AAAGAAGTGA TTGATGCAGT 951
AAACAAGGCT GGTTGGAGAA TGAAAACAAC AACCGCTAAT GGTCAAACAG 1001
GTCAAGCTGA CAAGTTTGAA ACCGTTACAT CAGGCACAAA TGTAACCTTT 1051
GCTAGTGGTA AAGGTACAAC TGCGACTGTA AGTAAAGATG ATCAAGGCAA 1101
CATCACTGTT ATGTATGATG TAAATGTCGG CGATGCCCTA AACGTCAATC 1151
AGCTGCAAAA CAGCGGTTGG AATTTGGATT CCAAAGCGGT TGCAGGTTCT 1201
TCGGGCAAAG TCATCAGCGG CAATGTTTCG CCGAGCAAGG GAAAGATGGA 1251
TGAAACCGTC AACATTAATG CCGGCAACAA CATCGACATT AGCCGCAACG 1301
GTAAAAATAT CGACATCGCC ACTTCGATGG CGCCGCAGTT TTCCAGCGTT 1351
TCGCTCGGCG CGGGGGCAGA TGCGCCCACT TTAAGCGTGG ATGACGAGGG 1401
CGCGTTGAAT GTCGGCAGCA AGGATGCCAA CAAACCCGTC CGCATTACCA 1451
ATGTCGCCCC GGGCGTTAAA GANGGGGATG TTACAAACGT CNCACAACTT 1501
AAAGGCGTGG CGCAAAACTT GAACAACCGC ATCGACAATG TGGACGGCAA 1551
CGCGCGTGCN GGCATCGCCC AAGCGATTGC AACCGCAGGT CTGGTTCAGG 1601
CGTATCTGCC CGGCAAGAGT ATGATGGCGA TCGGCGGCGG CACTTATCGC 1651
GGCGAAGCCG GTTACGCCAT CGGCTACTCC AGTATTTCCG ACGGCGGAAA 1701
TTGGATTATC AAAGGCACGG CTTCCGGCAA TTCGCGCGGC CATTTCGGTG 1751
CTTCCGCATC TGTCGGTTAT CAGTGGTAA
[0302] This encodes a protein having amino acid sequence <SEQ ID
6; ORF40a>:
10 1 MNKIYRIIWN SALNPXVAVS ELTRNHTKRA SATVKTAVLA TLLFATVQAN 51
ATDEDEKEEL ESVQRSVVGS IQASMEGSGE LETISLSHTN DSKEFVDPYI 101
VVTLKAGDNL KIKONTHENT NASSFTYSLK KDLTGLINVX TEKLSFGANG 151
KKVNIISDTK GLNFAXETAG TNGDTTVHLN GIGSTLTDTL AGSSASHVDA 201
GNXSTHYTRA ASIKDVLNAG WNIKGVKXGS TTGQSENVDF VRTYDTVEFL 251
SADTXTTTVN VESKDNGKRT EVXIGAXTSV IKEKDGKLVT GKGKGENGSS 301
TDEGEGLVTA KEVIDAVNKA GWRMKTTTAN GQTGQADKFE TVTSGTNVTF 351
ASGKGTTATV SXDDQGNITV MYDVNVGDAL NVNQLONSGW NLDSKAVAGS 401
SGKVISGNVS PSKGKMDETV NINAGNNIEI SRNGKNIDIA TSMAPQFSSV 451
SLGAGADAPT LSVDDEGALN VGSKDANKPV RITNVAPGVK XGDVTNVXQL 501
KGVAQNLNNR IDNYOGNARA GIAQAIATAG LVQAYLPGKS NNAIGGGTYR 551
GEAGYAIGYS SISDGGNWII KGTASGNSRG HFGASASVGY QW
[0303] The originally-identified partial strain B sequence (ORF40)
shows 65.7% identity over a 254 aa overlap with ORF40a:
11 10 20 30 orf40.pep TLLFATVQASANQEEQEEDLYLDPVQRTVA
.vertline..vertline..vertline..vertl-
ine..vertline..vertline..vertline..vertline..vertline.:.vertline.::.vertli-
ne.::.vertline..vertline.:.vertline. :
.vertline..vertline..vertline.:.ve- rtline. orf40a
SALNAXVAVSELTRNHTKRASATVKTAVLATLLFATVQANATDEDEEEEL--- ESVQRSV- 20
30 40 50 60 40 50 60 70 80 orf40.pep
VLIVNSDKEGTGEKEKVEEN-SDWAVYFNEKGVLTAREITXKAGDNLKIKQN------GT
.vertline. :::: .vertline..vertline.:.vertline..vertline.
.vertline. : : :: : .vertline. : :: :.vertline.
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline. :: orf40a
VGSIQASMEGSGELETISLSMTNDSKEFVDPYIV----VTLKAGDNLKIKQNTNENTNAS 70 80
90 100 110 120 90 100 110 120 130 140 orf40.pep
NFTYSLKKDLTDLTSVGTEKLSFSANGNKVNITSDTKGLNFAKETAGTNGDTTVHLNGIG
:.vertline..vertline..vertline..vertline..vertline..vertline..vertline..v-
ertline..vertline..vertline. .vertline. :.vertline.
.vertline..vertline..vertline..vertline..vertline..vertline.:.vertline..v-
ertline..vertline.:.vertline..vertline..vertline..vertline.
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline..vertline..vertline..vertline..vertline..vertline..-
vertline..vertline..vertline..vertline..vertline. orf40a
SFTYSLKKDLTGLINVXTEKLSFGANGKKVNIISDTKGLNFAKETAGTNGDTTVHLNGIG 130
140 150 160 170 180 150 160 170 180 190 200 orf40.pep
STLTDTLLNTGATTNVTNDNVTDDEKKRAASVKDVLNAGWNIKGVKPGTTA--SDNVDFV
.vertline..vertline..vertline..vertline..vertline..vertline..vertline.
:::.vertline.: :.vertline. .vertline. : :
.vertline..vertline..vertli-
ne..vertline.:.vertline..vertline..vertline..vertline..vertline..vertline.-
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ver-
tline. .vertline.:.vertline.:
.vertline.:.vertline..vertline..vertline..v- ertline..vertline.
orf40a STLTDTLAGSSAS-HVDAGNXST-HYTRAASIKDVLNAGWN-
IKGVKXGSTTGQSENVDFV 190 200 210 220 230 240 210 220 230 240
orf40.pep RTYDTVEFLSADTKTTTVNVESKDNGKKTEVKIGAKTSVIKEKD
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline.
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline.:.vertline..vertl-
ine..vertline..vertline..vertline..vertline..vertline..vertline..vertline.-
.vertline..vertline..vertline..vertline..vertline..vertline..vertline.
orf40a RTYDTVEFLSADTXTTTVNVESKDNGKRTEVKIGAKTSVIKEKDGKLVTGKGKGENGSST
250 260 270 280 290 300
[0304] The complete strain B sequence (ORF44-1) and ORF40a show
83.7% identity in 601 aa overlap:
12 10 20 30 40 50 60 orf40-1.pep
MNKIYRIIWNSALNAWVVVSELTRNHTKRASATVKTAVLATLLFATVQASAN- NEEQEEDL
.vertline..vertline..vertline..vertline..vertline..vert-
line..vertline..vertline..vertline..vertline..vertline..vertline..vertline-
..vertline..vertline.
.vertline.:.vertline..vertline..vertline..vertline..-
vertline..vertline..vertline..vertline..vertline..vertline..vertline..vert-
line..vertline..vertline..vertline..vertline..vertline..vertline..vertline-
..vertline..vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline.:.vertline.::.vertline.::.v-
ertline..vertline.:.vertline. orf40a MNKIYRIIWNSALNAXVAVSELTRNHTK-
RASATVKTAVLATLLFATVQANATDEDEEEEL 10 20 30 40 50 60 70 80 90 100 110
119 orf40-1.pep
YLDPVQRTVAVLIVNSDKEGTGEKEKVEEN-SDWAVYFNEKGVLTAREITLKAGDNLKIK :
.vertline..vertline..vertline.:.vertline. .vertline. ::::
.vertline..vertline.:.vertline..vertline. .vertline. : : :: :
.vertline. : ::
:.vertline..vertline..vertline..vertline..vertline..v-
ertline..vertline..vertline..vertline..vertline..vertline. orf40a
--ESVQRSV-VGSIQASMEGSGELETISLSMTNDSKEFVDPYIV----VTLKAGDNLKIK 70 80
90 100 110 120 130 140 150 160 170 orf40-1.pep
QN------GTNFTYSLKKDLTDLTSVGTEKLSFSANGNKVNITSDTKGLNFAKETAGTNG
.vertline..vertline.
:::.vertline..vertline..vertline..vertline..ver-
tline..vertline..vertline..vertline..vertline. .vertline.
:.vertline.
.vertline..vertline..vertline..vertline..vertline..vertline.:.vertline..v-
ertline..vertline.:.vertline..vertline..vertline..vertline.
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline. orf40a QNTNENTNASSFTYSLKKDLTGLINVXTEKLSFG-
ANGKKVNIISDTKGLNFAKETAGTNG 120 130 140 150 160 170 180 190 200 210
220 230 orf40-1.pep DTTVHLNGIGSTLTDTLLNTGATTNVTN-
DNVTDDEKKRAASVKDVLNAGWNIKGVKPGTT .vertline..vertline..vertline..-
vertline..vertline..vertline..vertline..vertline..vertline..vertline..vert-
line..vertline..vertline..vertline..vertline..vertline..vertline.
:::.vertline.: :.vertline. .vertline. : :
.vertline..vertline..vertli-
ne..vertline.:.vertline..vertline..vertline..vertline..vertline..vertline.-
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ver-
tline. .vertline.:.vertline. orf40a DTTVHLNGIGSTLTDTLAGSSAS-HVDAG-
NXST-HYTRAASIKDVLNAGWNIKGVKXGST 180 190 200 210 220 230 240 250 260
270 280 290 orf40-1.pep
A--SDNVDFVRTYDTVEFLSADTKTTTVNVESKDNGKKTEVKIGAKTSVIKEKDGKLVTG :
.vertline.:.vertline..vertline..vertline..vertline..vertline..vertline..v-
ertline..vertline..vertline..vertline..vertline..vertline..vertline..vertl-
ine..vertline..vertline..vertline..vertline.
.vertline..vertline..vertline-
..vertline..vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline.:.vertline..vertline..vertline..vertline..vertl-
ine..vertline..vertline..vertline..vertline..vertline..vertline..vertline.-
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ver-
tline..vertline..vertline. orf40a TGQSENVDFVRTYDTVEFLSADTXTTTVNVE-
SKDNGKRTEVKIGAKTSVIKEKDGKLVTG 240 250 260 270 280 290 300 310 320
330 340 350 orf40-1.pep
KDKGENGSSTDEGEGLVTAKEVIDAVNKAGWRMKTTTANGQTGQADKFETVTSGTNVTFA
.vertline.
.vertline..vertline..vertline..vertline..vertline..vertline..v-
ertline..vertline..vertline..vertline..vertline..vertline..vertline..vertl-
ine..vertline..vertline..vertline..vertline..vertline..vertline..vertline.-
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ver-
tline..vertline..vertline..vertline..vertline..vertline..vertline..vertlin-
e..vertline..vertline..vertline..vertline..vertline..vertline..vertline..v-
ertline..vertline..vertline..vertline..vertline..vertline..vertline..vertl-
ine..vertline..vertline..vertline..vertline..vertline..vertline..vertline.
orf40a KGKGENGSSTDEGEGLVTAKEVIDAVNKAGWRMKTTTANGQTGQADKFETVTSGTNV-
TFA 300 310 320 330 340 350 360 370 360 390 400 410 orf40-1.pep
SGKGTTATVSKDDQGNITVMYDVNVGDALNVNQLQNSGWNLDSKAVA- GSSGKVISGNVSP
.vertline..vertline..vertline..vertline..vertline.-
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ver-
tline..vertline..vertline..vertline..vertline..vertline..vertline..vertlin-
e..vertline..vertline..vertline..vertline..vertline..vertline..vertline..v-
ertline..vertline..vertline..vertline..vertline..vertline..vertline..vertl-
ine..vertline..vertline..vertline..vertline..vertline..vertline..vertline.-
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ver-
tline..vertline..vertline..vertline..vertline..vertline..vertline..vertlin-
e..vertline..vertline..vertline. orf40a SGKGTTATVSKDDQGNITVMYDVNV-
GDALNVNQLQNSGWNLDSKAVAGSSGKVISGNVSP 360 370 360 390 400 410 420 430
440 450 460 470 orf40-1.pep
SKGKMDETVNINAGNNIEITRNGKNIDIATSMTPQFSSVSLGAGADAPTLSVDGD-ALNV
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline..vertline..vertline.:.vertline..vertline..vertline.-
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ver-
tline..vertline.:.vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline..vertline..vertline..vertline..vertline..vertline..-
vertline..vertline..vertline..vertline..vertline..vertline..vertline.
: .vertline..vertline..vertline..vertline. orf40a
SKGKMDETVNINAGNNIEISRNGKNIDIATSMAPQFSSVSLGAGADAPTLSVDDEGALNV 420
430 440 450 460 470 480 490 500 510 520 530 orf40-1.pep
GSKKDNKPVRITNVAPGVKEGDVTNVAQLKGVAQNLNNRIDNVDGNARAGIAQAIATAG- L
.vertline..vertline..vertline. .vertline..vertline..vertline.-
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ver-
tline..vertline..vertline..vertline.
.vertline..vertline..vertline..vertli- ne..vertline..vertline.
.vertline..vertline..vertline..vertline..vertline.-
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ver-
tline..vertline..vertline..vertline..vertline..vertline..vertline..vertlin-
e..vertline..vertline..vertline..vertline..vertline..vertline..vertline..v-
ertline..vertline..vertline..vertline..vertline..vertline. orf40a
GSKDANKPVRITNVAPGVKXGDVTNVXQLKGVAQNLNNRIDNVDGNARAGIAQAIATAGL 480
490 500 510 520 530 540 550 560 570 580 590 orf40-1.pep
VQAYLPGKSMMAIGGGTYRGEAGYAIGYSSISDGGNWIIKGTASGNSRGHFGASASVGY- Q
.vertline..vertline..vertline..vertline..vertline..vertline..v-
ertline..vertline..vertline..vertline..vertline..vertline..vertline..vertl-
ine..vertline..vertline..vertline..vertline..vertline..vertline..vertline.-
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ver-
tline..vertline..vertline..vertline..vertline..vertline..vertline..vertlin-
e..vertline..vertline..vertline..vertline..vertline..vertline..vertline..v-
ertline..vertline..vertline..vertline..vertline..vertline..vertline..vertl-
ine..vertline..vertline..vertline..vertline..vertline..vertline..vertline.-
.vertline..vertline. orf40a VQAYLPGKSMMAIGGGTYRGEAGYAIGYSSISDGGNW-
IIKGTASGNSRGHFGASASVGYQ 540 550 560 570 580 590 orf40-1.pep WX
.vertline..vertline. orf40a WX
[0305] Computer analysis of these amino acid sequences gave the
following results:
[0306] Homology with Hsf Protein Encoded by the Type b Surface
Fibrils Locus of H. influenzae (Accession Number U41852)
[0307] ORF40 and Hsf protein show 54% aa identity in 251 aa
overlap:
13 Orf40 1 TLLFATVQASANQEEQEEDLYLDPVQRTVAVLVINSDXXXXXXXXXXXXNSDWA-
VYFNEK 60 TLLFATVQA+A E++E LDPV RT VL +SD NS+W +YF+ K Hsf 41
TLLFATVQANATDEDEE----LDPVVRTAPVLSFHSDKEGTGEKE- VTE-NSNWGIYFDNK 95
Orf40 61 GVLTAREITXKAGDNLKIKQN------GT-
NFTYSLKKDLTDLTSVGTEKLSFSANGNKVN 114 GVL A IT KAGDNLKIKQN
++FTYSLKKDLTDLTSV TEKLSF ANG+KV+ Hsf 96 GVLKAGAITLKAGDNLKIKQNTDE-
STNASSFTYSLKKDLTDLTSVATEKLSFGANGDKVD 155 Orf40 115
ITSDTKGLNFAKETAGTNGDTTVhLNGIGSTLTDTLLNTGAXXXXXXXXXXXXEKKRAAS 174
ITSD GL AK G+ VHLNG+ STL D + NTG EK RAA+ Hsf 156
ITSDANGLKLAK-----TGNGNVHLNGLDSTLPDAVTNTGVLSSSSFTPNDV-EKTRAAT 209
Orf40 175 VKDVLNAGWNIKGVKPGTTASDNVDFVRTYDTVEFLSADTKTTTVNV-
ESKDNGKKTEVKI 234 VKDVLNAGWNIKG K ++VD V Y+ VEF++ D T V ++K+NGK
TEVK Hsf 210 VKDVLNAGWNIKGAKTAGGNVESVDLVSAYNNVEFITGDKNTL-
DVVLTAKENGKTTEVKF 269 Orf40 235 GAKTSVIKEKD 245 KTSVIKEKD Hsf 270
TPKTSVIKEKD 280
[0308] ORF40a also shows homology to Hsf:
14 gi.vertline.1666683 (U41852) hsf gene product [Haemophilus
influenzae] Length = 2353 Score = 153 (67.7 bits), Expect =
1.5-116, Sum P(11) = 1.5e-116 Identities = 33/36 (91%), Positives =
34/36 (94%) Query: 16 VAVSELTRNHTKRASATVKTAVLATLLFATVQANAT 51 V
VSELTR HTKRASATV+TAVLATLLFATVQNAT Sbjct: 17
VVVSELTRTHTKRASATVETAVLATLLFATVQANAT 52 Score = 161 (71.2 bits),
Expect = 1.5e-116, Sum P(11) 1.5e-116 Identities = 32/38 (84%),
Positives = 36/38 (94%) Query: 101 VTLKAGDNLKIKQNTNENTNASS-
FTYSLKKDLTGLINV 138 +TLAGDNLKIKQNT+E+TNASSFTYSLKKDLT L +V Sbjct:
103 ITLKAGDNLKIKQNTDESTNASSFFYSLKKDLTDLTSV 140 Score = 110 (48.7
bits), Expect = 1.5e-116, Sum P(11) = 1.5e-116 Identities = 21/29
(72%), Positives = 25/29 (86%) Query: 138
VTEKLSFGANGKKVNIISDTKGLNFAKET 166 V++KLS G NG KVNI SDTKGLNFAK++
Sbjct: 1439 VSDKLSLGTNGNKVNITSDTXGLNFAKDS 1467 Score = 85 (37.6
bits), Expect = 1.5e-116, Sum P(11) = 1.5e-116 Identities = 18/32
(56%), Positives = 20/32 (62%) Query: 169
TNGDTTVHLNGIGSTLTDTLAGSSASHVDAGN 200 T D +HLNGI STLTDTL S A+ GN
Sbjct: 1469 TGDDANIHLNGIASTLTDTLLNSGATTNLGGN 1500 Score = 92 (40.7
bits), Expect = 1.5e-116, Sum P(11) = 1.5e-116 Identities = 16/19
(84%), Positives = 19/19 (100%) Query: 206 RAASIKOVLNAGWNIKGVK 224
RAAS+KDVLNAGWN++GVK Sbjct: 1509 RAASVKDVLNAGWNVRGVK 1527 Score = 90
(39.8 bits), Expect = 1.5e-116, Sum P(11) = 1.5e-116 Identities =
17/28 (60%), Positives 20/28 (71%) Query: 226
STTGQSENVDFVRTYDTVEFLSADTTTT 253 S Q EN+DFV TYDTV+F+S D TT Sbjct:
1530 SANNQVENIDFVATYDTVDFVSGDKDTT 1557
[0309] Based on homology with Hsf, it was predicted that this
protein from N. meningitidis, and its epitopes, could be useful
antigens for vaccines or diagnostics.
[0310] ORF40-1 (61 kDa) was cloned in pET and pGex vectors and
expressed in E. coli, as described above. The products of protein
expression and purification were analyzed by SDS-PAGE. FIG. 1A
shows the results of affinity purification of the His-fusion
protein, and FIG. 1B shows the results of expression of the
GST-fusion in E. coli. Purified His-fusion protein was used to
immunise mice, whose sera were used for FACS analysis (FIG. 1C), a
bactericidal assay (FIG. 1D), and ELISA (positive result). These
experiments confirm that ORF40-1 is a surface-exposed protein, and
that it is a useful immunogen.
[0311] FIG. 1E shows plots of hydrophilicity, antigenic index, and
AMPHI regions for ORF40-1.
Example 2
[0312] The following partial DNA sequence was identified in N.
meningitidis <SEQ ID 7>
15 1 ATGTFACGTt TGACTGCtTT AGCCGTATGC ACCGCCCTCG CTTTGGGCGC 51
GTGTT~GCCG CAAAATTCCG ACTCTGCCCC ACAAGCCAAA GaACAGGCGG 101
TTTCCGCCGC ACAAACCGAA GgCGCGTCCG TTACCGTCAA AACCGCGCGC 151
GGCGACGTTC AAATACCGCA AAACCCCGAA CGCATCGCCG TTTACGATTT 201
GGGTATGCTC GACACCTTGA GCAAACTGGG CGTGAAAACC GGTTTGTCCG 251
TCGATAAAAA CCGCCTGCCG TATTTAGAGG AATATTTCAA AACGACAAAA 301
CCTGCcGGCA CTTTGTTCGA GCCGGATTAC GAAACGCTCA ACGCTTACAA 351
ACCGCAGCTC ATCATCATCG GCAGCCGCGC CgCCAAGGCG TTTGACAAAT 401
TGAAcGAAAT CGCGCCGACC ATCGrmwTGA CCGCCGATAC CGCCAACCTC 451
AAAGAAAGTG CCAArGAGGC ATCGACGCTG GCGCAAATCT TC..
[0313] This corresponds to the amino acid sequence <SEQ ID 8;
ORF38>:
16 1 MLRLTALAVC TALALGACSP QNSDSAPOAK EQAVSAAQTE GASVTVKTAR 51
GDVQIPQNPE RIAVYDLGHL DTLSKLGVKT GLSVDKNRLP YLEEYFKTTK 101
PAGTLFEPDY ETLNAYKPQL IIIGSRAAKA FDKLNEIAPT IXXTADTANL 151
KESAKEASTL AQIF..
[0314] Further work revealed the complete nucleotide sequence
<SEQ ID 9>:
17 1 ATGTTACGTT TGACTGCTTT AGCCGTATGC ACCGCCCTCG CTTTGGGCGC 51
GTGTTCGCCG CAAAATTCCG ACTCTGCCCC ACAAGCCAAA GAACAGGCGG 101
TTTCCGCCGC ACAAACCGAA GGCGCGTCCG TTACCGTCAA AACCGCGCGC 151
GGCGACGTTC AAATACCGCA AAACCCCGAA CGCATCGCCG TTTACGATTT 201
GGGTATGCTC GACACCTTGA GCAAACTGGG CGTGAAAACC GGTTTGTCCG 251
TCGATAAAAA CCGCCTGCCG TATTTAGAGG AATATTTCAA AACGACAAAA 301
CCTGCCGGCA CTTTGTTCGA GCCGGATTAC GAAACGCTCA ACGCTTACAA 351
ACCGCAGCTC ATCATCATCG GCAGCCGCGC CGCCAAGGCG TTTGACAAAT 401
TGAACGAAAT CGCGCCGACC ATCGAAATGA CCGCCGATAC CGCCAACCTC 451
AAAGAAAGTG CCAAAGAGCG CATCGACGCG CTGGCGCAAA TCTTCGGCAA 501
ACAGGCGGAA GCCGACAAGC TGAAGGCGGA AATCGACGCG TCTTTTGAAG 551
CCGCGAAAAC TGCCGCACAA GGTAAGGGCA AAGGTTTGGT GATTTTGGTC 601
AACGGCGGCA AGATGTCGGC TTTCGGCCCG TCTTCACGCT TGGGCGGCTG 651
GCTGCACAAA GACATCGGCG TTCCCGCTGT CGATGAATCA ATTAAAGAAG 701
GCAGCCACGG TCAGCCTATC AGCTTTGAAT ACCTGAAAGA GAAAAATCCC 751
GACTGGCTGT TTGTCCTTGA CCGAAGCGCG GCCATCGGCG AAGAGGGTCA 801
GGCGGCGAAA GACGTGTTGG ATAATCCGCT GGTTGCCGAA ACAACCGCTT 851
GGAAAAAAGG ACAGGTCGTG TACCTCGTTC CTGAAACTTA TTTGGCAGCC 901
GGTGGCGCGC AAGAGCTGCT GAATGCAAGC AAACAGGTTG CCGACGCTTT 951
TAACGCGGCA AAATAA
[0315] This corresponds to the amino acid sequence <SEQ ID 10;
ORF38-1>:
18 1 MLRLTALAVC TALALGACSP QNSDSAPQAK EQAVSAAQTE GASVTVKTAR 51
GDVQIPQNPE RIAVYDLQIL DTLSXLGVKT GLSVDKNRLP YLEEYFKTTK 101
PAGTLFEPDY ETLNAYKPQL IIIGSRAAKA FDKLNEIAPT IENTADTANL 151
KESAKERIDA LAQIFGKQAE ADKLKAEIDA SFEAAKTAAQ GKGKGLVILV 201
NGGKMSAFGP SSRLGGWLKK DIGVPAVDES IKEGSHGQPI SFEYLKEKNP 251
DWLFVLDRSA AIGEEGQAAK DVLDNPLVAE TTAWKKGQVV YLVPETYLAA 301
GGAQELLNAS KQVADAFNAA K*
[0316] Computer analysis of this amino acid sequence reveals a
putative prokaryotic membrane lipoprotein lipid attachment site
(underlined).
[0317] Further work identified the corresponding gene in strain A
of N. meningitidis <SEQ ID 11>:
19 1 ATGTTACGTT TGACTGCTTT AGCCGTATGC ACCGCCCTCG CTTTGGGCGC 51
GTGTTCGCCG CAAAATTCCG ACTCTGCCCC ACAAGCCAAA GAACAGGCGG 101
TTTCCGCCGC ACAATCCGAA GGCGTGTCCG TTACCGTCAA AACGGCGCGC 151
GGCGATGTTC AAATACCGCA AAACCCCGAA CGTATCGCCG TTTACGATTT 201
GGGTATGCTC GACACCTTGA GCAAACTGGG CGTGAAAACC GGTTTGTCCG 251
TCGATAAAAA CCGCCTGCCG TATTTAGAGG AATATTTCAA AACGACAAAA 301
CCTGCCGGAA CTTTGTTCGA GCCGGATTAC GAAACGCTCA ACGCTTACAA 351
ACCGCAGCTC ATCATCATCG GCAGCCGCGC AGCCAAAGCG TTTGACAAAT 401
TGAACGAAAT CGCGCCGACC ATCGAAATGA CCGCCGATAC CGCCAACCTC 451
AAAGAAAGTG CCAAAGAGCG TATCGACGCG CTGGCGCAAA TCTTCGGCAA 501
AAAGGCGGAA GCCGACAAGC TGAAGGCGGA AATCGACGCG TCTTTTGAAG 551
CCGCGAAAAC TGCCGCGCAA GGCAAAGGCA AGGGTTTGGT GATTTTGGTC 601
AAcGGCGGCA AGATGTCCGC CTTCGGCCCG TCTTCACGAC TGGGCGGCTG 651
GCTGCACAAA GACATCGGCG TTCCCGCTGT TGACGAAGCC ATCAAAGAAG 701
GCAGCCACGG TCAGCCTATC AGCTTTGAAT ACCTGAAAGA GAAAAATCCC 751
GACTGGCTGT TTGTCCTTGA CCGCAGCGCG GCCATCGGCG AAAAGGGTCA 601
GGCGGCGAAA GACGTGTTGA ACAATCCGCT GGTTGCCGAA ACAACCGCTT 851
GGAAAAATGG ACAAGTCGTT TACCTTGTTC CTGAAACTTA TTTGGCAGCC 901
GGTGGCGCGC AAGAGCTACT GAATGCAAGC AAACAGGTTG CCGACGCTTT 951
TAACGCGGCA AAATAA
[0318] This encodes a protein having amino acid sequence <SEQ ID
12; ORF38a>:
20 1 MLRLTALAVC TALALGACSP QNSDSAPOAK EQAVSAAQSE GVSVTVKTAR 51
GDVQIPQNPE RIAVYDLGHL DTLSKLGVKT GLSVDKNRLP YLEEYFKTTK 101
PAGTLFEPDY ETLNAYKPQL IIIGSRAAKA FDKLNEIAPT IENTADTANL 151
KESAKERIDA LAOIFGKKAE ADKLKAEIDA SFEAAKTAAQ GKGKGLVILV 201
NGGKMSAFGP SSRLGGWLHK DIGVPAVDEA IKEGSHGQPI SFEYLKEKNP 251
DWLFVLDRSA AIGEEGQAAK DVLNNPLVAE TTAWKKGQVV YLVPETYLAA 301
GGAQELLNAS KQVAOAFWAA K*
[0319] The originally-identified partial strain B sequence (ORF38)
shows 95.2% identity over a 165 aa overlap with ORF38a:
21 10 20 30 40 50 60 orf38.pep
MLRLTALAVCTALALGACSPQNSDSAPQAKEQAVSAAQTEGASVTVKTARGDVQIPQN- PE
.vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline..vertline..vertline..vertline..vertline..vertline..-
vertline..vertline..vertline..vertline..vertline..vertline..vertline..vert-
line..vertline..vertline..vertline..vertline..vertline..vertline..vertline-
..vertline..vertline.:.vertline..vertline.:.vertline..vertline..vertline..-
vertline..vertline..vertline..vertline..vertline..vertline..vertline..vert-
line..vertline..vertline..vertline..vertline..vertline..vertline..vertline-
. orf38a
MLRLTALAVCTALALGACSPQNSDSAPQAKEQAVSAAQSEGVSVTVKTARGDVQIPQN- PE 10
20 30 40 50 60 70 80 90 100 110 120 orf38.pep
RIAVYDLGMLDTLSKLGVKTGLSVDKNRLPYLEEYFKTTKPAGTLFEPDYET- LNAYKPQL
.vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline..vertline..vertline..vertline..vertline..vertline..-
vertline..vertline..vertline..vertline..vertline..vertline..vertline..vert-
line..vertline..vertline..vertline..vertline..vertline..vertline..vertline-
..vertline..vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline..vertline..vertline..vertline..vertline..vertline..-
vertline..vertline..vertline..vertline..vertline..vertline..vertline..vert-
line..vertline..vertline. orf38a
RIAVYDLGMLDTLSKLGVKTGLSVDKNRLPYLEE- YFKTTKPAGTLFEPDYETLNAYKPQL 70
80 90 100 110 120 130 140 150 160 orf38.pep
IIIGSRAAKAFDKLNEIAPTIXXTADTANLKESAKE-ASTLAQIF
.vertline..vertline..vertline..vertline..vertline..vertline..vertlin-
e..vertline..vertline..vertline..vertline..vertline..vertline..vertline..v-
ertline..vertline..vertline..vertline..vertline..vertline..vertline.
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline.
::.vertline..vertline..vertline..vertline..vertline. orf39a
IIIGSRAAKAFDKLNEIAPTIEMTADTANLKESAKERIDALAQIFGKKAEADKLKAEIDA 130
140 150 160 orf38a
SFEAAKTAAQGKGKGLVILVNGGKMSAFGPSSRLGGWLHKDIGVPAVDEAIKEGSHGQPI 190
200 210 220 230 240
[0320] The complete strain B sequence (ORF38-1) and ORF38a show
98.4% identity in 321 aa overlap:
22 orf38a.pep
MLRLTALAVCTALALGACSPQNSDSAPQAKEQAVSAAQSEGVSVTVKTARGDV- QIPQNPE
.vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline..vertline..vertline..vertline..vertline..vertline..-
vertline..vertline..vertline..vertline..vertline..vertline..vertline..vert-
line..vertline..vertline..vertline..vertline..vertline..vertline..vertline-
..vertline..vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline.:.vertline..vertline.:.vertline..vertline..vert-
line..vertline..vertline..vertline..vertline..vertline..vertline..vertline-
..vertline..vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline. orf38-1
MLRLTALAVCTALALGACSPQNSDSAPQAKEQAVSAAQTEGASVTVKTARG- DVQIPQNPE
orf38a.pep RIAVYDLGMLDTLSKLGVKTGLSVDKNRLPYLEEYFK-
TTKPAGTLFEPDYETLNAYKPQL .vertline..vertline..vertline..vertline..v-
ertline..vertline..vertline..vertline..vertline..vertline..vertline..vertl-
ine..vertline..vertline..vertline..vertline..vertline..vertline..vertline.-
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ver-
tline..vertline..vertline..vertline..vertline..vertline..vertline..vertlin-
e..vertline..vertline..vertline..vertline..vertline..vertline..vertline..v-
ertline..vertline..vertline..vertline..vertline..vertline..vertline..vertl-
ine..vertline..vertline..vertline..vertline..vertline..vertline..vertline.-
.vertline..vertline..vertline..vertline. orf38-1
RIAVYDLGMLDTLSKLGVKTGLSVDKNRLPYLEEYFKTTKPAGTLFEPDYETLNAYKPQL
orf38a.pep
IIIGSRAAKAFDKLNEIAPTIEMTADTANLKESAKERIDALAQIFGKKAEADKLKAEID- A
.vertline..vertline..vertline..vertline..vertline..vertline..ver-
tline..vertline..vertline..vertline..vertline..vertline..vertline..vertlin-
e..vertline..vertline..vertline..vertline..vertline..vertline..vertline..v-
ertline..vertline..vertline..vertline..vertline..vertline..vertline..vertl-
ine..vertline..vertline..vertline..vertline..vertline..vertline..vertline.-
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ver-
tline..vertline..vertline..vertline.:.vertline..vertline..vertline..vertli-
ne..vertline..vertline..vertline..vertline..vertline..vertline..vertline..-
vertline. orf38-1
IIIGSRAAKAFDKLNEIAPTIEMTADTANLKESAKERIDALAQIFGKQA- EADKLKAEIDA
orf38a.pep SFEAAKTAAQGKGKGLVILVNGGKMSAFGPSSRLG-
GWLHKDIGVPAVDEAIKEGSHGQPI .vertline..vertline..vertline..vertline.-
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ver-
tline..vertline..vertline..vertline..vertline..vertline..vertline..vertlin-
e..vertline..vertline..vertline..vertline..vertline..vertline..vertline..v-
ertline..vertline..vertline..vertline..vertline..vertline..vertline..vertl-
ine..vertline..vertline..vertline..vertline..vertline..vertline..vertline.-
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ver-
tline.:.vertline..vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline..vertline. orf38-1
SFEAAKTAAQGKGKGLVILVNGGKM- SAFGPSSRLGGWLHKDIGVPAVDESIKEGSHGQPI
orf38a.pep
SFEYLKEKNPDWLFVLDRSAAIGEEGQAAKDVLNNPLVAETTAWKKGQVVYLVPETYLAA
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline..vertline..vertline..vertline..vertline..vertline..-
vertline..vertline..vertline..vertline..vertline..vertline..vertline..vert-
line..vertline..vertline..vertline.:.vertline..vertline..vertline..vertlin-
e..vertline..vertline..vertline..vertline..vertline..vertline..vertline..v-
ertline..vertline..vertline..vertline..vertline..vertline..vertline..vertl-
ine..vertline..vertline..vertline..vertline..vertline..vertline..vertline.
orf38-1 SFEYLKEKNPDWLFVLDRSAAIGEEGQAAKDVLDNPLVAETTAWKKGQVVYLVPETYL-
AA orf38a.pep GGAQELLNASKQVADAFNAAK
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline..vertline..vertline..vertline..vertline.
orf38-1 GGAQELLNASKQVADAFNAAK
[0321] Computer analysis of these sequences revealed the
following:
[0322] Homology with a Lipoprotein (lipo) of C. jejuni (Accession
Number X82427)
[0323] ORF38 and lipo show 38% aa identity in 96 aa overlap:
23 Orf38: 40 EGASVTVKTARGDVQIPQNPERIAVYDLGMLDTLSKLGVKTGLS-VKDNRLPY-
LEEYFKT 98 EG S VK + G+ + P+NP ++ + DLG+LDT L + ++ V LP + FK Lipo:
51 EGDSFLVKDSLGENKTPKNPSKVVILDLGILDTFDALKLNDKVAG- VPAKNLPKYLQQFKN
110 Orf38: 99 TKPAGTLFEPDYETLNAYKPQLIIIGS- RAAKAFDKL 134 G + + D+E
+NA KP LIII R +K +DKL Lipo: 111
KPSVGGVQQVDFEAINALKPDLIIISGRQSKFYDKL 146
[0324] Based on this analysis, it was predicted that this protein
from N. meningitidis, and its epitopes, could be useful antigens
for vaccines or diagnostics.
[0325] ORF38-1 (32 kDa) was cloned in pET and pGex vectors and
expressed in E. coli, as described above. The products of protein
expression and purification were analyzed by SDS-PAGE. FIG. 2A
shows the results of affinity purification of the His-fusion
protein, and FIG. 2B shows the results of expression of the
GST-fusion in E. coli. Purified His-fusion protein was used to
immunise mice, whose sera were used for Western blot analysis (FIG.
2C) and FACS analysis (FIG. 2D). These experiments confirm that
ORF38-1 is a surface-exposed protein, and that it is a useful
immunogen.
[0326] FIG. 2E shows plots of hydrophilicity, antigenic index, and
AMPHI regions for ORF38-1.
Example 3
[0327] The following N. meningitidis DNA sequence was identified
<SEQ ID 13>:
24 1 ATGAAACTTC TGACCACCGC AATCCTGTCT TCCGCAATCG CGCTCAGCAG 51
TATGGCTGCC GCCGCTGGCA CGGACAACCC CACTGTTGCA AAAAAAACCG 101
TCAGCTACGT CTGCCAGCAA GGTAAAAAAG TCAAAGTAAC CTACGGCTTC 151
AACAAACAGG GTCTGACCAC ATACGCTTCC GCCGTCATCA ACGGCAAACG 201
CGTGCAAATG CCTGTCAATT TGGACAAATC CGACAATGTG GAAACATTCT 251
ACGGCAAAGA AGGCGGTTAT GTTTTGGGTA CCGGCGTGAT GGATGGCAAA 301
TCCTACCGCA AACAGCCCAT TATGATTACC GCACCTGACA ACCAAATCGT 351
CTTCAAAGAC TGTTCCCCAC GTTAA
[0328] This corresponds to the amino acid sequence <SEQ ID 14;
ORF44>:
25 1 MKLLTTAILS SAIALSSMAA AAGTDWPTVA KKTVSYVCQQ GKKVKVTYGF 51
NKQGLTTYAS AVINGKRVQH PVNLDKSDNV ETFYGKEGGY VLGTGVMDGK 101
SYRKQPIHIT APDNQIVFKD CSPR*
[0329] Computer analysis of this amino acid sequence predicted the
leader peptide shown underlined.
[0330] Further work identified the corresponding gene in strain A
of N. meningitidis <SEQ ID 15>:
26 1 ATGAAACTTC TGACCACCGC AATCCTGTCT TCCGCAATCG CGCTCAGCAG 51
TATGGCTGCT GCTGCCGGCA CGAACAACCC CACCGTTGCC AAAAAAACCG 101
TCAGCTACGT CTGCCAGCAA GGTAAAAAAG TCAAAGTAAC CTACGGCTTT 151
AACAAACAGG GCCTGACCAC ATACGCTTCC GCCGTCATCA ACGGCAAACG 201
TGTGCAAATG CCTGTCAATT TGGACAAATC CGACAATGTG GAAACATTCT 251
ACGGCAAAGA AGGCGGTTAT GTTTTGGGTA CCGGCGTGAT GGATGGCAAA 301
TCCTATCGCA AACAGCCTAT TATGATTACC GCACCTGACA ACCAAATCGT 351
CTTCAAAGAC TGTTCCCCAC GTTAA
[0331] This encodes a protein having amino acid sequence <SEQ ID
16; ORF44a>:
27 1 MKLLTTAILS SAIALSSMAA AAGTNNPTVA KKTVSYVCQQ GKKVKVTYGF 51
NKQGLTTYAS AVINGKRVQM PVNLDKSDNV ETFYGKEGGY VLGTGVMDGK 101
SYRKQPIMIT APDNQIVFKD CSPR*
[0332] The strain B sequence (ORF44) shows 99.2% identity over a
124 aa overlap with ORF44a:
28 10 20 30 40 50 60 orf44.pep
MKLLTTAILSSAIALSSMAAAAGTDNPTVAKKTVSYVCQQGKKVKVTYGFNKQGLTTY- AS
.vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline..vertline..vertline..vertline..vertline..vertline..-
vertline..vertline..vertline.:.vertline..vertline..vertline..vertline..ver-
tline..vertline..vertline..vertline..vertline..vertline..vertline..vertlin-
e..vertline..vertline..vertline..vertline..vertline..vertline..vertline..v-
ertline..vertline..vertline..vertline..vertline..vertline..vertline..vertl-
ine..vertline..vertline..vertline..vertline..vertline..vertline..vertline.-
.vertline. orf44a
MKLLTTAILSSAIALSSMAAAAGTNNPTVAKKTVSYVCQQGKKVKVTYG- FNKQGLTTYAS 10
20 30 40 50 60 70 80 90 100 110 120 orf44.pep
AVINGKRVQMPVNLDKSDNVETFYGKEGGYVLGTGVMDGKSYRKQPI- MITAPDNQIVFKD
.vertline..vertline..vertline..vertline..vertline..v-
ertline..vertline..vertline..vertline..vertline..vertline..vertline..vertl-
ine..vertline..vertline..vertline..vertline..vertline..vertline..vertline.-
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ver-
tline..vertline..vertline..vertline..vertline..vertline..vertline..vertlin-
e..vertline..vertline..vertline..vertline..vertline..vertline..vertline..v-
ertline..vertline..vertline..vertline..vertline..vertline..vertline..vertl-
ine..vertline..vertline..vertline..vertline..vertline..vertline..vertline.-
.vertline..vertline..vertline. orf44a
AVINGKRVQMPVNLDKSDNVETFYGKEGG- YVLGTGVMDGKSYRKQPIMITAPDNQIVFKD 70
80 90 100 110 120 orf44.pep CSPRX
.vertline..vertline..vertline..vertline..vertline. orf44a CSPRX
[0333] Computer analysis gave the following results:
[0334] Homology with the LecA Adhesin of Eikenella corrodens
(Accession Number D78153)
[0335] ORF44 and LecA protein show 45% aa identity in 91 aa
overlap:
29 Orf44 33 TVSYVCQQGKKVKVTYGFNKQGLTTYASAVINGKRVQMPVNLDKSDNVETFYGK-
EGGYVL 92 +V+YVCQQG+++ V Y FN G+ T A +N + +++P NL SDNV+T + GY L
LecA 135 SVAYVCQQGRRLNVNYRFNSAGVPTSAELRVNNRNLRLPYNLSASDN-
VDTVF-SANGYRL 193 Orf44 93 GTGVHDGKSYRKQPIHITAPDNQIVFKDCS- P 123 T
MD +YR Q I+++AP+ Q+++KDCSP LecA 194 TTNAMDSANYRSQDIIVSAPNGQNLYKDCSP
224
[0336] Based on homology with the adhesin, it was predicted that
this protein from N. meningitidis, and its epitopes, could be
useful antigens for vaccines or diagnostics.
[0337] ORF44-1 (11.2 kDa) was cloned in pET and pGex vectors and
expressed in E. coli, as described above. The products of protein
expression and purification were analyzed by SDS-PAGE. FIG. 3A
shows the results of affinity purification of the His-fusion
protein, and FIG. 3B shows the results of expression of the
GST-fusion in E-coli. Purified His-fusion protein was used to
immunise mice, whose sera were used for ELISA, which gave positive
results, and for a bactericidal assay (FIG. 3C). These experiments
confirm that ORF44-1 is a surface-exposed protein, and that it is a
useful immunogen.
[0338] FIG. 3D shows plots of hydrophilicity, antigenic index, and
AMPHI regions for ORF44-1.
Example 4
[0339] The following partial DNA sequence was identified in N.
meningitidis <SEQ ID 17>
30 1 GGCACCGAAT TCAAAACCAC CCTTTCCGGA GCCGACATAC AGGCAGGGGT 51
GGGTGAAAAA GCCCGAGCCG ATGCGAAAAT TATCCTAAAA GGCATCGTTA 101
ACCGCATCCA AACCGAAGAA AAGCTGGAAT CCAACTCGAC CGTATGGCAA 151
AAGCAGGCCG GAAGCGGCAG CACGGTTGAA ACGCTGAAGC TACCGAGCTT 201
TGAAGGGCCG GCACTGCCTA AGCTGACCGC TCCCGGCGGC TATATCGCCG 251
ACATCCCCAA AGGCAACCTC AAAACCGAAA TCGAAAAGCT GGCCAAACAG 301
CCCGAATATG CCTATCTGAA ACAGCTTCAG ACGGTCAAGG ACGTGAACTG 351
GAACCAAGTA CAGCTCGCTT ACGACAAATG GGACTATAAA CAGGAAGGCC 401
TAACCGGAGC CGGAGCCGCA ATTANCGCAC TGGCCGTTAC CGTGGTCACC 451
TCAGGCGCAG GAACCGGAGC CGTATTGGGA TTAANACGNG TGGCCGCCGC 501
CGCAACCGAT GCAGCATTT...
[0340] This corresponds to the amino acid sequence <SEQ ID 18;
ORF49>:
31 1 GTEFKTTLSG ADIQAGVGEK ARADPKIILK GIVNRIQTEE KLESNSTVWQ 51
KQAGSGSTVE TLKLPSFEGP ALPKLTAPGG YIADIPKGNL KTEIEKLAKQ 101
PEYAYLKQLQ TVKDVNWNQV QLAYDKWDYK QEGLTCAGAA IXALAVTVVT 151
SGAGTGAVLG LXRVAAAATD AAF..
[0341] Further work revealed the complete nucleotide sequence
<SEQ ID 19>:
32 1 ATGCAACTGC TGGCAGCCGA AGGCATTCAC CAACACCAAT TGAATGTTCA 51
GAAAAGTACC CGTTTCATCG GCATCAAAGT GGGTAAAAGC AATTACAGCA 101
AAAACGAGCT GAACGAAACC AAACTGCCCG TACGCGTTAT CGCCCAAACA 151
GCCAAAACCC GTTCCGGCTG GGATACCGTA CTCGAAGGCA CCGAATTCAA 201
AACCACCCTT TCCGGAGCCG ACATACAGGC AGGGGTGGGT GAAAAAGCCC 251
GAGCCGATGC GAAAATTATC CTAAAAGGCA TCGTTAACCG CATCCAAACC 301
GAAGAAAAGC TGGAATCCAA CTCGACCGTA TGGCAAAAGC AGGCCGGAAG 351
CGGCAGCACG GTTGAAACGC TGAAGCTACC GAGCTTTGAA GGGCCGGCAC 401
TGCCTAAGCT GACCGCTCCC GGCGGCTATA TCGCCGACAT CCCCAAAGGC 451
AACCTCAAAA CCGAAATCGA AAAGCTGGCC AAACAGCCCG AATATGCCTA 501
TCTGAAACAG CTTCAGACGG TCAAGGACGT GAACTGGAAC CAAGTACAGC 551
TCGCTTACGA CAAATGGGAC TATAAACAGG AAGGCCTAAC CGGAGCCGGA 601
GCCGCAATTA TCGCACTGGC CGTTACCGTG GTCACCTCAG GCGCAGGAAC 651
CGGAGCCGTA TTGGGATTAA ACGGTGCGGC CGCCGCCGCA ACCGATGCAG 701
CATTTGCCTC TTTGGCCAGC CAGGCTTCCG TATCGTFCAT CAACAACAAA 751
CGCAATATCG GTAACACCCT GAAAGAGCTG GGCAGAAGCA GCACGGTGAA 801
AAATCTGATG GTTGCCGTCG CTACCGCAGG CGTAGCCGAC AAAATCGGTG 851
CTTCGGCACT GAACAATGTC AGCGATAAGC AGTGGATCAA CAACCTGACC 901
GTCAACCTGG CCAATGCGGG CAGTGCCGCA CTGATTAATA CCGCTGTCAA 951
CGGCGGCAGC CTGAAAGACA ATCTGGAAGC GAATATCCTT GCGGCTTTGG 1001
TGAATACTGC GCATGGAGAG GCAGCAAGTA AAATCAAACA GTTGGATCAG 1051
CACTACATTG CCCATAAGAT TGCCCATGCC ATAGCGGGCT GTGCGGCAGC 1101
GGCGGCGAAT AAGGGCAAGT GTCAAGATGG TGCGATCGGT GCGGCGGTCG 1151
GTGAAATCCT TGGCGAAACC CTACTGGACG GCAGAGACCC TGGCAGCCTG 1201
AATGTGAAGG ACAGGGCAAA AATCATTGCT AAGGCGAAGC TGGCAGCAGG 1251
GGCGGTTGCG GCGTTGAGTA AGGGGGATGT GAGTACGGCG GCGAATGCGG 1301
CTGCTGTGGC GGTAGAGAAT AATTCTTTAA ATOATATACA GGATCGTTTG 1351
TTGAGTGGAA ATTATGCTTT ATGTATGAGT GCAGGAGGAG CAGAAAGCTT 1401
TTGTGAGTCT TATCGACCAC TGGGCTTGCC ACACTTTGTA AGTGTTTCAG 1451
GAGAAATGAA ATTACCTAAT AAATTCGGGA ATCGTATGGT TAATGGAAAA 1531
TTAATTATTA ACACTAGAAA TGGCAATGTA TATTTCTCTG TAGGTAAAAT 1551
ATGGAGTACT GTAAAATCAA CAAAATCAAA TATAAGTGGG GTATCTGTCG 1601
GTTGGGTTTT AAATGTTTCC CCTAATGATT ATTTAAAAGA AGCATTTATG 1651
AATGATTTCA GAAATAGTAA TCAAAATAAA GCCTATGCAG AAATGATTTC 1701
CCAGACTTTG GTAGGTGAGA GTGTTGGTGG TAGTCTTTGT CTGACAAGAG 1751
CCTGCTTTTC GGTAAGTTCA ACAATATCTA AATCTAAATC TCCTTTTAAA 1801
GATTCAAAAA TTATTGGGGA AATCGGTTTG GGAAGTGGTG TTGCTGCAGG 1851
AGTAGAAAAA ACAATATACA TAGGTAACAT AAAAGATATT GATAAATTTA 1901
TTAGTGCAAA CATAAAAAAA TAG
[0342] This corresponds to the amino acid sequence <SEQ ID 20;
ORF49-1>:
33 1 MQLLAAEGIH QHQLNVQKST RFIGIKVGKS NYSKNELNET KLPVRVIAQT 51
AKTRSGWDTV LEGTEFKTTL SGADIQAGVG EKARADAKII LKGIVNRIQT 101
EEKLESNSTV WQKQAGSGST VETLKLPSFE GPALPKLTAP GGYIADIPKG 151
NLKTEIEKLA KQPEYAYLKQ LQTVKDVNWN QVQLAYDKWD YKQEGLTGAG 201
AAIIALAVTV VTSGAGTGAV LGLNGAAAAA TDAAFASLAS QASVSFINNK 251
GNIGNTLKEL GRSSTVKNLM VAVATAGVAD KIGASALNNV SDKQWINNLT 301
VNLANAGSAA LINTAVNGGS LKDNLEANIL AALVNTAHGE AASKIKQLDQ 351
HYIAHKIAHA IAGCAAAAAN KGKCQDGAIG AAVGEILGET LLDGRDPGSL 401
NVKDRAKIIA KAKLAAGAVA ALSKGDVSTA ANAAAVAVEN NSLNDIQDRL 451
LSGNYALCNS AGGAESFCES YRPLGLPHFV SVSGENKLPN KFGNRNVNGK 501
LIINTRNGNV YFSVGKIWST VKSTKSNISG VSVGWVLNVS PNDYLKEASM 551
NDFRNSNQNK AYAEMISQTL VGESVGGSLC LTRACFSVSS TISKSKSPFK 601
DSKIIGEIGL GSGVAAGVEK TIYIGNIKDI DKFISANIKK *
[0343] Computer analysis predicts a transmembrane domain and also
indicates that ORF49 has no significant amino acid homology with
known proteins. A corresponding ORF from N. meningitidis strain A
was, however, identified:
[0344] ORF49 shows 86.1% identity over a 173 aa overlap with an ORF
(ORF49a) from strain A of N. meningitidis:
34 10 20 30 orf49.pep GTEFKTTLSGADIQAGVGEKARADA- KIILK
.vertline..vertline..vertline-
..vertline..vertline..vertline..vertline..vertline.:.vertline..vertline..v-
ertline..vertline..vertline..vertline..vertline..vertline.
.vertline..vertline..vertline..vertline.:.vertline..vertline..vertline..v-
ertline..vertline..vertline..vertline. orf49a
SKNELNETKLPVRVVAQXAATRSGWDTVLEGTEFKTTLAGADIQAGVXEKARVDAKIILK 40 50
60 70 80 90 40 50 60 70 80 90 orf49.pep
GIVNRIQTEEKLESNSTVWQKQAGSGSTVETLKLPSFEGPALPKLTAPGGYIADIPKGNL
.vertline..vertline..vertline..vertline..vertline..vertline..vertlin-
e.:.vertline..vertline..vertline..vertline..vertline.:.vertline..vertline.-
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ver-
tline.
.vertline..vertline..vertline.:.vertline..vertline..vertline..vertl-
ine..vertline..vertline..vertline..vertline..vertline.:.vertline.:
.vertline..vertline..vertline.:.vertline..vertline..vertline..vertline..v-
ertline..vertline.:.vertline..vertline..vertline..vertline..vertline..vert-
line..vertline. orf49a
GIVNRIQSEEKLETNSTVWQKQAGRGSTIETLKLPSFESPTPPK- LSAPGGYIVDIPKGNL 100
110 120 130 140 150 100 110 120 130 140 150 orf49.pep
KTEIEKLAKQPEYAYLKQLQTVKDVNWNQVQLAYDKWDYKQE- GLTGAGAAIXALAVTVVT
.vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline.:.vertline..vertline..vertline..vertline..vertline.-
.vertline..vertline..vertline..vertline..vertline..vertline..vertline.::.v-
ertline.::.vertline..vertline..vertline..vertline..vertline..vertline..ver-
tline..vertline..vertline..vertline.:.vertline..vertline..vertline..vertli-
ne..vertline..vertline..vertline..vertline..vertline.
.vertline..vertline..vertline..vertline..vertline.
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline. orf49a
KTEIEKLSKQPEYAYLKQLQVAKNINWNQVQLAYDRWDYKQEGLTEAGAAII- ALAVTVVT 160
170 180 190 200 210 160 170 orf49.pep SGAGTGAVLGLXRVAAAATDAAF
.vertline..vertline..vertline..vertline..-
vertline..vertline..vertline..vertline..vertline..vertline..vertline.
:
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline. orf49a
SGAGTGAVLGLNGAXAAATDAAFASLASQASVSFINNKGDVGKTLKELGRSS- TVKNLVVA 220
230 240 250 260 270
[0345] ORF49-1 and ORF49a show 83.2% identity in 457 aa
overlap:
35 orf49a.pep
XQLLAEEGIHKHELDVQKSRRFIGIKVGXSNYSKNELNETKLPVRVVAQXAAT- RSGWDTV
.vertline..vertline..vertline..vertline.
.vertline..vertline..vertline..vertline.:.vertline.:.vertline.:.vertline.-
.vertline..vertline..vertline.
.vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline.
.vertline..vertline..vertline..vertl-
ine..vertline..vertline..vertline..vertline..vertline..vertline..vertline.-
.vertline..vertline..vertline..vertline..vertline..vertline.:.vertline..ve-
rtline.:.vertline.
.vertline..vertline..vertline..vertline..vertline..vert-
line..vertline..vertline. orf49-1
MQLLAAEGIHQHQLNVQKSTRFIGIKVGKSNYS- KNELNETKLPVRVIAQTAKTRSGWDTV
orf49a.pep
LEGTEFKTTLAGADIQAGVXEKARVDAKIILKGIVNRIQSEEKLETNSTVWQKQAGRGST
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline.:.vertline..vertline..vertline..vertline..vertl-
ine..vertline..vertline..vertline.
.vertline..vertline..vertline..vertline-
.:.vertline..vertline..vertline..vertline..vertline..vertline..vertline..v-
ertline..vertline..vertline..vertline..vertline..vertline..vertline.:.vert-
line..vertline..vertline..vertline..vertline.:.vertline..vertline..vertlin-
e..vertline..vertline..vertline..vertline..vertline..vertline..vertline.
.vertline..vertline..vertline. orf49-1 LEGTEFKTTLSGADIQAGVGEKARADA-
XIILKGIVNRIQTEEKLESNSTVWQKQAGSGST orf49a.pep
IETLKLPSFESPTPPKLSAPGGYIVDIPKGNLKTEIEKLSKQPEYAYLKQLQVAKNINWN
:.vertline..vertline..vertline..vertline..vertline..vertline..vertline..v-
ertline..vertline.:.vertline.:
.vertline..vertline..vertline.:.vertline..v-
ertline..vertline..vertline..vertline..vertline.:.vertline..vertline..vert-
line..vertline..vertline..vertline..vertline..vertline..vertline..vertline-
..vertline..vertline..vertline..vertline.:.vertline..vertline..vertline..v-
ertline..vertline..vertline..vertline..vertline..vertline..vertline..vertl-
ine..vertline.::.vertline.::.vertline..vertline..vertline. orf49-1
VETLKLPSFEGPALPKLTAPGGYIADIPKGNLKTEIEKLAKQPEYAYLKQLQTVKDVNWN
orf49a.pep
QVQLAYDRWDYKQEGLTEAGAAIIALAVTVVTSGAGTGAVLGLNGAXAAATDAAFASLA- S
.vertline..vertline..vertline..vertline..vertline..vertline..ver-
tline.:.vertline..vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline.
.vertline..vertline..vertline..vertline..vertline.-
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ver-
tline..vertline..vertline..vertline..vertline..vertline..vertline..vertlin-
e..vertline..vertline..vertline..vertline..vertline..vertline..vertline..v-
ertline.
.vertline..vertline..vertline..vertline..vertline..vertline..vert-
line..vertline..vertline..vertline..vertline..vertline..vertline.
orf49-1
QVQLAYDKWDYKQEGLTGAGAAIIALAVTVVTSGAGTGAVLGLNGAAAAATDAAFASLAS
orf49a.pep QASVSFINNKGDVGKTLKELGRSSTVKNLVVAAATAGVADKIGASALXNVS-
DKQWINNLT .vertline..vertline..vertline..vertline..vertline..vertl-
ine..vertline..vertline..vertline..vertline..vertline.::.vertline.:.vertli-
ne..vertline..vertline..vertline..vertline..vertline..vertline..vertline..-
vertline..vertline..vertline..vertline..vertline..vertline.:.vertline..ver-
tline.:.vertline..vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline..vertline..vertline..vertline..vertline..vertline.
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline. orf49-1
QASVSFINNKGNIGNTLKELGRSSTVKNLMVAVATAGVADKIGASALNNVSDKQWINNLT
orf49a.pep
VNLANAGSAALINTAVNGGSLKDXLEANILAALVNTAHGEAASKIKQLDQHYIVHKIAH- A
.vertline..vertline..vertline..vertline..vertline..vertline..ver-
tline..vertline..vertline..vertline..vertline..vertline..vertline..vertlin-
e..vertline..vertline..vertline..vertline..vertline..vertline..vertline..v-
ertline..vertline.
.vertline..vertline..vertline..vertline..vertline..vert-
line..vertline..vertline..vertline..vertline..vertline..vertline..vertline-
..vertline..vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline.:.vertline..vertline..vertline..vertline..vertline..vertline.
orf49-1 VNLANAGSAALINTAVNGGSLKDNLEANILAALVNTAHGEAASKIKQLDQHYIAHKIA-
HA orf49a.pep IAGCAAAAANKGKCQDGAIGAAVGEIVGEALTNGKNPDTLTAKE-
REQILAYSKLVAGTVS .vertline..vertline..vertline..vertline..vertline-
..vertline..vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline..vertline..vertline..vertline..vertline.:.vertline.-
.vertline.:.vertline. :.vertline.::.vertline.
:.vertline.::.vertline.:.ver- tline. :.vertline.:.vertline.
:.vertline..vertline.:.vertline..vertline.:.- vertline.: orf49-1
IAGCAAAAANKGKCQDGAIGAAVGEILGETLLDGRDPGSLNVKDRAKI- IAKAKLAAGAVA
orf49a.pep GVVGGDVNAAANAAEVAVKNNQLSDXEGREFDNE-
MTACAKQNXPQLCRKNTVKKYQNVAD :: .vertline..vertline..vertline.::.ve-
rtline..vertline..vertline..vertline..vertline.
.vertline..vertline..vertl-
ine.:.vertline..vertline.:.vertline.:.vertline. : .vertline. ::::::
.vertline. orf49-1 ALSKGDVSTAANAAAVAVENNSLNDIQDRLLSGNYALCMSAGGAESF-
CESYRPLGLPHFV orf49a.pep KRLAASIAICTDISRSTECRTIRKQHLIDSRSL-
HSSWEAGLIGKDDEWYKLFSKSYTQAD orf49-1
SVSGEMKLPNKFGNRMVNGKLIINTRNGNVYFSVGKIWSTVKSTKSNISGVSVGWVLNVS
[0346] The complete length ORF49a nucleotide sequence <SEQ ID
21> is:
36 1 NTGCAACTGC TGGCAGAAGA AGGCATCCAC AAGCACGAGT TGGATGTCCA 51
AAAAAGCCGC CGCTTTATCG GCATCAAGGT AGGTNAGAGC AATTACAGTA 101
AAAACGAACT GAACGAAACC AAATTGCCTG TCCGCGTCGT CGCCCAAANT 151
GCAGCCACCC GTTCAGGCTG GGATACCGTG CTCGAAGGTA CCGAATTCAA 201
AACCACGCTG GCCGGTGCCG ACATTCAGGC AGGTGTANGC GAAAAAGCCC 251
GTGTCGATGC GAAAATTATC CTCAAAGGCA TTGTGAACCG TATCCAGTCG 301
GAAGAAAAAT TAGAAACCAA CTCAACCGTA TGGCAGAAAC AGGCCGGACG 351
CGGCAGCACT ATCGAAACGC TAAAACTGCC CAGCTTCGAA AGCCCTACTC 401
CGCCCAAATT GTCCGCACCC GGCGGNTATA TCGTCGACAT TCCGAAAGGC 451
AATCTGAAAA CCGAAATCGA AAAGCTGTCC AAACAGCCCG AGTATGCCTA 501
TCTGAAACAG CTCCAAGTAG CGAAAAACAT CAACTGGAAT CAGGTGCAGC 551
TTGCTTACGA CAGATGGGAC TACAAACAGG AGGGCTTAAC CGAAGCAGGT 601
GCGGCGATTA TCGCACTGGC CGTTACCGTG GTCACCTCAG GCGCAGGAAC 651
CGGAGCCGTA TTGGGATTAA ACGGTGCGNC CGCCGCCGCA ACCGATGCAG 701
CATTCGCCTC TTTGGCCAGC CAGGCTTCCG TATCGTTCAT CAACAACAAA 751
GGCGATGTCG GCAAAACCCT GAAAGAGCTG GGCAGAAGCA GCACGGTGAA 801
AAATCTGGTG GTTGCCGCCG CTACCGCAGG CGTAGCCGAC AAAATCGGCG 851
CTTCGGCACT GANCAATGTC AGCGATAAGC AGTGGATCAA CAACCTGACC 901
GTCAACCTAG CCAATGCGGG CAGTGCCGCA CTGATTAATA CCGCTGTCAA 951
CGGCGGCAGC CTGAAAGACA NTCTGGAAGC GAATATCCTT GCGGCTTTGG 1001
TCAATACCGC GCATGGAGAA GCAGCCAGTA AAATCAAACA GTTGGATCAG 1051
CACTACATAG TCCACAAGAT TGCCCATGCC ATAGCGGGCT GTGCGGCAGC 1101
GGCGGCGAAT AAGGGCAAGT GTCAGGATGG TGCGATAGGT GCGGCTGTGG 1151
GCGAGATAGT CGGGGAGGCT TTGACAAACG GCAAAAATCC TGACACTTTG 1201
ACAGCTAAAG AACGCGAACA GATTTTGGCA TACAGCAAAC TGGTTGCCGG 1251
TACGGTAAGC GGTGTGGTCG GCGGCGATGT AAATGCGGCG GCGAATGCGG 1301
CTGAGGTAGC GGTGAAAAAT AATCAGCTTA GCGACTAAGA GGGTAGAGAA 1351
TTTGATAACG AAATGACTGC ATGCGCCAAA CAGAATANTC CTCAACTGTG 1401
CAGAAAAAAT ACTGTAAAAA AGTATCAAAA TGTTGCTGAT AAAAGACTTG 1451
CTGCTTCGAT TGCAATATGT ACGGATATAT CCCGTAGTAC TGAATGTAGA 1501
ACAATCAGAA AACAACATTT GATCGATAGT AGAAGCCTTC ATTCATCTTG 1551
GGAAGCAGGT CTAATTGGTA AAGATGATGA ATGGTATAAA TTATTCAGCA 1601
AATCTTACAC CCAAGCAGAT TTGGCTTTAC AGTCTTATCA TTTGAATACT 1651
GCTGCTAAAT CTTGGCTTCA ATCGGGCAAT ACAAAGCCTT TATCCGAATG 1701
GATGTCCGAC CAAGGTTATA CACTTATTTC AGGAGTTAAT CCTAGATTCA 1751
TTCCAATACC AAGAGGGITF GTAAAACAAA ATACACCTAT TACTAATGTC 1801
AAATACCCGG AAGGCATCAG TTTCGATACA AACCTANAAA GACATCTGGC 1851
AAATGCTGAT GGTTTTAGTC AAGAACAGGG CATTAAAGGA GCCCATAACC 1901
GCACCAATNT TATGGCAGAA CTAAATTCAC GAGGAGGANG NGTAAAATCT 1951
GAAACCCANA CTGATATTGA AGGCATTACC CGAATTAAAT ATGAGATTCC 2001
TACACTAGAC AGGACAGGTA AACCTGATGG TGGATTTAAG GAAATTTCAA 2051
GTATAAAAAC TGTTTATAAT CCTAAAAANT TTTNNGATGA TAAAATACTT 2101
CAAATGGCTC AANATGCTGN TTCACAAGGA TATTCAAAAG CCTCTAAAAT 2151
TGCTCAAAAT GAAAGAACTA AATCAATATC GGAAAGAAAA AATGTCATTC 2201
AATTCTCAGA AACCTTTGAC GGAATCAAAT TTAGANNNTA TNTNGATGTA 2251
AATACAGGAA GAATTACAAA CATTCACCCA GAATAATTTA A
[0347] This encodes a protein having amino acid sequence <SEQ ID
22>:
37 1 XQLLAEEGIH KHELDVQKSR RFIGIKVGXS NYSKNELNET KLPVRVVAQX 51
AATRSGWDTV LEGTEFKTTL AGADIQAGVX EKARVOAKII LKGIVNRIQS 101
EEKLETNSTV WQKQAGRGST IETLKLPSFE SPTPPKLSAP GGYIVDIPKG 151
NLKTEIEKLS KQPEYAYLKQ LQVAKNINWN QVQLAYDRWD YKQEGLTEAG 201
AAIIALAVTV VTSGAGTGAV LGLNGAXAAA TORAFASLAS QASVSFINNK 251
GDVGKTLKEL GRSSTVKNLV VAAATAGVAD KIGASALXNV SDKQNINNLT 301
VNLANAGSAA LINTAVNGGS LKDXLEANIL AALVNTAHGE AASKIKQLDQ 351
HYIVHKIAHA IAGCAAAAAN KGKCQDGAIG AAVGEIVGEA LTNGKNPDTL 401
TAKEREQILA YSKLVAGTVS GVVGGDVNAA ANAAEVAVKN NQLSDXEGRE 451
FDWEHTACAK QNXPQLCRXN TVKKYQNVAD KRLAASIAIC TDISRSTECR 501
TIRKQHLIDS RSLHSSWEAG LIGKDDEWYK LFSKSYTQAD LALOSYHLNT 551
AAKSWLQSGN TKPLSEWNSD QGYTLISGVN PRFIPIPRGF VKQNTPITNV 601
KYPEGISFDT NLXRHLATAD GFSQEQGIKG AHNRTNXMAE LNSRGGXVKS 651
ETXTDIEGIT RIKYEIPTLD RTGKPDGGFK EISSIKTVYN FKXFKDDKIL 701
QMAQXAXSQG YSKASKIAQN ERTKSISERK NVIQFSETFD GIKFRXYXDV 751
NTGRITNIHP E
[0348] Based on the presence of a putative transmembrane domain, it
is predicted that these proteins from N. meningitidis, and their
epitopes, could be useful antigens for vaccines or diagnostics.
Example 5
[0349] The following partial DNA sequence was identified in N.
meningitidis SEQ ID 23>
38 1 ..CGGATCGTTG TAGGTTTGCG GATTTCTTGC GCCGTAGTCA CCGTAGTCCC 51
AAGTATAACC CAAGGCTTTG TCTTCGCCTT TCATTCCGAT AAGGGATATG 101
ACGCTTTGGT CGGTATAGCC GTCTTGGGAA CCTTTGTCCA CCCAACGCAT 151
ATCTGCCTGC GGATTCTCAT TGCCGCTTCT TGGCTGCTGA TTTTTCTGCC 201
TTCGCGTTTT TCAACTTCGC GCTTGAGGGC TTCGGCATAT TTGTCGGCCA 251
ACGCCATTTC TTTCGGATGC AGCTGCCTAT TGTTCCAATC TACATTCGCA 301
CCCACCACAG CACCACCACT ACCACCAGTT GCATAG
[0350] This corresponds to the amino acid sequence <SEQ ID 24;
ORF50>:
39 1 ..RIVVGLRISC AVVTVVPSIT QGFVFAFHSD KGYDALVGIA VLGTFVHPTH 51
ICLRILIAAS WLLIFLPSRF STSRLRASAY LSANAISFGC SCLLFQSTFA 101
PTTAPPLPPV A*
[0351] Computer analysis predicts two transmembrane domains and
also indicates that ORF50 has no significant amino acid homology
with known proteins.
[0352] Based on the presence of a putative transmembrane domain, it
is predicted that this protein from N. meningitidis, and its
epitopes, could be useful antigens for vaccines or diagnostics.
Example 6
[0353] The following partial DNA sequence was identified in N.
meningitidis <SEQ ID 25>
40 1 ..AAGTTTGACT TTACCTGGTT TATTCCGGCG GTAATCAAAT ACCGCCGGTT 51
GTTTTTTGAA GTATTGGTGG TGTCGGTGGT GTTGCAGCTG TTTGCGCTGA 101
TTACGCCTCT GTTTTTCCAA GTGGTGATGG ACAAGGTGCT GGTACATCGG 151
GGATTCTCTA CTTTGGATGT GGTGTCGGTG GCTTTGTTGG TGGTGTCGCT 201
GTTTGAGATT GTGTTGGGCG GTTTGCGGAC GTATCTGTTT GCACATACGA 251
CTTCACGTAT TGATGTGGAA TTGGGCGCGC GTTTGTTCCG GCATCTGCTT 301
TCCCTGCCTT TATCCTATTT CGAGCACAGA CGAGTGGGTG ATACGGTGGC 351
TCGGGTGCGG GAATTGGAGC AGATTCGCAA TTTCTTGACC GGTCAGGCGC 401
TGACTTCGGT GTTGGATTTG GCGTTTTCGT TTATCTTTCT GGCGGTGATG 451
TGGTATTACA GCTCCACTCT GACTTGGGTG GTATTGGCTT CGTTG..... // 1451
.......... .......... .......... .......... .......... 1501
.......... .......... .......... .......... ..ATTTGCGC 1551
CAACCGGACG GTGCTGATTA TCGCCCACCG TCTGTCCACT GTTAAAACGG 1601
CACACCGGAT CATTGCCATG GATAAAGGCA GGATTGTGGA AGCGGGAACA 1651
CAGCAGGAAT TGCTGGCGAA CG..AACGGA TATTACCGCT ATCTGTATGA 1701
TTTACAGAAC GGGTAG
[0354] This corresponds to the amino acid sequence <SEQ ID 26;
ORF39>:
41 1 ..KFDFTWFIPA VIKYRRLFFE VLVVSVVLQL FALITPLFFQ VVMDKVLVHR 51
GFSTLDVVSV ALLVVSLFEI VLGGLRTYLF AHTTSRIDVE LGARLFRHLL 101
SLPLSYFEHP RVGDTVARVR ELEQIRNFLT GQALTSVLDL AFSFIFLAVM 151
WYYSSTLTWV VLASL..... .......... .......... .......... // 501
.......... ....ICANRT VLIIAHRLST VKTAHRIIAH DKGRIVEAGT 551
QQELLANXNG YYRYLYDLQN G*
[0355] Further work revealed the complete nucleotide sequence
<SEQ ID 27>:
42 1 ATGTCTATCG TATCCGCACC GCTCCCCGCC CTTTCCGCCC TCATCATCCT 51
CGCCCATTAC CACGGCATTG CCGCCAATCC TGCCGATATA CAGCATGAAT 101
TTTGTACTTC CGCACAGAGC GATTTAAATG AAACGCAATG GCTGTTAGCC 151
GCCAAATCTT TGGGATTGAA GGCAAAGGTA GTCCGCCAGC CTATTAAACG 201
TTTGGCTATG GCGACTTTAC CCGCATTGGT ATGGTGTGAT GACGGCAACC 251
ATTTCATTTT GGCCAAAACA GACGGTGAGG GTGAGCATGC CCAATTTTFG 301
ATACAGGATT TGGTTACGAA TAAGTCTGCG GTATTGTCTT TTGCCGAATT 351
TTCTAACAGA TATTCGGGCA AACTGATATT GGTTGCTTCC CGCGCTTCGG 401
TATTGGGCAG TTTGGCAAAG TTTGACTTTA CCTGGTTTAT TCCGGCGGTA 451
ATCAAATACC GCCGGTTGTT TTTTGAAGTA TTGGTGGTGT CGGTGGTGTT 501
GCAGCTGTTT GCGCTGATTA CGCCTCTGTT TTTCCAAGTG GTGATGGACA 551
AGGTGCTGGT ACATCGGGGA TTCTCTACTT TGGATGTGGT GTCGGTGGCT 601
TTGTTGGTGG TGTCGCTGTT TGAGATTGTG TTGGGCGGTT TGCGGACGTA 651
TCTGTTTGCA CATACGACTT CACGTATTGA TGTGGAATTG GGCGCGCGTT 701
TGTTCCGGCA TCTGCTTTCC CTGCCTTTAT CCTATTTCGA GCACAGACGA 751
GTGGGTGATA CGGTGGCTCG GGTGCGGGAA TTGGAGCAGA TTCGCAATTT 801
CTTGACCGGT CAGGCGCTGA CTTCGGTGTT GGATTTGGCG TTTTCGTTTA 951
TCTTTCTGGC GGTGATGTGG TATTACAGCT CCACTCTGAC TTGGGTGGTA 901
TTGGCTTCGT TGCCTGCCTA TGCGTTTTGG TCGGCATTTA TCAGTCCGAT 951
ACTGCGGACG CGTCTGAACG ATAAGTTCGC GCGCAATGCA GACAACCAGT 1001
CGTTTTTAGT AGAAAGCATC ACTGCGGTGG GTACGGTAAA GGCGATGGCG 1051
GTGGAGCCGC AGATGACGCA GCGTTGGGAC AATCAGTTGG CGGCTTATGT 1101
GGCTTCGGGA TTTCGGGTAA CGAAGTTGGC GGTGGTCGGC CAGCAGGGGG 1151
TGCAGCTGAT TCAGAAGCTG GTGACGGTGG CGACGTTGTG GATTGGCGCA 1201
CGGCTGGTAA TTGAGAGCAA GCTGACGGTG GGGCAGCTGA TTGCGTTTAA 1251
TATGCTCTCG GGACACGTGG CGGCGCCTGT TATCCGTTTG GCGCAGTTGT 1301
GGCAGGATTT CCAGCAGGTG GGGATTTCGG TGGCGCGTTT GGGGGATATT 1351
CTGAATGCGC CGACCGAGAA TGCGTCTTCG CATTTGGCTT TGCCCGATAT 1401
CCGGGGGGAG ATTACGTTCG AACATGTCGA TTTCCGCTAT AAGGCGGACG 1451
GCAGGCTGAT TTTGCAGGAT TTGAACCTGC GGATTCCGGC GGGGGAAGTG 1501
CTGGGGATTG TGGGACGTTC GGGGTCGGGC AAATCCACAC TCACCAAATT 1551
GGTGCAGCGT CTGTATGTAC CGGAGCAGGG ACGGGTGTTG GTGGACGGCA 1601
ACGATTTGGC TTTGGCCGCT CCTGCCTGGC TGCGGCGGCA GGTCGGCGTG 1651
GTCTTGCAGG AGAATGTGCT GCTCAACCGC AGCATACGCG ACAATATCGC 1701
GCTGACGGAT ACGGGTATGC CGCTGGAACG CATTATCGAA GCAGCCAAAC 1751
TGGCGGGCGC ACACGAGTTT ATTATGGAGC TGCCGGAAGG CTACGGCACC 1801
GTGGTGGGCG AACAAGGGGC CGGCTTGTCG GGCGGACAGC GGCAGCGTAT 1951
TGCGATTGCC CGCGCGTTAA TCACCAATCC GCGCATTCTG ATTTTTGATG 1901
AAGCCACCAG CGCGCTGGAT TATGAAAGTG AACGAGCGAT TATGCAGAAC 1951
ATGCAGGCCA TTTGCGCCAA CCGGACGGTG CTGATTATCG CCCACCGTCT 2001
GTCCACTGTT AAAACGGCAC ACCGGATCAT TGCCATGGAT AAAGGCAGGA 2051
TTGTGGAAGC GGGAACACAG CAGGAATTGC TGGCGAAGCC GAACGGATAT 2101
TACCGCTATC TGTATGATTT ACAGAACGGG TAG
[0356] This corresponds to the amino acid sequence <SEQ ID 28;
ORF39-1>:
43 1 MSIVSAPLPA LSALIILAMY HGIAANPADI QHEFCTSAQS DLNETQWLLA 51
AKSLGLKAKV VRQPIKRLAM ATLPALVWCD DGNHFILAKT DGEGEHAQFL 101
IQDLVTNKSA VLSFAEFSNR YSGKLILVAS RASVLGSLAK FDFTWFIPAV 151
IKYRRLFFEV LVVSVVLQLF ALITPLFFQV VMDKVLVHRG FSTLDVVSVA 201
LLVVSLFEIV LGGLRTYLFA HTTSRIDVEL GARLFRHLLS LPLSYFEHPA 251
VGDTVARVRE LEQIRNFLTG QALTSVLDLA FSFIFLAVMW YYSSTLTWVV 301
LASLPAYAFW SAFISPILRT RLNDKFAPNA DNQSFLVESI TAVGTVKAMA 351
VEPQHTQRWD NQLAAYVASG FRVTKLAVVG QQGVQLIQKL VTVATLWIGA 401
RLVIESRLTV GQLIAFNMLS GQVAAPVIRL AQLWQDFQQV GISVARLGDI 451
VVAPTENASS HLALPDIRGE ITFEHVDFRY KADGRLILQD LNLRIRAGEV 501
LGIVGRSGSG KSTLTKLVQR LYVPEQGRVL VDGNDLALAA PAWLRRQVGV 551
VLOENVLLNR SIRDNIALTD TGNPLERIIE AAKLAGAHEF IMELPEGYGT 601
VVGEQGAGLS GGQRQRIAIA RALITNPRIL IFDEATSALD YESERAINQN 651
MQAICANRTV LIIAHRLSTV KTAHRIIAND KGRIVEAGTQ QELLAKPNGY 701
YRYLYDLQNG *
[0357] Computer analysis of this amino acid sequence gave the
following results:
[0358] Homology with a Predicted ORF from N. meningitidis (Strain
A)
[0359] ORF39 shows 100% identity over a 165 aa overlap with an ORF
(ORF39a) from strain A of N. meningitidis:
44 10 20 30 orf39.pep KFDFTWFIPAVIKYRRLFFEVLVV- SVVLQL
.vertline..vertline..vertli-
ne..vertline..vertline..vertline..vertline..vertline..vertline..vertline..-
vertline..vertline..vertline..vertline..vertline..vertline..vertline..vert-
line..vertline..vertline..vertline..vertline..vertline..vertline..vertline-
..vertline..vertline..vertline..vertline..vertline. orf39a
AVLSFAEFSNRYSGKLILVASRASVLGSLAKFDFTWFIPAVIKYRRLFFEVLVVSVVLQL 110
120 130 140 150 160 40 50 60 70 80 90 orf39.pep
FALITPLFFQVVMDKVLVHRGFSTLDVVSVALLVVSLFEIVLGGLRTYLFAHTTSRIDVE
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline..vertline..vertline..vertline..vertline..vertline..-
vertline..vertline..vertline..vertline..vertline..vertline..vertline..vert-
line..vertline..vertline..vertline..vertline..vertline..vertline..vertline-
..vertline..vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline..vertline..vertline..vertline..vertline..vertline..-
vertline. orf39a FALITPLFFQVVMDKVLVHRGFSTLDVVSVALLVVSLFEIVLGGLRTY-
LFAHTTSRIDVE 170 180 190 200 210 220 100 110 120 130 140 150
orf39.pep LGARLFRHLLSLPLSYFEHRRVGDTVARVRELEQIRNFLTGQALTSVL-
DLAFSFIFLAVM .vertline..vertline..vertline..vertline..vertline..-
vertline..vertline..vertline..vertline..vertline..vertline..vertline..vert-
line..vertline..vertline..vertline..vertline..vertline..vertline..vertline-
..vertline..vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline..vertline..vertline..vertline..vertline..vertline..-
vertline..vertline..vertline..vertline..vertline..vertline..vertline..vert-
line..vertline..vertline..vertline..vertline..vertline..vertline..vertline-
..vertline..vertline..vertline. orf39a LGARLFRHLLSLPLSYFEHRRVGDTV-
ARVRELEQIRNFLTGQALTSVLDLAFSFIFLAVM 230 240 250 260 270 280 160 170
180 190 200 210 orf39.pep WYYSSTLTWVVLASLXXXXXXXXX-
XXXXXXXXXXXXXXXXXXXICANRTVLIIAHRLSTV .vertline..vertline..vertli-
ne..vertline..vertline..vertline..vertline..vertline..vertline..vertline..-
vertline..vertline..vertline..vertline..vertline. orf39a
WYYSSTLTWVVLASLPAYAFWSAFISPILRTRLNDKFARNADNQSFLVESITAVGTVKAM 290
300 310 320 330 340
[0360] ORF39-1 and ORF39a show 99.4% identity in 710 aa
overlap:
45 orf39-1.pep
MSIVSAPLPALSALIILAHYHGIAANPADIQHEFCTSAQSDLNETQWLLAAK- SLGLKAKV
.vertline..vertline..vertline..vertline..vertline..vertl-
ine..vertline..vertline..vertline..vertline..vertline..vertline..vertline.-
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ver-
tline..vertline..vertline..vertline..vertline..vertline..vertline..vertlin-
e..vertline..vertline..vertline..vertline..vertline..vertline..vertline..v-
ertline..vertline..vertline..vertline..vertline..vertline..vertline..vertl-
ine..vertline..vertline..vertline..vertline..vertline..vertline..vertline.-
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ver-
tline..vertline..vertline. orf39a
MSIVSAPLPALSALIILAHYHGIAANPADIQHE- FCTSAQSDLNETQWLLAAKSLGLKAKV
orf39-1.pep
VRQPIKRLAMATLPALVWCDDGNHFILAKTDGEGEHAQFLIQDLVTNKSAVLSFAEFSNR
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline..vertline..vertline..vertline..vertline..vertline..-
vertline..vertline..vertline..vertline..vertline..vertline..vertline..vert-
line..vertline..vertline.
.vertline..vertline..vertline..vertline..vertlin-
e.:.vertline..vertline..vertline..vertline..vertline.:.vertline..vertline.-
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ver-
tline..vertline..vertline..vertline..vertline..vertline. orf39a
VRQPIKRLAMATLPALVWCDDGNHFILAKTDGGGEHAQYLIQDLTTNKSAVLSFAEFSNR
orf39-1.pep
YSGKLILVASRASVLGSLAKFDFTWFIPAVIKYRRLFFEVLVVSVVLQLFALITPLFF- QV
.vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline..vertline..vertline..vertline..vertline..vertline..-
vertline..vertline..vertline..vertline..vertline..vertline..vertline..vert-
line..vertline..vertline..vertline..vertline..vertline..vertline..vertline-
..vertline..vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline..vertline..vertline..vertline..vertline..vertline..-
vertline..vertline. orf39a
YSGKLILVASRASVLGSLAKFDFTWFIPAVIKYRRLFFEV- LVVSVVLQLFALITPLFFQV
orf39-1.pep VMDKVLVHRGFSTLDVVSVALLVVS-
LFEIVLGGLRTYLFAHTTSRIDVELGARLFRHLLS .vertline..vertline..vertline.-
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ver-
tline..vertline..vertline..vertline..vertline..vertline..vertline..vertlin-
e..vertline..vertline..vertline..vertline..vertline..vertline..vertline..v-
ertline..vertline..vertline..vertline..vertline..vertline..vertline..vertl-
ine..vertline..vertline..vertline..vertline..vertline..vertline..vertline.-
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ver-
tline..vertline..vertline..vertline..vertline..vertline..vertline..vertlin-
e..vertline..vertline..vertline..vertline..vertline. orf39a
VMDKVLVHRGFSTLDVVSVALLVVSLFEIVLGGLRTYLFAHTTSRIDVELGARLFRHLLS
orf39-1.pep
LPLSYFEHRRVGDTVARVRELEQIRNFLTGQALTSVLDLAFSFIFLAVMWYYSSTLTW- VV
.vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline..vertline..vertline..vertline..vertline..vertline..-
vertline..vertline..vertline..vertline..vertline..vertline..vertline..vert-
line..vertline..vertline..vertline..vertline..vertline..vertline..vertline-
..vertline..vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline..vertline..vertline..vertline..vertline..vertline..-
vertline..vertline. orf39a
LPLSYFEHRRVGDTVARVRELEQIRNFLTGQALTSVLDLA- FSFIFLAVMWYYSSTLTWVV
orf39-1.pep LASLPAYAFWSAFISPILRTRLNDK-
FARNADNQSFLVESITAVGTVKAMAVEPQMTQRWD .vertline..vertline..vertline.-
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ver-
tline..vertline..vertline..vertline..vertline..vertline..vertline..vertlin-
e..vertline..vertline..vertline..vertline..vertline..vertline..vertline..v-
ertline..vertline..vertline..vertline..vertline..vertline..vertline..vertl-
ine..vertline..vertline..vertline..vertline..vertline..vertline..vertline.-
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ver-
tline..vertline..vertline..vertline..vertline..vertline..vertline..vertlin-
e..vertline..vertline..vertline..vertline..vertline. orf39a
LASLPAYAFWSAFISPILRTRLNDKFARNADNQSFLVESITAVGTVKAMAVEPQMTQRWD
orf39-1.pep
NQLAAQVASGFRVTKLAVVGQQGVQLIQKLVTVATLWIGARLVIESKLTVGQLIAFNM- LS
.vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline..vertline..vertline..vertline..vertline..vertline..-
vertline..vertline..vertline..vertline..vertline..vertline..vertline..vert-
line..vertline..vertline..vertline..vertline..vertline..vertline..vertline-
..vertline..vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline..vertline..vertline..vertline..vertline..vertline..-
vertline..vertline. orf39a
NQLAAQVASGFRVTKLAVVGQQGVQLIQKLVTVATLWIGA- RLVIESKLTVGQLIAFNMLS
orf39-1.pep GQVAAPVIRLAQLWQDFQQVGISVA-
RLGDILNAPTENASSHLALPDIRGEITFEHVDFRY .vertline..vertline..vertline.-
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ver-
tline..vertline..vertline..vertline..vertline..vertline..vertline..vertlin-
e..vertline..vertline..vertline..vertline..vertline..vertline..vertline..v-
ertline..vertline..vertline..vertline..vertline..vertline..vertline..vertl-
ine..vertline..vertline..vertline..vertline..vertline..vertline..vertline.-
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ver-
tline..vertline..vertline..vertline..vertline..vertline..vertline..vertlin-
e..vertline..vertline..vertline..vertline..vertline. orf39a
GQVAAPVIRLAQLWQDFQQVGISVARLGDILNAPTENASSHLALPDIRGEITFEHVDFRY
orf39-1.pep
KADGRLILQDLNLRIRAGEVLGIVGRSGSGKSTLTKLVQRLYVPEQGRVLVDGNDLAL- AA
.vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline..vertline..vertline..vertline..vertline..vertline..-
vertline..vertline..vertline..vertline..vertline..vertline..vertline..vert-
line..vertline..vertline..vertline..vertline..vertline..vertline..vertline-
..vertline..vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline..vertline..vertline..vertline..vertline..vertline..-
vertline..vertline. orf39a
KADGRLILQDLNLRIRAGEVLGIVGRSGSGKSTLTKLVQR- LYVPEQGRVLVDGNDLALAA
orf39-1.pep PAWLRRQVGVVLQENVLLNRSIRDN-
IALTDTGMPLERIIEAAKLAGAHEFIHELPEGYGT .vertline..vertline..vertline.-
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ver-
tline..vertline..vertline..vertline..vertline..vertline..vertline..vertlin-
e..vertline..vertline..vertline..vertline..vertline..vertline..vertline..v-
ertline..vertline..vertline..vertline..vertline..vertline..vertline..vertl-
ine..vertline..vertline..vertline..vertline..vertline..vertline..vertline.-
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ver-
tline..vertline..vertline..vertline..vertline..vertline..vertline..vertlin-
e..vertline..vertline..vertline..vertline..vertline. orf39a
PAWLRRQVGVVLQENVLLNRSIRDNIALTDTGMPLERIIEAAKLAGAHEFIHELPEGYGT
orf39-1.pep
VVGEQGAGLSGGQRQRIAIARALITNPRILIFDEATSALDYESERAIMQNMQAICANR- TV
.vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline..vertline..vertline..vertline..vertline..vertline..-
vertline..vertline..vertline..vertline..vertline..vertline..vertline..vert-
line..vertline..vertline..vertline..vertline..vertline..vertline..vertline-
..vertline..vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline..vertline..vertline..vertline..vertline..vertline..-
vertline..vertline. orf39a
VVGEQGAGLSGGQRQRIAIARALITNPRILIFDEATSALD- YESERAIMQNMQAICANRTV
orf39-1.pep LIIAHRLSTVKTAHRIIAMDKGRIV- EAGTQQELLAKPNGYYRYLYDLQNGX
.vertline..vertline..vertline..vertline-
..vertline..vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline..vertline..vertline..vertline..vertline..vertline..-
vertline..vertline..vertline..vertline..vertline..vertline..vertline..vert-
line..vertline..vertline..vertline..vertline..vertline..vertline..vertline-
..vertline..vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline. orf39a
LIIAHRLSTVKTAHRIIAMDKGRIVEAGTQQE- LLAKPNGYYRYLYDLQNGX
[0361] The complete length ORF39a nucleotide sequence <SEQ ID
29> is:
46 1 ATGTCTATCG TATCCGCACC GCTCCCCGCC CTTTCCGCCC TCATCATCCT 51
CGCCCATYAC CACGGCATTG CCGCCAATCC TGCCGATATA CAGCATGAAT 101
TTTGTACTTC CGCACAGAGC GATTTAAATG AAACGCAATG GCTGTTAGCC 151
GCCAAATCTT TGGGATTGAA GGCAAAGGTA GTCCGCCAGC CTATTAAACG 201
TTTGGCTATG GCGACTTTAC CCGCATTGGT ATGGTGTGAT GACGGCAACC 251
ATTTTATTTT GGCTAAAACA GACGGTGGGG GTGAGCATGC CCAATATCTA 301
ATACAGGATT TAACTACGAA TAAGTCTGCG GTATTGTCTT TTGCCGAATT 351
TTCTAACAGA TATTCGGGCA AACTGATATT GGTTGCTTCC CGCGCTTCGG 401
TATTGGGCAG TTTGGCAAAG TTTGACTTTA CCTGGTTTAT TCCGGCGGTA 451
ATCAAATACC GCCGGTTGTT TTTTGAAGTA TTGGTGGTGT CGGTGGTGTT 501
GCAGCTGTTT GCGCTGATTA CGCCTCTGTT TTTCCAAGTG GTGATGGACA 551
AGGTGCTGGT ACATCGGGGA TTCTCTATTT TGGATGTGGT GTCGGTGGCT 601
TTGTTGGTGG TGTCGCTGTT TGAGATTGTG TTGGGCGGTT TGCGGACGTA 651
TCTGTTTGCA CATACGACTT CACGTATTGA TGTGGAATTG GGCGCGCGTT 701
TGTTCCGGCA TCTGCTTTCC CTGCCTTTAT CCTATTTCGA GCACAGACGA 751
GTGGGTGATA CGGTGGCTCG GGTGCGGGAA TTGGAGCAGA TTCGCAATTT 801
CTTGACCGGT CAGGCGCTGA CTTCGGTGTT GGATTTGGCG TTTTCGTTTA 951
TCTTTCTGGC GGTGATGTGG TATTACAGCT CCACTCTGAC TTGGGTGGTA 901
TTGGCTTCGT TGCCTGCCTA TGCGTTTTGG TCGGCATTTA TCAGTCCGAT 951
ACTGCGGACG CGTCTGAACG ATAAGTTCGC GCGCAATGCA GACAACCAGT 1001
CGTTTTTAGT AGAAAGCATC ACTGCGGTGG GTACGGTAAA GGCGATGGCG 1051
GTGGAGCCGC AGATGACGCA GCGTTGGGAC AATCAGTTGG CGGCTTATGT 1101
GGCTTCGGGA TTTCGGGTAA CGAAGTTGGC GGTGGTCGGC CAGCAGGGGG 1151
TGCAGCTGAT TCAGAAGCTG GTGACGGTGG CGACGTTGTG GATTGGCGCA 1201
CGGCTGGTAA TTGAGAGCAA GCTGACGGTG GGGCAGCTGA TTGCGTTTAA 1251
TATGCTCTCG GGACAGGTGG CGGCGCCTGT TATCCGTTTG GCGCAGTTGT 1301
GGCAGGATTT CCAGCAGGTG GGGATTTCGG TGGCGCGTTT CGGGGATATT 1351
CTGAATGCGC CGACCGAGAA TGCGTCTTCG CATTTGGCTT TGCCCGATAT 1401
CCGGGGGGAG ATTACGTTCG AACATGTCGA TTTCCGCTAT AAGGCGGACG 1451
GCAGGCTGAT TTTGCAGGAT TTGAACCTGC GGATTCGGGC GGGGGAAGTG 1501
CTGGGGATTG TGGGACGTTC GGGGTCGGGC AAATCCACAC TCACCAAATT 1551
GGTGCAGCGT CTGTATGTAC CGGCGCAGGG ACGGGTGTTG GTGGACGGCA 1601
ACGATTTGGC TTTGGCCGCT CCTGCTTGGC TGCGGCGGCA GGTCGGCGTG 1651
GTCTTGCAGG AGAATGTGCT GCTCAACCGC AGCATACGCG ACAATATCGC 1701
GCTGACGGAT ACGGGTATGC CGCTGGAACG CATTATCGAA GCAGCCAAAC 1751
TGGCGGGCGC ACACGAGTTT ATTATGGAGC TGCCGGAAGG CTACGGCACC 1801
GTGGTGGGCG AACAAGGGGC CGGCTTGTCG GGCGGACAGC GGCAGCGTAT 1851
TGCGATTGCC CGCGCGTTAA TCACCAATCC GCGCATTCTG ATTTTTGATG 1901
AAGCCACCAG CGCGCTGGAT TATGAAAGTG AACGAGCGAT TATGCAGAAC 1951
ATGCAGGCCA TTTGCGCCAA CCGGACGGTG CTGATTATCG CCCACCGTCT 2001
GTCCACTGTT AAAACGGCAC ACCGGATCAT TGCCATGGAT AAAGGCAGGA 2051
TTGTGGAAGC GGGAACACAG CAGGAATTGC TGGCGAAGCC GAACGGATAT 2101
TACCGCTATC TGTATGATTT ACAGAACGGG TAG
[0362] This encodes a protein having amino acid sequence <SEQ ID
30>:
47 1 MSIVSAPLPA LSALIILAHY HGIAANPADI QHEFCTSAQS DLNETQWLLA 51
AKSLGLKAKV VRQPIKRLAN ATLPALVWCD DGNHFILAKT DGGGEHAQYL 101
IQDLTTNKSA VLSFAEFSNR YSGKLILVAS RASVIASLAX FDFTWFIPAV 151
IKYRRLFFEV LVVSVVLQLF ALITPLFFQV VNDKVLVHRG FSTLDVVSVA 201
LLVVSLFEIV LGGLRTYLFA HTTSRIDVEL GARLFRHLLS LPLSYFEHRR 251
VGDTVARVRE LEQIRNFLTG QALTSVLDLA FSFIFLAVMW YYSSTLTWVV 301
LASLPAYAFW SAFISPILRT RLNDKFARNA ONQSFLVESI TAVGTVKAMA 351
VEPQNTQRWD NQLAAYVASG FRVTKLAVVG QQGVQLIQKL VTVATLWIGA 401
RLVIESKLTV GQLIAFNHLS GQVAAPVIRL AQLWQOFQQV GISVARLGDI 451
LNAPTENASS HLALPDIRGE ITFEHVDFRY KADGRLILQD LNLRIRAGEV 501
LGIVGRSGSG KSTLTKLVQR LYVPAQGRVL VDGNDLALAA PAWLREQVGV 551
VLQENVLLNR SIRDNIALTD TGMPLERIIE AAKLAGAHEF IHPLPEGYGT 601
VVGEQGAGLS GGQRQRIAIA RALITNPRIL IFDEATSALD YESERAIMQN 651
NQAICANRTV LIIAHRLSTV KTAMRIIAMD KGRIVEAGTQ QELLAKPNGY 701
YRYLYOLQNG *
[0363] ORF39a is homologous to a cytolysin from A.
pleuropneumoniae:
48 sp.vertline.P26760.vertline.RT1B_ACTPL RTX-I TOXIN DETERMINANT B
(TOXIN RTX-I SECRETION ATP- BINDING PROTEIN) (APX-IB) (HLY-IB)
(CYTOLYSIN IB) (CLY-IB) >gi.vertline.97137.vertline.pir.vertlin-
e..vertline.D43599 cytolysin IB - Actinobacillus pleuropneumoniae
(serotype 9) >gi.vertline.36944 (X61112) ClyI-B protein
[Actinobacillus pleuropneumoniae] Length = 707 Score = 931 bits
(2379), Expect =0.0 Identities = 472/690 (68%), Positives = 540/690
(77%), Gaps = 3/690 (0%) Query: 20
YHGIAANPADIQHEFCTSAQSDLNETQWXXXXXXXXXXXXVVRQPIKRLAMATLPALVWC 79 YH
IA NP +++H+F + L+ T W V++ I RLA LPALVW Sbjct: 20
YHNIAVNPEELKHKFDLEGKG-LDLTAWLLAAKSLELKAKQVKKAIDRLAFIALPALVWR 78
Query: 80 DDGNHFILAKTDGGGEHAQYLIQDLTTNKSAVLSFAEFSNRYS-
GKLILVASRASVLGSLA 139 +DG HFIL K D E +YLI DL T+ +L AEF + Y
GKLILVASRAS++G LA Sbjct: 79 EDGKHFILTKIDN--EAKKYLIFDLETHN-
PRILEQAEFESLYQGKLILVASRASIVGKLA 136 Query: 140
KFDFTWFIPAVIKYRRXXXXXXXXXXXXXXXXXITPLFFQVVMDKVLVHRGFXXXXXXXX 199
KFDFTWFIPAVIKYR+ ITPLFFQVVMDKVLVHRGF Sbjct: 137
KFDFTWFIPAVIKYRKIFIETLIVSIFLQIFALITPLFFQVVMDKVLVHRGFSTLNVITV 196
Query: 200 XXXXXXXFEIVLGGLRTYLFAHTTSRIDVELGARLFRHLLSL-
PLSYFEHRRVGDTVARVR 259 FEIVL
GLRTY+FAH+TSRIDVELGARLFRHLL+LP+SYFE+RRVGDTVARVR Sbjct: 197
ALAIVVLFEIVLNGLRTYIFAHSTSRIDVELGARLFRHLLALPISYFENRRVGDTVARVR 256
Query: 260 ELEQIRNFLTGQALTSVLDLAFSFIFLAVMWYYSSTLTWVVLASLPAYAFWSAFI-
SPILR 319 EL+QIRNFLTGQALTSVLDL FSFIF AVMWYYS LT V+L SLP Y WS
FISPILR Sbjct: 257 ELDQIRNFLTGQALTSVLDIMFSFIFFAVMWYYSPKLTLVI-
LGSLPFYNGWSIFISPILR 316 Query: 320 TRLNDKFARNADNQSFLVESITA-
VGTVKAMAVEPQNTQRWDNQLAAYVASGFRVTKLAVV 379 RL++KFAR ADNQSFLVES+TA+
T+KA+AV PQMT WD QLA+YV++GFRVT LA + Sbjct: 317
RRLDEKFARGADNQSFLVESVTAINTIKALAVTPQMTNTWDKQLASYVSAGFRVTTLATI 376
Query: 380 GQQGVQLIQKLVTVATLWIGARLVIESKLTVGOLIAFNNLSGQVAAPVIRLAQLW-
QDFQQ 439 GQQGVQ IQK+V V TLW+GA LVI L++GQLIAFNNLSGQV
APVIRLAQLWQDFQQ Sbjct: 377 GQQGVQFIQKVVNVITLWLGAMLVISGDLSIGQLIAFNN-
LSGQVIAPVIRLAQLWQDFQQ 436 Query: 440
VGISVAPLGDILNAPTENASSHLALPDIRGEITFEHVDFRYKADGRLILQDLNLRIRAGE 499
VGISV RLGD+LN+PTE+ LALP+I+G+ITF ++ FRYX D +IL D+NL I+ GE Sbjct: 437
VGISVTRLGDVLNSPTESYQGKLALPEIKGDITFRNIRFRYXPDAPVILNDVNLSIQQG- E 496
Query: 500 VLGIVGRSGSGKSTLTKLVQRLYVPAOGRVLVDGNDLALAA-
PAWLRRQVGVVLQENVLLN 559 V+GIVGRSGSGKSTLTKL+QR Y+P G+VL+DG+DLALA P
WLRRQVGVVLQ+NVLLN Sbjct: 497
VIGIVGRSGSGKSTLTKLIQRFYIPENGQVLIDGHDLALADPNWLRRQVGVVLQDNVLLN 556
Query: 560 RSIRDNIALTDTGMPLERIIEAAKLAGAIIEFINELPEGYGTVVGEQGNLSGGQR-
QRIAI 619 RSIRDNIAL D GMP+E+I+ AAKLAGAHEFI EL EGY
T+VGEQGAGLSGGQRQRIAI Sbjct: 557 RSIRDNIALADPGMPMEKIVHAAKLAGAHEFISE-
LREGYNTIVGEOGAGLSGGQRQRIAI 616 Query: 620
ARALITNPRILIFDEATSALDYESERAIMQNMQAICANRTVLIIAHRLSTVKTAHRIIAM 679
ARAL+ NP+ILIFDEATSALDYESE IM+NM IC RTV+IIAHRLSTVK A RII M Sbjct:
617 ARALVNNPKILIFDEATSALDYESEHIIMRNMHQICKGRTVIIIAHRLSTVKNADRIIVM
676 Query: 680 DKGRIVEAGTQQELLAKPNGYYRYLYDLQN 709 +KG+IVE G +ELLA
PNG Y YL+ LQ+ Sbjct: 677 EKGQIVEQGKHKELLADPNGLYHYLHQLQS 706
[0364] Homology with the HlyB Leucotoxin Secretion ATP-Binding
Protein of Haemophilus actinomycetemcomitans (Accession Number
X53955)
[0365] ORF39 and HlyB protein show 71% and 69% amino acid identity
in 167 and 55 overlap at the N- and C-terminal regions,
respectively:
49 Orf39 1 KFDFTWFIPAVIKYRRXXXXXXXXXXXXXXXXXITPLFFQVVMDKVLVHRGFXX-
XXXXXX 60 KFDFTWFIPAVIKYR+ ITPLFFQVVMDKVLVHRGF HlyB 137
KFDFTWFIPAVIKYRKIFIETLIVSIFLQIFALITPL- FFQVVMDKVLVHRGFSTLNVITV 196
Orf39 61
XXXXXXXFEIVLGGLRTYLFAHTTSRIDVELGARLFRHLLSLPLSYFEHRRVGDTVARVR 120
FEI+LGGLRTY+FAH+TSRIDVELGARLFMLL+LP+SYFE RRVGDTVARVR HlyB 197
ALAIVVLFEIILGGLRTYVFAHSTSRIDVELGARLFRHLLALPISYFEARRVGDTVARVR 256
Orf39 121 ELEQIRNFLTGQALTSVLDLAFSFIFLAVMWYYSSTLTWVVLASLIC 167
EL+QIRNFLTGQALTS+LDL FSFIF AVMWYYS LT VVL SL C HlyB 257
ELDQIRNFLTGQALTSILDLLFSFIFFAVMWYYSPKLTLVVLGSLPC 303 // Orf39 166
ICANRTVLIIAHRLSTVKTAHRIIAMDKGRIVEAGTQQELLANXNGYYRYLYDLQ 220 IC
NRTVLIIAHRLSTVK A RII MDKG I+E G QELL + G Y YL+ LQ HlyB 651
ICQNRTVLIIAHRLSTVKNADRIIVMDKGEIIEQGKHQELLKDEKGLYSYLHQLQ 705
[0366] Based on this analysis, it is predicted that this protein
from N. meningitidis, and its epitopes, could be useful antigens
for vaccines or diagnostics.
Example 7
[0367] The following partial DNA sequence was identified in N.
meningitidis <SEQ ID 31>
50 1 ATGAAATACT TGATCCGCAC CGCCTTACTC GCAGTCGCAG CCGCCGGCAT 51
CTACGCCTGC CAACCGCAAT CCGAAGCCGC AGTGCAAGTC AAGGCTGAAA 101
ACAGCCTGAC CGCTATGCGC TTAGCCGTCG CCGACAAACA GGCAGAGATT 151
GACGGGTTGA ACGCCCAAAk sGACGCCGAA ATCAGA...
[0368] This corresponds to the amino acid sequence SEQ ID 32;
ORF52>:
51 1 MKYLIRTALL AVAAAGIYAC QPQSEAAVQV KAZNSLTANR LAVADKQAEI 51
DGLNAQXDAE IR..
[0369] Further work revealed the complete nucleotide sequence
<SEQ ID 33>:
52 1 ATGAAATACT TGATCCGCAC CGCCTTACTC GCAGTCGCAG CCGCCGGCAT 51
CTACGCCTGC CAACCGCAAT CCGAAGCCGC AGTGCAAGTC AAGGCTGAAA 101
ACAGCCTGAC CGCTATGCGC TTAGCCGTCG CCGACAAACA GGCAGAGATT 151
GACGGGTTGA ACGCCCAAAT CGACGCCGAA ATCAGACAAC GCGAAGCCGA 201
AGAATTGAAA GACTACCGAT GGATACACGG CGACGCGGAA GTGCCGGAGC 251
TGGAAAAATG A
[0370] This corresponds to the amino acid sequence <SEQ ID 34;
ORF52-1>:
53 1 MKYLIRTALL AVAAAGIYAC QPQSEAAVQV KAENSLTAMR LAVADKQAEI 51
DGLNAQIDAE IRQREAEELK DThWIHGDAE VPELEK
[0371] Computer analysis of this amino acid sequence predicts a
prokaryotic membrane lipoprotein lipid attachment site
(underlined).
[0372] ORF52-1 (7 kDa) was cloned in the pGex vectors and expressed
in E. coli, as described above. The products of protein expression
and purification were analyzed by SDS-PAGE. FIG. 4A shows the
results of affinity purification of the GST-fusion. FIG. 4B shows
plots of hydrophilicity, antigenic index, and AMPHI regions for
ORF52-1.
[0373] Based on this analysis, it is predicted that this protein
from N. meningitidis, and its epitopes, could be useful antigens
for vaccines or diagnostics.
Example 8
[0374] The following DNA sequence was identified in N. meningitidis
<SEQ ID 35>
54 1 ATGGTTATCG GAATATTACT CGCATCAAGC AAGCATGCTC TTGTCATTAC 51
TCTATTGTTA AATCCCGTCT TCCATGCATC CAGTTGCGTA TCGCGTTSGG 101
CAATACGGAA TAAAATCTGC TGTTCTGCTT TGGCTAAATT TGCCAAATTG 151
TTTATTGTTT CTTTAGGAGC AGCTTGCTTA GCCGCCTTCG CTTTCGACAA 201
CGCCCCCACA GGCGCTTCCC AAGCGTTGCC TTCCGTTACC GCACCCGTGG 251
CGATTCCCGC GCCCGCTTCG GCAGCCTGA
[0375] This corresponds to the amino acid sequence <SEQ ID 36;
ORF56>:
55 1 MVIGILLASS KHALVITLLL NPVFHASSCV SRXAIRNKIC CSALAKFAKL 51
FIVSLGAACL AAFAFDNAPT GASQALPTVT APVAIPAPAS AA*
[0376] Further work revealed the complete nucleotide sequence
<SEQ ID 37>:
56 1 ATGGCTTGTA CAGGTTTGAT GGTTTTTCCG TTAATGGTYA TCGGAATATT 51
ACTTGCATCA AGCAAGCCTG CTCCTTTCCT TACTCTATTG TTAAATCCCG 101
TCTTCCATGC ATCCAGTTGC GTATCGCGTT GGGCAATACG GAATAAAATC 151
TGCTGTTCTG CTTTGGCTAA ATTTGCCAAA TTGTTTATTG TTTCTTTAGG 201
AGCAGCTTGC TTAGCCGCCT TCGCTTTCGA CAACGCCCCC ACAGGCGCTT 251
CCCAAGCGTT GCCTACCGTT ACCGCACCCG TGGCGATTCC CGCGCCCGCT 301
TCGGCAGCCT GA
[0377] This corresponds to the amino acid sequence <SEQ ID 38;
ORF56-1>:
57 1 MACTGLMVFP LNVZGILLAS SKPAPFLTLL LNPVFHASSC VSRWAIRNKI 51
CCSALAKFAK LFIVSLGAAC LAAFAFDNAP TGASQALPTV TAPVAIPAPA 101 SAA*
[0378] Computer analysis of this amino acid sequence predicts a
leader peptide (underlined) and suggests that ORF56 might be a
membrane or periplasmic protein.
[0379] Based on this analysis, it is predicted that this protein
from N. meningitidis, and its epitopes, could be useful antigens
for vaccines or diagnostics.
Example 9
[0380] The following partial DNA sequence was identified in N.
meningitidis <SEQ ID 39>
58 1 ATGTTCAGTA TTTTAAATGT GTTTCTTCAT TGTATTCTGG CTTGTGTAGT 51
CTCTGGTGAG ACGCCTACTA TATTTGGTAT CCTTGCTCTT TTTTACTTAT 101
TGTATCTTTC TTATCTTGCT GTTTTTAAGA TTTTCTTTTC TTTTTTCTTA 151
GACAGAGTTT CACTCCGGTC TCCCAGGCTG GAGTGCAAAT GGCATGACCC 201
TTTGGCTCAC TGGCTCACGG CCACTTCTGC TATTCTGCCG CCTCAGCCTC 251
CAGGG...
[0381] This corresponds to the amino acid sequence <SEQ ID 40;
ORF63>:
59 1 MFSILNVFLR CILACVVSGE TPTIFGILAL FYLLYLSYLA VFKIFFSFFL 51
DRVSLRSPRL ECKWNDPLAH WLTATSAILP PQPPG...
[0382] Computer analysis of this amino acid sequence predicts a
transmembrane region.
[0383] Based on this analysis, it is predicted that this protein
from N. meningitidis, and its epitopes, could be useful antigens
for vaccines or diagnostics.
Example 10
[0384] The following partial DNA sequence was identified in N.
meningitidis <SEQ ID 41>
60 1 ..GTGCGGACGT GGTTGGTTTT TTGGTTGCAG CGTTTGAAAT ACCCGTTGTT 51
GCTTTGGATT GCGGATATGT TGCTGTACCG GTTGTTGGGC GGCGCGGAAA 101
TCGAATGCGG CCGTTGCCCT GTGCCGCCGA TGACGGATTG GCAGCATTTT 151
TTGCCGGCGA TGGGAACGGT GTCGGCTTGG GTGGCGGTGA TTTGGGCATA 201
CCTGATGATT GAAAGTGAAA AAAACGGAAG ATATTGA
[0385] This corresponds to the amino acid sequence <SEQ ID 42;
ORF69>:
61 1 ..VRTWLVFWLQ RLKYPLLLWI ADNLLYRLLG GAE1ECGRCP VPPMTDWQHF 51
LPANGTVSAW VAVIWAYLMI ESEKNGRY*
[0386] Computer analysis of this amino acid sequence predicts a
transmembrane region.
[0387] A corresponding ORF from strain A of N. meningitidis was
also identified:
[0388] Homology with a Predicted ORF from N. meningitidis (Strain
A)
[0389] ORF69 shows 96.2% identity over a 78 aa overlap with an ORF
(ORF69a) from strain A of N. meningitidis:
62 10 20 30 40 50 60 orf69.pep
VRTWLVFWLQRLKYPLLLWIADMLLYRLLGGAEIECGRCPVPPMTDWQHFLPAMGTVS- AW
.vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline..vertline..vertline.
.vertline..vertline..vertline.-
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ver-
tline..vertline..vertline..vertline..vertline..vertline..vertline..vertlin-
e..vertline..vertline..vertline..vertline..vertline..vertline..vertline..v-
ertline..vertline..vertline..vertline..vertline..vertline..vertline..vertl-
ine.:.vertline..vertline..vertline..vertline.:.vertline..vertline.
orf69a VRTWLVFWLQRLKYPLLLCIADMLLYRLLGGAEIECGRCPVPPMTDWQHFLPTMGTVAAW
10 20 30 40 50 60 70 79 orf69.pep VAVIWAYLMIESEKNGRYX
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline..vertline..vertline. orf69a
VAVIWAYLMIESEKNGRYX 70 79
[0390] The ORF69a nucleotide sequence <SEQ ID 43> is:
63 1 GTGCGGACGT GGTTGGTTTT TTGGTTGCAG CGTTTGAAAT ACCCGTTGTT 51
GCTTTGTATT GCGGATATGC TGCTGTACCG GTTGTTGGGC GGCGCGGAAA 101
TCGAATGCGG CCGTTGCCCT GTACCGCCGA TGACGGATTG GCAGCATTTT 151
TTGCCGACGA TGGGAACGGT GGCGGCTTGG GTGGCGGTGA TTTGGGCATA 201
CCTGATGATT GAAAGTGAAA AAAACGGAAG ATATTGA
[0391] This encodes a protein having amino acid sequence <SEQ ID
44>:
64 1 VRTWLVFWLQ RLKYPLLLCI ADMLLYRLLG GAEIECGRCP VPPNTDWQHF 51
LPTMGTVAAW VAVIWAYLMI ESEKNGRY*
[0392] Based on this analysis, it is predicted that this protein
from N. meningitidis, and its epitopes, could be useful antigens
for vaccines or diagnostics.
Example 11
[0393] The following DNA sequence was identified in N. meningitidis
<SEQ ID 45>
65 1 ATGTTTCAAA ATTTTGATTT GGGCGTGTTC CTGCTTGCCG TCCTCCCCGT 51
GCTGCCCTCC ATTACCGTCT CGCACGTGGC GCGCGGCTAT ACGGCGCGCT 101
ACTGGGGAGA CAACACTGCC GAACAATACG GCAGGCTGAC ACTGAACCCC 151
CTGCCCCATA TCGATTTGGT CGGCACAATC ATCgTACCGC TGCTTACTTT 201
GATGTTCACG CCCTTCCTGT TCGGCTGGGC GCGTCCGATT CCTATCGATT 251
CGCGCAACTT CCGCAACCCG cGCCTTGCCT GGCGTTGCGT TGCCGCGTCC 301
GGCCCGCTGT CGAATCTAGC GATGGCTGTw CTGTGGGGCG TGGTTTTGGT 351
GCTGACTCCG TATGTCGGCG GGGCGTATCA GATGCCGTTG GCTCAAATGG 401
CAAACTACGG TATTCTGATC AATGCGATTC TGTTCGCGCT CAACATCATC 451
CCCATCCTGC CTTGGGACGG CGGCATTTTC ATCGACACCT TCCTGTCGGC 501
GAAATATTCG CAAGCGTTCC GCAAAATCGA ACCTTATGGG ACGTGGATTA 551
TCCTACTGCT GATGCTGACC SGGGTTTTGG GTGCGTTTAT wGCACCGATT 601
sTGCGGmTGc GTGATTGCrT TTGTGCAGAT GTwCGTCTGA CTGGCTTTCA 651
GACGGCATAA
[0394] This corresponds to the amino acid sequence <SEQ ID 46;
ORF77>:
66 1 MFQNFDLGVF LLAVLPVLPS ITVSNVARGY TARYWGDNTA EQYGRLTLNP 51
LPHIDLVGTI IVPLLTLMFT PFLFGWPRPI PIDSRNFRNP RLAWRCVAAS 101
GPLSNLAMAV LWGVVLVLTP YVGGAYQMPL AQMANYGILI NAILFPLNII 151
PILPWDGGIF IDTFLSAKYS QAFRKIEPYG TWIILLLMLT XVLGAFIAPI 201
XRXRDCXCAD VRLTGFQTA*
[0395] Further work revealed the complete nucleotide sequence
<SEQ ID 47>:
67 1 ATGTTTCAAA ATTTTGATTT GGGCGTGTTT CTGCTTGCCG TCCTGCCCGT 51
GCTGCTCTCC ATTACCGTCA GGGAGGTGGC GCGCGGCTAT ACGGCGCGCT 101
ACTGGGGAGA CAACACTGCC GAACAATACG GCAGGCTGAC ACTGAACCCC 151
CTGCCCCATA TCGATTTGGT CGGCACAATC ATCGTACCGC TGCTTACTTT 201
GATGTTCACG CCCTTCCTGT TCGGCTGGGC GCGTCCGATT CCTATCGATT 251
CGCGCAACTT CCGCAACCCG CGCCTTGCCT GGCGTTGCGT TGCCGCGTCC 301
GGCCCGCTGT CGAATCTAGC GATGGCTGTT CTGTGGGGCG TGGTTTTGGT 351
GCTGACTCCG TATGTCGGCG GGGCGTATCA GATGCCGTTG GCTCAAATGG 401
CAAACTACGG TATTCTGATC AATGCGATTC TGTTCGCGCT CAACATCATC 451
CCCATCCTGC CTTGGGACGG CGGCATTTTC ATCGACACCT TCCTGTCGGC 501
GAAATATTCG CAAGCGTTCC GCAAAATCGA ACCTTATGGG ACGTGGATTA 551
TCCTACTGCT GATGCTGACC GGGGTTTTGG GTGCGTTTAT TGCACCGATT 601
GTGCGGCTGG TGATTGCGTT TGTGCAGATG TTCGTCTGA
[0396] This corresponds to the amino acid sequence <SEQ ID 48;
ORF77-1>:
68 1 MFQNFDLGVF LLAVLPVLLS ITVREVARGY TARYWGDNTA EQYGRLTLNP 51
LPHIDLVGTI IVPLLTLMFT PFLFGWARPI PIDSRNFRNP RLAWRCVAAS 101
GPLSNLAMAV LWGVVLVLTP YVGGAYQMPL AQMANYGILI NAILFALNII 151
PILPWDGGIF IDTFLSAXYS QAYRRIEPYG TWIILLLNLT GVLGAFIAPI 201
VRLVIAFVQH FV*
[0397] Computer analysis of this amino acid sequence reveals a
putative leader sequence and several transmembrane domains.
[0398] A corresponding ORF from strain A of N. meningitidis was
also identified:
[0399] Homology with a Predicted ORF from N. meningitidis (Strain
A)
[0400] ORF77 shows 96.5% identity over a 173 aa overlap with an ORF
(ORF77a) from strain A of N. meningitidis:
69 10 20 30 40 50 60 ort77.pep
MFQNFDLGVFLLAVLPVLPSITVSHVARGYTARYWGDNTAEQYGRLTLNPLPHIDLVG- TI
.vertline..vertline..vertline..vertl-
ine..vertline..vertline..vertline..vertline..vertline..vertline..vertline.-
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ver-
tline..vertline..vertline..vertline..vertline..vertline..vertline..vertlin-
e..vertline..vertline..vertline..vertline..vertline..vertline..vertline.
orf77a RGYTARYWGDNTAEQYGRLTLNPLPHIDLVGTI 10 20 30 70 80 90 100 110
120 orf77.pep
IVPLLTLMFTPFLFGWARPIPIDSRNFRNPRLAWRCVAASGPLSNLAMAVLWGVVLVLT- P
.vertline..vertline..vertline..vertline..vertline..vertline..ver-
tline..vertline..vertline..vertline..vertline..vertline..vertline..vertlin-
e..vertline..vertline..vertline..vertline..vertline..vertline..vertline..v-
ertline..vertline..vertline..vertline..vertline..vertline..vertline..vertl-
ine..vertline..vertline..vertline..vertline..vertline..vertline..vertline.-
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ver-
tline..vertline..vertline..vertline..vertline..vertline..vertline..vertlin-
e..vertline..vertline..vertline..vertline..vertline..vertline..vertline..v-
ertline..vertline. orf77a
IVPLLTLMFTPFLFGWARPIPIDSRNFRNPRLAWRCVAASG- PLSNLAMAVLWGVVLVLTP 40
50 60 70 80 90 130 140 150 160 170 180 orf77.pep
YVGGAYQMPLAQMANYGILINAILFALNIIPILPWDGGI- FIDTFLSAKYSQAFRKIEPYG
.vertline..vertline..vertline..vertline..ver-
tline..vertline..vertline..vertline..vertline..vertline..vertline..vertlin-
e..vertline..vertline..vertline..vertline.
.vertline..vertline..vertline..-
vertline..vertline..vertline..vertline.
.vertline..vertline..vertline..ver-
tline..vertline..vertline..vertline..vertline..vertline..vertline..vertlin-
e..vertline..vertline..vertline..vertline..vertline..vertline..vertline..v-
ertline..vertline..vertline..vertline..vertline.
.vertline..vertline..vert-
line..vertline..vertline..vertline..vertline..vertline..vertline..vertline-
..vertline. orf77a
YVGGAYQMPLAQMANYXILINAILXALNIIPILPWDGGIFIDTFLSAK- XSQAFRKIEPYG 100
110 120 130 140 150 190 200 210 220 orf77.pep
TWIILLLMLTGVLGAFIAPIVRLVIAFVQMFVX
.vertline..vertline..vertline..vertline.
.vertline..vertline..vertline..v-
ertline..vertline..vertline..vertline..vertline..vertline..vertline.
.vertline..vertline..vertline..vertline..vertline.:.vertline..vertline..v-
ertline..vertline..vertline..vertline..vertline..vertline..vertline..vertl-
ine..vertline. orf77a TWIIXLLMLTGVLGAXIAPIVQLVIAFVQMFVX 160 170
180
[0401] ORF77-1 and ORF77a show 96.8% identity in 185 aa
overlap:
70 10 20 30 40 50 60 orf77-1.pep
MFQNFDLGVFLLAVLPVLLSITVREVARGYTARYWGDNTAEQYGRLTLNPLPHIDL- VGTI
.vertline..vertline..vertline..ver-
tline..vertline..vertline..vertline..vertline..vertline..vertline..vertlin-
e..vertline..vertline..vertline..vertline..vertline..vertline..vertline..v-
ertline..vertline..vertline..vertline..vertline..vertline..vertline..vertl-
ine..vertline..vertline..vertline..vertline..vertline..vertline..vertline.
orf77a RGYTARYWGDNTAEQYGRLTLNPLPHIDLVGT- I 10 20 30 70 80 90 100
110 120 orf77-1.pep
IVPLLTLMFTPFLFGWARPIPIDSRNFRNPRLAWRCVAASGPLSNLAMAVLWGVVLV- LTP
.vertline..vertline..vertline..vertline..vertline..vertline..v-
ertline..vertline..vertline..vertline..vertline..vertline..vertline..vertl-
ine..vertline..vertline..vertline..vertline..vertline..vertline..vertline.-
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ver-
tline..vertline..vertline..vertline..vertline..vertline..vertline..vertlin-
e..vertline..vertline..vertline..vertline..vertline..vertline..vertline..v-
ertline..vertline..vertline..vertline..vertline..vertline..vertline..vertl-
ine..vertline..vertline..vertline..vertline..vertline..vertline..vertline.-
.vertline..vertline. orf77a
IVPLLTLMFTPFLFGWARPIPIDSRNFRNPRLAWRCVAA- SGPLSNLAMAVLWGVVLVLTP 40
50 60 70 80 90 130 140 150 160 170 180 orf77-1.pep
YVGGAYQMPLAQMANYGILINAILFALNIIPILPWDG- GIFIDTFLSAKYSQAFRKIEPYG
.vertline..vertline..vertline..vertline..v-
ertline..vertline..vertline..vertline..vertline..vertline..vertline..vertl-
ine..vertline..vertline..vertline..vertline.
.vertline..vertline..vertline-
..vertline..vertline..vertline..vertline.
.vertline..vertline..vertline..v-
ertline..vertline..vertline..vertline..vertline..vertline..vertline..vertl-
ine..vertline..vertline..vertline..vertline..vertline..vertline..vertline.-
.vertline..vertline..vertline..vertline..vertline.
.vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline. orf77a
YVGGAYQMPLAQMANYXILINAILXALNIIPILPWDGGIFIDTFLS- AKXSQAFRKIEPYG 100
110 120 130 140 150 190 200 210 orf77-1.pep
TWIILLLMLTGVLGAFIAPIVRLVIAFVQMFVX .vertline..vertline..vertline..-
vertline.
.vertline..vertline..vertline..vertline..vertline..vertline..ver-
tline..vertline..vertline..vertline.
.vertline..vertline..vertline..vertli-
ne..vertline.:.vertline..vertline..vertline..vertline..vertline..vertline.-
.vertline..vertline..vertline..vertline..vertline. orf77a
TWIIXLLMLTGVLGAXIAPIVQLVIAFVQMFVX 160 170 180
[0402] A partial ORF77a nucleotide sequence <SEQ ID 49> was
identified:
71 1 ..CGCGGCTATA CAGCGCGCTA CTGGGGTGAC AACACTGCCG AACAATACGG 51
CAGGCTGACA CTGAACCCCC TGCCCCATAT CGATTTGGTC GGCACAATCA 101
TCGTACCGCT GCTTACTTTG ATGTTTACGC CCTTCCTGTT CGGCTGGGCG 151
CGTCCGATTC CTATCGATTC GCGCAACTTC CGCAACCCGC GCCTTGCCTG 201
GCGTTGCGTT GCCGCGTCCG GCCCGCTGTC GAATCTGGCG ATGGCTGTTC 251
TGTGGGGCGT GGTTTTGGTG CTGACTCCGT ATGTCGGTGG GGCGTATCAG 301
ATGCCGTTGG CNCAAATGGC AAACTACNNN ATTCTGATCA ATGCGATTCT 351
GTNCGCGCTC AACATCATCC CCATCCTGCC TTGGGACGGC GGCATTTTCA 401
TCGACACCTT CCTGTCGGCN AAATANTCGC AAGCGTTCCG CAAAATCGAA 451
CCTTATGGGA CGTGGATTAT CCNGCTGCTT ATGCTGACCG GGGTTTTGGG 501
TGCGTNTATT GCACCGATTG TGCAGCTGGT GATTGCGTTT GTGCAGATGT 551
TCGTCTGA
[0403] This encodes a protein having amino acid sequence <SEQ ID
50>:
72 1 ..RGYTARYWGD NTAEQYGRLT LNPLPHIDLV GTIIVPLLTL MFTPFLFGWA 51
RPIPIDSRNF RNPRLAWRCV AASGFLSNLA MAVLWGVVLV LTPYVGGAYQ 101
MPLAQNANYX ILINAILXAL NIIPILPWDG GIFIDTFLSA KXSQAFRKIE 151
PYGTWIIXLL MLTGVLGAXI APIVQLVIAF VQNFV*
[0404] Based on this analysis, it is predicted that this protein
from N. meningitidis, and its epitopes, could be useful antigens
for vaccines or diagnostics.
Example 12
[0405] The following partial DNA sequence was identified in N.
meningitidis SEQ ID 51>
73 1 ATGAACCTGA TTTCACGTTA CATCATCCGT CAAATGGCGG TTATGGCGGT 51
TTACGCGCTC CTTGCCTTCC TCGCTTTGTA CAGCTTTTTT GAAATCCTGT 101
ACGAAACCGG CAACCTCGGC AAAGGCAGTT ACGGCATATG GGAAATGCTG 151
GGCTACACCG CCCTCAAAAT GCCCGCCCGC GCCTACGAAC TGATTCCCCT 201
CGCCGTCCTT ATCGGCGGAC TGGTCTCCCT CAGCCAGCTT GCCGCCGGCA 251
GCGAACTGAC CGTCATCAAA GCCAGCGGCA TGAGCACCAA AAAGCTGCTG 301
TTGATTCTGT CGCAGTTCGG TTTTATTTTT GCTATTGCCA CCGTCGCGCT 351
CGGCGAATGG GTTGCGCCCA CACTGAGCCA AAAAGCCGAA AACATCAAAG 401
CCGCCGCCAT CAACGGCAAA ATCAACACCG GCAATACCGG CCTTTGGCTG 451
AAAGAAAAAA ACAGCGTGAT CAATGTGCGC GAAATGTTGC CCGACCAT..
[0406] This corresponds to the amino acid sequence SEQ ID 52;
ORF112>:
74 1 HNLISRYIIR QMAVMAVYAL LAFLALYSFF EILYETGNLG KGSYGIWEML 51
GYTALIQPAR AYELIPLAVL IGGLVSLSQL AAGSELTVIK ASGNSTKKLL 101
LILSQFGFIF AIATVPLGEW VAPTLSQKAE NIKAAAINGK ISTGNTGLWL 151
KEKNSVINVR EHLPDH...
[0407] Further work revealed further partial nucleotide sequence
<SEQ ID 53>:
75 1 ATGAACCTGA TTTCACGTTA CATCATCCGT CAAATGGCGG TTATGGCGGT 51
TTACGCGCTC CTTGCCTTCC TCGCTTTGTA CAGCTTTTTT GAAATCCTGT 101
ACGAAACCGG CAACCTCGGC AAAGGCAGTT ACGGCATATG GGAAATGCTG 151
GGCTACACCG CCCTCAAAAT GCCCGCCCGC GCCTACGAAC TGATTCCCCT 201
CGCCGTCCTT ATCGGCGGAC TGGTCTCCCT CAGCCAGCTT GCCGCCGGCA 251
GCGAACTGAC CGTCATCAAA GCCAGCGGCA TGAGCACCAA AAAGCTGCTG 301
TTGATTCTGT CGCAGTTCGG TTTTATTTTT GCTATTGCCA CCGTCGCGCT 351
CGGCGAATGG GTTGCGCCCA CACTGAGCCA AAAAGCCGAA AACATCAAAG 401
CCGCCGCCAT CAACGGCAAA ATCAGCACCG GCAATACCGG CCTTGCTCTG 451
AAAGAAAAAA ACAGCTTAAT CAATGTGCGC GAAATGTTGC CCGACCATAC 501
GCTTTTGGGC ATCAAAATTT GGGCGCGCAA CGATAAAAAC GAATTGGCAG 551
AGGCAGTGGA AGCCGATTCC GCCGTTTTGA ACAGCGACGG CAGTTGGCAG 601
TTGAAAAACA TCCGCCGCAG CACGCTTGGC GAAGACAAAG TCGAGGTCTC 651
TATTGCGGCT GAAGAAAACT GGCCGATTTC CGTCAAACGC AACCTGATGG 701
ACGTATTGCT CGTCAAACCC GACCAAATGT CCGTCGGCGA ACTGACCACC 751
TACATCCGCC ACCTCCAAAA CAACAGCCAA AACACCCGAA TCTACGCCAT 601
CGCATGGTGG CGCAAATTGG TTTACCCCGC CGCAGCCTGG GTGATGGCGC 851
TCGTCGCCTT TGCCTTTACC CCGCAAACCA CCCGCCACGG CAATATGGGC 901
TTAAAACTCT TCGGCGGCAT CTGTSTCGGA TTGCTGTTCC ACCTTGCCGG 951
ACGGCTCTTT GGGTTTACCA GCCAACTCGG...
[0408] This corresponds to the amino acid sequence <SEQ ID 54;
ORF112-1>:
76 1 MNLISRYIIR QMAVMAVYAL LAFLALYSFF EILYETGNLG KGSYGIWEHL 51
GYTALKMPAR AYELIPLAVL IGGLVSLSQL AAGSELTVIK ASGMSTKKLL 101
LILSQFGFIF AIATVALGEW VAPTLSQKAE NIKAAAINGK ISTGNTGLWL 151
KEKNSXINVR EHLPDHTLLG IKIWARNDKN ELAEAVEADS AVLNSDGSWQ 201
LKNIRRSTLG EDKVEVSIAA EENWPISVKR NLTDVLLVKP DQMSVGELTT 251
YIRHLONNSQ NTRIYAIAWW RKLVYPAAAW VMALVAFAFT PQTTRHGNMG 301
LKLFGGICXG LLFHLAGRLF GFTSQL...
[0409] Computer analysis of this amino acid sequence predicts two
transmembrane domains.
[0410] A corresponding ORF from strain A of N. meningitidis was
also identified:
[0411] Homology with a Predicted ORF from N. meningitidis (Strain
A)
[0412] ORF112 shows 96.4% identity over a 166 aa overlap with an
ORF (ORF112a) from strain A of N. meningitidis:
77 10 20 30 40 50 60 orf112.pep
MNLISRYIIRQMAVMAVYALLAFLALYSFFEILYETGNLGKGSYGIWEMLGYTALKM- PAR
.vertline..vertline..vertline..vertline..vertline..vertline..v-
ertline..vertline..vertline..vertline..vertline..vertline..vertline..vertl-
ine..vertline..vertline..vertline..vertline..vertline..vertline..vertline.-
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ver-
tline..vertline..vertline..vertline..vertline..vertline..vertline..vertlin-
e..vertline..vertline..vertline..vertline..vertline..vertline..vertline..v-
ertline..vertline..vertline..vertline..vertline.
.vertline..vertline..vert-
line..vertline..vertline..vertline..vertline. .vertline..vertline.
orf112a
MNLISRYIIRQMAVMAVYALLAFLALYSFFEILYETGNLGKGSYGIWEMXGYTALKMXAR 10 20
30 40 50 60 70 80 90 100 110 120 orf112.pep
AYELIPLAVLIGGLVSLSQLAAGSELTVIKASGMSTKKLLLILSQFGFIFAIATVALGEW
.vertline..vertline..vertline..vertline.:.vertline..vertline..ver-
tline..vertline..vertline..vertline..vertline..vertline..vertline..vertlin-
e..vertline.
.vertline..vertline..vertline..vertline..vertline..vertline..-
vertline..vertline..vertline.:.vertline..vertline..vertline..vertline..ver-
tline..vertline..vertline..vertline..vertline..vertline..vertline..vertlin-
e..vertline..vertline..vertline..vertline..vertline..vertline..vertline..v-
ertline..vertline..vertline..vertline..vertline..vertline..vertline..vertl-
ine..vertline..vertline..vertline..vertline..vertline..vertline.
orf112a
AYELMPLAVLIGGLVSXSQLAAGSELTVIKASGMSXKKLLLILSQFGFIFAIATVALGEW 70 80
90 100 110 120 130 140 150 160 orf112.pep
VAPTLSQKAENIKAAAINGKISTGNTGLWLKEKNSVINVREMLPDH
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline..vertline..vertline..vertline..vertline..vertline..-
vertline..vertline..vertline..vertline..vertline..vertline..vertline..vert-
line..vertline..vertline..vertline..vertline..vertline.:.vertline..vertlin-
e..vertline..vertline..vertline..vertline..vertline..vertline..vertline..v-
ertline. orf112a
VAPTLSQKAENIKAAAINGKISTGNTGLWLKEKNSIINVREMLPDHTLLG- IKIWARNDKN 130
140 150 160 orf112a
ELAEAVEADSAVLNSDGSWQLKNIRRSTLGEDKVEVSIAAEEXWPISVKRNLMDVLLVKP 190
200 210 220 230 240
[0413] A partial ORF112a nucleotide sequence <SEQ ID 55> was
identified:
78 1 ATGAACCTGA TTTCACGTTA CATCATCCGT CAAATGGCGG TTATGGCGGT 51
TTACGCGCTC CTTGCCTTCC TCGCTTTGTA CAGCTTTTTT GAAATCCTGT 101
ACGAAACCGG CAACCTCGGC AAAGGCAGTT ACGGCATATG GGAAATGNTG 151
GGNTACACCG CCCTCAAAAT GNCCGCCCGC GCCTACGAAC TGATGCCCCT 201
CGCCGTCCTT ATCGGCGGAC TGGTCTCTNT CAGCCAGCTT GCCGCCGGCA 251
GCGAACTGAN CGTCATCAAA GCCAGCGGCA TGAGCACCAA AAAGCTGCTG 301
TTGATTCTGT CGCAGTTCGG TTTTATTTTT GCTATTGCCA CCGTCGCGCT 351
CGGCGAATGG GTTGCGCCCA CACTGAGCCA AAAAGCCGAA AACATCAAAG 401
CCGCGGCCAT CAACGGCAAA ATCAGTACCG GCAATACCGG CCTTTGGCTG 451
AAAGAAAAAA ACAGCATTAT CAATGTGCGC GAAATGTTGC CCGACCATAC 501
CCTGCTGGGC ATTAAAATCT GGGCCCGCAA CGATAAAAAC GAACTGGCAG 551
AGGCAGTGGA AGCCGATTCC GCCGTTTTGA ACAGCGACGG CAGTTGGCAG 601
TTGAAAAACA TCCGCCGCAG CACGCTTGGC GAAGACAAAG TCGAGGTCTC 651
TATTGCGGCT GAAGAAAANT GGCCGATTTC CGTCAAACGC AACCTGATGG 701
ACGTATTGCT CGTCAAACCC GACCAAATGT CCGTCGGCGA ACTGACCACC 751
TACATCCGCC ACCTCCAAAN NNACAGCCAA AACACCCGAA TCTACGCCAT 801
CGCATGGTGG CGCAAATTGG TTTACCCCGC CGCAGCCTGG GTGATGGCGC 851
TCGTCGCCTT TGCCTTTACC CCGCAAACCA CCCGCCACGG CAATATGGGC 901
TTAAAANTCT TCGGCGGCAT CTGTCTCGGP TTGCTGTTCC ACCTTGCCGG 951
NCGGCTCTTC NGGTTTACCA GCCAACTCTA CGGCATCCCG CCCTTCCTCG 1001
NCGGCGCACT ACCTACCATA GCCTTCGCCT TGCTCGCCGT TTGGCTGATA 1051
CGCAAACAGG AAAAACGCTA A
[0414] This encodes a protein having amino acid sequence <SEQ ID
56>:
79 1 MNLISRYIIR QMAVMAVYAL LAFLALYSFF EILYETGNLG KGSYGIWEMK 51
GYTALKMXAR AYELMPLAVL IGGLVSXSQL AAGSELXVIX ASGNSTKKLL 101
LILSQFGFIF AIATVALGEV VAPTLSQKAE NIKAAAINGK ISTGNTGLWL 151
KEKNSIINVR EMLPDHTLLG IKIWAIWDKN ELAEAVFADS AVLNSDGSWQ 201
LKNIRRSTLG EDKVEVSIAA EEXWPISVKR NLMDVLLVKP DQMSVGELTT 251
YIRHLQXXSQ NTRIYAIAWW RKLVYPAAAW VMALVAFAFT PQTTRHGNMG 301
LKXFGGICLG LLFHLAGRLF XFTSQLYGIP PFLXGALPTI AFALLAVWLI 351
RKQEKR*
[0415] ORF112a and ORF112-1 show 96.3% identity in 326 aa
overlap:
80 orf112a.pep
MNLISRYIIRQMAVMAVYALLAFLALYSFFEILYETGNLGKGSYGIWEMXGY- TALKMXAR
.vertline..vertline..vertline..vertline..vertline..vertl-
ine..vertline..vertline..vertline..vertline..vertline..vertline..vertline.-
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ver-
tline..vertline..vertline..vertline..vertline..vertline..vertline..vertlin-
e..vertline..vertline..vertline..vertline..vertline..vertline..vertline..v-
ertline..vertline..vertline..vertline..vertline..vertline..vertline..vertl-
ine..vertline..vertline..vertline..vertline..vertline..vertline.
.vertline..vertline..vertline..vertline..vertline..vertline..vertline.
.vertline..vertline. orf112-1 MNLISRYIIRQMAVMAVYALLAFLALYSFFEILYET-
GNLGKGSYGIWEMLGYTALKMXAR orf112a.pep
AYEIIPLAVLIGGLVSXSQLAAGSELXVIKASGHSTKKLLLILSQFGFIFAIATVALGEW
.vertline..vertline..vertline..vertline.:.vertline..vertline..vertline..v-
ertline..vertline..vertline..vertline..vertline..vertline..vertline..vertl-
ine.
.vertline..vertline..vertline..vertline..vertline..vertline..vertline-
..vertline..vertline.:.vertline..vertline..vertline..vertline..vertline..v-
ertline..vertline..vertline..vertline..vertline..vertline..vertline..vertl-
ine..vertline..vertline..vertline..vertline..vertline..vertline..vertline.-
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ver-
tline..vertline..vertline..vertline..vertline..vertline. orf112-1
AYEIIPLAVLIGGLVSLSQLAAGSELTVIKASGHSTKKLLLILSQFGFIFAIATVALGEW
orf112a.pep
VAPTLSQKAENIKAAAINGKISTGNTGLWLKEKNSIINVREMLPDHTLLGIKIWARND- KN
.vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline..vertline..vertline..vertline..vertline..vertline..-
vertline..vertline..vertline..vertline..vertline..vertline..vertline..vert-
line..vertline..vertline..vertline..vertline..vertline..vertline.
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline..vertline..vertline..vertline..vertline..vertline..-
vertline..vertline. orf112-1
VAPTLSQKAENIKAAAINGKISTGNTGLWLKEKNSXIN- VREMLPDHTLLGIKIWARNDKN
orf112a.pep ELAEAVEADSAVLNSDGSWQLKN-
IRRSTLGEDKVEVSIAAEEXWPISVKRNLMDVLLVKP .vertline..vertline..vertlin-
e..vertline..vertline..vertline..vertline..vertline..vertline..vertline..v-
ertline..vertline..vertline..vertline..vertline..vertline..vertline..vertl-
ine..vertline..vertline..vertline..vertline..vertline..vertline..vertline.-
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ver-
tline..vertline..vertline..vertline..vertline..vertline..vertline..vertlin-
e..vertline..vertline.
.vertline..vertline..vertline..vertline..vertline..-
vertline..vertline..vertline..vertline..vertline..vertline..vertline..vert-
line..vertline..vertline..vertline..vertline. orf112-1
ELAEAVEADSAVLNSDGSWQLKNIRRSTLGEDKVEVSIAAEENWPISVKRNLMDVLLVKP
orf112a.pep
DQMSVGELTTYIRHLQXXSQNTRIYAIAWWRKLVYPAAAWVMALVAFAFTPQTTRHGN- MG
.vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline.
.vertline..vertline..vertline..vertline..vertline-
..vertline..vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline..vertline..vertline..vertline..vertline..vertline..-
vertline..vertline..vertline..vertline..vertline..vertline..vertline..vert-
line..vertline..vertline..vertline..vertline..vertline..vertline..vertline-
. orf112-1
DQMSVGELTTYIRHLQXXSQNTRIYAIAWWRKLVYPAAAWVMALVAFAFTPQTTRH- GNMG
orf112a.pep LKXFGGICLGLLFHLAGRLFXFTSQLYGIPPFLXGALPTIA-
FALLAVWLIRKQEXRX .vertline..vertline. .vertline..vertline..vertlin-
e..vertline..vertline.
.vertline..vertline..vertline..vertline..vertline..-
vertline..vertline..vertline..vertline..vertline..vertline.
.vertline..vertline..vertline..vertline..vertline. orf112-1
LKLFGGICXGLLFHLAGRLFGFTSQL
[0416] Based on this analysis, it is predicted that this protein
from N. meningitidis, and its epitopes, could be useful antigens
for vaccines or diagnostics.
Example 13
[0417] The following partial DNA sequence was identified in N.
meningitidis <SEQ ID 57>
81 1 ..GCAGTAGCCG AAACTGCCAA CAGCCAGGGC AAAGGTAAAC AGGCAGGCAG 51
TTCGGTTTCT GTTTCACTGA AAACTTCAGG CGACCTTTGC GGCAAACTCA 101
AAACCACCCT TAAAACTTTG GTCTGCTCTT TGGTTTCCCT GAGTATGGTA 151
TTGCCTGCCC ATGCCCAAAT TACCACCGAC AAATCACCAC CTAAAAACCA 201
GCAGGTCGTT ATCCTTAAAA CCAACACTGG TGCCCCCTTG GTGAATATCC 251
AAACTCCGAA TGGACGCGGA TTGAGCCACA ACCGCTA.TA CGCATTTGAT 301
GTTGACAACA AAGGGGCAGT GTTAAACAAC GACCGTAACA ATAATCCGTT 351
TGTGGTCAAA GGCAGTGCGC AATTGATTTT GAACGAGGTA CGCGGTACGG 401
CTAGCAAACT CAACGGCATC GTTACCGTAG GCGGTCAAAA GGCCGACGTG 451
ATTATTGCCA ACCCCAACGG CATTACCGTT AATGGCGGCG GCTTTAAAAA 501
TGTCGGTCGG GGCATCTTAA CTACCGGTGC GCCCCAAATC GGCAAAGACG 551
GTGCACTGAC AGGATTTGAT GTGCGTCAAG GCACATTGGA CCGTAGTAGC 601
AGCAGGTTGG AATGATAAAG GCGGAGCmrm yTACACCGGG GTACTTGCTC 651
GTGCAGTTGC TTTGCAGGGG AAATTwmmGG GTAAA.AACT GGCGGTTTCT 701
ACCGGTCCTC AGAAAGTAGA TTACGCCAGC GGCGAAATCA GTGCAGGTAC 751
GGCAGCGGGT ACGAAACCGA cTATTGCCCT TGATACTGCC GCACTGGGCG 901
GTATGTACGC CGACAGCATC ACACTGATTG CCAATGAAAA AGGCGTAGGC 951
GTCTAA
[0418] This corresponds to the amino acid sequence <SEQ ID 58;
ORF114>:
82 1 ..AVAETANSQG KGKQAGSSVS VSLKTSGDLC GKLKTTLKTL VCSLVSLSHV 51
LPAHAQITTD KSAPKNQQVV ILKTNTGAPL VNIQTPNGRG LSHNRXYAFD 101
VDNKGAVLNN DRNNNPFVVK GSAQLILNEV RGTASKLNGI VTVGGQKADV 151
IIANPNGITV NGGGFXNVGR GILTTGAPQI GKDGALTGFD VVKAHVTVXA 201
AGWNDKGGAX YTGVLAPAVA LQGKXXGLXL AVSTGPQKVD YASGEISAGT 251
AAGTKPTIAL DTAALGGNYA DSITLIANEX GVGV*
[0419] Further work revealed the complete nucleotide sequence SEQ
ID 59>:
83 1 ATGAATAAAG GTTTACATCG CATTATCTTT AGTAAAAAGC ACAGCACCAT 51
GGTTGCAGTA GCCGAAACTG CCAACAGCCA GGGCAAAGGT AAACAGGCAG 101
GCAGTTCGGT TTCTGTTTCA CTGAAAACTT CAGGCGACCT TTGCGGCAAA 151
CTCAAAACCA CCCTTAAAAC TTTGGTCTGC TTTTTGGTTT CCCTGAGTAT 201
GGTATTGCCT GCCCATGCCC AAATTACCAC CGACAAATCA GCACCTAAAA 251
ACCAGCAGGT CGTTATCCTT AAAACCAACA CTGGTGCCCC CTTGGTGAAT 301
ATCCAAACTC CGAATGGACG CGGATTGAGC CACAACCGCT ATACGCAGTT 351
TGATGTTGAC AACAAAGGGG CAGTGTTAAA CAACGACCGT AACAATAATC 401
CGTTTGTGGT CAAAGGCAGT GCGCAATTGA TTTTGAACGA GGTACGCGGT 451
ACGGCTAGCA AACTCAACGG CATCGTTACC GTAGGCGGTC AAAAGGCCGA 501
CGTGATTATT GCCAACCCCA ACGGCATTAC CGTTAATGGC GGCGGCTTTA 551
AAAATGTCGG TCGGGGCATC TTAACTACCG GTGCGCCCCA AATCGGCAAA 601
GACGGTGCAC TGACAGGATT TGATGTGCGT CAAGGCACAT TGACCGTAGG 651
AGCAGCAGGT TGGAATGATA AAGGCGGAGC CGACTACACC GGGGTACTTG 701
CTCGTGCAGT TGCTTTGCAG GGGAAATTAC AGGGTAAAAA CCTGGCGGTT 751
TCThCCGGTC CTCAGAAAGT AGATTACGCC AGCGGCGAAA TCAGTGCAGG 801
TACGGCAGCG GGTACGAAAC CGACTATTGC CCTTGATACT GCCGCACTGG 951
GCGGTATGTA CGCCGACACC ATCACACTGA TTGCCAATGA AAAAGGCGTA 901
GGCGTCAAAA ATGCCGGCAC ACTCGAAGCG GCCAAGCAAT TGATTGTGAC 951
TTCGTCAGGC CGCATTGAAA ACAGCGGCCG CATCGCCACC ACTGCCGACG 1001
GCACCGAAGC TTCACCGACT TATCTCTCCA TCGAAACCAC CGAAAAAGGA 1051
GCGGCAGGCA CATTTATCTC CAATGGTGGT CGGATCGAGA GCAAAGGCTT 1101
ATTGGTTATT GAGACGGGAG AAGATATCAG CTTGCGTAAC GGAGCCGTGG 1151
TGCAGAATAA CGGCAGTCTC CCAGCTACCA CGGTATTAAA TGCTGGTCAT 1201
AATTTGGTGA TTGAGAGCAA AACTAATGTG AACAATGCCA AAGGCCCGGC 1251
TACTCTGTCG GCCGACGGCC GTACCGTCAT CAAGGAGGCC AGTATTCAGA 1301
CTGGCACTAC CGTATACAGT TCCAGCAAAG GCAACGCCGA ATTAGGCAAT 1351
AACACACGCA TTACCGGGGC AGATGTTACC GTATTATCCA ACGGCACCAT 1401
CAGCAGTTCC GCCGTAATAG ATGCCAAAGA CACCGCACAC ATCGAAGCAG 1451
GCAAACCGCT TTCTTTGGAA GCTTCAACAG TTACCTCCGA TATCCGCTTA 1501
AACGGAGGCA GTATCAAGGG CGGCAAGCAG CTTGCTTTAC TGGCAGACGA 1551
TAACATTACT GCCAAAACTA CCAATCTGAA TACTCCCGGC AATCTGTATG 1601
TTCATACAGG TAAAGATCTG AATTIGAATG TTGATAAAGA TTTGTCIGCC 1651
GCCAGCATCC ATTTGAAATC GGATAACGCT GCCCATATTA CCGGCACCAG 1701
TAAAACCCTC ACTGCCTCAA AAGACATGGG TGTGGAGGCA GGCTCGCTGA 1751
ATGTTACCAA TACCAATCTG CGTACCAACT CGGGTAATCT GCACATTCAG 1801
GCAGCCAAAG GCAATATTCA GCTTCGCAAT ACCAAGCTGA ACGCAGCCAA 1851
GGCTCTCGAA ACCACCGCAT TGCAGGGCAA TATCGTTTCA GACGGCCTTC 1901
ATGCTGTTTC TGCAGACGGT CATGTATCCT TATCGGCCAA CGGTAATGCC 1951
GACTTTACCG GTCACAATAC CCTGACAGCC AAGGCCGATG TCAATGCAGG 2001
ATCGGTTGGT AAAGGCCGTC TGAAAGCAGA CAATACCAAT ATCACTTCAT 2051
CTTCAGGAGA TATTACGTTG GTTGCCGGCA ACGGTATTCA GCTTGGTGAC 2101
GGAAAACAAC GCAATTCAAT CAACGGAAAA CACATCAGCA TCAAAAACAA 2151
CGGTGGTAAT GCCGACTTAA AAAACCTTAA CGTCCATGCC AAAAGCGGGG 2201
CATTGAACAT TCATTCCGAC CGGGCATTGA GCATAGAAAA TACCAAGCTG 2251
GAGTCTACCC ATAATACGCA TCTTAATGCA CAACACGAAG GGGTAACGCT 2301
CAACCAAGTA GATGCCTACG CACACCGTCA TCTAAGCATT ACCGGCAGCC 2351
AGATTTGGCA AAACGACAAA CTGCCTTCTG CCAACAAGCT GGTGGCTAAC 2401
GGTGTATTGG CACTCAATGC GCGCTATTCC CAAATTGCCG ACAACACCAC 2451
GCTGAGAGCG GGTGCAATCA ACCTTATTGC CGGTACCGCC CTAGTCAAGC 2501
GCGGCAACAT CAATTGGAGT ACCGTTGCGA CCAAAACTTT GGAAGATAAT 2551
GCCGAATTAA AACCATTGGC CGGACGGCTG AATATTGAAG CAGGTAGCGG 2601
CACATTAACC ATCGAACCTG CCAACCGCAT CAGTGCGCAT ACCGACCTGA 2651
GCATCAAAAC AGGCGGAAAA TTGCTGTTGT CTGCAAAAGG AGGAAATGCA 2701
GGTGCGCCTA GTGCTCAAGT TTCCTCATTG GAAGCAAAAG GCAATATCCG 2751
TCTGGTTACA GGAGAAACAG ATTTAAGAGG TTCTAAAATT ACAGCCGGTA 2801
AAAACTTGGT TGTCGCCACC ACCAAAGGCA AGTTGAATAT CGAAGCCGTA 2951
AACAACTCAT TCAGCAATTA TTTTCCTACA CAAAAAGCGG CTGAACTCAA 2901
CCAAAAATCC AAAGAATTGG AACAGCAGAT TGCGCAGTTG AAAAAAAGCT 2951
CGCCTAAAAG CAAGCTGATT CCAACCCTGC AAGAAGAACG CGACCGTCTC 3001
GCTTTCTATA TTCAAGCCAT CAACAAGGAA GTTAAAGGTA AAAAACCCAA 3051
AGGCAAAGAA TACCTGCAAG CCAAGCTTTC TGCACAAAAT ATTGACTTGA 3101
TTTCCGCACA AGGCATCGAA ATCAGCGGTT CCGATATTAC CGCTTCCAAA 3151
AAACTGAACC TTCACGCCGC AGGCGTATTG CCAAAGGCAG CAGATTCAGA 3201
GGCGGCTGCT ATTCTGATTG ACGGCATAAC CGACCAATAT GAAATTGGCA 3251
AGCCCACCTA CAAGAGTCAC TACGACAAAG CTGCTCTGAA CAAGCCTTCA 3301
CGTTTGACCG GACGTACAGG GGTAAGTATT CATGCAGCTG CGGCACTCGA 3351
TGATGCACGT ATTATTATCG GTGCATCCGA AATCAAAGCT CCCTCAGGCA 3401
GCATAGACAT CAAAGCCCAT AGTGATATTG TACTGGAGGC TGGACAAAAC 3451
GATGCCTATA CCTTCTTAAA AACCAAAGGT AAAAGCGGCA AAATCATCAG 3501
AAAAACCAAG TTTACCAGCA CCCGCGACCA CCTGATTATG CCAGCCCCCG 3551
TCGAGCTGAC CGCCAACGGC ATAACGCTTC AGGCAGGCGG CAACATCGAA 3601
GCTAATACCA CCCGCTTCAA TGCCCCTGCA GGTAAAGTTA CCCTGGTTGC 3651
GGGTGAAGAG CTGCAACTGC TGGCAGAASA AGGCATCCAC AAGCACGAGT 3701
TGGATGTCCA AAAAAGCCGC CGCTTTATCG GCATCAAGGT AGGCAAGAGC 3751
AATTACAGTA AAAACGAACT GAACGAAACC AAATTGCCTG TCCGCGTCGT 3801
CGCCCAAACT GCAGCCACCC GTTCAGGCTG GGATACAGTG CTCGAAGGTA 3051
CCGAATTCAA AACCACGCTG GCCGGTGCGG ACATTCAGGC AGGTGTAGGC 3901
GAAAAAGCCC GTGCCGATGC GAAAATTATC CTCAAAGGCA TTGTGAACCG 3951
TATCCAGTCG GAAGAAAAAT TAGAAACCAA CTCAACCGTA TGGCAGAAAC 4001
AGGCCGGACG CGGCAGCACT ATCGAAACGC TGAAACTGCC CAGCTTCGAA 4051
AGCCCTACTC CGCCCAAACT GACCGCCCCC GGTGGCTATA TCGTCGACAT 4101
TCCGAAAGGC AATTTGAAAA CCGAAATCGA AAAGCTGGCC AAACAGCCCG 4151
AGTATGCCTA TCTGAAACAG CTCCAAGTAG CGAAAAACGT CAACTGGAAC 4201
CAGGTGCAAC TGGCTTACGA TAAATGGGAC TATAAGCAGG AAGGCTTAAC 4251
CAGAGCCGGT GCAGCGATTG TTACCATAAT CGTAACCGCA CTGACTTATG 4301
GATACGGCGC AACCGCAGCG GGCGGTGTAG CCGCTTCAGG AAGTAGTACA 4351
GCCGCAGCTG CCGGAACAGC CGCCACAACG ACAGCAGCAG CTACTACCGT 4401
TTCTACAGCG ACTGCCATGC AAACCGCTGC TTTAGCCTCC TTGTATAGCC 4451
AAGCAGCTGT ATCCATCATC AATAATAAAG GTGATGTCGG CAAAGCGTTG 4501
AAAGATCTCG GCACCAGTGA TACGGTCAAG CAGATTGTCA CTTCTGCCCT 4551
GACGGCGGGT GCATTAAATC AGATGGGCGC AGATATIGCC CAATTGAACA 4601
GCAAGGTAAG AACCGAACTG TTCAGCAGTA CGGGCAATCA AACTATTGCC 4651
AACCTTGGAG GCAGATTGGC TACCAATCTC AGTAATGCAG GTATCTCAGC 4701
TGGTATCAAT ACCGCCGTCA ACGGCGGCAG CCTGAAAGAC AACTTAGGCA 4751
ATGCCGCATT AGGAGCATTG GTTAATAGCT TCCAAGGAGA AGCCGCCAGC 4801
AAAATCAAAA CAACCTTCAG CGACGATTAT GTTGCCAAAC AGTTCGCCCA 4851
CGCTTTGGCT GGGTGTGTTA GCGGATTGGT ACAAGGAAAA TGTAAAGACG 4901
GGGCAATTGG CGCAGCAGTT GGGGAAATCG TAGCCGACTC CATGCTTGGC 4951
GGCAGAAACC CTGCTACACT CAGCGATGCG GAAAAGCATA AGGTTATCAG 5001
TTACTCGAAG ATTATTGCCG GCAGCGTGGC GGCACTCAAC GGCGGCGATG 5051
TGAATACTGC GGCGAATGCG GCTGAGGTGG CGGTAGTGAA TAATGCTTTG 5101
AATTTTGACA GTACCCCTAC CAATGCGAAA AAGCATCAAC CGCAGAAGCC 5151
CGACAAAACC GCACTGGAAA AAATTATCCA AGGTATTATG CCTGCACATG 5201
CAGCAGGTGC GATGACTAAT CCGCAGGATA AGGATGCTGC CATTTGGATA 5251
AGCAATATCC GTAATGGCAT CACAGGCCCG ATTGTGATTA CCAGCTATGG 5301
GGTTTATGCT GCAGGTTGGA CAGCTCCGCT GATCGGTACA GCGGGTAAAT 5351
TAGCTATCAG CACCTGCATG GCTAATCCTT CTGGTTGTAC TGTCATGGTC 5401
ACTCAGGCTG CCGAAGCGGG CGCGGGAATC GCCACGGGTG CGGTAACGGT 5451
AGGCAACGCT TGGGAAGCGC CTGTGGGGGC GTTGTCGAAA GCGAAGGCGG 5501
CCAAGCAGGC TATACCAACC CAGACAGTTA AAGAACTTGA TGGCTTACTA 5551
CAAGAATCAA AAAATATAGG TGGTGTAAAT ACACGAATAA ATATAGCGAA 5601
TAGTACTACT CGATATACAC CAATGAGACA AACGGGACAA CCGCTATCTG 5651
CTGGCTTTGA GCATGTFCTT GAGGGGGACT TCCATAGGCC TATTGCGAAT 5701
AACCGTTCAG TTTTTACCAT CTCCCCAAAT GAATTGAAGG TTATACTTCA 5751
AAGTAATAAA GTAGTTTCTT CTCCCGTATC GATGACTCCT GATGGCCAAT 5801
ATATGCGGAC TGTCGATGTA GGAAAAGTTA TTGGTACTAC TTCTATTAAA 5651
GAAGGTGGAC AACCCACAAC TACAATTAAA GTATTTACAG ATAAGTCAGG 5901
AAATTTGATT ACTACATACC CAGTAAAAGG AAACTAA
[0420] This corresponds to the amino acid sequence <SEQ ID 60;
ORF114-1>:
84 1 HNKGLHRIIF SXKHSTMVAV AETANSQGKG KQAGSSVSVS LKTSGDLCGK 51
LKTTLKTLVC SLVSLSHVLP AHAQITTDKS APKNQQVVIL KFNTGAPLVN 101
IQTPNGRGLS HNRYTQFDVD NKGAVLNNDR NNNPFVVKGS AQLILNEVRG 151
TASKLNGIVT VGGQKADVII ANPNGITVNG GGFKNVGRGI LTTGAPQIGK 201
DGALTGFDVR QGTLTVGAAG WNDKGGADYT GVLAAAVALQ GKLQGKLLAV 251
STGFQKVDYA SGEISAGTAA GTKPTIALDT AALGGHYADS ITLIANEKGV 301
GVKNAGTLKA AXQLIVTSSG RIENSGRIAT TADGTFASPT YLSIETTEKG 351
AAGTFISNGG RIESKGLLVI ETGEDISLRN GAVVQINGSR PATTVLNAGH 401
HLVIESKTNV NNAKGFATLS ADGRTVIKEA SIQTGTTVYS SSKGTAELGN 451
NTRZTGADVT VLSNGTISSS AVIDAKOTAN IEAGKPLSLT ASTVTSDIRL 501
NGGSIKGGKQ LALLADDNIT AXTTNLNTPG NLYVHTGKDL NIMVDKDLSA 551
ASIHLKSDNA AHITGTSKTL TASKDMGVEA GSLNVTNTNL RTNSGNLHIQ 601
AAKGNIQLRN TKLNAAKALE TTALQGNIVS OGLHAVSADG HVSLLANGNA 651
DFTGHNTLTA KADVNAGSVG KGRLKADNTN ITSSSGDITL VAGNGIQLGD 701
GKQRNSINGK HISIKNNGGN ADLIQLNVHA KSGALNIHSD RALSIENTKL 751
ESTRNTHLNA QHERVTLNQV DAYAHRHLSI TGSQIWQNOK LPSANKLVTN 801
GVLALNARYS QIADNTTLRA GAINLTAGTA LVKRGNINWS TVSTKTLEDN 851
AELKPLAGRL NIEAGSGTLT IEPANRISAH TDLSIKTGGK LLLSAKGGNA 901
GAFSAQVSSL EAKGNIRLVT GETDLRGSKI TAGKNLVVAT TKGKLNIEAV 951
NNSFSNYFPT QKAAELNQKS KELEQQIAQL KKSSPKSKLI PTLQEERDRL 1001
AFYIQAINKE VKGKKPKGKE YLQAKLSAQN IDLISAQGIE ISGSDITASK 1051
KLNLHAAGVL PKAADSEAAA ILIDGITDQY EIGKPTYKSH YOKAALNKPS 1101
RLTGRTGVSI HAAAALDDAR IIIGASEIKA FSGSIDIKAH SDIVLEAGQN 1151
DAYTFLKTKG KSGKIIRXTK FTSTRDHLIM PAPVELTANG ITLQAGGNIE 1201
ANTTRFNAPA GKVTLVAGEE LQLLAEEGIH KHELDVQKSR RFIGIKVGKS 1251
NYSKNELNET KLPVRVVAQT AATRSGWDTV LEGTEFKTTL AGADIQAGVG 1301
EKAPADAKII LKGIVNRIQS EEKLETNSTV WQKQAGRGST IETLKLPSFE 1351
SPTPPKLTAP GGYIVDIPKG NLKTEIEKLA KQPEPEYLKQ LQVAKNVNWN 1401
QVQLAYDKWD YKQEGLTRAG AAIVTIIVTA LTYGYGATAA GGVAASGSST 1451
AAAAGTAATT TAAATTVSTA TANQTAALAS LYSQAAVSII NNKGDVGKAL 1501
KDLGTSDTVK QIVISALTAG ALNQMGADIA QLNSKVRTEL FSSTGVQTIA 1551
NLGGRLATNL SNAGISAGIN TAVNGGSLKD NLGNAALGAL VNSFQGEAAS 1601
KIKTTFSDDY VAKQFAHALA GCVSGLVQGK CKDGAIGAAV GEIVADSNLG 1651
GRNPATLSDA EKHKVISYSK IIAGSVAALN GGDVNTAANA AEVAVVNNAL 1701
NFDSTPTNAK KNQPQKPDKT ALEKIIQGIM PAHAAGAMTN PQDKDAAIWI 1751
SNIRNGITGP IVITSYGVYA AGWTAPLIGT AGKLAISTCM ANPSGCTVNV 1801
TQAAEAGAGI ATGAVTVGNA WEAPVGALSK AKAAKQAIPT QTVKELDGLL 1851
QESKNIGAVN TRINIANSTT RYTPNRQTGQ PVSAGFENVL EGHFHRPIAN 1901
NRSVFTXSPN ELKVILQSNK VVSSPVSMTP DGQYNRTVDV GKVIGTTSIK 1951
EGGQPTTTIK VFTDKSGNLI TTYPVKGN*
[0421] Computer analysis of this amino acid sequence predicts a
transmembrane region and also gives the following results:
[0422] Homology with a Predicted ORF from N. meningitidis (Strain
A)
[0423] ORF114 shows 91.9% identity over a 284 aa overlap with an
ORF (ORF114a) from strain A of N. meningitidis:
85 10 20 30 40 orf114.pep
AVAETANSQGKGKQAGSSVSVSLKTSGDLCGKLKTTLKTLV- C
.vertline..vertline..vertline..vertline..vertl-
ine..vertline..vertline..vertline..vertline..vertline..vertline..vertline.-
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ver-
tline..vertline..vertline..vertline..vertline..vertline..vertline..vertlin-
e..vertline..vertline..vertline..vertline..vertline..vertline..vertline..v-
ertline..vertline..vertline..vertline..vertline..vertline..vertline..vertl-
ine. orf114a
MNKGLHRIIFSKKHSTMVAVAETANSQGKGKQAGSSVSVSLKTSGDLCGKLKTT- LKTLVC 10
20 30 40 50 60 50 60 70 80 90 100 orf114.pep
SLVSLSMVLPAHAQITTDKSAPKNQQVVILKTNTGAPLVNIQTPNGRGLS- HNRXYAFDVD
.vertline..vertline..vertline..vertline..vertline..vert-
line..vertline.
.vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline.
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline..vertline..vertline..vertline..vertline..vertline..-
vertline..vertline..vertline..vertline..vertline..vertline.
.vertline..vertline..vertline..vertline. orf114a
SLVSLSMXXXXXXQITTDKSAPKNXQVVILKTNTGAPLVNIQTPNGRGLSHNRYTQFDVD 70 80
90 100 110 120 110 120 130 140 150 160 orf114.pep
NKGAVLNNDRNNNPFVVKGSAQLILNEVRGTALKLNGIVTVGGQKADVIIANPNGITVNG
.vertline..vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline..vertline..vertline..vertline..vertline..vertline..-
vertline.:.vertline..vertline..vertline..vertline..vertline..vertline..ver-
tline..vertline..vertline..vertline..vertline..vertline..vertline..vertlin-
e..vertline..vertline..vertline..vertline..vertline..vertline..vertline..v-
ertline..vertline..vertline..vertline..vertline..vertline..vertline..vertl-
ine..vertline..vertline..vertline..vertline..vertline..vertline..vertline.-
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ver-
tline. orf114a
NKGAVLNNDRNNNPFLVKGSAQLILNEVRGTASKLNGIVTVGGQKADVIIAN- PNGITVNG 130
140 150 160 170 180 170 180 190 200 210 220 orf114.pep
GGFKNVGRGILTTGAPQIGKDGALTGFDVVKAHWTVXAAGWNDKGGAXY- TGVLARAVALQ
.vertline..vertline..vertline..vertline..vertline..ver-
tline..vertline..vertline..vertline..vertline..vertline..vertline.
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline. :: .vertline..vertline.
.vertline..vertline..vertline..vert-
line..vertline..vertline..vertline..vertline..vertline..vertline.
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline. orf114a
GGFKNVGRGILTIGAPQIGKDGALTGFDVRQGTLTVAAAGWNDKGGADYTGVLARAVALQ 190
200 210 220 230 240 230 240 250 260 270 290 orf114.pep
GKXXGKXLAVSTGPQKVDYASGEISAGTAAGTKPTIALDTAALGGMYADSITLIANEKGV
.vertline..vertline. .vertline..vertline. .vertline..vertline..ver-
tline..vertline..vertline..vertline..vertline..vertline..vertline..vertlin-
e..vertline..vertline..vertline..vertline..vertline..vertline..vertline..v-
ertline..vertline..vertline..vertline..vertline..vertline..vertline..vertl-
ine..vertline..vertline..vertline..vertline..vertline..vertline..vertline.-
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ver-
tline..vertline..vertline..vertline..vertline..vertline..vertline..vertlin-
e..vertline. .vertline..vertline..vertline..vertline. orf114a
GKLQGKNLAVSTGPQKVDYASGEISAGTAAGTKPTIALDTAALGGMYADSITLIAXEKGV 250
260 270 280 290 300 orf114.pep GVX .vertline..vertline. orf114a
GVKNAGTLEAAKQLIVTSSGRIENSGRIATTADGTEASPTYLXIETTEKGAXGTFISNGG 310
320 330 340 350 360
[0424] The complete length ORF114a nucleotide sequence <SEQ ID
61> is:
86 1 ATGAATAAAG GTTTACATCG CATTATCTTT AGTAAAAAGC ACAGCACCAT 51
GGTTGCAGTA GCCGAAACTG CCAACAGCCA GGGCAAAGGT AAACAGGCAG 101
GCAGTTCGGT TTCTGTTTCA CTGAAAACTT CAGGCGACCT TTGCGGCAAA 151
CTCAAAACCA CCCTTAAAAC CTTGGTCTGC TCTTTGGTTT CCCTGAGTAT 201
GGNATTNCNN NNCNNTNCCC AAATTACCAC CGACAAATCA GCACCTAAAA 251
ACCANCAGGT CGTTATCCTT AAAACCAACA CTGGTGCCCC CTTGGTGAAT 301
ATCCAAACTC CGAATGGACG CGGATTGAGC CACAACCGCT ATACGCAGTT 351
TGATGTTGAC AACAAAGGGG CAGTGTTAAA CAACGACCGT AACAATAATC 401
CGTTTCTGGT CAAAGGCAGT GCGCAATTGA TTTTGAACGA GGTACGCGGT 451
ACGGCTAGCA AACTCAACGG CATCGTTACC GTAGGCGGTC AAAAGGCCGA 501
CGTGATTATT GCCAACCCCA ACGGCATTAC TGTTAATGGC GGCGGCTTTA 551
AAAATGTCGG TCGGGGCATC TTAACTATCG GTGCGCCCCA AATCGGCAAA 601
GACGGTGCAC TGACAGGATT TGATGTGCGT CAAGGCACAT TGACCGTAGG 651
AGCAGCAGGT TGGAATGATA AAGGCGGAGC CGACTACACC GGGGTACTTG 701
CTCGTGCAGT TGCTTTGCAG GGGAAATTAC AAGGTAAAAA CCTGGCGGTT 751
TCTACCGGTC CTCAGAAAGT AGATTACGCC AGCGGCGAAA TCAGTGCAGG 801
TACGGCAGCG GGTACGAAAC CGACTATTGC CCTTGATACT GCCGCACTGG 951
GCGGTATGTA CGCCGAGAAA ATCACACTGA TTGCCAATGA AAAAGGCGTA 901
GGcGTCAAAA ATGCCGGCAC ACTCGAAGCG GCCAAGCAAT TGATTGTGAC 951
TTCGTCAGGC CGCATTGAAA ACAGCGGCCG CATCGCCACC ACTGCCGACG 1001
GCACCGAAGC TTCACCGACT TATCTNNCNA TCGAAACCAC CGAAAAAGGA 1051
GCNNCAGGCA CATTTATCTC CAATGGTGGT CGGATCGAGA GCAAAGGCTT 1101
ATTGGTTATT GAGACGGGAG AAGATATCAT CTTGCGTAAC GGAGCCGTGG 1151
TGCAGAATAA CGGCAGTCGC CCAGCTACCA CGGTATTAAA TGCTGGTCAT 1201
AATTTGGTGA TTGAGAGTAA AACTAATGTG AACAATGCCA AAGGCTCGNC 1251
TAATCTGTCG GCCGGCGGTC GTACTACGAT CAATGATGCT ACTATTCAAG 1301
CGGGCAGTTC CGTGTACAGC TCCACCAAAG GCGATACTGA NTTGGGTGAA 1351
AATACCCGTA TTATTGCTGA AAACGTAACC GTATTATCTA ACGGTAGTAT 1401
TGGCAGTGCT GCTGTAATTG AGGCTAAAGA CACTGCACAC ATTGAATCGG 1451
GCAAACCGCT TTCTTTAGAA ACCTCGACCG TTGCCTCCAA CATCCGTTTG 1501
AACAACGGTA ACATTAAAGG CGGAAAGCAG CTTGCTTTAC TGGCAGACGA 1551
TAACATTACT GCCAAAACTA CCAATCTGAA TACTCCCGGC AATCTGTATG 1601
TTCATACAGG TAAAGATCTG AATTTGAATG TTGATAAAGA TTTGTCTGCC 1651
GCCAGCATCC ATTTGAAATC GGATAACGCT GCCCATATTA CCGGCACCAG 1701
TAAAACCCTC ACTGCCTCAA AAGACATGGG TGTGGAGGCA GGCTTGCTGA 1751
ATGTTACCAA TACCAATCTG CGTACCAACT CGGGTAATCT GCACATTCAG 1801
GCAGCCAAAG GCAATATTCA GCTTCGCAAT ACCAAGCTGA ACGCAGCCAA 1851
GGCTCTCGAA ACCACCGCAT TGCAGGGCAA TATCGTTTCA GACGGCCTTC 1901
ATGCTGTTTC TGCAGACGGT CATGTATCCT TATTGGCCAA CGGTAATGCC 1951
GACTTTACCG GTCACAATAC CCTGACAGCC AAGGCCGATG TCNATGCAGG 2001
ATCGGTTGGT AAAGGCCGTC TGAAAGCAGA CAATACCAAT ATCACTTCAT 2051
CTTCAGGAGA TATTACGTTG GTTGCCGNNN NCGGTATTCA GCTTGGTGAC 2101
GGAAAACAAC GCAATTCAAT CAACGGAAAA CACATCAGCA TCAAAAACAA 2151
CGGTGGTAAT GCCGACTTAA AAAACCTTAA CGTCCATGCC AAAAGCGGGG 2201
CATTGAACAT TCATTCCGAC CGGGCATTGA GCATAGAAAA TACNAAGCTG 2251
GAGTCTACCC ATAATACGCA TCTTAATGCA CAACACGAGC GGGTAACGCT 2301
CAACCAAGTA GATGCCTACG CACACCGTCA TCTAAGCATT ANCGGCAGCC 2351
AGATTTGGCA AAACGACAAA CTGCCTTCTG CCAACAAGCT GGTGGCTAAC 2401
GGTGTATTGG CAATCAATGC GCGCTATTCC CAAATTGCCG ACAACACCAC 2451
GCTGAGAGCG GGTGCAATCA ACCTTACTGC CGGTACCGCC CTAGTCAAGC 2501
GCGGCAACAT CAATTGGATT ACCGTTTCGA CCAAGACTTT GGAAGATAAT 2551
GCCGAATTAA AACCATTGGC CGGACGGCTG AATATTGAAG CAGGTAGCGG 2601
CACATTAACC ATCGAACCTG CCAACCGCAT CAGTGCGCAT ACCGACCTGA 2651
GCATCAAAAC AGGCGGAAAA TTGCTGTTGT CTGCAAAAGG AGGAAATGCA 2701
GGTGCGCNTA GTGCTCAAGT TTCCTCATTG GAAGCAAAAG GCAATATCCG 2751
TCTGGTTACA GGAGNAACAG ATTTAAGAGG TTCTAAAATT ACAGCCGGTA 2901
AAAACTTGGT TGTCGCCACC ACCAAAGGCA AGTTGAATAT CGAAGCCGTA 2951
AACAACTCAT TCAGCAATTA TTTTCNTACA CAAAAAGNGN NNGNNCTCAA 2901
CCAAAAATCC AAAGAATTGG AACAACAGAT TGCGCAGTIG AAAAAAAGCT 2951
CGCNTAAAAG CAAGCTGATT CCAACCCTGC AAGAAGAACG CGACCGTCTC 3001
GCTTTCTATA TTCAAGCCAT CAACAAGGAA GTTAAAGGTA AAAAACCCAA 3051
AGGCAAAGAA TACCTGCAAG CCAAGCTTTC TGCACAAAAT ATTGACTTGA 3101
TTTCCGCACA AGGCATCGAA ATCAGCGGTT CCGATATTAC CGCTTCCAAA 3151
AAACTGAACC TTCACGCCGC AGGCGTATTG CCAAAGGCAG CAGATTCAGA 3201
GGCGGCTGCT ATTCTGATTG ACGGCATAAC CGACCAATAT GAAATTGGCA 3251
AGCCCACCTA CAAGAGTCAC TACGACAAAG CTGCTCTGAA CAAGCCTTCA 3301
CGTTTGACCG GACGTACGGG GGTAAGTATT CATGCAGCTG CGGCACTCGA 3351
TGATGCACGT ATTATTATCG GTGCATCCGA AATCAAAGCT CCCTCAGGCA 3401
GCATAGACAT CAAAGCCCAT AGTGATATTG TACTGGAGGC TGGACAAAAC 3451
GATGCCTATA CCTTCTTAAA AACCAAAGGT AAAAGCGGCA NAATNATCAG 3501
AAAAACNAAG TTTACCAGCA CCNGCGANCA CCTGATTATG CCAGCCCCNG 3551
TCGAGCTGAC CGCCAACGGT ATCACGCTTC ACGCAGGCGG CAACATCGAA 3601
GCTAATACCA CCCGCTTCAA TGCCCCTGCA GGTAAAGTIA CCCTGGTTGC 3651
GGGTGAANAG NTGCAACTGC TGGCAGAAGA AGGCATCCAC AAGCACGAGT 3701
TGGATGTCCA AAAAAGCCGC CGCTTTATCG GCATCAAGGT AGGTNAGAGC 3751
AATTACAGTA AAAACGAACT GAACGAAACC AAATTGCCTG TCCGCGTCGT 3801
CGCCCAAAAT GCAGCCACCC GTTCAGGCTG GGAThCCGTG CTCGAAGGTA 3851
CCGAATTCAA ATCCACGCTG GCCGGTGCCG ACATTCAGGC AGGTGTANGC 3901
GAAAAAGCCC GTGTCGATGC GAAAATCATC CTCAAAGGCA TTGTGAACCG 3951
TATCCAGTCG GAAGAAAAAT TAGAAACCAA CTCAACCGTA TGGCAGAAAC 4001
AGGCCGGACG CGGCAGCACT ATCGAAACGC TAAAACTGCC CAGCTTCGAA 4051
AGCCCTACTC CGCCCAAATT GTCCGCACCC GGCGGNTATA TCGTCGACAT 4101
TCCGAAAGGC AATCTGAAAA CCGAAATCGA AAAGCTGTCC AAACAGCCCG 4151
AGTATGCCtA TCTGAAACAG CTCCAAGTAG CGAAAAACAT CAACTGGAAT 4201
CAGGTGCAGC TTGCTTACGA CAGATGGGAC TACAAACAGG AGGGCTTAAC 4251
CGAAGCAGGT GCGGCGATTA TCGCACTGGC CGTTACCGTG GTCACCTCAG 4301
GCGCAGGAAC CGGAGCCGTA TTGGGATTAA ACGGTGCGNC CGCCGCCGCA 4351
ACCGATGCAG CATTCGCCTC TTTGGCCAGC CAGGCTTCCG TATCGTTCAT 4401
CAACAACAAA GGCGATGTCG GCAAAACCCT GAAAGAGCTG GGCAGAAGCA 4451
GCACGGTGAA AAATCTGGTG GTTGCCGCCG CTACCGCAGG CGTAGCCGAC 4501
AAAATCGGCG CTTCGGCACT GANCAATGTC AGCGATAAGC AGTGGATCAA 4551
CAACCTGACC GTCAACCTAG CCAATGNCGG GCAGTGCCGC ACTGAttaa
[0425] This encodes a protein having amino acid sequence <SEQ ID
62>:
87 1 MNKGLHRIIF SKKHSTMVAV AETANSQGKG KQAGSSVSVS LKTSGDLCGK 51
LKTTLKTLVC SLVSLSMXXX XXXQITTDKS APIDXQVVIL KTNTGAPLVN 101
IQTPNGRGLS HNRYTQFDVD NKGAVLNNDR NNNPFLVKGS AQLILNEVRG 151
TASKLNGIVT VGGQKADVII ANPNGITVNG GGFKNVGRGI LTIGAPQIGK 201
DGALTGFDVR QGTLTVGAAG WNDKGGADYT GVLARAVALQ GKLQGKNLAV 251
STGPQKVDYA SGEISAGTAA GTKPTIALDT AALGGMYADS ITLTAXEKGV 301
GVKNAGTLEA AKQLIVTSSG RIENSGRIAT TADGTEASPT YLXIETTEKG 351
AXGTFISNGG RIESKGLLVI ETGEDIXLPA GAVVQNNGSR PATTVLNAGH 401
NLVIESKTNV NNAXGSXNLS AGGRTTINDA TIQAGSSVYS STKGDTXLGE 451
NTRIIAENVT VLSNGSIGSA AVIEAKDTAN IESGKPLSLE TSTVASNIRL 501
NNGNIKGGKQ LALLADDNIT AKTTNLNTPG NLYVHTGKDL NLNVDKDLSA 551
ASIHLKSDNA AHITGTSKTL TASKDNGVEA GLLNVTNTNL RTNSGNLHIQ 601
AAKGNZQLRH TKLNAAKALE TTALQGNIVS DGLHAVSADG HVSLLANGNA 651
DFTGHNTLTA KADVXAGSVG KGRLKADNTN ITSSSGDITL VAXXGIQLGD 701
GKQRNSINGK HISIKNNGGN ADLKNLNVHA KSGALNIHSO RALSIENTKL 751
ESTHNTHLNA QHERVTLNQV DAYAHRHLSI XGSQIWQNDK LPSANKLVAN 801
GVLAXNARYS QIADNTTLRA CAINLTAGTA LVKRGNINWS TVSTKTLEDN 851
AELKPLAGRL NIEAGSGTLT IEFANRISAH TDLSIKTGGK LLLSAXGGNA 901
GAXSAQVSSL EAKGNIRLVT GXTDLRGSKI TAGKNLVVAT TKGKLNIEAV 951
NNSFSNYFXT QKXXXLNQKS KELEOQIAQL KKSSXKSKLI PTLQEERDRL 1001
AFYIQAINKE VKGKKPKGKE YLQAXLSAQN IDLISAQGIE ISGSDITASK 1051
KLNLHAAGVL PKAADSEAAA ILIDGITOQY EIGKPTYKSH YDKAALNKPS 1101
RLTGRTGVSI HAAAALDDAR IIIGASEIKA PSGSIDIKAR SDIVLEAGQN 1151
DAYTFLXTKG KSGXXIRKTK FTSTXXHLIM PAPVELTANG ITLQAGGNIE 1201
ANTTRFHAPA GKVTLVAGEK XQLLAEEGIK KHELDVQKSR RFIGIKVGXS 1251
NYSINELNET KLPVRVVAQX AATRSGWDTV LEGTEFKTTL AGADIQAGVX 1301
EKARVQAXII LKGIVNRIQS EEKLETNSTV WQKQAGRGST IETLKLPSFE 1351
SPTPPKLSAP GGYIVDIPKG NLKTEIEKLS KQPEYAYLKQ LQVAKNINWN 1401
QVQLAYQRWD YKQEGLTEAG AAIIALAVTV VTSGAGTGAV LGLNGAXAAA 1451
TDAAFASLAS QASVSFINNK GDVGKTLKEL GRSSTVKNLV VAAATAGVAD 1501
KIGASALXNV SDKQWINNLT VNLANXGQCR TD*
[0426] ORF114-1 and ORF114a show 89.8% identity in 1564 aa
overlap
88 orf114a.pep
MNKGLHRIIFSKKHSTMVAVAETANSQGKGKQAGSSVSVSLKTSGDLCGKLK- TTLKTLVC
.vertline..vertline..vertline..vertline..vertline..vertl-
ine..vertline..vertline..vertline..vertline..vertline..vertline..vertline.-
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ver-
tline..vertline..vertline..vertline..vertline..vertline..vertline..vertlin-
e..vertline..vertline..vertline..vertline..vertline..vertline..vertline..v-
ertline..vertline..vertline..vertline..vertline..vertline..vertline..vertl-
ine..vertline..vertline..vertline..vertline..vertline..vertline..vertline.-
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ver-
tline..vertline..vertline. orf114-1
MNKGLHRIIFSKKHSTMVAVAETANSQGKGK- QAGSSVSVSLKTSGDLCGKLKTTLKTLVC
orf114a.pep
SLVSLSMXXXXXXQITTDKSAPKNXQVVILKTNTGAPLVNIQTPNGRGLSHNRYTQFDVD
.vertline..vertline..vertline..vertline..vertline..vertline..vertline.
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..-
vertline..vertline..vertline..vertline.
.vertline..vertline..vertline..ver-
tline..vertline..vertline..vertline..vertline..vertline..vertline..vertlin-
e..vertline..vertline..vertline..vertline..vertline..vertline..vertline..v-
ertline..vertline..vertline..vertline..vertline..vertline..vertline..vertl-
ine..vertline..vertline..vertline..vertline..vertline..vertline..vertline.-
.vertline..vertline. orf114-1
SLVSLSMXXXXXXQITTDKSAPKNQQVVILKTNTGAP- LVNIQTPNGRGLSHNRYTQFDVD
orf114a.pep
NKGAVLNNDRNNNPFLVKGSAQLILNEVRGTASKLNGIVTVGGQKADVIIANPNGITVNG
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline..vertline..vertli-
ne.:.vertline..vertline..vertline..vertline..vertline..vertline..vertline.-
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ver-
tline..vertline..vertline..vertline..vertline..vertline..vertline..vertlin-
e..vertline..vertline..vertline..vertline..vertline..vertline..vertline..v-
ertline..vertline..vertline..vertline..vertline..vertline..vertline..vertl-
ine..vertline..vertline..vertline..vertline..vertline..vertline..vertline.
orf114-1 NKGAVLNNDRNNNPFVVKGSAQLILNEVRGTASKLNGIVTVGGQKADVIIANPNGIT-
VNG orf114a.pep GGFKNVGRGILTIGAPQIGKDGALTGFDVRQGTLTVGAAGWN-
DKGGADYTGVLARAVALQ .vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline..vertline..vertline..vertline..vertline..vertline.
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline..vertline..vertline..vertline..vertline..vertline..-
vertline..vertline..vertline..vertline..vertline..vertline..vertline..vert-
line..vertline..vertline..vertline..vertline..vertline..vertline..vertline-
..vertline..vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline. orf114-1
GGFKNVGRGILTTGAPQIGKDGALTGFDVR- QGTLTVGAAGWNDKGGADYTGVLARAVALQ
orf114a.pep
GKLQGKNLAVSTGFQKVDYASGEISAGTAAGTKPTIALDTAALGGMYADSITLIAXEKGV
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline..vertline..vertline..vertline..vertline..vertline..-
vertline..vertline..vertline..vertline..vertline..vertline..vertline..vert-
line..vertline..vertline..vertline..vertline..vertline..vertline..vertline-
..vertline..vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline..vertline.
.vertline..vertline..vertline..vertline. orf114-1
GKLOGKNLAVSTGPQKVDYASGEISAGTAAGTKPTIALDTAALGGMYADSITLIANE- KGV
orf114a.pep GVKNAGTLEAAXQLIVTSSGRIENSGRIATTADGTLASPTYL-
XIETTEKGAXGTFISNGG .vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline..vertline..vertline..vertline..vertline..vertline..-
vertline..vertline..vertline..vertline..vertline..vertline..vertline..vert-
line..vertline..vertline..vertline..vertline..vertline..vertline..vertline-
..vertline..vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline..vertline..vertli-
ne.
.vertline..vertline..vertline..vertline..vertline..vertline..vertline.-
.vertline.
.vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline. orf114-1
GVKNAGTLEAAXQLIVTSSGRIENSGRIATTADGTLASPT- YLSIETTEKGAAGTFISNGG
orf114a.pep RIESKGLLVIETGEDIXLRNGAVVQ-
NNGSRPATTVLNAGHNLVIESKTNVNNAKGSXNLS .vertline..vertline..vertline.-
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ver-
tline..vertline..vertline..vertline..vertline..vertline.
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline..vertline..vertline..vertline..vertline..vertline..-
vertline..vertline..vertline..vertline..vertline..vertline..vertline..vert-
line..vertline..vertline..vertline..vertline..vertline..vertline..vertline-
..vertline. :.vertline..vertline. orf114-1 RIESKGLLVIETGEDISLRNGAV-
VQNNGSRPATTVLNAGHNLVIESKTNVNNAKGPANLS orf114a.pep
AGGRTTINDATIQAGSSVYSSTKGDTXLGENTRIIAENVTVLSNGSIGSAAVIEAKDTAH
.vertline.
.vertline..vertline..vertline.:.vertline.::.vertline.:.vertlin-
e..vertline.:.vertline.::.vertline..vertline..vertline..vertline.:.vertlin-
e..vertline.::
.vertline..vertline.:.vertline..vertline..vertline..vertlin- e. :
:.vertline..vertline..vertline..vertline..vertline..vertline..vertlin-
e..vertline..vertline.:.vertline.:.vertline..vertline..vertline.:.vertline-
..vertline..vertline..vertline..vertline..vertline. orf114-1
ADGRTVIKEASIQTGTTVYSSSKGNAELGNNTRITGADVTVLSNGTISSSAVIDAKDTAH
orf114a.pep
IESGKPLSLETSTVASNIRLNNGNIKGGKQLALLADDNITAKTTNLNTPGNLYVHTGK- DL
.vertline..vertline.:.vertline..vertline..vertline..vertline..v-
ertline..vertline..vertline..vertline..vertline..vertline..vertline.:.vert-
line..vertline..vertline.:.vertline.:.vertline..vertline..vertline..vertli-
ne.:.vertline.:.vertline..vertline..vertline..vertline..vertline..vertline-
..vertline..vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline..vertline..vertline..vertline..vertline..vertline..-
vertline..vertline..vertline..vertline. orf114-1
IEAGKPLSLEASTVTSDIRLNGGSIKGGKQLALLADDNITAKTTNLNTPGNLYVHTGKDL
orf114a.pep
NLNVDKDLSAASIHLKSDNAAHITGTSKTLTASKDMGVEAGLLNVTNTNLRTNSGNLH- IQ
.vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline..vertline..vertline..vertline..vertline..vertline..-
vertline..vertline..vertline..vertline..vertline..vertline..vertline..vert-
line..vertline..vertline..vertline..vertline..vertline..vertline..vertline-
..vertline..vertline..vertline..vertline..vertline.
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline..vertline. orf114-1
NLNVDKDLSAASIHLKSDNAAHIT- GTSKTLTASKDMGVEAGSLNVTNTNLRTNSGNLHIQ
orf114a.pep
AAKGNIQLRNTKLNAAKALETTALQGNIVSDGLHAVSADGHVSLLANGNADFTGHNTLTA
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline..vertline..vertline..vertline..vertline..vertline..-
vertline..vertline..vertline..vertline..vertline..vertline..vertline..vert-
line..vertline..vertline..vertline..vertline..vertline..vertline..vertline-
..vertline..vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline..vertline..vertline..vertline..vertline..vertline..-
vertline. orf114-1
AAKGNIQLRNTKLNAAKALETTALQGNIVSDGLHAVSADGHVSLLANG- NADFTGHNTLTA
orf114a.pep KADVXAGSVGKGRLKADNTNITSSSGDITLVAX-
XGIQLGDGKQRNSINGKHISIKNNGGN .vertline..vertline..vertline..vertlin-
e.
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..-
vertline..vertline..vertline..vertline..vertline..vertline..vertline..vert-
line..vertline..vertline..vertline..vertline..vertline..vertline..vertline-
..vertline..vertline..vertline..vertline..vertline.
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline..vertline..vertline..vertline..vertline..vertline..-
vertline..vertline..vertline..vertline. orf114-1
KADVNAGSVGKGRLKADNTNITSSSGDITLVAGNGIQLGDGKQRNSINGKHISIKNNGGN
orf114a.pep
ADLKNLNVHAKSGALNIHSDRALSIENTKLESTHNTHLNAQHERVTLNQVDAYAHRHL- SI
.vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline..vertline..vertline..vertline..vertline..vertline..-
vertline..vertline..vertline..vertline..vertline..vertline..vertline..vert-
line..vertline..vertline..vertline..vertline..vertline..vertline..vertline-
..vertline..vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline..vertline..vertline..vertline..vertline..vertline..-
vertline..vertline. orf114-1
ADLKNLNVHAKSGALNIHSDRALSIENTKLESTHNTHL- NAQHERVTLNQVDAYAHRHLSI
orf114a.pep XGSQIWQNDKLPSANKLVANGVL-
AXNARYSQIADNTTLRAGAINLTAGTALVKRGNINWS :.vertline..vertline..vertli-
ne..vertline..vertline..vertline..vertline..vertline..vertline..vertline..-
vertline..vertline..vertline..vertline..vertline..vertline..vertline..vert-
line..vertline..vertline..vertline..vertline..vertline.
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline..vertline..vertline..vertline..vertline..vertline..-
vertline..vertline..vertline..vertline..vertline..vertline..vertline..vert-
line..vertline..vertline..vertline..vertline..vertline. orf114-1
TGSQIWQNDKLPSANKLVANGVLALNARYSQIADNTTLRAGAINLTAGTALVKRGNINWS
orf114a.pep
TVSTKTLEDNAELKPLAGRLNIEAGSGTLTIEPANRISAHTDLSIKTGGKLLLSAKGG- NA
.vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline..vertline..vertline..vertline..vertline..vertline..-
vertline..vertline..vertline..vertline..vertline..vertline..vertline..vert-
line..vertline..vertline..vertline..vertline..vertline..vertline..vertline-
..vertline..vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline..vertline..vertline..vertline..vertline..vertline..-
vertline..vertline. orf114-1
TVSTKTLEDNAELKPLAGRLNIEAGSGTLTIEPANRIS- AHTDLSIKTGGKLLLSAKGGNA
orf114a.pep GAXSAQVSSLEAKGNIRLVTGXT-
DLRGSKITAGKNLVVATTKGKLNIEAVNNSFSNYFXT .vertline..vertline.
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline..vertline.
.vertline..vertline..vertline..vertline.-
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ver-
tline..vertline..vertline..vertline..vertline..vertline..vertline..vertlin-
e..vertline..vertline..vertline..vertline..vertline..vertline..vertline..v-
ertline..vertline..vertline..vertline..vertline..vertline..vertline..vertl-
ine..vertline..vertline. .vertline. orf114-1
GAPSAQVSSLEAKGNIRLVTGETDLRGSKITAGKNLVVATTKGKLNIEAVNNSFSNYFPT
orf114a.pep
QKXXXLNQKSKELEQQIAQLKKSSXKSKLIPTLQEERDRLAFYIQAINKEVKGKKPKG- KE
.vertline..vertline. .vertline..vertline..vertline..vertline.-
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ver-
tline..vertline..vertline..vertline..vertline..vertline..vertline..vertlin-
e.
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..-
vertline..vertline..vertline..vertline..vertline..vertline..vertline..vert-
line..vertline..vertline..vertline..vertline..vertline..vertline..vertline-
..vertline..vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline. orf114-1
QKAAELNQKSKELEQQIAQLKKSSPKSKLIPTLQEERDRLAFYIQAINKEVKGKKPKGKE
orf114a.pep
YLQAKLSAQNIDLISAQGIEISGSDITASKKLNLHAAGVLPKAADSEAAAILIDGITD- QY
.vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline..vertline..vertline..vertline..vertline..vertline..-
vertline..vertline..vertline..vertline..vertline..vertline..vertline..vert-
line..vertline..vertline..vertline..vertline..vertline..vertline..vertline-
..vertline..vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline..vertline..vertline..vertline..vertline..vertline..-
vertline..vertline. orf114-1
YLQAKLSAQNIDLISAQGIEISGSDITASKKLNLHAAG- VLPKAADSEAAAILIDGITDQY
orf114a.pep EIGKPTYKSHYDKAALNKPSRLT-
GRTGVSIHAAAALDDARIIIGASEIKAPSGSIDIKAH .vertline..vertline..vertlin-
e..vertline..vertline..vertline..vertline..vertline..vertline..vertline..v-
ertline..vertline..vertline..vertline..vertline..vertline..vertline..vertl-
ine..vertline..vertline..vertline..vertline..vertline..vertline..vertline.-
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ver-
tline..vertline..vertline..vertline..vertline..vertline..vertline..vertlin-
e..vertline..vertline..vertline..vertline..vertline..vertline..vertline..v-
ertline..vertline..vertline..vertline..vertline..vertline..vertline..vertl-
ine..vertline..vertline..vertline..vertline..vertline. orf114-1
EIGKPTYKSHYDKAALNKPSRLTGRTGVSIHAAAALDDARIIIGASEIKAPSGSIDIKAH
orf114a.pep
SDIVLEAGQNDAYTFLXTKGKSGXXIRKTKFTSTXXHLIMPAPVELTANGITLQAGGN- IE
.vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline.
.vertline..vertline..vertline..vertline..vertline.- .vertline.
.vertline..vertline..vertline..vertline..vertline..vertline..v-
ertline..vertline..vertline.
.vertline..vertline..vertline..vertline..ver-
tline..vertline..vertline..vertline..vertline..vertline..vertline..vertlin-
e..vertline..vertline..vertline..vertline..vertline..vertline..vertline..v-
ertline..vertline..vertline..vertline..vertline. orf114-1
SDIVLEAGQNDAYTFLKTKGKSGKIIRKTKFTSTRDHLIMPAPVELTANGITLQAGGNIE
orf114a.pep
ANTTRFNAPAGKVTLVAGEXXQLLAEEGIHKHELDVQKSRRFIGIKVGXSNYSKNELN- ET
.vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline..vertline..vertline..vertline.
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline..vertline..vertline..vertline..vertline..vertline..-
vertline..vertline..vertline..vertline..vertline.
.vertline..vertline..ver-
tline..vertline..vertline..vertline..vertline..vertline..vertline..vertlin-
e..vertline. orf114-1
ANTTRFNAPAGKVTLVAGEELQLLAEEGIHKHELDVQKSRRFIGI- KVGKSNYSKNELNET
orf114a.pep KLPVRVVAQXAATRSGWDTVLEGTEFKTTL-
AGADIQAGVXEKARVDAKIILKGIVNRIQS .vertline..vertline..vertline..vert-
line..vertline..vertline..vertline..vertline..vertline.:.vertline..vertlin-
e..vertline..vertline..vertline..vertline..vertline..vertline..vertline..v-
ertline..vertline..vertline..vertline..vertline..vertline..vertline..vertl-
ine..vertline..vertline..vertline..vertline..vertline..vertline..vertline.-
.vertline..vertline..vertline..vertline..vertline.
.vertline..vertline..ve-
rtline..vertline.:.vertline..vertline..vertline..vertline..vertline..vertl-
ine..vertline..vertline..vertline..vertline..vertline..vertline..vertline.-
.vertline..vertline. orf114-1
KLPVRVVAQTAATRSGWDTVLEGTEFKTTLAGADIQA- GVGEKARADAKIILKGIVNRIQS
orf114a.pep
EEKLETNSTVWQKQAGRGSTIETLKLPSFESPTPPKLSAPGGYIVDIPKGNLKTEIEKLS
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline..vertline..vertline..vertline..vertline..vertline..-
vertline..vertline..vertline..vertline..vertline..vertline..vertline..vert-
line..vertline..vertline..vertline..vertline..vertline..vertline..vertline-
..vertline.:.vertline..vertline..vertline..vertline..vertline..vertline..v-
ertline..vertline..vertline..vertline..vertline..vertline..vertline..vertl-
ine..vertline..vertline..vertline..vertline..vertline..vertline.:
orf114-1
EEKLETNSTVWQKQAGRGSTIETLKLPSFESPTPPKLSTPGGYIVDIPKGNLKTEIEKLA
orf114a.pep KQPEYAYLKQLQVAKNINWNQVQLAYDRWDYKQEGLTEAGAAIIALAVT-
VVTSGAGTGAV .vertline..vertline..vertline..vertline..vertline..ver-
tline..vertline..vertline..vertline..vertline..vertline..vertline..vertlin-
e..vertline..vertline..vertline.:.vertline..vertline..vertline..vertline..-
vertline..vertline..vertline..vertline..vertline..vertline.:.vertline..ver-
tline..vertline..vertline..vertline..vertline..vertline..vertline..vertlin-
e.:.vertline..vertline..vertline..vertline..vertline.:::
.vertline..vertline.::.vertline. .vertline. .vertline.: .vertline.:
orf114-1
KQPEYAYLKQLQVAKNVNWNQVQLAYDKWDYKQEGLTRAGAAIVTIIVTALTYGYGATAA
orf114a.pep LGLNGA--------------XAATD----------AAFASLASQASVS-
FINNKGDVGKTL 1477 .vertline.: ::
:.vertline..vertline..vertline..vertline.
.vertline..vertline.:.vertline..vertline..vertline.
.vertline..vertline..vertline.:.vertline..vertline.:.vertline..vertline..-
vertline..vertline..vertline..vertline..vertline..vertline..vertline.:.ver-
tline. orf114-1
GGVAASGSSTAAAAGTAATTTAAATTVSTATAMQTAALASLYSQAAVSIIN- NKGDVGKAL 1500
orf114a.pep KELGRSSTVKNLVVAAATAGVADKIGA-----
------SALXNVSDKQWINNL----TVNL 1523 .vertline.:.vertline..vertline.
.vertline.:.vertline..vertline..vertline.::.vertline.::.vertline.
.vertline..vertline..vertline.: :::.vertline..vertline. :
.vertline. : : :.vertline. .vertline. .vertline..vertline.
::.vertline..vertline. orf114-1 KDLGTSDTVKQIVTSALTAGALNQMGADIAQLNS-
KVRTELFSSTGNQTIANLGGRLATNL 1560 orf114a.pep ANXGQCRTDX :.vertline.
.vertline. orf114-1 SNAGISAGINTAVN...
[0427] Homology with pspA Putative Secreted Protein of N.
meningitidis (Accession Number AF030941)
[0428] ORF114 and pspA protein show 36% aa identity in 302 aa
overlap:
89 Orf114: 1
AVAETANSQGKGKQAGSSVSVSL----KTSGDXXXXXXXXXXXXXXXXXXXXXX- XPAHAQ 56
AVAE + GK Q + SV + S PA A pspA: 19
AVAENVHRDGKSMQDSEAASVRVTGAASVSSARAAFGFRMAAFSVMLALGVA- AFSPAPAS 78
Orf114: 57 -ITTDKSAPKNQQVVILKTNTGAPLVNIQTPNGRG-
LSHNRXYAFDVDNKGAVLNNDRNN- 114 I DKSAPKNQQ VIL+T G P VNIQTP+ +G+S NR
FDVD KG +LNN R+N pspA: 79 GIIADKSAPKNQQAVILQTANGLPQVNIQT-
PSSQGVSVNRFKQFDVDEKGVILNNSRSNT 138 Orf114: 115
----------NPFVVKGSAQLILNEV-RGTASKLNGIVTVGGQKADVIIANPNGITVNGG 163 NP
+ +G A++I+N++ S LNG + VGG++A+V++ANP+GI VNGG pspA: 139
QTQLGGWIQGNPHLARGEARVIVNQIDSSNPSLLNGYIEVGGKRAEVVVANPSGIRVNGG 198
Orf114: 164 GFKNVGRGILTTGAPQIGKDGALTGFDVVKAHWTVXAAGWNDKGGAXYTG-
VLARAVALQG 223 G N LT+G P + +G LTGFDV + G D A YT +L+RA + papA: 199
GLINAASVTLTSGVPVL-NNGNLTGFDVSSGKVVIGGKGL-DTSDAD- YTRILSRAAEINA 256
Orf114: 224 KXXGKXLAVSTGPQKVDYASGEISAGTA-
AGTK----PTIALDTAALGGMYADSITLIANE 279 GK + V +G K+D+ +A + PT+A+DTA
LGGMYAD ITLI+ + pspA: 257 GVWGKDVKVVSGKNKLDFDGSLAK-
TASAPSSSDSVTPTVAIDTATLGGMYAQKITLISTD 316 Orf114: 280 KG 291 G papA:
317 NG 318
[0429] ORF114a is also homologous to pspA:
90 gil2623258 (AF030941) putative secreted protein (Neisseria
meningitidis) Length = 2273 Score +32 261 bits (659), Expect +32
3e-69 Identities = 203/663 (30%), Positives 314/663 (46%), Gaps
76/663 (11%) Query: 1
MNKGLHRIIFSKKHSTMVAVAETANSQGKGKQAGSSVSVSLK-----TSGDXXXXXXXXX 55 MNK
+++IF+KK S M+AVAE + GK Q + SV + +S Sbjct: 1
MNKRCYKVIFNKKRSCMMAVAENVHRDGKSMQDSEAASVRVTGAASVSSARAAFGFRMAA 60
Query: 56 XXXXXXXXXXXXXXXXXXQITTKDSAPKNXQVVILKTNTGAPLVNIQTPNGRGL-
SHNRYT 115 I DKSAPKN Q VIL+T G P VNIQTP+ +G+S NR+ Sbjct: 61
FSVMLALGVAAFSPAPASGIIADKSAPKNQQAVILQTANGLPQVNIQTPS- SQGVSVNRFK 120
Query: 116 QFDVDNKGAVLNNDRNN-----------NPF-
LVKGSAQLILNEV-RGTASKLNGIVTVGG 163 QFDVD KG +LNN R+N-----------NP L
+G A++I+N++ S LNG + VGG Sbjct: 121 QFDVDEKGVILNNSRSNTQTQLGGWI-
QGNPHLARGEARVIVNQIDSSNPSLLNGYIEVGG 180 Query: 164
QKADVIIANPNGITVNGGGFKNVGRGILTIGAPQIGKDGALTGFDVRQGTLTVGAAGWND 223
++A+V++ANP+GI VNGGG N LT G P + +G LTGFDV G + +G G D Sbjct: 181
KRAEVVVANPSGIRVNGGGLINAASVTLTSGVPVL-NNGNLTGFDVSSGKVVIGGKGL-D 238
Query: 224 KGGADYTGVLARAVALQGKLQGKNLAVSTGPQKVDYASGEI-
SAGTAAGTK----PTIALD 279 ADYT +L+RA + + GK++ V +G K+D+ +A + PT+A+D
Sbjct: 239 TSDADYTRILSRAAEINAGVWGKDVKVVSGKNKLDF-
DGSLAKTASAPSSSDSVTPTVAID 298 Query: 280
TAALGGMYADSITLIAXEKGVGVKNAGTLEAAK-QLIVTSSGRIENSGRIATTADGTEAS 338 TA
LGGMYAD ITLI+ + G ++N G + AA + +++ G++ NSG I Sbjct: 299
TATLGGMYADKITLISTDNGAVIRNKGRIFAATGGVTLSADGKLSNSGSI-------DAA 351
Query: 339 PTYLXIETTEKGAXGTFISNGGRIESKGLLVIETGEDIXLRNGAVVQNNGSRPA-
TTVLNA 398 + +T + + G I S V++ + I + G + GS + + Sbjct: 352
EITISAQTVD--------NRQGFIRSGKGSVLKVSDGINNQAGLI----G- SAGLLDIRDT 399
Query: 399 GHNLVIESKTNVNNAKGS----XNLSAGGRT-
TINDATIQAGSSVYSSTKGDTXLGENTRI 454 G +S ++NN G+ ++S ++ ND + A V S +
D G+ Sbjct: 400 G-----KSSLHINNTDGTIIAGKDVSLQAK-
SLDNDGILTAARDV-SVSLHDDFAGKRDIE 453 Query: 455
IAENVTVLSNGSIGSAAVIEAKDTAHIESGKPLSLETSTVASNIRLNNGNIKGGKQLALL 514 +T
+ G + + +I+A DT + + + + + + S R G L+ Sbjct: 454
AGRTLTFSTQGRLKNTRIIQAGDTVSLTAAQIDNTVSGKIQSGNRTGLNGKNGITNRGLI 513
Query: 515 ADDNIT-----AKTTNLNTPGNLYVHTGKDLNLNVDKDLSAASIHLKSD-
NAAHITGTSKT 569 + IT AK+ N T G +Y G + + D L+ AA Sbjct: 514
NSNGITLLQTEAKSDNAGT-GRIY---GSRVAVEADTLLNREETVNGETKA- A-------V 562
Query: 570 LTASKDMGVEAGXXXXXXXXXXXXSGNLHIQA-
A---KGNIQLRNTKL-NAAKALETTALQ 625 + A + + + A SG+LHI +A +Q NT L N +
A+E++ Sbjct: 563 IAARERLDIGAREIENREAALLSSSGDLHI-
GSALNGSRQVQGANTSLHNRSAAIESS--- 619 Query: 626 GNI 628 GNI Sbjct:
620 GNI 622 Score +32 37.5 bits (65), Expect = 0.53 Identities =
87/432 (20%), Positives +32 159/432 (36%), Gaps = 62/432 (14%)
Query: 239
LQGKLQGKNLAVSTGPQKVDYASGEISAGTAAGTKPTIALDTAALGGMYADSITLIAXEK 298
LQG LQGKN+ + G + +G I A A K A + + S T + Sbjct: 1023
LQGDLQGKNIFAAAGSDITN--TGSIGAENALLLK--------ASNNIESRSETRSNQNE 1072
Query: 299 GVGVKNAGTLEAAKQLIVTSSGRI--ENSGRIATTADGTE-
ASPTYLXIETTEKGAXG-TF 355 V+N G + A L +G + + I TA E T + G T Sbjct:
1073 QGSVRNIGRV-AGIYLTGRQNGSVLLDAGNNIVLTA- S-----------ELTNQSEDGQTV
1120 Query: 356
ISNGGRIESKGLLVIETGEDIXLRNGAVVQNNGSRPATTVLNAGHNLVIESK-------T 408 ++
GG I S + I + V++ + +T+ G NL + +K Sbjct: 1121
LNAGGDIRSDTTGISRNQNTIFDSDNYVIRKEQNEVGSTIRTRG-NLSLNAKGDIRIPAA 1179
Query: 409 NVNNAKGSXNLSAGGRTTINDATIQAGSS--------VYSSTKGDTXLGENTR-
IIAENVT 460 V + +G L+AG D ++AG + Y+ G + TR + Sbjct: 1180
EVGSEQGRLKLAAG-----RDIKVEAGKAHTETEDALKYTGRSGGGIKQKMT- RHLKNQNG 1234
Query: 461 VLSNGSIGSAAVIEAKDTAHIESGKPLSLETS-
TVASWIRLNNGNIKGGKQLALLADDNIT 520 +G++ +I +G + + T+ S NN +K + + A+ N
Sbjct: 1235 QAVSGTLDGKEIILVSGRDITVTGSNI-
IADNHTILS--AKNNIVLKAAETRSRSAEMNKK 1292 Query: 521
AKTTNLNTPG-NLYVHTGKDLNLNVDKDLSAASIHLKSDN-------AAHITGTSKTLTA 572 K+
+ + G + KD N + +S + S N H T T T+++ Sbjct: 1293
EKSGLMGSGGIGFTAGSKKDTQTNRSETVSHTESVVGSLNGNTLISAGKHYTQTGSTISS 1352
Query: 573 SK-DMGVEAGXXXXXXXXXXXXSGNLHIQAAKG-----NI-
QLRNTKLNAAKALETTALQG 626 + D+G+ +G + + KG ++ + NT + A A++ G Sbjct:
1353 PQGDVGISSGKISIDAAQNRYSQESKQVYEQKGV- TVAISVPVVNTVMGAVDAVKAVQTVG
1412 Query: 627 NIVSDGLHAVSA 638 + ++A++A Sbjct: 1413 KSKNSRVNAMAA
1424
[0430] Amino acids 1-1423 of ORF114-1 were cloned in the pGex
vector and expressed in E. coli, as described above. GST-fusion
expression was visible using SDS-PAGE, and FIG. 5 shows plots of
hydrophilicity, antigenic index, and AMPHI regions for
ORF114-1.
[0431] Based on these results, including the homology with the
putative secreted protein of N. meningitidis and on the presence of
a transmembrane domain, it is predicted that this protein from N.
meningitidis, and its epitopes, could be useful antigens for
vaccines or diagnostics.
Example 14
[0432] The following partial DNA sequence was identified in N.
meningitidis <SEQ ID 63>
91 1 CGCTTCATTC ATGATGAAGC AGTCGGCAGC AACATCGGCG GCGGCAAAAT 51
GATTGTTGCA GCCGGGCAGG ATATCAATGT ACGCGGCAnA AGCCTTATTT 101
CTGATAAGGG CATTGTTTTA AAAGCAGGAC ACGACATCGA TATTTCTACT 151
GCCCATAATC GCTATACCGG CAATGAATAC CACGAGAGCA wAAAwTCAGG 201
CGTCATGGGT ACTGGCGGAT TGGGCTTTAC TATCGGTAAC CGGAAAACTA 251
CCGATGACAC TGATCGTACC AATATTGTsC ATACAGGCAG CATTATAGGC 301
AGCCTGAaTG GAGACACCGT TACAGTTGCA GGAAACCGCT ACCGACAAAC 351
CGGCAGTACC GTCTCCAGCC CCGACGGGCG CAATACCGTC ACAGCCAAAw 401
GCATAGATGT AGAGTTCGCA AACAACCGGT ATGCCACTGA CTACGcCCAT 451
ACCCAGGGAA CAAAAAGGCC TTACCGTCGC CCTCAATGTC CCGGTTGTCC 501
AAGCTGCACA AAACTTCATA CAAGCAGCCC AAAATGTGGG CAAAAGTAAA 551
AATAAACGCG TTAATGCCAT GGCTGCAGCC AATGCTGCAT GGCAGAGTTA 601
TCAAGCAACC CAACAAATGC AACAATTTGC TCCAAGCAGC AGTGCGGGAC 651
AAGGTCAAAA CTACAATCAA AGCCCCAGTA TCAGTGTGTC CATTAC.TAC 701
GGCGAACAGA AAAGTCGTAA CGAGCAAAAA AGACATTACA CCGAAgCGGC 751
AgCAAGTCAA ATTATCGGCA AAGGGCAAAC CACACTTGCG GCAACAGGAA 801
GTGGGGAGCA GTCCAATATC AATATTACAG GTTCCGATGT CATCGGCCAT 951
GCAGGTACTC C.CTCATTGC AAGCAACCAT ATCAGACTCC AATCTGCCAA 901
ACAGGACGGC AGCGAGCAAA GCAAAAACAA AAGCAGTGGT TGGAATGCAG 951
GCGTACGTnn CAAAATAGGC AAcGGCATCA GGTTTGGAAT TACCGCCGGA 1001
GGAAATATCG GTAAAGGTAA AGAGCAAGGG GGAAGTACTA CCCACCGCCA 1051
CACCCATGTC GGCAGCACAA CCGGCAAAAC TACCATCCGA AGCGGCGGGG 1101
GATACCACCC TCAAAGGTGT GCAGCTCATC GGCAAAGGCA TACAGGCAGA 1151
TACGCGCAAC CTGCATATAG AAAGTGTTCA AGATACTGAA ACCTATCAGA 1201
GCAAACAGCA AAACGGCAAT GTCCAAGTTt ACTGTCGGTT ACGGATTCAG 1251
TGCAAGCGGC AGTTACCGCC AAAGCAAAGT CAAAGCAGAC CATGCCTCCG 1301
TAACCGGGCA AAgCGGTATT TATGCCGGAG AAGACGGCTA TCAAATyAAA 1351
GTyAGAGACA ACACAGACCT yAAGGGCGGT ATCATCACGT CTAGCCAAAG 1401
CGCAGAAGAT AAGGGCAAAA ACCTTTTTCA GACGGCCACC CTTACTGCCA 1451
GCGACATTCA AAACCACAGC CGCTACGAAG GCAGAAGCTT CGGCATAGGC 1501
GGCAGTTTCG ACCTGAACGG CGGCTGGGAC GGCACGGTTA CCGACAAACA 1551
AGGCAGGCCT ACCGACAGGA TAAGCCCGGC AGCCGGCTAC GGCAGCGACG 1601
GAGACAGCAA AAACAGCACC ACCCGCAGCG GCGTCAACAC CCACAACATA 1651
CACATCACCG ACGAAGCGGG ACAACTTGCC CGAACAGGCA GGACTGCAAA 1701
AGAAACCGAA GCGCGTATCT ACACCGGCAT CGACACCGAA ACTGCGGATC 1751
AACACTCAGG CCATCTGAAA AACAGCTTCG AC...
[0433] This corresponds to the amino acid sequence <SEQ ID 64;
ORF116>:
92 1 ..RFIHDEAVGS NIGGGKNIVA AGQDINVRGX SLISDKGIVL KAGADIDIST 51
AHNRYTGNEY HESXXSGVMG TGGLGFTIGN RKTTDDTDRT NIVHTGSIIG 101
SLNGDTVTVA GNRYRQTGST VSSPEGRNTV TAKXIDVEFA NNRYATDYAH 151
TQEQKGLTVA LNVPVVQAAQ NFIQAAQNVG KSKNKRVNAM AAANAAWQSY 201
QATQQMQQFA PSSSAGQGQN YNQSPSISVS IXYGEQKSRN EQKRNYTEAA 251
ASQIIGKGQT TLAATGSGEQ SNINITGSDV IGHAGTXLIA DNHIRLQSAX 301
QDGSEQSKNK SSGWNAGVRX KIGNGIRFGI TAGGNIGKGK EQGGSTTHRH 351
THVGSTTGKT TIRSGGDTTL KGVQLIGXGI QADTRNLHIE SVQDTETYQS 401
KQQNGNVQVT VGYGFSASGS YRQSKVKADH ASVTGQSGIY AGEDGYQIKV 451
RDNTDLKGGI ITSSQSAEDK GKNLFQTATL TASDIQNHSR YEGRSFGIGG 501
SFDLNGGWDG TVTDKQGRPT DRISPAAGYG SDGDSKNSTT RSGVNTHNIH 551
ITDEAGQLAR TGRTAKETEA RIYTGIDTET ADQHSGHLKN SFD...
[0434] Computer analysis of this amino acid sequence gave the
following results:
[0435] Homology with pspA Putative Secreted Protein of N.
meningitidis (Accession Number AF030941)
[0436] ORF116 and pspA protein show 38% aa identity in 502 aa
overlap:
93 Orf116: 6 EAVGSNIGGGKMIVAAGQDINVRGXSLISDKGIVLKAGHDIDISTAHNRYT-
GNEYHESXX 65 +AV + G ++I+ +G+DI V G ++I+D +L A ++I + A R E ++ PspA:
1235 QAVSGTLDGKEIILVSGRDITVTGSNIIADNHTILSAKNNIVLKA- AETRSRSAEMNKKEK
1294 Orf116: 66 XXXXXXXXXXXXXXNRKXXXXXXR-
TNIVHTGSIIGSLNGDTVTVAGNRYRQTGSTVSSPE 125 ++K + HT S++GSLNG+T+ AG Y
QTGST+SSP+ PspA: 1295
SGLMGSGGIGFTAGSKKDTQTNRSETVSHTESVVGSLNGNTLISAGKHYTQTGSTISSPQ 1354
Orf116: 126 GRNTVTAKXIDVEFANNRYATDYAHTQEQKGLTVALNVPXXXX---XXXXXX-
XXXXXGKS 182 G +++ I ++ A NRY+ + EQKG+TVA++VP GKS PspA: 1355
GDVGISSGKISIDAAQNRYSQESKQVYEQKGVTVAISVPVVNTVMG- AVDAVKAVQTVGKS 1414
Orf116: 183 KNKRVXXXXXXXXXWQSYQATQQMQ-
QFA--PSSSAGQGQNYNQSPSISVSIXYGEQKSRN 240 KN RV + + + A P +AGQG ISVS+
YGEQK+ + PspA: 1415
KNSRVNAMAAANALNKGVDSGVALYNAARNPKKAAGQG--------ISVSVTYGEQKNTS 1466
Orf116: 241 EQKRHYTEAAASQIIGKGQTTLAATGSGEQSNINITGSDVIGHAGTXLIADN-
HIRLQSAK 300 E + T+ +I G G+ +L A+G+G+ S I ITGSDV G GT L A+N +++++A+
PspA: 1467 ESRIKGTQVQEGKITGGGKVSLTASGAGKDSRITITGSDVYGG-
KGTRLKAENAVQIEAAR 1526 Orf116: 301
QDGSEQSKNKSSGWNAGVRXKIGNGIRFGITAXXXXXXXXXXXXSTTHRHTHVGSTTGKT 360 Q
E+S+NKS+G+NAGV I GI FG TA T +R++H+GS +T PspA: 1527
QTHQERSENKSAGFNAGVAIAINKGISFGFTAGANYGKGYGNGDETAYRNSHIGSKDSQT 1586
Orf116: 361 TIRSGGDTTLKGVQLIGKGIQADTRNLHIESVQDTETYQ-
SKQQNGNVQVTVGYGFSASGS 420 I SGGDT +KG QL GKG+ +LHIES+QDT ++ KQ+N +
QVTVGYGFS GS PspA: 1587 AIESGGDTVIKGGQLKGKGVGVTAESLHIE-
SLQDTAVFKGKQENVSAQVTVGYGFSVGGS 1646 Orf116: 421
YRQSKVKADHASVTGQSGIYAGEDGYQIKVRDNTDLKGGIITSSQSAEDKGKNLFQTATL 480 Y
+SK +D+ASV QSGI+AG DGY+I+V T L G + S DK KNL +T+ + PspA: 1647
YNRSKSSSDYASVNEQSGIFAGGDGYRIRVNGKTGLVGAAVVSD---ADKSKNLLKTSEI 1703
Orf116: 481 TASDIQNHSRYEGRSFGIGGSF 502 DIQNH+ + G+ G F PspA: 1704
WHKDIQNHASAAASALGLSGGF 1725
[0437] Based on homology with pspA, it is predicted that this
protein from N. meningitidis, and its epitopes, could be useful
antigens for vaccines or diagnostics.
Example 15
[0438] The following partial DNA sequence was identified in N.
meningitidis SEQ ID 65>
94 1 ..ACGACCGGCA GCCTCGGCGG CATACTGGCC GGCGGCGGCA CTTCCCTTGC 51
CGCACCGTAT TTGGACAAAG CGGCGGAAAA CCTCGGTCCG GCGGGCAAAG 101
CGGCGGTCAA CGCACTGGGC GGTGCGGCCA TCGGCTATGC AACTGGTGGT 151
AGTGGTGGTG CTGTGGTGGG TGCGAATGTA GATTGGAACA ATAGGCAGCT 201
GCATCCGAAA GAAATGGCGT TGGCCGACAA ATATGCCGAA GCCCTCAAGC 251
GCGAAGTTGA AAAACGCGAA GGCAGAAAAA TCAGCAGCCA AGAAGCGGCA 301
ATGAGAATCC GCAGGCAGAT ATGCGTTGGG TGGACAAAGG TTCCCAAGAC 351
GGCTATACCG ACCAAAGCGT CATATCCCTT ATCGGAATGA
[0439] This corresponds to the amino acid sequence <SEQ ID 66;
ORF118>:
95 1 ..TTGSLGGILA GGGTSLAAPY LDKAAENLGP AGKAAVNALG GAAIGYATGG 51
SGGAVVGANV DWNNRQLHPK EMALADKYAE ALKREVEKRE GRKISSQEAA 101
MRIRRQICVG WTKVPKTAIP TKASYPLSE*
[0440] Computer analysis of this amino acid sequence reveals two
putative transmembrane domains.
[0441] Based on this analysis, it is predicted that this protein
from N. meningitidis, and its epitopes, could be useful antigens
for vaccines or diagnostics.
Example 16
[0442] The following partial DNA sequence was identified in N.
meningitidis SEQ ID 67>
96 1 ..CAATGCCGTC TGAAAAGCTC ACAATYTTAC AGACGGCATT TGTTATGCAA 51
GTACATATAC AGATTCCCTA TATACTGCCC AGrkGCGTGC GTgGCTGAAG 101
ACACCCCCTA CGCTTGCTAT TTGrAACAGC TCCAAGTCAC CAAAGACGTC 151
AACTGGAACC AGGTACWACT GGCGTACGAC AAATGGGACT ATAAACAGGA 201
AGGCTTAACC GGAGCCGGAG CAGCGATTAT TGCGCTGGCT GTTACCGTGG 251
TTACTGCGGG CGCGGGAgCC GGAGCCGCAC TGGGcTTAAA CGGCGCGGCc 301
GCAGCGGCAA CCGATGCCGC ATTCGCCTCG CTGGCCAGCC AGGcTTCCGT 351
ATCGCTCATC AaCAACAAAG GCAATATCGG TAaCACCCTG AAAGAGCTGG 401
GCAGAAGCAG CACGGTGAAA AATCTGATGG TTGCCGTCGc tACCGCAgGC 451
GTagCcgaCA AAATCGGTGC TTCGGCACTG AACAATGTCA GCGATAAGCA 501
GTGGATCAAC AACCTGACCG TCAACCTGGC CAATGCGGGC AGTGCCGCAC 551
TGATTAATAC CGCTGTCAAC GGCGGCAGCc tgAAAGACAA TCTGGAAGCG 601
AATATCCTTG CGGCTTTGGT GAATACTGCG CATGGAGAAG CAGCCAGTAA 651
AATCAAACAG TTGGATCAGC ACTACATTAC CCACAAGATT GCCCaTGCCA 701
TAGCGGGCTG TGCGGcTGCG GCGGCGAATA AGGGCAAGTG TCAGGATGGT 751
GCGATAgGTG CGGCTGTGGG CGAGATAGTC GGGGAgGCTT TGACAAACGG 801
CAAAAATCCT GACACTTTGA CAGCTAAAgA ACGCGaACAG ATTTTGGCAT 851
ACAGCAAACT GGTTGCCGGT ACGGTAAGCG GTGTGGTCGG CGGCGATGTA 901
AATGCGGCGG CGAATGCGGC TGAGGTAGCG GTGAAAAATA ATCAGCTTAG 951
CGACAAAtGA
[0443] This corresponds to the amino acid sequence <SEQ ID 68;
ORF41>:
97 1 ..QCRLKSSQFY RRHLLCKYIY RFPIYCPXAC VAEDTPYACY LXQLQVTKDV 51
HWNQVXLAYD KWDYKQEGLT GAGAAIIALA VTVVTAGAGA GAALGLNGAA 101
AAATDAAFAS LASQASVSLI NNKGNIGNTL KELGRSSTVK NU4VAVATAG 151
VADKIGASAL NNVSDKQWIN NLTVNLANAG SAALINTAVN GGSLKDNLEA 201
NILAALVNTA HGEAASKIKQ LDQHYITHKI AHAIAGCAAA AANKGKCQDG 251
AIGAAVGEIV GEALTNGKNP DTLTAKEREQ ILAYSKLVAG TVSGVVGGDV 301
NAAANAAEVA VKNNQLSDK*
[0444] Further work revealed the complete nucleotide sequence
<SEQ ID 69>:
98 1 ATGCAAGTAA ATATTCAGAT TCCCTATATA CTGCCCAGAT GCGTGCGTGC 51
TGAAGACACC CCCTACGCTT GCTATTTGAA ACAGCTCCAA GTCACCAAAG 101
ACGTCAACTG GAACCAGGTA CAACTGGCGT ACGACAAATG GGACTATAAA 151
CAGGAAGGCT TAACCGGAGC CGGAGCAGCG ATTATTGCGC TGGCTGTTAC 201
CGTGGTTACT GCGGGCGCGG GAGCCGGAGC CGCACTGGGC TTAAACGGCG 251
CGGCCGCAGC GGCAACCGAT GCCGCATTCG CCTCGCTGGC CAGCCAGGCT 301
TCCGTATCGC TCATCAACAA CAAAGGCAAT ATCGGTAACA CCCTGAAAGA 351
GCTGGGCAGA AGCAGCACGG TGAAAAATCT GATGGTTGCC GTCGCTACCG 401
CAGGCGTAGC CGACAAAATC GGTGCTTCGG CACTGAACAA TGTCAGCGAT 451
AAGCAGTGGA TCAACAACCT GACCGTCAAC CTGGCCAATG CGGGCAGTGC 501
CGCACTGATT AATACCGCTG TCAACGGCGG CAGCCTGAAA GACAATCTGG 551
AAGCGAATAT CCTTGCGGCT TTGGTGAATA CTGCGCATGG AGAAGCAGCC 601
AGTAAAATCA AACAGTTGGA TCAGCACTAC ATTACCCACA AGATTGCCCA 651
TGCCATAGCG GGCTGTGCGG CTGCGGCGGC GAATAAGGGC AAGTGTCAGG 701
ATGGTGCGAT AGGTGCGGCT GTGGGCGAGA TAGTCGGGGA GGCTTTGACA 751
AACGGCAAAA ATCCTGACAC TTTGACAGCT AAAGAACGCG AACAGATTTT 801
GGCATACAGC AAACTGGTTG CCGGTACGGT AAGCGGTGTG GTCGGCGGCG 851
ATGTAAATGC GGCGGCGAAT GCGGCTGAGG TAGCGGTGAA AAATAATCAG 901
CTTAGCGACA AAGAGGGTAG AGAATTTGAT AACGAAATGA CTGCATGCGC 951
CAAACAGAAT AATCCTCAAC TGTGCAGAAA AAATACTGTA AAAAAGTATC 1001
AAAATGTTGC TGATAAAAGA CTTGCTGCTT CGATTGCAAT ATGTACGGAT 1051
ATATCCCGTA GTACTGAATG TAGAACAATC AGAAAACAAC ATTTGATCGA 1101
TAGTAGAAGC CTTCATTCAT CTTGGGAAGC AGGTCTAATT GGTAAAGATG 1151
ATGAATGGTA TAAATTATTC AGCAAATCTT ACACCCAAGC AGATTTGGCT 1201
TTACAGTCTT ATCATTTGAA TACTGCTGCT AAATCTTGGC TTCAATCGGG 1251
CAATACAAAG CCTTTATCCG AATGGATGTC CGACCAAGGT TATACACTTA 1301
TTTCAGGAGT TAATCCTAGA TTCATTCCAA TACCAAGAGG GTTTGTAAAA 1351
CAAAATACAC CTATTACTAA TGTCAAATAC CCGGAAGGCA TCAGTTTCGA 1401
TACAAACCTA AAAAGACATC TGGCAAATGC TGATGGTTTT AGTCAAAAAC 1451
AGGGCATTAA AGGAGCCCAT AACCGCACCA ATTTTATGGC AGAACTAAAT 1501
TCACGAGGAG GACGCGTAAA ATCTGAAACC CAAACIGATA TTGAAGGCAT 1551
TACCCGAATT AAATATGAGA TTCCTACACT AGACAGGACA GGTAAACCTG 1601
ATGGTGGATT TAAGGAAATT TCAAGTATAA AAACTGTTTA TAATCCTAAA 1651
AAATTTTCTG ATGATAAAAT ACTTCAAATG GCTCAAAATG CTGCTTCACA 1701
AGGATATTCA AAAGCCTCTA AAATTGCTCA AAATGAAAGA ACTAAATCAA 1751
TATCGGAAAG AAAAAATGTC ATTCAATTCT CAGAAACCTT TGACGGAATC 1801
AAATTTAGAT CATATTTTGA TGTAAATACA GGAAGAATTA CAAACATTCA 1851
CCCAGAATAA
[0445] This corresponds to the amino acid sequence <SEQ ID 70;
ORF41-1>:
99 1 MQVNIQIPYI LPRCVRAEDT PYACYLKQLQ VTKDVNWNQV QLAYOKWDYK 51
QEGLTGAGAA IIALAVTVVT AGAGAGAALG LNGAAAAATD AAFASLASQA 101
SVSLINNKGN IGNTLKELGR SSTVKNLHVA VATAGVADKI GASALNNVSD 151
KQWINNLTVN LANAGSAALI NTAVNGGSLX DNLEANILAA LVNTAHGEAA 201
SKIKQLDQHY ITHKIAHAIA GCAAAAANKG KCQDGAIGAA VGEIVGEALT 251
NGKNPDTLTA KEREQILAYS KLVAGTVSGV VGGDVNAAAN AAEVAVKNNQ 301
LSDKLGREFD NEMTACAKQN NPQLCRKNTV KKYQNVADKR LAASIAICTD 351
ISRSTECRTI RKQHLIDSRS LHSSWEAGLX GKDDEWYKLF SKSYTQADLA 401
LQSYHLNTAA KSWLOSGNTK PLSEWNSDQG YTLISGVNPR FIPIPRGFVK 451
QHTFITNVKY PEGISFDTNL KRMLANADGF SQKQGIKGAH NRTNFNAELN 501
SRGGRVKSET QTDIEGITRI KYEIPTLDRT GKPDGGFKEI SSIKTVYNPK 551
KFSDDKILQH AQNAASQGYS KASKIAQNER TKSISERKNV IQFSETFDGI 601
KFRSYFDVNT GRITNIHPE*
[0446] Computer analysis of this amino acid sequence predicts a
transmembrane domain, and homology with an ORF from N. meningitidis
(strain A) was also found.
[0447] ORF41 shows 92.8% identity over a 279 aa overlap with an ORF
(ORF41a) from strain A of N. meningitidis:
100 10 20 30 40 50 60 69 orf41.pep
YRRHLLCKYIYRFPIYCPXACVAEDTPYACYLXQLQVTKDVNWNQVXLAY- DKWDYKQEGL 11
1111:1::11111 1111:11111111 orf41a YLKQLQVAXNINWNQVQLAYDRWDYKQEGL
10 20 30 70 80 90 100 110 120 129 orf41.pep
TGAGAAIIALAVTVVTAGAGAGAALGLNGAAAAATDAAFASLASQASVSLINNKGNIGNT
.vertline.
.vertline..vertline..vertline..vertline..vertline..vertline..v-
ertline..vertline..vertline..vertline..vertline..vertline..vertline..vertl-
ine.:.vertline..vertline..vertline.:.vertline..vertline.:.vertline..vertli-
ne..vertline..vertline..vertline..vertline.
.vertline..vertline..vertline.-
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ver-
tline..vertline..vertline..vertline..vertline..vertline..vertline..vertlin-
e.:.vertline..vertline..vertline..vertline..vertline.::.vertline.:.vertlin-
e. orf41a TEAGAAIIALAVTVVTSGAGTGAVLGLNGAXAAATDAAFASLASQASVSFINNKG-
DVGKT 40 50 60 70 80 90 130 140 150 160 170 180 189 orf41.pep
LKELGRSSTVKNLMVAVATAGVADKIGASALNNVSDKQWINNLT- VNLANAGSAALINTAV
.vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline..vertline..vertline..vertline..vertline..vertline..-
vertline.:.vertline..vertline.:.vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline.
.vertline..vertline..vertline..vertline..vertline.-
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ver-
tline..vertline..vertline..vertline..vertline..vertline..vertline..vertlin-
e..vertline..vertline..vertline..vertline..vertline..vertline..vertline..v-
ertline. orf41a LKELGRSSTVKNLVVAAATAGVADKIGASALXNVSDKQWINNLTVNLAN-
AGSAALINTAV 100 110 120 130 140 150 190 200 210 220 230 240 249
orf41.pep NGGSLKDNLEANILAALVNTAHGEAASKIKQLDQHYITH-
KIAHAIAGCAAAAANKGKCQD .vertline..vertline..vertline..vertline..v-
ertline..vertline..vertline.
.vertline..vertline..vertline..vertline..vert-
line..vertline..vertline..vertline..vertline..vertline..vertline..vertline-
..vertline..vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline.:.vertline..vertline..vertline..vertline..vertline.-
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ver-
tline..vertline..vertline..vertline..vertline..vertline..vertline..vertlin-
e..vertline..vertline. orf41a NGGSLKDXLEANILAALVNTAHGEAASKIKQLDQH-
YIVHKIAHAIAGCAAAAANKGKCQD 160 170 180 190 200 210 250 260 270 280
290 300 309 orf41.pep
GAIGAAVGEIVGEALTNGKNPDTLTAKEREQILAYSKLVAGTVSGVVGGDVNAAANAAEV
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline..vertline..vertline..vertline..vertline..vertline..-
vertline..vertline..vertline..vertline..vertline..vertline..vertline..vert-
line..vertline..vertline..vertline..vertline..vertline..vertline..vertline-
..vertline..vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline..vertline..vertline..vertline..vertline..vertline..-
vertline. orf41a GAIGAAVGEIVGEALTNGKNPDTLTAKEREQILAYSKLVAGTVSGVVG-
GDVNAAANAAEV 220 230 240 250 260 270 310 320 orf41.pep AVKNNQLSDKX
.vertline..vertline..vertline..vertline..vertline..vertline..vertl-
ine..vertline..vertline. orf41a AVKNNQLSDXEGREFDNENTACAKQNXPQLCRX-
WIVKKYQNVADKRLAASIAICTDISRS 280 290 300 310 320 330
[0448] A partial ORF41a nucleotide sequence <SEQ ID 71>
is:
101 1 TATCTGAAAC AGCTCCAAGT AGCGAAAAAC ATCAACTGGA ATCAGGTGCA 51
GCTTGCTTAC GACAGATGGG ACTACAAACA GGAGGGCTTA ACCGAAGCAG 101
GTGCGGCGAT TATCGCACTG GCCGTTACCG TGGTCACCTC AGGCGCAGGA 151
ACCGGAGCCG TATTGGGATT AAACGGTGCG NCCGCCGCCG CAACCGATGC 201
AGCATTCGCC TCTTTGGCCA GCCAGGCTTC CGTATCGTTC ATCAACAACA 251
AAGGCGATGT CGGCAAAACC CTGAAAGAGC TGGGCAGAAG CAGCACGGTG 301
AAAAATCTGG TGGTTGCCGC CGCTACCGCA GGCGTAGCCG ACAAAATCGG 351
CGCTTCGGCA CTGANCAATG TCAGCGATAA GCAGTGGATC AACAACCTGA 401
CCGTCAACCT AGCCAATGCG GGCAGTGCCG CACTGATTAA TACCGCTGTC 451
AACGGCGGCA GCCTGAAAGA CANTCTGGAA GCGAATATCC TTGCGGCTTT 501
GGTCAATACC GCGCATGGAG AAGCAGCCAG TAAAATCAAA CAGTTGGATC 551
AGCACTACAT AGTCCACAAG ATTGCCCATG CCATAGCGGG CTGTGCGGCA 601
GCGGCGGCGA ATAAGGGCAA GTGTCAGGAT GGTGCGATAG GTGCGGCTGT 651
GGGCGAGATA GTCGGGGAGG CTTTGACAAA CGGCAAAAAT CCTGACACTT 701
TGACAGCTAA AGAACGCGAA CAGATTTTGG CATACAGCAA ACTGGTTGCC 751
GGTACGGTAA GCGGTGTGGT CGGCGGCGAT GTAAATGCGG CGGCGAATGC 801
GGCTGAGGTA GCGGTGAAAA ATAATCAGCT TAGCGACNAA GAGGGTAGAG 851
AATTTGATAA CGAAATGACT GCATGCGCCA AACAGAATAN TCCTCAACTG 901
TGCAGAAAAA ATACTGTAAA AAAGTATCAA AATGTTGCTG ATAAAAGACT 951
TGCTGCTTCG ATTGCAATAT GTACGGATAT ATCCCGTAGT ACTGAATGTA 1001
GAACAATCAG AAAACAACAT TTGATCGATA GTAGAAGCCT TCATTCATCT 1051
TGGGAAGCAG GTCTAATTGG TAAAGATGAT GAATGGTATA AATTATTCAG 1101
CAAATCTTAC ACCCAAGCAG ATTTGGCTTT ACAGTCTTAT CATTTGAATA 1151
CTGCTGCTAA ATCTTGGCTT CAATCGGGCA ATACAAAGCC TTTATCCGAA 1201
TGGATGTCCG ACCAAGGTTA TACACTTATT TCAGGAGTTA ATCCTAGATT 1251
CATTCCAATA CCAAGAGGGT TTGTAAAACA AAATACACCT ATTACTAATG 1301
TCAAATACCC GGAAGGCATC AGTTTCGATA CAAACCTANA AAGACATCTG 1351
GCAAATGCTG ATGGTTTTAG TCAAGAACAG GGCATTAAAG GAGCCCATAA 1401
CCGCACCAAT NTTATGGCAG AACTAAATTC ACGAGGAGGA NGNGTAAAAT 1451
CTGAAACCCA NACTGATATT GAAGGCATTA CCCGAATTAA ATATGATATT 1501
CCTACACTAG ACAGGACAGG TAAACCTGAT GGTGGATTTA AGGAAATTTC 1551
AAGTATAAAA ACTGTTTATA ATCCTAAAAA NTTTTNNGAT GATAAAATAC 1601
TTCAAATGGC TCAANATGCT GNTTCACAAG GATATTCAAA AGCCTCTAAA 1651
ATTGCTCAAA ATGAAAGAAC TAAATCAATA TCGGAAAGAA AAAATGTCAT 1701
TCAATTCTCA GAAACCTTTG ACGGAATCAA ATTTAGANNN TATNTNGATG 1751
TAAATACAGG AAGAATTACA AACATTCACC CAGAATAA
[0449] This encodes a protein having the partial amino acid
sequence <SEQ ID 72>:
102 1 YLKQLQVAKN INWNQVQLAY DRWDYKQEGL TEAGAAIIAL AVTVVTSGAG 51
TGAVLGLNGA XAAATDAAFA SLASQASVSF INNKGDVGKT LKELGRSSTV 101
KNLVVAAATA GVADKIGASA LXNVSDKQWI NNLTVNLANA GSAALINTAV 151
NGGSLKDXLE ANILAALVNT AHGEAASKIK QLDQHYIVRK IAHAIAGCAA 201
AAANKGKCQD GAIGAAVGEI VGEALTNGKN PDTLTAKERE QILAYSKLVA 251
GTVSGVVGGD VNAAANAAEV AVKNNQLSDX EGREFONENT ACAKQNXPQL 301
CRKNTVKKYQ NVADKRLAAS IAICTDISRS TECRTIRKQH LIDSRSLHSS 351
WEAGLIGKDD EWYKLFSKSY TQADLALQSY BLNTAAKSWL QSGNTKPLSE 401
VNSDQGYTLI SGVNPRFIFI PRGFVKQNTP ITNVKYPEGI SFDTNLXRHL 451
ANADGFSQEQ GIKGAHNRTN XMAELNSRGG XVKSETXTDI EGITRIKYEI 501
PTLDRTGKPD GGFKEISSIK TVYNPKXFXD DKILQMAQXA XSQGYSKASK 551
IAQNERTKSI SERKNVIQFS ETFDGIKFRX YXDVNTGRIT NIHPE*
[0450] ORF41a and ORF41-1 show 94.8% identity in 595 aa
overlap:
103 10 20 30 orf41a.pep YLKQLQVAKNINWNQVQLAYDRWDYKQEGLTEAGAA
.vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline.:.vertline.::.vertline..vertline..vertline..ver-
tline..vertline..vertline..vertline..vertline..vertline..vertline.:.vertli-
ne..vertline..vertline..vertline..vertline..vertline..vertline..vertline..-
vertline. .vertline..vertline..vertline..vertline. orf41-1
MQVNIQIPYILPRCVRAEDTPYACYLKQLQVTKDVNWNQVQLAYDKWDYKQEGLTGAGAA 10 20
30 40 50 60 40 50 60 70 80 90 orf41a.pep
IIALAVTVVTSGAGTGAVLGLNGAXAAATDAAFASLASQASVSFINNKGDVGKTLKELGR
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline.:.vertline..vertline..vertline.:.vertline..vert-
line.:.vertline..vertline..vertline..vertline..vertline..vertline.
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline..vertline.:.vertline..vertline..vertline..vertline.-
.vertline.::.vertline.:.vertline..vertline..vertline..vertline..vertline..-
vertline..vertline. orf41-1
IIALAVTVVTAGAGAGAALGLNGAAAAATDAAFASLASQ- ASVSLINNKGNIGNTLKELGR 70
80 90 100 110 120 100 110 120 130 140 150 orf41a.pep
SSTVKNLVVAAATAGVADKIGASALXNVSDKQWINNLTVNL- ANAGSAALINTAVNGGSLK
.vertline..vertline..vertline..vertline..vertl-
ine..vertline..vertline.:.vertline..vertline.:.vertline..vertline..vertlin-
e..vertline..vertline..vertline..vertline..vertline..vertline..vertline..v-
ertline..vertline..vertline..vertline.
.vertline..vertline..vertline..vert-
line..vertline..vertline..vertline..vertline..vertline..vertline..vertline-
..vertline..vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline..vertline..vertline..vertline..vertline..vertline..-
vertline. orf41-1
SSTVKNLMVAVATAGVADKIGASALNNVSDKQWINNLTVNLANAGSAAL- INTAVNGGSLK 130
140 150 160 170 180 160 170 180 190 200 210 orf41a.pep
DXLEANILAALVNTAHGEAASKIKQLDQHYIVHKIAHAIAGCAAAAANKGK- CQDGAIGAA
.vertline. .vertline..vertline..vertline..vertline..vert-
line..vertline..vertline..vertline..vertline..vertline..vertline..vertline-
..vertline..vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline.:.vertline..vertline..vertline..vertline..vertline.-
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ver-
tline..vertline..vertline..vertline..vertline..vertline..vertline..vertlin-
e..vertline..vertline..vertline..vertline..vertline..vertline..vertline..v-
ertline. orf41-1
DNLEANILAALVNTAHGEAASKIKQLDQHYITHKIAHAIAGCAAAAANKG- KCQDGAIGAA 190
200 210 220 230 240 220 230 240 250 260 270 orf41a.pep
VGEIVGEALTNGKNPDTLTAKEREQILAYSKLVAGTVSGVVGGDVNAAANA- AEVAVKNNQ
.vertline..vertline..vertline..vertline..vertline..vertl-
ine..vertline..vertline..vertline..vertline..vertline..vertline..vertline.-
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ver-
tline..vertline..vertline..vertline..vertline..vertline..vertline..vertlin-
e..vertline..vertline..vertline..vertline..vertline..vertline..vertline..v-
ertline..vertline..vertline..vertline..vertline..vertline..vertline..vertl-
ine..vertline..vertline..vertline..vertline..vertline..vertline..vertline.-
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ver-
tline..vertline..vertline. orf41-1
VGEIVGEALTNGKNPDTLTAKEREQILAYSKL- VAGTVSGVVGGDVNAAANAAEVAVKNNQ 250
260 270 280 290 300 280 290 300 310 320 330 orf41a.pep
LSDXEGREFDNEMTACAKQNXPQLCRKNTVK- KYQNVADKRLAASIAICTDISRSTECRTI
.vertline..vertline..vertline.
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline.
.vertline..vertline..vertline..vertline..vertline..vertline.-
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ver-
tline..vertline..vertline..vertline..vertline..vertline..vertline..vertlin-
e..vertline..vertline..vertline..vertline..vertline..vertline..vertline..v-
ertline..vertline..vertline..vertline..vertline..vertline..vertline..vertl-
ine..vertline..vertline..vertline. orf41-1
LSDKEGREFDNEMTACAKQNNPQL- CRKNTVKKYQNVADKRLAASIAICTDISRSTECRTI 310
320 330 340 350 360 340 350 360 370 380 390 orf41a.pep
RKQHLIDSRSLHSSWEAGLIGKODEWYKLFSKSYTQADLALQSYHLNTAMCSWLQSGNTK
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline..vertline..vertline..vertline..vertline..vertline..-
vertline..vertline..vertline..vertline..vertline..vertline..vertline..vert-
line..vertline..vertline..vertline..vertline..vertline..vertline..vertline-
..vertline..vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline..vertline..vertline..vertline..vertline..vertline..-
vertline. orf41-1
RKQHLIDSRSLHSSWEAGLIGKDDEWYKLFSKSYTQADLALQSYHLNTA- AXSWLOSGNTK 370
380 390 400 410 420 400 410 420 430 440 450 orf41a.pep
PLSEWMSDQGYTLISGVNPRFIPIPRGFVKQNTPITNVKYPEGISFDTNLX- RHLANADGF
.vertline..vertline..vertline..vertline..vertline..vertl-
ine..vertline..vertline..vertline..vertline..vertline..vertline..vertline.-
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ver-
tline..vertline..vertline..vertline..vertline..vertline..vertline..vertlin-
e..vertline..vertline..vertline..vertline..vertline..vertline..vertline..v-
ertline..vertline..vertline..vertline..vertline..vertline..vertline..vertl-
ine..vertline..vertline..vertline..vertline..vertline..vertline..vertline.
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline. orf41-1
PLSEWMSDQGYTLISGVNPRFIPIPRGFVKQNTPITNVKYP- EGISFDTNLKRHLANADGF 430
440 450 460 470 480 460 470 480 490 500 510 orf41a.pep
SQEQGIKGAHNRTNXMAELNSRGGXVKSETXTDIEGITRIK- YEIPTLDRTGKPDGGFKEI
.vertline..vertline.:.vertline..vertline..vert-
line..vertline..vertline..vertline..vertline..vertline..vertline..vertline-
..vertline.
.vertline..vertline..vertline..vertline..vertline..vertline..v-
ertline..vertline..vertline.
.vertline..vertline..vertline..vertline..vert- line.
.vertline..vertline..vertline..vertline..vertline..vertline..vertlin-
e..vertline..vertline..vertline..vertline..vertline..vertline..vertline..v-
ertline..vertline..vertline..vertline..vertline..vertline..vertline..vertl-
ine..vertline..vertline..vertline..vertline..vertline..vertline..vertline.
orf41-1 SQKQGIKGAHNRTNFMAELNSRGGRVKSETQTDIEGITRIKYEIPTLDRTGKPDGGFK-
EI 490 500 510 520 530 540 520 530 540 550 560 570 orf41a.pep
SSIKTVYNPKXFXDDKILQMAQXAXSQGYSKASKIAQNERTKSISERKNVIQFSETFDGI
.vertline..vertline..vertline..vertline..vertline..vertline..vert-
line..vertline..vertline..vertline. .vertline.
.vertline..vertline..vertli-
ne..vertline..vertline..vertline..vertline..vertline..vertline.
.vertline.
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline..vertline..vertline..vertline..vertline..vertline..-
vertline..vertline..vertline..vertline..vertline..vertline..vertline..vert-
line..vertline..vertline..vertline..vertline..vertline. orf41-1
SSIKTVYNPKKFSDDKILQMAQNAASQGYSKASKIAQNERTKSISERKNVIQFSETFDGI 550
560 570 580 590 600 580 590 orf41a.pep KFRXYXDVNTGRITNIHPEX
.vertline..vertline..vertline. .vertline.
.vertline..vertline..vertline..-
vertline..vertline..vertline..vertline..vertline..vertline..vertline..vert-
line..vertline..vertline..vertline. orf41-1 KFRSYFDVNTGRITNIHPEX
610 620
[0451] Amino acids 25-619 of ORF41-1 were amplified as described
above. FIG. 6 shows plots of hydrophilicity, antigenic index, and
AMPHI regions for ORF41-1.
[0452] Based on this analysis, it is predicted that this protein
from N. meningitidis, and its epitopes, could be useful antigens
for vaccines or diagnostics.
Example 17
[0453] The following DNA sequence was identified in N. meningitidis
<SEQ ID 73>
104 1 ATGGCAATCA TTACATTGTA TTATTCTGTC AATGGTATTT TAAATGTATG 51
TGCAAAAGCA AAAAATATTC AAGTAGTTGC CAATAATAAG AATATGGTTC 101
TTTTTGGGTT TTTGGSmrGC ATCATCGGCG GTTCAACCAA TGCCATGTCT 151
CCCATATTGT TAATATTTTT GCTTAGCGAA ACAGAAAATA AAAATcgTAT 201
CGTAAAATCA AGCAATCTAT GCTATCTTTT GGCGAAAATT GTTCAAATAT 251
ATATGCTAAG AGACCAGTAT TGGTTATTAA ATAAGAGTGA ATACGdTTTA 301
ATATTTTTAC TGTCCGTATT GTCTGTTATT GGATTGTATG TTGGAATTCG 351
GTTAAGGACT AAGATTAGCC CAaATTTTTT TAAAATGTTA ATTTTTATTG 401
tTTTATTGGT ATTGGCtCTG AAAATCGGGC AttCGGGTTT AAtCAAACTT 451 TAA
[0454] This corresponds to the amino acid sequence <SEQ ID 74;
ORF51>:
105 1 HAIITLYYSV NGILNVCAKA KNIQVVANNK NMVLFGFLXX IICGSTNANS 51
PILLIFLLSE TENKNRIVKS SNLCYLLAKI VQIYMLRDQY WLLNKSEYXL 101
IFLLSVLSVI GLYVGIRLRT KISPNFFKML IFIVLLVLAL KIGHSGLIKL 151 *
[0455] Further work revealed the complete nucleotide sequence
<SEQ ID 75>:
106 1 ATGCAAGAAA TAATGCAATC TATCGTTTTT GTTGCTGCCG CAATACTGCA 51
CGGAATTACA GGCATGGGAT TTCCGATGCT CGGTACAACC GCATTGGCTT 101
TTATCATGCC ATTGTCTAAG GTTGTTGCCT TGGTGGCATT ACCAAGCCTG 151
TTAATGAGCT TGTTGGTTCT ATGCAGCAAT AACAAAAAGG GTTTTTGGCA 201
AGAGATTGTT TATTATTTAA AAACCTATAA ATTGCTTGCT ATCGGCAGCG 251
TCGTTGGCAG CATTTTGGGG GTGAAGTTGC TTTTGATACT TCCAGTGTCT 301
TGGCTGCTTT TACTGATGGC AATCATTACA TTGTATTATT CTGTCAATGG 351
TATTTTAAAT GTATGTGCAA AAGCAAAAAA TATTCAAGTA GTTGCCAATA 401
ATAAGAATAT GGTTCTTTTT GGGTTTTTGG CAGGCATCAT CGGCGGTTCA 451
ACCAATGCCA TGTCTCCCAT ATTGTTAATA TTTTTGCTTA GCGAAACAGA 501
AAATAAAAAT CGTATCGTAA AATCAAGCAA TCTATGCTAT CTTTTGGCGA 551
AAATTGTTCA AATATATATG CTAAGAGACC AGTATTGGTT ATTAAATAAG 601
AGTGAATACG GTTTAATATT TTTACTGTCC GTATTGTCTG TTATTGGATT 651
GTATGTTGGA ATTCGGTTAA GGACTAAGAT TAGCCCAAAT TTTTTTAAAA 701
TGTTAATTTT TATTGTTTTA TTGGTATTGG CTCTGAAAAT CGGGCATTCG 751
GGTTTAATCA AACTTTAA
[0456] This corresponds to the amino acid sequence <SEQ ID 76;
ORF51-1>:
107 1 MQEIMQSIVF VAAAILHGIT GMGFPMLGTT ALAFIMPLSK VVALVALPSL 51
LMSLLVLCSN NKKGFWQEIV YYLKTYKLLA IGSVVGSILG VKLLLILPVS 101
WLLLLMAIIT LYYSVNGILN VCAKAKNIQV VANNKNNVLF GFLAGIIGGS 151
TNAMSPILLI FLLSETENKN RIVKSSNLCY LLAKIVQIYN LRDQYWLLNK 201
SEYGLIFLLS VLSVIGLYVG IRLRTKISPN FFKMLIFIVL LVLALKIGHS 251
GLIKL*
[0457] Computer analysis of this amino acid sequence reveals three
putative transmembrane domains. A corresponding ORF from strain A
of N. meningitidis was also identified:
[0458] Homology with a Predicted ORF from N. meningitidis (Strain
A)
[0459] ORF51 shows 96.7% identity over a 150 aa overlap with an ORF
(ORF51a) from strain A of N. meningitidis:
108 10 20 30 orf51.pep MAIITLYYSVNGILNVCAKAKNIQVV- ANNK
.vertline..vertline..vertline..-
vertline..vertline..vertline..vertline..vertline..vertline..vertline..vert-
line..vertline..vertline..vertline..vertline..vertline..vertline..vertline-
..vertline..vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline. orf51a
YKLLAIGSVVGSILGVKLLLILPVSWLLLLMAIITLYYSVNGILNVCAKAKNIQVVANNK 80 90
100 110 120 130 40 50 60 70 80 90 orf51.pep
NMVLFGFLXXIIGGSTNAMSPILLIFLLSETENKNRIVKSSNLCYLLAKIVQIYMLRDQY
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline.
.vertline..vertline..vertline..vertline..vertline..vertline..vertl-
ine..vertline..vertline..vertline..vertline..vertline..vertline..vertline.-
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ver-
tline..vertline..vertline..vertline..vertline..vertline..vertline.:.vertli-
ne..vertline..vertline..vertline..vertline..vertline..vertline..vertline..-
vertline..vertline..vertline..vertline..vertline..vertline..vertline..vert-
line..vertline..vertline..vertline..vertline..vertline..vertline.
orf51a NMVLFGFLAGIIGGSTNAMSPILLIFLLSETENKNRIAKSSNLCYLLAKIVQIYMLRDQY
140 150 160 170 180 190 100 110 120 130 140 150 orf51.pep
WLLNKSEYXLIFLLSVLSVIGLYVGIRLRTKISPNFFKMLIFIVLLVLALKIGHSGLIKL
.vertline..vertline..vertline..vertline..vertline..vertline..vertlin-
e..vertline.
.vertline..vertline..vertline..vertline..vertline..vertline..-
vertline..vertline..vertline..vertline..vertline..vertline..vertline..vert-
line..vertline..vertline..vertline..vertline..vertline..vertline..vertline-
..vertline..vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline..vertline..vertline..vertline..vertline..vertline..-
vertline.:.vertline..vertline..vertline..vertline..vertline..vertline.
orf51a WLLNKSEYGLIFLLSVLSVIGLYVGIRLRTKISPNFFKMLIFIVLLVLALKIGYSGLIKL
200 210 220 230 240 250
[0460] ORF51-1 and ORF51a show 99.2% identity in 255 aa
overlap:
109 orf51a.pep
MQEIMQSIVFVAAAILHGITGMGFPMLGTTALAFIMPLSKVVALVALPSLLM- SLLVLCSN
.vertline..vertline..vertline..vertline..vertline..vertl-
ine..vertline..vertline..vertline..vertline..vertline..vertline..vertline.-
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ver-
tline..vertline..vertline..vertline..vertline..vertline..vertline..vertlin-
e..vertline..vertline..vertline..vertline..vertline..vertline..vertline..v-
ertline..vertline..vertline..vertline..vertline..vertline..vertline..vertl-
ine..vertline..vertline..vertline..vertline..vertline..vertline..vertline.-
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ver-
tline..vertline..vertline. orf51-1
MQEIMQSIVFVAAAILHGITGMGFPMLGTTAL- AFIMPLSKVVALVALPSLLMSLLVLCSN
orf51a.pep
NKKGFWQEIVYYLKTYKLLAIGSVVGSILGVKLLLILPVSWLLLLMAIITLYYSVNGILN
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline..vertline..vertline..vertline..vertline..vertline..-
vertline..vertline..vertline..vertline..vertline..vertline..vertline..vert-
line..vertline..vertline..vertline..vertline..vertline..vertline..vertline-
..vertline..vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline..vertline..vertline..vertline..vertline..vertline..-
vertline. orf51-1
NKKGFWQEIVYYLKTYKLLAIGSVVGSILGVKLLLILPVSWLLLLMAII- TLYYSVNGILN
orf51a.pep VCAKAKNIQVVANNKNMVLFGFLAGIIGGSTNAMS-
PILLIFLLSETENKNRIAKSSNLCY .vertline..vertline..vertline..vertline.-
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ver-
tline..vertline..vertline..vertline..vertline..vertline..vertline..vertlin-
e..vertline..vertline..vertline..vertline..vertline..vertline..vertline..v-
ertline..vertline..vertline..vertline..vertline..vertline..vertline..vertl-
ine..vertline..vertline..vertline..vertline..vertline..vertline..vertline.-
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ver-
tline..vertline..vertline..vertline.:.vertline..vertline..vertline..vertli-
ne..vertline..vertline..vertline. orf51-1
VCAKAKNIQVVANNKNMVLFGFLAG- IIGGSTNAMSPILLIFLLSETENKNRIVKSSNLCY
orf51a.pep
LLAKIVQIYMLRDQYWLLNKSEYGLIFLLSVLSVIGLYVGIRLRTKISPNFFKMLIFIVL
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline..vertline..vertline..vertline..vertline..vertline..-
vertline..vertline..vertline..vertline..vertline..vertline..vertline..vert-
line..vertline..vertline..vertline..vertline..vertline..vertline..vertline-
..vertline..vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline..vertline..vertline..vertline..vertline..vertline..-
vertline. orf51-1
LLAKIVQIYMLRDQYWLLNKSEYGLIFLLSVLSVIGLYVGIRLRTKISP- NFFKMLIFIVL
orf51a.pep LVLALKIGYSGLIKLX
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline.:.vertline..vertline..vertline..vertline..vertline..vertline..vertl-
ine. orf51-1 LVLALKIGHSGLIKLX
[0461] The complete length ORF51a nucleotide sequence SEQ D 77>
is:
110 1 ATGCAAGAAA TAATGCAATC TATCGTTTTT GTTGCTGCCG CAATACTGCA 51
CGGAATTACA GGCATGGGAT TTCCGATGCT CGGTACAACC GCATTGGCTT 101
TTATCATGCC ATTGTCTAAG GTTGTTGCCT TGGTGGCATT ACCAAGCCTG 151
TTAATGAGCT TGTTGGTTCT ATGCAGCAAT AACAAAAAGG GTTTTTGGCA 201
AGAGATTGTT TATTATTTAA AAACCTATAA ATTGCTTGCT ATCGGCAGCG 251
TCGTTGGCAG CATTTTGGGG GTGAAGTTGC TTTTGATACT TCCAGTGTCT 301
TGGCTGCTTT TACTGATGGC AATCATTACA TTGTATTATT CTGTCAATGG 351
TATTTTAAAT GTATGTGCAA AAGCAAAAAA TATTCAAGTA GTTGCCAATA 401
ATAAGAATAT GGTTCTTTTT GGGTTTTTGG CAGGCATCAT CGGCGGTTCA 451
ACCAATGCCA TGTCTCCCAT ATTGTTAATA TTTTTGCTTA GCGAAACAGA 501
GAATAAAAAT CGTATCGCAA AATCAAGCAA TCTATGCTAT CTTTTGGCAA 551
AAATTGTTCA AATATATATG CTAAGAGACC AGTATTGGTT ATThAATAAG 601
AGTGAATACG GTTTAATATT TTTACTGTCC GTATTGTCTG TTATTGGATT 651
GTATGTTGGA ATTCGGTTAA GGACTAAGAT TAGCCCAAAT TTTTTTAAAA 701
TGTTAATTTT TATTGTTTTA TTGGTATTGG CTCTGAAAAT CGGGTATTCA 751
GGTTTAATCA AACTTTAA
[0462] This encodes a protein having amino acid sequence <SEQ ID
78>:
111 1 MQEIMQSIVF VAAAILHGIT GMGFPNLGTT ALAFIMPLSK VVALVALPSL 51
LMSLLVLCSN NKKGFWQEIV YYLKTYKLLA IGSVVGSILG VKLLLILPVS 101
WLLLLMAIIT LYYSVNGILN VCAKAKNIQV VANNKNMVLF GFLAGIIGGS 151
TNAMSFILLI FLLSETENKN RIAXSSNLCY LLAKIVQIYM LRDQYWLLNK 201
SEYGLIFLLS VLSVIGLYVG IRLRTKISPN FFKMLIFIVL LVLALKIGYS 251
GLIKL*
[0463] Based on this analysis, it is predicted that this protein
from N. meningitidis, and its epitopes, could be useful antigens
for vaccines or diagnostics.
Example 18
[0464] The following partial DNA sequence was identified in N.
meningitidis <SEQ ID 79>
112 1 ATGAGACATA TGAAAATACA AAATTATTTA CTAGTATTTA TAGTTTTACA 51
TATAGCCTTG ATAGTAATTA ATATAGTGTT TGGTTATTTT GTTTTTCTAT 101
TTGATTTTTT TGCGTTTTTG TTTTTTGCAA ACGTCTTTCT TGCTGTAAAT 151
TTATTATTTT TAGAAAAAAA CATAAAAAAC AAATTATTGT TTTTATTGCC 201
GATTTCTATT ATTATATGGA TGGTAATTCA TATTAGTATG ATAAATATAA 251
AATTTTATAA ATTTGAGCAT CAAATAAAGG AACAAAATAT ATCCTCGATT 301
ACTGGGGTGA TAAAACCACA TGATAGTTAT AATTATGTTT ATGACTCAAA 351
TGGATATGCT AAATTAAAAG ATAATCATAG ATATGGTAGG GTAATTAGAG 401
AAACACCTTA TATTGATGTA GTTGCATCTG ATGTTAAAAA TAAATCCATA 451
AGATTAAGCT TGGTTTGTGG TATTCATTCA TATGCTCCAT GTGCCAATTT 501
TATAAAATTT GTCAGG..
[0465] This corresponds to the amino acid sequence <SEQ ID 80;
ORF82>:
113 1 MRHMKIQNYL LVFIVLHIAL IVINIVFGYF VFLFDFFAFL FFANVFLAVN 51
LLFLEKNIKN KLLFLLPISI IIWMVIHISM INIKFYKFEH QIKEQNISSI 101
TGVIKPNDSY NYVYDSNGYA KLKDWHRYGR VIRETPYIDV VASDVKNKSI 151
RLSLVCGIHS YAPCANFIKF VR..
[0466] Further work revealed the complete nucleotide sequence SEQ
ID 81>:
114 1 ATGAGACATA TGAAAAATAA AAATTATTTA CTAGTATTTA TAGTTTTACA 51
TATAGCCTTG ATAGTAATTA ATATAGTGTT TGGTTATTTT GTTTTTCTAT 101
TTGATTTTTT TGCGTTTTTG TTTTTTGCAA ACGTCTTTCT TGCTGTAAAT 151
TTATTATTTT TAAAAAAAAA CATAAAAAAC AAATTATTGT TTTTATTGCC 201
GATTTCTATT ATTATATGGA TGGTAATTCA TATTAGTATG ATAAATATAA 251
AATTTTATAA ATTTGAGCAT CAAATAAAGG AACAAAATAT ATCCTCGATT 301
ACTGGGGTGA TAAAACCACA TGATAGTTAT AATTATGTTT ATGACTCAAA 351
TGGATATGCT AAATTAAAAG ATAATCATAG ATATGGTAAG GTAATTAGAG 401
AAACACCTTA TATTGATGTA GTTGCATCTG ATGTTAAAAA TAAATCCATA 451
AGATTAAGCT TGGTTTGTGG TATFCATTCA TATGCFCCAT GTGCCAATTT 501
TATAAAATTT GCAAAAAAAC CTGTTAAAAT TTATTTTTAT AATCAACCTC 551
AAGGAGATTT TATAGATAAT GTAATATTTG AAATTAATGA TGGAAACAAA 601
AGTTTGTACT TGTTAGATAA GTATAAAACA TTTTTTCTTA TTGAAAACAG 651
TGTTTGTATC GTATTAATTA TTTTATATTT AAAATTTAAT TTGCTTTTAT 701
ATAGGACTTA CTTCAATGAG TTGGAATAG
[0467] This corresponds to the amino acid sequence <SEQ ID 82;
ORF82-1>:
115 1 MRHMKNKNYL LVFIVLHIAL IVINIVFGYF VFLFDFFAFL FFANVFLAVN 51
LLFLEKNIKH KLLFLLPISI IIWMVIHISH INIKFYKFEH QIKEQNISSI 101
TGVIKPHDSY NYVYDSNGYA KLKDNHRYGR VIRETPYIDV VASDVKNKSI 151
RLSLVCGIHS YAPCANFIKF AKKPVKIYFY NQPQGDFIDN VIFEINDGNK 201
SLYLLDKYKT FFLIENSVCI VLIILYLKFN LLLYRTYFNE LE*
[0468] Computer analysis of this amino acid sequence reveals a
predicted leader peptide.
[0469] A corresponding ORF from strain A of N. meningitidis was
also identified:
[0470] Homology with a Predicted ORF from N. meningitidis (Strain
A)
[0471] ORF82 shows 97.1% identity over a 172 aa overlap with an ORF
(ORF82a) from strain A of N. meningitidis:
116 10 20 30 40 50 60 orf82 pep
MRHMKIQNYLLVFIVLHIALIVINIVFGYFVFLFDFFAFLFFANVFLAVNLLFLEK- NIKN
.vertline..vertline..vertline..vertline..vertline.
:.vertline..vertline..vertline..vertline..vertline..vertline..vertline..v-
ertline..vertline..vertline..vertline.:.vertline..vertline..vertline..vert-
line..vertline..vertline..vertline..vertline..vertline..vertline..vertline-
..vertline..vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline..vertline..vertline..vertline..vertline..vertline..-
vertline..vertline..vertline..vertline..vertline..vertline..vertline..vert-
line. orf82a
MRHMKIKNYLLVFIVLHITLIVINIVFGYFVFLFDFFAFLFFANVFLAVNLLFL- EKNIKN 10
20 30 40 50 60 70 80 90 100 110 120 orf82 pep
KLLFLLPISIIIWMVIHISMINIKFYKFEHQIKEQNISSITGVIKPHDS- YNYVYDSNGYA
.vertline..vertline..vertline..vertline..vertline..ver-
tline..vertline..vertline..vertline..vertline..vertline..vertline..vertlin-
e..vertline..vertline..vertline..vertline..vertline..vertline..vertline..v-
ertline..vertline..vertline..vertline..vertline..vertline..vertline..vertl-
ine..vertline..vertline..vertline..vertline..vertline..vertline..vertline.-
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ver-
tline..vertline..vertline..vertline..vertline..vertline..vertline..vertlin-
e..vertline..vertline..vertline..vertline..vertline..vertline..vertline..v-
ertline..vertline..vertline. orf82a
KLLFLLPISIIIWMVIHISMINIKFYKFEHQ- IKEQNISSITGVIKFHDSYNYVYDSNGYA 70
80 90 100 110 120 130 140 150 160 170 orf82 pep
KLKDNHRYGRVIRETPYIDVVASDVKNKSIRLSLVCGIH- SYAPCANFIKFVR
.vertline..vertline..vertline..vertline..vertline..v-
ertline..vertline..vertline..vertline..vertline..vertline..vertline..vertl-
ine..vertline..vertline..vertline..vertline..vertline..vertline..vertline.-
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ver-
tline..vertline..vertline..vertline..vertline..vertline..vertline..vertlin-
e..vertline..vertline..vertline..vertline..vertline..vertline..vertline..v-
ertline..vertline..vertline..vertline..vertline..vertline..vertline..vertl-
ine.:: orf82a
KLKDNHRYGRVIRETPYIDVVASDVKNKSIRLSLVCGIHSYAPCANFIKFAKK- PVKIYFY 130
140 150 160 170 orf82a.pep
MRHMKNKNYLLVFIVLHITLIVINIVFGYFVFLFDFFAFLFFANVFLAVNLLFL- EKNIKN
.vertline..vertline..vertline..vertline..vertline..vertline-
..vertline..vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline.:.vertline..vertline..vertl-
ine..vertline..vertline..vertline..vertline..vertline..vertline..vertline.-
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ver-
tline..vertline..vertline..vertline..vertline..vertline..vertline..vertlin-
e..vertline..vertline..vertline..vertline..vertline..vertline..vertline..v-
ertline..vertline..vertline..vertline..vertline..vertline..vertline..vertl-
ine..vertline. orf82-1
MRHMKNKNYLLVFIVLHIALIVINIVFGYFVFLFDFFAFLFFAN- VFLAVNLLFLEKNIKN
orf82a.pep KLLFLLPISIIIWMVIHISMINIKFYKFEH-
QIKEQNISSITGVIKPHDSYNYVYDSNGYA .vertline..vertline..vertline..vert-
line..vertline..vertline..vertline..vertline..vertline..vertline..vertline-
..vertline..vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline..vertline..vertline..vertline..vertline..vertline..-
vertline..vertline..vertline..vertline..vertline..vertline..vertline..vert-
line..vertline..vertline..vertline..vertline..vertline..vertline..vertline-
..vertline..vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline. orf82-1
KLLFLLPISIIIWMVIHISMINIKFYKFEHQIKEQNISSITGVIKPHDSYNYVYDSNGYA
orf82a.pep
KLKDNHRYGRVIRETPYIDVVASDVKNKSIRLSLVCGIHSYAPCANFIKFAKKPVKIYF- Y
.vertline..vertline..vertline..vertline..vertline..vertline..ver-
tline..vertline..vertline..vertline..vertline..vertline..vertline..vertlin-
e..vertline..vertline..vertline..vertline..vertline..vertline..vertline..v-
ertline..vertline..vertline..vertline..vertline..vertline..vertline..vertl-
ine..vertline..vertline..vertline..vertline..vertline..vertline..vertline.-
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ver-
tline..vertline..vertline..vertline..vertline..vertline..vertline..vertlin-
e..vertline..vertline..vertline..vertline..vertline..vertline..vertline..v-
ertline..vertline. orf82-1
KLKDNHRYGRVIRETPYIDVVASDVKNKSIRLSLVCGIHS- YAPCANFIKFAKKPVKIYFY
orf82a.pep NQPQGDFIDNVIFEINKGKKSLYLLD-
KYKTFFLIENSVCIVLIILYLKFNLLLYRTYFNE .vertline..vertline..vertline..-
vertline..vertline..vertline..vertline..vertline..vertline..vertline..vert-
line..vertline..vertline..vertline..vertline..vertline..vertline..vertline-
..vertline..vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline..vertline..vertline..vertline..vertline..vertline..-
vertline..vertline..vertline..vertline..vertline..vertline..vertline..vert-
line..vertline..vertline..vertline..vertline..vertline..vertline..vertline-
..vertline..vertline..vertline..vertline..vertline. orf82-1
NQPQGDFIDNVIFEINKGKKSLYLLDKYKTFFLIENSVCIVLIILYLKFNLLLYRTYFNE
orf82a.pep LEX .vertline..vertline..vertline. orf82-1 LEX
[0472] ORF82a and ORF82-1 show 99.2% identity in 242 aa
overlap:
117 orf82a.pep
MRHMKNKNYLLVFIVLHITLIVINIVFGYGVFLFDFFAFLFFANVFLAVNLL- FLEKNIKN
.vertline..vertline..vertline..vertline..vertline..vertl-
ine..vertline..vertline..vertline..vertline..vertline..vertline..vertline.-
.vertline..vertline..vertline..vertline..vertline.:.vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline..vertline..vertline..vertline..vertline..vertline..-
vertline..vertline..vertline..vertline..vertline..vertline..vertline..vert-
line..vertline..vertline..vertline..vertline..vertline..vertline..vertline-
..vertline..vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline. orf82-1
MRHMKNKNYLLVFIVLHIALIVINIVFGYGVFLFDFFAFLF- FANVFLAVNLLFLEKNIKN
orf82a.pep KLLFLLPISIIIWMVIHISMINIKFYK-
FEHQIKEQNISSITGVIKPHDSYNYVYDSNGYA .vertline..vertline..vertline..v-
ertline..vertline..vertline..vertline..vertline..vertline..vertline..vertl-
ine..vertline..vertline..vertline..vertline..vertline..vertline..vertline.-
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ver-
tline..vertline..vertline..vertline..vertline..vertline..vertline..vertlin-
e..vertline..vertline..vertline..vertline..vertline..vertline..vertline..v-
ertline..vertline..vertline..vertline..vertline..vertline..vertline..vertl-
ine..vertline..vertline..vertline..vertline..vertline..vertline..vertline.-
.vertline..vertline..vertline..vertline..vertline. orf82-1
KLLFLLPISIIIWMVIHISMINIKFYKFEHQIKEQNISSITGVIKPHDSYNYVYDSNGYA
orf82a.pep
KLKDNHRYGRVIRETPYIDVVASDVKNKSIRLSLVCGIHSYAPCANFIKFAKKPVKIYF- Y
.vertline..vertline..vertline..vertline..vertline..vertline..ver-
tline..vertline..vertline..vertline..vertline..vertline..vertline..vertlin-
e..vertline..vertline..vertline..vertline..vertline..vertline..vertline..v-
ertline..vertline..vertline..vertline..vertline..vertline..vertline..vertl-
ine..vertline..vertline..vertline..vertline..vertline..vertline..vertline.-
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ver-
tline..vertline..vertline..vertline..vertline..vertline..vertline..vertlin-
e..vertline..vertline..vertline..vertline..vertline..vertline..vertline..v-
ertline..vertline. orf82-1
KLKDNHRYGRVIRETPYIDVVASDVKNKSIRLSLVCGIHS- YAPCANFIKFAKKPVKIYFY
orf82a.pep NQPQGDFIDNVIFEINDGKKSLYLLD-
KYKTFFLIENSVCIVLIILYLKFNLLLYRTYFNE .vertline..vertline..vertline..-
vertline..vertline..vertline..vertline..vertline..vertline..vertline..vert-
line..vertline..vertline..vertline..vertline..vertline..vertline..vertline-
.:.vertline..vertline..vertline..vertline..vertline..vertline..vertline..v-
ertline..vertline..vertline..vertline..vertline..vertline..vertline..vertl-
ine..vertline..vertline..vertline..vertline..vertline..vertline..vertline.-
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ver-
tline..vertline..vertline..vertline..vertline..vertline..vertline..vertlin-
e..vertline..vertline..vertline..vertline. orf82-1
NQPQGDFIDNVIFEINDGNKSLYLLDKYKTFFLIENSVCIVLIILYLKFNLLLYRTYFNE
orf82a.pep LEX .vertline..vertline..vertline. orf82-1 LEX
[0473] The complete length ORF82a nucleotide sequence <SEQ D
83> is:
118 1 ATGAGACATA TGAAAAATAA AAATTATTTA CTAGTATTTA TAGTTTTACA 51
TATAACCTTG ATAGTAATTA ATATAGTGTT TGGTTATTTT GTTTTTCTAT 101
TTGATTTTTT TGCGTTTTTG TTTTTTGCAA ACGTCTTTCT TGCTGTAAAT 151
TTATTATTTT TAGAAAAAAA CATAAAAAAC AAATTATTGT TTTTATTGCC 201
GATTTCTATT ATTATATGGA TGGTAATTCA TATTAGTATG ATAAATATAA 251
AATTTTATAA ATTTGAGCAT CAAATAAAGG AACAAAATAT ATCCTCGATT 301
ACTGGGGTGA TAAAACCACA TGATAGTTAT AATTATGTTT ATGACTCAAA 351
TGGATATGCT AAATTAAAAG ATAATCATAG ATATGGTAGG GTAATTACAG 401
AAACACCTTA TATTGATGTA GTIGCATCTG ATGTTAAAAA TAAATCCATA 451
AGATIAAGCT TGGTTTGTGG TATTCATTCA TATGCTCCAT GTGCCAATTT 501
TATAAAATTT GCAAAAAAAC CTGTTAAAAT TTATTTTTAT AATCAACCTC 551
AAGGAGATTT TATAGATAAT GTAATATTTG AAATTAATGA TGGAAAAAAA 601
AGTTTGTACT TGTTAGATAA GTATAAAACA TTTTTTCTTA TTGAAAACAG 651
TGTTTGTATC GTATTAATTA TTTTATATTT AAAATTTAAT TTGCTTTTAT 701
ATAGGACTTA CTTCAATGAG TTGGAATAG
[0474] This encodes a protein having amino acid sequence <SEQ ID
84>:
119 1 MRHMKNKNYL LVFIVLHITL IVINIVFGYF VFLFDFFAFL FFANVFLAVN 51
LLFLEKNIKN KLLFLLPISI IIWMVIHISM INIKFYKFEH QIKEQNISSI 101
TGVIKPHDSY NYVYDSNGYA KLKDNHRYGR VIRETPYIDV VASDVIQKSI 151
RLSLVCGIHS YAPCANFIKF AXKPVKIYFY NQPQGDFXDN VIFEINDGKK 201
SLYLLDKYKT FFLIENSVCI VLIILYLKFN LLLYRTYFNE LE*
[0475] Based on this analysis, it is predicted that this protein
from N. meningitidis, and its epitopes, could be useful antigens
for vaccines or diagnostics.
Example 19
[0476] The following partial DNA sequence was identified in N.
meningitidis <SEQ ID 85>
120 1 ..ACCCCCAACA GCGTGACCGT CTTGCCGTCT TTCGGCGGAT TCGGGCGTAC 51
CGGCGCGACC ATCAATGCAG CAGGCGGGGT CGGCATGACT GCCTTTTCGA 101
CAACCTTAAT TTCCGTAGCC GAGGGCGCGG TTGTAGAGCT GCAGGCCGTG 151
AGAGCCAAAG CCGTCAATGC AACCGCCGCT TGCATTTTTA CGGTCTTGAG 201
TAAGGACATT TTCGATTTCC TTTTTATTTT CCGTTTTCAG ACGGCTGACT 251
TCCGCCTGTA TTTTCGCCAA AGCCATGCCG ACAGCGTGCG CCTTGACTTC 301
ATATTTAAAA GCTTCCGCGC GTGCCAGTTC CAGTTCGCGC GCATAGTTTT 351
GAGCCGACAA CAGCAGGGCT TGCGCCTTGT CGCGCTCCAT CTTGTCGATG 401
ACCGCCTGCA GCTTCGCAAA TGCCGACTFG TAGCCTTGAT GGTGCGACAC 451
AGCCAAGCCC GTGCCGACAA GCGCGATAAT GGCAATCGGT TGCCAGTAAT 501
TCGCCAGCAG TTTCACGAGA TTCATTCTCG ACCTCCTGAC GCTTCACGCT 551 GA
[0477] This corresponds to the amino acid sequence <SEQ ID 86;
ORF124>:
121 1 ..TPNSVTVLPS FGGFGRTGAT INAAGGVGMT AFSTTLISVA EGAVVELQAV 51
RAKAVNATAA CIFTVLSKDI FDFLFIFRFQ TADFRLYFRQ SHADSVRLDF 101
IFKSFRACQF QFARIVLSRQ QQGLRLVALH LVDORLQLRX CRLVALMVRH 151
SQARADKRDN GNRLPVIRQQ FHEIHSRPPD ASR*
[0478] Computer analysis of this amino acid sequence predicts a
transmembrane domain.
[0479] Further work revealed the complete nucleotide sequence SEQ
ID 87>:
122 1 ATGACTGCCT TTTCGACAAC CTTAATTTCC GTAGCCGAGG GCGCGGTTGT 51
AGAGCTGCAG GCCGTGAGAG CCAAAGCCGT CAATGCAACC GCCGCTTGCA 101
TTTTTACGGT CTTGAGTAAG GACATTTTCG ATTTCCTTTT TATTTTCCGT 151
TTTCAGACGG CTGACTTCCG CCTGTTTTTT CGCCAAAGCC ATGCCGACAG 201
CGTGCGCCTT GACTTCATAT TTTTTAGCTT CCGcGCGTGC CAGTTCCAGT 251
TCGCGCGCAT AGTTTTGAGC CGACAACAGC AGGGCTTGCG CCTTGTCGCG 301
CTCCATCTTG TCGATGACCG CCTGCTGCTT CGCAAATGCC GACTTGTAGC 351
CTTGATGGTG CGACACAGCC AAGCCCGTGC CGACAAGCGC GATAATGGCA 401
ATCGGTTGCC AGTTATTCGC CAGCAGTTTC ACGAGATTCA TTCTCGACCT 451
CCTGACGCTT CACGCTGA
[0480] This corresponds to the amino acid sequence SEQ ID 88;
ORF124-1>:
123 1 MTAFSTTLIS VAEGAVVELQ AVRAKAVNAT AACIFTVLSK DIFDFLFIFR 51
FQTADFRLFF RQSHADSVRL DFIFFSFRAC QFQFARIVLS RQQQGLRLVA 101
LHLVDDRLLL RKCRLVAIMV RHSQARADKR DNGNRLPVIR QQFHEIHSRP 151
PDASR*
[0481] A corresponding ORF from strain A of N. meningitidis was
also identified:
[0482] Homology with a Predicted ORF from N. meningitidis (Strain
A)
[0483] ORF124 shows 87.5% identity over a 152 aa overlap with an
ORF (ORF124a) from strain A of N. meningitidis:
124 10 20 30 40 50 60 orf124.pep
TPNSVTVLPSFGGFGRTGATINAAGGVGMTAFSTTLISVAEGAVVELQAVRAKAV- NATAA
.vertline..vertline..vertline..v-
ertline..vertline..vertline..vertline..vertline..vertline..vertline..vertl-
ine..vertline..vertline..vertline..vertline.:.vertline..vertline..vertline-
..vertline..vertline..vertline.
.vertline..vertline..vertline..vertline..v-
ertline.:.vertline..vertline..vertline. orf124a
MTAFSTTLISVAEGALVELQAVMAKAVNTTAA 10 20 30 70 80 90 100 110 120
orf124.pep
CIFTVLSKDIFDFLFIFRFQTADFRLYFRQSHADSVRLDFIFKSFRACQFQFARIVLSRQ
.vertline..vertline..vertline..vertline..vertline..vertline..vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline..vertline..vertline..vertline..vertline..vertline..-
vertline..vertline..vertline..vertline.:.vertline..vertline..vertline..ver-
tline..vertline..vertline..vertline.:.vertline..vertline..vertline..vertli-
ne..vertline..vertline..vertline. .vertline..vertline..vertline.:
.vertline..vertline..vertline..vertline.
:.vertline..vertline..vertline..- vertline..vertline. orf124a
CIFTVLSKDIFDFLFIFRFQTADFRLFFRQSHADGVRLD- FIFFSFRTRLFQFAGVVLSRQ 40
50 60 70 80 90 130 140 150 160 170 180 orf124.pep
QQGLRLVALHLVDDRLQLRKCRLVALMVRHSQARADK- RDNGNRLPVIRQQFHEIHSRPPD
.vertline..vertline..vertline..vertline..v-
ertline..vertline..vertline..vertline..vertline..vertline.:::.vertline..ve-
rtline..vertline. .vertline..vertline..vertline.
.vertline..vertline..vert-
line..vertline..vertline..vertline..vertline..vertline..vertline.
.vertline.:.vertline..vertline..vertline..vertline..vertline..vertline.:.-
vertline..vertline..vertline..vertline..vertline..vertline..vertline..vert-
line..vertline..vertline..vertline..vertline..vertline..vertline..vertline-
..vertline..vertline..vertline..vertline..vertline. orf124a
QQGLRLVALHFLNDRLLLRKSRLVALMVRHRQTRADKRDDGNRLPVIRQQFHEIHSRPPD 100
110 120 130 140 150 orf124.pep ASRX : orf124a VX
[0484] ORF124a and ORF124-1 show 89.5% identity in 152 aa
overlap:
125 orf124-1.pep
MTAFSTTLISVAEGAVVELQAVRAKAVNATAACIFTVLSKDIFDFLFIFR- FQTADFRLFF
.vertline..vertline..vertline..vertline..vertline..ver-
tline..vertline..vertline..vertline..vertline..vertline..vertline..vertlin-
e..vertline..vertline.:.vertline..vertline..vertline..vertline..vertline..-
vertline.
.vertline..vertline..vertline..vertline..vertline.:.vertline..ve-
rtline..vertline..vertline..vertline..vertline..vertline..vertline..vertli-
ne..vertline..vertline..vertline..vertline..vertline..vertline..vertline..-
vertline..vertline..vertline..vertline..vertline..vertline..vertline..vert-
line..vertline..vertline..vertline..vertline..vertline..vertline..vertline-
. orf124a
MTAFSTTLISVAEGALVELQAVMAKAVNTTAACIFTVLSKDIFDFLFIFRFQTADFR- LFF
orf124-1.pep RQSHADSVRLDFIFFSFRACQFQFARIVLSRQQQGLRLVAL-
HLVDDRLLLRKCRLVALMV .vertline..vertline..vertline..vertline..vertl-
ine..vertline.:.vertline..vertline..vertline..vertline..vertline..vertline-
..vertline..vertline..vertline..vertline..vertline.:
.vertline..vertline..vertline..vertline.
:.vertline..vertline..vertline..-
vertline..vertline..vertline..vertline..vertline..vertline..vertline..vert-
line..vertline..vertline..vertline..vertline.:::.vertline..vertline..vertl-
ine..vertline..vertline..vertline..vertline.
.vertline..vertline..vertline-
..vertline..vertline..vertline..vertline. orf124a
RQSHADGVRLDFIFFSFRTRLFQFAGVVLSRQQQGLRLVALHFLNDRLLLRKSRLVALMV
orf124-1.pep RHSQARADKRDNGNRLPVIRQQFHEIHSRPPDASRX
.vertline..vertline.
.vertline.:.vertline..vertline..vertline..vertline..-
vertline..vertline.:.vertline..vertline..vertline..vertline..vertline..ver-
tline..vertline..vertline..vertline..vertline..vertline..vertline..vertlin-
e..vertline..vertline..vertline..vertline..vertline..vertline..vertline.:
orf124a RHRQTRADKRDDGNRLPVIRQQFHEIHSRPPDVX
[0485] The complete length ORF124a nucleotide sequence <SEQ ID
89> is:
126 1 ATGACCGCCT TTTCGACAAC CTTAATTTCC GTAGCCGAGG GCGCGCTTGT 51
AGAGCTGCAA GCCGTGATGG CCAAAGCCGT CAATACAACC GCCGCCTGCA 101
TTTTTACGGT CTTGAGTAAG GACATTTTCG ATTTCCTTTT TATTTTCCGT 151
TTTCAGACGG CTGACTTCCG CCTGTTTTTT CGCCAAAGCC ATGCCGACGG 201
CGTGCGCCTT GACTTCATAT TTTTTAGCTT CCGCACGCGC CTGTTCCAGT 251
TCGCGGGCGT AGTTTTGAGC CGACAACAGC AGGGCTTGCG CCTTGTCGCG 301
CTTCATTTTC TCAATGACCG CCTGCTGCTT CGCAAAAGCC GACTTGTAGC 351
CTTGATGGTG CGACACCGCC AAACCCGTGC CGACAAGCGC GATGATGGCA 401
ATCGGTTGCC AGTTATTCGC CAGCAGTTTC ACGAGATTCA TTCTCGACCT 451
CCTGACGTTT GA
[0486] This encodes a protein having amino acid sequence <SEQ ID
90>:
127 1 MTAFSTTLIS VAEGALVELQ AVNAXAVNTT AACIFTVLSK DIFDFLFIFR 51
FQTADFRLFF RQSHADGVRL DFIFFSFRTR LFQFAGVVLS RQQQGLRLVA 101
LHFLNDELLL RKSRLVALHV RHRQTRADKR DDGNRLPVIR QQFHEIHSRP 151 PDV*
[0487] ORF124-1 was amplified as described above. FIG. 7 shows
plots of hydrophilicity, antigenic index, and AMPHI regions for
ORF124-1.
[0488] Based on this analysis, it is predicted that this protein
from N. meningitidis, and its epitopes, could be useful antigens
for vaccines or diagnostics.
Example 20
[0489] Table III lists several Neisseria strains which were used to
assess the conservation of the sequence of ORF 40 among different
strains.
128TABLE III List of Neisseria Strains Used for Gene Variability
Study of ORF 40 Identification number Strains Source/reference
Group B zn02_1 BZ198 R. Moxon/Seiler et al., 1996 zn03_1 NG3/88 R.
Moxon/Seiler et al., 1996 zn04_1 297-0 R. Moxon/Seiler et al., 1996
zn06_1 BZ147 R. Moxon/Seiler et al., 1996 zn07_1 BZ169 R.
Moxon/Seiler et al., 1996 zn08_1 528 R. Moxon/Seiler et al., 1996
zn10_1 BZ133 R. Moxon/Seiler et al., 1996 zn11_1ass NGE31 R.
Moxon/Seiler et al., 1996 zn14_1 NGH38 R. Moxon/Seiler et al., 1996
zn16_1 NGH15 R. Moxon/Seiler et al., 1996 zn18_1 BZ232 R.
Moxon/Seiler et al., 1996 zn19_1 BZ83 R. Moxon/Seiler et al., 1996
zn20_1 44/76 R. Moxon/Seiler et al., 1996 zn21_1 MC58 R. Moxon
Group A zn22_1 205900 R. Moxon zn23_1 F6124 R. Moxon z2491_1 Z2491
R. Moxon/Maiden et al., 1998 Group C zn24_1 90/18311 R. Moxon
zn25_1ass 93/4286 R. Moxon Others zn28_1ass 860800 (group Y) R.
Moxon/Maiden et al., 1998 zn29_1ass E32 (group Z) R. Moxon/Maiden
et al., 1998 References: Seiler A. et al., Mol. Microbiol., 1996,
19(4): 841-856. Maiden et al., Proc. Natl. Acad. Sci. USA, 1998,
95: 3140-3145.
[0490] The amino acid sequences for each listed strain are as
follows:
129 >Z2491 <SEQ ID 91> MNKIYRIIWNSALNAWVAVSELTRNHT-
KRASATVKTAVLATLLFATVQANATDEDEEEEL
ESVQRSVVGSIQASMEGSGELETISLSMTNDSK- EFVDPYIVVTLKAGDNLKIKQNTNENT
NASSFTYSLKKDLTGLINVETEKLSFGANGKKVNIISDT- KGLNFAKETAGTNGDTTVHLN
GIGSTLTDTLAGSSASHVDAGNQSTHYTRAASIKDVLNAGWNIKG- VKTGSTTGQSENVDF
VRTYDTVEFLSADTKTTTVNVESKDNGKRTEVKIGAKTSVIKEKDGKLVTG- KGKGENGSS
TDEGEGLVTAKEVIDAVNKAGWRMKTTTANGQTGQADKFETVTSGTNVTFASGKGTT- ATV
SKDDQGNITVMYDVNVGDALNVNQLQNSGWNLDSKAVAGSSGKISGNVSPSKADEMDETV
NINAGNNIEISRNGKNIDIATSNAPQFSSVSLGAGADAPTLSVDDEGALNVGSKDANKPV
RINVAPGVKEGDVTNVAQLKGVAQNLNNRIDNVWDGNARAGIAQAIATAGLVQAYLPGKS
MMAIGGGTYRGEAGYAIGYSSISDGGNWIIKGTASGNSRGHFGASASVGYQW* >ZN02_1
<SEQ ID 92> MNKIYRIIWNSALNAWVVVSELTRNHTKRASATVATA-
VLATLLFATVQANATDDDDLYLE
PVQRTAVLSFRSDKEGTGEKEGTEDSHGGAVYFDEKRVLKAGA- ITLKAGDNLKIKQNTNE
NTNDSSFTYSLKKDLTDLTSVETEKLSFGAAGNKVNITSDTKGLNFAKE- TAGTAGDPTVH
LNGIGSTLTDTLLNTGATTNVTNDNVTDDEKKRAASVKDVLNAGWNIKGVKPGTT- ASDNV
DFVRTYDTVEFLSADTKTTTNVSKDNGKKTEVICIGAIVTSVIKEKDGKLVTGKGKDENG
SSTDEGEGLVTAKEVIDAVNKAGWRMKTTTANGQTGQADKFETVTSGTNVTFASGKGTTA
TVSKODQGNITVRYDVNVGDALNVNQLQNSGWNLDSKAVAGSSGKVISGNVSPSKGRMDE
TVNINAGNNIEITRNGKNIDIATSMAPQFSSVSLGAGADAPTLSVDDEGALNVGSKDTNK
PVRITNVAPGVKEGDVTNVAQLKGVAQNLNNRIDNVDGNARAGIAQAIATAGLVQAYLPG
KSMMAIGGDTYRGEAGYAIGYSSISDGGNWIIKGTASGNSRGHFGASASVGYQW* >ZN03_1
<SEQ ID 93> MNKIYRIIWNSALNAWVAVSELTRNHTKRASATVATA-
VLATLLFATVQASTTDDDDLYLE
PVQRTAPVLSFHADSEGTGEKEVTEDSNWGVYFDKKGVLTAGT- ITLKAGDNLKIKQNTDE
NTNDSSFTYSLKKDLTDLTSVETEKLSFGANGNKVNITSDTKGLNFAKE- TAGTNGDPTVH
LNGIGSTLTDTLLNTGATTNVTNDNVTDDEKKRAASVKDVLNAGWNIKGVKPGTT- ASDNV
DFVRTYDTVEFLSADTRTTTVNVESKDNGKKTEVKIGAKTSVIKEKDGKLVTGKGKDENG
SSTDEGEGLVTAKEVIDAVNKAGWRMKTTTANGQTGQADKFETVTSGTNVTFASGKGTTA
TVSKDDQGNITVKYDVNVGDALNVNQLQNSGWNLDSKAVAGSSGKVISGNVSPSKGKMDE
TVNINAGNNIEITRNGKNIDIATSMAPQFSSVSLGAGADAPTLSVDDEGALNVGSKDTNK
PVRITNVAPGVKEGDVTNVAQLKGVAQNLNNRIDNVDGNARAGIAQAIATAGLVQAYLPG
KSMMAIGGDTYRGEAGYAIGYSSISDGGNMIIKGTASGNSRGHFGASASVGYQW* >ZN04_1
<SEQ ID 94> MNKIYRIIWNSALNAWVAVSELTRNHTKRASATVATA-
VLATLLFATVQASTTDDDDLYLE
PVQRTAPVLSFHADSEGTGEKEVTEDSNWGVYFDKKGVLTAGT- ITLKAGDNLKIKQNTDE
NTNDSSFTYSLKKDLTDLTSVETEKLSFGANGNKVNITSDTKGLNFAKE- TAGTNGDPTVH
LNGIGSTLTDTLLNTGATTNVTNDNVTDDEKKRAASVKDVLNAGWNIKGVKPGTT- ASDNV
DFVRTYDTVEFLSADTRTTTVNVESKDNGKKTEVKIGAKTSVIKEKDGKLVTGKGKDENG
SSTDEGEGLVTAKEVIDAVNKAGWRMKTTTANGQTGQADKFETVTSGTNVTFASGKGTTA
TVSKDDQGNITVKYDVNVGDALNVNQLQNSGWNLDSKAVAGSSGKVISGNVSPSKGKMDE
TVNINAGNNIEITRNGKNIDIATSMAPQFSSVSLGAGADAPTLSVDDEGALNVGSKDTNK
PVRITNVAPGVKEGDVTNVAQLKGVAQNLNNRIDNVDGNARAGIAQAIATAGLVQAYLPG
KSMMAIGGDTYRGEAGYAIGYSSISDGGNMIIKGTASGNSRGHFGASASVGYQW* >ZN06_1
<SEQ ID 95> MNKIYRIIWNSALNAWVAVSELTRNHTKRASATVKTA-
VLATLLFATVQANATDEDEEEEL
ESVQRSVVGSIQASMEGSGELETISLSMTNDSKEFVDPYIVVT- LKAGDNLKIKQNTNENT
NASSFTYSLKKDLTGLINVETEKLSFGANGKKVNIISDTKGLNFAKETA- GTNGDTTVHLN
GIGSTLTDTLAGSSASHVDAGNQSTHYTRAASIKDVLNAGWNIKGVKTGSTTGQS- ENVDF
VRTYDTVEFLSADTKTTTVNVESKDNGKRTEVKIGAKTSVIKEKDGKLVTGKGKGENGSS
TDEGEGLVTAKEVIDAVNKAGWRMKTTTANGQTGQADKFETVTSGTNVTFASGKGTTATV
SKDDQGNITVMYDVNVGDALNVNQLQNSGWNLDSKAVAGSSGKISGNVSPSKADEMDETV
NINAGNNIEISRNGKNIDIATSNAPQFSSVSLGAGADAPTLSVDDEGALNVGSKDANKPV
RINVAPGVKEGDVTNVAQLKGVAQNLNNRIDNVWDGNARAGIAQAIATAGLVQAYLPGKS
MMAIGGGTYRGEAGYAIGYSSISDGGNWIIKGTASGNSRGHFGASASVGYQW* >ZN07_1
<SEQ ID 96> MNKIYRIIWNSALNAWVAVSELTRNHTKRASATVKTA-
VLATLLFATVQANATDEDEEEEL
ESVQRSVVGSIQASMEGSGELETISLSMTNDSKEFVDPYIVVT- LKAGDNLKIKQNTNENT
NASSFTYSLKKDLTGLINVETEKLSFGANGKKVNIISDTKGLNFAKETA- GTNGDTTVHLN
GIGSTLTDTLAGSSASHVDAGNQSTHYTRAASIKDVLNAGWNIKGVKTGSTTGQS- ENVDF
VRTYDTVEFLSADTKTTTVNVESKDNGKRTEVKIGAKTSVIKEKDGKLVTGKGKGENGSS
TDEGEGLVTAKEVIDAVNKAGWRMKTTTANGQTGQADKFETVTSGTNVTFASGKGTTATV
SKDDQGNITVMYDVNVGDALNVNQLQNSGWNLDSKAVAGSSGKISGNVSPSKADEMDETV
NINAGNNIEISRNGKNIDIATSNAPQFSSVSLGAGADAPTLSVDDEGALNVGSKDANKPV
RINVAPGVKEGDVTNVAQLKGVAQNLNNRIDNVWDGNARAGIAQAIATAGLVQAYLPGKS
MMAIGGGTYRGEAGYAIGYSSISDGGNWIIKGTASGNSRGHFGASASVGYQW* >ZN08_1
<SEQ ID 97> MNKIYRIIWNSALNAWVVVSELTRNHTKRASATVETA-
VLATLLFATVQANATDTDEDDEL
EPVVRSALVLQFMIDKEGNGEIESTGDIGWSIYYDDHNTLHGA- TVTLKAGDNLKIKQNTD
ENTNASSFTYSLKKDLTDLTSVGTEELSFGANGNKVNITSDTKGLNFAK- KTAGTNGDTTV
HLNGIGSTLTDTLAGSSASHVDAGNQSTHYTRAASIKDVLNAGWNIKGVKTGSTT- GQSEN
VDFVRTYDTVEFLSADTKTTTVNVESKDNGKRTEVKIGAKTSVIKEKDGKLVTGKGKGEN
GSSTEDGEGELVTAKEVIDAVNKAGWRMKTTANGQTGQADKFETVTSGTNVTFASGKGTT
ATVSKDDQGNITVKYDVNVGDALNVNQLQNSGWNLDSKAVAGSSGKISGNAVSPSKGKMD
ETVNINAGNNIEITRNGKNIDIATSMTPQFSSVSLGAGADAPLTLSVDDEALNVGSKDAN
KPVRITNVAPGVKEGDVTNVAQLKGVAQNLNNHIDNVDGNARAGIAQAIATAGLVQAYLP
GKSMMAIGGGTYRGEAGYAIGYSSISDGGNWIIKGTASGNSRGHFGASASVGYQW* >ZN10_1
<SEQ ID 98> MNKIYRIIWNSALNAWVAVSELTRNHTKRASATVKTA-
VLATLLFATVQANATDEDEEEEL
ESVQRSVVGSIQASMEGSGELETISLSMTNDSKEFVDPYIVVT- LKAGDNLKIKQNTNENT
NASSFTYSLKKDLTGLINVETEKLSFGANGKKVNIISDTKGLNFAKETA- GTNGDTTVHLN
GIGSTLTDTLAGSSASHVDAGNQSTHYTRAASIKDVLNAGWNIKGVKTGSTTGQS- ENVDF
VRTYDTVEFLSADTKTTTVNVESKDNGKRTEVKIGAKTSVIKEKDGKLVTGKGKGENGSS
TDEGEGLVTAKEVIDAVNKAGWRMKTTTANGQTGQADKFETVTSGTNVTFASGKGTTATV
SKDDQGNITVMYDVNVGDALNVNQLQNSGWNLDSKAVAGSSGKVISGNVSPSKGKMDETV
NINAGNNIEISRNGKNIDIATSMAPQFSSVSLGAGADAPTLSVDDEGALNVGSKDANKPV
RITNVAPGVKEGDVTNVAQLKGVAQNLNNRIDNVDGNARAGIAQAIATAGLVQAYLPGKS
MMAIGGGYTRGEAGYAIGYSSISDGGNWIIKGTASGNSRGHFGASASVGYQW* >ZN11_1
ASS <SEQ ID 99> MNKIYRIIWNSALNAWVAVSELTRNHTKRASAT-
VATAVLATLLFATVQASTTDDDDLYLE
PVQRTAPVLSFHADSEGTGEKEVTEDSNWGVYFDKKGVL- TAGTITLKAGDNLKIKQNTDE
NTNDSSFTYSLKKDLTDLTSVETEKLSFGANGNKVNITSDTKGLN- FAKETAGTNGDPTVH
LNGIGSTLTDTLLNTGATTNVTNDNVTDDEKKRAASVKDVLNAGWNIKGVK- PGTTASDNV
DFVRTYDTVEFLSADTRTTTVNVESKDNGKKTEVKIGAKTSVIKEKDGKLVTGKGKD- ENG
SSTDEGEGLVTAKEVIDAVNKAGWRMKTTTANGQTGQADKFETVTSGTNVTFASGKGTTA
TVSKDDQGNITVKYDVNVGDALNVNQLQNSGWNLDSKAVAGSSGKVISGNVSPSKGKMDE
TVNINAGNNIEITRNGKNIDIATSMAPQFSSVSLGAGADAPTLSVDDEGALNVGSKDTNK
PVRITNVAPGVKEGDVTNVAQLKGVAQNLNNRIDNVDGNARAGIAQAIATAGLVQAYLPG
KSMMAIGGDTYRGEAGYAIGYSSISDGGNMIIKGTASGNSRGHFGASASVGYQW* >ZN14_1
<SEQ ID 100> MNKIYRIIWNSALNAWVVVSELTRNHTKRASATVET-
AVLATLLFATVQANATDTDEDDEL
EPVVRSALVLQFMIDKEGNGEIESTGDIGWSIYYDDHNTLHG- ATVTLKAGDNLKIKQNTD
ENTNASSFTYSLKKDLTDLTSVGTEELSFGANGNKVNITSDTKGLNFA- KKTAGTNGDTTV
HLNGIGSTLTDTLAGSSASHVDAGNQSTHYTRAASIKDVLNAGWNIKGVKTGST- TGQSEN
VDFVRTYDTVEFLSADTKTTTVNVESKDNGKRTEVKIGAKTSVIKEKDGKLVTGKGKGEN
GSSTEDGEGELVTAKEVIDAVNKAGWRMKTTANGQTGQADKFETVTSGTNVTFASGKGTT
ATVSKDDQGNITVKYDVNVGDALNVNQLQNSGWNLDSKAVAGSSGKISGNAVSPSKGKMD
ETVNINAGNNIEITRNGKNIDIATSMTPQFSSVSLGAGADAPLTLSVDDEALNVGSKDAN
KPVRITNVAPGVKEGDVTNVAQLKGVAQNLNNHIDNVDGNARAGIAQAIATAGLVQAYLP
GKSMMAIGGGTYRGEAGYAIGYSSISDGGNWIIKGTASGNSRGHFGASASVGYQW* >ZN16_1
<SEQ ID 101> MNKIYRIIWNSALNAWVVVSELTRNHTKRASATVAT-
AVLATLLFATVQANATDDDDLYLE
PVQRTAVVLSFRSDKEGTGEKEGTEDSNWAVYFDEKRVLKAG- AITLKAGDNLKIKQNTNE
NTNENTNDSSFTYSLKKDLTDLTSVETEKLSFGANGNKVNITSDTKGL- NFAKETAGTNGD
PTVHLNGIGSTLTDTLLNTGATTNVTNDNVTDDEKKRAASVKDVLNAGWNIKGV- KPGTTA
SDNVDFVRTYDTVEFLSADTKTTTVNVESKDNGKKTEVKIGAKTSVIKEKDGKLVTGKGK
DENGSSTDEGEGLVTAKEVIDAVNKAGWRMKTTTANGQTGQADKFETVTSGTKVTFASGN
GTTATVSKDDQGNITVKYDVNVGDALNVNQLQNSGWNLDSKAVAGSSGKVISGNVSPSKG
KMDETVNINAGNNIEITRNGKNIDIATSMTPQFSSVSLGAGADAPTLSVDDEGALNVGSK
DANKPVRITNVAPGVKEGDVTNVAQLKGVAQNLNNRIDNVDGNARAGIAQAIATAGLAQA
YLPGKSMMAIGGGTYRGEAGYAIGYSSISDTGNWVIKGTASGNSRGHFGASASVGYQW*
>ZN18_1 <SEQ ID 102> MNKIYRIIWNSALNAWVAVSELTRNHTKRASATV-
ATAVLATLLFATVQASTTDDDDLYLE
PVQRTAPVLSFHADSEGTGEKEVTEDSNWGVYFDKKGVLT- AGTITLKAGDNLKIKQNTDE
NTNDSSFTYSLKKDLTDLTSVETEKLSFGANGNKVNITSDTKGLNF- AKETAGTNGDPTVH
LNGIGSTLTDTLLNTGATTNVTNDNVTDDEKKRAASVKDVLNAGWNIKGVKP- GTTASDNV
DFVRTYDTVEFLSADTRTTTVNVESKDNGKKTEVKIGAKTSVIKEKDGKLVTGKGKDE- NG
SSTDEGEGLVTAKEVIDAVNKAGWRMKTTTANGQTGQADKFETVTSGTNVTFASGKGTTA
TVSKDDQGNITVKYDVNVGDALNVNQLQNSGWNLDSKAVAGSSGKVISGNVSPSKGKMDE
TVNINAGNNIEITRNGKNIDIATSMAPQFSSVSLGAGADAPTLSVDDEGALNVGSKDTNK
PVRITNVAPGVKEGDVTNVAQLKGVAQNLNNRIDNVDGNARAGIAQAIATAGLVQAYLPG
KSMMAIGGDTYRGEAGYAIGYSSISDGGNMIIKGTASGNSRGHFGASASVGYQW* >ZN19_1
<SEQ ID 103> MNKIYRIIWNSALNAWVVVSELTRNHTKRASATVKT-
AVLATLLFATVQASANNEEQEEDL
YLDPVQRTVAVLIVNSDKEGTGEKEKVEENSDWAVYFNEKGV- LTAREITLKAGDNLKIKQ
NGTNFTYSLKKDLTDLTSVGTEKLSFSANGNKVNITSDTKGLNFAKET- AGTNGDTTVHLN
GIGSTLTDTLLNTGATTNVTNDNVTDDEKKRAASVKDVLNAGWNIKGVKPGTTA- SDNVDF
VRTYDTVEFLSADTKTTTVNVESKDNGKKTEVKIGAKTSVIKEKDGKLVTGKDKGENGSS
TDEGEGLVTAKEVIDAVNKAGWRMKTTTANGQTGQADKFETVTSGTNVTFASGKGTTATV
SKDDQGNITVMYDVNVGDALNVNQLQNSGWNLDSKAVAGSSGKVISGNVSPSKGKMDETV
NINAGNNIEITRNGKNIDIATSMTPQFSSVSLGAGADAPTLSVDGDALNVGSKKDNKPVR
ITNVAPGVKEGDVTNVAQLKGVAQNLNNRIDNVDGNARAGIAQAIATAGLVQAYLPGKSM
MAIGGGTYRGEAGYAIGYSSISDGGNWIIKGTASGNSRGHFGASASVGYQW* >ZN20_1
<SEQ ID 104> MNKIYRIIWNSALNAWVVVSELTRNHTKRASATVKT-
AVLATLLFATVQASANNEEQEEDL
YLDPVQRTVAVLIVNSDKEGTGEKEKVEENSDWAVYFNEKGV- LTAREITLKAGDNLKIKQ
NGTNFTYSLKKDLTDLTSVGTEKLSFSANGNKVNITSDTKGLNFAKET- AGTNGDTTVHLN
GIGSTLTDTLLNTGATTNVTNDNVTDDEKKRAASVKDVLNAGWNIKGVKPGTTA- SDNVDF
VRTYDTVEFLSADTKTTTVNVESKDNGKKTEVKIGAKTSVIKEKDGKLVTGKDKGENGSS
TDEGEGLVTAKEVIDAVNKAGWRMKTTTANGQTGQADKFETVTSGTNVTFASGKGTTATV
SKDDQGNITVMYDVNVGDALNVNQLQNSGWNLDSKAVAGSSGKVISGNVSPSKGKMDETV
NINAGNNIEITRNGKNIDIATSMTPQFSSVSLGAGADAPTLSVDGDALNVGSKKDNKPVR
ITNVAPGVKEGDVTNVAQLKGVAQNLNNRIDNVDGNARAGIAQAIATAGLVQAYLPGKSM
MAIGGGTYRGEAGYAIGYSSISDGGNWIIKGTASGNSRGHFGASASVGYQW* >ZN21_1
<SEQ ID 105> MNKIYRIIWNSALNAWVVVSELTRNHTKRASATVKT-
AVLATLLFATVQASANNEEQEEDL
YLDPVQRTVAVLIVNSDKEGTGEKEKVEENSDWAVYFNEKGV- LTAREITLKAGDNLKIKQ
NGTNFTYSLKKDLTDLTSVGTEKLSFSANGNKVNITSDTKGLNFAKET- AGTNGDTTVHLN
GIGSTLTDTLLNTGATTNVTNDNVTDDEKKRAASVKDVLNAGWNIKGVKPGTTA- SDNVDF
VRTYDTVEFLSADTKTTTVNVESKDNGKKTEVKIGAKTSVIKEKDGKLVTGKDKGENGSS
TDEGEGLVTAKEVIDAVNKAGWRMKTTTANGQTGQADKFETVTSGTNVTFASGKGTTATV
SKDDQGNITVMYDVNVGDALNVNQLQNSGWNLDSKAVAGSSGKVISGNVSPSKGKMDETV
NINAGNNIEITRNGKNIDIATSMTPQFSSVSLGAGADAPTLSVDGDALNVGSKKDNKPVR
ITNVAPGVKEGDVTNVAQLKGVAQNLNNRIDNVDGNARAGIAQAIATAGLVQAYLPGKSM
MAIGGGTYRGEAGYAIGYSSISDGGNWIIKGTASGNSRGHFGASASVGYQW* >ZN22_1
<SEQ ID 106> MNKIYRIIWNSALNAWVAVSELTRNHTKRASATVKT-
AVLATLLFATVQANATDEDEEEEL
ESVQRSVVGSIQASMEGSGELETISLSMTNDSKEFVDPYIVV- TLKAGDNLKIKQNTNENT
NASSFTYSLKKDLTGLINVETEKLSFGANGKKVNIISDTKGLNFAKET- AGTNGDTTVHLN
GIGSTLTDTLAGSSASHVDAGNQSTHYTRAASIKDVLNAGWNIKGVKTGSTTGQ- SENVDF
VRTYDTVEFLSADTKTTTVNVESKDNGKRTEVKIGAKTSVIKEKDGKLVTGKGKGENGSS
TDEGEGLVTAKEVIDAVNKAGWRMKTTTANGQTGQADKFETVTSGTNVTFASGKGTTATV
SKDDQGNITVMYDVNVGDALNVNQLQNSGWNLDSKAVAGSSGKVISGNVSPSKGKMDETV
NINAGNNIEISRNGKNIDIATSMAPQFSSVSLGAGADAPTLSVDDEGALNVGSKDANKPV
RITNVAPGVKEGDVTNVAQLKGVAQNLNNRIDNVDGNARAGIAQAIATAGLVQAYLPGKS
MMAIGGGYTRGEAGYAIGYSSISDGGNWIIKGTASGNSRGHFGASASVGYQW* >ZN23_1
<SEQ ID 107> MNKIYRIIWNSALNAWVAVSELTRNHTKRASATVKT-
AVLATLLFATVQANATDEDEEEEL
ESVQRSVVGSIQASMEGSGELETISLSMTNDSKEFVDPYIVV- TLKAGDNLKIKQNTNENT
NASSFTYSLKKDLTGLINVETEKLSFGANGKKVNIISDTKGLNFAKET- AGTNGDTTVHLN
GIGSTLTDTLAGSSASHVDAGNQSTHYTRAASIKDVLNAGWNIKGVKTGSTTGQ- SENVDF
VRTYDTVEFLSADTKTTTVNVESKDNGKRTEVKIGAKTSVIKEKDGKLVTGKGKGENGSS
TDEGEGLVTAKEVIDAVNKAGWRMKTTTANGQTGQADKFETVTSGTNVTFASGKGTTATV
SKDDQGNITVMYDVNVGDALNVNQLQNSGWNLDSKAVAGSSGKVISGNVSPSKGKMDETV
NINAGNNIEISRNGKNIDIATSMAPQFSSVSLGAGADAPTLSVDDEGALNVGSKDANKPV
RITNVAPGVKEGDVTNVAQLKGVAQNLNNRIDNVDGNARAGIAQAIATAGLVQAYLPGKS
MMAIGGGYTRGEAGYAIGYSSISDGGNWIIKGTASGNSRGHFGASASVGYQW* >ZN24_1
<SEQ ID 108> MNKIYRIIWNSALNAWVVVSELTRNHTKRASATVAT-
AVLATLLSATVQANATDTDEDEEL
ESVVRSALVLQFMIDKEGNGEIESTGDIGWSIYYDDHNTLHG- ATVTLKAGDNLKIKQSGK
DFTYSLKKELKDLTSVETEKLSFGANGNKVNITSDTKGLNFAKETAGT- NGDPTVHLNGIG
STLTDTLAGSSASHVDAGNQSTHYTRAASIKDVLNAGWNIKGVKTGSTTGQSEN- VDFVRT
YDTVEFLSADTKTTTVNVESKDNGKRTEVKIGAKTSVIKEKDGKLVTGKGKGENGSSTDE
GEGLVTAKEVIDAVNKAGWRMKTTTANGQTGQADKFETVTSGTKVTFASGNGTTATVSKD
DQGNITVKYDVNVGDALNVNQLQNSGWNLDSKAVAGSSGKVISGNVSPSKGKMDETVNIN
AGNNIEITRNGKNIDIATSMTPQFSSVSLGAGADAPTLSVDDEGALNVGSKDANKPVRIT
NVAPGVKEGDVTNVAQLKGVAQNLNNRIDNVDGNARAGIAQAIATAGLAQAYLPGKSMMA
IGGGTYRGEAGYAIGYSSISDTGNWVIKGTASGNSRGHFGTSASVGYQW* >ZN25_ASS
<SEQ ID 109> MNKIYRIIWNSALNAWVVVSELTRNHTKRASATV-
ATAVLATLLSATVQANATDTDEDEEL
ESVVRSALVLQFMIDKEGNGEIESTGDIGWSIYYDDHNTL- HGATVTLKAGDNLKIKQSGK
DFTYSLKKELKDLTSVETEKLSFGANGNKVNITSDTKGLNFAKETA- GTNGDPTVHLNGIG
STLTDTLAGSSASHVDAGNQSTHYTRAASIKDVLNAGWNIKGVKTGSTTGQS- ENVDFVRT
YDTVEFLSADTKTTTVNVESKDNGKRTEVKIGAKTSVIKEKDGKLVTGKGKGENGSST- DE
GEGLVTAKEVIDAVNKAGWRMKTTTANGQTGQADKFETVTSGTKVTFASGNGTTATVSKD
DQGNITVKYDVNVGDALNVNQLQNSGWNLDSKAVAGSSGKVISGNVSPSKGKMDETVNIN
AGNNIEITRNGKNIDIATSMTPQFSSVSLGAGADAPTLSVDDEGALNVGSKDANKPVRIT
NVAPGVKEGDVTNVAQLKGVAQNLNNRIDNVDGNARAGIAQAIATAGLAQAYLPGKSMMA
IGGGTYRGEAGYAIGYSSISDTGNWVIKGTASGNSRGHFGTSASVGYQW* >ZN28_ASS
<SEQ ID 110> MNKIYRIIWNSALNAWVAVSELTRNHTKRASATV-
KTAVLATLLFATVQANATDEDEEEEL
ESVQRSVVGSIQASMEGSGELETISLSMTNDSKEFVDPYI- VVTLKAGDNLKIKQNTNENT
NASSFTYSLKKDLTGLINVETEKLSFGANGKKVNIISDTKGLNFAK- ETAGTNGDTTVHLN
GIGSTLTDTLAGSSASHVDAGNQSTHYTRAASIKDVLNAGWNIKGVKTGSTT- GQSENVDF
VRTYDTVEFLSADTKTTTVNVESKDNGKRTEVKIGAKTSVIKEKDGKLVTGKGKGENG- SS
TDEGEGLVTAKEVIDAVNKAGWRMKTTTANGQTGQADKFETVTSGTNVTFASGKGTTATV
SKDDQGNITVMYDVNVGDALNVNQLQNSGWNLDSKAVAGSSGKVISGNVSPSKGKMDETV
NINAGNNIEISRNGKNIDIATSMAPQFSSVSLGAGADAPTLSVDDEGALNVGSKDANKPV
RITNVAPGVKEGDVTNVAQLKGVAQNLNNRIDNVDGNARAGIAQAIATAGLVQAYLPGKS
MMAIGGGYTRGEAGYAIGYSSISDGGNWIIKGTASGNSRGHFGASASVGYQW* >ZN29_ASS
<SEQ ID 111> MNKIYRIIWNSALNAWVVVSELTRNHTKRASATV-
ETAVLATLLFATVQANATDTDEDDEL
EPVVRTAPVLSFHSDKEGTGEKEEVGASSNLTVYFDKNRV- LKAGTITLKAGDNLKIKQNT
NENTNENTNASSFTYSLKKDLTGLINVETEKLSFGANGKKVNIISD- TKGLNFAKETAGTN
GDPTVHLNGIGSTLTDTLAGSSASHVDAGNQSTHYTRAASIKDVLNAGWNIK- GVKTGSTT
GQSENVDFVRTYDTVEFLSADTKTTTVNVESKDNGKRTEVKIGAKTSVIKEKDGKLVT- GK
GKGENGSSTDEGEGLVTAKEVIDAVNKAGWRMKTTTANGQTGQADKFETVTSGTKVTFAS
GNGTTATVSKDDQGNITVKYDVNVGDALNVNQLQNSGWNLDSKAVAGSSGKVISGNVSPS
KGKMDETVNINAGNNIEITRNGKNIDIATSMTPQFSSVSLGAGADAPTLSVVEAGALNVG
SKDANKPVRITNVAPGVKEGDVTNVAQLKGVAQNLNNRIDNVDGNARAGIAQAIATAGLV
QAYLPGKSMMAIGGGTYRGEAGYAIGYSSISDGGNWIIKGTASGNSRGHFGASASVGYQW *
[0491] FIG. 8 shows the results of aligning the sequences of each
of these strains. Dark shading indicates regions of homology, and
gray shading indicates the conservation of amino acids with similar
characteristics. As is readily discernible, there is significant
conservation among the various strains of ORF 40, further
confirming its utility as an antigen for both vaccines and
diagnostics.
[0492] It will be appreciated that the invention has been described
by means of example only, and that modifications may be made whilst
remaining within the spirit and scope of the invention.
Appendix 1
[0493]
130 Scarlato, Continuation of U.S. App. Ser. No. 10/695,499, filed
herewith Ruelle, U.S. Pat. No. 6,780,419 18. (New) An isolated
polypeptide comprising 1. An isolated polypeptide comprising a a
member selected from the group consisting of member selected from
the group consisting of (a) the amino acid sequence of SEQ ID (a)
the amino acid sequence of SEQ ID NO: 4; and NO: 2; (b) an
immunogenic fragment of at (b) an immunogenic fragment of at least
least 15 contiguous amino acids of SEQ ID 15 contiguous amino acids
of SEQ ID NO: 2; NO: 4, wherein the immunogenic fragment, wherein
the immunogenic fragment, when when administered to a subject in a
suitable administered to a subject in a suitable composition which
can include an adjuvant, or composition which can include an
adjuvant, or a suitable carrier coupled to the polypeptide, a
suitable carrier coupled to the polypeptide, induces an antibody or
T-cell meditated induces an antibody or T-cell meditated immune
response that recognizes the isolated immune response that
recognizes the isolated polypeptide SEQ ID NO: 4. polypeptide SEQ
ID NO: 2. 19. (New) The isolated polypeptide of claim 2. The
isolated polypeptide of claim 1, 18, wherein the polypeptide is
according to (a). wherein the polypeptide is according to (a). 20.
(New) The isolated polypeptide of claim 3. The isolated polypeptide
of claim 1, 18, wherein the polypeptide is according to (b).
wherein the polypeptide is according to (b). 21. (New) The isolated
polypeptide of claim 4. The isolated polypeptide of claim 1, 18,
wherein the immunogenic fragment of (b) wherein the immunogenic
fragment of (b) comprises at least 20 contiguous amino acids of
comprises at least 20 contiguous amino acids of SEQ ID NO: 4;
wherein the immunogenic SEQ ID NO: 2; wherein the immunogenic
fragment, when administered to a subject in a fragment, when
administered to a subject in a suitable composition which can
include an suitable composition which can include an adjuvant, or a
suitable carrier coupled to the adjuvant, or a suitable carrier
coupled to the polypeptide, induces an antibody or T-cell
polypeptide, induces an antibody or T-cell meditated immune
response that recognizes the meditated immune response that
recognizes the isolated polypeptide SEQ ID NO: 4. isolated
polypeptide SEQ ID NO: 2. 22. (New) The isolated polypeptide of
claim 5. The isolated polypeptide of claim 1, 18, wherein the
isolated polypeptide consists of wherein the isolated polypeptide
consists of SEQ ID NO: 4. SEQ ID NO: 2. 23. (New) A fusion protein
comprising the 6. A fusion protein comprising the isolated isolated
polypeptide of claim 18. polypeptide of claim 1. 24. (New) An
immunogenic composition 7. An immunogenic composition comprising
comprising the polypeptide of claim 18, and a the polypeptide of
claim 1, and a pharmaceutically acceptable carrier.
pharmaceutically acceptable carrier. 25. (New) The isolated
polypeptide of claim 9. The isolated polypeptide of claim 1, 18,
wherein the isolated polypeptide is a wherein the isolated
polypeptide is a recombinant polypeptide. recombinant polypeptide.
26. (New) The isolated polypeptide of claim 10. The isolated
polypeptide of claim 2, 19, wherein the isolated polypeptide is a
wherein the isolated polypeptide is a recombinant polypeptide.
recombinant polypeptide. 27. (New) The isolated polypeptide of
claim 11. The isolated polypeptide of claim 3, 20, wherein the
isolated polypeptide is a wherein the isolated polypeptide is a
recombinant polypeptide. recombinant polypeptide. 28. (New) An
immunogenic composition 12. An immunogenic composition comprising
comprising the isolated polypeptide of claim 19. the isolated
polypeptide of claim 2. 29. (New) An immunogenic composition 13. An
immunogenic composition comprising comprising the isolated
polypeptide of claim 20. the isolated polypeptide of claim 3. 30.
(New) A fusion protein comprising the 14. A fusion protein
comprising the isolated isolated polypeptide of claim 19.
polypeptide of claim 2. 31. (New) A fusion protein comprising the
15. A fusion protein comprising the isolated isolated polypeptide
of claim 20. polypeptide of claim 3.
Appendix 2
[0494]
131 Written Description Support in the Current Application Written
Description (Continuation of Application Support in Application
Added Claim # No. 10/695,499) No. PCT/IB99/00103 Claims 18-31
Throughout the Throughout the application and at least at
application and at least at the following citations: the following
citations: Page 3, lines 2-24; Page 2, line 29 to page 3, Page 31,
line 7 to page 34, line 20; line 17; Page 30, line 6 to page Page
52, lines 10-18; 33, line 11; Page 65, line 3 to page 70, Page 50,
lines 12-20; line 3. Page 61, line 11 to page 66, line 6. Claims
23, 30, Throughout the Throughout the and 31 application and at
least at application and at least at the following citations: the
following citations: Page 3, lines 24-27; Page 3, lines 21-24; Page
9, line 26 to page 10, Page 9, lines 11-18; line 4; Page 20, line 6
to page Page 21, lines 1-22. 21, line 4. Claims 25-27 Throughout
the Throughout the application and at least at application and at
least at the following citations: the following citations: Page 3,
lines 24-27; Page 3, lines 17-20; Page 8, line 15 to page 28, Page
8, line 1 to page 27, line 23. line 25.
Appendix 3
Disclosure of Constructive Reductions to Practice within the Scope
of the Interfering Subject Matter in Application No. GB 9800760.2,
filed Jan. 14, 1998
[0495]
132 Number of Amino Acids Location in ORF40 of Location in SEQ 2 in
Fragment Application No. GB 9800760.2 of `419 Patent 25 Residues
85-109 Residues 127-151 16 Residues 111-126 Residues 153-168 98
Residues 131-228 Residues 173-270 16 Residues 230-245 Residues
272-287
[0496]
Sequence CWU 1
1
195 1 736 DNA Neisseria meningitidis 1 acactgttgt ttgcaacggt
tcaggcaagt gctaaccaat gaagagcaag aagaagattt 60 atatttagac
cccgtacaac gcactgttgc cgtgttgata gtcaattccg ataaagaagg 120
cacgggagaa aaagaaaaag tagaagaaaa ttcagattgg gcagtatatt tcaacgagaa
180 aggagtacta acagccagag aaatcaccyt caaagccggc gacaacctga
aaatcaaaca 240 aaacggcaca aacttcacct actcgctgaa aaaagacctc
acagatctga ccagtgttgg 300 aactgaaaaa ttatcgttta gcgcaaacgg
caataaagtc aacatcacaa gcgacaccaa 360 aggcttgaat tttgcgaaag
aaacggctgg sacgaacggc gacaccacgg ttcatctgaa 420 cggtattggt
tcgactttga ccgatacgct gctgaatacc ggagcgacca caaacgtaac 480
caacgacaac gttaccgatg acgagaaaaa acgtgcggca agcgttaaag acgtattaaa
540 cgctggctgg aacattaaag gcgttaaacc cggtacaaca gcttccgata
acgttgattt 600 cgtccgcact tacgacacag tcgagttctt gagcgcagat
acgaaaacaa cgactgttaa 660 tgtggaaagc aaagacaacg gcaagaaaac
cgaagttaaa atcggtgcga agacttctgt 720 tattaaagaa aaagac 736 2 245
PRT Neisseria meningitidis SITE (70) unknown 2 Thr Leu Leu Phe Ala
Thr Val Gln Ala Ser Ala Asn Gln Glu Glu Gln 1 5 10 15 Glu Glu Asp
Leu Tyr Leu Asp Pro Val Gln Arg Thr Val Ala Val Leu 20 25 30 Ile
Val Asn Ser Asp Lys Glu Gly Thr Gly Glu Lys Glu Lys Val Glu 35 40
45 Glu Asn Ser Asp Trp Ala Val Tyr Phe Asn Glu Lys Gly Val Leu Thr
50 55 60 Ala Arg Glu Ile Thr Xaa Lys Ala Gly Asp Asn Leu Lys Ile
Lys Gln 65 70 75 80 Asn Gly Thr Asn Phe Thr Tyr Ser Leu Lys Lys Asp
Leu Thr Asp Leu 85 90 95 Thr Ser Val Gly Thr Glu Lys Leu Ser Phe
Ser Ala Asn Gly Asn Lys 100 105 110 Val Asn Ile Thr Ser Asp Thr Lys
Gly Leu Asn Phe Ala Lys Glu Thr 115 120 125 Ala Gly Thr Asn Gly Asp
Thr Thr Val His Leu Asn Gly Ile Gly Ser 130 135 140 Thr Leu Thr Asp
Thr Leu Leu Asn Thr Gly Ala Thr Thr Asn Val Thr 145 150 155 160 Asn
Asp Asn Val Thr Asp Asp Glu Lys Lys Arg Ala Ala Ser Val Lys 165 170
175 Asp Val Leu Asn Ala Gly Trp Asn Ile Lys Gly Val Lys Pro Gly Thr
180 185 190 Thr Ala Ser Asp Asn Val Asp Phe Val Arg Thr Tyr Asp Thr
Val Glu 195 200 205 Phe Leu Ser Ala Asp Thr Lys Thr Thr Thr Val Asn
Val Glu Ser Lys 210 215 220 Asp Asn Gly Lys Lys Thr Glu Val Lys Ile
Gly Ala Lys Thr Ser Val 225 230 235 240 Ile Lys Glu Lys Asp 245 3
1776 DNA Neisseria meningitidis 3 atgaacaaaa tataccgcat catttggaat
agtgccctca atgcctgggt cgtcgtatcc 60 gagctcacac gcaaccacac
caaacgcgcc tccgcaaccg tgaagaccgc cgtattggcg 120 acactgttgt
ttgcaacggt tcaggcaagt gctaacaatg aagagcaaga agaagattta 180
tatttagacc ccgtacaacg cactgttgcc gtgttgatag tcaattccga taaagaaggc
240 acgggagaaa aagaaaaagt agaagaaaat tcagattggg cagtatattt
caacgagaaa 300 ggagtactaa cagccagaga aatcaccctc aaagccggcg
acaacctgaa aatcaaacaa 360 aacggcacaa acttcaccta ctcgctgaaa
aaagacctca cagatctgac cagtgttgga 420 actgaaaaat tatcgtttag
cgcaaacggc aataaagtca acatcacaag cgacaccaaa 480 ggcttgaatt
ttgcgaaaga aacggctggg acgaacggcg acaccacggt tcatctgaac 540
ggtattggtt cgactttgac cgatacgctg ctgaataccg gagcgaccac aaacgtaacc
600 aacgacaacg ttaccgatga cgagaaaaaa cgtgcggcaa gcgttaaaga
cgtattaaac 660 gctggctgga acattaaagg cgttaaaccc ggtacaacag
cttccgataa cgttgatttc 720 gtccgcactt acgacacagt cgagttcttg
agcgcagata cgaaaacaac gactgttaat 780 gtggaaagca aagacaacgg
caagaaaacc gaagttaaaa tcggtgcgaa gacttctgtt 840 attaaagaaa
aagacggtaa gttggttact ggtaaagaca aaggcgagaa tggttcttct 900
acagacgaag gcgaaggctt agtgactgca aaagaagtga ttgatgcagt aaacaaggct
960 ggttggagaa tgaaaacaac aaccgctaat ggtcaaacag gtcaagctga
caagtttgaa 1020 accgttacat caggcacaaa tgtaaccttt gctagtggta
aaggtacaac tgcgactgta 1080 agtaaagatg atcaaggcaa catcactgtt
atgtatgatg taaatgtcgg cgatgcccta 1140 aacgtcaatc agctgcaaaa
cagcggttgg aatttggatt ccaaagcggt tgcaggttct 1200 tcgggcaaag
tcatcagcgg caatgtttcg ccgagcaagg gaaagatgga tgaaaccgtc 1260
aacattaatg ccggcaacaa catcgagatt acccgcaacg gtaaaaatat cgacatcgcc
1320 acttcgatga ccccgcagtt ttccagcgtt tcgctcggcg cgggggcgga
tgcgcccact 1380 ttgagcgtgg atggggacgc attgaatgtc ggcagcaaga
aggacaacaa acccgtccgc 1440 attaccaatg tcgccccggg cgttaaagag
ggggatgtta caaacgtcgc acaacttaaa 1500 ggcgtggcgc aaaacttgaa
caaccgcatc gacaatgtgg acggcaacgc gcgtgcgggc 1560 atcgcccaag
cgattgcaac cgcaggtctg gttcaggcgt atttgcccgg caagagtatg 1620
atggcgatcg gcggcggcac ttatcgcggc gaagccggtt acgccatcgg ctactccagt
1680 atttccgacg gcggaaattg gattatcaaa ggcacggctt ccggcaattc
gcgcggccat 1740 ttcggtgctt ccgcatctgt cggttatcag tggtaa 1776 4 591
PRT Neisseria meningitidis 4 Met Asn Lys Ile Tyr Arg Ile Ile Trp
Asn Ser Ala Leu Asn Ala Trp 1 5 10 15 Val Val Val Ser Glu Leu Thr
Arg Asn His Thr Lys Arg Ala Ser Ala 20 25 30 Thr Val Lys Thr Ala
Val Leu Ala Thr Leu Leu Phe Ala Thr Val Gln 35 40 45 Ala Ser Ala
Asn Asn Glu Glu Gln Glu Glu Asp Leu Tyr Leu Asp Pro 50 55 60 Val
Gln Arg Thr Val Ala Val Leu Ile Val Asn Ser Asp Lys Glu Gly 65 70
75 80 Thr Gly Glu Lys Glu Lys Val Glu Glu Asn Ser Asp Trp Ala Val
Tyr 85 90 95 Phe Asn Glu Lys Gly Val Leu Thr Ala Arg Glu Ile Thr
Leu Lys Ala 100 105 110 Gly Asp Asn Leu Lys Ile Lys Gln Asn Gly Thr
Asn Phe Thr Tyr Ser 115 120 125 Leu Lys Lys Asp Leu Thr Asp Leu Thr
Ser Val Gly Thr Glu Lys Leu 130 135 140 Ser Phe Ser Ala Asn Gly Asn
Lys Val Asn Ile Thr Ser Asp Thr Lys 145 150 155 160 Gly Leu Asn Phe
Ala Lys Glu Thr Ala Gly Thr Asn Gly Asp Thr Thr 165 170 175 Val His
Leu Asn Gly Ile Gly Ser Thr Leu Thr Asp Thr Leu Leu Asn 180 185 190
Thr Gly Ala Thr Thr Asn Val Thr Asn Asp Asn Val Thr Asp Asp Glu 195
200 205 Lys Lys Arg Ala Ala Ser Val Lys Asp Val Leu Asn Ala Gly Trp
Asn 210 215 220 Ile Lys Gly Val Lys Pro Gly Thr Thr Ala Ser Asp Asn
Val Asp Phe 225 230 235 240 Val Arg Thr Tyr Asp Thr Val Glu Phe Leu
Ser Ala Asp Thr Lys Thr 245 250 255 Thr Thr Val Asn Val Glu Ser Lys
Asp Asn Gly Lys Lys Thr Glu Val 260 265 270 Lys Ile Gly Ala Lys Thr
Ser Val Ile Lys Glu Lys Asp Gly Lys Leu 275 280 285 Val Thr Gly Lys
Asp Lys Gly Glu Asn Gly Ser Ser Thr Asp Glu Gly 290 295 300 Glu Gly
Leu Val Thr Ala Lys Glu Val Ile Asp Ala Val Asn Lys Ala 305 310 315
320 Gly Trp Arg Met Lys Thr Thr Thr Ala Asn Gly Gln Thr Gly Gln Ala
325 330 335 Asp Lys Phe Glu Thr Val Thr Ser Gly Thr Asn Val Thr Phe
Ala Ser 340 345 350 Gly Lys Gly Thr Thr Ala Thr Val Ser Lys Asp Asp
Gln Gly Asn Ile 355 360 365 Thr Val Met Tyr Asp Val Asn Val Gly Asp
Ala Leu Asn Val Asn Gln 370 375 380 Leu Gln Asn Ser Gly Trp Asn Leu
Asp Ser Lys Ala Val Ala Gly Ser 385 390 395 400 Ser Gly Lys Val Ile
Ser Gly Asn Val Ser Pro Ser Lys Gly Lys Met 405 410 415 Asp Glu Thr
Val Asn Ile Asn Ala Gly Asn Asn Ile Glu Ile Thr Arg 420 425 430 Asn
Gly Lys Asn Ile Asp Ile Ala Thr Ser Met Thr Pro Gln Phe Ser 435 440
445 Ser Val Ser Leu Gly Ala Gly Ala Asp Ala Pro Thr Leu Ser Val Asp
450 455 460 Gly Asp Ala Leu Asn Val Gly Ser Lys Lys Asp Asn Lys Pro
Val Arg 465 470 475 480 Ile Thr Asn Val Ala Pro Gly Val Lys Glu Gly
Asp Val Thr Asn Val 485 490 495 Ala Gln Leu Lys Gly Val Ala Gln Asn
Leu Asn Asn Arg Ile Asp Asn 500 505 510 Val Asp Gly Asn Ala Arg Ala
Gly Ile Ala Gln Ala Ile Ala Thr Ala 515 520 525 Gly Leu Val Gln Ala
Tyr Leu Pro Gly Lys Ser Met Met Ala Ile Gly 530 535 540 Gly Gly Thr
Tyr Arg Gly Glu Ala Gly Tyr Ala Ile Gly Tyr Ser Ser 545 550 555 560
Ile Ser Asp Gly Gly Asn Trp Ile Ile Lys Gly Thr Ala Ser Gly Asn 565
570 575 Ser Arg Gly His Phe Gly Ala Ser Ala Ser Val Gly Tyr Gln Trp
580 585 590 5 1779 DNA Neisseria meningitidis misc_feature (48) any
nucleotide 5 atgaacaaaa tataccgcat catttggaat agtgccctca atgcctgngt
cgccgtatcc 60 gagctcacac gcaaccacac caaacgcgcc tccgcaaccg
tgaagaccgc cgtattggcg 120 acactgttgt ttgcaacggt tcaggcgaat
gctaccgatg aagatgaaga agaagagtta 180 gaatccgtac aacgctctgt
cgtagggagc attcaagcca gtatggaagg cagcggcgaa 240 ttggaaacga
tatcattatc aatgactaac gacagcaagg aatttgtaga cccatacata 300
gtagttaccc tcaaagccgg cgacaacctg aaaatcaaac aaaacaccaa tgaaaacacc
360 aatgccagta gcttcaccta ctcgctgaaa aaagacctca caggcctgat
caatgttgan 420 actgaaaaat tatcgtttgg cgcaaacggc aagaaagtca
acatcataag cgacaccaaa 480 ggcttgaatt tcgcgaaaga aacggctggg
acgaacggcg acaccacggt tcatctgaac 540 ggtatcggtt cgactttgac
cgatacgctt gcgggttctt ctgcttctca cgttgatgcg 600 ggtaaccnaa
gtacacatta cactcgtgca gcaagtatta aggatgtgtt gaatgcgggt 660
tggaatatta agggtgttaa annnggctca acaactggtc aatcagaaaa tgtcgatttc
720 gtccgcactt acgacacagt cgagttcttg agcgcagata cgnaaacaac
gacngttaat 780 gtggaaagca aagacaacgg caagagaacc gaagttaaaa
tcggtgcgaa gacttctgtt 840 attaaagaaa aagacggtaa gttggttact
ggtaaaggca aaggcgagaa tggttcttct 900 acagacgaag gcgaaggctt
agtgactgca aaagaagtga ttgatgcagt aaacaaggct 960 ggttggagaa
tgaaaacaac aaccgctaat ggtcaaacag gtcaagctga caagtttgaa 1020
accgttacat caggcacaaa tgtaaccttt gctagtggta aaggtacaac tgcgactgta
1080 agtaaagatg atcaaggcaa catcactgtt atgtatgatg taaatgtcgg
cgatgcccta 1140 aacgtcaatc agctgcaaaa cagcggttgg aatttggatt
ccaaagcggt tgcaggttct 1200 tcgggcaaag tcatcagcgg caatgtttcg
ccgagcaagg gaaagatgga tgaaaccgtc 1260 aacattaatg ccggcaacaa
catcgagatt agccgcaacg gtaaaaatat cgacatcgcc 1320 acttcgatgg
cgccgcagtt ttccagcgtt tcgctcggcg cgggggcaga tgcgcccact 1380
ttaagcgtgg atgacgaggg cgcgttgaat gtcggcagca aggatgccaa caaacccgtc
1440 cgcattacca atgtcgcccc gggcgttaaa ganggggatg ttacaaacgt
cncacaactt 1500 aaaggcgtgg cgcaaaactt gaacaaccgc atcgacaatg
tggacggcaa cgcgcgtgcn 1560 ggcatcgccc aagcgattgc aaccgcaggt
ctggttcagg cgtatctgcc cggcaagagt 1620 atgatggcga tcggcggcgg
cacttatcgc ggcgaagccg gttacgccat cggctactcc 1680 agtatttccg
acggcggaaa ttggattatc aaaggcacgg cttccggcaa ttcgcgcggc 1740
catttcggtg cttccgcatc tgtcggttat cagtggtaa 1779 6 592 PRT Neisseria
meningitidis SITE (16) unknown 6 Met Asn Lys Ile Tyr Arg Ile Ile
Trp Asn Ser Ala Leu Asn Ala Xaa 1 5 10 15 Val Ala Val Ser Glu Leu
Thr Arg Asn His Thr Lys Arg Ala Ser Ala 20 25 30 Thr Val Lys Thr
Ala Val Leu Ala Thr Leu Leu Phe Ala Thr Val Gln 35 40 45 Ala Asn
Ala Thr Asp Glu Asp Glu Glu Glu Glu Leu Glu Ser Val Gln 50 55 60
Arg Ser Val Val Gly Ser Ile Gln Ala Ser Met Glu Gly Ser Gly Glu 65
70 75 80 Leu Glu Thr Ile Ser Leu Ser Met Thr Asn Asp Ser Lys Glu
Phe Val 85 90 95 Asp Pro Tyr Ile Val Val Thr Leu Lys Ala Gly Asp
Asn Leu Lys Ile 100 105 110 Lys Gln Asn Thr Asn Glu Asn Thr Asn Ala
Ser Ser Phe Thr Tyr Ser 115 120 125 Leu Lys Lys Asp Leu Thr Gly Leu
Ile Asn Val Xaa Thr Glu Lys Leu 130 135 140 Ser Phe Gly Ala Asn Gly
Lys Lys Val Asn Ile Ile Ser Asp Thr Lys 145 150 155 160 Gly Leu Asn
Phe Ala Lys Glu Thr Ala Gly Thr Asn Gly Asp Thr Thr 165 170 175 Val
His Leu Asn Gly Ile Gly Ser Thr Leu Thr Asp Thr Leu Ala Gly 180 185
190 Ser Ser Ala Ser His Val Asp Ala Gly Asn Xaa Ser Thr His Tyr Thr
195 200 205 Arg Ala Ala Ser Ile Lys Asp Val Leu Asn Ala Gly Trp Asn
Ile Lys 210 215 220 Gly Val Lys Xaa Gly Ser Thr Thr Gly Gln Ser Glu
Asn Val Asp Phe 225 230 235 240 Val Arg Thr Tyr Asp Thr Val Glu Phe
Leu Ser Ala Asp Thr Xaa Thr 245 250 255 Thr Thr Val Asn Val Glu Ser
Lys Asp Asn Gly Lys Arg Thr Glu Val 260 265 270 Lys Ile Gly Ala Lys
Thr Ser Val Ile Lys Glu Lys Asp Gly Lys Leu 275 280 285 Val Thr Gly
Lys Gly Lys Gly Glu Asn Gly Ser Ser Thr Asp Glu Gly 290 295 300 Glu
Gly Leu Val Thr Ala Lys Glu Val Ile Asp Ala Val Asn Lys Ala 305 310
315 320 Gly Trp Arg Met Lys Thr Thr Thr Ala Asn Gly Gln Thr Gly Gln
Ala 325 330 335 Asp Lys Phe Glu Thr Val Thr Ser Gly Thr Asn Val Thr
Phe Ala Ser 340 345 350 Gly Lys Gly Thr Thr Ala Thr Val Ser Lys Asp
Asp Gln Gly Asn Ile 355 360 365 Thr Val Met Tyr Asp Val Asn Val Gly
Asp Ala Leu Asn Val Asn Gln 370 375 380 Leu Gln Asn Ser Gly Trp Asn
Leu Asp Ser Lys Ala Val Ala Gly Ser 385 390 395 400 Ser Gly Lys Val
Ile Ser Gly Asn Val Ser Pro Ser Lys Gly Lys Met 405 410 415 Asp Glu
Thr Val Asn Ile Asn Ala Gly Asn Asn Ile Glu Ile Ser Arg 420 425 430
Asn Gly Lys Asn Ile Asp Ile Ala Thr Ser Met Ala Pro Gln Phe Ser 435
440 445 Ser Val Ser Leu Gly Ala Gly Ala Asp Ala Pro Thr Leu Ser Val
Asp 450 455 460 Asp Glu Gly Ala Leu Asn Val Gly Ser Lys Asp Ala Asn
Lys Pro Val 465 470 475 480 Arg Ile Thr Asn Val Ala Pro Gly Val Lys
Xaa Gly Asp Val Thr Asn 485 490 495 Val Xaa Gln Leu Lys Gly Val Ala
Gln Asn Leu Asn Asn Arg Ile Asp 500 505 510 Asn Val Asp Gly Asn Ala
Arg Ala Gly Ile Ala Gln Ala Ile Ala Thr 515 520 525 Ala Gly Leu Val
Gln Ala Tyr Leu Pro Gly Lys Ser Met Met Ala Ile 530 535 540 Gly Gly
Gly Thr Tyr Arg Gly Glu Ala Gly Tyr Ala Ile Gly Tyr Ser 545 550 555
560 Ser Ile Ser Asp Gly Gly Asn Trp Ile Ile Lys Gly Thr Ala Ser Gly
565 570 575 Asn Ser Arg Gly His Phe Gly Ala Ser Ala Ser Val Gly Tyr
Gln Trp 580 585 590 7 492 DNA Neisseria meningitidis 7 atgttacgtt
tgactgcttt agccgtatgc accgccctcg ctttgggcgc gtgttcgccg 60
caaaattccg actctgcccc acaagccaaa gaacaggcgg tttccgccgc acaaaccgaa
120 ggcgcgtccg ttaccgtcaa aaccgcgcgc ggcgacgttc aaataccgca
aaaccccgaa 180 cgcatcgccg tttacgattt gggtatgctc gacaccttga
gcaaactggg cgtgaaaacc 240 ggtttgtccg tcgataaaaa ccgcctgccg
tatttagagg aatatttcaa aacgacaaaa 300 cctgccggca ctttgttcga
gccggattac gaaacgctca acgcttacaa accgcagctc 360 atcatcatcg
gcagccgcgc cgccaaggcg tttgacaaat tgaacgaaat cgcgccgacc 420
atcgrmwtga ccgccgatac cgccaacctc aaagaaagtg ccaargaggc atcgacgctg
480 gcgcaaatct tc 492 8 164 PRT Neisseria meningitidis SITE
(142)..(143) unknown 8 Met Leu Arg Leu Thr Ala Leu Ala Val Cys Thr
Ala Leu Ala Leu Gly 1 5 10 15 Ala Cys Ser Pro Gln Asn Ser Asp Ser
Ala Pro Gln Ala Lys Glu Gln 20 25 30 Ala Val Ser Ala Ala Gln Thr
Glu Gly Ala Ser Val Thr Val Lys Thr 35 40 45 Ala Arg Gly Asp Val
Gln Ile Pro Gln Asn Pro Glu Arg Ile Ala Val 50 55 60 Tyr Asp Leu
Gly Met Leu Asp Thr Leu Ser Lys Leu Gly Val Lys Thr 65 70 75 80 Gly
Leu Ser Val Asp Lys Asn Arg Leu Pro Tyr Leu Glu Glu Tyr Phe 85 90
95 Lys Thr Thr Lys Pro Ala Gly Thr Leu Phe Glu Pro Asp Tyr Glu Thr
100 105 110 Leu Asn Ala Tyr Lys Pro Gln Leu Ile Ile Ile Gly Ser Arg
Ala Ala 115 120 125 Lys Ala Phe Asp Lys Leu Asn Glu Ile Ala Pro Thr
Ile Xaa Xaa Thr 130 135 140 Ala Asp Thr Ala Asn Leu Lys Glu Ser Ala
Lys Glu Ala Ser Thr Leu 145 150 155 160 Ala Gln Ile Phe 9 966 DNA
Neisseria
meningitidis 9 atgttacgtt tgactgcttt agccgtatgc accgccctcg
ctttgggcgc gtgttcgccg 60 caaaattccg actctgcccc acaagccaaa
gaacaggcgg tttccgccgc acaaaccgaa 120 ggcgcgtccg ttaccgtcaa
aaccgcgcgc ggcgacgttc aaataccgca aaaccccgaa 180 cgcatcgccg
tttacgattt gggtatgctc gacaccttga gcaaactggg cgtgaaaacc 240
ggtttgtccg tcgataaaaa ccgcctgccg tatttagagg aatatttcaa aacgacaaaa
300 cctgccggca ctttgttcga gccggattac gaaacgctca acgcttacaa
accgcagctc 360 atcatcatcg gcagccgcgc cgccaaggcg tttgacaaat
tgaacgaaat cgcgccgacc 420 atcgaaatga ccgccgatac cgccaacctc
aaagaaagtg ccaaagagcg catcgacgcg 480 ctggcgcaaa tcttcggcaa
acaggcggaa gccgacaagc tgaaggcgga aatcgacgcg 540 tcttttgaag
ccgcgaaaac tgccgcacaa ggtaagggca aaggtttggt gattttggtc 600
aacggcggca agatgtcggc tttcggcccg tcttcacgct tgggcggctg gctgcacaaa
660 gacatcggcg ttcccgctgt cgatgaatca attaaagaag gcagccacgg
tcagcctatc 720 agctttgaat acctgaaaga gaaaaatccc gactggctgt
ttgtccttga ccgaagcgcg 780 gccatcggcg aagagggtca ggcggcgaaa
gacgtgttgg ataatccgct ggttgccgaa 840 acaaccgctt ggaaaaaagg
acaggtcgtg tacctcgttc ctgaaactta tttggcagcc 900 ggtggcgcgc
aagagctgct gaatgcaagc aaacaggttg ccgacgcttt taacgcggca 960 aaataa
966 10 321 PRT Neisseria meningitidis 10 Met Leu Arg Leu Thr Ala
Leu Ala Val Cys Thr Ala Leu Ala Leu Gly 1 5 10 15 Ala Cys Ser Pro
Gln Asn Ser Asp Ser Ala Pro Gln Ala Lys Glu Gln 20 25 30 Ala Val
Ser Ala Ala Gln Thr Glu Gly Ala Ser Val Thr Val Lys Thr 35 40 45
Ala Arg Gly Asp Val Gln Ile Pro Gln Asn Pro Glu Arg Ile Ala Val 50
55 60 Tyr Asp Leu Gly Met Leu Asp Thr Leu Ser Lys Leu Gly Val Lys
Thr 65 70 75 80 Gly Leu Ser Val Asp Lys Asn Arg Leu Pro Tyr Leu Glu
Glu Tyr Phe 85 90 95 Lys Thr Thr Lys Pro Ala Gly Thr Leu Phe Glu
Pro Asp Tyr Glu Thr 100 105 110 Leu Asn Ala Tyr Lys Pro Gln Leu Ile
Ile Ile Gly Ser Arg Ala Ala 115 120 125 Lys Ala Phe Asp Lys Leu Asn
Glu Ile Ala Pro Thr Ile Glu Met Thr 130 135 140 Ala Asp Thr Ala Asn
Leu Lys Glu Ser Ala Lys Glu Arg Ile Asp Ala 145 150 155 160 Leu Ala
Gln Ile Phe Gly Lys Gln Ala Glu Ala Asp Lys Leu Lys Ala 165 170 175
Glu Ile Asp Ala Ser Phe Glu Ala Ala Lys Thr Ala Ala Gln Gly Lys 180
185 190 Gly Lys Gly Leu Val Ile Leu Val Asn Gly Gly Lys Met Ser Ala
Phe 195 200 205 Gly Pro Ser Ser Arg Leu Gly Gly Trp Leu His Lys Asp
Ile Gly Val 210 215 220 Pro Ala Val Asp Glu Ser Ile Lys Glu Gly Ser
His Gly Gln Pro Ile 225 230 235 240 Ser Phe Glu Tyr Leu Lys Glu Lys
Asn Pro Asp Trp Leu Phe Val Leu 245 250 255 Asp Arg Ser Ala Ala Ile
Gly Glu Glu Gly Gln Ala Ala Lys Asp Val 260 265 270 Leu Asp Asn Pro
Leu Val Ala Glu Thr Thr Ala Trp Lys Lys Gly Gln 275 280 285 Val Val
Tyr Leu Val Pro Glu Thr Tyr Leu Ala Ala Gly Gly Ala Gln 290 295 300
Glu Leu Leu Asn Ala Ser Lys Gln Val Ala Asp Ala Phe Asn Ala Ala 305
310 315 320 Lys 11 966 DNA Neisseria meningitidis 11 atgttacgtt
tgactgcttt agccgtatgc accgccctcg ctttgggcgc gtgttcgccg 60
caaaattccg actctgcccc acaagccaaa gaacaggcgg tttccgccgc acaatccgaa
120 ggcgtgtccg ttaccgtcaa aacggcgcgc ggcgatgttc aaataccgca
aaaccccgaa 180 cgtatcgccg tttacgattt gggtatgctc gacaccttga
gcaaactggg cgtgaaaacc 240 ggtttgtccg tcgataaaaa ccgcctgccg
tatttagagg aatatttcaa aacgacaaaa 300 cctgccggaa ctttgttcga
gccggattac gaaacgctca acgcttacaa accgcagctc 360 atcatcatcg
gcagccgcgc agccaaagcg tttgacaaat tgaacgaaat cgcgccgacc 420
atcgaaatga ccgccgatac cgccaacctc aaagaaagtg ccaaagagcg tatcgacgcg
480 ctggcgcaaa tcttcggcaa aaaggcggaa gccgacaagc tgaaggcgga
aatcgacgcg 540 tcttttgaag ccgcgaaaac tgccgcgcaa ggcaaaggca
agggtttggt gattttggtc 600 aacggcggca agatgtccgc cttcggcccg
tcttcacgac tgggcggctg gctgcacaaa 660 gacatcggcg ttcccgctgt
tgacgaagcc atcaaagaag gcagccacgg tcagcctatc 720 agctttgaat
acctgaaaga gaaaaatccc gactggctgt ttgtccttga ccgcagcgcg 780
gccatcggcg aagagggtca ggcggcgaaa gacgtgttga acaatccgct ggttgccgaa
840 acaaccgctt ggaaaaaagg acaagtcgtt taccttgttc ctgaaactta
tttggcagcc 900 ggtggcgcgc aagagctact gaatgcaagc aaacaggttg
ccgacgcttt taacgcggca 960 aaataa 966 12 321 PRT Neisseria
meningitidis 12 Met Leu Arg Leu Thr Ala Leu Ala Val Cys Thr Ala Leu
Ala Leu Gly 1 5 10 15 Ala Cys Ser Pro Gln Asn Ser Asp Ser Ala Pro
Gln Ala Lys Glu Gln 20 25 30 Ala Val Ser Ala Ala Gln Ser Glu Gly
Val Ser Val Thr Val Lys Thr 35 40 45 Ala Arg Gly Asp Val Gln Ile
Pro Gln Asn Pro Glu Arg Ile Ala Val 50 55 60 Tyr Asp Leu Gly Met
Leu Asp Thr Leu Ser Lys Leu Gly Val Lys Thr 65 70 75 80 Gly Leu Ser
Val Asp Lys Asn Arg Leu Pro Tyr Leu Glu Glu Tyr Phe 85 90 95 Lys
Thr Thr Lys Pro Ala Gly Thr Leu Phe Glu Pro Asp Tyr Glu Thr 100 105
110 Leu Asn Ala Tyr Lys Pro Gln Leu Ile Ile Ile Gly Ser Arg Ala Ala
115 120 125 Lys Ala Phe Asp Lys Leu Asn Glu Ile Ala Pro Thr Ile Glu
Met Thr 130 135 140 Ala Asp Thr Ala Asn Leu Lys Glu Ser Ala Lys Glu
Arg Ile Asp Ala 145 150 155 160 Leu Ala Gln Ile Phe Gly Lys Lys Ala
Glu Ala Asp Lys Leu Lys Ala 165 170 175 Glu Ile Asp Ala Ser Phe Glu
Ala Ala Lys Thr Ala Ala Gln Gly Lys 180 185 190 Gly Lys Gly Leu Val
Ile Leu Val Asn Gly Gly Lys Met Ser Ala Phe 195 200 205 Gly Pro Ser
Ser Arg Leu Gly Gly Trp Leu His Lys Asp Ile Gly Val 210 215 220 Pro
Ala Val Asp Glu Ala Ile Lys Glu Gly Ser His Gly Gln Pro Ile 225 230
235 240 Ser Phe Glu Tyr Leu Lys Glu Lys Asn Pro Asp Trp Leu Phe Val
Leu 245 250 255 Asp Arg Ser Ala Ala Ile Gly Glu Glu Gly Gln Ala Ala
Lys Asp Val 260 265 270 Leu Asn Asn Pro Leu Val Ala Glu Thr Thr Ala
Trp Lys Lys Gly Gln 275 280 285 Val Val Tyr Leu Val Pro Glu Thr Tyr
Leu Ala Ala Gly Gly Ala Gln 290 295 300 Glu Leu Leu Asn Ala Ser Lys
Gln Val Ala Asp Ala Phe Asn Ala Ala 305 310 315 320 Lys 13 375 DNA
Neisseria meningitidis 13 atgaaacttc tgaccaccgc aatcctgtct
tccgcaatcg cgctcagcag tatggctgcc 60 gccgctggca cggacaaccc
cactgttgca aaaaaaaccg tcagctacgt ctgccagcaa 120 ggtaaaaaag
tcaaagtaac ctacggcttc aacaaacagg gtctgaccac atacgcttcc 180
gccgtcatca acggcaaacg cgtgcaaatg cctgtcaatt tggacaaatc cgacaatgtg
240 gaaacattct acggcaaaga aggcggttat gttttgggta ccggcgtgat
ggatggcaaa 300 tcctaccgca aacagcccat tatgattacc gcacctgaca
accaaatcgt cttcaaagac 360 tgttccccac gttaa 375 14 124 PRT Neisseria
meningitidis 14 Met Lys Leu Leu Thr Thr Ala Ile Leu Ser Ser Ala Ile
Ala Leu Ser 1 5 10 15 Ser Met Ala Ala Ala Ala Gly Thr Asp Asn Pro
Thr Val Ala Lys Lys 20 25 30 Thr Val Ser Tyr Val Cys Gln Gln Gly
Lys Lys Val Lys Val Thr Tyr 35 40 45 Gly Phe Asn Lys Gln Gly Leu
Thr Thr Tyr Ala Ser Ala Val Ile Asn 50 55 60 Gly Lys Arg Val Gln
Met Pro Val Asn Leu Asp Lys Ser Asp Asn Val 65 70 75 80 Glu Thr Phe
Tyr Gly Lys Glu Gly Gly Tyr Val Leu Gly Thr Gly Val 85 90 95 Met
Asp Gly Lys Ser Tyr Arg Lys Gln Pro Ile Met Ile Thr Ala Pro 100 105
110 Asp Asn Gln Ile Val Phe Lys Asp Cys Ser Pro Arg 115 120 15 375
DNA Neisseria meningitidis 15 atgaaacttc tgaccaccgc aatcctgtct
tccgcaatcg cgctcagcag tatggctgct 60 gctgccggca cgaacaaccc
caccgttgcc aaaaaaaccg tcagctacgt ctgccagcaa 120 ggtaaaaaag
tcaaagtaac ctacggcttt aacaaacagg gcctgaccac atacgcttcc 180
gccgtcatca acggcaaacg tgtgcaaatg cctgtcaatt tggacaaatc cgacaatgtg
240 gaaacattct acggcaaaga aggcggttat gttttgggta ccggcgtgat
ggatggcaaa 300 tcctatcgca aacagcctat tatgattacc gcacctgaca
accaaatcgt cttcaaagac 360 tgttccccac gttaa 375 16 124 PRT Neisseria
meningitidis 16 Met Lys Leu Leu Thr Thr Ala Ile Leu Ser Ser Ala Ile
Ala Leu Ser 1 5 10 15 Ser Met Ala Ala Ala Ala Gly Thr Asn Asn Pro
Thr Val Ala Lys Lys 20 25 30 Thr Val Ser Tyr Val Cys Gln Gln Gly
Lys Lys Val Lys Val Thr Tyr 35 40 45 Gly Phe Asn Lys Gln Gly Leu
Thr Thr Tyr Ala Ser Ala Val Ile Asn 50 55 60 Gly Lys Arg Val Gln
Met Pro Val Asn Leu Asp Lys Ser Asp Asn Val 65 70 75 80 Glu Thr Phe
Tyr Gly Lys Glu Gly Gly Tyr Val Leu Gly Thr Gly Val 85 90 95 Met
Asp Gly Lys Ser Tyr Arg Lys Gln Pro Ile Met Ile Thr Ala Pro 100 105
110 Asp Asn Gln Ile Val Phe Lys Asp Cys Ser Pro Arg 115 120 17 519
DNA Neisseria meningitidis misc_feature (425) any nucleotide 17
ggcaccgaat tcaaaaccac cctttccgga gccgacatac aggcaggggt gggtgaaaaa
60 gcccgagccg atgcgaaaat tatcctaaaa ggcatcgtta accgcatcca
aaccgaagaa 120 aagctggaat ccaactcgac cgtatggcaa aagcaggccg
gaagcggcag cacggttgaa 180 acgctgaagc taccgagctt tgaagggccg
gcactgccta agctgaccgc tcccggcggc 240 tatatcgccg acatccccaa
aggcaacctc aaaaccgaaa tcgaaaagct ggccaaacag 300 cccgaatatg
cctatctgaa acagcttcag acggtcaagg acgtgaactg gaaccaagta 360
cagctcgctt acgacaaatg ggactataaa caggaaggcc taaccggagc cggagccgca
420 attancgcac tggccgttac cgtggtcacc tcaggcgcag gaaccggagc
cgtattggga 480 ttaanacgng tggccgccgc cgcaaccgat gcagcattt 519 18
173 PRT Neisseria meningitidis SITE (142) unknown 18 Gly Thr Glu
Phe Lys Thr Thr Leu Ser Gly Ala Asp Ile Gln Ala Gly 1 5 10 15 Val
Gly Glu Lys Ala Arg Ala Asp Ala Lys Ile Ile Leu Lys Gly Ile 20 25
30 Val Asn Arg Ile Gln Thr Glu Glu Lys Leu Glu Ser Asn Ser Thr Val
35 40 45 Trp Gln Lys Gln Ala Gly Ser Gly Ser Thr Val Glu Thr Leu
Lys Leu 50 55 60 Pro Ser Phe Glu Gly Pro Ala Leu Pro Lys Leu Thr
Ala Pro Gly Gly 65 70 75 80 Tyr Ile Ala Asp Ile Pro Lys Gly Asn Leu
Lys Thr Glu Ile Glu Lys 85 90 95 Leu Ala Lys Gln Pro Glu Tyr Ala
Tyr Leu Lys Gln Leu Gln Thr Val 100 105 110 Lys Asp Val Asn Trp Asn
Gln Val Gln Leu Ala Tyr Asp Lys Trp Asp 115 120 125 Tyr Lys Gln Glu
Gly Leu Thr Gly Ala Gly Ala Ala Ile Xaa Ala Leu 130 135 140 Ala Val
Thr Val Val Thr Ser Gly Ala Gly Thr Gly Ala Val Leu Gly 145 150 155
160 Leu Xaa Arg Val Ala Ala Ala Ala Thr Asp Ala Ala Phe 165 170 19
1923 DNA Neisseria meningitidis 19 atgcaactgc tggcagccga aggcattcac
caacaccaat tgaatgttca gaaaagtacc 60 cgtttcatcg gcatcaaagt
gggtaaaagc aattacagca aaaacgagct gaacgaaacc 120 aaactgcccg
tacgcgttat cgcccaaaca gccaaaaccc gttccggctg ggataccgta 180
ctcgaaggca ccgaattcaa aaccaccctt tccggagccg acatacaggc aggggtgggt
240 gaaaaagccc gagccgatgc gaaaattatc ctaaaaggca tcgttaaccg
catccaaacc 300 gaagaaaagc tggaatccaa ctcgaccgta tggcaaaagc
aggccggaag cggcagcacg 360 gttgaaacgc tgaagctacc gagctttgaa
gggccggcac tgcctaagct gaccgctccc 420 ggcggctata tcgccgacat
ccccaaaggc aacctcaaaa ccgaaatcga aaagctggcc 480 aaacagcccg
aatatgccta tctgaaacag cttcagacgg tcaaggacgt gaactggaac 540
caagtacagc tcgcttacga caaatgggac tataaacagg aaggcctaac cggagccgga
600 gccgcaatta tcgcactggc cgttaccgtg gtcacctcag gcgcaggaac
cggagccgta 660 ttgggattaa acggtgcggc cgccgccgca accgatgcag
catttgcctc tttggccagc 720 caggcttccg tatcgttcat caacaacaaa
ggcaatatcg gtaacaccct gaaagagctg 780 ggcagaagca gcacggtgaa
aaatctgatg gttgccgtcg ctaccgcagg cgtagccgac 840 aaaatcggtg
cttcggcact gaacaatgtc agcgataagc agtggatcaa caacctgacc 900
gtcaacctgg ccaatgcggg cagtgccgca ctgattaata ccgctgtcaa cggcggcagc
960 ctgaaagaca atctggaagc gaatatcctt gcggctttgg tgaatactgc
gcatggagag 1020 gcagcaagta aaatcaaaca gttggatcag cactacattg
cccataagat tgcccatgcc 1080 atagcgggct gtgcggcagc ggcggcgaat
aagggcaagt gtcaagatgg tgcgatcggt 1140 gcggcggtcg gtgaaatcct
tggcgaaacc ctactggacg gcagagaccc tggcagcctg 1200 aatgtgaagg
acagggcaaa aatcattgct aaggcgaagc tggcagcagg ggcggttgcg 1260
gcgttgagta agggggatgt gagtacggcg gcgaatgcgg ctgctgtggc ggtagagaat
1320 aattctttaa atgatataca ggatcgtttg ttgagtggaa attatgcttt
atgtatgagt 1380 gcaggaggag cagaaagctt ttgtgagtct tatcgaccac
tgggcttgcc acactttgta 1440 agtgtttcag gagaaatgaa attacctaat
aaattcggga atcgtatggt taatggaaaa 1500 ttaattatta acactagaaa
tggcaatgta tatttctctg taggtaaaat atggagtact 1560 gtaaaatcaa
caaaatcaaa tataagtggg gtatctgtcg gttgggtttt aaatgtttcc 1620
cctaatgatt atttaaaaga agcatctatg aatgatttca gaaatagtaa tcaaaataaa
1680 gcctatgcag aaatgatttc ccagactttg gtaggtgaga gtgttggtgg
tagtctttgt 1740 ctgacaagag cctgcttttc ggtaagttca acaatatcta
aatctaaatc tccttttaaa 1800 gattcaaaaa ttattgggga aatcggtttg
ggaagtggtg ttgctgcagg agtagaaaaa 1860 acaatataca taggtaacat
aaaagatatt gataaattta ttagtgcaaa cataaaaaaa 1920 tag 1923 20 640
PRT Neisseria meningitidis 20 Met Gln Leu Leu Ala Ala Glu Gly Ile
His Gln His Gln Leu Asn Val 1 5 10 15 Gln Lys Ser Thr Arg Phe Ile
Gly Ile Lys Val Gly Lys Ser Asn Tyr 20 25 30 Ser Lys Asn Glu Leu
Asn Glu Thr Lys Leu Pro Val Arg Val Ile Ala 35 40 45 Gln Thr Ala
Lys Thr Arg Ser Gly Trp Asp Thr Val Leu Glu Gly Thr 50 55 60 Glu
Phe Lys Thr Thr Leu Ser Gly Ala Asp Ile Gln Ala Gly Val Gly 65 70
75 80 Glu Lys Ala Arg Ala Asp Ala Lys Ile Ile Leu Lys Gly Ile Val
Asn 85 90 95 Arg Ile Gln Thr Glu Glu Lys Leu Glu Ser Asn Ser Thr
Val Trp Gln 100 105 110 Lys Gln Ala Gly Ser Gly Ser Thr Val Glu Thr
Leu Lys Leu Pro Ser 115 120 125 Phe Glu Gly Pro Ala Leu Pro Lys Leu
Thr Ala Pro Gly Gly Tyr Ile 130 135 140 Ala Asp Ile Pro Lys Gly Asn
Leu Lys Thr Glu Ile Glu Lys Leu Ala 145 150 155 160 Lys Gln Pro Glu
Tyr Ala Tyr Leu Lys Gln Leu Gln Thr Val Lys Asp 165 170 175 Val Asn
Trp Asn Gln Val Gln Leu Ala Tyr Asp Lys Trp Asp Tyr Lys 180 185 190
Gln Glu Gly Leu Thr Gly Ala Gly Ala Ala Ile Ile Ala Leu Ala Val 195
200 205 Thr Val Val Thr Ser Gly Ala Gly Thr Gly Ala Val Leu Gly Leu
Asn 210 215 220 Gly Ala Ala Ala Ala Ala Thr Asp Ala Ala Phe Ala Ser
Leu Ala Ser 225 230 235 240 Gln Ala Ser Val Ser Phe Ile Asn Asn Lys
Gly Asn Ile Gly Asn Thr 245 250 255 Leu Lys Glu Leu Gly Arg Ser Ser
Thr Val Lys Asn Leu Met Val Ala 260 265 270 Val Ala Thr Ala Gly Val
Ala Asp Lys Ile Gly Ala Ser Ala Leu Asn 275 280 285 Asn Val Ser Asp
Lys Gln Trp Ile Asn Asn Leu Thr Val Asn Leu Ala 290 295 300 Asn Ala
Gly Ser Ala Ala Leu Ile Asn Thr Ala Val Asn Gly Gly Ser 305 310 315
320 Leu Lys Asp Asn Leu Glu Ala Asn Ile Leu Ala Ala Leu Val Asn Thr
325 330 335 Ala His Gly Glu Ala Ala Ser Lys Ile Lys Gln Leu Asp Gln
His Tyr 340 345 350 Ile Ala His Lys Ile Ala His Ala Ile Ala Gly Cys
Ala Ala Ala Ala 355 360 365 Ala Asn Lys Gly Lys Cys Gln Asp Gly Ala
Ile Gly Ala Ala Val Gly 370 375 380 Glu Ile Leu Gly Glu Thr Leu Leu
Asp Gly Arg Asp Pro Gly Ser Leu 385 390 395 400 Asn Val Lys Asp Arg
Ala Lys Ile Ile Ala Lys Ala Lys Leu Ala Ala 405 410 415 Gly Ala Val
Ala Ala Leu Ser Lys Gly Asp Val Ser Thr Ala Ala Asn 420 425 430 Ala
Ala Ala Val Ala Val Glu Asn Asn Ser Leu Asn Asp Ile Gln Asp 435
440 445 Arg Leu Leu Ser Gly Asn Tyr Ala Leu Cys Met Ser Ala Gly Gly
Ala 450 455 460 Glu Ser Phe Cys Glu Ser Tyr Arg Pro Leu Gly Leu Pro
His Phe Val 465 470 475 480 Ser Val Ser Gly Glu Met Lys Leu Pro Asn
Lys Phe Gly Asn Arg Met 485 490 495 Val Asn Gly Lys Leu Ile Ile Asn
Thr Arg Asn Gly Asn Val Tyr Phe 500 505 510 Ser Val Gly Lys Ile Trp
Ser Thr Val Lys Ser Thr Lys Ser Asn Ile 515 520 525 Ser Gly Val Ser
Val Gly Trp Val Leu Asn Val Ser Pro Asn Asp Tyr 530 535 540 Leu Lys
Glu Ala Ser Met Asn Asp Phe Arg Asn Ser Asn Gln Asn Lys 545 550 555
560 Ala Tyr Ala Glu Met Ile Ser Gln Thr Leu Val Gly Glu Ser Val Gly
565 570 575 Gly Ser Leu Cys Leu Thr Arg Ala Cys Phe Ser Val Ser Ser
Thr Ile 580 585 590 Ser Lys Ser Lys Ser Pro Phe Lys Asp Ser Lys Ile
Ile Gly Glu Ile 595 600 605 Gly Leu Gly Ser Gly Val Ala Ala Gly Val
Glu Lys Thr Ile Tyr Ile 610 615 620 Gly Asn Ile Lys Asp Ile Asp Lys
Phe Ile Ser Ala Asn Ile Lys Lys 625 630 635 640 21 2291 DNA
Neisseria meningitidis misc_feature (1) any nucleotide 21
ntgcaactgc tggcagaaga aggcatccac aagcacgagt tggatgtcca aaaaagccgc
60 cgctttatcg gcatcaaggt aggtnagagc aattacagta aaaacgaact
gaacgaaacc 120 aaattgcctg tccgcgtcgt cgcccaaant gcagccaccc
gttcaggctg ggataccgtg 180 ctcgaaggta ccgaattcaa aaccacgctg
gccggtgccg acattcaggc aggtgtangc 240 gaaaaagccc gtgtcgatgc
gaaaattatc ctcaaaggca ttgtgaaccg tatccagtcg 300 gaagaaaaat
tagaaaccaa ctcaaccgta tggcagaaac aggccggacg cggcagcact 360
atcgaaacgc taaaactgcc cagcttcgaa agccctactc cgcccaaatt gtccgcaccc
420 ggcggntata tcgtcgacat tccgaaaggc aatctgaaaa ccgaaatcga
aaagctgtcc 480 aaacagcccg agtatgccta tctgaaacag ctccaagtag
cgaaaaacat caactggaat 540 caggtgcagc ttgcttacga cagatgggac
tacaaacagg agggcttaac cgaagcaggt 600 gcggcgatta tcgcactggc
cgttaccgtg gtcacctcag gcgcaggaac cggagccgta 660 ttgggattaa
acggtgcgnc cgccgccgca accgatgcag cattcgcctc tttggccagc 720
caggcttccg tatcgttcat caacaacaaa ggcgatgtcg gcaaaaccct gaaagagctg
780 ggcagaagca gcacggtgaa aaatctggtg gttgccgccg ctaccgcagg
cgtagccgac 840 aaaatcggcg cttcggcact gancaatgtc agcgataagc
agtggatcaa caacctgacc 900 gtcaacctag ccaatgcggg cagtgccgca
ctgattaata ccgctgtcaa cggcggcagc 960 ctgaaagaca ntctggaagc
gaatatcctt gcggctttgg tcaataccgc gcatggagaa 1020 gcagccagta
aaatcaaaca gttggatcag cactacatag tccacaagat tgcccatgcc 1080
atagcgggct gtgcggcagc ggcggcgaat aagggcaagt gtcaggatgg tgcgataggt
1140 gcggctgtgg gcgagatagt cggggaggct ttgacaaacg gcaaaaatcc
tgacactttg 1200 acagctaaag aacgcgaaca gattttggca tacagcaaac
tggttgccgg tacggtaagc 1260 ggtgtggtcg gcggcgatgt aaatgcggcg
gcgaatgcgg ctgaggtagc ggtgaaaaat 1320 aatcagctta gcgacnaaga
gggtagagaa tttgataacg aaatgactgc atgcgccaaa 1380 cagaatantc
ctcaactgtg cagaaaaaat actgtaaaaa agtatcaaaa tgttgctgat 1440
aaaagacttg ctgcttcgat tgcaatatgt acggatatat cccgtagtac tgaatgtaga
1500 acaatcagaa aacaacattt gatcgatagt agaagccttc attcatcttg
ggaagcaggt 1560 ctaattggta aagatgatga atggtataaa ttattcagca
aatcttacac ccaagcagat 1620 ttggctttac agtcttatca tttgaatact
gctgctaaat cttggcttca atcgggcaat 1680 acaaagcctt tatccgaatg
gatgtccgac caaggttata cacttatttc aggagttaat 1740 cctagattca
ttccaatacc aagagggttt gtaaaacaaa atacacctat tactaatgtc 1800
aaatacccgg aaggcatcag tttcgataca aacctanaaa gacatctggc aaatgctgat
1860 ggttttagtc aagaacaggg cattaaagga gcccataacc gcaccaatnt
tatggcagaa 1920 ctaaattcac gaggaggang ngtaaaatct gaaacccana
ctgatattga aggcattacc 1980 cgaattaaat atgagattcc tacactagac
aggacaggta aacctgatgg tggatttaag 2040 gaaatttcaa gtataaaaac
tgtttataat cctaaaaant tttnngatga taaaatactt 2100 caaatggctc
aanatgctgn ttcacaagga tattcaaaag cctctaaaat tgctcaaaat 2160
gaaagaacta aatcaatatc ggaaagaaaa aatgtcattc aattctcaga aacctttgac
2220 ggaatcaaat ttagannnta tntngatgta aatacaggaa gaattacaaa
cattcaccca 2280 gaataattta a 2291 22 761 PRT Neisseria meningitidis
SITE (1) unknown 22 Xaa Gln Leu Leu Ala Glu Glu Gly Ile His Lys His
Glu Leu Asp Val 1 5 10 15 Gln Lys Ser Arg Arg Phe Ile Gly Ile Lys
Val Gly Xaa Ser Asn Tyr 20 25 30 Ser Lys Asn Glu Leu Asn Glu Thr
Lys Leu Pro Val Arg Val Val Ala 35 40 45 Gln Xaa Ala Ala Thr Arg
Ser Gly Trp Asp Thr Val Leu Glu Gly Thr 50 55 60 Glu Phe Lys Thr
Thr Leu Ala Gly Ala Asp Ile Gln Ala Gly Val Xaa 65 70 75 80 Glu Lys
Ala Arg Val Asp Ala Lys Ile Ile Leu Lys Gly Ile Val Asn 85 90 95
Arg Ile Gln Ser Glu Glu Lys Leu Glu Thr Asn Ser Thr Val Trp Gln 100
105 110 Lys Gln Ala Gly Arg Gly Ser Thr Ile Glu Thr Leu Lys Leu Pro
Ser 115 120 125 Phe Glu Ser Pro Thr Pro Pro Lys Leu Ser Ala Pro Gly
Gly Tyr Ile 130 135 140 Val Asp Ile Pro Lys Gly Asn Leu Lys Thr Glu
Ile Glu Lys Leu Ser 145 150 155 160 Lys Gln Pro Glu Tyr Ala Tyr Leu
Lys Gln Leu Gln Val Ala Lys Asn 165 170 175 Ile Asn Trp Asn Gln Val
Gln Leu Ala Tyr Asp Arg Trp Asp Tyr Lys 180 185 190 Gln Glu Gly Leu
Thr Glu Ala Gly Ala Ala Ile Ile Ala Leu Ala Val 195 200 205 Thr Val
Val Thr Ser Gly Ala Gly Thr Gly Ala Val Leu Gly Leu Asn 210 215 220
Gly Ala Xaa Ala Ala Ala Thr Asp Ala Ala Phe Ala Ser Leu Ala Ser 225
230 235 240 Gln Ala Ser Val Ser Phe Ile Asn Asn Lys Gly Asp Val Gly
Lys Thr 245 250 255 Leu Lys Glu Leu Gly Arg Ser Ser Thr Val Lys Asn
Leu Val Val Ala 260 265 270 Ala Ala Thr Ala Gly Val Ala Asp Lys Ile
Gly Ala Ser Ala Leu Xaa 275 280 285 Asn Val Ser Asp Lys Gln Trp Ile
Asn Asn Leu Thr Val Asn Leu Ala 290 295 300 Asn Ala Gly Ser Ala Ala
Leu Ile Asn Thr Ala Val Asn Gly Gly Ser 305 310 315 320 Leu Lys Asp
Xaa Leu Glu Ala Asn Ile Leu Ala Ala Leu Val Asn Thr 325 330 335 Ala
His Gly Glu Ala Ala Ser Lys Ile Lys Gln Leu Asp Gln His Tyr 340 345
350 Ile Val His Lys Ile Ala His Ala Ile Ala Gly Cys Ala Ala Ala Ala
355 360 365 Ala Asn Lys Gly Lys Cys Gln Asp Gly Ala Ile Gly Ala Ala
Val Gly 370 375 380 Glu Ile Val Gly Glu Ala Leu Thr Asn Gly Lys Asn
Pro Asp Thr Leu 385 390 395 400 Thr Ala Lys Glu Arg Glu Gln Ile Leu
Ala Tyr Ser Lys Leu Val Ala 405 410 415 Gly Thr Val Ser Gly Val Val
Gly Gly Asp Val Asn Ala Ala Ala Asn 420 425 430 Ala Ala Glu Val Ala
Val Lys Asn Asn Gln Leu Ser Asp Xaa Glu Gly 435 440 445 Arg Glu Phe
Asp Asn Glu Met Thr Ala Cys Ala Lys Gln Asn Xaa Pro 450 455 460 Gln
Leu Cys Arg Lys Asn Thr Val Lys Lys Tyr Gln Asn Val Ala Asp 465 470
475 480 Lys Arg Leu Ala Ala Ser Ile Ala Ile Cys Thr Asp Ile Ser Arg
Ser 485 490 495 Thr Glu Cys Arg Thr Ile Arg Lys Gln His Leu Ile Asp
Ser Arg Ser 500 505 510 Leu His Ser Ser Trp Glu Ala Gly Leu Ile Gly
Lys Asp Asp Glu Trp 515 520 525 Tyr Lys Leu Phe Ser Lys Ser Tyr Thr
Gln Ala Asp Leu Ala Leu Gln 530 535 540 Ser Tyr His Leu Asn Thr Ala
Ala Lys Ser Trp Leu Gln Ser Gly Asn 545 550 555 560 Thr Lys Pro Leu
Ser Glu Trp Met Ser Asp Gln Gly Tyr Thr Leu Ile 565 570 575 Ser Gly
Val Asn Pro Arg Phe Ile Pro Ile Pro Arg Gly Phe Val Lys 580 585 590
Gln Asn Thr Pro Ile Thr Asn Val Lys Tyr Pro Glu Gly Ile Ser Phe 595
600 605 Asp Thr Asn Leu Xaa Arg His Leu Ala Asn Ala Asp Gly Phe Ser
Gln 610 615 620 Glu Gln Gly Ile Lys Gly Ala His Asn Arg Thr Asn Xaa
Met Ala Glu 625 630 635 640 Leu Asn Ser Arg Gly Gly Xaa Val Lys Ser
Glu Thr Xaa Thr Asp Ile 645 650 655 Glu Gly Ile Thr Arg Ile Lys Tyr
Glu Ile Pro Thr Leu Asp Arg Thr 660 665 670 Gly Lys Pro Asp Gly Gly
Phe Lys Glu Ile Ser Ser Ile Lys Thr Val 675 680 685 Tyr Asn Pro Lys
Xaa Phe Xaa Asp Asp Lys Ile Leu Gln Met Ala Gln 690 695 700 Xaa Ala
Xaa Ser Gln Gly Tyr Ser Lys Ala Ser Lys Ile Ala Gln Asn 705 710 715
720 Glu Arg Thr Lys Ser Ile Ser Glu Arg Lys Asn Val Ile Gln Phe Ser
725 730 735 Glu Thr Phe Asp Gly Ile Lys Phe Arg Xaa Tyr Xaa Asp Val
Asn Thr 740 745 750 Gly Arg Ile Thr Asn Ile His Pro Glu 755 760 23
336 DNA Neisseria meningitidis 23 cggatcgttg taggtttgcg gatttcttgc
gccgtagtca ccgtagtccc aagtataacc 60 caaggctttg tcttcgcctt
tcattccgat aagggatatg acgctttggt cggtatagcc 120 gtcttgggaa
cctttgtcca cccaacgcat atctgcctgc ggattctcat tgccgcttct 180
tggctgctga tttttctgcc ttcgcgtttt tcaacttcgc gcttgagggc ttcggcatat
240 ttgtcggcca acgccatttc tttcggatgc agctgcctat tgttccaatc
tacattcgca 300 cccaccacag caccaccact accaccagtt gcatag 336 24 111
PRT Neisseria meningitidis 24 Arg Ile Val Val Gly Leu Arg Ile Ser
Cys Ala Val Val Thr Val Val 1 5 10 15 Pro Ser Ile Thr Gln Gly Phe
Val Phe Ala Phe His Ser Asp Lys Gly 20 25 30 Tyr Asp Ala Leu Val
Gly Ile Ala Val Leu Gly Thr Phe Val His Pro 35 40 45 Thr His Ile
Cys Leu Arg Ile Leu Ile Ala Ala Ser Trp Leu Leu Ile 50 55 60 Phe
Leu Pro Ser Arg Phe Ser Thr Ser Arg Leu Arg Ala Ser Ala Tyr 65 70
75 80 Leu Ser Ala Asn Ala Ile Ser Phe Gly Cys Ser Cys Leu Leu Phe
Gln 85 90 95 Ser Thr Phe Ala Pro Thr Thr Ala Pro Pro Leu Pro Pro
Val Ala 100 105 110 25 1716 DNA Neisseria meningitidis unsure
(496)..(1542) N = Unknown 25 aagtttgact ttacctggtt tattccggcg
gtaatcaaat accgccggtt gttttttgaa 60 gtattggtgg tgtcggtggt
gttgcagctg tttgcgctga ttacgcctct gtttttccaa 120 gtggtgatgg
acaaggtgct ggtacatcgg ggattctcta ctttggatgt ggtgtcggtg 180
gctttgttgg tggtgtcgct gtttgagatt gtgttgggcg gtttgcggac gtatctgttt
240 gcacatacga cttcacgtat tgatgtggaa ttgggcgcgc gtttgttccg
gcatctgctt 300 tccctgcctt tatcctattt cgagcacaga cgagtgggtg
atacggtggc tcgggtgcgg 360 gaattggagc agattcgcaa tttcttgacc
ggtcaggcgc tgacttcggt gttggatttg 420 gcgttttcgt ttatctttct
ggcggtgatg tggtattaca gctccactct gacttgggtg 480 gtattggctt
cgttgnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 540
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn
600 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn
nnnnnnnnnn 660 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn
nnnnnnnnnn nnnnnnnnnn 720 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 780 nnnnnnnnnn nnnnnnnnnn
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 840 nnnnnnnnnn
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 900
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn
960 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn
nnnnnnnnnn 1020 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn
nnnnnnnnnn nnnnnnnnnn 1080 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 1140 nnnnnnnnnn nnnnnnnnnn
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 1200 nnnnnnnnnn
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 1260
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn
1320 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn
nnnnnnnnnn 1380 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn
nnnnnnnnnn nnnnnnnnnn 1440 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 1500 nnnnnnnnnn nnnnnnnnnn
nnnnnnnnnn nnnnnnnnnn nnatttgcgc caaccggacg 1560 gtgctgatta
tcgcccaccg tctgtccact gttaaaacgg cacaccggat cattgccatg 1620
gataaaggca ggattgtgga agcgggaaca cagcaggaat tgctggcgaa cgnnaacgga
1680 tattaccgct atctgtatga tttacagaac gggtag 1716 26 571 PRT
Neisseria meningitidis UNSURE (166)..(514) x = Unknown 26 Lys Phe
Asp Phe Thr Trp Phe Ile Pro Ala Val Ile Lys Tyr Arg Arg 1 5 10 15
Leu Phe Phe Glu Val Leu Val Val Ser Val Val Leu Gln Leu Phe Ala 20
25 30 Leu Ile Thr Pro Leu Phe Phe Gln Val Val Met Asp Lys Val Leu
Val 35 40 45 His Arg Gly Phe Ser Thr Leu Asp Val Val Ser Val Ala
Leu Leu Val 50 55 60 Val Ser Leu Phe Glu Ile Val Leu Gly Gly Leu
Arg Thr Tyr Leu Phe 65 70 75 80 Ala His Thr Thr Ser Arg Ile Asp Val
Glu Leu Gly Ala Arg Leu Phe 85 90 95 Arg His Leu Leu Ser Leu Pro
Leu Ser Tyr Phe Glu His Arg Arg Val 100 105 110 Gly Asp Thr Val Ala
Arg Val Arg Glu Leu Glu Gln Ile Arg Asn Phe 115 120 125 Leu Thr Gly
Gln Ala Leu Thr Ser Val Leu Asp Leu Ala Phe Ser Phe 130 135 140 Ile
Phe Leu Ala Val Met Trp Tyr Tyr Ser Ser Thr Leu Thr Trp Val 145 150
155 160 Val Leu Ala Ser Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
Xaa 165 170 175 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
Xaa Xaa Xaa 180 185 190 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
Xaa Xaa Xaa Xaa Xaa 195 200 205 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
Xaa Xaa Xaa Xaa Xaa Xaa Xaa 210 215 220 Xaa Xaa Xaa Xaa Xaa Xaa Xaa
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 225 230 235 240 Xaa Xaa Xaa Xaa
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 245 250 255 Xaa Xaa
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 260 265 270
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 275
280 285 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
Xaa 290 295 300 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
Xaa Xaa Xaa 305 310 315 320 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
Xaa Xaa Xaa Xaa Xaa Xaa 325 330 335 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 340 345 350 Xaa Xaa Xaa Xaa Xaa Xaa
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 355 360 365 Xaa Xaa Xaa Xaa
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 370 375 380 Xaa Xaa
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 385 390 395
400 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
405 410 415 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
Xaa Xaa 420 425 430 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
Xaa Xaa Xaa Xaa 435 440 445 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
Xaa Xaa Xaa Xaa Xaa Xaa 450 455 460 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 465 470 475 480 Xaa Xaa Xaa Xaa Xaa
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 485 490 495 Xaa Xaa Xaa
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 500 505 510 Xaa
Xaa Ile Cys Ala Asn Arg Thr Val Leu Ile Ile Ala His Arg Leu 515 520
525 Ser Thr Val Lys Thr Ala His Arg Ile Ile Ala Met Asp Lys Gly Arg
530 535 540 Ile Val Glu Ala Gly Thr Gln Gln Glu Leu Leu Ala Asn Xaa
Asn Gly 545 550 555 560 Tyr Tyr Arg Tyr Leu Tyr Asp Leu Gln Asn Gly
565 570 27 2133 DNA Neisseria meningitidis 27 atgtctatcg tatccgcacc
gctccccgcc ctttccgccc tcatcatcct cgcccattac 60 cacggcattg
ccgccaatcc tgccgatata cagcatgaat tttgtacttc cgcacagagc 120
gatttaaatg aaacgcaatg gctgttagcc gccaaatctt tgggattgaa ggcaaaggta
180 gtccgccagc ctattaaacg tttggctatg gcgactttac ccgcattggt
atggtgtgat 240 gacggcaacc atttcatttt ggccaaaaca gacggtgagg
gtgagcatgc ccaatttttg 300 atacaggatt tggttacgaa taagtctgcg
gtattgtctt ttgccgaatt ttctaacaga 360 tattcgggca aactgatatt
ggttgcttcc cgcgcttcgg tattgggcag tttggcaaag 420 tttgacttta
cctggtttat tccggcggta atcaaatacc gccggttgtt ttttgaagta 480
ttggtggtgt cggtggtgtt gcagctgttt gcgctgatta cgcctctgtt tttccaagtg
540 gtgatggaca aggtgctggt acatcgggga ttctctactt tggatgtggt
gtcggtggct 600 ttgttggtgg tgtcgctgtt tgagattgtg ttgggcggtt
tgcggacgta tctgtttgca 660 catacgactt cacgtattga tgtggaattg
ggcgcgcgtt tgttccggca tctgctttcc 720 ctgcctttat cctatttcga
gcacagacga gtgggtgata cggtggctcg ggtgcgggaa 780 ttggagcaga
ttcgcaattt cttgaccggt caggcgctga cttcggtgtt ggatttggcg 840
ttttcgttta tctttctggc ggtgatgtgg tattacagct ccactctgac ttgggtggta
900 ttggcttcgt tgcctgccta tgcgttttgg tcggcattta tcagtccgat
actgcggacg 960 cgtctgaacg ataagttcgc gcgcaatgca gacaaccagt
cgtttttagt agaaagcatc 1020 actgcggtgg gtacggtaaa ggcgatggcg
gtggagccgc agatgacgca gcgttgggac 1080 aatcagttgg cggcttatgt
ggcttcggga tttcgggtaa cgaagttggc ggtggtcggc 1140 cagcaggggg
tgcagctgat tcagaagctg gtgacggtgg cgacgttgtg gattggcgca 1200
cggctggtaa ttgagagcaa gctgacggtg gggcagctga ttgcgtttaa tatgctctcg
1260 ggacaggtgg cggcgcctgt tatccgtttg gcgcagttgt ggcaggattt
ccagcaggtg 1320 gggatttcgg tggcgcgttt gggggatatt ctgaatgcgc
cgaccgagaa tgcgtcttcg 1380 catttggctt tgcccgatat ccggggggag
attacgttcg aacatgtcga tttccgctat 1440 aaggcggacg gcaggctgat
tttgcaggat ttgaacctgc ggattcgggc gggggaagtg 1500 ctggggattg
tgggacgttc ggggtcgggc aaatccacac tcaccaaatt ggtgcagcgt 1560
ctgtatgtac cggagcaggg acgggtgttg gtggacggca acgatttggc tttggccgct
1620 cctgcctggc tgcggcggca ggtcggcgtg gtcttgcagg agaatgtgct
gctcaaccgc 1680 agcatacgcg acaatatcgc gctgacggat acgggtatgc
cgctggaacg cattatcgaa 1740 gcagccaaac tggcgggcgc acacgagttt
attatggagc tgccggaagg ctacggcacc 1800 gtggtgggcg aacaaggggc
cggcttgtcg ggcggacagc ggcagcgtat tgcgattgcc 1860 cgcgcgttaa
tcaccaatcc gcgcattctg atttttgatg aagccaccag cgcgctggat 1920
tatgaaagtg aacgagcgat tatgcagaac atgcaggcca tttgcgccaa ccggacggtg
1980 ctgattatcg cccaccgtct gtccactgtt aaaacggcac accggatcat
tgccatggat 2040 aaaggcagga ttgtggaagc gggaacacag caggaattgc
tggcgaagcc gaacggatat 2100 taccgctatc tgtatgattt acagaacggg tag
2133 28 710 PRT Neisseria meningitidis 28 Met Ser Ile Val Ser Ala
Pro Leu Pro Ala Leu Ser Ala Leu Ile Ile 1 5 10 15 Leu Ala His Tyr
His Gly Ile Ala Ala Asn Pro Ala Asp Ile Gln His 20 25 30 Glu Phe
Cys Thr Ser Ala Gln Ser Asp Leu Asn Glu Thr Gln Trp Leu 35 40 45
Leu Ala Ala Lys Ser Leu Gly Leu Lys Ala Lys Val Val Arg Gln Pro 50
55 60 Ile Lys Arg Leu Ala Met Ala Thr Leu Pro Ala Leu Val Trp Cys
Asp 65 70 75 80 Asp Gly Asn His Phe Ile Leu Ala Lys Thr Asp Gly Glu
Gly Glu His 85 90 95 Ala Gln Phe Leu Ile Gln Asp Leu Val Thr Asn
Lys Ser Ala Val Leu 100 105 110 Ser Phe Ala Glu Phe Ser Asn Arg Tyr
Ser Gly Lys Leu Ile Leu Val 115 120 125 Ala Ser Arg Ala Ser Val Leu
Gly Ser Leu Ala Lys Phe Asp Phe Thr 130 135 140 Trp Phe Ile Pro Ala
Val Ile Lys Tyr Arg Arg Leu Phe Phe Glu Val 145 150 155 160 Leu Val
Val Ser Val Val Leu Gln Leu Phe Ala Leu Ile Thr Pro Leu 165 170 175
Phe Phe Gln Val Val Met Asp Lys Val Leu Val His Arg Gly Phe Ser 180
185 190 Thr Leu Asp Val Val Ser Val Ala Leu Leu Val Val Ser Leu Phe
Glu 195 200 205 Ile Val Leu Gly Gly Leu Arg Thr Tyr Leu Phe Ala His
Thr Thr Ser 210 215 220 Arg Ile Asp Val Glu Leu Gly Ala Arg Leu Phe
Arg His Leu Leu Ser 225 230 235 240 Leu Pro Leu Ser Tyr Phe Glu His
Arg Arg Val Gly Asp Thr Val Ala 245 250 255 Arg Val Arg Glu Leu Glu
Gln Ile Arg Asn Phe Leu Thr Gly Gln Ala 260 265 270 Leu Thr Ser Val
Leu Asp Leu Ala Phe Ser Phe Ile Phe Leu Ala Val 275 280 285 Met Trp
Tyr Tyr Ser Ser Thr Leu Thr Trp Val Val Leu Ala Ser Leu 290 295 300
Pro Ala Tyr Ala Phe Trp Ser Ala Phe Ile Ser Pro Ile Leu Arg Thr 305
310 315 320 Arg Leu Asn Asp Lys Phe Ala Arg Asn Ala Asp Asn Gln Ser
Phe Leu 325 330 335 Val Glu Ser Ile Thr Ala Val Gly Thr Val Lys Ala
Met Ala Val Glu 340 345 350 Pro Gln Met Thr Gln Arg Trp Asp Asn Gln
Leu Ala Ala Tyr Val Ala 355 360 365 Ser Gly Phe Arg Val Thr Lys Leu
Ala Val Val Gly Gln Gln Gly Val 370 375 380 Gln Leu Ile Gln Lys Leu
Val Thr Val Ala Thr Leu Trp Ile Gly Ala 385 390 395 400 Arg Leu Val
Ile Glu Ser Lys Leu Thr Val Gly Gln Leu Ile Ala Phe 405 410 415 Asn
Met Leu Ser Gly Gln Val Ala Ala Pro Val Ile Arg Leu Ala Gln 420 425
430 Leu Trp Gln Asp Phe Gln Gln Val Gly Ile Ser Val Ala Arg Leu Gly
435 440 445 Asp Ile Leu Asn Ala Pro Thr Glu Asn Ala Ser Ser His Leu
Ala Leu 450 455 460 Pro Asp Ile Arg Gly Glu Ile Thr Phe Glu His Val
Asp Phe Arg Tyr 465 470 475 480 Lys Ala Asp Gly Arg Leu Ile Leu Gln
Asp Leu Asn Leu Arg Ile Arg 485 490 495 Ala Gly Glu Val Leu Gly Ile
Val Gly Arg Ser Gly Ser Gly Lys Ser 500 505 510 Thr Leu Thr Lys Leu
Val Gln Arg Leu Tyr Val Pro Glu Gln Gly Arg 515 520 525 Val Leu Val
Asp Gly Asn Asp Leu Ala Leu Ala Ala Pro Ala Trp Leu 530 535 540 Arg
Arg Gln Val Gly Val Val Leu Gln Glu Asn Val Leu Leu Asn Arg 545 550
555 560 Ser Ile Arg Asp Asn Ile Ala Leu Thr Asp Thr Gly Met Pro Leu
Glu 565 570 575 Arg Ile Ile Glu Ala Ala Lys Leu Ala Gly Ala His Glu
Phe Ile Met 580 585 590 Glu Leu Pro Glu Gly Tyr Gly Thr Val Val Gly
Glu Gln Gly Ala Gly 595 600 605 Leu Ser Gly Gly Gln Arg Gln Arg Ile
Ala Ile Ala Arg Ala Leu Ile 610 615 620 Thr Asn Pro Arg Ile Leu Ile
Phe Asp Glu Ala Thr Ser Ala Leu Asp 625 630 635 640 Tyr Glu Ser Glu
Arg Ala Ile Met Gln Asn Met Gln Ala Ile Cys Ala 645 650 655 Asn Arg
Thr Val Leu Ile Ile Ala His Arg Leu Ser Thr Val Lys Thr 660 665 670
Ala His Arg Ile Ile Ala Met Asp Lys Gly Arg Ile Val Glu Ala Gly 675
680 685 Thr Gln Gln Glu Leu Leu Ala Lys Pro Asn Gly Tyr Tyr Arg Tyr
Leu 690 695 700 Tyr Asp Leu Gln Asn Gly 705 710 29 2133 DNA
Neisseria meningitidis 29 atgtctatcg tatccgcacc gctccccgcc
ctttccgccc tcatcatcct cgcccattac 60 cacggcattg ccgccaatcc
tgccgatata cagcatgaat tttgtacttc cgcacagagc 120 gatttaaatg
aaacgcaatg gctgttagcc gccaaatctt tgggattgaa ggcaaaggta 180
gtccgccagc ctattaaacg tttggctatg gcgactttac ccgcattggt atggtgtgat
240 gacggcaacc attttatttt ggctaaaaca gacggtgggg gtgagcatgc
ccaatatcta 300 atacaggatt taactacgaa taagtctgcg gtattgtctt
ttgccgaatt ttctaacaga 360 tattcgggca aactgatatt ggttgcttcc
cgcgcttcgg tattgggcag tttggcaaag 420 tttgacttta cctggtttat
tccggcggta atcaaatacc gccggttgtt ttttgaagta 480 ttggtggtgt
cggtggtgtt gcagctgttt gcgctgatta cgcctctgtt tttccaagtg 540
gtgatggaca aggtgctggt acatcgggga ttctctactt tggatgtggt gtcggtggct
600 ttgttggtgg tgtcgctgtt tgagattgtg ttgggcggtt tgcggacgta
tctgtttgca 660 catacgactt cacgtattga tgtggaattg ggcgcgcgtt
tgttccggca tctgctttcc 720 ctgcctttat cctatttcga gcacagacga
gtgggtgata cggtggctcg ggtgcgggaa 780 ttggagcaga ttcgcaattt
cttgaccggt caggcgctga cttcggtgtt ggatttggcg 840 ttttcgttta
tctttctggc ggtgatgtgg tattacagct ccactctgac ttgggtggta 900
ttggcttcgt tgcctgccta tgcgttttgg tcggcattta tcagtccgat actgcggacg
960 cgtctgaacg ataagttcgc gcgcaatgca gacaaccagt cgtttttagt
agaaagcatc 1020 actgcggtgg gtacggtaaa ggcgatggcg gtggagccgc
agatgacgca gcgttgggac 1080 aatcagttgg cggcttatgt ggcttcggga
tttcgggtaa cgaagttggc ggtggtcggc 1140 cagcaggggg tgcagctgat
tcagaagctg gtgacggtgg cgacgttgtg gattggcgca 1200 cggctggtaa
ttgagagcaa gctgacggtg gggcagctga ttgcgtttaa tatgctctcg 1260
ggacaggtgg cggcgcctgt tatccgtttg gcgcagttgt ggcaggattt ccagcaggtg
1320 gggatttcgg tggcgcgttt gggggatatt ctgaatgcgc cgaccgagaa
tgcgtcttcg 1380 catttggctt tgcccgatat ccggggggag attacgttcg
aacatgtcga tttccgctat 1440 aaggcggacg gcaggctgat tttgcaggat
ttgaacctgc ggattcgggc gggggaagtg 1500 ctggggattg tgggacgttc
ggggtcgggc aaatccacac tcaccaaatt ggtgcagcgt 1560 ctgtatgtac
cggcgcaggg acgggtgttg gtggacggca acgatttggc tttggccgct 1620
cctgcttggc tgcggcggca ggtcggcgtg gtcttgcagg agaatgtgct gctcaaccgc
1680 agcatacgcg acaatatcgc gctgacggat acgggtatgc cgctggaacg
cattatcgaa 1740 gcagccaaac tggcgggcgc acacgagttt attatggagc
tgccggaagg ctacggcacc 1800 gtggtgggcg aacaaggggc cggcttgtcg
ggcggacagc ggcagcgtat tgcgattgcc 1860 cgcgcgttaa tcaccaatcc
gcgcattctg atttttgatg aagccaccag cgcgctggat 1920 tatgaaagtg
aacgagcgat tatgcagaac atgcaggcca tttgcgccaa ccggacggtg 1980
ctgattatcg cccaccgtct gtccactgtt aaaacggcac accggatcat tgccatggat
2040 aaaggcagga ttgtggaagc gggaacacag caggaattgc tggcgaagcc
gaacggatat 2100 taccgctatc tgtatgattt acagaacggg tag 2133 30 710
PRT Neisseria meningitidis 30 Met Ser Ile Val Ser Ala Pro Leu Pro
Ala Leu Ser Ala Leu Ile Ile 1 5 10 15 Leu Ala His Tyr His Gly Ile
Ala Ala Asn Pro Ala Asp Ile Gln His 20 25 30 Glu Phe Cys Thr Ser
Ala Gln Ser Asp Leu Asn Glu Thr Gln Trp Leu 35 40 45 Leu Ala Ala
Lys Ser Leu Gly Leu Lys Ala Lys Val Val Arg Gln Pro 50 55 60 Ile
Lys Arg Leu Ala Met Ala Thr Leu Pro Ala Leu Val Trp Cys Asp 65 70
75 80 Asp Gly Asn His Phe Ile Leu Ala Lys Thr Asp Gly Gly Gly Glu
His 85 90 95 Ala Gln Tyr Leu Ile Gln Asp Leu Thr Thr Asn Lys Ser
Ala Val Leu 100 105 110 Ser Phe Ala Glu Phe Ser Asn Arg Tyr Ser Gly
Lys Leu Ile Leu Val 115 120 125 Ala Ser Arg Ala Ser Val Leu Gly Ser
Leu Ala Lys Phe Asp Phe Thr 130 135 140 Trp Phe Ile Pro Ala Val Ile
Lys Tyr Arg Arg Leu Phe Phe Glu Val 145 150 155 160 Leu Val Val Ser
Val Val Leu Gln Leu Phe Ala Leu Ile Thr Pro Leu 165 170 175 Phe Phe
Gln Val Val Met Asp Lys Val Leu Val His Arg Gly Phe Ser 180 185 190
Thr Leu Asp Val Val Ser Val Ala Leu Leu Val Val Ser Leu Phe Glu 195
200 205 Ile Val Leu Gly Gly Leu Arg Thr Tyr Leu Phe Ala His Thr Thr
Ser 210 215 220 Arg Ile Asp Val Glu Leu Gly Ala Arg Leu Phe Arg His
Leu Leu Ser 225 230 235 240 Leu Pro Leu Ser Tyr Phe Glu His Arg Arg
Val Gly Asp Thr Val Ala 245 250 255 Arg Val Arg Glu Leu Glu Gln Ile
Arg Asn Phe Leu Thr Gly Gln Ala 260 265 270 Leu Thr Ser Val Leu Asp
Leu Ala Phe Ser Phe Ile Phe Leu Ala Val 275 280 285 Met Trp Tyr Tyr
Ser Ser Thr Leu Thr Trp Val Val Leu Ala Ser Leu 290 295 300 Pro Ala
Tyr Ala Phe Trp Ser Ala Phe Ile Ser Pro Ile Leu Arg Thr 305 310 315
320 Arg Leu Asn Asp Lys Phe Ala Arg Asn Ala Asp Asn Gln Ser Phe Leu
325 330 335 Val Glu Ser Ile Thr Ala Val Gly Thr Val Lys Ala Met Ala
Val Glu 340 345 350 Pro Gln Met Thr Gln Arg Trp Asp Asn Gln Leu Ala
Ala Tyr Val Ala 355 360 365 Ser Gly Phe Arg Val Thr Lys Leu Ala Val
Val Gly Gln Gln Gly Val 370 375 380 Gln Leu Ile Gln Lys Leu Val Thr
Val Ala Thr Leu Trp Ile Gly Ala 385 390 395 400 Arg Leu Val Ile Glu
Ser Lys Leu Thr Val Gly Gln Leu Ile Ala Phe 405 410 415 Asn Met Leu
Ser Gly Gln Val Ala Ala Pro Val Ile Arg Leu Ala Gln 420 425 430 Leu
Trp Gln Asp Phe Gln Gln Val Gly Ile Ser Val Ala Arg Leu Gly 435 440
445 Asp Ile Leu Asn Ala Pro Thr Glu Asn Ala Ser Ser His Leu Ala Leu
450 455 460 Pro Asp Ile Arg Gly Glu Ile Thr Phe Glu His Val Asp Phe
Arg Tyr 465 470 475 480 Lys Ala Asp Gly Arg Leu Ile Leu Gln Asp Leu
Asn Leu Arg Ile Arg 485 490 495 Ala Gly Glu Val Leu Gly Ile Val Gly
Arg Ser Gly Ser Gly Lys Ser 500 505 510 Thr Leu Thr Lys Leu Val Gln
Arg Leu Tyr Val Pro Ala Gln Gly Arg 515 520 525 Val Leu Val Asp Gly
Asn Asp Leu Ala Leu Ala Ala Pro Ala Trp Leu 530 535 540 Arg Arg Gln
Val Gly Val Val Leu Gln Glu Asn Val Leu Leu Asn Arg 545 550 555 560
Ser Ile Arg Asp Asn Ile Ala Leu Thr Asp Thr Gly Met Pro Leu Glu 565
570 575 Arg Ile Ile Glu Ala Ala Lys Leu Ala Gly Ala His Glu Phe Ile
Met 580 585 590 Glu Leu Pro Glu Gly Tyr Gly Thr Val Val Gly Glu Gln
Gly Ala Gly 595 600 605 Leu Ser Gly Gly Gln Arg Gln Arg Ile Ala Ile
Ala Arg Ala Leu Ile 610 615 620 Thr Asn Pro Arg Ile Leu Ile Phe Asp
Glu Ala Thr Ser Ala Leu Asp 625 630 635 640 Tyr Glu Ser Glu Arg Ala
Ile Met Gln Asn Met Gln Ala Ile Cys Ala 645 650 655 Asn Arg Thr Val
Leu Ile Ile Ala His Arg Leu Ser Thr Val Lys Thr 660 665 670 Ala His
Arg Ile Ile Ala Met Asp Lys Gly Arg Ile Val Glu Ala Gly 675 680 685
Thr Gln Gln Glu Leu Leu Ala Lys Pro Asn Gly Tyr Tyr Arg Tyr Leu 690
695 700 Tyr Asp Leu Gln Asn Gly 705 710 31 186 DNA Neisseria
meningitidis 31 atgaaatact tgatccgcac cgccttactc gcagtcgcag
ccgccggcat ctacgcctgc 60 caaccgcaat ccgaagccgc agtgcaagtc
aaggctgaaa acagcctgac cgctatgcgc 120 ttagccgtcg ccgacaaaca
ggcagagatt gacgggttga acgcccaaak sgacgccgaa 180 atcaga 186 32 62
PRT Neisseria meningitidis SITE (57) unknown 32 Met Lys Tyr Leu Ile
Arg Thr Ala Leu Leu Ala Val Ala Ala Ala Gly 1 5 10 15 Ile Tyr Ala
Cys Gln Pro Gln Ser Glu Ala Ala Val Gln Val Lys Ala 20 25 30 Glu
Asn Ser Leu Thr Ala Met Arg Leu Ala Val Ala Asp Lys Gln Ala 35 40
45 Glu Ile Asp Gly Leu Asn Ala Gln Xaa Asp Ala Glu Ile Arg 50 55 60
33 261 DNA Neisseria meningitidis 33 atgaaatact tgatccgcac
cgccttactc gcagtcgcag ccgccggcat ctacgcctgc 60 caaccgcaat
ccgaagccgc agtgcaagtc aaggctgaaa acagcctgac cgctatgcgc 120
ttagccgtcg ccgacaaaca ggcagagatt gacgggttga acgcccaaat cgacgccgaa
180 atcagacaac gcgaagccga agaattgaaa gactaccgat ggatacacgg
cgacgcggaa 240 gtgccggagc tggaaaaatg a 261 34 86 PRT Neisseria
meningitidis 34 Met Lys Tyr Leu Ile Arg Thr Ala Leu Leu Ala Val Ala
Ala Ala Gly 1 5 10 15 Ile Tyr Ala Cys Gln Pro Gln Ser Glu Ala Ala
Val Gln Val Lys Ala 20 25 30 Glu Asn Ser Leu Thr Ala Met Arg Leu
Ala Val Ala Asp Lys Gln Ala 35 40 45 Glu Ile Asp Gly Leu Asn Ala
Gln Ile Asp Ala Glu Ile Arg Gln Arg 50 55 60 Glu Ala Glu Glu Leu
Lys Asp Tyr Arg Trp Ile His Gly Asp Ala Glu 65 70 75 80 Val Pro Glu
Leu Glu Lys 85 35 279 DNA Neisseria meningitidis 35 atggttatcg
gaatattact cgcatcaagc aagcatgctc ttgtcattac tctattgtta 60
aatcccgtct tccatgcatc cagttgcgta tcgcgttsgg caatacggaa taaaatctgc
120 tgttctgctt tggctaaatt tgccaaattg tttattgttt ctttaggagc
agcttgctta 180 gccgccttcg ctttcgacaa cgcccccaca ggcgcttccc
aagcgttgcc taccgttacc 240 gcacccgtgg cgattcccgc gcccgcttcg
gcagcctga 279 36 92 PRT Neisseria meningitidis SITE (33) unknown 36
Met Val Ile Gly Ile Leu Leu Ala Ser Ser Lys His Ala Leu Val Ile 1 5
10 15 Thr Leu Leu Leu Asn Pro Val Phe His Ala Ser Ser Cys Val Ser
Arg 20
25 30 Xaa Ala Ile Arg Asn Lys Ile Cys Cys Ser Ala Leu Ala Lys Phe
Ala 35 40 45 Lys Leu Phe Ile Val Ser Leu Gly Ala Ala Cys Leu Ala
Ala Phe Ala 50 55 60 Phe Asp Asn Ala Pro Thr Gly Ala Ser Gln Ala
Leu Pro Thr Val Thr 65 70 75 80 Ala Pro Val Ala Ile Pro Ala Pro Ala
Ser Ala Ala 85 90 37 312 DNA Neisseria meningitidis 37 atggcttgta
caggtttgat ggtttttccg ttaatggtta tcggaatatt acttgcatca 60
agcaagcctg ctcctttcct tactctattg ttaaatcccg tcttccatgc atccagttgc
120 gtatcgcgtt gggcaatacg gaataaaatc tgctgttctg ctttggctaa
atttgccaaa 180 ttgtttattg tttctttagg agcagcttgc ttagccgcct
tcgctttcga caacgccccc 240 acaggcgctt cccaagcgtt gcctaccgtt
accgcacccg tggcgattcc cgcgcccgct 300 tcggcagcct ga 312 38 103 PRT
Neisseria meningitidis 38 Met Ala Cys Thr Gly Leu Met Val Phe Pro
Leu Met Val Ile Gly Ile 1 5 10 15 Leu Leu Ala Ser Ser Lys Pro Ala
Pro Phe Leu Thr Leu Leu Leu Asn 20 25 30 Pro Val Phe His Ala Ser
Ser Cys Val Ser Arg Trp Ala Ile Arg Asn 35 40 45 Lys Ile Cys Cys
Ser Ala Leu Ala Lys Phe Ala Lys Leu Phe Ile Val 50 55 60 Ser Leu
Gly Ala Ala Cys Leu Ala Ala Phe Ala Phe Asp Asn Ala Pro 65 70 75 80
Thr Gly Ala Ser Gln Ala Leu Pro Thr Val Thr Ala Pro Val Ala Ile 85
90 95 Pro Ala Pro Ala Ser Ala Ala 100 39 255 DNA Neisseria
meningitidis 39 atgttcagta ttttaaatgt gtttcttcat tgtattctgg
cttgtgtagt ctctggtgag 60 acgcctacta tatttggtat ccttgctctt
ttttacttat tgtatctttc ttatcttgct 120 gtttttaaga ttttcttttc
ttttttctta gacagagttt cactccggtc tcccaggctg 180 gagtgcaaat
ggcatgaccc tttggctcac tggctcacgg ccacttctgc tattctgccg 240
cctcagcctc caggg 255 40 85 PRT Neisseria meningitidis 40 Met Phe
Ser Ile Leu Asn Val Phe Leu His Cys Ile Leu Ala Cys Val 1 5 10 15
Val Ser Gly Glu Thr Pro Thr Ile Phe Gly Ile Leu Ala Leu Phe Tyr 20
25 30 Leu Leu Tyr Leu Ser Tyr Leu Ala Val Phe Lys Ile Phe Phe Ser
Phe 35 40 45 Phe Leu Asp Arg Val Ser Leu Arg Ser Pro Arg Leu Glu
Cys Lys Trp 50 55 60 His Asp Pro Leu Ala His Trp Leu Thr Ala Thr
Ser Ala Ile Leu Pro 65 70 75 80 Pro Gln Pro Pro Gly 85 41 237 DNA
Neisseria meningitidis 41 gtgcggacgt ggttggtttt ttggttgcag
cgtttgaaat acccgttgtt gctttggatt 60 gcggatatgt tgctgtaccg
gttgttgggc ggcgcggaaa tcgaatgcgg ccgttgccct 120 gtgccgccga
tgacggattg gcagcatttt ttgccggcga tgggaacggt gtcggcttgg 180
gtggcggtga tttgggcata cctgatgatt gaaagtgaaa aaaacggaag atattga 237
42 78 PRT Neisseria meningitidis 42 Val Arg Thr Trp Leu Val Phe Trp
Leu Gln Arg Leu Lys Tyr Pro Leu 1 5 10 15 Leu Leu Trp Ile Ala Asp
Met Leu Leu Tyr Arg Leu Leu Gly Gly Ala 20 25 30 Glu Ile Glu Cys
Gly Arg Cys Pro Val Pro Pro Met Thr Asp Trp Gln 35 40 45 His Phe
Leu Pro Ala Met Gly Thr Val Ser Ala Trp Val Ala Val Ile 50 55 60
Trp Ala Tyr Leu Met Ile Glu Ser Glu Lys Asn Gly Arg Tyr 65 70 75 43
237 DNA Neisseria meningitidis 43 gtgcggacgt ggttggtttt ttggttgcag
cgtttgaaat acccgttgtt gctttgtatt 60 gcggatatgc tgctgtaccg
gttgttgggc ggcgcggaaa tcgaatgcgg ccgttgccct 120 gtaccgccga
tgacggattg gcagcatttt ttgccgacga tgggaacggt ggcggcttgg 180
gtggcggtga tttgggcata cctgatgatt gaaagtgaaa aaaacggaag atattga 237
44 78 PRT Neisseria meningitidis 44 Val Arg Thr Trp Leu Val Phe Trp
Leu Gln Arg Leu Lys Tyr Pro Leu 1 5 10 15 Leu Leu Cys Ile Ala Asp
Met Leu Leu Tyr Arg Leu Leu Gly Gly Ala 20 25 30 Glu Ile Glu Cys
Gly Arg Cys Pro Val Pro Pro Met Thr Asp Trp Gln 35 40 45 His Phe
Leu Pro Thr Met Gly Thr Val Ala Ala Trp Val Ala Val Ile 50 55 60
Trp Ala Tyr Leu Met Ile Glu Ser Glu Lys Asn Gly Arg Tyr 65 70 75 45
660 DNA Neisseria meningitidis 45 atgtttcaaa attttgattt gggcgtgttc
ctgcttgccg tcctccccgt gctgccctcc 60 attaccgtct cgcacgtggc
gcgcggctat acggcgcgct actggggaga caacactgcc 120 gaacaatacg
gcaggctgac actgaacccc ctgccccata tcgatttggt cggcacaatc 180
atcgtaccgc tgcttacttt gatgttcacg cccttcctgt tcggctgggc gcgtccgatt
240 cctatcgatt cgcgcaactt ccgcaacccg cgccttgcct ggcgttgcgt
tgccgcgtcc 300 ggcccgctgt cgaatctagc gatggctgtw ctgtggggcg
tggttttggt gctgactccg 360 tatgtcggcg gggcgtatca gatgccgttg
gctcaaatgg caaactacgg tattctgatc 420 aatgcgattc tgttcgcgct
caacatcatc cccatcctgc cttgggacgg cggcattttc 480 atcgacacct
tcctgtcggc gaaatattcg caagcgttcc gcaaaatcga accttatggg 540
acgtggatta tcctactgct gatgctgacc sgggttttgg gtgcgtttat wgcaccgatt
600 stgcggmtgc gtgattgcrt ttgtgcagat gtwcgtctga ctggctttca
gacggcataa 660 46 219 PRT Neisseria meningitidis SITE (191) unknown
46 Met Phe Gln Asn Phe Asp Leu Gly Val Phe Leu Leu Ala Val Leu Pro
1 5 10 15 Val Leu Pro Ser Ile Thr Val Ser His Val Ala Arg Gly Tyr
Thr Ala 20 25 30 Arg Tyr Trp Gly Asp Asn Thr Ala Glu Gln Tyr Gly
Arg Leu Thr Leu 35 40 45 Asn Pro Leu Pro His Ile Asp Leu Val Gly
Thr Ile Ile Val Pro Leu 50 55 60 Leu Thr Leu Met Phe Thr Pro Phe
Leu Phe Gly Trp Ala Arg Pro Ile 65 70 75 80 Pro Ile Asp Ser Arg Asn
Phe Arg Asn Pro Arg Leu Ala Trp Arg Cys 85 90 95 Val Ala Ala Ser
Gly Pro Leu Ser Asn Leu Ala Met Ala Val Leu Trp 100 105 110 Gly Val
Val Leu Val Leu Thr Pro Tyr Val Gly Gly Ala Tyr Gln Met 115 120 125
Pro Leu Ala Gln Met Ala Asn Tyr Gly Ile Leu Ile Asn Ala Ile Leu 130
135 140 Phe Ala Leu Asn Ile Ile Pro Ile Leu Pro Trp Asp Gly Gly Ile
Phe 145 150 155 160 Ile Asp Thr Phe Leu Ser Ala Lys Tyr Ser Gln Ala
Phe Arg Lys Ile 165 170 175 Glu Pro Tyr Gly Thr Trp Ile Ile Leu Leu
Leu Met Leu Thr Xaa Val 180 185 190 Leu Gly Ala Phe Ile Ala Pro Ile
Xaa Arg Xaa Arg Asp Cys Xaa Cys 195 200 205 Ala Asp Val Arg Leu Thr
Gly Phe Gln Thr Ala 210 215 47 639 DNA Neisseria meningitidis 47
atgtttcaaa attttgattt gggcgtgttt ctgcttgccg tcctgcccgt gctgctctcc
60 attaccgtca gggaggtggc gcgcggctat acggcgcgct actggggaga
caacactgcc 120 gaacaatacg gcaggctgac actgaacccc ctgccccata
tcgatttggt cggcacaatc 180 atcgtaccgc tgcttacttt gatgttcacg
cccttcctgt tcggctgggc gcgtccgatt 240 cctatcgatt cgcgcaactt
ccgcaacccg cgccttgcct ggcgttgcgt tgccgcgtcc 300 ggcccgctgt
cgaatctagc gatggctgtt ctgtggggcg tggttttggt gctgactccg 360
tatgtcggcg gggcgtatca gatgccgttg gctcaaatgg caaactacgg tattctgatc
420 aatgcgattc tgttcgcgct caacatcatc cccatcctgc cttgggacgg
cggcattttc 480 atcgacacct tcctgtcggc gaaatattcg caagcgttcc
gcaaaatcga accttatggg 540 acgtggatta tcctactgct gatgctgacc
ggggttttgg gtgcgtttat tgcaccgatt 600 gtgcggctgg tgattgcgtt
tgtgcagatg ttcgtctga 639 48 212 PRT Neisseria meningitidis 48 Met
Phe Gln Asn Phe Asp Leu Gly Val Phe Leu Leu Ala Val Leu Pro 1 5 10
15 Val Leu Leu Ser Ile Thr Val Arg Glu Val Ala Arg Gly Tyr Thr Ala
20 25 30 Arg Tyr Trp Gly Asp Asn Thr Ala Glu Gln Tyr Gly Arg Leu
Thr Leu 35 40 45 Asn Pro Leu Pro His Ile Asp Leu Val Gly Thr Ile
Ile Val Pro Leu 50 55 60 Leu Thr Leu Met Phe Thr Pro Phe Leu Phe
Gly Trp Ala Arg Pro Ile 65 70 75 80 Pro Ile Asp Ser Arg Asn Phe Arg
Asn Pro Arg Leu Ala Trp Arg Cys 85 90 95 Val Ala Ala Ser Gly Pro
Leu Ser Asn Leu Ala Met Ala Val Leu Trp 100 105 110 Gly Val Val Leu
Val Leu Thr Pro Tyr Val Gly Gly Ala Tyr Gln Met 115 120 125 Pro Leu
Ala Gln Met Ala Asn Tyr Gly Ile Leu Ile Asn Ala Ile Leu 130 135 140
Phe Ala Leu Asn Ile Ile Pro Ile Leu Pro Trp Asp Gly Gly Ile Phe 145
150 155 160 Ile Asp Thr Phe Leu Ser Ala Lys Tyr Ser Gln Ala Phe Arg
Lys Ile 165 170 175 Glu Pro Tyr Gly Thr Trp Ile Ile Leu Leu Leu Met
Leu Thr Gly Val 180 185 190 Leu Gly Ala Phe Ile Ala Pro Ile Val Arg
Leu Val Ile Ala Phe Val 195 200 205 Gln Met Phe Val 210 49 558 DNA
Neisseria meningitidis misc_feature (312) any nucleotide 49
cgcggctata cagcgcgcta ctggggtgac aacactgccg aacaatacgg caggctgaca
60 ctgaaccccc tgccccatat cgatttggtc ggcacaatca tcgtaccgct
gcttactttg 120 atgtttacgc ccttcctgtt cggctgggcg cgtccgattc
ctatcgattc gcgcaacttc 180 cgcaacccgc gccttgcctg gcgttgcgtt
gccgcgtccg gcccgctgtc gaatctggcg 240 atggctgttc tgtggggcgt
ggttttggtg ctgactccgt atgtcggtgg ggcgtatcag 300 atgccgttgg
cncaaatggc aaactacnnn attctgatca atgcgattct gtncgcgctc 360
aacatcatcc ccatcctgcc ttgggacggc ggcattttca tcgacacctt cctgtcggcn
420 aaatantcgc aagcgttccg caaaatcgaa ccttatggga cgtggattat
ccngctgctt 480 atgctgaccg gggttttggg tgcgtntatt gcaccgattg
tgcagctggt gattgcgttt 540 gtgcagatgt tcgtctga 558 50 185 PRT
Neisseria meningitidis SITE (110) unknown 50 Arg Gly Tyr Thr Ala
Arg Tyr Trp Gly Asp Asn Thr Ala Glu Gln Tyr 1 5 10 15 Gly Arg Leu
Thr Leu Asn Pro Leu Pro His Ile Asp Leu Val Gly Thr 20 25 30 Ile
Ile Val Pro Leu Leu Thr Leu Met Phe Thr Pro Phe Leu Phe Gly 35 40
45 Trp Ala Arg Pro Ile Pro Ile Asp Ser Arg Asn Phe Arg Asn Pro Arg
50 55 60 Leu Ala Trp Arg Cys Val Ala Ala Ser Gly Pro Leu Ser Asn
Leu Ala 65 70 75 80 Met Ala Val Leu Trp Gly Val Val Leu Val Leu Thr
Pro Tyr Val Gly 85 90 95 Gly Ala Tyr Gln Met Pro Leu Ala Gln Met
Ala Asn Tyr Xaa Ile Leu 100 105 110 Ile Asn Ala Ile Leu Xaa Ala Leu
Asn Ile Ile Pro Ile Leu Pro Trp 115 120 125 Asp Gly Gly Ile Phe Ile
Asp Thr Phe Leu Ser Ala Lys Xaa Ser Gln 130 135 140 Ala Phe Arg Lys
Ile Glu Pro Tyr Gly Thr Trp Ile Ile Xaa Leu Leu 145 150 155 160 Met
Leu Thr Gly Val Leu Gly Ala Xaa Ile Ala Pro Ile Val Gln Leu 165 170
175 Val Ile Ala Phe Val Gln Met Phe Val 180 185 51 498 DNA
Neisseria meningitidis 51 atgaacctga tttcacgtta catcatccgt
caaatggcgg ttatggcggt ttacgcgctc 60 cttgccttcc tcgctttgta
cagctttttt gaaatcctgt acgaaaccgg caacctcggc 120 aaaggcagtt
acggcatatg ggaaatgctg ggctacaccg ccctcaaaat gcccgcccgc 180
gcctacgaac tgattcccct cgccgtcctt atcggcggac tggtctccct cagccagctt
240 gccgccggca gcgaactgac cgtcatcaaa gccagcggca tgagcaccaa
aaagctgctg 300 ttgattctgt cgcagttcgg ttttattttt gctattgcca
ccgtcgcgct cggcgaatgg 360 gttgcgccca cactgagcca aaaagccgaa
aacatcaaag ccgccgccat caacggcaaa 420 atcagcaccg gcaataccgg
cctttggctg aaagaaaaaa acagcgtgat caatgtgcgc 480 gaaatgttgc ccgaccat
498 52 166 PRT Neisseria meningitidis 52 Met Asn Leu Ile Ser Arg
Tyr Ile Ile Arg Gln Met Ala Val Met Ala 1 5 10 15 Val Tyr Ala Leu
Leu Ala Phe Leu Ala Leu Tyr Ser Phe Phe Glu Ile 20 25 30 Leu Tyr
Glu Thr Gly Asn Leu Gly Lys Gly Ser Tyr Gly Ile Trp Glu 35 40 45
Met Leu Gly Tyr Thr Ala Leu Lys Met Pro Ala Arg Ala Tyr Glu Leu 50
55 60 Ile Pro Leu Ala Val Leu Ile Gly Gly Leu Val Ser Leu Ser Gln
Leu 65 70 75 80 Ala Ala Gly Ser Glu Leu Thr Val Ile Lys Ala Ser Gly
Met Ser Thr 85 90 95 Lys Lys Leu Leu Leu Ile Leu Ser Gln Phe Gly
Phe Ile Phe Ala Ile 100 105 110 Ala Thr Val Ala Leu Gly Glu Trp Val
Ala Pro Thr Leu Ser Gln Lys 115 120 125 Ala Glu Asn Ile Lys Ala Ala
Ala Ile Asn Gly Lys Ile Ser Thr Gly 130 135 140 Asn Thr Gly Leu Trp
Leu Lys Glu Lys Asn Ser Val Ile Asn Val Arg 145 150 155 160 Glu Met
Leu Pro Asp His 165 53 980 DNA Neisseria meningitidis 53 atgaacctga
tttcacgtta catcatccgt caaatggcgg ttatggcggt ttacgcgctc 60
cttgccttcc tcgctttgta cagctttttt gaaatcctgt acgaaaccgg caacctcggc
120 aaaggcagtt acggcatatg ggaaatgctg ggctacaccg ccctcaaaat
gcccgcccgc 180 gcctacgaac tgattcccct cgccgtcctt atcggcggac
tggtctccct cagccagctt 240 gccgccggca gcgaactgac cgtcatcaaa
gccagcggca tgagcaccaa aaagctgctg 300 ttgattctgt cgcagttcgg
ttttattttt gctattgcca ccgtcgcgct cggcgaatgg 360 gttgcgccca
cactgagcca aaaagccgaa aacatcaaag ccgccgccat caacggcaaa 420
atcagcaccg gcaataccgg cctttggctg aaagaaaaaa acagcrtkat caatgtgcgc
480 gaaatgttgc ccgaccatac gcttttgggc atcaaaattt gggcgcgcaa
cgataaaaac 540 gaattggcag aggcagtgga agccgattcc gccgttttga
acagcgacgg cagttggcag 600 ttgaaaaaca tccgccgcag cacgcttggc
gaagacaaag tcgaggtctc tattgcggct 660 gaagaaaact ggccgatttc
cgtcaaacgc aacctgatgg acgtattgct cgtcaaaccc 720 gaccaaatgt
ccgtcggcga actgaccacc tacatccgcc acctccaaaa caacagccaa 780
aacacccgaa tctacgccat cgcatggtgg cgcaaattgg tttaccccgc cgcagcctgg
840 gtgatggcgc tcgtcgcctt tgcctttacc ccgcaaacca cccgccacgg
caatatgggc 900 ttaaaactct tcggcggcat ctgtstcgga ttgctgttcc
accttgccgg acggctcttt 960 gggtttacca gccaactcgg 980 54 326 PRT
Neisseria meningitidis SITE (156) unknown 54 Met Asn Leu Ile Ser
Arg Tyr Ile Ile Arg Gln Met Ala Val Met Ala 1 5 10 15 Val Tyr Ala
Leu Leu Ala Phe Leu Ala Leu Tyr Ser Phe Phe Glu Ile 20 25 30 Leu
Tyr Glu Thr Gly Asn Leu Gly Lys Gly Ser Tyr Gly Ile Trp Glu 35 40
45 Met Leu Gly Tyr Thr Ala Leu Lys Met Pro Ala Arg Ala Tyr Glu Leu
50 55 60 Ile Pro Leu Ala Val Leu Ile Gly Gly Leu Val Ser Leu Ser
Gln Leu 65 70 75 80 Ala Ala Gly Ser Glu Leu Thr Val Ile Lys Ala Ser
Gly Met Ser Thr 85 90 95 Lys Lys Leu Leu Leu Ile Leu Ser Gln Phe
Gly Phe Ile Phe Ala Ile 100 105 110 Ala Thr Val Ala Leu Gly Glu Trp
Val Ala Pro Thr Leu Ser Gln Lys 115 120 125 Ala Glu Asn Ile Lys Ala
Ala Ala Ile Asn Gly Lys Ile Ser Thr Gly 130 135 140 Asn Thr Gly Leu
Trp Leu Lys Glu Lys Asn Ser Xaa Ile Asn Val Arg 145 150 155 160 Glu
Met Leu Pro Asp His Thr Leu Leu Gly Ile Lys Ile Trp Ala Arg 165 170
175 Asn Asp Lys Asn Glu Leu Ala Glu Ala Val Glu Ala Asp Ser Ala Val
180 185 190 Leu Asn Ser Asp Gly Ser Trp Gln Leu Lys Asn Ile Arg Arg
Ser Thr 195 200 205 Leu Gly Glu Asp Lys Val Glu Val Ser Ile Ala Ala
Glu Glu Asn Trp 210 215 220 Pro Ile Ser Val Lys Arg Asn Leu Met Asp
Val Leu Leu Val Lys Pro 225 230 235 240 Asp Gln Met Ser Val Gly Glu
Leu Thr Thr Tyr Ile Arg His Leu Gln 245 250 255 Asn Asn Ser Gln Asn
Thr Arg Ile Tyr Ala Ile Ala Trp Trp Arg Lys 260 265 270 Leu Val Tyr
Pro Ala Ala Ala Trp Val Met Ala Leu Val Ala Phe Ala 275 280 285 Phe
Thr Pro Gln Thr Thr Arg His Gly Asn Met Gly Leu Lys Leu Phe 290 295
300 Gly Gly Ile Cys Xaa Gly Leu Leu Phe His Leu Ala Gly Arg Leu Phe
305 310 315 320 Gly Phe Thr Ser Gln Leu 325 55 1071 DNA Neisseria
meningitidis misc_feature (148) any nucleotide 55 atgaacctga
tttcacgtta catcatccgt caaatggcgg ttatggcggt ttacgcgctc 60
cttgccttcc tcgctttgta cagctttttt gaaatcctgt acgaaaccgg caacctcggc
120 aaaggcagtt acggcatatg ggaaatgntg ggntacaccg ccctcaaaat
gnccgcccgc 180 gcctacgaac tgatgcccct cgccgtcctt atcggcggac
tggtctctnt cagccagctt 240 gccgccggca gcgaactgan cgtcatcaaa
gccagcggca tgagcaccaa aaagctgctg 300 ttgattctgt cgcagttcgg
ttttattttt gctattgcca ccgtcgcgct cggcgaatgg 360 gttgcgccca
cactgagcca aaaagccgaa aacatcaaag ccgcggccat caacggcaaa 420
atcagtaccg gcaataccgg cctttggctg
aaagaaaaaa acagcattat caatgtgcgc 480 gaaatgttgc ccgaccatac
cctgctgggc attaaaatct gggcccgcaa cgataaaaac 540 gaactggcag
aggcagtgga agccgattcc gccgttttga acagcgacgg cagttggcag 600
ttgaaaaaca tccgccgcag cacgcttggc gaagacaaag tcgaggtctc tattgcggct
660 gaagaaaant ggccgatttc cgtcaaacgc aacctgatgg acgtattgct
cgtcaaaccc 720 gaccaaatgt ccgtcggcga actgaccacc tacatccgcc
acctccaaan nnacagccaa 780 aacacccgaa tctacgccat cgcatggtgg
cgcaaattgg tttaccccgc cgcagcctgg 840 gtgatggcgc tcgtcgcctt
tgcctttacc ccgcaaacca cccgccacgg caatatgggc 900 ttaaaantct
tcggcggcat ctgtctcgga ttgctgttcc accttgccgg ncggctcttc 960
nggtttacca gccaactcta cggcatcccg cccttcctcg ncggcgcact acctaccata
1020 gccttcgcct tgctcgccgt ttggctgata cgcaaacagg aaaaacgcta a 1071
56 356 PRT Neisseria meningitidis SITE (50) unknown 56 Met Asn Leu
Ile Ser Arg Tyr Ile Ile Arg Gln Met Ala Val Met Ala 1 5 10 15 Val
Tyr Ala Leu Leu Ala Phe Leu Ala Leu Tyr Ser Phe Phe Glu Ile 20 25
30 Leu Tyr Glu Thr Gly Asn Leu Gly Lys Gly Ser Tyr Gly Ile Trp Glu
35 40 45 Met Xaa Gly Tyr Thr Ala Leu Lys Met Xaa Ala Arg Ala Tyr
Glu Leu 50 55 60 Met Pro Leu Ala Val Leu Ile Gly Gly Leu Val Ser
Xaa Ser Gln Leu 65 70 75 80 Ala Ala Gly Ser Glu Leu Xaa Val Ile Lys
Ala Ser Gly Met Ser Thr 85 90 95 Lys Lys Leu Leu Leu Ile Leu Ser
Gln Phe Gly Phe Ile Phe Ala Ile 100 105 110 Ala Thr Val Ala Leu Gly
Glu Trp Val Ala Pro Thr Leu Ser Gln Lys 115 120 125 Ala Glu Asn Ile
Lys Ala Ala Ala Ile Asn Gly Lys Ile Ser Thr Gly 130 135 140 Asn Thr
Gly Leu Trp Leu Lys Glu Lys Asn Ser Ile Ile Asn Val Arg 145 150 155
160 Glu Met Leu Pro Asp His Thr Leu Leu Gly Ile Lys Ile Trp Ala Arg
165 170 175 Asn Asp Lys Asn Glu Leu Ala Glu Ala Val Glu Ala Asp Ser
Ala Val 180 185 190 Leu Asn Ser Asp Gly Ser Trp Gln Leu Lys Asn Ile
Arg Arg Ser Thr 195 200 205 Leu Gly Glu Asp Lys Val Glu Val Ser Ile
Ala Ala Glu Glu Xaa Trp 210 215 220 Pro Ile Ser Val Lys Arg Asn Leu
Met Asp Val Leu Leu Val Lys Pro 225 230 235 240 Asp Gln Met Ser Val
Gly Glu Leu Thr Thr Tyr Ile Arg His Leu Gln 245 250 255 Xaa Xaa Ser
Gln Asn Thr Arg Ile Tyr Ala Ile Ala Trp Trp Arg Lys 260 265 270 Leu
Val Tyr Pro Ala Ala Ala Trp Val Met Ala Leu Val Ala Phe Ala 275 280
285 Phe Thr Pro Gln Thr Thr Arg His Gly Asn Met Gly Leu Lys Xaa Phe
290 295 300 Gly Gly Ile Cys Leu Gly Leu Leu Phe His Leu Ala Gly Arg
Leu Phe 305 310 315 320 Xaa Phe Thr Ser Gln Leu Tyr Gly Ile Pro Pro
Phe Leu Xaa Gly Ala 325 330 335 Leu Pro Thr Ile Ala Phe Ala Leu Leu
Ala Val Trp Leu Ile Arg Lys 340 345 350 Gln Glu Lys Arg 355 57 854
DNA Neisseria meningitidis 57 gcagtagccg aaactgccaa cagccagggc
aaaggtaaac aggcaggcag ttcggtttct 60 gtttcactga aaacttcagg
cgacctttgc ggcaaactca aaaccaccct taaaactttg 120 gtctgctctt
tggtttccct gagtatggta ttgcctgccc atgcccaaat taccaccgac 180
aaatcagcac ctaaaaacca gcaggtcgtt atccttaaaa ccaacactgg tgcccccttg
240 gtgaatatcc aaactccgaa tggacgcgga ttgagccaca accgctatac
gcatttgatg 300 ttgacaacaa aggggcagtg ttaaacaacg accgtaacaa
taatccgttt gtggtcaaag 360 gcagtgcgca attgattttg aacgaggtac
gcggtacggc tagcaaactc aacggcatcg 420 ttaccgtagg cggtcaaaag
gccgacgtga ttattgccaa ccccaacggc attaccgtta 480 atggcggcgg
ctttaaaaat gtcggtcggg gcatcttaac taccggtgcg ccccaaatcg 540
gcaaagacgg tgcactgaca ggatttgatg tgcgtcaagg cacattggac cgtagragca
600 gcaggttgga atgataaagg cggagcmrmy tacaccgggg tacttgctcg
tgcagttgct 660 ttgcagggga aattwmmggg taaaaactgg cggtttctac
cggtcctcag aaagtagatt 720 acgccagcgg cgaaatcagt gcaggtacgg
cagcgggtac gaaaccgact attgcccttg 780 atactgccgc actgggcggt
atgtacgccg acagcatcac actgattgcc aatgaaaaag 840 gcgtaggcgt ctaa 854
58 284 PRT Neisseria meningitidis SITE (96) unknown 58 Ala Val Ala
Glu Thr Ala Asn Ser Gln Gly Lys Gly Lys Gln Ala Gly 1 5 10 15 Ser
Ser Val Ser Val Ser Leu Lys Thr Ser Gly Asp Leu Cys Gly Lys 20 25
30 Leu Lys Thr Thr Leu Lys Thr Leu Val Cys Ser Leu Val Ser Leu Ser
35 40 45 Met Val Leu Pro Ala His Ala Gln Ile Thr Thr Asp Lys Ser
Ala Pro 50 55 60 Lys Asn Gln Gln Val Val Ile Leu Lys Thr Asn Thr
Gly Ala Pro Leu 65 70 75 80 Val Asn Ile Gln Thr Pro Asn Gly Arg Gly
Leu Ser His Asn Arg Xaa 85 90 95 Tyr Ala Phe Asp Val Asp Asn Lys
Gly Ala Val Leu Asn Asn Asp Arg 100 105 110 Asn Asn Asn Pro Phe Val
Val Lys Gly Ser Ala Gln Leu Ile Leu Asn 115 120 125 Glu Val Arg Gly
Thr Ala Ser Lys Leu Asn Gly Ile Val Thr Val Gly 130 135 140 Gly Gln
Lys Ala Asp Val Ile Ile Ala Asn Pro Asn Gly Ile Thr Val 145 150 155
160 Asn Gly Gly Gly Phe Lys Asn Val Gly Arg Gly Ile Leu Thr Thr Gly
165 170 175 Ala Pro Gln Ile Gly Lys Asp Gly Ala Leu Thr Gly Phe Asp
Val Val 180 185 190 Lys Ala His Trp Thr Val Xaa Ala Ala Gly Trp Asn
Asp Lys Gly Gly 195 200 205 Ala Xaa Tyr Thr Gly Val Leu Ala Arg Ala
Val Ala Leu Gln Gly Lys 210 215 220 Xaa Xaa Gly Lys Xaa Leu Ala Val
Ser Thr Gly Pro Gln Lys Val Asp 225 230 235 240 Tyr Ala Ser Gly Glu
Ile Ser Ala Gly Thr Ala Ala Gly Thr Lys Pro 245 250 255 Thr Ile Ala
Leu Asp Thr Ala Ala Leu Gly Gly Met Tyr Ala Asp Ser 260 265 270 Ile
Thr Leu Ile Ala Asn Glu Lys Gly Val Gly Val 275 280 59 5937 DNA
Neisseria meningitidis 59 atgaataaag gtttacatcg cattatcttt
agtaaaaagc acagcaccat ggttgcagta 60 gccgaaactg ccaacagcca
gggcaaaggt aaacaggcag gcagttcggt ttctgtttca 120 ctgaaaactt
caggcgacct ttgcggcaaa ctcaaaacca cccttaaaac tttggtctgc 180
tctttggttt ccctgagtat ggtattgcct gcccatgccc aaattaccac cgacaaatca
240 gcacctaaaa accagcaggt cgttatcctt aaaaccaaca ctggtgcccc
cttggtgaat 300 atccaaactc cgaatggacg cggattgagc cacaaccgct
atacgcagtt tgatgttgac 360 aacaaagggg cagtgttaaa caacgaccgt
aacaataatc cgtttgtggt caaaggcagt 420 gcgcaattga ttttgaacga
ggtacgcggt acggctagca aactcaacgg catcgttacc 480 gtaggcggtc
aaaaggccga cgtgattatt gccaacccca acggcattac cgttaatggc 540
ggcggcttta aaaatgtcgg tcggggcatc ttaactaccg gtgcgcccca aatcggcaaa
600 gacggtgcac tgacaggatt tgatgtgcgt caaggcacat tgaccgtagg
agcagcaggt 660 tggaatgata aaggcggagc cgactacacc ggggtacttg
ctcgtgcagt tgctttgcag 720 gggaaattac agggtaaaaa cctggcggtt
tctaccggtc ctcagaaagt agattacgcc 780 agcggcgaaa tcagtgcagg
tacggcagcg ggtacgaaac cgactattgc ccttgatact 840 gccgcactgg
gcggtatgta cgccgacagc atcacactga ttgccaatga aaaaggcgta 900
ggcgtcaaaa atgccggcac actcgaagcg gccaagcaat tgattgtgac ttcgtcaggc
960 cgcattgaaa acagcggccg catcgccacc actgccgacg gcaccgaagc
ttcaccgact 1020 tatctctcca tcgaaaccac cgaaaaagga gcggcaggca
catttatctc caatggtggt 1080 cggatcgaga gcaaaggctt attggttatt
gagacgggag aagatatcag cttgcgtaac 1140 ggagccgtgg tgcagaataa
cggcagtcgc ccagctacca cggtattaaa tgctggtcat 1200 aatttggtga
ttgagagcaa aactaatgtg aacaatgcca aaggcccggc tactctgtcg 1260
gccgacggcc gtaccgtcat caaggaggcc agtattcaga ctggcactac cgtatacagt
1320 tccagcaaag gcaacgccga attaggcaat aacacacgca ttaccggggc
agatgttacc 1380 gtattatcca acggcaccat cagcagttcc gccgtaatag
atgccaaaga caccgcacac 1440 atcgaagcag gcaaaccgct ttctttggaa
gcttcaacag ttacctccga tatccgctta 1500 aacggaggca gtatcaaggg
cggcaagcag cttgctttac tggcagacga taacattact 1560 gccaaaacta
ccaatctgaa tactcccggc aatctgtatg ttcatacagg taaagatctg 1620
aatttgaatg ttgataaaga tttgtctgcc gccagcatcc atttgaaatc ggataacgct
1680 gcccatatta ccggcaccag taaaaccctc actgcctcaa aagacatggg
tgtggaggca 1740 ggctcgctga atgttaccaa taccaatctg cgtaccaact
cgggtaatct gcacattcag 1800 gcagccaaag gcaatattca gcttcgcaat
accaagctga acgcagccaa ggctctcgaa 1860 accaccgcat tgcagggcaa
tatcgtttca gacggccttc atgctgtttc tgcagacggt 1920 catgtatcct
tattggccaa cggtaatgcc gactttaccg gtcacaatac cctgacagcc 1980
aaggccgatg tcaatgcagg atcggttggt aaaggccgtc tgaaagcaga caataccaat
2040 atcacttcat cttcaggaga tattacgttg gttgccggca acggtattca
gcttggtgac 2100 ggaaaacaac gcaattcaat caacggaaaa cacatcagca
tcaaaaacaa cggtggtaat 2160 gccgacttaa aaaaccttaa cgtccatgcc
aaaagcgggg cattgaacat tcattccgac 2220 cgggcattga gcatagaaaa
taccaagctg gagtctaccc ataatacgca tcttaatgca 2280 caacacgagc
gggtaacgct caaccaagta gatgcctacg cacaccgtca tctaagcatt 2340
accggcagcc agatttggca aaacgacaaa ctgccttctg ccaacaagct ggtggctaac
2400 ggtgtattgg cactcaatgc gcgctattcc caaattgccg acaacaccac
gctgagagcg 2460 ggtgcaatca accttactgc cggtaccgcc ctagtcaagc
gcggcaacat caattggagt 2520 accgtttcga ccaaaacttt ggaagataat
gccgaattaa aaccattggc cggacggctg 2580 aatattgaag caggtagcgg
cacattaacc atcgaacctg ccaaccgcat cagtgcgcat 2640 accgacctga
gcatcaaaac aggcggaaaa ttgctgttgt ctgcaaaagg aggaaatgca 2700
ggtgcgccta gtgctcaagt ttcctcattg gaagcaaaag gcaatatccg tctggttaca
2760 ggagaaacag atttaagagg ttctaaaatt acagccggta aaaacttggt
tgtcgccacc 2820 accaaaggca agttgaatat cgaagccgta aacaactcat
tcagcaatta ttttcctaca 2880 caaaaagcgg ctgaactcaa ccaaaaatcc
aaagaattgg aacagcagat tgcgcagttg 2940 aaaaaaagct cgcctaaaag
caagctgatt ccaaccctgc aagaagaacg cgaccgtctc 3000 gctttctata
ttcaagccat caacaaggaa gttaaaggta aaaaacccaa aggcaaagaa 3060
tacctgcaag ccaagctttc tgcacaaaat attgacttga tttccgcaca aggcatcgaa
3120 atcagcggtt ccgatattac cgcttccaaa aaactgaacc ttcacgccgc
aggcgtattg 3180 ccaaaggcag cagattcaga ggcggctgct attctgattg
acggcataac cgaccaatat 3240 gaaattggca agcccaccta caagagtcac
tacgacaaag ctgctctgaa caagccttca 3300 cgtttgaccg gacgtacagg
ggtaagtatt catgcagctg cggcactcga tgatgcacgt 3360 attattatcg
gtgcatccga aatcaaagct ccctcaggca gcatagacat caaagcccat 3420
agtgatattg tactggaggc tggacaaaac gatgcctata ccttcttaaa aaccaaaggt
3480 aaaagcggca aaatcatcag aaaaaccaag tttaccagca cccgcgacca
cctgattatg 3540 ccagcccccg tcgagctgac cgccaacggc ataacgcttc
aggcaggcgg caacatcgaa 3600 gctaatacca cccgcttcaa tgcccctgca
ggtaaagtta ccctggttgc gggtgaagag 3660 ctgcaactgc tggcagaaga
aggcatccac aagcacgagt tggatgtcca aaaaagccgc 3720 cgctttatcg
gcatcaaggt aggcaagagc aattacagta aaaacgaact gaacgaaacc 3780
aaattgcctg tccgcgtcgt cgcccaaact gcagccaccc gttcaggctg ggataccgtg
3840 ctcgaaggta ccgaattcaa aaccacgctg gccggtgcgg acattcaggc
aggtgtaggc 3900 gaaaaagccc gtgccgatgc gaaaattatc ctcaaaggca
ttgtgaaccg tatccagtcg 3960 gaagaaaaat tagaaaccaa ctcaaccgta
tggcagaaac aggccggacg cggcagcact 4020 atcgaaacgc tgaaactgcc
cagcttcgaa agccctactc cgcccaaact gaccgccccc 4080 ggtggctata
tcgtcgacat tccgaaaggc aatttgaaaa ccgaaatcga aaagctggcc 4140
aaacagcccg agtatgccta tctgaaacag ctccaagtag cgaaaaacgt caactggaac
4200 caggtgcaac tggcttacga taaatgggac tataagcagg aaggcttaac
cagagccggt 4260 gcagcgattg ttaccataat cgtaaccgca ctgacttatg
gatacggcgc aaccgcagcg 4320 ggcggtgtag ccgcttcagg aagtagtaca
gccgcagctg ccggaacagc cgccacaacg 4380 acagcagcag ctactaccgt
ttctacagcg actgccatgc aaaccgctgc tttagcctcc 4440 ttgtatagcc
aagcagctgt atccatcatc aataataaag gtgatgtcgg caaagcgttg 4500
aaagatctcg gcaccagtga tacggtcaag cagattgtca cttctgccct gacggcgggt
4560 gcattaaatc agatgggcgc agatattgcc caattgaaca gcaaggtaag
aaccgaactg 4620 ttcagcagta cgggcaatca aactattgcc aaccttggag
gcagactggc taccaatctc 4680 agtaatgcag gtatctcagc tggtatcaat
accgccgtca acggcggcag cctgaaagac 4740 aacttaggca atgccgcatt
aggagcattg gttaatagct tccaaggaga agccgccagc 4800 aaaatcaaaa
caaccttcag cgacgattat gttgccaaac agttcgccca cgctttggct 4860
gggtgtgtta gcggattggt acaaggaaaa tgtaaagacg gggcaattgg cgcagcagtt
4920 ggggaaatcg tagccgactc catgcttggc ggcagaaacc ctgctacact
cagcgatgcg 4980 gaaaagcata aggttatcag ttactcgaag attattgccg
gcagcgtggc ggcactcaac 5040 ggcggcgatg tgaatactgc ggcgaatgcg
gctgaggtgg cggtagtgaa taatgctttg 5100 aattttgaca gtacccctac
caatgcgaaa aagcatcaac cgcagaagcc cgacaaaacc 5160 gcactggaaa
aaattatcca aggtattatg cctgcacatg cagcaggtgc gatgactaat 5220
ccgcaggata aggatgctgc catttggata agcaatatcc gtaatggcat cacaggcccg
5280 attgtgatta ccagctatgg ggtttatgct gcaggttgga cagctccgct
gatcggtaca 5340 gcgggtaaat tagctatcag cacctgcatg gctaatcctt
ctggttgtac tgtcatggtc 5400 actcaggctg ccgaagcggg cgcgggaatc
gccacgggtg cggtaacggt aggcaacgct 5460 tgggaagcgc ctgtgggggc
gttgtcgaaa gcgaaggcgg ccaagcaggc tataccaacc 5520 cagacagtta
aagaacttga tggcttacta caagaatcaa aaaatatagg tgctgtaaat 5580
acacgaatta atatagcgaa tagtactact cgatatacac caatgagaca aacgggacaa
5640 ccggtatctg ctggctttga gcatgttctt gaggggcact tccataggcc
tattgcgaat 5700 aaccgttcag tttttaccat ctccccaaat gaattgaagg
ttatacttca aagtaataaa 5760 gtagtttctt ctcccgtatc gatgactcct
gatggccaat atatgcggac tgtcgatgta 5820 ggaaaagtta ttggtactac
ttctattaaa gaaggtggac aacccacaac tacaattaaa 5880 gtatttacag
ataagtcagg aaatttgatt actacatacc cagtaaaagg aaactaa 5937 60 1978
PRT Neisseria meningitidis 60 Met Asn Lys Gly Leu His Arg Ile Ile
Phe Ser Lys Lys His Ser Thr 1 5 10 15 Met Val Ala Val Ala Glu Thr
Ala Asn Ser Gln Gly Lys Gly Lys Gln 20 25 30 Ala Gly Ser Ser Val
Ser Val Ser Leu Lys Thr Ser Gly Asp Leu Cys 35 40 45 Gly Lys Leu
Lys Thr Thr Leu Lys Thr Leu Val Cys Ser Leu Val Ser 50 55 60 Leu
Ser Met Val Leu Pro Ala His Ala Gln Ile Thr Thr Asp Lys Ser 65 70
75 80 Ala Pro Lys Asn Gln Gln Val Val Ile Leu Lys Thr Asn Thr Gly
Ala 85 90 95 Pro Leu Val Asn Ile Gln Thr Pro Asn Gly Arg Gly Leu
Ser His Asn 100 105 110 Arg Tyr Thr Gln Phe Asp Val Asp Asn Lys Gly
Ala Val Leu Asn Asn 115 120 125 Asp Arg Asn Asn Asn Pro Phe Val Val
Lys Gly Ser Ala Gln Leu Ile 130 135 140 Leu Asn Glu Val Arg Gly Thr
Ala Ser Lys Leu Asn Gly Ile Val Thr 145 150 155 160 Val Gly Gly Gln
Lys Ala Asp Val Ile Ile Ala Asn Pro Asn Gly Ile 165 170 175 Thr Val
Asn Gly Gly Gly Phe Lys Asn Val Gly Arg Gly Ile Leu Thr 180 185 190
Thr Gly Ala Pro Gln Ile Gly Lys Asp Gly Ala Leu Thr Gly Phe Asp 195
200 205 Val Arg Gln Gly Thr Leu Thr Val Gly Ala Ala Gly Trp Asn Asp
Lys 210 215 220 Gly Gly Ala Asp Tyr Thr Gly Val Leu Ala Arg Ala Val
Ala Leu Gln 225 230 235 240 Gly Lys Leu Gln Gly Lys Asn Leu Ala Val
Ser Thr Gly Pro Gln Lys 245 250 255 Val Asp Tyr Ala Ser Gly Glu Ile
Ser Ala Gly Thr Ala Ala Gly Thr 260 265 270 Lys Pro Thr Ile Ala Leu
Asp Thr Ala Ala Leu Gly Gly Met Tyr Ala 275 280 285 Asp Ser Ile Thr
Leu Ile Ala Asn Glu Lys Gly Val Gly Val Lys Asn 290 295 300 Ala Gly
Thr Leu Glu Ala Ala Lys Gln Leu Ile Val Thr Ser Ser Gly 305 310 315
320 Arg Ile Glu Asn Ser Gly Arg Ile Ala Thr Thr Ala Asp Gly Thr Glu
325 330 335 Ala Ser Pro Thr Tyr Leu Ser Ile Glu Thr Thr Glu Lys Gly
Ala Ala 340 345 350 Gly Thr Phe Ile Ser Asn Gly Gly Arg Ile Glu Ser
Lys Gly Leu Leu 355 360 365 Val Ile Glu Thr Gly Glu Asp Ile Ser Leu
Arg Asn Gly Ala Val Val 370 375 380 Gln Asn Asn Gly Ser Arg Pro Ala
Thr Thr Val Leu Asn Ala Gly His 385 390 395 400 Asn Leu Val Ile Glu
Ser Lys Thr Asn Val Asn Asn Ala Lys Gly Pro 405 410 415 Ala Thr Leu
Ser Ala Asp Gly Arg Thr Val Ile Lys Glu Ala Ser Ile 420 425 430 Gln
Thr Gly Thr Thr Val Tyr Ser Ser Ser Lys Gly Asn Ala Glu Leu 435 440
445 Gly Asn Asn Thr Arg Ile Thr Gly Ala Asp Val Thr Val Leu Ser Asn
450 455 460 Gly Thr Ile Ser Ser Ser Ala Val Ile Asp Ala Lys Asp Thr
Ala His 465 470 475 480 Ile Glu Ala Gly Lys Pro Leu Ser Leu Glu Ala
Ser Thr Val Thr Ser 485 490 495 Asp Ile Arg Leu Asn Gly Gly Ser Ile
Lys Gly Gly Lys Gln Leu Ala 500 505 510 Leu Leu Ala Asp Asp Asn Ile
Thr Ala Lys Thr Thr Asn Leu Asn Thr 515 520 525 Pro Gly Asn Leu Tyr
Val His Thr Gly Lys Asp Leu Asn Leu Asn Val 530 535 540 Asp Lys Asp
Leu Ser Ala Ala Ser Ile His Leu Lys Ser Asp Asn Ala 545 550 555 560
Ala His Ile Thr Gly Thr Ser
Lys Thr Leu Thr Ala Ser Lys Asp Met 565 570 575 Gly Val Glu Ala Gly
Ser Leu Asn Val Thr Asn Thr Asn Leu Arg Thr 580 585 590 Asn Ser Gly
Asn Leu His Ile Gln Ala Ala Lys Gly Asn Ile Gln Leu 595 600 605 Arg
Asn Thr Lys Leu Asn Ala Ala Lys Ala Leu Glu Thr Thr Ala Leu 610 615
620 Gln Gly Asn Ile Val Ser Asp Gly Leu His Ala Val Ser Ala Asp Gly
625 630 635 640 His Val Ser Leu Leu Ala Asn Gly Asn Ala Asp Phe Thr
Gly His Asn 645 650 655 Thr Leu Thr Ala Lys Ala Asp Val Asn Ala Gly
Ser Val Gly Lys Gly 660 665 670 Arg Leu Lys Ala Asp Asn Thr Asn Ile
Thr Ser Ser Ser Gly Asp Ile 675 680 685 Thr Leu Val Ala Gly Asn Gly
Ile Gln Leu Gly Asp Gly Lys Gln Arg 690 695 700 Asn Ser Ile Asn Gly
Lys His Ile Ser Ile Lys Asn Asn Gly Gly Asn 705 710 715 720 Ala Asp
Leu Lys Asn Leu Asn Val His Ala Lys Ser Gly Ala Leu Asn 725 730 735
Ile His Ser Asp Arg Ala Leu Ser Ile Glu Asn Thr Lys Leu Glu Ser 740
745 750 Thr His Asn Thr His Leu Asn Ala Gln His Glu Arg Val Thr Leu
Asn 755 760 765 Gln Val Asp Ala Tyr Ala His Arg His Leu Ser Ile Thr
Gly Ser Gln 770 775 780 Ile Trp Gln Asn Asp Lys Leu Pro Ser Ala Asn
Lys Leu Val Ala Asn 785 790 795 800 Gly Val Leu Ala Leu Asn Ala Arg
Tyr Ser Gln Ile Ala Asp Asn Thr 805 810 815 Thr Leu Arg Ala Gly Ala
Ile Asn Leu Thr Ala Gly Thr Ala Leu Val 820 825 830 Lys Arg Gly Asn
Ile Asn Trp Ser Thr Val Ser Thr Lys Thr Leu Glu 835 840 845 Asp Asn
Ala Glu Leu Lys Pro Leu Ala Gly Arg Leu Asn Ile Glu Ala 850 855 860
Gly Ser Gly Thr Leu Thr Ile Glu Pro Ala Asn Arg Ile Ser Ala His 865
870 875 880 Thr Asp Leu Ser Ile Lys Thr Gly Gly Lys Leu Leu Leu Ser
Ala Lys 885 890 895 Gly Gly Asn Ala Gly Ala Pro Ser Ala Gln Val Ser
Ser Leu Glu Ala 900 905 910 Lys Gly Asn Ile Arg Leu Val Thr Gly Glu
Thr Asp Leu Arg Gly Ser 915 920 925 Lys Ile Thr Ala Gly Lys Asn Leu
Val Val Ala Thr Thr Lys Gly Lys 930 935 940 Leu Asn Ile Glu Ala Val
Asn Asn Ser Phe Ser Asn Tyr Phe Pro Thr 945 950 955 960 Gln Lys Ala
Ala Glu Leu Asn Gln Lys Ser Lys Glu Leu Glu Gln Gln 965 970 975 Ile
Ala Gln Leu Lys Lys Ser Ser Pro Lys Ser Lys Leu Ile Pro Thr 980 985
990 Leu Gln Glu Glu Arg Asp Arg Leu Ala Phe Tyr Ile Gln Ala Ile Asn
995 1000 1005 Lys Glu Val Lys Gly Lys Lys Pro Lys Gly Lys Glu Tyr
Leu Gln Ala 1010 1015 1020 Lys Leu Ser Ala Gln Asn Ile Asp Leu Ile
Ser Ala Gln Gly Ile Glu 1025 1030 1035 1040 Ile Ser Gly Ser Asp Ile
Thr Ala Ser Lys Lys Leu Asn Leu His Ala 1045 1050 1055 Ala Gly Val
Leu Pro Lys Ala Ala Asp Ser Glu Ala Ala Ala Ile Leu 1060 1065 1070
Ile Asp Gly Ile Thr Asp Gln Tyr Glu Ile Gly Lys Pro Thr Tyr Lys
1075 1080 1085 Ser His Tyr Asp Lys Ala Ala Leu Asn Lys Pro Ser Arg
Leu Thr Gly 1090 1095 1100 Arg Thr Gly Val Ser Ile His Ala Ala Ala
Ala Leu Asp Asp Ala Arg 1105 1110 1115 1120 Ile Ile Ile Gly Ala Ser
Glu Ile Lys Ala Pro Ser Gly Ser Ile Asp 1125 1130 1135 Ile Lys Ala
His Ser Asp Ile Val Leu Glu Ala Gly Gln Asn Asp Ala 1140 1145 1150
Tyr Thr Phe Leu Lys Thr Lys Gly Lys Ser Gly Lys Ile Ile Arg Lys
1155 1160 1165 Thr Lys Phe Thr Ser Thr Arg Asp His Leu Ile Met Pro
Ala Pro Val 1170 1175 1180 Glu Leu Thr Ala Asn Gly Ile Thr Leu Gln
Ala Gly Gly Asn Ile Glu 1185 1190 1195 1200 Ala Asn Thr Thr Arg Phe
Asn Ala Pro Ala Gly Lys Val Thr Leu Val 1205 1210 1215 Ala Gly Glu
Glu Leu Gln Leu Leu Ala Glu Glu Gly Ile His Lys His 1220 1225 1230
Glu Leu Asp Val Gln Lys Ser Arg Arg Phe Ile Gly Ile Lys Val Gly
1235 1240 1245 Lys Ser Asn Tyr Ser Lys Asn Glu Leu Asn Glu Thr Lys
Leu Pro Val 1250 1255 1260 Arg Val Val Ala Gln Thr Ala Ala Thr Arg
Ser Gly Trp Asp Thr Val 1265 1270 1275 1280 Leu Glu Gly Thr Glu Phe
Lys Thr Thr Leu Ala Gly Ala Asp Ile Gln 1285 1290 1295 Ala Gly Val
Gly Glu Lys Ala Arg Ala Asp Ala Lys Ile Ile Leu Lys 1300 1305 1310
Gly Ile Val Asn Arg Ile Gln Ser Glu Glu Lys Leu Glu Thr Asn Ser
1315 1320 1325 Thr Val Trp Gln Lys Gln Ala Gly Arg Gly Ser Thr Ile
Glu Thr Leu 1330 1335 1340 Lys Leu Pro Ser Phe Glu Ser Pro Thr Pro
Pro Lys Leu Thr Ala Pro 1345 1350 1355 1360 Gly Gly Tyr Ile Val Asp
Ile Pro Lys Gly Asn Leu Lys Thr Glu Ile 1365 1370 1375 Glu Lys Leu
Ala Lys Gln Pro Glu Tyr Ala Tyr Leu Lys Gln Leu Gln 1380 1385 1390
Val Ala Lys Asn Val Asn Trp Asn Gln Val Gln Leu Ala Tyr Asp Lys
1395 1400 1405 Trp Asp Tyr Lys Gln Glu Gly Leu Thr Arg Ala Gly Ala
Ala Ile Val 1410 1415 1420 Thr Ile Ile Val Thr Ala Leu Thr Tyr Gly
Tyr Gly Ala Thr Ala Ala 1425 1430 1435 1440 Gly Gly Val Ala Ala Ser
Gly Ser Ser Thr Ala Ala Ala Ala Gly Thr 1445 1450 1455 Ala Ala Thr
Thr Thr Ala Ala Ala Thr Thr Val Ser Thr Ala Thr Ala 1460 1465 1470
Met Gln Thr Ala Ala Leu Ala Ser Leu Tyr Ser Gln Ala Ala Val Ser
1475 1480 1485 Ile Ile Asn Asn Lys Gly Asp Val Gly Lys Ala Leu Lys
Asp Leu Gly 1490 1495 1500 Thr Ser Asp Thr Val Lys Gln Ile Val Thr
Ser Ala Leu Thr Ala Gly 1505 1510 1515 1520 Ala Leu Asn Gln Met Gly
Ala Asp Ile Ala Gln Leu Asn Ser Lys Val 1525 1530 1535 Arg Thr Glu
Leu Phe Ser Ser Thr Gly Asn Gln Thr Ile Ala Asn Leu 1540 1545 1550
Gly Gly Arg Leu Ala Thr Asn Leu Ser Asn Ala Gly Ile Ser Ala Gly
1555 1560 1565 Ile Asn Thr Ala Val Asn Gly Gly Ser Leu Lys Asp Asn
Leu Gly Asn 1570 1575 1580 Ala Ala Leu Gly Ala Leu Val Asn Ser Phe
Gln Gly Glu Ala Ala Ser 1585 1590 1595 1600 Lys Ile Lys Thr Thr Phe
Ser Asp Asp Tyr Val Ala Lys Gln Phe Ala 1605 1610 1615 His Ala Leu
Ala Gly Cys Val Ser Gly Leu Val Gln Gly Lys Cys Lys 1620 1625 1630
Asp Gly Ala Ile Gly Ala Ala Val Gly Glu Ile Val Ala Asp Ser Met
1635 1640 1645 Leu Gly Gly Arg Asn Pro Ala Thr Leu Ser Asp Ala Glu
Lys His Lys 1650 1655 1660 Val Ile Ser Tyr Ser Lys Ile Ile Ala Gly
Ser Val Ala Ala Leu Asn 1665 1670 1675 1680 Gly Gly Asp Val Asn Thr
Ala Ala Asn Ala Ala Glu Val Ala Val Val 1685 1690 1695 Asn Asn Ala
Leu Asn Phe Asp Ser Thr Pro Thr Asn Ala Lys Lys His 1700 1705 1710
Gln Pro Gln Lys Pro Asp Lys Thr Ala Leu Glu Lys Ile Ile Gln Gly
1715 1720 1725 Ile Met Pro Ala His Ala Ala Gly Ala Met Thr Asn Pro
Gln Asp Lys 1730 1735 1740 Asp Ala Ala Ile Trp Ile Ser Asn Ile Arg
Asn Gly Ile Thr Gly Pro 1745 1750 1755 1760 Ile Val Ile Thr Ser Tyr
Gly Val Tyr Ala Ala Gly Trp Thr Ala Pro 1765 1770 1775 Leu Ile Gly
Thr Ala Gly Lys Leu Ala Ile Ser Thr Cys Met Ala Asn 1780 1785 1790
Pro Ser Gly Cys Thr Val Met Val Thr Gln Ala Ala Glu Ala Gly Ala
1795 1800 1805 Gly Ile Ala Thr Gly Ala Val Thr Val Gly Asn Ala Trp
Glu Ala Pro 1810 1815 1820 Val Gly Ala Leu Ser Lys Ala Lys Ala Ala
Lys Gln Ala Ile Pro Thr 1825 1830 1835 1840 Gln Thr Val Lys Glu Leu
Asp Gly Leu Leu Gln Glu Ser Lys Asn Ile 1845 1850 1855 Gly Ala Val
Asn Thr Arg Ile Asn Ile Ala Asn Ser Thr Thr Arg Tyr 1860 1865 1870
Thr Pro Met Arg Gln Thr Gly Gln Pro Val Ser Ala Gly Phe Glu His
1875 1880 1885 Val Leu Glu Gly His Phe His Arg Pro Ile Ala Asn Asn
Arg Ser Val 1890 1895 1900 Phe Thr Ile Ser Pro Asn Glu Leu Lys Val
Ile Leu Gln Ser Asn Lys 1905 1910 1915 1920 Val Val Ser Ser Pro Val
Ser Met Thr Pro Asp Gly Gln Tyr Met Arg 1925 1930 1935 Thr Val Asp
Val Gly Lys Val Ile Gly Thr Thr Ser Ile Lys Glu Gly 1940 1945 1950
Gly Gln Pro Thr Thr Thr Ile Lys Val Phe Thr Asp Lys Ser Gly Asn
1955 1960 1965 Leu Ile Thr Thr Tyr Pro Val Lys Gly Asn 1970 1975 61
4599 DNA Neisseria meningitidis misc_feature (203) any nucleotide
61 atgaataaag gtttacatcg cattatcttt agtaaaaagc acagcaccat
ggttgcagta 60 gccgaaactg ccaacagcca gggcaaaggt aaacaggcag
gcagttcggt ttctgtttca 120 ctgaaaactt caggcgacct ttgcggcaaa
ctcaaaacca cccttaaaac cttggtctgc 180 tctttggttt ccctgagtat
ggnattncnn nncnntnccc aaattaccac cgacaaatca 240 gcacctaaaa
accancaggt cgttatcctt aaaaccaaca ctggtgcccc cttggtgaat 300
atccaaactc cgaatggacg cggattgagc cacaaccgct atacgcagtt tgatgttgac
360 aacaaagggg cagtgttaaa caacgaccgt aacaataatc cgtttctggt
caaaggcagt 420 gcgcaattga ttttgaacga ggtacgcggt acggctagca
aactcaacgg catcgttacc 480 gtaggcggtc aaaaggccga cgtgattatt
gccaacccca acggcattac cgttaatggc 540 ggcggcttta aaaatgtcgg
tcggggcatc ttaactatcg gtgcgcccca aatcggcaaa 600 gacggtgcac
tgacaggatt tgatgtgcgt caaggcacat tgaccgtagg agcagcaggt 660
tggaatgata aaggcggagc cgactacacc ggggtacttg ctcgtgcagt tgctttgcag
720 gggaaattac agggtaaaaa cctggcggtt tctaccggtc ctcagaaagt
agattacgcc 780 agcggcgaaa tcagtgcagg tacggcagcg ggtacgaaac
cgactattgc ccttgatact 840 gccgcactgg gcggtatgta cgccgacagc
atcacactga ttgccantga aaaaggcgta 900 ggcgtcaaaa atgccggcac
actcgaagcg gccaagcaat tgattgtgac ttcgtcaggc 960 cgcattgaaa
acagcggccg catcgccacc actgccgacg gcaccgaagc ttcaccgact 1020
tatctnncna tcgaaaccac cgaaaaagga gcnncaggca catttatctc caatggtggt
1080 cggatcgaga gcaaaggctt attggttatt gagacgggag aagatatcan
cttgcgtaac 1140 ggagccgtgg tgcagaataa cggcagtcgc ccagctacca
cggtattaaa tgctggtcat 1200 aatttggtga ttgagagtaa aactaatgtg
aacaatgcca aaggctcgnc taatctgtcg 1260 gccggcggtc gtactacgat
caatgatgct actattcaag cgggcagttc cgtgtacagc 1320 tccaccaaag
gcgatactga nttgggtgaa aatacccgta ttattgctga aaacgtaacc 1380
gtattatcta acggtagtat tggcagtgct gctgtaattg aggctaaaga cactgcacac
1440 attgaatcgg gcaaaccgct ttctttagaa acctcgaccg ttgcctccaa
catccgtttg 1500 aacaacggta acattaaagg cggaaagcag cttgctttac
tggcagacga taacattact 1560 gccaaaacta ccaatctgaa tactcccggc
aatctgtatg ttcatacagg taaagatctg 1620 aatttgaatg ttgataaaga
tttgtctgcc gccagcatcc atttgaaatc ggataacgct 1680 gcccatatta
ccggcaccag taaaaccctc actgcctcaa aagacatggg tgtggaggca 1740
ggcttgctga atgttaccaa taccaatctg cgtaccaact cgggtaatct gcacattcag
1800 gcagccaaag gcaatattca gcttcgcaat accaagctga acgcagccaa
ggctctcgaa 1860 accaccgcat tgcagggcaa tatcgtttca gacggccttc
atgctgtttc tgcagacggt 1920 catgtatcct tattggccaa cggtaatgcc
gactttaccg gtcacaatac cctgacagcc 1980 aaggccgatg tcnatgcagg
atcggttggt aaaggccgtc tgaaagcaga caataccaat 2040 atcacttcat
cttcaggaga tattacgttg gttgccgnnn ncggtattca gcttggtgac 2100
ggaaaacaac gcaattcaat caacggaaaa cacatcagca tcaaaaacaa cggtggtaat
2160 gccgacttaa aaaaccttaa cgtccatgcc aaaagcgggg cattgaacat
tcattccgac 2220 cgggcattga gcatagaaaa tacnaagctg gagtctaccc
ataatacgca tcttaatgca 2280 caacacgagc gggtaacgct caaccaagta
gatgcctacg cacaccgtca tctaagcatt 2340 ancggcagcc agatttggca
aaacgacaaa ctgccttctg ccaacaagct ggtggctaac 2400 ggtgtattgg
cantcaatgc gcgctattcc caaattgccg acaacaccac gctgagagcg 2460
ggtgcaatca accttactgc cggtaccgcc ctagtcaagc gcggcaacat caattggagt
2520 accgtttcga ccaagacttt ggaagataat gccgaattaa aaccattggc
cggacggctg 2580 aatattgaag caggtagcgg cacattaacc atcgaacctg
ccaaccgcat cagtgcgcat 2640 accgacctga gcatcaaaac aggcggaaaa
ttgctgttgt ctgcaaaagg aggaaatgca 2700 ggtgcgcnta gtgctcaagt
ttcctcattg gaagcaaaag gcaatatccg tctggttaca 2760 ggagnaacag
atttaagagg ttctaaaatt acagccggta aaaacttggt tgtcgccacc 2820
accaaaggca agttgaatat cgaagccgta aacaactcat tcagcaatta ttttcntaca
2880 caaaaagngn nngnnctcaa ccaaaaatcc aaagaattgg aacagcagat
tgcgcagttg 2940 aaaaaaagct cgcntaaaag caagctgatt ccaaccctgc
aagaagaacg cgaccgtctc 3000 gctttctata ttcaagccat caacaaggaa
gttaaaggta aaaaacccaa aggcaaagaa 3060 tacctgcaag ccaagctttc
tgcacaaaat attgacttga tttccgcaca aggcatcgaa 3120 atcagcggtt
ccgatattac cgcttccaaa aaactgaacc ttcacgccgc aggcgtattg 3180
ccaaaggcag cagattcaga ggcggctgct attctgattg acggcataac cgaccaatat
3240 gaaattggca agcccaccta caagagtcac tacgacaaag ctgctctgaa
caagccttca 3300 cgtttgaccg gacgtacggg ggtaagtatt catgcagctg
cggcactcga tgatgcacgt 3360 attattatcg gtgcatccga aatcaaagct
ccctcaggca gcatagacat caaagcccat 3420 agtgatattg tactggaggc
tggacaaaac gatgcctata ccttcttana aaccaaaggt 3480 aaaagcggca
naatnatcag aaaaacnaag tttaccagca ccngcganca cctgattatg 3540
ccagccccng tcgagctgac cgccaacggt atcacgcttc aggcaggcgg caacatcgaa
3600 gctaatacca cccgcttcaa tgcccctgca ggtaaagtta ccctggttgc
gggtgaanag 3660 ntgcaactgc tggcagaaga aggcatccac aagcacgagt
tggatgtcca aaaaagccgc 3720 cgctttatcg gcatcaaggt aggtnagagc
aattacagta aaaacgaact gaacgaaacc 3780 aaattgcctg tccgcgtcgt
cgcccaaant gcagccaccc gttcaggctg ggataccgtg 3840 ctcgaaggta
ccgaattcaa aaccacgctg gccggtgccg acattcaggc aggtgtangc 3900
gaaaaagccc gtgtcgatgc gaaaattatc ctcaaaggca ttgtgaaccg tatccagtcg
3960 gaagaaaaat tagaaaccaa ctcaaccgta tggcagaaac aggccggacg
cggcagcact 4020 atcgaaacgc taaaactgcc cagcttcgaa agccctactc
cgcccaaatt gtccgcaccc 4080 ggcggntata tcgtcgacat tccgaaaggc
aatctgaaaa ccgaaatcga aaagctgtcc 4140 aaacagcccg agtatgccta
tctgaaacag ctccaagtag cgaaaaacat caactggaat 4200 caggtgcagc
ttgcttacga cagatgggac tacaaacagg agggcttaac cgaagcaggt 4260
gcggcgatta tcgcactggc cgttaccgtg gtcacctcag gcgcaggaac cggagccgta
4320 ttgggattaa acggtgcgnc cgccgccgca accgatgcag cattcgcctc
tttggccagc 4380 caggcttccg tatcgttcat caacaacaaa ggcgatgtcg
gcaaaaccct gaaagagctg 4440 ggcagaagca gcacggtgaa aaatctggtg
gttgccgccg ctaccgcagg cgtagccgac 4500 aaaatcggcg cttcggcact
gancaatgtc agcgataagc agtggatcaa caacctgacc 4560 gtcaacctag
ccaatgncgg gcagtgccgc actgattaa 4599 62 1532 PRT Neisseria
meningitidis SITE (68)..(73) unknown 62 Met Asn Lys Gly Leu His Arg
Ile Ile Phe Ser Lys Lys His Ser Thr 1 5 10 15 Met Val Ala Val Ala
Glu Thr Ala Asn Ser Gln Gly Lys Gly Lys Gln 20 25 30 Ala Gly Ser
Ser Val Ser Val Ser Leu Lys Thr Ser Gly Asp Leu Cys 35 40 45 Gly
Lys Leu Lys Thr Thr Leu Lys Thr Leu Val Cys Ser Leu Val Ser 50 55
60 Leu Ser Met Xaa Xaa Xaa Xaa Xaa Xaa Gln Ile Thr Thr Asp Lys Ser
65 70 75 80 Ala Pro Lys Asn Xaa Gln Val Val Ile Leu Lys Thr Asn Thr
Gly Ala 85 90 95 Pro Leu Val Asn Ile Gln Thr Pro Asn Gly Arg Gly
Leu Ser His Asn 100 105 110 Arg Tyr Thr Gln Phe Asp Val Asp Asn Lys
Gly Ala Val Leu Asn Asn 115 120 125 Asp Arg Asn Asn Asn Pro Phe Leu
Val Lys Gly Ser Ala Gln Leu Ile 130 135 140 Leu Asn Glu Val Arg Gly
Thr Ala Ser Lys Leu Asn Gly Ile Val Thr 145 150 155 160 Val Gly Gly
Gln Lys Ala Asp Val Ile Ile Ala Asn Pro Asn Gly Ile 165 170 175 Thr
Val Asn Gly Gly Gly Phe Lys Asn Val Gly Arg Gly Ile Leu Thr 180 185
190 Ile Gly Ala Pro Gln Ile Gly Lys Asp Gly Ala Leu Thr Gly Phe Asp
195 200 205 Val Arg Gln Gly Thr Leu Thr Val Gly Ala Ala Gly Trp Asn
Asp Lys 210 215 220 Gly Gly Ala Asp Tyr Thr Gly Val Leu Ala Arg Ala
Val Ala Leu Gln 225 230 235 240 Gly Lys Leu Gln Gly Lys Asn Leu Ala
Val Ser Thr Gly Pro Gln Lys 245 250 255 Val Asp Tyr Ala Ser Gly Glu
Ile Ser Ala Gly Thr Ala Ala Gly Thr
260 265 270 Lys Pro Thr Ile Ala Leu Asp Thr Ala Ala Leu Gly Gly Met
Tyr Ala 275 280 285 Asp Ser Ile Thr Leu Ile Ala Xaa Glu Lys Gly Val
Gly Val Lys Asn 290 295 300 Ala Gly Thr Leu Glu Ala Ala Lys Gln Leu
Ile Val Thr Ser Ser Gly 305 310 315 320 Arg Ile Glu Asn Ser Gly Arg
Ile Ala Thr Thr Ala Asp Gly Thr Glu 325 330 335 Ala Ser Pro Thr Tyr
Leu Xaa Ile Glu Thr Thr Glu Lys Gly Ala Xaa 340 345 350 Gly Thr Phe
Ile Ser Asn Gly Gly Arg Ile Glu Ser Lys Gly Leu Leu 355 360 365 Val
Ile Glu Thr Gly Glu Asp Ile Xaa Leu Arg Asn Gly Ala Val Val 370 375
380 Gln Asn Asn Gly Ser Arg Pro Ala Thr Thr Val Leu Asn Ala Gly His
385 390 395 400 Asn Leu Val Ile Glu Ser Lys Thr Asn Val Asn Asn Ala
Lys Gly Ser 405 410 415 Xaa Asn Leu Ser Ala Gly Gly Arg Thr Thr Ile
Asn Asp Ala Thr Ile 420 425 430 Gln Ala Gly Ser Ser Val Tyr Ser Ser
Thr Lys Gly Asp Thr Xaa Leu 435 440 445 Gly Glu Asn Thr Arg Ile Ile
Ala Glu Asn Val Thr Val Leu Ser Asn 450 455 460 Gly Ser Ile Gly Ser
Ala Ala Val Ile Glu Ala Lys Asp Thr Ala His 465 470 475 480 Ile Glu
Ser Gly Lys Pro Leu Ser Leu Glu Thr Ser Thr Val Ala Ser 485 490 495
Asn Ile Arg Leu Asn Asn Gly Asn Ile Lys Gly Gly Lys Gln Leu Ala 500
505 510 Leu Leu Ala Asp Asp Asn Ile Thr Ala Lys Thr Thr Asn Leu Asn
Thr 515 520 525 Pro Gly Asn Leu Tyr Val His Thr Gly Lys Asp Leu Asn
Leu Asn Val 530 535 540 Asp Lys Asp Leu Ser Ala Ala Ser Ile His Leu
Lys Ser Asp Asn Ala 545 550 555 560 Ala His Ile Thr Gly Thr Ser Lys
Thr Leu Thr Ala Ser Lys Asp Met 565 570 575 Gly Val Glu Ala Gly Leu
Leu Asn Val Thr Asn Thr Asn Leu Arg Thr 580 585 590 Asn Ser Gly Asn
Leu His Ile Gln Ala Ala Lys Gly Asn Ile Gln Leu 595 600 605 Arg Asn
Thr Lys Leu Asn Ala Ala Lys Ala Leu Glu Thr Thr Ala Leu 610 615 620
Gln Gly Asn Ile Val Ser Asp Gly Leu His Ala Val Ser Ala Asp Gly 625
630 635 640 His Val Ser Leu Leu Ala Asn Gly Asn Ala Asp Phe Thr Gly
His Asn 645 650 655 Thr Leu Thr Ala Lys Ala Asp Val Xaa Ala Gly Ser
Val Gly Lys Gly 660 665 670 Arg Leu Lys Ala Asp Asn Thr Asn Ile Thr
Ser Ser Ser Gly Asp Ile 675 680 685 Thr Leu Val Ala Xaa Xaa Gly Ile
Gln Leu Gly Asp Gly Lys Gln Arg 690 695 700 Asn Ser Ile Asn Gly Lys
His Ile Ser Ile Lys Asn Asn Gly Gly Asn 705 710 715 720 Ala Asp Leu
Lys Asn Leu Asn Val His Ala Lys Ser Gly Ala Leu Asn 725 730 735 Ile
His Ser Asp Arg Ala Leu Ser Ile Glu Asn Thr Lys Leu Glu Ser 740 745
750 Thr His Asn Thr His Leu Asn Ala Gln His Glu Arg Val Thr Leu Asn
755 760 765 Gln Val Asp Ala Tyr Ala His Arg His Leu Ser Ile Xaa Gly
Ser Gln 770 775 780 Ile Trp Gln Asn Asp Lys Leu Pro Ser Ala Asn Lys
Leu Val Ala Asn 785 790 795 800 Gly Val Leu Ala Xaa Asn Ala Arg Tyr
Ser Gln Ile Ala Asp Asn Thr 805 810 815 Thr Leu Arg Ala Gly Ala Ile
Asn Leu Thr Ala Gly Thr Ala Leu Val 820 825 830 Lys Arg Gly Asn Ile
Asn Trp Ser Thr Val Ser Thr Lys Thr Leu Glu 835 840 845 Asp Asn Ala
Glu Leu Lys Pro Leu Ala Gly Arg Leu Asn Ile Glu Ala 850 855 860 Gly
Ser Gly Thr Leu Thr Ile Glu Pro Ala Asn Arg Ile Ser Ala His 865 870
875 880 Thr Asp Leu Ser Ile Lys Thr Gly Gly Lys Leu Leu Leu Ser Ala
Lys 885 890 895 Gly Gly Asn Ala Gly Ala Xaa Ser Ala Gln Val Ser Ser
Leu Glu Ala 900 905 910 Lys Gly Asn Ile Arg Leu Val Thr Gly Xaa Thr
Asp Leu Arg Gly Ser 915 920 925 Lys Ile Thr Ala Gly Lys Asn Leu Val
Val Ala Thr Thr Lys Gly Lys 930 935 940 Leu Asn Ile Glu Ala Val Asn
Asn Ser Phe Ser Asn Tyr Phe Xaa Thr 945 950 955 960 Gln Lys Xaa Xaa
Xaa Leu Asn Gln Lys Ser Lys Glu Leu Glu Gln Gln 965 970 975 Ile Ala
Gln Leu Lys Lys Ser Ser Xaa Lys Ser Lys Leu Ile Pro Thr 980 985 990
Leu Gln Glu Glu Arg Asp Arg Leu Ala Phe Tyr Ile Gln Ala Ile Asn 995
1000 1005 Lys Glu Val Lys Gly Lys Lys Pro Lys Gly Lys Glu Tyr Leu
Gln Ala 1010 1015 1020 Lys Leu Ser Ala Gln Asn Ile Asp Leu Ile Ser
Ala Gln Gly Ile Glu 1025 1030 1035 1040 Ile Ser Gly Ser Asp Ile Thr
Ala Ser Lys Lys Leu Asn Leu His Ala 1045 1050 1055 Ala Gly Val Leu
Pro Lys Ala Ala Asp Ser Glu Ala Ala Ala Ile Leu 1060 1065 1070 Ile
Asp Gly Ile Thr Asp Gln Tyr Glu Ile Gly Lys Pro Thr Tyr Lys 1075
1080 1085 Ser His Tyr Asp Lys Ala Ala Leu Asn Lys Pro Ser Arg Leu
Thr Gly 1090 1095 1100 Arg Thr Gly Val Ser Ile His Ala Ala Ala Ala
Leu Asp Asp Ala Arg 1105 1110 1115 1120 Ile Ile Ile Gly Ala Ser Glu
Ile Lys Ala Pro Ser Gly Ser Ile Asp 1125 1130 1135 Ile Lys Ala His
Ser Asp Ile Val Leu Glu Ala Gly Gln Asn Asp Ala 1140 1145 1150 Tyr
Thr Phe Leu Xaa Thr Lys Gly Lys Ser Gly Xaa Xaa Ile Arg Lys 1155
1160 1165 Thr Lys Phe Thr Ser Thr Xaa Xaa His Leu Ile Met Pro Ala
Pro Val 1170 1175 1180 Glu Leu Thr Ala Asn Gly Ile Thr Leu Gln Ala
Gly Gly Asn Ile Glu 1185 1190 1195 1200 Ala Asn Thr Thr Arg Phe Asn
Ala Pro Ala Gly Lys Val Thr Leu Val 1205 1210 1215 Ala Gly Glu Xaa
Xaa Gln Leu Leu Ala Glu Glu Gly Ile His Lys His 1220 1225 1230 Glu
Leu Asp Val Gln Lys Ser Arg Arg Phe Ile Gly Ile Lys Val Gly 1235
1240 1245 Xaa Ser Asn Tyr Ser Lys Asn Glu Leu Asn Glu Thr Lys Leu
Pro Val 1250 1255 1260 Arg Val Val Ala Gln Xaa Ala Ala Thr Arg Ser
Gly Trp Asp Thr Val 1265 1270 1275 1280 Leu Glu Gly Thr Glu Phe Lys
Thr Thr Leu Ala Gly Ala Asp Ile Gln 1285 1290 1295 Ala Gly Val Xaa
Glu Lys Ala Arg Val Asp Ala Lys Ile Ile Leu Lys 1300 1305 1310 Gly
Ile Val Asn Arg Ile Gln Ser Glu Glu Lys Leu Glu Thr Asn Ser 1315
1320 1325 Thr Val Trp Gln Lys Gln Ala Gly Arg Gly Ser Thr Ile Glu
Thr Leu 1330 1335 1340 Lys Leu Pro Ser Phe Glu Ser Pro Thr Pro Pro
Lys Leu Ser Ala Pro 1345 1350 1355 1360 Gly Gly Tyr Ile Val Asp Ile
Pro Lys Gly Asn Leu Lys Thr Glu Ile 1365 1370 1375 Glu Lys Leu Ser
Lys Gln Pro Glu Tyr Ala Tyr Leu Lys Gln Leu Gln 1380 1385 1390 Val
Ala Lys Asn Ile Asn Trp Asn Gln Val Gln Leu Ala Tyr Asp Arg 1395
1400 1405 Trp Asp Tyr Lys Gln Glu Gly Leu Thr Glu Ala Gly Ala Ala
Ile Ile 1410 1415 1420 Ala Leu Ala Val Thr Val Val Thr Ser Gly Ala
Gly Thr Gly Ala Val 1425 1430 1435 1440 Leu Gly Leu Asn Gly Ala Xaa
Ala Ala Ala Thr Asp Ala Ala Phe Ala 1445 1450 1455 Ser Leu Ala Ser
Gln Ala Ser Val Ser Phe Ile Asn Asn Lys Gly Asp 1460 1465 1470 Val
Gly Lys Thr Leu Lys Glu Leu Gly Arg Ser Ser Thr Val Lys Asn 1475
1480 1485 Leu Val Val Ala Ala Ala Thr Ala Gly Val Ala Asp Lys Ile
Gly Ala 1490 1495 1500 Ser Ala Leu Xaa Asn Val Ser Asp Lys Gln Trp
Ile Asn Asn Leu Thr 1505 1510 1515 1520 Val Asn Leu Ala Asn Xaa Gly
Gln Cys Arg Thr Asp 1525 1530 63 1782 DNA Neisseria meningitidis
misc_feature (89) any nucleotide 63 cgcttcattc atgatgaagc
agtcggcagc aacatcggcg gcggcaaaat gattgttgca 60 gccgggcagg
atatcaatgt acgcggcana agccttattt ctgataaggg cattgtttta 120
aaagcaggac acgacatcga tatttctact gcccataatc gctataccgg caatgaatac
180 cacgagagca waaawtcagg cgtcatgggt actggcggat tgggctttac
tatcggtaac 240 cggaaaacta ccgatgacac tgatcgtacc aatattgtsc
atacaggcag cattataggc 300 agcctgaatg gagacaccgt tacagttgca
ggaaaccgct accgacaaac cggcagtacc 360 gtctccagcc ccgaggggcg
caataccgtc acagccaaaw gcatagatgt agagttcgca 420 aacaaccggt
atgccactga ctacgcccat acccagggaa caaaaaggcc ttaccgtcgc 480
cctcaatgtc ccggttgtcc aagctgcaca aaacttcata caagcagccc aaaatgtggg
540 caaaagtaaa aataaacgcg ttaatgccat ggctgcagcc aatgctgcat
ggcagagtta 600 tcaagcaacc caacaaatgc aacaatttgc tccaagcagc
agtgcgggac aaggtcaaaa 660 ctacaatcaa agccccagta tcagtgtgtc
cattacntac ggcgaacaga aaagtcgtaa 720 cgagcaaaaa agacattaca
ccgaagcggc agcaagtcaa attatcggca aagggcaaac 780 cacacttgcg
gcaacaggaa gtggggagca gtccaatatc aatattacag gttccgatgt 840
catcggccat gcaggtactc cnctcattgc cgacaaccat atcagactcc aatctgccaa
900 acaggacggc agcgagcaaa gcaaaaacaa aagcagtggt tggaatgcag
gcgtacgtnn 960 caaaataggc aacggcatca ggtttggaat taccgccgga
ggaaatatcg gtaaaggtaa 1020 agagcaaggg ggaagtacta cccaccgcca
cacccatgtc ggcagcacaa ccggcaaaac 1080 taccatccga agcggcgggg
gataccaccc tcaaaggtgt gcagctcatc ggcaaaggca 1140 tacaggcaga
tacgcgcaac ctgcatatag aaagtgttca agatactgaa acctatcaga 1200
gcaaacagca aaacggcaat gtccaagttt actgtcggtt acggattcag tgcaagcggc
1260 agttaccgcc aaagcaaagt caaagcagac catgcctccg taaccgggca
aagcggtatt 1320 tatgccggag aagacggcta tcaaatyaaa gtyagagaca
acacagacct yaagggcggt 1380 atcatcacgt ctagccaaag cgcagaagat
aagggcaaaa acctttttca gacggccacc 1440 cttactgcca gcgacattca
aaaccacagc cgctacgaag gcagaagctt cggcataggc 1500 ggcagtttcg
acctgaacgg cggctgggac ggcacggtta ccgacaaaca aggcaggcct 1560
accgacagga taagcccggc agccggctac ggcagcgacg gagacagcaa aaacagcacc
1620 acccgcagcg gcgtcaacac ccacaacata cacatcaccg acgaagcggg
acaacttgcc 1680 cgaacaggca ggactgcaaa agaaaccgaa gcgcgtatct
acaccggcat cgacaccgaa 1740 actgcggatc aacactcagg ccatctgaaa
aacagcttcg ac 1782 64 593 PRT Neisseria meningitidis SITE (30)
unknown 64 Arg Phe Ile His Asp Glu Ala Val Gly Ser Asn Ile Gly Gly
Gly Lys 1 5 10 15 Met Ile Val Ala Ala Gly Gln Asp Ile Asn Val Arg
Gly Xaa Ser Leu 20 25 30 Ile Ser Asp Lys Gly Ile Val Leu Lys Ala
Gly His Asp Ile Asp Ile 35 40 45 Ser Thr Ala His Asn Arg Tyr Thr
Gly Asn Glu Tyr His Glu Ser Xaa 50 55 60 Xaa Ser Gly Val Met Gly
Thr Gly Gly Leu Gly Phe Thr Ile Gly Asn 65 70 75 80 Arg Lys Thr Thr
Asp Asp Thr Asp Arg Thr Asn Ile Val His Thr Gly 85 90 95 Ser Ile
Ile Gly Ser Leu Asn Gly Asp Thr Val Thr Val Ala Gly Asn 100 105 110
Arg Tyr Arg Gln Thr Gly Ser Thr Val Ser Ser Pro Glu Gly Arg Asn 115
120 125 Thr Val Thr Ala Lys Xaa Ile Asp Val Glu Phe Ala Asn Asn Arg
Tyr 130 135 140 Ala Thr Asp Tyr Ala His Thr Gln Glu Gln Lys Gly Leu
Thr Val Ala 145 150 155 160 Leu Asn Val Pro Val Val Gln Ala Ala Gln
Asn Phe Ile Gln Ala Ala 165 170 175 Gln Asn Val Gly Lys Ser Lys Asn
Lys Arg Val Asn Ala Met Ala Ala 180 185 190 Ala Asn Ala Ala Trp Gln
Ser Tyr Gln Ala Thr Gln Gln Met Gln Gln 195 200 205 Phe Ala Pro Ser
Ser Ser Ala Gly Gln Gly Gln Asn Tyr Asn Gln Ser 210 215 220 Pro Ser
Ile Ser Val Ser Ile Xaa Tyr Gly Glu Gln Lys Ser Arg Asn 225 230 235
240 Glu Gln Lys Arg His Tyr Thr Glu Ala Ala Ala Ser Gln Ile Ile Gly
245 250 255 Lys Gly Gln Thr Thr Leu Ala Ala Thr Gly Ser Gly Glu Gln
Ser Asn 260 265 270 Ile Asn Ile Thr Gly Ser Asp Val Ile Gly His Ala
Gly Thr Xaa Leu 275 280 285 Ile Ala Asp Asn His Ile Arg Leu Gln Ser
Ala Lys Gln Asp Gly Ser 290 295 300 Glu Gln Ser Lys Asn Lys Ser Ser
Gly Trp Asn Ala Gly Val Arg Xaa 305 310 315 320 Lys Ile Gly Asn Gly
Ile Arg Phe Gly Ile Thr Ala Gly Gly Asn Ile 325 330 335 Gly Lys Gly
Lys Glu Gln Gly Gly Ser Thr Thr His Arg His Thr His 340 345 350 Val
Gly Ser Thr Thr Gly Lys Thr Thr Ile Arg Ser Gly Gly Asp Thr 355 360
365 Thr Leu Lys Gly Val Gln Leu Ile Gly Lys Gly Ile Gln Ala Asp Thr
370 375 380 Arg Asn Leu His Ile Glu Ser Val Gln Asp Thr Glu Thr Tyr
Gln Ser 385 390 395 400 Lys Gln Gln Asn Gly Asn Val Gln Val Thr Val
Gly Tyr Gly Phe Ser 405 410 415 Ala Ser Gly Ser Tyr Arg Gln Ser Lys
Val Lys Ala Asp His Ala Ser 420 425 430 Val Thr Gly Gln Ser Gly Ile
Tyr Ala Gly Glu Asp Gly Tyr Gln Ile 435 440 445 Lys Val Arg Asp Asn
Thr Asp Leu Lys Gly Gly Ile Ile Thr Ser Ser 450 455 460 Gln Ser Ala
Glu Asp Lys Gly Lys Asn Leu Phe Gln Thr Ala Thr Leu 465 470 475 480
Thr Ala Ser Asp Ile Gln Asn His Ser Arg Tyr Glu Gly Arg Ser Phe 485
490 495 Gly Ile Gly Gly Ser Phe Asp Leu Asn Gly Gly Trp Asp Gly Thr
Val 500 505 510 Thr Asp Lys Gln Gly Arg Pro Thr Asp Arg Ile Ser Pro
Ala Ala Gly 515 520 525 Tyr Gly Ser Asp Gly Asp Ser Lys Asn Ser Thr
Thr Arg Ser Gly Val 530 535 540 Asn Thr His Asn Ile His Ile Thr Asp
Glu Ala Gly Gln Leu Ala Arg 545 550 555 560 Thr Gly Arg Thr Ala Lys
Glu Thr Glu Ala Arg Ile Tyr Thr Gly Ile 565 570 575 Asp Thr Glu Thr
Ala Asp Gln His Ser Gly His Leu Lys Asn Ser Phe 580 585 590 Asp 65
390 DNA Neisseria meningitidis 65 acgaccggca gcctcggcgg catactggcc
ggcggcggca cttcccttgc cgcaccgtat 60 ttggacaaag cggcggaaaa
cctcggtccg gcgggcaaag cggcggtcaa cgcactgggc 120 ggtgcggcca
tcggctatgc aactggtggt agtggtggtg ctgtggtggg tgcgaatgta 180
gattggaaca ataggcagct gcatccgaaa gaaatggcgt tggccgacaa atatgccgaa
240 gccctcaagc gcgaagttga aaaacgcgaa ggcagaaaaa tcagcagcca
agaagcggca 300 atgagaatcc gcaggcagat atgcgttggg tggacaaagg
ttcccaagac ggctataccg 360 accaaagcgt catatccctt atcggaatga 390 66
129 PRT Neisseria meningitidis 66 Thr Thr Gly Ser Leu Gly Gly Ile
Leu Ala Gly Gly Gly Thr Ser Leu 1 5 10 15 Ala Ala Pro Tyr Leu Asp
Lys Ala Ala Glu Asn Leu Gly Pro Ala Gly 20 25 30 Lys Ala Ala Val
Asn Ala Leu Gly Gly Ala Ala Ile Gly Tyr Ala Thr 35 40 45 Gly Gly
Ser Gly Gly Ala Val Val Gly Ala Asn Val Asp Trp Asn Asn 50 55 60
Arg Gln Leu His Pro Lys Glu Met Ala Leu Ala Asp Lys Tyr Ala Glu 65
70 75 80 Ala Leu Lys Arg Glu Val Glu Lys Arg Glu Gly Arg Lys Ile
Ser Ser 85 90 95 Gln Glu Ala Ala Met Arg Ile Arg Arg Gln Ile Cys
Val Gly Trp Thr 100 105 110 Lys Val Pro Lys Thr Ala Ile Pro Thr Lys
Ala Ser Tyr Pro Leu Ser 115 120 125 Glu 67 960 DNA Neisseria
meningitidis 67 caatgccgtc tgaaaagctc acaattttac agacggcatt
tgttatgcaa gtacatatac 60 agattcccta tatactgccc agrkgcgtgc
gtggctgaag acacccccta cgcttgctat 120 ttgraacagc tccaagtcac
caaagacgtc aactggaacc aggtacwact ggcgtacgac 180 aaatgggact
ataaacagga aggcttaacc ggagccggag cagcgattat tgcgctggct 240
gttaccgtgg ttactgcggg cgcgggagcc ggagccgcac tgggcttaaa cggcgcggcc
300 gcagcggcaa ccgatgccgc attcgcctcg ctggccagcc aggcttccgt
atcgctcatc 360 aacaacaaag gcaatatcgg taacaccctg aaagagctgg
gcagaagcag
cacggtgaaa 420 aatctgatgg ttgccgtcgc taccgcaggc gtagccgaca
aaatcggtgc ttcggcactg 480 aacaatgtca gcgataagca gtggatcaac
aacctgaccg tcaacctggc caatgcgggc 540 agtgccgcac tgattaatac
cgctgtcaac ggcggcagcc tgaaagacaa tctggaagcg 600 aatatccttg
cggctttggt gaatactgcg catggagaag cagccagtaa aatcaaacag 660
ttggatcagc actacattac ccacaagatt gcccatgcca tagcgggctg tgcggctgcg
720 gcggcgaata agggcaagtg tcaggatggt gcgataggtg cggctgtggg
cgagatagtc 780 ggggaggctt tgacaaacgg caaaaatcct gacactttga
cagctaaaga acgcgaacag 840 attttggcat acagcaaact ggttgccggt
acggtaagcg gtgtggtcgg cggcgatgta 900 aatgcggcgg cgaatgcggc
tgaggtagcg gtgaaaaata atcagcttag cgacaaatga 960 68 319 PRT
Neisseria meningitidis SITE (28) unknown 68 Gln Cys Arg Leu Lys Ser
Ser Gln Phe Tyr Arg Arg His Leu Leu Cys 1 5 10 15 Lys Tyr Ile Tyr
Arg Phe Pro Ile Tyr Cys Pro Xaa Ala Cys Val Ala 20 25 30 Glu Asp
Thr Pro Tyr Ala Cys Tyr Leu Xaa Gln Leu Gln Val Thr Lys 35 40 45
Asp Val Asn Trp Asn Gln Val Xaa Leu Ala Tyr Asp Lys Trp Asp Tyr 50
55 60 Lys Gln Glu Gly Leu Thr Gly Ala Gly Ala Ala Ile Ile Ala Leu
Ala 65 70 75 80 Val Thr Val Val Thr Ala Gly Ala Gly Ala Gly Ala Ala
Leu Gly Leu 85 90 95 Asn Gly Ala Ala Ala Ala Ala Thr Asp Ala Ala
Phe Ala Ser Leu Ala 100 105 110 Ser Gln Ala Ser Val Ser Leu Ile Asn
Asn Lys Gly Asn Ile Gly Asn 115 120 125 Thr Leu Lys Glu Leu Gly Arg
Ser Ser Thr Val Lys Asn Leu Met Val 130 135 140 Ala Val Ala Thr Ala
Gly Val Ala Asp Lys Ile Gly Ala Ser Ala Leu 145 150 155 160 Asn Asn
Val Ser Asp Lys Gln Trp Ile Asn Asn Leu Thr Val Asn Leu 165 170 175
Ala Asn Ala Gly Ser Ala Ala Leu Ile Asn Thr Ala Val Asn Gly Gly 180
185 190 Ser Leu Lys Asp Asn Leu Glu Ala Asn Ile Leu Ala Ala Leu Val
Asn 195 200 205 Thr Ala His Gly Glu Ala Ala Ser Lys Ile Lys Gln Leu
Asp Gln His 210 215 220 Tyr Ile Thr His Lys Ile Ala His Ala Ile Ala
Gly Cys Ala Ala Ala 225 230 235 240 Ala Ala Asn Lys Gly Lys Cys Gln
Asp Gly Ala Ile Gly Ala Ala Val 245 250 255 Gly Glu Ile Val Gly Glu
Ala Leu Thr Asn Gly Lys Asn Pro Asp Thr 260 265 270 Leu Thr Ala Lys
Glu Arg Glu Gln Ile Leu Ala Tyr Ser Lys Leu Val 275 280 285 Ala Gly
Thr Val Ser Gly Val Val Gly Gly Asp Val Asn Ala Ala Ala 290 295 300
Asn Ala Ala Glu Val Ala Val Lys Asn Asn Gln Leu Ser Asp Lys 305 310
315 69 1860 DNA Neisseria meningitidis 69 atgcaagtaa atattcagat
tccctatata ctgcccagat gcgtgcgtgc tgaagacacc 60 ccctacgctt
gctatttgaa acagctccaa gtcaccaaag acgtcaactg gaaccaggta 120
caactggcgt acgacaaatg ggactataaa caggaaggct taaccggagc cggagcagcg
180 attattgcgc tggctgttac cgtggttact gcgggcgcgg gagccggagc
cgcactgggc 240 ttaaacggcg cggccgcagc ggcaaccgat gccgcattcg
cctcgctggc cagccaggct 300 tccgtatcgc tcatcaacaa caaaggcaat
atcggtaaca ccctgaaaga gctgggcaga 360 agcagcacgg tgaaaaatct
gatggttgcc gtcgctaccg caggcgtagc cgacaaaatc 420 ggtgcttcgg
cactgaacaa tgtcagcgat aagcagtgga tcaacaacct gaccgtcaac 480
ctggccaatg cgggcagtgc cgcactgatt aataccgctg tcaacggcgg cagcctgaaa
540 gacaatctgg aagcgaatat ccttgcggct ttggtgaata ctgcgcatgg
agaagcagcc 600 agtaaaatca aacagttgga tcagcactac attacccaca
agattgccca tgccatagcg 660 ggctgtgcgg ctgcggcggc gaataagggc
aagtgtcagg atggtgcgat aggtgcggct 720 gtgggcgaga tagtcgggga
ggctttgaca aacggcaaaa atcctgacac tttgacagct 780 aaagaacgcg
aacagatttt ggcatacagc aaactggttg ccggtacggt aagcggtgtg 840
gtcggcggcg atgtaaatgc ggcggcgaat gcggctgagg tagcggtgaa aaataatcag
900 cttagcgaca aagagggtag agaatttgat aacgaaatga ctgcatgcgc
caaacagaat 960 aatcctcaac tgtgcagaaa aaatactgta aaaaagtatc
aaaatgttgc tgataaaaga 1020 cttgctgctt cgattgcaat atgtacggat
atatcccgta gtactgaatg tagaacaatc 1080 agaaaacaac atttgatcga
tagtagaagc cttcattcat cttgggaagc aggtctaatt 1140 ggtaaagatg
atgaatggta taaattattc agcaaatctt acacccaagc agatttggct 1200
ttacagtctt atcatttgaa tactgctgct aaatcttggc ttcaatcggg caatacaaag
1260 cctttatccg aatggatgtc cgaccaaggt tatacactta tttcaggagt
taatcctaga 1320 ttcattccaa taccaagagg gtttgtaaaa caaaatacac
ctattactaa tgtcaaatac 1380 ccggaaggca tcagtttcga tacaaaccta
aaaagacatc tggcaaatgc tgatggtttt 1440 agtcaaaaac agggcattaa
aggagcccat aaccgcacca attttatggc agaactaaat 1500 tcacgaggag
gacgcgtaaa atctgaaacc caaactgata ttgaaggcat tacccgaatt 1560
aaatatgaga ttcctacact agacaggaca ggtaaacctg atggtggatt taaggaaatt
1620 tcaagtataa aaactgttta taatcctaaa aaattttctg atgataaaat
acttcaaatg 1680 gctcaaaatg ctgcttcaca aggatattca aaagcctcta
aaattgctca aaatgaaaga 1740 actaaatcaa tatcggaaag aaaaaatgtc
attcaattct cagaaacctt tgacggaatc 1800 aaatttagat catattttga
tgtaaataca ggaagaatta caaacattca cccagaataa 1860 70 619 PRT
Neisseria meningitidis 70 Met Gln Val Asn Ile Gln Ile Pro Tyr Ile
Leu Pro Arg Cys Val Arg 1 5 10 15 Ala Glu Asp Thr Pro Tyr Ala Cys
Tyr Leu Lys Gln Leu Gln Val Thr 20 25 30 Lys Asp Val Asn Trp Asn
Gln Val Gln Leu Ala Tyr Asp Lys Trp Asp 35 40 45 Tyr Lys Gln Glu
Gly Leu Thr Gly Ala Gly Ala Ala Ile Ile Ala Leu 50 55 60 Ala Val
Thr Val Val Thr Ala Gly Ala Gly Ala Gly Ala Ala Leu Gly 65 70 75 80
Leu Asn Gly Ala Ala Ala Ala Ala Thr Asp Ala Ala Phe Ala Ser Leu 85
90 95 Ala Ser Gln Ala Ser Val Ser Leu Ile Asn Asn Lys Gly Asn Ile
Gly 100 105 110 Asn Thr Leu Lys Glu Leu Gly Arg Ser Ser Thr Val Lys
Asn Leu Met 115 120 125 Val Ala Val Ala Thr Ala Gly Val Ala Asp Lys
Ile Gly Ala Ser Ala 130 135 140 Leu Asn Asn Val Ser Asp Lys Gln Trp
Ile Asn Asn Leu Thr Val Asn 145 150 155 160 Leu Ala Asn Ala Gly Ser
Ala Ala Leu Ile Asn Thr Ala Val Asn Gly 165 170 175 Gly Ser Leu Lys
Asp Asn Leu Glu Ala Asn Ile Leu Ala Ala Leu Val 180 185 190 Asn Thr
Ala His Gly Glu Ala Ala Ser Lys Ile Lys Gln Leu Asp Gln 195 200 205
His Tyr Ile Thr His Lys Ile Ala His Ala Ile Ala Gly Cys Ala Ala 210
215 220 Ala Ala Ala Asn Lys Gly Lys Cys Gln Asp Gly Ala Ile Gly Ala
Ala 225 230 235 240 Val Gly Glu Ile Val Gly Glu Ala Leu Thr Asn Gly
Lys Asn Pro Asp 245 250 255 Thr Leu Thr Ala Lys Glu Arg Glu Gln Ile
Leu Ala Tyr Ser Lys Leu 260 265 270 Val Ala Gly Thr Val Ser Gly Val
Val Gly Gly Asp Val Asn Ala Ala 275 280 285 Ala Asn Ala Ala Glu Val
Ala Val Lys Asn Asn Gln Leu Ser Asp Lys 290 295 300 Glu Gly Arg Glu
Phe Asp Asn Glu Met Thr Ala Cys Ala Lys Gln Asn 305 310 315 320 Asn
Pro Gln Leu Cys Arg Lys Asn Thr Val Lys Lys Tyr Gln Asn Val 325 330
335 Ala Asp Lys Arg Leu Ala Ala Ser Ile Ala Ile Cys Thr Asp Ile Ser
340 345 350 Arg Ser Thr Glu Cys Arg Thr Ile Arg Lys Gln His Leu Ile
Asp Ser 355 360 365 Arg Ser Leu His Ser Ser Trp Glu Ala Gly Leu Ile
Gly Lys Asp Asp 370 375 380 Glu Trp Tyr Lys Leu Phe Ser Lys Ser Tyr
Thr Gln Ala Asp Leu Ala 385 390 395 400 Leu Gln Ser Tyr His Leu Asn
Thr Ala Ala Lys Ser Trp Leu Gln Ser 405 410 415 Gly Asn Thr Lys Pro
Leu Ser Glu Trp Met Ser Asp Gln Gly Tyr Thr 420 425 430 Leu Ile Ser
Gly Val Asn Pro Arg Phe Ile Pro Ile Pro Arg Gly Phe 435 440 445 Val
Lys Gln Asn Thr Pro Ile Thr Asn Val Lys Tyr Pro Glu Gly Ile 450 455
460 Ser Phe Asp Thr Asn Leu Lys Arg His Leu Ala Asn Ala Asp Gly Phe
465 470 475 480 Ser Gln Lys Gln Gly Ile Lys Gly Ala His Asn Arg Thr
Asn Phe Met 485 490 495 Ala Glu Leu Asn Ser Arg Gly Gly Arg Val Lys
Ser Glu Thr Gln Thr 500 505 510 Asp Ile Glu Gly Ile Thr Arg Ile Lys
Tyr Glu Ile Pro Thr Leu Asp 515 520 525 Arg Thr Gly Lys Pro Asp Gly
Gly Phe Lys Glu Ile Ser Ser Ile Lys 530 535 540 Thr Val Tyr Asn Pro
Lys Lys Phe Ser Asp Asp Lys Ile Leu Gln Met 545 550 555 560 Ala Gln
Asn Ala Ala Ser Gln Gly Tyr Ser Lys Ala Ser Lys Ile Ala 565 570 575
Gln Asn Glu Arg Thr Lys Ser Ile Ser Glu Arg Lys Asn Val Ile Gln 580
585 590 Phe Ser Glu Thr Phe Asp Gly Ile Lys Phe Arg Ser Tyr Phe Asp
Val 595 600 605 Asn Thr Gly Arg Ile Thr Asn Ile His Pro Glu 610 615
71 1788 DNA Neisseria meningitidis misc_feature (181) any
nucleotide 71 tatctgaaac agctccaagt agcgaaaaac atcaactgga
atcaggtgca gcttgcttac 60 gacagatggg actacaaaca ggagggctta
accgaagcag gtgcggcgat tatcgcactg 120 gccgttaccg tggtcacctc
aggcgcagga accggagccg tattgggatt aaacggtgcg 180 nccgccgccg
caaccgatgc agcattcgcc tctttggcca gccaggcttc cgtatcgttc 240
atcaacaaca aaggcgatgt cggcaaaacc ctgaaagagc tgggcagaag cagcacggtg
300 aaaaatctgg tggttgccgc cgctaccgca ggcgtagccg acaaaatcgg
cgcttcggca 360 ctgancaatg tcagcgataa gcagtggatc aacaacctga
ccgtcaacct agccaatgcg 420 ggcagtgccg cactgattaa taccgctgtc
aacggcggca gcctgaaaga cantctggaa 480 gcgaatatcc ttgcggcttt
ggtcaatacc gcgcatggag aagcagccag taaaatcaaa 540 cagttggatc
agcactacat agtccacaag attgcccatg ccatagcggg ctgtgcggca 600
gcggcggcga ataagggcaa gtgtcaggat ggtgcgatag gtgcggctgt gggcgagata
660 gtcggggagg ctttgacaaa cggcaaaaat cctgacactt tgacagctaa
agaacgcgaa 720 cagattttgg catacagcaa actggttgcc ggtacggtaa
gcggtgtggt cggcggcgat 780 gtaaatgcgg cggcgaatgc ggctgaggta
gcggtgaaaa ataatcagct tagcgacnaa 840 gagggtagag aatttgataa
cgaaatgact gcatgcgcca aacagaatan tcctcaactg 900 tgcagaaaaa
atactgtaaa aaagtatcaa aatgttgctg ataaaagact tgctgcttcg 960
attgcaatat gtacggatat atcccgtagt actgaatgta gaacaatcag aaaacaacat
1020 ttgatcgata gtagaagcct tcattcatct tgggaagcag gtctaattgg
taaagatgat 1080 gaatggtata aattattcag caaatcttac acccaagcag
atttggcttt acagtcttat 1140 catttgaata ctgctgctaa atcttggctt
caatcgggca atacaaagcc tttatccgaa 1200 tggatgtccg accaaggtta
tacacttatt tcaggagtta atcctagatt cattccaata 1260 ccaagagggt
ttgtaaaaca aaatacacct attactaatg tcaaataccc ggaaggcatc 1320
agtttcgata caaacctana aagacatctg gcaaatgctg atggttttag tcaagaacag
1380 ggcattaaag gagcccataa ccgcaccaat nttatggcag aactaaattc
acgaggagga 1440 ngngtaaaat ctgaaaccca nactgatatt gaaggcatta
cccgaattaa atatgagatt 1500 cctacactag acaggacagg taaacctgat
ggtggattta aggaaatttc aagtataaaa 1560 actgtttata atcctaaaaa
nttttnngat gataaaatac ttcaaatggc tcaanatgct 1620 gnttcacaag
gatattcaaa agcctctaaa attgctcaaa atgaaagaac taaatcaata 1680
tcggaaagaa aaaatgtcat tcaattctca gaaacctttg acggaatcaa atttagannn
1740 tatntngatg taaatacagg aagaattaca aacattcacc cagaataa 1788 72
595 PRT Neisseria meningitidis SITE (61) unknown 72 Tyr Leu Lys Gln
Leu Gln Val Ala Lys Asn Ile Asn Trp Asn Gln Val 1 5 10 15 Gln Leu
Ala Tyr Asp Arg Trp Asp Tyr Lys Gln Glu Gly Leu Thr Glu 20 25 30
Ala Gly Ala Ala Ile Ile Ala Leu Ala Val Thr Val Val Thr Ser Gly 35
40 45 Ala Gly Thr Gly Ala Val Leu Gly Leu Asn Gly Ala Xaa Ala Ala
Ala 50 55 60 Thr Asp Ala Ala Phe Ala Ser Leu Ala Ser Gln Ala Ser
Val Ser Phe 65 70 75 80 Ile Asn Asn Lys Gly Asp Val Gly Lys Thr Leu
Lys Glu Leu Gly Arg 85 90 95 Ser Ser Thr Val Lys Asn Leu Val Val
Ala Ala Ala Thr Ala Gly Val 100 105 110 Ala Asp Lys Ile Gly Ala Ser
Ala Leu Xaa Asn Val Ser Asp Lys Gln 115 120 125 Trp Ile Asn Asn Leu
Thr Val Asn Leu Ala Asn Ala Gly Ser Ala Ala 130 135 140 Leu Ile Asn
Thr Ala Val Asn Gly Gly Ser Leu Lys Asp Xaa Leu Glu 145 150 155 160
Ala Asn Ile Leu Ala Ala Leu Val Asn Thr Ala His Gly Glu Ala Ala 165
170 175 Ser Lys Ile Lys Gln Leu Asp Gln His Tyr Ile Val His Lys Ile
Ala 180 185 190 His Ala Ile Ala Gly Cys Ala Ala Ala Ala Ala Asn Lys
Gly Lys Cys 195 200 205 Gln Asp Gly Ala Ile Gly Ala Ala Val Gly Glu
Ile Val Gly Glu Ala 210 215 220 Leu Thr Asn Gly Lys Asn Pro Asp Thr
Leu Thr Ala Lys Glu Arg Glu 225 230 235 240 Gln Ile Leu Ala Tyr Ser
Lys Leu Val Ala Gly Thr Val Ser Gly Val 245 250 255 Val Gly Gly Asp
Val Asn Ala Ala Ala Asn Ala Ala Glu Val Ala Val 260 265 270 Lys Asn
Asn Gln Leu Ser Asp Xaa Glu Gly Arg Glu Phe Asp Asn Glu 275 280 285
Met Thr Ala Cys Ala Lys Gln Asn Xaa Pro Gln Leu Cys Arg Lys Asn 290
295 300 Thr Val Lys Lys Tyr Gln Asn Val Ala Asp Lys Arg Leu Ala Ala
Ser 305 310 315 320 Ile Ala Ile Cys Thr Asp Ile Ser Arg Ser Thr Glu
Cys Arg Thr Ile 325 330 335 Arg Lys Gln His Leu Ile Asp Ser Arg Ser
Leu His Ser Ser Trp Glu 340 345 350 Ala Gly Leu Ile Gly Lys Asp Asp
Glu Trp Tyr Lys Leu Phe Ser Lys 355 360 365 Ser Tyr Thr Gln Ala Asp
Leu Ala Leu Gln Ser Tyr His Leu Asn Thr 370 375 380 Ala Ala Lys Ser
Trp Leu Gln Ser Gly Asn Thr Lys Pro Leu Ser Glu 385 390 395 400 Trp
Met Ser Asp Gln Gly Tyr Thr Leu Ile Ser Gly Val Asn Pro Arg 405 410
415 Phe Ile Pro Ile Pro Arg Gly Phe Val Lys Gln Asn Thr Pro Ile Thr
420 425 430 Asn Val Lys Tyr Pro Glu Gly Ile Ser Phe Asp Thr Asn Leu
Xaa Arg 435 440 445 His Leu Ala Asn Ala Asp Gly Phe Ser Gln Glu Gln
Gly Ile Lys Gly 450 455 460 Ala His Asn Arg Thr Asn Xaa Met Ala Glu
Leu Asn Ser Arg Gly Gly 465 470 475 480 Xaa Val Lys Ser Glu Thr Xaa
Thr Asp Ile Glu Gly Ile Thr Arg Ile 485 490 495 Lys Tyr Glu Ile Pro
Thr Leu Asp Arg Thr Gly Lys Pro Asp Gly Gly 500 505 510 Phe Lys Glu
Ile Ser Ser Ile Lys Thr Val Tyr Asn Pro Lys Xaa Phe 515 520 525 Xaa
Asp Asp Lys Ile Leu Gln Met Ala Gln Xaa Ala Xaa Ser Gln Gly 530 535
540 Tyr Ser Lys Ala Ser Lys Ile Ala Gln Asn Glu Arg Thr Lys Ser Ile
545 550 555 560 Ser Glu Arg Lys Asn Val Ile Gln Phe Ser Glu Thr Phe
Asp Gly Ile 565 570 575 Lys Phe Arg Xaa Tyr Xaa Asp Val Asn Thr Gly
Arg Ile Thr Asn Ile 580 585 590 His Pro Glu 595 73 453 DNA
Neisseria meningitidis 73 atggcaatca ttacattgta ttattctgtc
aatggtattt taaatgtatg tgcaaaagca 60 aaaaatattc aagtagttgc
caataataag aatatggttc tttttgggtt tttggsmrgc 120 atcatcggcg
gttcaaccaa tgccatgtct cccatattgt taatattttt gcttagcgaa 180
acagaaaata aaaatcgtat cgtaaaatca agcaatctat gctatctttt ggcgaaaatt
240 gttcaaatat atatgctaag agaccagtat tggttattaa ataagagtga
atacgdttta 300 atatttttac tgtccgtatt gtctgttatt ggattgtatg
ttggaattcg gttaaggact 360 aagattagcc caaatttttt taaaatgtta
atttttattg ttttattggt attggctctg 420 aaaatcgggc attcgggttt
aatcaaactt taa 453 74 150 PRT Neisseria meningitidis SITE
(39)..(40) unknown 74 Met Ala Ile Ile Thr Leu Tyr Tyr Ser Val Asn
Gly Ile Leu Asn Val 1 5 10 15 Cys Ala Lys Ala Lys Asn Ile Gln Val
Val Ala Asn Asn Lys Asn Met 20 25 30 Val Leu Phe Gly Phe Leu Xaa
Xaa Ile Ile Gly Gly Ser Thr Asn Ala 35 40 45 Met Ser Pro Ile Leu
Leu Ile Phe Leu Leu Ser Glu Thr Glu Asn Lys 50 55 60 Asn Arg Ile
Val Lys Ser Ser Asn Leu Cys Tyr Leu Leu Ala Lys Ile 65 70 75 80 Val
Gln Ile Tyr Met Leu Arg Asp Gln Tyr Trp Leu Leu Asn Lys Ser 85 90
95 Glu Tyr Xaa Leu Ile Phe Leu Leu Ser Val Leu Ser Val Ile Gly
Leu 100 105 110 Tyr Val Gly Ile Arg Leu Arg Thr Lys Ile Ser Pro Asn
Phe Phe Lys 115 120 125 Met Leu Ile Phe Ile Val Leu Leu Val Leu Ala
Leu Lys Ile Gly His 130 135 140 Ser Gly Leu Ile Lys Leu 145 150 75
768 DNA Neisseria meningitidis 75 atgcaagaaa taatgcaatc tatcgttttt
gttgctgccg caatactgca cggaattaca 60 ggcatgggat ttccgatgct
cggtacaacc gcattggctt ttatcatgcc attgtctaag 120 gttgttgcct
tggtggcatt accaagcctg ttaatgagct tgttggttct atgcagcaat 180
aacaaaaagg gtttttggca agagattgtt tattatttaa aaacctataa attgcttgct
240 atcggcagcg tcgttggcag cattttgggg gtgaagttgc ttttgatact
tccagtgtct 300 tggctgcttt tactgatggc aatcattaca ttgtattatt
ctgtcaatgg tattttaaat 360 gtatgtgcaa aagcaaaaaa tattcaagta
gttgccaata ataagaatat ggttcttttt 420 gggtttttgg caggcatcat
cggcggttca accaatgcca tgtctcccat attgttaata 480 tttttgctta
gcgaaacaga aaataaaaat cgtatcgtaa aatcaagcaa tctatgctat 540
cttttggcga aaattgttca aatatatatg ctaagagacc agtattggtt attaaataag
600 agtgaatacg gtttaatatt tttactgtcc gtattgtctg ttattggatt
gtatgttgga 660 attcggttaa ggactaagat tagcccaaat ttttttaaaa
tgttaatttt tattgtttta 720 ttggtattgg ctctgaaaat cgggcattcg
ggtttaatca aactttaa 768 76 255 PRT Neisseria meningitidis 76 Met
Gln Glu Ile Met Gln Ser Ile Val Phe Val Ala Ala Ala Ile Leu 1 5 10
15 His Gly Ile Thr Gly Met Gly Phe Pro Met Leu Gly Thr Thr Ala Leu
20 25 30 Ala Phe Ile Met Pro Leu Ser Lys Val Val Ala Leu Val Ala
Leu Pro 35 40 45 Ser Leu Leu Met Ser Leu Leu Val Leu Cys Ser Asn
Asn Lys Lys Gly 50 55 60 Phe Trp Gln Glu Ile Val Tyr Tyr Leu Lys
Thr Tyr Lys Leu Leu Ala 65 70 75 80 Ile Gly Ser Val Val Gly Ser Ile
Leu Gly Val Lys Leu Leu Leu Ile 85 90 95 Leu Pro Val Ser Trp Leu
Leu Leu Leu Met Ala Ile Ile Thr Leu Tyr 100 105 110 Tyr Ser Val Asn
Gly Ile Leu Asn Val Cys Ala Lys Ala Lys Asn Ile 115 120 125 Gln Val
Val Ala Asn Asn Lys Asn Met Val Leu Phe Gly Phe Leu Ala 130 135 140
Gly Ile Ile Gly Gly Ser Thr Asn Ala Met Ser Pro Ile Leu Leu Ile 145
150 155 160 Phe Leu Leu Ser Glu Thr Glu Asn Lys Asn Arg Ile Val Lys
Ser Ser 165 170 175 Asn Leu Cys Tyr Leu Leu Ala Lys Ile Val Gln Ile
Tyr Met Leu Arg 180 185 190 Asp Gln Tyr Trp Leu Leu Asn Lys Ser Glu
Tyr Gly Leu Ile Phe Leu 195 200 205 Leu Ser Val Leu Ser Val Ile Gly
Leu Tyr Val Gly Ile Arg Leu Arg 210 215 220 Thr Lys Ile Ser Pro Asn
Phe Phe Lys Met Leu Ile Phe Ile Val Leu 225 230 235 240 Leu Val Leu
Ala Leu Lys Ile Gly His Ser Gly Leu Ile Lys Leu 245 250 255 77 768
DNA Neisseria meningitidis 77 atgcaagaaa taatgcaatc tatcgttttt
gttgctgccg caatactgca cggaattaca 60 ggcatgggat ttccgatgct
cggtacaacc gcattggctt ttatcatgcc attgtctaag 120 gttgttgcct
tggtggcatt accaagcctg ttaatgagct tgttggttct atgcagcaat 180
aacaaaaagg gtttttggca agagattgtt tattatttaa aaacctataa attgcttgct
240 atcggcagcg tcgttggcag cattttgggg gtgaagttgc ttttgatact
tccagtgtct 300 tggctgcttt tactgatggc aatcattaca ttgtattatt
ctgtcaatgg tattttaaat 360 gtatgtgcaa aagcaaaaaa tattcaagta
gttgccaata ataagaatat ggttcttttt 420 gggtttttgg caggcatcat
cggcggttca accaatgcca tgtctcccat attgttaata 480 tttttgctta
gcgaaacaga gaataaaaat cgtatcgcaa aatcaagcaa tctatgctat 540
cttttggcaa aaattgttca aatatatatg ctaagagacc agtattggtt attaaataag
600 agtgaatacg gtttaatatt tttactgtcc gtattgtctg ttattggatt
gtatgttgga 660 attcggttaa ggactaagat tagcccaaat ttttttaaaa
tgttaatttt tattgtttta 720 ttggtattgg ctctgaaaat cgggtattca
ggtttaatca aactttaa 768 78 255 PRT Neisseria meningitidis 78 Met
Gln Glu Ile Met Gln Ser Ile Val Phe Val Ala Ala Ala Ile Leu 1 5 10
15 His Gly Ile Thr Gly Met Gly Phe Pro Met Leu Gly Thr Thr Ala Leu
20 25 30 Ala Phe Ile Met Pro Leu Ser Lys Val Val Ala Leu Val Ala
Leu Pro 35 40 45 Ser Leu Leu Met Ser Leu Leu Val Leu Cys Ser Asn
Asn Lys Lys Gly 50 55 60 Phe Trp Gln Glu Ile Val Tyr Tyr Leu Lys
Thr Tyr Lys Leu Leu Ala 65 70 75 80 Ile Gly Ser Val Val Gly Ser Ile
Leu Gly Val Lys Leu Leu Leu Ile 85 90 95 Leu Pro Val Ser Trp Leu
Leu Leu Leu Met Ala Ile Ile Thr Leu Tyr 100 105 110 Tyr Ser Val Asn
Gly Ile Leu Asn Val Cys Ala Lys Ala Lys Asn Ile 115 120 125 Gln Val
Val Ala Asn Asn Lys Asn Met Val Leu Phe Gly Phe Leu Ala 130 135 140
Gly Ile Ile Gly Gly Ser Thr Asn Ala Met Ser Pro Ile Leu Leu Ile 145
150 155 160 Phe Leu Leu Ser Glu Thr Glu Asn Lys Asn Arg Ile Ala Lys
Ser Ser 165 170 175 Asn Leu Cys Tyr Leu Leu Ala Lys Ile Val Gln Ile
Tyr Met Leu Arg 180 185 190 Asp Gln Tyr Trp Leu Leu Asn Lys Ser Glu
Tyr Gly Leu Ile Phe Leu 195 200 205 Leu Ser Val Leu Ser Val Ile Gly
Leu Tyr Val Gly Ile Arg Leu Arg 210 215 220 Thr Lys Ile Ser Pro Asn
Phe Phe Lys Met Leu Ile Phe Ile Val Leu 225 230 235 240 Leu Val Leu
Ala Leu Lys Ile Gly Tyr Ser Gly Leu Ile Lys Leu 245 250 255 79 516
DNA Neisseria meningitidis 79 atgagacata tgaaaataca aaattattta
ctagtattta tagttttaca tatagccttg 60 atagtaatta atatagtgtt
tggttatttt gtttttctat ttgatttttt tgcgtttttg 120 ttttttgcaa
acgtctttct tgctgtaaat ttattatttt tagaaaaaaa cataaaaaac 180
aaattattgt ttttattgcc gatttctatt attatatgga tggtaattca tattagtatg
240 ataaatataa aattttataa atttgagcat caaataaagg aacaaaatat
atcctcgatt 300 actggggtga taaaaccaca tgatagttat aattatgttt
atgactcaaa tggatatgct 360 aaattaaaag ataatcatag atatggtagg
gtaattagag aaacacctta tattgatgta 420 gttgcatctg atgttaaaaa
taaatccata agattaagct tggtttgtgg tattcattca 480 tatgctccat
gtgccaattt tataaaattt gtcagg 516 80 172 PRT Neisseria meningitidis
80 Met Arg His Met Lys Ile Gln Asn Tyr Leu Leu Val Phe Ile Val Leu
1 5 10 15 His Ile Ala Leu Ile Val Ile Asn Ile Val Phe Gly Tyr Phe
Val Phe 20 25 30 Leu Phe Asp Phe Phe Ala Phe Leu Phe Phe Ala Asn
Val Phe Leu Ala 35 40 45 Val Asn Leu Leu Phe Leu Glu Lys Asn Ile
Lys Asn Lys Leu Leu Phe 50 55 60 Leu Leu Pro Ile Ser Ile Ile Ile
Trp Met Val Ile His Ile Ser Met 65 70 75 80 Ile Asn Ile Lys Phe Tyr
Lys Phe Glu His Gln Ile Lys Glu Gln Asn 85 90 95 Ile Ser Ser Ile
Thr Gly Val Ile Lys Pro His Asp Ser Tyr Asn Tyr 100 105 110 Val Tyr
Asp Ser Asn Gly Tyr Ala Lys Leu Lys Asp Asn His Arg Tyr 115 120 125
Gly Arg Val Ile Arg Glu Thr Pro Tyr Ile Asp Val Val Ala Ser Asp 130
135 140 Val Lys Asn Lys Ser Ile Arg Leu Ser Leu Val Cys Gly Ile His
Ser 145 150 155 160 Tyr Ala Pro Cys Ala Asn Phe Ile Lys Phe Val Arg
165 170 81 729 DNA Neisseria meningitidis 81 atgagacata tgaaaaataa
aaattattta ctagtattta tagttttaca tatagccttg 60 atagtaatta
atatagtgtt tggttatttt gtttttctat ttgatttttt tgcgtttttg 120
ttttttgcaa acgtctttct tgctgtaaat ttattatttt tagaaaaaaa cataaaaaac
180 aaattattgt ttttattgcc gatttctatt attatatgga tggtaattca
tattagtatg 240 ataaatataa aattttataa atttgagcat caaataaagg
aacaaaatat atcctcgatt 300 actggggtga taaaaccaca tgatagttat
aattatgttt atgactcaaa tggatatgct 360 aaattaaaag ataatcatag
atatggtagg gtaattagag aaacacctta tattgatgta 420 gttgcatctg
atgttaaaaa taaatccata agattaagct tggtttgtgg tattcattca 480
tatgctccat gtgccaattt tataaaattt gcaaaaaaac ctgttaaaat ttatttttat
540 aatcaacctc aaggagattt tatagataat gtaatatttg aaattaatga
tggaaacaaa 600 agtttgtact tgttagataa gtataaaaca ttttttctta
ttgaaaacag tgtttgtatc 660 gtattaatta ttttatattt aaaatttaat
ttgcttttat ataggactta cttcaatgag 720 ttggaatag 729 82 242 PRT
Neisseria meningitidis 82 Met Arg His Met Lys Asn Lys Asn Tyr Leu
Leu Val Phe Ile Val Leu 1 5 10 15 His Ile Ala Leu Ile Val Ile Asn
Ile Val Phe Gly Tyr Phe Val Phe 20 25 30 Leu Phe Asp Phe Phe Ala
Phe Leu Phe Phe Ala Asn Val Phe Leu Ala 35 40 45 Val Asn Leu Leu
Phe Leu Glu Lys Asn Ile Lys Asn Lys Leu Leu Phe 50 55 60 Leu Leu
Pro Ile Ser Ile Ile Ile Trp Met Val Ile His Ile Ser Met 65 70 75 80
Ile Asn Ile Lys Phe Tyr Lys Phe Glu His Gln Ile Lys Glu Gln Asn 85
90 95 Ile Ser Ser Ile Thr Gly Val Ile Lys Pro His Asp Ser Tyr Asn
Tyr 100 105 110 Val Tyr Asp Ser Asn Gly Tyr Ala Lys Leu Lys Asp Asn
His Arg Tyr 115 120 125 Gly Arg Val Ile Arg Glu Thr Pro Tyr Ile Asp
Val Val Ala Ser Asp 130 135 140 Val Lys Asn Lys Ser Ile Arg Leu Ser
Leu Val Cys Gly Ile His Ser 145 150 155 160 Tyr Ala Pro Cys Ala Asn
Phe Ile Lys Phe Ala Lys Lys Pro Val Lys 165 170 175 Ile Tyr Phe Tyr
Asn Gln Pro Gln Gly Asp Phe Ile Asp Asn Val Ile 180 185 190 Phe Glu
Ile Asn Asp Gly Asn Lys Ser Leu Tyr Leu Leu Asp Lys Tyr 195 200 205
Lys Thr Phe Phe Leu Ile Glu Asn Ser Val Cys Ile Val Leu Ile Ile 210
215 220 Leu Tyr Leu Lys Phe Asn Leu Leu Leu Tyr Arg Thr Tyr Phe Asn
Glu 225 230 235 240 Leu Glu 83 729 DNA Neisseria meningitidis 83
atgagacata tgaaaaataa aaattattta ctagtattta tagttttaca tataaccttg
60 atagtaatta atatagtgtt tggttatttt gtttttctat ttgatttttt
tgcgtttttg 120 ttttttgcaa acgtctttct tgctgtaaat ttattatttt
tagaaaaaaa cataaaaaac 180 aaattattgt ttttattgcc gatttctatt
attatatgga tggtaattca tattagtatg 240 ataaatataa aattttataa
atttgagcat caaataaagg aacaaaatat atcctcgatt 300 actggggtga
taaaaccaca tgatagttat aattatgttt atgactcaaa tggatatgct 360
aaattaaaag ataatcatag atatggtagg gtaattagag aaacacctta tattgatgta
420 gttgcatctg atgttaaaaa taaatccata agattaagct tggtttgtgg
tattcattca 480 tatgctccat gtgccaattt tataaaattt gcaaaaaaac
ctgttaaaat ttatttttat 540 aatcaacctc aaggagattt tatagataat
gtaatatttg aaattaatga tggaaaaaaa 600 agtttgtact tgttagataa
gtataaaaca ttttttctta ttgaaaacag tgtttgtatc 660 gtattaatta
ttttatattt aaaatttaat ttgcttttat ataggactta cttcaatgag 720
ttggaatag 729 84 242 PRT Neisseria meningitidis 84 Met Arg His Met
Lys Asn Lys Asn Tyr Leu Leu Val Phe Ile Val Leu 1 5 10 15 His Ile
Thr Leu Ile Val Ile Asn Ile Val Phe Gly Tyr Phe Val Phe 20 25 30
Leu Phe Asp Phe Phe Ala Phe Leu Phe Phe Ala Asn Val Phe Leu Ala 35
40 45 Val Asn Leu Leu Phe Leu Glu Lys Asn Ile Lys Asn Lys Leu Leu
Phe 50 55 60 Leu Leu Pro Ile Ser Ile Ile Ile Trp Met Val Ile His
Ile Ser Met 65 70 75 80 Ile Asn Ile Lys Phe Tyr Lys Phe Glu His Gln
Ile Lys Glu Gln Asn 85 90 95 Ile Ser Ser Ile Thr Gly Val Ile Lys
Pro His Asp Ser Tyr Asn Tyr 100 105 110 Val Tyr Asp Ser Asn Gly Tyr
Ala Lys Leu Lys Asp Asn His Arg Tyr 115 120 125 Gly Arg Val Ile Arg
Glu Thr Pro Tyr Ile Asp Val Val Ala Ser Asp 130 135 140 Val Lys Asn
Lys Ser Ile Arg Leu Ser Leu Val Cys Gly Ile His Ser 145 150 155 160
Tyr Ala Pro Cys Ala Asn Phe Ile Lys Phe Ala Lys Lys Pro Val Lys 165
170 175 Ile Tyr Phe Tyr Asn Gln Pro Gln Gly Asp Phe Ile Asp Asn Val
Ile 180 185 190 Phe Glu Ile Asn Asp Gly Lys Lys Ser Leu Tyr Leu Leu
Asp Lys Tyr 195 200 205 Lys Thr Phe Phe Leu Ile Glu Asn Ser Val Cys
Ile Val Leu Ile Ile 210 215 220 Leu Tyr Leu Lys Phe Asn Leu Leu Leu
Tyr Arg Thr Tyr Phe Asn Glu 225 230 235 240 Leu Glu 85 552 DNA
Neisseria meningitidis 85 acccccaaca gcgtgaccgt cttgccgtct
ttcggcggat tcgggcgtac cggcgcgacc 60 atcaatgcag caggcggggt
cggcatgact gccttttcga caaccttaat ttccgtagcc 120 gagggcgcgg
ttgtagagct gcaggccgtg agagccaaag ccgtcaatgc aaccgccgct 180
tgcattttta cggtcttgag taaggacatt ttcgatttcc tttttatttt ccgttttcag
240 acggctgact tccgcctgta ttttcgccaa agccatgccg acagcgtgcg
ccttgacttc 300 atatttaaaa gcttccgcgc gtgccagttc cagttcgcgc
gcatagtttt gagccgacaa 360 cagcagggct tgcgccttgt cgcgctccat
cttgtcgatg accgcctgca gcttcgcaaa 420 tgccgacttg tagccttgat
ggtgcgacac agccaagccc gtgccgacaa gcgcgataat 480 ggcaatcggt
tgccagtaat tcgccagcag tttcacgaga ttcattctcg acctcctgac 540
gcttcacgct ga 552 86 183 PRT Neisseria meningitidis 86 Thr Pro Asn
Ser Val Thr Val Leu Pro Ser Phe Gly Gly Phe Gly Arg 1 5 10 15 Thr
Gly Ala Thr Ile Asn Ala Ala Gly Gly Val Gly Met Thr Ala Phe 20 25
30 Ser Thr Thr Leu Ile Ser Val Ala Glu Gly Ala Val Val Glu Leu Gln
35 40 45 Ala Val Arg Ala Lys Ala Val Asn Ala Thr Ala Ala Cys Ile
Phe Thr 50 55 60 Val Leu Ser Lys Asp Ile Phe Asp Phe Leu Phe Ile
Phe Arg Phe Gln 65 70 75 80 Thr Ala Asp Phe Arg Leu Tyr Phe Arg Gln
Ser His Ala Asp Ser Val 85 90 95 Arg Leu Asp Phe Ile Phe Lys Ser
Phe Arg Ala Cys Gln Phe Gln Phe 100 105 110 Ala Arg Ile Val Leu Ser
Arg Gln Gln Gln Gly Leu Arg Leu Val Ala 115 120 125 Leu His Leu Val
Asp Asp Arg Leu Gln Leu Arg Lys Cys Arg Leu Val 130 135 140 Ala Leu
Met Val Arg His Ser Gln Ala Arg Ala Asp Lys Arg Asp Asn 145 150 155
160 Gly Asn Arg Leu Pro Val Ile Arg Gln Gln Phe His Glu Ile His Ser
165 170 175 Arg Pro Pro Asp Ala Ser Arg 180 87 468 DNA Neisseria
meningitidis 87 atgactgcct tttcgacaac cttaatttcc gtagccgagg
gcgcggttgt agagctgcag 60 gccgtgagag ccaaagccgt caatgcaacc
gccgcttgca tttttacggt cttgagtaag 120 gacattttcg atttcctttt
tattttccgt tttcagacgg ctgacttccg cctgtttttt 180 cgccaaagcc
atgccgacag cgtgcgcctt gacttcatat tttttagctt ccgcgcgtgc 240
cagttccagt tcgcgcgcat agttttgagc cgacaacagc agggcttgcg ccttgtcgcg
300 ctccatcttg tcgatgaccg cctgctgctt cgcaaatgcc gacttgtagc
cttgatggtg 360 cgacacagcc aagcccgtgc cgacaagcgc gataatggca
atcggttgcc agttattcgc 420 cagcagtttc acgagattca ttctcgacct
cctgacgctt cacgctga 468 88 155 PRT Neisseria meningitidis 88 Met
Thr Ala Phe Ser Thr Thr Leu Ile Ser Val Ala Glu Gly Ala Val 1 5 10
15 Val Glu Leu Gln Ala Val Arg Ala Lys Ala Val Asn Ala Thr Ala Ala
20 25 30 Cys Ile Phe Thr Val Leu Ser Lys Asp Ile Phe Asp Phe Leu
Phe Ile 35 40 45 Phe Arg Phe Gln Thr Ala Asp Phe Arg Leu Phe Phe
Arg Gln Ser His 50 55 60 Ala Asp Ser Val Arg Leu Asp Phe Ile Phe
Phe Ser Phe Arg Ala Cys 65 70 75 80 Gln Phe Gln Phe Ala Arg Ile Val
Leu Ser Arg Gln Gln Gln Gly Leu 85 90 95 Arg Leu Val Ala Leu His
Leu Val Asp Asp Arg Leu Leu Leu Arg Lys 100 105 110 Cys Arg Leu Val
Ala Leu Met Val Arg His Ser Gln Ala Arg Ala Asp 115 120 125 Lys Arg
Asp Asn Gly Asn Arg Leu Pro Val Ile Arg Gln Gln Phe His 130 135 140
Glu Ile His Ser Arg Pro Pro Asp Ala Ser Arg 145 150 155 89 462 DNA
Neisseria meningitidis 89 atgaccgcct tttcgacaac cttaatttcc
gtagccgagg gcgcgcttgt agagctgcaa 60 gccgtgatgg ccaaagccgt
caatacaacc gccgcctgca tttttacggt cttgagtaag 120 gacattttcg
atttcctttt tattttccgt tttcagacgg ctgacttccg cctgtttttt 180
cgccaaagcc atgccgacgg cgtgcgcctt gacttcatat tttttagctt ccgcacgcgc
240 ctgttccagt tcgcgggcgt agttttgagc cgacaacagc agggcttgcg
ccttgtcgcg 300 cttcattttc tcaatgaccg
cctgctgctt cgcaaaagcc gacttgtagc cttgatggtg 360 cgacaccgcc
aaacccgtgc cgacaagcgc gatgatggca atcggttgcc agttattcgc 420
cagcagtttc acgagattca ttctcgacct cctgacgttt ga 462 90 153 PRT
Neisseria meningitidis 90 Met Thr Ala Phe Ser Thr Thr Leu Ile Ser
Val Ala Glu Gly Ala Leu 1 5 10 15 Val Glu Leu Gln Ala Val Met Ala
Lys Ala Val Asn Thr Thr Ala Ala 20 25 30 Cys Ile Phe Thr Val Leu
Ser Lys Asp Ile Phe Asp Phe Leu Phe Ile 35 40 45 Phe Arg Phe Gln
Thr Ala Asp Phe Arg Leu Phe Phe Arg Gln Ser His 50 55 60 Ala Asp
Gly Val Arg Leu Asp Phe Ile Phe Phe Ser Phe Arg Thr Arg 65 70 75 80
Leu Phe Gln Phe Ala Gly Val Val Leu Ser Arg Gln Gln Gln Gly Leu 85
90 95 Arg Leu Val Ala Leu His Phe Leu Asn Asp Arg Leu Leu Leu Arg
Lys 100 105 110 Ser Arg Leu Val Ala Leu Met Val Arg His Arg Gln Thr
Arg Ala Asp 115 120 125 Lys Arg Asp Asp Gly Asn Arg Leu Pro Val Ile
Arg Gln Gln Phe His 130 135 140 Glu Ile His Ser Arg Pro Pro Asp Val
145 150 91 592 PRT Neisseria meningitidis 91 Met Asn Lys Ile Tyr
Arg Ile Ile Trp Asn Ser Ala Leu Asn Ala Trp 1 5 10 15 Val Ala Val
Ser Glu Leu Thr Arg Asn His Thr Lys Arg Ala Ser Ala 20 25 30 Thr
Val Lys Thr Ala Val Leu Ala Thr Leu Leu Phe Ala Thr Val Gln 35 40
45 Ala Asn Ala Thr Asp Glu Asp Glu Glu Glu Glu Leu Glu Ser Val Gln
50 55 60 Arg Ser Val Val Gly Ser Ile Gln Ala Ser Met Glu Gly Ser
Gly Glu 65 70 75 80 Leu Glu Thr Ile Ser Leu Ser Met Thr Asn Asp Ser
Lys Glu Phe Val 85 90 95 Asp Pro Tyr Ile Val Val Thr Leu Lys Ala
Gly Asp Asn Leu Lys Ile 100 105 110 Lys Gln Asn Thr Asn Glu Asn Thr
Asn Ala Ser Ser Phe Thr Tyr Ser 115 120 125 Leu Lys Lys Asp Leu Thr
Gly Leu Ile Asn Val Glu Thr Glu Lys Leu 130 135 140 Ser Phe Gly Ala
Asn Gly Lys Lys Val Asn Ile Ile Ser Asp Thr Lys 145 150 155 160 Gly
Leu Asn Phe Ala Lys Glu Thr Ala Gly Thr Asn Gly Asp Thr Thr 165 170
175 Val His Leu Asn Gly Ile Gly Ser Thr Leu Thr Asp Thr Leu Ala Gly
180 185 190 Ser Ser Ala Ser His Val Asp Ala Gly Asn Gln Ser Thr His
Tyr Thr 195 200 205 Arg Ala Ala Ser Ile Lys Asp Val Leu Asn Ala Gly
Trp Asn Ile Lys 210 215 220 Gly Val Lys Thr Gly Ser Thr Thr Gly Gln
Ser Glu Asn Val Asp Phe 225 230 235 240 Val Arg Thr Tyr Asp Thr Val
Glu Phe Leu Ser Ala Asp Thr Lys Thr 245 250 255 Thr Thr Val Asn Val
Glu Ser Lys Asp Asn Gly Lys Arg Thr Glu Val 260 265 270 Lys Ile Gly
Ala Lys Thr Ser Val Ile Lys Glu Lys Asp Gly Lys Leu 275 280 285 Val
Thr Gly Lys Gly Lys Gly Glu Asn Gly Ser Ser Thr Asp Glu Gly 290 295
300 Glu Gly Leu Val Thr Ala Lys Glu Val Ile Asp Ala Val Asn Lys Ala
305 310 315 320 Gly Trp Arg Met Lys Thr Thr Thr Ala Asn Gly Gln Thr
Gly Gln Ala 325 330 335 Asp Lys Phe Glu Thr Val Thr Ser Gly Thr Asn
Val Thr Phe Ala Ser 340 345 350 Gly Lys Gly Thr Thr Ala Thr Val Ser
Lys Asp Asp Gln Gly Asn Ile 355 360 365 Thr Val Met Tyr Asp Val Asn
Val Gly Asp Ala Leu Asn Val Asn Gln 370 375 380 Leu Gln Asn Ser Gly
Trp Asn Leu Asp Ser Lys Ala Val Ala Gly Ser 385 390 395 400 Ser Gly
Lys Val Ile Ser Gly Asn Val Ser Pro Ser Lys Gly Lys Met 405 410 415
Asp Glu Thr Val Asn Ile Asn Ala Gly Asn Asn Ile Glu Ile Ser Arg 420
425 430 Asn Gly Lys Asn Ile Asp Ile Ala Thr Ser Met Ala Pro Gln Phe
Ser 435 440 445 Ser Val Ser Leu Gly Ala Gly Ala Asp Ala Pro Thr Leu
Ser Val Asp 450 455 460 Asp Glu Gly Ala Leu Asn Val Gly Ser Lys Asp
Ala Asn Lys Pro Val 465 470 475 480 Arg Ile Thr Asn Val Ala Pro Gly
Val Lys Glu Gly Asp Val Thr Asn 485 490 495 Val Ala Gln Leu Lys Gly
Val Ala Gln Asn Leu Asn Asn Arg Ile Asp 500 505 510 Asn Val Asp Gly
Asn Ala Arg Ala Gly Ile Ala Gln Ala Ile Ala Thr 515 520 525 Ala Gly
Leu Val Gln Ala Tyr Leu Pro Gly Lys Ser Met Met Ala Ile 530 535 540
Gly Gly Gly Thr Tyr Arg Gly Glu Ala Gly Tyr Ala Ile Gly Tyr Ser 545
550 555 560 Ser Ile Ser Asp Gly Gly Asn Trp Ile Ile Lys Gly Thr Ala
Ser Gly 565 570 575 Asn Ser Arg Gly His Phe Gly Ala Ser Ala Ser Val
Gly Tyr Gln Trp 580 585 590 92 594 PRT Neisseria meningitidis 92
Met Asn Lys Ile Tyr Arg Ile Ile Trp Asn Ser Ala Leu Asn Ala Trp 1 5
10 15 Val Val Val Ser Glu Leu Thr Arg Asn His Thr Lys Arg Ala Ser
Ala 20 25 30 Thr Val Ala Thr Ala Val Leu Ala Thr Leu Leu Phe Ala
Thr Val Gln 35 40 45 Ala Asn Ala Thr Asp Asp Asp Asp Leu Tyr Leu
Glu Pro Val Gln Arg 50 55 60 Thr Ala Val Val Leu Ser Phe Arg Ser
Asp Lys Glu Gly Thr Gly Glu 65 70 75 80 Lys Glu Gly Thr Glu Asp Ser
Asn Trp Ala Val Tyr Phe Asp Glu Lys 85 90 95 Arg Val Leu Lys Ala
Gly Ala Ile Thr Leu Lys Ala Gly Asp Asn Leu 100 105 110 Lys Ile Lys
Gln Asn Thr Asn Glu Asn Thr Asn Asp Ser Ser Phe Thr 115 120 125 Tyr
Ser Leu Lys Lys Asp Leu Thr Asp Leu Thr Ser Val Glu Thr Glu 130 135
140 Lys Leu Ser Phe Gly Ala Asn Gly Asn Lys Val Asn Ile Thr Ser Asp
145 150 155 160 Thr Lys Gly Leu Asn Phe Ala Lys Glu Thr Ala Gly Thr
Asn Gly Asp 165 170 175 Pro Thr Val His Leu Asn Gly Ile Gly Ser Thr
Leu Thr Asp Thr Leu 180 185 190 Leu Asn Thr Gly Ala Thr Thr Asn Val
Thr Asn Asp Asn Val Thr Asp 195 200 205 Asp Glu Lys Lys Arg Ala Ala
Ser Val Lys Asp Val Leu Asn Ala Gly 210 215 220 Trp Asn Ile Lys Gly
Val Lys Pro Gly Thr Thr Ala Ser Asp Asn Val 225 230 235 240 Asp Phe
Val Arg Thr Tyr Asp Thr Val Glu Phe Leu Ser Ala Asp Thr 245 250 255
Lys Thr Thr Thr Val Asn Val Glu Ser Lys Asp Asn Gly Lys Lys Thr 260
265 270 Glu Val Lys Ile Gly Ala Lys Thr Ser Val Ile Lys Glu Lys Asp
Gly 275 280 285 Lys Leu Val Thr Gly Lys Gly Lys Asp Glu Asn Gly Ser
Ser Thr Asp 290 295 300 Glu Gly Glu Gly Leu Val Thr Ala Lys Glu Val
Ile Asp Ala Val Asn 305 310 315 320 Lys Ala Gly Trp Arg Met Lys Thr
Thr Thr Ala Asn Gly Gln Thr Gly 325 330 335 Gln Ala Asp Lys Phe Glu
Thr Val Thr Ser Gly Thr Asn Val Thr Phe 340 345 350 Ala Ser Gly Lys
Gly Thr Thr Ala Thr Val Ser Lys Asp Asp Gln Gly 355 360 365 Asn Ile
Thr Val Lys Tyr Asp Val Asn Val Gly Asp Ala Leu Asn Val 370 375 380
Asn Gln Leu Gln Asn Ser Gly Trp Asn Leu Asp Ser Lys Ala Val Ala 385
390 395 400 Gly Ser Ser Gly Lys Val Ile Ser Gly Asn Val Ser Pro Ser
Lys Gly 405 410 415 Lys Met Asp Glu Thr Val Asn Ile Asn Ala Gly Asn
Asn Ile Glu Ile 420 425 430 Thr Arg Asn Gly Lys Asn Ile Asp Ile Ala
Thr Ser Met Ala Pro Gln 435 440 445 Phe Ser Ser Val Ser Leu Gly Ala
Gly Ala Asp Ala Pro Thr Leu Ser 450 455 460 Val Asp Asp Glu Gly Ala
Leu Asn Val Gly Ser Lys Asp Thr Asn Lys 465 470 475 480 Pro Val Arg
Ile Thr Asn Val Ala Pro Gly Val Lys Glu Gly Asp Val 485 490 495 Thr
Asn Val Ala Gln Leu Lys Gly Val Ala Gln Asn Leu Asn Asn Arg 500 505
510 Ile Asp Asn Val Asp Gly Asn Ala Arg Ala Gly Ile Ala Gln Ala Ile
515 520 525 Ala Thr Ala Gly Leu Val Gln Ala Tyr Leu Pro Gly Lys Ser
Met Met 530 535 540 Ala Ile Gly Gly Asp Thr Tyr Arg Gly Glu Ala Gly
Tyr Ala Ile Gly 545 550 555 560 Tyr Ser Ser Ile Ser Asp Gly Gly Asn
Trp Ile Ile Lys Gly Thr Ala 565 570 575 Ser Gly Asn Ser Arg Gly His
Phe Gly Ala Ser Ala Ser Val Gly Tyr 580 585 590 Gln Trp 93 594 PRT
Neisseria meningitidis 93 Met Asn Lys Ile Tyr Arg Ile Ile Trp Asn
Ser Ala Leu Asn Ala Trp 1 5 10 15 Val Ala Val Ser Glu Leu Thr Arg
Asn His Thr Lys Arg Ala Ser Ala 20 25 30 Thr Val Ala Thr Ala Val
Leu Ala Thr Leu Leu Phe Ala Thr Val Gln 35 40 45 Ala Ser Thr Thr
Asp Asp Asp Asp Leu Tyr Leu Glu Pro Val Gln Arg 50 55 60 Thr Ala
Pro Val Leu Ser Phe His Ala Asp Ser Glu Gly Thr Gly Glu 65 70 75 80
Lys Glu Val Thr Glu Asp Ser Asn Trp Gly Val Tyr Phe Asp Lys Lys 85
90 95 Gly Val Leu Thr Ala Gly Thr Ile Thr Leu Lys Ala Gly Asp Asn
Leu 100 105 110 Lys Ile Lys Gln Asn Thr Asp Glu Asn Thr Asn Ala Ser
Ser Phe Thr 115 120 125 Tyr Ser Leu Lys Lys Asp Leu Thr Asp Leu Thr
Ser Val Glu Thr Glu 130 135 140 Lys Leu Ser Phe Gly Ala Asn Gly Lys
Lys Val Asn Ile Thr Ser Asp 145 150 155 160 Thr Lys Gly Leu Asn Phe
Ala Lys Glu Thr Ala Gly Thr Asn Gly Asp 165 170 175 Thr Thr Val His
Leu Asn Gly Ile Gly Ser Thr Leu Thr Asp Thr Leu 180 185 190 Leu Asn
Thr Gly Ala Thr Thr Asn Val Thr Asn Asp Asn Val Thr Asp 195 200 205
Asp Glu Lys Lys Arg Ala Ala Ser Val Lys Asp Val Leu Asn Ala Gly 210
215 220 Trp Asn Ile Lys Gly Val Lys Pro Gly Thr Thr Ala Ser Asp Asn
Val 225 230 235 240 Asp Phe Val Arg Thr Tyr Asp Thr Val Glu Phe Leu
Ser Ala Asp Thr 245 250 255 Lys Thr Thr Thr Val Asn Val Glu Ser Lys
Asp Asn Gly Lys Lys Thr 260 265 270 Glu Val Lys Ile Gly Ala Lys Thr
Ser Val Ile Lys Glu Lys Asp Gly 275 280 285 Lys Leu Val Thr Gly Lys
Asp Lys Gly Glu Asn Gly Ser Ser Thr Asp 290 295 300 Glu Gly Glu Gly
Leu Val Thr Ala Lys Glu Val Ile Asp Ala Val Asn 305 310 315 320 Lys
Ala Gly Trp Arg Met Lys Thr Thr Thr Ala Asn Gly Gln Thr Gly 325 330
335 Gln Ala Asp Lys Phe Glu Thr Val Thr Ser Gly Thr Lys Val Thr Phe
340 345 350 Ala Ser Gly Asn Gly Thr Thr Ala Thr Val Ser Lys Asp Asp
Gln Gly 355 360 365 Asn Ile Thr Val Lys Tyr Asp Val Asn Val Gly Asp
Ala Leu Asn Val 370 375 380 Asn Gln Leu Gln Asn Ser Gly Trp Asn Leu
Asp Ser Lys Ala Val Ala 385 390 395 400 Gly Ser Ser Gly Lys Val Ile
Ser Gly Asn Val Ser Pro Ser Lys Gly 405 410 415 Lys Met Asp Glu Thr
Val Asn Ile Asn Ala Gly Asn Asn Ile Glu Ile 420 425 430 Thr Arg Asn
Gly Lys Asn Ile Asp Ile Ala Thr Ser Met Thr Pro Gln 435 440 445 Phe
Ser Ser Val Ser Leu Gly Ala Gly Ala Asp Ala Pro Thr Leu Ser 450 455
460 Val Asp Asp Glu Gly Ala Leu Asn Val Gly Ser Lys Asp Ala Asn Lys
465 470 475 480 Pro Val Arg Ile Thr Asn Val Ala Pro Gly Val Lys Glu
Gly Asp Val 485 490 495 Thr Asn Val Ala Gln Leu Lys Gly Val Ala Gln
Asn Leu Asn Asn His 500 505 510 Ile Asp Asn Val Asp Gly Asn Ala Arg
Ala Gly Ile Ala Gln Ala Ile 515 520 525 Ala Thr Ala Gly Leu Val Gln
Ala Tyr Leu Pro Gly Lys Ser Met Met 530 535 540 Ala Ile Gly Gly Gly
Thr Tyr Arg Gly Glu Ala Gly Tyr Ala Ile Gly 545 550 555 560 Tyr Ser
Ser Ile Ser Asp Gly Gly Asn Trp Ile Ile Lys Gly Thr Ala 565 570 575
Ser Gly Asn Ser Arg Gly His Phe Gly Ala Ser Ala Ser Val Gly Tyr 580
585 590 Gln Trp 94 594 PRT Neisseria meningitidis 94 Met Asn Lys
Ile Tyr Arg Ile Ile Trp Asn Ser Ala Leu Asn Ala Trp 1 5 10 15 Val
Val Val Ser Glu Leu Thr Arg Asn His Thr Lys Arg Ala Ser Ala 20 25
30 Thr Val Ala Thr Ala Val Leu Ala Thr Leu Leu Phe Ala Thr Val Gln
35 40 45 Ala Asn Ala Thr Asp Asp Asp Asp Leu Tyr Leu Glu Pro Val
Gln Arg 50 55 60 Thr Ala Val Val Leu Ser Phe Arg Ser Asp Lys Glu
Gly Thr Gly Glu 65 70 75 80 Lys Glu Gly Thr Glu Asp Ser Asn Trp Ala
Val Tyr Phe Asp Glu Lys 85 90 95 Arg Val Leu Lys Ala Gly Ala Ile
Thr Leu Lys Ala Gly Asp Asn Leu 100 105 110 Lys Ile Lys Gln Asn Thr
Asn Glu Asn Thr Asn Asp Ser Ser Phe Thr 115 120 125 Tyr Ser Leu Lys
Lys Asp Leu Thr Asp Leu Thr Ser Val Glu Thr Glu 130 135 140 Lys Leu
Ser Phe Gly Ala Asn Gly Asn Lys Val Asn Ile Thr Ser Asp 145 150 155
160 Thr Lys Gly Leu Asn Phe Ala Lys Glu Thr Ala Gly Thr Asn Gly Asp
165 170 175 Pro Thr Val His Leu Asn Gly Ile Gly Ser Thr Leu Thr Asp
Thr Leu 180 185 190 Leu Asn Thr Gly Ala Thr Thr Asn Val Thr Asn Asp
Asn Val Thr Asp 195 200 205 Asp Glu Lys Lys Arg Ala Ala Ser Val Lys
Asp Val Leu Asn Ala Gly 210 215 220 Trp Asn Ile Lys Gly Val Lys Pro
Gly Thr Thr Ala Ser Asp Asn Val 225 230 235 240 Asp Phe Val Arg Thr
Tyr Asp Thr Val Glu Phe Leu Ser Ala Asp Thr 245 250 255 Lys Thr Thr
Thr Val Asn Val Glu Ser Lys Asp Asn Gly Lys Lys Thr 260 265 270 Glu
Val Lys Ile Gly Ala Lys Thr Ser Val Ile Lys Glu Lys Asp Gly 275 280
285 Lys Leu Val Thr Gly Lys Gly Lys Asp Glu Asn Gly Ser Ser Thr Asp
290 295 300 Glu Gly Glu Gly Leu Val Thr Ala Lys Glu Val Ile Asp Ala
Val Asn 305 310 315 320 Lys Ala Gly Trp Arg Met Lys Thr Thr Thr Ala
Asn Gly Gln Thr Gly 325 330 335 Gln Ala Asp Lys Phe Glu Thr Val Thr
Ser Gly Thr Asn Val Thr Phe 340 345 350 Ala Ser Gly Lys Gly Thr Thr
Ala Thr Val Ser Lys Asp Asp Gln Gly 355 360 365 Asn Ile Thr Val Lys
Tyr Asp Val Asn Val Gly Asp Ala Leu Asn Val 370 375 380 Asn Gln Leu
Gln Asn Ser Gly Trp Asn Leu Asp Ser Lys Ala Val Ala 385 390 395 400
Gly Ser Ser Gly Lys Val Ile Ser Gly Asn Val Ser Pro Ser Lys Gly 405
410 415 Lys Met Asp Glu Thr Val Asn Ile Asn Ala Gly Asn Asn Ile Glu
Ile 420 425 430 Thr Arg Asn Gly Lys Asn Ile Asp Ile Ala Thr Ser Met
Ala Pro Gln 435 440 445 Phe Ser Ser Val Ser Leu Gly Ala Gly Ala Asp
Ala Pro Thr Leu Ser 450 455 460 Val Asp Asp Glu Gly
Ala Leu Asn Val Gly Ser Lys Asp Thr Asn Lys 465 470 475 480 Pro Val
Arg Ile Thr Asn Val Ala Pro Gly Val Lys Glu Gly Asp Val 485 490 495
Thr Asn Val Ala Gln Leu Lys Gly Val Ala Gln Asn Leu Asn Asn Arg 500
505 510 Ile Asp Asn Val Asp Gly Asn Ala Arg Ala Gly Ile Ala Gln Ala
Ile 515 520 525 Ala Thr Ala Gly Leu Val Gln Ala Tyr Leu Pro Gly Lys
Ser Met Met 530 535 540 Ala Ile Gly Gly Asp Thr Tyr Arg Gly Glu Ala
Gly Tyr Ala Ile Gly 545 550 555 560 Tyr Ser Ser Ile Ser Asp Gly Gly
Asn Trp Ile Ile Lys Gly Thr Ala 565 570 575 Ser Gly Asn Ser Arg Gly
His Phe Gly Ala Ser Ala Ser Val Gly Tyr 580 585 590 Gln Trp 95 591
PRT Neisseria meningitidis 95 Met Asn Lys Ile Tyr Arg Ile Ile Trp
Asn Ser Ala Leu Asn Ala Trp 1 5 10 15 Val Val Val Ser Glu Leu Thr
Arg Asn His Thr Lys Arg Ala Ser Ala 20 25 30 Thr Val Glu Thr Ala
Val Leu Ala Thr Leu Leu Phe Ala Thr Val Gln 35 40 45 Ala Ser Ala
Asn Asn Glu Glu Gln Glu Glu Asp Leu Tyr Leu Asp Pro 50 55 60 Val
Gln Arg Thr Val Ala Val Leu Ile Val Asn Ser Asp Lys Glu Gly 65 70
75 80 Thr Gly Glu Lys Glu Lys Val Glu Glu Asn Ser Asp Trp Ala Val
Tyr 85 90 95 Phe Asn Glu Lys Gly Val Leu Thr Ala Arg Glu Ile Thr
Leu Lys Ala 100 105 110 Gly Asp Asn Leu Lys Ile Lys Gln Asn Gly Thr
Asn Phe Thr Tyr Ser 115 120 125 Leu Lys Lys Asp Leu Thr Asp Leu Thr
Ser Val Gly Thr Glu Lys Leu 130 135 140 Ser Phe Ser Ala Asn Gly Asn
Lys Val Asn Ile Thr Ser Asp Thr Lys 145 150 155 160 Gly Leu Asn Phe
Ala Lys Glu Thr Ala Gly Thr Asn Gly Asp Thr Thr 165 170 175 Val His
Leu Asn Gly Ile Gly Ser Thr Leu Thr Asp Thr Leu Leu Asn 180 185 190
Thr Gly Ala Thr Thr Asn Val Thr Asn Asp Asn Val Thr Asp Asp Glu 195
200 205 Lys Lys Arg Ala Ala Ser Val Lys Asp Val Leu Asn Ala Gly Trp
Asn 210 215 220 Ile Lys Gly Val Lys Pro Gly Thr Thr Ala Ser Asp Asn
Val Asp Phe 225 230 235 240 Val Arg Thr Tyr Asp Thr Val Glu Phe Leu
Ser Ala Asp Thr Lys Thr 245 250 255 Thr Thr Val Asn Val Glu Ser Lys
Asp Asn Gly Lys Lys Thr Glu Val 260 265 270 Lys Ile Gly Ala Lys Thr
Ser Val Ile Lys Glu Lys Asp Gly Lys Leu 275 280 285 Val Thr Gly Lys
Asp Lys Gly Glu Asn Gly Ser Ser Thr Asp Glu Gly 290 295 300 Glu Gly
Leu Val Thr Ala Lys Glu Val Ile Asp Ala Val Asn Lys Ala 305 310 315
320 Gly Trp Arg Met Lys Thr Thr Thr Ala Asn Gly Gln Thr Gly Gln Ala
325 330 335 Asp Lys Phe Glu Thr Val Thr Ser Gly Thr Asn Val Thr Phe
Ala Ser 340 345 350 Gly Lys Gly Thr Thr Ala Thr Val Ser Lys Asp Asp
Gln Gly Asn Ile 355 360 365 Thr Val Met Tyr Asp Val Asn Val Gly Asp
Ala Leu Asn Val Asn Gln 370 375 380 Leu Gln Asn Ser Gly Trp Asn Leu
Asp Ser Lys Ala Val Ala Gly Ser 385 390 395 400 Ser Gly Lys Val Ile
Ser Gly Asn Val Ser Pro Ser Lys Gly Lys Met 405 410 415 Asp Glu Thr
Val Asn Ile Asn Ala Gly Asn Asn Ile Glu Ile Thr Arg 420 425 430 Asn
Gly Lys Asn Ile Asp Ile Ala Thr Ser Met Thr Pro Gln Phe Ser 435 440
445 Ser Val Ser Leu Gly Ala Gly Ala Asp Ala Pro Thr Leu Ser Val Asp
450 455 460 Gly Asp Ala Leu Asn Val Gly Ser Lys Lys Asp Asn Lys Pro
Val Arg 465 470 475 480 Ile Thr Asn Val Ala Pro Gly Val Lys Glu Gly
Asp Val Thr Asn Val 485 490 495 Ala Gln Leu Lys Gly Val Ala Gln Asn
Leu Asn Asn Arg Ile Asp Asn 500 505 510 Val Asp Gly Asn Ala Arg Ala
Gly Ile Ala Gln Ala Ile Ala Thr Ala 515 520 525 Gly Leu Val Gln Ala
Tyr Leu Pro Gly Lys Ser Met Met Ala Ile Gly 530 535 540 Gly Gly Thr
Tyr Arg Gly Glu Ala Gly Tyr Ala Ile Gly Tyr Ser Ser 545 550 555 560
Ile Ser Asp Gly Gly Asn Trp Ile Ile Lys Gly Thr Ala Ser Gly Asn 565
570 575 Ser Arg Gly His Phe Gly Ala Ser Ala Ser Val Gly Tyr Gln Trp
580 585 590 96 591 PRT Neisseria meningitidis 96 Met Asn Lys Ile
Tyr Arg Ile Ile Trp Asn Ser Ala Leu Asn Ala Trp 1 5 10 15 Val Val
Val Ser Glu Leu Thr Arg Asn His Thr Lys Arg Ala Ser Ala 20 25 30
Thr Val Lys Thr Ala Val Leu Ala Thr Leu Leu Phe Ala Thr Val Gln 35
40 45 Ala Ser Ala Asn Asn Glu Glu Gln Glu Glu Asp Leu Tyr Leu Asp
Pro 50 55 60 Val Gln Arg Thr Val Ala Val Leu Ile Val Asn Ser Asp
Lys Glu Gly 65 70 75 80 Thr Gly Glu Lys Glu Lys Val Glu Glu Asn Ser
Asp Trp Ala Val Tyr 85 90 95 Phe Asn Glu Lys Gly Val Leu Thr Ala
Arg Glu Ile Thr Leu Lys Ala 100 105 110 Gly Asp Asn Leu Lys Ile Lys
Gln Asn Gly Thr Asn Phe Thr Tyr Ser 115 120 125 Leu Lys Lys Asp Leu
Thr Asp Leu Thr Ser Val Gly Thr Glu Lys Leu 130 135 140 Ser Phe Ser
Ala Asn Gly Asn Lys Val Asn Ile Thr Ser Asp Thr Lys 145 150 155 160
Gly Leu Asn Phe Ala Lys Glu Thr Ala Gly Thr Asn Gly Asp Thr Thr 165
170 175 Val His Leu Asn Gly Ile Gly Ser Thr Leu Thr Asp Thr Leu Leu
Asn 180 185 190 Thr Gly Ala Thr Thr Asn Val Thr Asn Asp Asn Val Thr
Asp Asp Glu 195 200 205 Lys Lys Arg Ala Ala Ser Val Lys Asp Val Leu
Asn Ala Gly Trp Asn 210 215 220 Ile Lys Gly Val Lys Pro Gly Thr Thr
Ala Ser Asp Asn Val Asp Phe 225 230 235 240 Val Arg Thr Tyr Asp Thr
Val Glu Phe Leu Ser Ala Asp Thr Lys Thr 245 250 255 Thr Thr Val Asn
Val Glu Ser Lys Asp Asn Gly Lys Lys Thr Glu Val 260 265 270 Lys Ile
Gly Ala Lys Thr Ser Val Ile Lys Glu Lys Asp Gly Lys Leu 275 280 285
Val Thr Gly Lys Asp Lys Gly Glu Asn Gly Ser Ser Thr Asp Glu Gly 290
295 300 Glu Gly Leu Val Thr Ala Lys Glu Val Ile Asp Ala Val Asn Lys
Ala 305 310 315 320 Gly Trp Arg Met Lys Thr Thr Thr Ala Asn Gly Gln
Thr Gly Gln Ala 325 330 335 Asp Lys Phe Glu Thr Val Thr Ser Gly Thr
Asn Val Thr Phe Ala Ser 340 345 350 Gly Lys Gly Thr Thr Ala Thr Val
Ser Lys Asp Asp Gln Gly Asn Ile 355 360 365 Thr Val Met Tyr Asp Val
Asn Val Gly Asp Ala Leu Asn Val Asn Gln 370 375 380 Leu Gln Asn Ser
Gly Trp Asn Leu Asp Ser Lys Ala Val Ala Gly Ser 385 390 395 400 Ser
Gly Lys Val Ile Ser Gly Asn Val Ser Pro Ser Lys Gly Lys Met 405 410
415 Asp Glu Thr Val Asn Ile Asn Ala Gly Asn Asn Ile Glu Ile Thr Arg
420 425 430 Asn Gly Lys Asn Ile Asp Ile Ala Thr Ser Met Thr Pro Gln
Phe Ser 435 440 445 Ser Val Ser Leu Gly Ala Gly Ala Asp Ala Pro Thr
Leu Ser Val Asp 450 455 460 Gly Asp Ala Leu Asn Val Gly Ser Lys Lys
Asp Asn Lys Pro Val Arg 465 470 475 480 Ile Thr Asn Val Ala Pro Gly
Val Lys Glu Gly Asp Val Thr Asn Val 485 490 495 Ala Gln Leu Lys Gly
Val Ala Gln Asn Leu Asn Asn Arg Ile Asp Asn 500 505 510 Val Asp Gly
Asn Ala Arg Ala Gly Ile Ala Gln Ala Ile Ala Thr Ala 515 520 525 Gly
Leu Val Gln Ala Tyr Leu Pro Gly Lys Ser Met Met Ala Ile Gly 530 535
540 Gly Gly Thr Tyr Arg Gly Glu Ala Gly Tyr Ala Ile Gly Tyr Ser Ser
545 550 555 560 Ile Ser Asp Gly Gly Asn Trp Ile Ile Lys Gly Thr Ala
Ser Gly Asn 565 570 575 Ser Arg Gly His Phe Gly Ala Ser Ala Ser Val
Gly Tyr Gln Trp 580 585 590 97 595 PRT Neisseria meningitidis 97
Met Asn Lys Ile Tyr Arg Ile Ile Trp Asn Ser Ala Leu Asn Ala Trp 1 5
10 15 Val Val Val Ser Glu Leu Thr Arg Asn His Thr Lys Arg Ala Ser
Ala 20 25 30 Thr Val Glu Thr Ala Val Leu Ala Thr Leu Leu Phe Ala
Thr Val Gln 35 40 45 Ala Asn Ala Thr Asp Thr Asp Glu Asp Asp Glu
Leu Glu Pro Val Val 50 55 60 Arg Ser Ala Leu Val Leu Gln Phe Met
Ile Asp Lys Glu Gly Asn Gly 65 70 75 80 Glu Ile Glu Ser Thr Gly Asp
Ile Gly Trp Ser Ile Tyr Tyr Asp Asp 85 90 95 His Asn Thr Leu His
Gly Ala Thr Val Thr Leu Lys Ala Gly Asp Asn 100 105 110 Leu Lys Ile
Lys Gln Asn Thr Asp Glu Asn Thr Asn Ala Ser Ser Phe 115 120 125 Thr
Tyr Ser Leu Lys Lys Asp Leu Thr Asp Leu Thr Ser Val Gly Thr 130 135
140 Glu Glu Leu Ser Phe Gly Ala Asn Gly Asn Lys Val Asn Ile Thr Ser
145 150 155 160 Asp Thr Lys Gly Leu Asn Phe Ala Lys Lys Thr Ala Gly
Thr Asn Gly 165 170 175 Asp Thr Thr Val His Leu Asn Gly Ile Gly Ser
Thr Leu Thr Asp Thr 180 185 190 Leu Ala Gly Ser Ser Ala Ser His Val
Asp Ala Gly Asn Gln Ser Thr 195 200 205 His Tyr Thr Arg Ala Ala Ser
Ile Lys Asp Val Leu Asn Ala Gly Trp 210 215 220 Asn Ile Lys Gly Val
Lys Thr Gly Ser Thr Thr Gly Gln Ser Glu Asn 225 230 235 240 Val Asp
Phe Val Arg Thr Tyr Asp Thr Val Glu Phe Leu Ser Ala Asp 245 250 255
Thr Lys Thr Thr Thr Val Asn Val Glu Ser Lys Asp Asn Gly Lys Arg 260
265 270 Thr Glu Val Lys Ile Gly Ala Lys Thr Ser Val Ile Lys Glu Lys
Asp 275 280 285 Gly Lys Leu Val Thr Gly Lys Gly Lys Gly Glu Asn Gly
Ser Ser Thr 290 295 300 Asp Glu Gly Glu Gly Leu Val Thr Ala Lys Glu
Val Ile Asp Ala Val 305 310 315 320 Asn Lys Ala Gly Trp Arg Met Lys
Thr Thr Thr Ala Asn Gly Gln Thr 325 330 335 Gly Gln Ala Asp Lys Phe
Glu Thr Val Thr Ser Gly Thr Asn Val Thr 340 345 350 Phe Ala Ser Gly
Lys Gly Thr Thr Ala Thr Val Ser Lys Asp Asp Gln 355 360 365 Gly Asn
Ile Thr Val Lys Tyr Asp Val Asn Val Gly Asp Ala Leu Asn 370 375 380
Val Asn Gln Leu Gln Asn Ser Gly Trp Asn Leu Asp Ser Lys Ala Val 385
390 395 400 Ala Gly Ser Ser Gly Lys Val Ile Ser Gly Asn Val Ser Pro
Ser Lys 405 410 415 Gly Lys Met Asp Glu Thr Val Asn Ile Asn Ala Gly
Asn Asn Ile Glu 420 425 430 Ile Thr Arg Asn Gly Lys Asn Ile Asp Ile
Ala Thr Ser Met Thr Pro 435 440 445 Gln Phe Ser Ser Val Ser Leu Gly
Ala Gly Ala Asp Ala Pro Thr Leu 450 455 460 Ser Val Asp Asp Glu Gly
Ala Leu Asn Val Gly Ser Lys Asp Ala Asn 465 470 475 480 Lys Pro Val
Arg Ile Thr Asn Val Ala Pro Gly Val Lys Glu Gly Asp 485 490 495 Val
Thr Asn Val Ala Gln Leu Lys Gly Val Ala Gln Asn Leu Asn Asn 500 505
510 His Ile Asp Asn Val Asp Gly Asn Ala Arg Ala Gly Ile Ala Gln Ala
515 520 525 Ile Ala Thr Ala Gly Leu Val Gln Ala Tyr Leu Pro Gly Lys
Ser Met 530 535 540 Met Ala Ile Gly Gly Gly Thr Tyr Arg Gly Glu Ala
Gly Tyr Ala Ile 545 550 555 560 Gly Tyr Ser Ser Ile Ser Asp Gly Gly
Asn Trp Ile Ile Lys Gly Thr 565 570 575 Ala Ser Gly Asn Ser Arg Gly
His Phe Gly Ala Ser Ala Ser Val Gly 580 585 590 Tyr Gln Trp 595 98
592 PRT Neisseria meningitidis 98 Met Asn Lys Ile Tyr Arg Ile Ile
Trp Asn Ser Ala Leu Asn Ala Trp 1 5 10 15 Val Ala Val Ser Glu Leu
Thr Arg Asn His Thr Lys Arg Ala Ser Ala 20 25 30 Thr Val Lys Thr
Ala Val Leu Ala Thr Leu Leu Phe Ala Thr Val Gln 35 40 45 Ala Asn
Ala Thr Asp Glu Asp Glu Glu Glu Glu Leu Glu Ser Val Gln 50 55 60
Arg Ser Val Val Gly Ser Ile Gln Ala Ser Met Glu Gly Ser Gly Glu 65
70 75 80 Leu Glu Thr Ile Ser Leu Ser Met Thr Asn Asp Ser Lys Glu
Phe Val 85 90 95 Asp Pro Tyr Ile Val Val Thr Leu Lys Ala Gly Asp
Asn Leu Lys Ile 100 105 110 Lys Gln Asn Thr Asn Glu Asn Thr Asn Ala
Ser Ser Phe Thr Tyr Ser 115 120 125 Leu Lys Lys Asp Leu Thr Gly Leu
Ile Asn Val Glu Thr Glu Lys Leu 130 135 140 Ser Phe Gly Ala Asn Gly
Lys Lys Val Asn Ile Ile Ser Asp Thr Lys 145 150 155 160 Gly Leu Asn
Phe Ala Lys Glu Thr Ala Gly Thr Asn Gly Asp Thr Thr 165 170 175 Val
His Leu Asn Gly Ile Gly Ser Thr Leu Thr Asp Thr Leu Ala Gly 180 185
190 Ser Ser Ala Ser His Val Asp Ala Gly Asn Gln Ser Thr His Tyr Thr
195 200 205 Arg Ala Ala Ser Ile Lys Asp Val Leu Asn Ala Gly Trp Asn
Ile Lys 210 215 220 Gly Val Lys Thr Gly Ser Thr Thr Gly Gln Ser Glu
Asn Val Asp Phe 225 230 235 240 Val Arg Thr Tyr Asp Thr Val Glu Phe
Leu Ser Ala Asp Thr Lys Thr 245 250 255 Thr Thr Val Asn Val Glu Ser
Lys Asp Asn Gly Lys Arg Thr Glu Val 260 265 270 Lys Ile Gly Ala Lys
Thr Ser Val Ile Lys Glu Lys Asp Gly Lys Leu 275 280 285 Val Thr Gly
Lys Gly Lys Gly Glu Asn Gly Ser Ser Thr Asp Glu Gly 290 295 300 Glu
Gly Leu Val Thr Ala Lys Glu Val Ile Asp Ala Val Asn Lys Ala 305 310
315 320 Gly Trp Arg Met Lys Thr Thr Thr Ala Asn Gly Gln Thr Gly Gln
Ala 325 330 335 Asp Lys Phe Glu Thr Val Thr Ser Gly Thr Asn Val Thr
Phe Ala Ser 340 345 350 Gly Lys Gly Thr Thr Ala Thr Val Ser Lys Asp
Asp Gln Gly Asn Ile 355 360 365 Thr Val Met Tyr Asp Val Asn Val Gly
Asp Ala Leu Asn Val Asn Gln 370 375 380 Leu Gln Asn Ser Gly Trp Asn
Leu Asp Ser Lys Ala Val Ala Gly Ser 385 390 395 400 Ser Gly Lys Val
Ile Ser Gly Asn Val Ser Pro Ser Lys Gly Lys Met 405 410 415 Asp Glu
Thr Val Asn Ile Asn Ala Gly Asn Asn Ile Glu Ile Ser Arg 420 425 430
Asn Gly Lys Asn Ile Asp Ile Ala Thr Ser Met Ala Pro Gln Phe Ser 435
440 445 Ser Val Ser Leu Gly Ala Gly Ala Asp Ala Pro Thr Leu Ser Val
Asp 450 455 460 Asp Glu Gly Ala Leu Asn Val Gly Ser Lys Asp Ala Asn
Lys Pro Val 465 470 475 480 Arg Ile Thr Asn Val Ala Pro Gly Val Lys
Glu Gly Asp Val Thr Asn 485 490 495 Val Ala Gln Leu Lys Gly Val Ala
Gln Asn Leu Asn Asn Arg Ile Asp 500 505 510 Asn Val Asp Gly Asn Ala
Arg Ala Gly Ile Ala Gln Ala Ile Ala Thr
515 520 525 Ala Gly Leu Val Gln Ala Tyr Leu Pro Gly Lys Ser Met Met
Ala Ile 530 535 540 Gly Gly Gly Thr Tyr Arg Gly Glu Ala Gly Tyr Ala
Ile Gly Tyr Ser 545 550 555 560 Ser Ile Ser Asp Gly Gly Asn Trp Ile
Ile Lys Gly Thr Ala Ser Gly 565 570 575 Asn Ser Arg Gly His Phe Gly
Ala Ser Ala Ser Val Gly Tyr Gln Trp 580 585 590 99 594 PRT
Neisseria meningitidis 99 Met Asn Lys Ile Tyr Arg Ile Ile Trp Asn
Ser Ala Leu Asn Ala Trp 1 5 10 15 Val Val Val Ser Glu Leu Thr Arg
Asn His Thr Lys Arg Ala Ser Ala 20 25 30 Thr Val Ala Thr Ala Val
Leu Ala Thr Leu Leu Phe Ala Thr Val Gln 35 40 45 Ala Ser Thr Thr
Asp Asp Asp Asp Leu Tyr Leu Glu Pro Val Gln Arg 50 55 60 Thr Ala
Pro Val Leu Ser Phe His Ala Asp Ser Glu Gly Thr Gly Glu 65 70 75 80
Lys Glu Val Thr Glu Asp Ser Asn Trp Gly Val Tyr Phe Asp Lys Lys 85
90 95 Gly Val Leu Thr Ala Gly Thr Ile Thr Leu Lys Ala Gly Asp Asn
Leu 100 105 110 Lys Ile Lys Gln Asn Thr Asp Glu Asn Thr Asn Ala Ser
Ser Phe Thr 115 120 125 Tyr Ser Leu Lys Lys Asp Leu Thr Asp Leu Thr
Ser Val Glu Thr Glu 130 135 140 Lys Leu Ser Phe Gly Ala Asn Gly Lys
Lys Val Asn Ile Thr Ser Asp 145 150 155 160 Thr Lys Gly Leu Asn Phe
Ala Lys Glu Thr Ala Gly Thr Asn Gly Asp 165 170 175 Thr Thr Val His
Leu Asn Gly Ile Gly Ser Thr Leu Thr Asp Thr Leu 180 185 190 Leu Asn
Thr Gly Ala Thr Thr Asn Val Thr Asn Asp Asn Val Thr Asp 195 200 205
Asp Glu Lys Lys Arg Ala Ala Ser Val Lys Asp Val Leu Asn Ala Gly 210
215 220 Trp Asn Ile Lys Gly Val Lys Pro Gly Thr Thr Ala Ser Asp Asn
Val 225 230 235 240 Asp Phe Val Arg Thr Tyr Asp Thr Val Glu Phe Leu
Ser Ala Asp Thr 245 250 255 Lys Thr Thr Thr Val Asn Val Glu Ser Lys
Asp Asn Gly Lys Lys Thr 260 265 270 Glu Val Lys Ile Gly Ala Lys Thr
Ser Val Ile Lys Glu Lys Asp Gly 275 280 285 Lys Leu Val Thr Gly Lys
Asp Lys Gly Glu Asn Gly Ser Ser Thr Asp 290 295 300 Glu Gly Glu Gly
Leu Val Thr Ala Lys Glu Val Ile Asp Ala Val Asn 305 310 315 320 Lys
Ala Gly Trp Arg Met Lys Thr Thr Thr Ala Asn Gly Gln Thr Gly 325 330
335 Gln Ala Asp Lys Phe Glu Thr Val Thr Ser Gly Thr Lys Val Thr Phe
340 345 350 Ala Ser Gly Asn Gly Thr Thr Ala Thr Val Ser Lys Asp Asp
Gln Gly 355 360 365 Asn Ile Thr Val Lys Tyr Asp Val Asn Val Gly Asp
Ala Leu Asn Val 370 375 380 Asn Gln Leu Gln Asn Ser Gly Trp Asn Leu
Asp Ser Lys Ala Val Ala 385 390 395 400 Gly Ser Ser Gly Lys Val Ile
Ser Gly Asn Val Ser Pro Ser Lys Gly 405 410 415 Lys Met Asp Glu Thr
Val Asn Ile Asn Ala Gly Asn Asn Ile Glu Ile 420 425 430 Thr Arg Asn
Gly Lys Asn Ile Asp Ile Ala Thr Ser Met Thr Pro Gln 435 440 445 Phe
Ser Ser Val Ser Leu Gly Ala Gly Ala Asp Ala Pro Thr Leu Ser 450 455
460 Val Asp Asp Glu Gly Ala Leu Asn Val Gly Ser Lys Asp Ala Asn Lys
465 470 475 480 Pro Val Arg Ile Thr Asn Val Ala Pro Gly Val Lys Glu
Gly Asp Val 485 490 495 Thr Asn Val Ala Gln Leu Lys Gly Val Ala Gln
Asn Leu Asn Asn His 500 505 510 Ile Asp Asn Val Asp Gly Asn Ala Arg
Ala Gly Ile Ala Gln Ala Ile 515 520 525 Ala Thr Ala Ser Leu Val Gln
Ala Tyr Leu Pro Gly Lys Ser Met Met 530 535 540 Ala Ile Gly Gly Gly
Thr Tyr Arg Gly Glu Ala Gly Tyr Ala Ile Gly 545 550 555 560 Tyr Ser
Ser Ile Ser Asp Gly Gly Asn Trp Ile Ile Lys Gly Thr Ala 565 570 575
Ser Gly Asn Ser Arg Gly His Phe Gly Ala Ser Ala Ser Val Gly Tyr 580
585 590 Gln Trp 100 599 PRT Neisseria meningitidis 100 Met Asn Lys
Ile Tyr Arg Ile Ile Trp Asn Ser Ala Leu Asn Ala Trp 1 5 10 15 Val
Ala Val Ser Glu Leu Thr Arg Asn His Thr Lys Arg Ala Ser Ala 20 25
30 Thr Val Lys Thr Ala Val Leu Ala Thr Leu Leu Phe Ala Thr Val Gln
35 40 45 Ala Asn Ala Thr Asp Glu Asp Glu Glu Glu Glu Leu Glu Pro
Val Val 50 55 60 Arg Ser Ala Leu Val Leu Gln Phe Met Ile Asp Lys
Glu Gly Asn Gly 65 70 75 80 Glu Asn Glu Ser Thr Gly Asn Ile Gly Trp
Ser Ile Tyr Tyr Asp Asn 85 90 95 His Asn Thr Leu His Gly Ala Thr
Val Thr Leu Lys Ala Gly Asp Asn 100 105 110 Leu Lys Ile Lys Gln Asn
Thr Asn Lys Asn Thr Asn Glu Asn Thr Asn 115 120 125 Asp Ser Ser Phe
Thr Tyr Ser Leu Lys Lys Asp Leu Thr Asp Leu Thr 130 135 140 Ser Val
Glu Thr Glu Lys Leu Ser Phe Gly Ala Asn Gly Asn Lys Val 145 150 155
160 Asn Ile Thr Ser Asp Thr Lys Gly Leu Asn Phe Ala Lys Glu Thr Ala
165 170 175 Gly Thr Asn Gly Asp Thr Thr Val His Leu Asn Gly Ile Gly
Ser Thr 180 185 190 Leu Thr Asp Thr Leu Leu Asn Thr Gly Ala Thr Thr
Asn Val Thr Asn 195 200 205 Asp Asn Val Thr Asp Asp Lys Lys Lys Arg
Ala Ala Ser Val Lys Asp 210 215 220 Val Leu Asn Ala Gly Trp Asn Ile
Lys Gly Val Lys Pro Gly Thr Thr 225 230 235 240 Ala Ser Asp Asn Val
Asp Phe Val His Thr Tyr Asp Thr Val Glu Phe 245 250 255 Leu Ser Ala
Asp Thr Lys Thr Thr Thr Val Asn Val Glu Ser Lys Asp 260 265 270 Asn
Gly Lys Arg Thr Glu Val Lys Ile Gly Ala Lys Thr Ser Val Ile 275 280
285 Lys Glu Lys Asp Gly Lys Leu Val Thr Gly Lys Gly Lys Gly Glu Asn
290 295 300 Gly Ser Ser Thr Asp Glu Gly Glu Gly Leu Val Thr Ala Lys
Glu Val 305 310 315 320 Ile Asp Ala Val Asn Lys Ala Gly Trp Arg Met
Lys Thr Thr Thr Ala 325 330 335 Asn Gly Gln Thr Gly Gln Ala Asp Lys
Phe Glu Thr Val Thr Ser Gly 340 345 350 Thr Asn Val Thr Phe Ala Ser
Gly Lys Gly Thr Thr Ala Thr Val Ser 355 360 365 Lys Asp Asp Gln Gly
Asn Ile Thr Val Lys Tyr Asp Val Asn Val Gly 370 375 380 Asp Ala Leu
Asn Val Asn Gln Leu Gln Asn Ser Gly Trp Asn Leu Asp 385 390 395 400
Ser Lys Ala Val Ala Gly Ser Ser Gly Lys Val Ile Ser Gly Asn Val 405
410 415 Ser Pro Ser Lys Gly Lys Met Asp Glu Thr Val Asn Ile Asn Ala
Gly 420 425 430 Asn Asn Ile Glu Ile Thr Arg Asn Gly Lys Asn Ile Asp
Ile Ala Thr 435 440 445 Ser Met Thr Pro Gln Phe Ser Ser Val Ser Leu
Gly Ala Gly Ala Asp 450 455 460 Ala Pro Thr Leu Ser Val Asp Asp Lys
Gly Ala Leu Asn Val Gly Ser 465 470 475 480 Lys Asp Ala Asn Lys Pro
Val Arg Ile Thr Asn Val Ala Pro Gly Val 485 490 495 Lys Glu Gly Asp
Val Thr Asn Val Ala Gln Leu Lys Gly Val Ala Gln 500 505 510 Asn Leu
Asn Asn Arg Ile Asp Asn Val Asp Gly Asn Ala Arg Ala Gly 515 520 525
Ile Ala Gln Ala Ile Ala Thr Ala Gly Leu Val Gln Ala Tyr Leu Pro 530
535 540 Gly Lys Ser Met Met Ala Ile Gly Gly Gly Thr Tyr Arg Gly Glu
Ala 545 550 555 560 Gly Tyr Ala Ile Gly Tyr Ser Ser Ile Ser Asp Gly
Gly Asn Trp Ile 565 570 575 Ile Lys Gly Thr Ala Ser Gly Asn Ser Arg
Gly His Phe Gly Ala Ser 580 585 590 Ala Ser Val Gly Tyr Gln Trp 595
101 598 PRT Neisseria meningitidis 101 Met Asn Lys Ile Tyr Arg Ile
Ile Trp Asn Ser Ala Leu Asn Ala Trp 1 5 10 15 Val Val Val Ser Glu
Leu Thr Arg Asn His Thr Lys Arg Ala Ser Ala 20 25 30 Thr Val Ala
Thr Ala Val Leu Ala Thr Leu Leu Phe Ala Thr Val Gln 35 40 45 Ala
Asn Ala Thr Asp Asp Asp Asp Leu Tyr Leu Glu Pro Val Gln Arg 50 55
60 Thr Ala Val Val Leu Ser Phe Arg Ser Asp Lys Glu Gly Thr Gly Glu
65 70 75 80 Lys Glu Gly Thr Glu Asp Ser Asn Trp Ala Val Tyr Phe Asp
Glu Lys 85 90 95 Arg Val Leu Lys Ala Gly Ala Ile Thr Leu Lys Ala
Gly Asp Asn Leu 100 105 110 Lys Ile Lys Gln Asn Thr Asn Glu Asn Thr
Asn Glu Asn Thr Asn Asp 115 120 125 Ser Ser Phe Thr Tyr Ser Leu Lys
Lys Asp Leu Thr Asp Leu Thr Ser 130 135 140 Val Glu Thr Glu Lys Leu
Ser Phe Gly Ala Asn Gly Asn Lys Val Asn 145 150 155 160 Ile Thr Ser
Asp Thr Lys Gly Leu Asn Phe Ala Lys Glu Thr Ala Gly 165 170 175 Thr
Asn Gly Asp Pro Thr Val His Leu Asn Gly Ile Gly Ser Thr Leu 180 185
190 Thr Asp Thr Leu Leu Asn Thr Gly Ala Thr Thr Asn Val Thr Asn Asp
195 200 205 Asn Val Thr Asp Asp Glu Lys Lys Arg Ala Ala Ser Val Lys
Asp Val 210 215 220 Leu Asn Ala Gly Trp Asn Ile Lys Gly Val Lys Pro
Gly Thr Thr Ala 225 230 235 240 Ser Asp Asn Val Asp Phe Val Arg Thr
Tyr Asp Thr Val Glu Phe Leu 245 250 255 Ser Ala Asp Thr Lys Thr Thr
Thr Val Asn Val Glu Ser Lys Asp Asn 260 265 270 Gly Lys Lys Thr Glu
Val Lys Ile Gly Ala Lys Thr Ser Val Ile Lys 275 280 285 Glu Lys Asp
Gly Lys Leu Val Thr Gly Lys Gly Lys Asp Glu Asn Gly 290 295 300 Ser
Ser Thr Asp Glu Gly Glu Gly Leu Val Thr Ala Lys Glu Val Ile 305 310
315 320 Asp Ala Val Asn Lys Ala Gly Trp Arg Met Lys Thr Thr Thr Ala
Asn 325 330 335 Gly Gln Thr Gly Gln Ala Asp Lys Phe Glu Thr Val Thr
Ser Gly Thr 340 345 350 Lys Val Thr Phe Ala Ser Gly Asn Gly Thr Thr
Ala Thr Val Ser Lys 355 360 365 Asp Asp Gln Gly Asn Ile Thr Val Lys
Tyr Asp Val Asn Val Gly Asp 370 375 380 Ala Leu Asn Val Asn Gln Leu
Gln Asn Ser Gly Trp Asn Leu Asp Ser 385 390 395 400 Lys Ala Val Ala
Gly Ser Ser Gly Lys Val Ile Ser Gly Asn Val Ser 405 410 415 Pro Ser
Lys Gly Lys Met Asp Glu Thr Val Asn Ile Asn Ala Gly Asn 420 425 430
Asn Ile Glu Ile Thr Arg Asn Gly Lys Asn Ile Asp Ile Ala Thr Ser 435
440 445 Met Thr Pro Gln Phe Ser Ser Val Ser Leu Gly Ala Gly Ala Asp
Ala 450 455 460 Pro Thr Leu Ser Val Asp Asp Glu Gly Ala Leu Asn Val
Gly Ser Lys 465 470 475 480 Asp Ala Asn Lys Pro Val Arg Ile Thr Asn
Val Ala Pro Gly Val Lys 485 490 495 Glu Gly Asp Val Thr Asn Val Ala
Gln Leu Lys Gly Val Ala Gln Asn 500 505 510 Leu Asn Asn Arg Ile Asp
Asn Val Asp Gly Asn Ala Arg Ala Gly Ile 515 520 525 Ala Gln Ala Ile
Ala Thr Ala Gly Leu Ala Gln Ala Tyr Leu Pro Gly 530 535 540 Lys Ser
Met Met Ala Ile Gly Gly Gly Thr Tyr Arg Gly Glu Ala Gly 545 550 555
560 Tyr Ala Ile Gly Tyr Ser Ser Ile Ser Asp Thr Gly Asn Trp Val Ile
565 570 575 Lys Gly Thr Ala Ser Gly Asn Ser Arg Gly His Phe Gly Ala
Ser Ala 580 585 590 Ser Val Gly Tyr Gln Trp 595 102 594 PRT
Neisseria meningitidis 102 Met Asn Lys Ile Tyr Arg Ile Ile Trp Asn
Ser Ala Leu Asn Ala Trp 1 5 10 15 Val Ala Val Ser Glu Leu Thr Arg
Asn His Thr Lys Arg Ala Ser Ala 20 25 30 Thr Val Ala Thr Ala Val
Leu Ala Thr Leu Leu Phe Ala Thr Val Gln 35 40 45 Ala Ser Thr Thr
Asp Asp Asp Asp Leu Tyr Leu Glu Pro Val Gln Arg 50 55 60 Thr Ala
Pro Val Leu Ser Phe His Ala Asp Ser Glu Gly Thr Gly Glu 65 70 75 80
Lys Glu Val Thr Glu Asp Ser Asn Trp Gly Val Tyr Phe Asp Lys Lys 85
90 95 Gly Val Leu Thr Ala Gly Thr Ile Thr Leu Lys Ala Gly Asp Asn
Leu 100 105 110 Lys Ile Lys Gln Asn Thr Asp Glu Asn Thr Asn Ala Ser
Ser Phe Thr 115 120 125 Tyr Ser Leu Lys Lys Asp Leu Thr Asp Leu Thr
Ser Val Glu Thr Glu 130 135 140 Lys Leu Ser Phe Gly Ala Asn Gly Lys
Lys Val Asn Ile Thr Ser Asp 145 150 155 160 Thr Lys Gly Leu Asn Phe
Ala Lys Glu Thr Ala Gly Thr Asn Gly Asp 165 170 175 Thr Thr Val His
Leu Asn Gly Ile Gly Ser Thr Leu Thr Asp Thr Leu 180 185 190 Leu Asn
Thr Gly Ala Thr Thr Asn Val Thr Asn Asp Asn Val Thr Asp 195 200 205
Asp Glu Lys Lys Arg Ala Ala Ser Val Lys Asp Val Leu Asn Ala Gly 210
215 220 Trp Asn Ile Lys Gly Val Lys Pro Gly Thr Thr Ala Ser Asp Asn
Val 225 230 235 240 Asp Phe Val Arg Thr Tyr Asp Thr Val Glu Phe Leu
Ser Ala Asp Thr 245 250 255 Lys Thr Thr Thr Val Asn Val Glu Ser Lys
Asp Asn Gly Lys Lys Thr 260 265 270 Glu Val Lys Ile Gly Ala Lys Thr
Ser Val Ile Lys Glu Lys Asp Gly 275 280 285 Lys Leu Val Thr Gly Lys
Asp Lys Gly Glu Asn Gly Ser Ser Thr Asp 290 295 300 Glu Gly Glu Gly
Leu Val Thr Ala Lys Glu Val Ile Asp Ala Val Asn 305 310 315 320 Lys
Ala Gly Trp Arg Met Lys Thr Thr Thr Ala Asn Gly Gln Thr Gly 325 330
335 Gln Ala Asp Lys Phe Glu Thr Val Thr Ser Gly Thr Lys Val Thr Phe
340 345 350 Ala Ser Gly Asn Gly Thr Thr Ala Thr Val Ser Lys Asp Asp
Gln Gly 355 360 365 Asn Ile Thr Val Lys Tyr Asp Val Asn Val Gly Asp
Ala Leu Asn Val 370 375 380 Asn Gln Leu Gln Asn Ser Gly Trp Asn Leu
Asp Ser Lys Ala Val Ala 385 390 395 400 Gly Ser Ser Gly Lys Val Ile
Ser Gly Asn Val Ser Pro Ser Lys Gly 405 410 415 Lys Met Asp Glu Thr
Val Asn Ile Asn Ala Gly Asn Asn Ile Glu Ile 420 425 430 Thr Arg Asn
Gly Lys Asn Ile Asp Ile Ala Thr Ser Met Thr Pro Gln 435 440 445 Phe
Ser Ser Val Ser Leu Gly Ala Gly Ala Asp Ala Pro Thr Leu Ser 450 455
460 Val Asp Asp Glu Gly Ala Leu Asn Val Gly Ser Lys Asp Ala Asn Lys
465 470 475 480 Pro Val Arg Ile Thr Asn Val Ala Pro Gly Val Lys Glu
Gly Asp Val 485 490 495 Thr Asn Val Ala Gln Leu Lys Gly Val Ala Gln
Asn Leu Asn Asn His 500 505 510 Ile Asp Asn Val Asp Gly Asn Ala Arg
Ala Gly Ile Ala Gln Ala Ile 515 520 525 Ala Thr Ala Gly Leu Val Gln
Ala Tyr Leu Pro Gly Lys Ser Met Met 530 535 540 Ala Ile Gly Gly Gly
Thr Tyr Arg Gly Glu Ala Gly Tyr Ala Ile Gly 545 550 555 560 Tyr Ser
Ser Ile Ser Asp Gly Gly Asn Trp Ile Ile Lys Gly Thr Ala
565 570 575 Ser Gly Asn Ser Arg Gly His Phe Gly Ala Ser Ala Ser Val
Gly Tyr 580 585 590 Gln Trp 103 591 PRT Neisseria meningitidis 103
Met Asn Lys Ile Tyr Arg Ile Ile Trp Asn Ser Ala Leu Asn Ala Trp 1 5
10 15 Val Val Val Ser Glu Leu Thr Arg Asn His Thr Lys Arg Ala Ser
Ala 20 25 30 Thr Val Lys Thr Ala Val Leu Ala Thr Leu Leu Phe Ala
Thr Val Gln 35 40 45 Ala Ser Ala Asn Asn Glu Glu Gln Glu Glu Asp
Leu Tyr Leu Asp Pro 50 55 60 Val Gln Arg Thr Val Ala Val Leu Ile
Val Asn Ser Asp Lys Glu Gly 65 70 75 80 Thr Gly Glu Lys Glu Lys Val
Glu Glu Asn Ser Asp Trp Ala Val Tyr 85 90 95 Phe Asn Glu Lys Gly
Val Leu Thr Ala Arg Glu Ile Thr Leu Lys Ala 100 105 110 Gly Asp Asn
Leu Lys Ile Lys Gln Asn Gly Thr Asn Phe Thr Tyr Ser 115 120 125 Leu
Lys Lys Asp Leu Thr Asp Leu Thr Ser Val Gly Thr Glu Lys Leu 130 135
140 Ser Phe Ser Ala Asn Gly Asn Lys Val Asn Ile Thr Ser Asp Thr Lys
145 150 155 160 Gly Leu Asn Phe Ala Lys Glu Thr Ala Gly Thr Asn Gly
Asp Thr Thr 165 170 175 Val His Leu Asn Gly Ile Gly Ser Thr Leu Thr
Asp Thr Leu Leu Asn 180 185 190 Thr Gly Ala Thr Thr Asn Val Thr Asn
Asp Asn Val Thr Asp Asp Glu 195 200 205 Lys Lys Arg Ala Ala Ser Val
Lys Asp Val Leu Asn Ala Gly Trp Asn 210 215 220 Ile Lys Gly Val Lys
Pro Gly Thr Thr Ala Ser Asp Asn Val Asp Phe 225 230 235 240 Val Arg
Thr Tyr Asp Thr Val Glu Phe Leu Ser Ala Asp Thr Lys Thr 245 250 255
Thr Thr Val Asn Val Glu Ser Lys Asp Asn Gly Lys Lys Thr Glu Val 260
265 270 Lys Ile Gly Ala Lys Thr Ser Val Ile Lys Glu Lys Asp Gly Lys
Leu 275 280 285 Val Thr Gly Lys Asp Lys Gly Glu Asn Gly Ser Ser Thr
Asp Glu Gly 290 295 300 Glu Gly Leu Val Thr Ala Lys Glu Val Ile Asp
Ala Val Asn Lys Ala 305 310 315 320 Gly Trp Arg Met Lys Thr Thr Thr
Ala Asn Gly Gln Thr Gly Gln Ala 325 330 335 Asp Lys Phe Glu Thr Val
Thr Ser Gly Thr Asn Val Thr Phe Ala Ser 340 345 350 Gly Lys Gly Thr
Thr Ala Thr Val Ser Lys Asp Asp Gln Gly Asn Ile 355 360 365 Thr Val
Met Tyr Asp Val Asn Val Gly Asp Ala Leu Asn Val Asn His 370 375 380
Leu Gln Asn Ser Gly Trp Asp Leu Asp Ser Lys Ala Val Ala Gly Ser 385
390 395 400 Ser Gly Lys Val Ile Ser Gly Asn Val Ser Pro Ser Lys Gly
Lys Met 405 410 415 Asp Glu Thr Val Asn Ile Asn Ala Gly Asn Asn Ile
Glu Ile Thr Arg 420 425 430 Asn Gly Lys Asn Ile Asp Ile Ala Thr Ser
Met Thr Pro Gln Phe Ser 435 440 445 Ser Val Ser Leu Gly Ala Gly Ala
Asp Ala Pro Thr Leu Ser Val Asp 450 455 460 Gly Asp Ala Leu Asn Val
Gly Ser Lys Lys Asp Asn Lys Pro Val Arg 465 470 475 480 Ile Thr Asn
Val Ala Pro Gly Val Lys Glu Gly Asp Val Thr Asn Val 485 490 495 Ala
Gln Leu Lys Gly Val Ala Gln Asn Leu Asn Asn Arg Ile Asp Asn 500 505
510 Val Asp Gly Asn Ala Arg Ala Gly Ile Ala Gln Ala Ile Ala Thr Ala
515 520 525 Gly Leu Val Gln Ala Tyr Leu Pro Gly Lys Ser Met Met Ala
Ile Gly 530 535 540 Gly Gly Thr Tyr Arg Gly Glu Ala Gly Tyr Ala Ile
Gly Tyr Ser Ser 545 550 555 560 Ile Ser Asp Gly Gly Asn Trp Ile Ile
Lys Gly Thr Ala Ser Gly Asn 565 570 575 Ser Arg Gly His Phe Gly Ala
Ser Ala Ser Val Gly Tyr Gln Trp 580 585 590 104 591 PRT Neisseria
meningitidis 104 Met Asn Lys Ile Tyr Arg Ile Ile Trp Asn Ser Ala
Leu Asn Ala Trp 1 5 10 15 Val Val Val Ser Glu Leu Thr Arg Asn His
Thr Lys Arg Ala Ser Ala 20 25 30 Thr Val Lys Thr Ala Val Leu Ala
Thr Leu Leu Phe Ala Thr Val Gln 35 40 45 Ala Ser Ala Asn Asn Glu
Glu Gln Glu Glu Asp Leu Tyr Leu Asp Pro 50 55 60 Val Gln Arg Thr
Val Ala Val Leu Ile Val Asn Ser Asp Lys Glu Gly 65 70 75 80 Thr Gly
Glu Lys Glu Lys Val Glu Glu Asn Ser Asp Trp Ala Val Tyr 85 90 95
Phe Asn Glu Lys Gly Val Leu Thr Ala Arg Glu Ile Thr Leu Lys Ala 100
105 110 Gly Asp Asn Leu Lys Ile Lys Gln Asn Gly Thr Asn Phe Thr Tyr
Ser 115 120 125 Leu Lys Lys Asp Leu Thr Asp Leu Thr Ser Val Gly Thr
Glu Lys Leu 130 135 140 Ser Phe Ser Ala Asn Gly Asn Lys Val Asn Ile
Thr Ser Asp Thr Lys 145 150 155 160 Gly Leu Asn Phe Ala Lys Glu Thr
Ala Gly Thr Asn Gly Asp Thr Thr 165 170 175 Val His Leu Asn Gly Ile
Gly Ser Thr Leu Thr Asp Thr Leu Leu Asn 180 185 190 Thr Gly Ala Thr
Thr Asn Val Thr Asn Asp Asn Val Thr Asp Asp Glu 195 200 205 Lys Lys
Arg Ala Ala Ser Val Lys Asp Val Leu Asn Ala Gly Trp Asn 210 215 220
Ile Lys Gly Val Lys Pro Gly Thr Thr Ala Ser Asp Asn Val Asp Phe 225
230 235 240 Val Arg Thr Tyr Asp Thr Val Glu Phe Leu Ser Ala Asp Thr
Lys Thr 245 250 255 Thr Thr Val Asn Val Glu Ser Lys Asp Asn Gly Lys
Lys Thr Glu Val 260 265 270 Lys Ile Gly Ala Lys Thr Ser Val Ile Lys
Glu Lys Asp Gly Lys Leu 275 280 285 Val Thr Gly Lys Asp Lys Gly Glu
Asn Gly Ser Ser Thr Asp Glu Gly 290 295 300 Glu Gly Leu Val Thr Ala
Lys Glu Val Ile Asp Ala Val Asn Lys Ala 305 310 315 320 Gly Trp Arg
Met Lys Thr Thr Thr Ala Asn Gly Gln Thr Gly Gln Ala 325 330 335 Asp
Lys Phe Glu Thr Val Thr Ser Gly Thr Asn Val Thr Phe Ala Ser 340 345
350 Gly Lys Gly Thr Thr Ala Thr Val Ser Lys Asp Asp Gln Gly Asn Ile
355 360 365 Thr Val Met Tyr Asp Val Asn Val Gly Asp Ala Leu Asn Val
Asn Gln 370 375 380 Leu Gln Asn Ser Gly Trp Asn Leu Asp Ser Lys Ala
Val Ala Gly Ser 385 390 395 400 Ser Gly Lys Val Ile Ser Gly Asn Val
Ser Pro Ser Lys Gly Lys Met 405 410 415 Asp Glu Thr Val Asn Ile Asn
Ala Gly Asn Asn Ile Glu Ile Thr Arg 420 425 430 Asn Gly Lys Asn Ile
Asp Ile Ala Thr Ser Met Thr Pro Gln Phe Ser 435 440 445 Ser Val Ser
Leu Gly Ala Gly Ala Asp Ala Pro Thr Leu Ser Val Asp 450 455 460 Gly
Asp Ala Leu Asn Val Gly Ser Lys Lys Asp Asn Lys Pro Val Arg 465 470
475 480 Ile Thr Asn Val Ala Pro Gly Val Lys Glu Gly Asp Val Thr Asn
Val 485 490 495 Ala Gln Leu Lys Gly Val Ala Gln Asn Leu Asn Asn Arg
Ile Asp Asn 500 505 510 Val Asp Gly Asn Ala Arg Ala Gly Ile Ala Gln
Ala Ile Ala Thr Ala 515 520 525 Gly Leu Val Gln Ala Tyr Leu Pro Gly
Lys Ser Met Met Ala Ile Gly 530 535 540 Gly Gly Thr Tyr Arg Gly Glu
Ala Gly Tyr Ala Ile Gly Tyr Ser Ser 545 550 555 560 Ile Ser Asp Gly
Gly Asn Trp Ile Ile Lys Gly Thr Ala Ser Gly Asn 565 570 575 Ser Arg
Gly His Phe Gly Ala Ser Ala Ser Val Gly Tyr Gln Trp 580 585 590 105
591 PRT Neisseria meningitidis 105 Met Asn Lys Ile Tyr Arg Ile Ile
Trp Asn Ser Ala Leu Asn Ala Trp 1 5 10 15 Val Val Val Ser Glu Leu
Thr Arg Asn His Thr Lys Arg Ala Ser Ala 20 25 30 Thr Val Lys Thr
Ala Val Leu Ala Thr Leu Leu Phe Ala Thr Val Gln 35 40 45 Ala Ser
Ala Asn Asn Glu Glu Gln Glu Glu Asp Leu Tyr Leu Asp Pro 50 55 60
Val Gln Arg Thr Val Ala Val Leu Ile Val Asn Ser Asp Lys Glu Gly 65
70 75 80 Thr Gly Glu Lys Glu Lys Val Glu Glu Asn Ser Asp Trp Ala
Val Tyr 85 90 95 Phe Asn Glu Lys Gly Val Leu Thr Ala Arg Glu Ile
Thr Leu Lys Ala 100 105 110 Gly Asp Asn Leu Lys Ile Lys Gln Asn Gly
Thr Asn Phe Thr Tyr Ser 115 120 125 Leu Lys Lys Asp Leu Thr Asp Leu
Thr Ser Val Gly Thr Glu Lys Leu 130 135 140 Ser Phe Ser Ala Asn Gly
Asn Lys Val Asn Ile Thr Ser Asp Thr Lys 145 150 155 160 Gly Leu Asn
Phe Ala Lys Glu Thr Ala Gly Thr Asn Gly Asp Thr Thr 165 170 175 Val
His Leu Asn Gly Ile Gly Ser Thr Leu Thr Asp Thr Leu Leu Asn 180 185
190 Thr Gly Ala Thr Thr Asn Val Thr Asn Asp Asn Val Thr Asp Asp Glu
195 200 205 Lys Lys Arg Ala Ala Ser Val Lys Asp Val Leu Asn Ala Gly
Trp Asn 210 215 220 Ile Lys Gly Val Lys Pro Gly Thr Thr Ala Ser Asp
Asn Val Asp Phe 225 230 235 240 Val Arg Thr Tyr Asp Thr Val Glu Phe
Leu Ser Ala Asp Thr Lys Thr 245 250 255 Thr Thr Val Asn Val Glu Ser
Lys Asp Asn Gly Lys Lys Thr Glu Val 260 265 270 Lys Ile Gly Ala Lys
Thr Ser Val Ile Lys Glu Lys Asp Gly Lys Leu 275 280 285 Val Thr Gly
Lys Asp Lys Gly Glu Asn Gly Ser Ser Thr Asp Glu Gly 290 295 300 Glu
Gly Leu Val Thr Ala Lys Glu Val Ile Asp Ala Val Asn Lys Ala 305 310
315 320 Gly Trp Arg Met Lys Thr Thr Thr Ala Asn Gly Gln Thr Gly Gln
Ala 325 330 335 Asp Lys Phe Glu Thr Val Thr Ser Gly Thr Asn Val Thr
Phe Ala Ser 340 345 350 Gly Lys Gly Thr Thr Ala Thr Val Ser Lys Asp
Asp Gln Gly Asn Ile 355 360 365 Thr Val Met Tyr Asp Val Asn Val Gly
Asp Ala Leu Asn Val Asn Gln 370 375 380 Leu Gln Asn Ser Gly Trp Asn
Leu Asp Ser Lys Ala Val Ala Gly Ser 385 390 395 400 Ser Gly Lys Val
Ile Ser Gly Asn Val Ser Pro Ser Lys Gly Lys Met 405 410 415 Asp Glu
Thr Val Asn Ile Asn Ala Gly Asn Asn Ile Glu Ile Thr Arg 420 425 430
Asn Gly Lys Asn Ile Asp Ile Ala Thr Ser Met Thr Pro Gln Phe Ser 435
440 445 Ser Val Ser Leu Gly Ala Gly Ala Asp Ala Pro Thr Leu Ser Val
Asp 450 455 460 Gly Asp Ala Leu Asn Val Gly Ser Lys Lys Asp Asn Lys
Pro Val Arg 465 470 475 480 Ile Thr Asn Val Ala Pro Gly Val Lys Glu
Gly Asp Val Thr Asn Val 485 490 495 Ala Gln Leu Lys Gly Val Ala Gln
Asn Leu Asn Asn Arg Ile Asp Asn 500 505 510 Val Asp Gly Asn Ala Arg
Ala Gly Ile Ala Gln Ala Ile Ala Thr Ala 515 520 525 Gly Leu Val Gln
Ala Tyr Leu Pro Gly Lys Ser Met Met Ala Ile Gly 530 535 540 Gly Gly
Thr Tyr Arg Gly Glu Ala Gly Tyr Ala Ile Gly Tyr Ser Ser 545 550 555
560 Ile Ser Asp Gly Gly Asn Trp Ile Ile Lys Gly Thr Ala Ser Gly Asn
565 570 575 Ser Arg Gly His Phe Gly Ala Ser Ala Ser Val Gly Tyr Gln
Trp 580 585 590 106 592 PRT Neisseria meningitidis 106 Met Asn Lys
Ile Tyr Arg Ile Ile Trp Asn Ser Ala Leu Asn Ala Trp 1 5 10 15 Val
Ala Val Ser Glu Leu Thr Arg Asn His Thr Lys Arg Ala Ser Ala 20 25
30 Thr Val Lys Thr Ala Val Leu Ala Thr Leu Leu Phe Ala Thr Val Gln
35 40 45 Ala Asn Ala Thr Asp Glu Asp Glu Glu Glu Glu Leu Glu Ser
Val Gln 50 55 60 Arg Ser Val Val Gly Ser Ile Gln Ala Ser Met Glu
Gly Ser Gly Glu 65 70 75 80 Leu Glu Thr Ile Ser Leu Ser Met Thr Asn
Asp Ser Lys Glu Phe Val 85 90 95 Asp Pro Tyr Ile Val Val Thr Leu
Lys Ala Gly Asp Asn Leu Lys Ile 100 105 110 Lys Gln Asn Thr Asn Glu
Asn Thr Asn Ala Ser Ser Phe Thr Tyr Ser 115 120 125 Leu Lys Lys Asp
Leu Thr Gly Leu Ile Asn Val Glu Thr Glu Lys Leu 130 135 140 Ser Phe
Gly Ala Asn Gly Lys Lys Val Asn Ile Ile Ser Asp Thr Lys 145 150 155
160 Gly Leu Asn Phe Ala Lys Glu Thr Ala Gly Thr Asn Gly Asp Thr Thr
165 170 175 Val His Leu Asn Gly Ile Gly Ser Thr Leu Thr Asp Thr Leu
Ala Gly 180 185 190 Ser Ser Ala Ser His Val Asp Ala Gly Asn Gln Ser
Thr His Tyr Thr 195 200 205 Arg Ala Ala Ser Ile Lys Asp Val Leu Asn
Ala Gly Trp Asn Ile Lys 210 215 220 Gly Val Lys Thr Gly Ser Thr Thr
Gly Gln Ser Glu Asn Val Asp Phe 225 230 235 240 Val Arg Thr Tyr Asp
Thr Val Glu Phe Leu Ser Ala Asp Thr Lys Thr 245 250 255 Thr Thr Val
Asn Val Glu Ser Lys Asp Asn Gly Lys Arg Thr Glu Val 260 265 270 Lys
Ile Gly Ala Lys Thr Ser Val Ile Lys Glu Lys Asp Gly Lys Leu 275 280
285 Val Thr Gly Lys Gly Lys Gly Glu Asn Gly Ser Ser Thr Asp Glu Gly
290 295 300 Glu Gly Leu Val Thr Ala Lys Glu Val Ile Asp Ala Val Asn
Lys Ala 305 310 315 320 Gly Trp Arg Met Lys Thr Thr Thr Ala Asn Gly
Gln Thr Gly Gln Ala 325 330 335 Asp Lys Phe Glu Thr Val Thr Ser Gly
Thr Asn Val Thr Phe Ala Ser 340 345 350 Gly Lys Gly Thr Thr Ala Thr
Val Ser Lys Asp Asp Gln Gly Asn Ile 355 360 365 Thr Val Met Tyr Asp
Val Asn Val Gly Asp Ala Leu Asn Val Asn Gln 370 375 380 Leu Gln Asn
Ser Gly Trp Asn Leu Asp Ser Lys Ala Val Ala Gly Ser 385 390 395 400
Ser Gly Lys Val Ile Ser Gly Asn Val Ser Pro Ser Lys Gly Lys Met 405
410 415 Asp Glu Thr Val Asn Ile Asn Ala Gly Asn Asn Ile Glu Ile Ser
Arg 420 425 430 Asn Gly Lys Asn Ile Asp Ile Ala Thr Ser Met Ala Pro
Gln Phe Ser 435 440 445 Ser Val Ser Leu Gly Ala Gly Ala Asp Ala Pro
Thr Leu Ser Val Asp 450 455 460 Asp Glu Gly Ala Leu Asn Val Gly Ser
Lys Asp Ala Asn Lys Pro Val 465 470 475 480 Arg Ile Thr Asn Val Ala
Pro Gly Val Lys Glu Gly Asp Val Thr Asn 485 490 495 Val Ala Gln Leu
Lys Gly Val Ala Gln Asn Leu Asn Asn Arg Ile Asp 500 505 510 Asn Val
Asp Gly Asn Ala Arg Ala Gly Ile Ala Gln Ala Ile Ala Thr 515 520 525
Ala Gly Leu Val Gln Ala Tyr Leu Pro Gly Lys Ser Met Met Ala Ile 530
535 540 Gly Gly Gly Thr Tyr Arg Gly Glu Ala Gly Tyr Ala Ile Gly Tyr
Ser 545 550 555 560 Ser Ile Ser Asp Gly Gly Asn Trp Ile Ile Lys Gly
Thr Ala Ser Gly 565 570 575 Asn Ser Arg Gly His Phe Gly Ala Ser Ala
Ser Val Gly Tyr Gln Trp 580 585 590 107 592 PRT Neisseria
meningitidis 107 Met Asn Lys Ile Tyr Arg Ile Ile Trp Asn Ser Ala
Leu Asn Ala Trp 1 5 10 15 Val Ala Val Ser Glu Leu Thr Arg Asn His
Thr Lys Arg Ala Ser Ala 20 25 30 Thr Val Lys Thr Ala Val Leu
Ala Thr Leu Leu Phe Ala Thr Val Gln 35 40 45 Ala Asn Ala Thr Asp
Glu Asp Glu Glu Glu Glu Leu Glu Ser Val Gln 50 55 60 Arg Ser Val
Val Gly Ser Ile Gln Ala Ser Met Glu Gly Ser Gly Glu 65 70 75 80 Leu
Glu Thr Ile Ser Leu Ser Met Thr Asn Asp Ser Lys Glu Phe Val 85 90
95 Asp Pro Tyr Ile Val Val Thr Leu Lys Ala Gly Asp Asn Leu Lys Ile
100 105 110 Lys Gln Asn Thr Asn Glu Asn Thr Asn Ala Ser Ser Phe Thr
Tyr Ser 115 120 125 Leu Lys Lys Asp Leu Thr Gly Leu Ile Asn Val Glu
Thr Glu Lys Leu 130 135 140 Ser Phe Gly Ala Asn Gly Lys Lys Val Asn
Ile Ile Ser Asp Thr Lys 145 150 155 160 Gly Leu Asn Phe Ala Lys Glu
Thr Ala Gly Thr Asn Gly Asp Thr Thr 165 170 175 Val His Leu Asn Gly
Ile Gly Ser Thr Leu Thr Asp Thr Leu Ala Gly 180 185 190 Ser Ser Ala
Ser His Val Asp Ala Gly Asn Gln Ser Thr His Tyr Thr 195 200 205 Arg
Ala Ala Ser Ile Lys Asp Val Leu Asn Ala Gly Trp Asn Ile Lys 210 215
220 Gly Val Lys Thr Gly Ser Thr Thr Gly Gln Ser Glu Asn Val Asp Phe
225 230 235 240 Val Arg Thr Tyr Asp Thr Val Glu Phe Leu Ser Ala Asp
Thr Lys Thr 245 250 255 Thr Thr Val Asn Val Glu Ser Lys Asp Asn Gly
Lys Arg Thr Glu Val 260 265 270 Lys Ile Gly Ala Lys Thr Ser Val Ile
Lys Glu Lys Asp Gly Lys Leu 275 280 285 Val Thr Gly Lys Gly Lys Gly
Glu Asn Gly Ser Ser Thr Asp Glu Gly 290 295 300 Glu Gly Leu Val Thr
Ala Lys Glu Val Ile Asp Ala Val Asn Lys Ala 305 310 315 320 Gly Trp
Arg Met Lys Thr Thr Thr Ala Asn Gly Gln Thr Gly Gln Ala 325 330 335
Asp Lys Phe Glu Thr Val Thr Ser Gly Thr Asn Val Thr Phe Ala Ser 340
345 350 Gly Lys Gly Thr Thr Ala Thr Val Ser Lys Asp Asp Gln Gly Asn
Ile 355 360 365 Thr Val Met Tyr Asp Val Asn Val Gly Asp Ala Leu Asn
Val Asn Gln 370 375 380 Leu Gln Asn Ser Gly Trp Asn Leu Asp Ser Lys
Ala Val Ala Gly Ser 385 390 395 400 Ser Gly Lys Val Ile Ser Gly Asn
Val Ser Pro Ser Lys Gly Lys Met 405 410 415 Asp Glu Thr Val Asn Ile
Asn Ala Gly Asn Asn Ile Glu Ile Ser Arg 420 425 430 Asn Gly Lys Asn
Ile Asp Ile Ala Thr Ser Met Ala Pro Gln Phe Ser 435 440 445 Ser Val
Ser Leu Gly Ala Gly Ala Asp Ala Pro Thr Leu Ser Val Asp 450 455 460
Asp Glu Gly Ala Leu Asn Val Gly Ser Lys Asp Ala Asn Lys Pro Val 465
470 475 480 Arg Ile Thr Asn Val Ala Pro Gly Val Lys Glu Gly Asp Val
Thr Asn 485 490 495 Val Ala Gln Leu Lys Gly Val Ala Gln Asn Leu Asn
Asn Arg Ile Asp 500 505 510 Asn Val Asp Gly Asn Ala Arg Ala Gly Ile
Ala Gln Ala Ile Ala Thr 515 520 525 Ala Gly Leu Val Gln Ala Tyr Leu
Pro Gly Lys Ser Met Met Ala Ile 530 535 540 Gly Gly Gly Thr Tyr Arg
Gly Glu Ala Gly Tyr Ala Ile Gly Tyr Ser 545 550 555 560 Ser Ile Ser
Asp Gly Gly Asn Trp Ile Ile Lys Gly Thr Ala Ser Gly 565 570 575 Asn
Ser Arg Gly His Phe Gly Ala Ser Ala Ser Val Gly Tyr Gln Trp 580 585
590 108 589 PRT Neisseria meningitidis 108 Met Asn Lys Ile Tyr Arg
Ile Ile Trp Asn Ser Ala Leu Asn Ala Trp 1 5 10 15 Val Val Val Ser
Glu Leu Thr Arg Asn His Thr Lys Arg Ala Ser Ala 20 25 30 Thr Val
Ala Thr Ala Val Leu Ala Thr Leu Leu Ser Ala Thr Val Gln 35 40 45
Ala Asn Ala Thr Asp Thr Asp Glu Asp Glu Glu Leu Glu Ser Val Val 50
55 60 Arg Ser Ala Leu Val Leu Gln Phe Met Ile Asp Lys Glu Gly Asn
Gly 65 70 75 80 Glu Ile Glu Ser Thr Gly Asp Ile Gly Trp Ser Ile Tyr
Tyr Asp Asp 85 90 95 His Asn Thr Leu His Gly Ala Thr Val Thr Leu
Lys Ala Gly Asp Asn 100 105 110 Leu Lys Ile Lys Gln Ser Gly Lys Asp
Phe Thr Tyr Ser Leu Lys Lys 115 120 125 Glu Leu Lys Asp Leu Thr Ser
Val Glu Thr Glu Lys Leu Ser Phe Gly 130 135 140 Ala Asn Gly Asn Lys
Val Asn Ile Thr Ser Asp Thr Lys Gly Leu Asn 145 150 155 160 Phe Ala
Lys Glu Thr Ala Gly Thr Asn Gly Asp Pro Thr Val His Leu 165 170 175
Asn Gly Ile Gly Ser Thr Leu Thr Asp Thr Leu Ala Gly Ser Ser Ala 180
185 190 Ser His Val Asp Ala Gly Asn Gln Ser Thr His Tyr Thr Arg Ala
Ala 195 200 205 Ser Ile Lys Asp Val Leu Asn Ala Gly Trp Asn Ile Lys
Gly Val Lys 210 215 220 Thr Gly Ser Thr Thr Gly Gln Ser Glu Asn Val
Asp Phe Val Arg Thr 225 230 235 240 Tyr Asp Thr Val Glu Phe Leu Ser
Ala Asp Thr Lys Thr Thr Thr Val 245 250 255 Asn Val Glu Ser Lys Asp
Asn Gly Lys Arg Thr Glu Val Lys Ile Gly 260 265 270 Ala Lys Thr Ser
Val Ile Lys Glu Lys Asp Gly Lys Leu Val Thr Gly 275 280 285 Lys Gly
Lys Gly Glu Asn Gly Ser Ser Thr Asp Glu Gly Glu Gly Leu 290 295 300
Val Thr Ala Lys Glu Val Ile Asp Ala Val Asn Lys Ala Gly Trp Arg 305
310 315 320 Met Lys Thr Thr Thr Ala Asn Gly Gln Thr Gly Gln Ala Asp
Lys Phe 325 330 335 Glu Thr Val Thr Ser Gly Thr Lys Val Thr Phe Ala
Ser Gly Asn Gly 340 345 350 Thr Thr Ala Thr Val Ser Lys Asp Asp Gln
Gly Asn Ile Thr Val Lys 355 360 365 Tyr Asp Val Asn Val Gly Asp Ala
Leu Asn Val Asn Gln Leu Gln Asn 370 375 380 Ser Gly Trp Asn Leu Asp
Ser Lys Ala Val Ala Gly Ser Ser Gly Lys 385 390 395 400 Val Ile Ser
Gly Asn Val Ser Pro Ser Lys Gly Lys Met Asp Glu Thr 405 410 415 Val
Asn Ile Asn Ala Gly Asn Asn Ile Glu Ile Thr Arg Asn Gly Lys 420 425
430 Asn Ile Asp Ile Ala Thr Ser Met Thr Pro Gln Phe Ser Ser Val Ser
435 440 445 Leu Gly Ala Gly Ala Asp Ala Pro Thr Leu Ser Val Asp Asp
Glu Gly 450 455 460 Ala Leu Asn Val Gly Ser Lys Asp Ala Asn Lys Pro
Val Arg Ile Thr 465 470 475 480 Asn Val Ala Pro Gly Val Lys Glu Gly
Asp Val Thr Asn Val Ala Gln 485 490 495 Leu Lys Gly Val Ala Gln Asn
Leu Asn Asn Arg Ile Asp Asn Val Asp 500 505 510 Gly Asn Ala Arg Ala
Gly Ile Ala Gln Ala Ile Ala Thr Ala Gly Leu 515 520 525 Ala Gln Ala
Tyr Leu Pro Gly Lys Ser Met Met Ala Ile Gly Gly Gly 530 535 540 Thr
Tyr Arg Gly Glu Ala Gly Tyr Ala Ile Gly Tyr Ser Ser Ile Ser 545 550
555 560 Asp Thr Gly Asn Trp Val Ile Lys Gly Thr Ala Ser Gly Asn Ser
Arg 565 570 575 Gly His Phe Gly Thr Ser Ala Ser Val Gly Tyr Gln Trp
580 585 109 589 PRT Neisseria meningitidis 109 Met Asn Lys Ile Tyr
Arg Ile Ile Trp Asn Ser Ala Leu Asn Ala Trp 1 5 10 15 Val Val Val
Ser Glu Leu Thr Arg Asn His Thr Lys Arg Ala Ser Ala 20 25 30 Thr
Val Ala Thr Ala Val Leu Ala Thr Leu Leu Ser Ala Thr Val Gln 35 40
45 Ala Asn Ala Thr Asp Thr Asp Glu Asp Glu Glu Leu Glu Ser Val Val
50 55 60 Arg Ser Ala Leu Val Leu Gln Phe Met Ile Asp Lys Glu Gly
Asn Gly 65 70 75 80 Glu Ile Glu Ser Thr Gly Asp Ile Gly Trp Ser Ile
Tyr Tyr Asp Asp 85 90 95 His Asn Thr Leu His Gly Ala Thr Val Thr
Leu Lys Ala Gly Asp Asn 100 105 110 Leu Lys Ile Lys Gln Ser Gly Lys
Asp Phe Thr Tyr Ser Leu Lys Lys 115 120 125 Glu Leu Lys Asp Leu Thr
Ser Val Glu Thr Glu Lys Leu Ser Phe Gly 130 135 140 Ala Asn Gly Asn
Lys Val Asn Ile Thr Ser Asp Thr Lys Gly Leu Asn 145 150 155 160 Phe
Ala Lys Glu Thr Ala Gly Thr Asn Gly Asp Pro Thr Val His Leu 165 170
175 Asn Gly Ile Gly Ser Thr Leu Thr Asp Thr Leu Ala Gly Ser Ser Ala
180 185 190 Ser His Val Asp Ala Gly Asn Gln Ser Thr His Tyr Thr Arg
Ala Ala 195 200 205 Ser Ile Lys Asp Val Leu Asn Ala Gly Trp Asn Ile
Lys Gly Val Lys 210 215 220 Thr Gly Ser Thr Thr Gly Gln Ser Glu Asn
Val Asp Phe Val Arg Thr 225 230 235 240 Tyr Asp Thr Val Glu Phe Leu
Ser Ala Asp Thr Lys Thr Thr Thr Val 245 250 255 Asn Val Glu Ser Lys
Asp Asn Gly Lys Arg Thr Glu Val Lys Ile Gly 260 265 270 Ala Lys Thr
Ser Val Ile Lys Glu Lys Asp Gly Lys Leu Val Thr Gly 275 280 285 Lys
Gly Lys Gly Glu Asn Gly Ser Ser Thr Asp Glu Gly Glu Gly Leu 290 295
300 Val Thr Ala Lys Glu Val Ile Asp Ala Val Asn Lys Ala Gly Trp Arg
305 310 315 320 Met Lys Thr Thr Thr Ala Asn Gly Gln Thr Gly Gln Ala
Asp Lys Phe 325 330 335 Glu Thr Val Thr Ser Gly Thr Lys Val Thr Phe
Ala Ser Gly Asn Gly 340 345 350 Thr Thr Ala Thr Val Ser Lys Asp Asp
Gln Gly Asn Ile Thr Val Lys 355 360 365 Tyr Asp Val Asn Val Gly Asp
Ala Leu Asn Val Asn Gln Leu Gln Asn 370 375 380 Ser Gly Trp Asn Leu
Asp Ser Lys Ala Val Ala Gly Ser Ser Gly Lys 385 390 395 400 Val Ile
Ser Gly Asn Val Ser Pro Ser Lys Gly Lys Met Asp Glu Thr 405 410 415
Val Asn Ile Asn Ala Gly Asn Asn Ile Glu Ile Thr Arg Asn Gly Lys 420
425 430 Asn Ile Asp Ile Ala Thr Ser Met Thr Pro Gln Phe Ser Ser Val
Ser 435 440 445 Leu Gly Ala Gly Ala Asp Ala Pro Thr Leu Ser Val Asp
Asp Glu Gly 450 455 460 Ala Leu Asn Val Gly Ser Lys Asp Ala Asn Lys
Pro Val Arg Ile Thr 465 470 475 480 Asn Val Ala Pro Gly Val Lys Glu
Gly Asp Val Thr Asn Val Ala Gln 485 490 495 Leu Lys Gly Val Ala Gln
Asn Leu Asn Asn Arg Ile Asp Asn Val Asp 500 505 510 Gly Asn Ala Arg
Ala Gly Ile Ala Gln Ala Ile Ala Thr Ala Gly Leu 515 520 525 Ala Gln
Ala Tyr Leu Pro Gly Lys Ser Met Met Ala Ile Gly Gly Gly 530 535 540
Thr Tyr Arg Gly Glu Ala Gly Tyr Ala Ile Gly Tyr Ser Ser Ile Ser 545
550 555 560 Asp Thr Gly Asn Trp Val Ile Lys Gly Thr Ala Ser Gly Asn
Ser Arg 565 570 575 Gly His Phe Gly Thr Ser Ala Ser Val Gly Tyr Gln
Trp 580 585 110 592 PRT Neisseria meningitidis 110 Met Asn Lys Ile
Tyr Arg Ile Ile Trp Asn Ser Ala Leu Asn Ala Trp 1 5 10 15 Val Ala
Val Ser Glu Leu Thr Arg Asn His Thr Lys Arg Ala Ser Ala 20 25 30
Thr Val Lys Thr Ala Val Leu Ala Thr Leu Leu Phe Ala Thr Val Gln 35
40 45 Ala Asn Ala Thr Asp Glu Asp Glu Glu Glu Glu Leu Glu Ser Val
Gln 50 55 60 Arg Ser Val Val Gly Ser Ile Gln Ala Ser Met Glu Gly
Ser Gly Glu 65 70 75 80 Leu Glu Thr Ile Ser Leu Ser Met Thr Asn Asp
Ser Lys Glu Phe Val 85 90 95 Asp Pro Tyr Ile Val Val Thr Leu Lys
Ala Gly Asp Asn Leu Lys Ile 100 105 110 Lys Gln Asn Thr Asn Glu Asn
Thr Asn Ala Ser Ser Phe Thr Tyr Ser 115 120 125 Leu Lys Lys Asp Leu
Thr Gly Leu Ile Asn Val Glu Thr Glu Lys Leu 130 135 140 Ser Phe Gly
Ala Asn Gly Lys Lys Val Asn Ile Ile Ser Asp Thr Lys 145 150 155 160
Gly Leu Asn Phe Ala Lys Glu Thr Ala Gly Thr Asn Gly Asp Thr Thr 165
170 175 Val His Leu Asn Gly Ile Gly Ser Thr Leu Thr Asp Met Leu Leu
Asn 180 185 190 Thr Gly Ala Thr Thr Asn Val Thr Asn Asp Asn Val Thr
Asp Asp Glu 195 200 205 Lys Lys Arg Ala Ala Ser Val Lys Asp Val Leu
Asn Ala Gly Trp Asn 210 215 220 Ile Lys Gly Val Lys Pro Gly Thr Thr
Ala Ser Asp Asn Val Asp Phe 225 230 235 240 Val Arg Thr Tyr Asp Thr
Val Glu Phe Leu Ser Ala Asp Thr Lys Thr 245 250 255 Thr Thr Val Asn
Val Glu Ser Lys Asp Asn Gly Lys Lys Thr Glu Val 260 265 270 Lys Ile
Gly Ala Lys Thr Ser Val Ile Lys Glu Lys Asp Gly Lys Leu 275 280 285
Val Thr Gly Lys Gly Lys Gly Glu Asn Gly Ser Ser Thr Asp Glu Gly 290
295 300 Glu Gly Leu Val Thr Ala Lys Glu Val Ile Asp Ala Val Asn Lys
Ala 305 310 315 320 Gly Trp Arg Met Lys Thr Thr Thr Ala Asn Gly Gln
Thr Gly Gln Ala 325 330 335 Asp Lys Phe Glu Thr Val Thr Ser Gly Thr
Asn Val Thr Phe Ala Ser 340 345 350 Gly Lys Gly Thr Thr Ala Thr Val
Ser Lys Asp Asp Gln Gly Asn Ile 355 360 365 Thr Val Met Tyr Asp Val
Asn Val Gly Asp Ala Leu Asn Val Asn Gln 370 375 380 Leu Gln Asn Ser
Gly Trp Asn Leu Asp Ser Lys Ala Val Ala Gly Ser 385 390 395 400 Ser
Gly Lys Val Ile Ser Gly Asn Val Ser Pro Ser Lys Gly Lys Met 405 410
415 Asp Glu Thr Val Asn Ile Asn Ala Gly Asn Asn Ile Glu Ile Thr Arg
420 425 430 Asn Gly Lys Asn Ile Asp Ile Ala Thr Ser Met Thr Pro Gln
Phe Ser 435 440 445 Ser Val Ser Leu Gly Ala Gly Ala Asp Ala Pro Thr
Leu Ser Val Asp 450 455 460 Asp Lys Gly Ala Leu Asn Val Gly Ser Lys
Asp Ala Asn Lys Pro Val 465 470 475 480 Arg Ile Thr Asn Val Ala Pro
Gly Val Lys Glu Gly Asp Val Thr Asn 485 490 495 Val Ala Gln Leu Lys
Gly Val Ala Gln Asn Leu Asn Asn Arg Ile Asp 500 505 510 Asn Val Asp
Gly Asn Ala Arg Ala Gly Ile Ala Gln Ala Ile Ala Thr 515 520 525 Ala
Gly Leu Val Gln Ala Tyr Leu Pro Gly Lys Ser Met Met Ala Ile 530 535
540 Gly Gly Gly Thr Tyr Arg Gly Glu Ala Gly Tyr Ala Ile Gly Tyr Ser
545 550 555 560 Ser Ile Ser Asp Gly Gly Asn Trp Ile Ile Lys Gly Thr
Ala Ser Gly 565 570 575 Asn Ser Arg Gly His Phe Gly Ala Ser Ala Ser
Val Gly Tyr Gln Trp 580 585 590 111 600 PRT Neisseria meningitidis
111 Met Asn Lys Ile Tyr Arg Ile Ile Trp Asn Ile Ala Leu Asn Ala Trp
1 5 10 15 Val Val Val Ser Glu Leu Thr Arg Asn His Thr Lys Arg Ala
Ser Ala 20 25 30 Thr Val Ala Thr Ala Val Leu Ala Thr Leu Leu Ser
Ala Thr Val Gln 35 40 45 Ala Asn Ala Thr Asp Glu Glu Asp Asn Glu
Asp Leu Glu Pro Val Val 50 55 60 Arg Thr Ala Pro Val Leu Ser Phe
His Ser Asp Lys Glu Gly Thr Gly 65 70 75 80 Glu Lys Glu Glu Val Gly
Ala Ser Ser Asn Leu Thr Val Tyr Phe Asp 85 90 95 Lys Asn Arg Val
Leu Lys Ala
Gly Thr Ile Thr Leu Lys Ala Gly Asp 100 105 110 Asn Leu Lys Ile Lys
Gln Asn Thr Asn Glu Asn Thr Asn Glu Asn Thr 115 120 125 Asn Ala Ser
Ser Phe Thr Tyr Ser Leu Lys Lys Asp Leu Thr Gly Leu 130 135 140 Ile
Asn Val Glu Thr Glu Lys Leu Ser Phe Gly Ala Asn Gly Lys Lys 145 150
155 160 Val Asn Ile Ile Ser Asp Thr Lys Gly Leu Asn Phe Ala Lys Glu
Thr 165 170 175 Ala Gly Thr Asn Gly Asp Pro Thr Val His Leu Asn Gly
Ile Gly Ser 180 185 190 Thr Leu Thr Asp Thr Leu Ala Gly Ser Ser Ala
Ser His Val Asp Ala 195 200 205 Gly Asn Gln Ser Thr His Tyr Thr Arg
Ala Ala Ser Ile Lys Asp Val 210 215 220 Leu Asn Ala Gly Trp Asn Ile
Lys Gly Val Lys Thr Gly Ser Thr Thr 225 230 235 240 Gly Gln Ser Glu
Asn Val Asp Phe Val Arg Thr Tyr Asp Thr Val Glu 245 250 255 Phe Leu
Ser Ala Asp Thr Lys Thr Thr Thr Val Asn Val Glu Ser Lys 260 265 270
Asp Asn Gly Lys Arg Thr Glu Val Lys Ile Gly Ala Lys Thr Ser Val 275
280 285 Ile Lys Glu Lys Asp Gly Lys Leu Val Thr Gly Lys Gly Lys Gly
Glu 290 295 300 Asn Gly Ser Ser Thr Asp Glu Gly Glu Gly Leu Val Thr
Ala Lys Glu 305 310 315 320 Val Ile Asp Ala Val Asn Lys Ala Gly Trp
Arg Met Lys Thr Thr Thr 325 330 335 Ala Asn Gly Gln Thr Gly Gln Ala
Asp Lys Phe Glu Thr Val Thr Ser 340 345 350 Gly Thr Lys Val Thr Phe
Ala Ser Gly Asn Gly Thr Thr Ala Thr Val 355 360 365 Ser Lys Asp Asp
Gln Gly Asn Ile Thr Val Lys Tyr Asp Val Asn Val 370 375 380 Gly Asp
Ala Leu Asn Val Asn Gln Leu Gln Asn Ser Gly Trp Asn Leu 385 390 395
400 Asp Ser Lys Ala Val Ala Gly Ser Ser Gly Lys Val Ile Ser Gly Asn
405 410 415 Val Ser Pro Ser Lys Gly Lys Met Asp Glu Thr Val Asn Ile
Asn Ala 420 425 430 Gly Asn Asn Ile Glu Ile Thr Arg Asn Gly Lys Asn
Ile Asp Ile Ala 435 440 445 Thr Ser Met Thr Pro Gln Phe Ser Ser Val
Ser Leu Gly Ala Gly Ala 450 455 460 Asp Ala Pro Thr Leu Ser Val Asp
Asp Glu Gly Ala Leu Asn Val Gly 465 470 475 480 Ser Lys Asp Ala Asn
Lys Pro Val Arg Ile Thr Asn Val Ala Pro Gly 485 490 495 Val Lys Glu
Gly Asp Val Thr Asn Val Ala Gln Leu Lys Gly Val Ala 500 505 510 Gln
Asn Leu Asn Asn Arg Ile Asp Asn Val Asp Gly Asn Ala Arg Ala 515 520
525 Gly Ile Ala Gln Ala Ile Ala Thr Ala Gly Leu Val Gln Ala Tyr Leu
530 535 540 Pro Gly Lys Ser Met Met Ala Ile Gly Gly Gly Thr Tyr Arg
Gly Glu 545 550 555 560 Ala Gly Tyr Ala Ile Gly Tyr Ser Ser Ile Ser
Asp Gly Gly Asn Trp 565 570 575 Ile Ile Lys Gly Thr Ala Ser Gly Asn
Ser Arg Gly His Phe Gly Ala 580 585 590 Ser Ala Ser Val Gly Tyr Gln
Trp 595 600 112 32 DNA Neisseria meningitidis 112 cgcggatccc
atatgtcgcc gcaaaattcc ga 32 113 28 DNA Neisseria meningitidis 113
cccgctcgag ttttgccgcg ttaaaagc 28 114 30 DNA Neisseria meningitidis
114 cgcggatccc atatgaccgt gaagaccgcc 30 115 28 DNA Neisseria
meningitidis 115 cccgctcgag ccactgataa ccgacaga 28 116 34 DNA
Neisseria meningitidis 116 cgcggatccc atatgtattt gaaacagctc caag 34
117 26 DNA Neisseria meningitidis 117 cccgctcgag ttctgggtga atgtta
26 118 29 DNA Neisseria meningitidis 118 gcggatccca tatgggcacg
gacaacccc 29 119 26 DNA Neisseria meningitidis 119 cccgctcgag
acgtggggaa cagtct 26 120 34 DNA Neisseria meningitidis 120
gcggatccca tatgaaaaat attcaagtag ttgc 34 121 27 DNA Neisseria
meningitidis 121 cccgctcgag aagtttgatt aaacccg 27 122 31 DNA
Neisseria meningitidis 122 cgcggatccc atatgtgcca accgcaatcc g 31
123 27 DNA Neisseria meningitidis 123 cccgctcgag tttttccagc tccggca
27 124 33 DNA Neisseria meningitidis 124 gcggatccca tatggttatc
ggaatattac tcg 33 125 25 DNA Neisseria meningitidis 125 cccgctcgag
ggctgcagaa gctgg 25 126 32 DNA Neisseria meningitidis 126
cgcggatccc atatgcggac gtggttggtt tt 32 127 30 DNA Neisseria
meningitidis 127 cccgctcgag atatcttccg tttttttcac 30 128 36 DNA
Neisseria meningitidis 128 cgcggatccg ctagcgtaaa tttattattt ttagaa
36 129 28 DNA Neisseria meningitidis 129 cccgctcgag ttccaactca
ttgaagta 28 130 35 DNA Neisseria meningitidis 130 cgcggatccc
atatgaataa aggtttacat cgcat 35 131 26 DNA Neisseria meningitidis
131 cccgctcgag aatcgctgca ccggct 26 132 30 DNA Neisseria
meningitidis 132 cgcggatccc atatgactgc cttttcgaca 30 133 26 DNA
Neisseria meningitidis 133 cccgctcgag gcgtgaagcg tcagga 26 134 15
DNA Artificial Sequence Description of Artificial Sequence BamHI -
NdeI 134 cgcggatccc atatg 15 135 15 DNA Artificial Sequence
Description of Artificial Sequence BamHI - NheI 135 cgcggatccg
ctagc 15 136 17 DNA Artificial Sequence Description of Artificial
Sequence EcoRI - NheI 136 ccggaattct agctagc 17 137 10 DNA
Artificial Sequence Description of Artificial Sequence XhoI 137
cccgctcgag 10 138 291 PRT Artificial Sequence Description of
Artificial Sequence ORF40a 138 Ser Ala Leu Asn Ala Xaa Val Ala Val
Ser Glu Leu Thr Arg Asn His 1 5 10 15 Thr Lys Arg Ala Ser Ala Thr
Val Lys Thr Ala Val Leu Ala Thr Leu 20 25 30 Leu Phe Ala Thr Val
Gln Ala Asn Ala Thr Asp Glu Asp Glu Glu Glu 35 40 45 Glu Leu Glu
Ser Val Gln Arg Ser Val Val Gly Ser Ile Gln Ala Ser 50 55 60 Met
Glu Gly Ser Gly Glu Leu Glu Thr Ile Ser Leu Ser Met Thr Asn 65 70
75 80 Asp Ser Lys Glu Phe Val Asp Pro Tyr Ile Val Val Thr Leu Lys
Ala 85 90 95 Gly Asp Asn Leu Lys Ile Lys Gln Asn Thr Asn Glu Asn
Thr Asn Ala 100 105 110 Ser Ser Phe Thr Tyr Ser Leu Lys Lys Asp Leu
Thr Gly Leu Ile Asn 115 120 125 Val Xaa Thr Glu Lys Leu Ser Phe Gly
Ala Asn Gly Lys Lys Val Asn 130 135 140 Ile Ile Ser Asp Thr Lys Gly
Leu Asn Phe Ala Lys Glu Thr Ala Gly 145 150 155 160 Thr Asn Gly Asp
Thr Thr Val His Leu Asn Gly Ile Gly Ser Thr Leu 165 170 175 Thr Asp
Thr Leu Ala Gly Ser Ser Ala Ser His Val Asp Ala Gly Asn 180 185 190
Xaa Ser Thr His Tyr Thr Arg Ala Ala Ser Ile Lys Asp Val Leu Asn 195
200 205 Ala Gly Trp Asn Ile Lys Gly Val Lys Xaa Gly Ser Thr Thr Gly
Gln 210 215 220 Ser Glu Asn Val Asp Phe Val Arg Thr Tyr Asp Thr Val
Glu Phe Leu 225 230 235 240 Ser Ala Asp Thr Xaa Thr Thr Thr Val Asn
Val Glu Ser Lys Asp Asn 245 250 255 Gly Lys Arg Thr Glu Val Lys Ile
Gly Ala Lys Thr Ser Val Ile Lys 260 265 270 Glu Lys Asp Gly Lys Leu
Val Thr Gly Lys Gly Lys Gly Glu Asn Gly 275 280 285 Ser Ser Thr 290
139 240 PRT Artificial Sequence Description of Artificial Sequence
Hsf 139 Thr Leu Leu Phe Ala Thr Val Gln Ala Asn Ala Thr Asp Glu Asp
Glu 1 5 10 15 Glu Leu Asp Pro Val Val Arg Thr Ala Pro Val Leu Ser
Phe His Ser 20 25 30 Asp Lys Glu Gly Thr Gly Glu Lys Glu Val Thr
Glu Asn Ser Asn Trp 35 40 45 Gly Ile Tyr Phe Asp Asn Lys Gly Val
Leu Lys Ala Gly Ala Ile Thr 50 55 60 Leu Lys Ala Gly Asp Asn Leu
Lys Ile Lys Gln Asn Thr Asp Glu Ser 65 70 75 80 Thr Asn Ala Ser Ser
Phe Thr Tyr Ser Leu Lys Lys Asp Leu Thr Asp 85 90 95 Leu Thr Ser
Val Ala Thr Glu Lys Leu Ser Phe Gly Ala Asn Gly Asp 100 105 110 Lys
Val Asp Ile Thr Ser Asp Ala Asn Gly Leu Lys Leu Ala Lys Thr 115 120
125 Gly Asn Gly Asn Val His Leu Asn Gly Leu Asp Ser Thr Leu Pro Asp
130 135 140 Ala Val Thr Asn Thr Gly Val Leu Ser Ser Ser Ser Phe Thr
Pro Asn 145 150 155 160 Asp Val Glu Lys Thr Arg Ala Ala Thr Val Lys
Asp Val Leu Asn Ala 165 170 175 Gly Trp Asn Ile Lys Gly Ala Lys Thr
Ala Gly Gly Asn Val Glu Ser 180 185 190 Val Asp Leu Val Ser Ala Tyr
Asn Asn Val Glu Phe Ile Thr Gly Asp 195 200 205 Lys Asn Thr Leu Asp
Val Val Leu Thr Ala Lys Glu Asn Gly Lys Thr 210 215 220 Thr Glu Val
Lys Phe Thr Pro Lys Thr Ser Val Ile Lys Glu Lys Asp 225 230 235 240
140 251 PRT Artificial Sequence Description of Artificial Sequence
overlap identity 140 Thr Leu Leu Phe Ala Thr Val Gln Ala Xaa Ala
Xaa Xaa Glu Xaa Xaa 1 5 10 15 Glu Xaa Xaa Xaa Xaa Leu Asp Pro Val
Xaa Arg Thr Xaa Xaa Val Leu 20 25 30 Xaa Xaa Xaa Ser Asp Xaa Xaa
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 35 40 45 Xaa Asn Ser Xaa Trp
Xaa Xaa Tyr Phe Xaa Xaa Lys Gly Val Leu Xaa 50 55 60 Ala Xaa Xaa
Ile Thr Xaa Lys Ala Gly Asp Asn Leu Lys Ile Lys Gln 65 70 75 80 Asn
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Phe Thr Tyr Ser Leu Lys 85 90
95 Lys Asp Leu Thr Asp Leu Thr Ser Val Xaa Thr Glu Lys Leu Ser Phe
100 105 110 Xaa Ala Asn Gly Xaa Lys Val Xaa Ile Thr Ser Asp Xaa Xaa
Gly Leu 115 120 125 Xaa Xaa Ala Lys Xaa Xaa Xaa Xaa Xaa Xaa Gly Xaa
Xaa Xaa Val His 130 135 140 Leu Asn Gly Xaa Xaa Ser Thr Leu Xaa Asp
Xaa Xaa Xaa Asn Thr Gly 145 150 155 160 Xaa Xaa Xaa Xaa Xaa Xaa Xaa
Xaa Xaa Xaa Xaa Xaa Xaa Glu Lys Xaa 165 170 175 Arg Ala Ala Xaa Val
Lys Asp Val Leu Asn Ala Gly Trp Asn Ile Lys 180 185 190 Gly Xaa Lys
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Val Asp Xaa Val Xaa 195 200 205 Xaa
Tyr Xaa Xaa Val Glu Phe Xaa Xaa Xaa Asp Xaa Xaa Thr Xaa Xaa 210 215
220 Val Xaa Xaa Xaa Xaa Lys Xaa Asn Gly Lys Xaa Thr Glu Val Lys Xaa
225 230 235 240 Xaa Xaa Lys Thr Ser Val Ile Lys Glu Lys Asp 245 250
141 36 PRT Artificial Sequence Description of Artificial Sequence
ORF40a 141 Val Ala Val Ser Glu Leu Thr Arg Asn His Thr Lys Arg Ala
Ser Ala 1 5 10 15 Thr Val Lys Thr Ala Val Leu Ala Thr Leu Leu Phe
Ala Thr Val Gln 20 25 30 Ala Asn Ala Thr 35 142 36 PRT Artificial
Sequence Description of Artificial Sequence homology 142 Val Xaa
Val Ser Glu Leu Thr Arg Xaa His Thr Lys Arg Ala Ser Ala 1 5 10 15
Thr Val Xaa Thr Ala Val Leu Ala Thr Leu Leu Phe Ala Thr Val Gln 20
25 30 Ala Asn Ala Thr 35 143 36 PRT Artificial Sequence Description
of Artificial Sequence Hsf 143 Val Val Val Ser Glu Leu Thr Arg Thr
His Thr Lys Arg Ala Ser Ala 1 5 10 15 Thr Val Glu Thr Ala Val Leu
Ala Thr Leu Leu Phe Ala Thr Val Gln 20 25 30 Ala Asn Ala Thr 35 144
38 PRT Artificial Sequence Description of Artificial Sequence
Orf40a 144 Val Thr Leu Lys Ala Gly Asp Asn Leu Lys Ile Lys Gln Asn
Thr Asn 1 5 10 15 Glu Asn Thr Asn Ala Ser Ser Phe Thr Tyr Ser Leu
Lys Lys Asp Leu 20 25 30 Thr Gly Leu Ile Asn Val 35 145 38 PRT
Artificial Sequence Description of Artificial Sequence homology 145
Xaa Thr Leu Lys Ala Gly Asp Asn Leu Lys Ile Lys Gln Asn Thr Xaa 1 5
10 15 Glu Xaa Thr Asn Ala Ser Ser Phe Thr Tyr Ser Leu Lys Lys Asp
Leu 20 25 30 Thr Xaa Leu Xaa Xaa Val 35 146 38 PRT Artificial
Sequence Description of Artificial Sequence Hsf 146 Ile Thr Leu Lys
Ala Gly Asp Asn Leu Lys Ile Lys Gln Asn Thr Asp 1 5 10 15 Glu Ser
Thr Asn Ala Ser Ser Phe Thr Tyr Ser Leu Lys Lys Asp Leu 20 25 30
Thr Asp Leu Thr Ser Val 35 147 29 PRT Artificial Sequence
Description of Artificial Sequence Orf40a 147 Val Thr Glu Lys Leu
Ser Phe Gly Ala Asn Gly Lys Lys Val Asn Ile 1 5 10 15 Ile Ser Asp
Thr Lys Gly Leu Asn Phe Ala Lys Glu Thr 20 25 148 29 PRT Artificial
Sequence Description of Artificial Sequence homology 148 Val Xaa
Xaa Lys Leu Ser Xaa Gly Xaa Asn Gly Xaa Lys Val Asn Ile 1 5 10 15
Xaa Ser Asp Thr Lys Gly Leu Asn Phe Ala Lys Xaa Xaa 20 25 149 29
PRT Artificial Sequence Description of Artificial Sequence Hsf 149
Val Ser Asp Lys Leu Ser Leu Gly Thr Asn Gly Asn Lys Val Asn Ile 1 5
10 15 Thr Ser Asp Thr Lys Gly Leu Asn Phe Ala Lys Asp Ser 20 25 150
32 PRT Artificial Sequence Description of Artificial Sequence
ORF40a 150 Thr Asn Gly Asp Thr Thr Val His Leu Asn Gly Ile Gly Ser
Thr Leu 1 5 10 15 Thr Asp Thr Leu Ala Gly Ser Ser Ala Ser His Val
Asp Ala Gly Asn 20 25 30 151 32 PRT Artificial Sequence Description
of Artificial Sequence homology 151 Thr Xaa Xaa Asp Xaa Xaa Xaa His
Leu Asn Gly Ile Xaa Ser Thr Leu 1 5 10 15 Thr Asp Thr Leu Xaa Xaa
Ser Xaa Ala Xaa Xaa Xaa Xaa Xaa Gly Asn 20 25 30 152 32 PRT
Artificial Sequence Description of Artificial Sequence Hsf 152 Thr
Gly Asp Asp Ala Asn Ile His Leu Asn Gly Ile Ala Ser Thr Leu 1 5 10
15 Thr Asp Thr Leu Leu Asn Ser Gly Ala Thr Thr Asn Leu Gly Gly Asn
20 25 30 153 19 PRT Artificial Sequence Description of Artificial
Sequence ORF40a 153 Arg Ala Ala Ser Ile Lys Asp Val Leu Asn Ala Gly
Trp Asn Ile Lys 1 5 10 15 Gly Val Lys 154 19 PRT Artificial
Sequence Description of Artificial Sequence homology 154 Arg Ala
Ala Ser Xaa Lys Asp Val Leu Asn Ala Gly Trp Asn Xaa Xaa 1 5 10 15
Gly Val Lys 155 19 PRT Artificial Sequence Description of
Artificial Sequence Hsf 155 Arg Ala Ala Ser Val Lys Asp Val Leu Asn
Ala Gly Trp Asn Val Arg 1 5 10 15 Gly Val Lys 156 28 PRT Artificial
Sequence Description of Artificial Sequence ORF40a 156 Ser Thr Thr
Gly Gln Ser Glu Asn Val Asp Phe Val Arg Thr Tyr Asp 1 5 10 15 Thr
Val Glu Phe Leu Ser Ala Asp Thr Thr Thr Thr 20 25 157 28 PRT
Artificial Sequence Description of Artificial Sequence homology 157
Ser Xaa Xaa Xaa Gln Xaa Glu Asn Xaa Asp Phe Val Xaa Thr Tyr Asp 1 5
10 15 Thr Val Xaa Phe Xaa Ser Xaa Asp Xaa Xaa Thr Thr 20 25 158 28
PRT Artificial Sequence Description of Artificial Sequence Hsf
158 Ser Ala Asn Asn Gln Val Glu Asn Ile Asp Phe Val Ala Thr Tyr Asp
1 5 10 15 Thr Val Asp Phe Val Ser Gly Asp Lys Asp Thr Thr 20 25 159
240 PRT Artificial Sequence Description of Artificial Sequence
ORF38a 159 Met Leu Arg Leu Thr Ala Leu Ala Val Cys Thr Ala Leu Ala
Leu Gly 1 5 10 15 Ala Cys Ser Pro Gln Asn Ser Asp Ser Ala Pro Gln
Ala Lys Glu Gln 20 25 30 Ala Val Ser Ala Ala Gln Ser Glu Gly Val
Ser Val Thr Val Lys Thr 35 40 45 Ala Arg Gly Asp Val Gln Ile Pro
Gln Asn Pro Glu Arg Ile Ala Val 50 55 60 Tyr Asp Leu Gly Met Leu
Asp Thr Leu Ser Lys Leu Gly Val Lys Thr 65 70 75 80 Gly Leu Ser Val
Asp Lys Asn Arg Leu Pro Tyr Leu Glu Glu Tyr Phe 85 90 95 Lys Thr
Thr Lys Pro Ala Gly Thr Leu Phe Glu Pro Asp Tyr Glu Thr 100 105 110
Leu Asn Ala Tyr Lys Pro Gln Leu Ile Ile Ile Gly Ser Arg Ala Ala 115
120 125 Lys Ala Phe Asp Lys Leu Asn Glu Ile Ala Pro Thr Ile Glu Met
Thr 130 135 140 Ala Asp Thr Ala Asn Leu Lys Glu Ser Ala Lys Glu Arg
Ile Asp Ala 145 150 155 160 Leu Ala Gln Ile Phe Gly Lys Lys Ala Glu
Ala Asp Lys Leu Lys Ala 165 170 175 Glu Ile Asp Ala Ser Phe Glu Ala
Ala Lys Thr Ala Ala Gln Gly Lys 180 185 190 Gly Lys Gly Leu Val Ile
Leu Val Asn Gly Gly Lys Met Ser Ala Phe 195 200 205 Gly Pro Ser Ser
Arg Leu Gly Gly Trp Leu His Lys Asp Ile Gly Val 210 215 220 Pro Ala
Val Asp Glu Ala Ile Lys Glu Gly Ser His Gly Gln Pro Ile 225 230 235
240 160 94 PRT Artificial Sequence Description of Artificial
Sequence ORF38 160 Glu Gly Ala Ser Val Thr Val Lys Thr Ala Arg Gly
Asp Val Gln Ile 1 5 10 15 Pro Gln Asn Pro Glu Arg Ile Ala Val Tyr
Asp Leu Gly Met Leu Asp 20 25 30 Thr Leu Ser Lys Leu Gly Val Lys
Thr Gly Leu Ser Val Asp Lys Asn 35 40 45 Arg Leu Pro Tyr Leu Glu
Glu Tyr Phe Lys Thr Thr Lys Pro Ala Gly 50 55 60 Thr Leu Phe Glu
Pro Asp Tyr Glu Thr Leu Asn Ala Tyr Lys Pro Gln 65 70 75 80 Leu Ile
Ile Ile Gly Ser Arg Ala Ala Lys Ala Phe Asp Lys 85 90 161 96 PRT
Artificial Sequence Description of Artificial Sequence overlap
identity 161 Glu Gly Xaa Ser Xaa Xaa Val Lys Xaa Xaa Xaa Gly Xaa
Xaa Xaa Xaa 1 5 10 15 Pro Xaa Asn Pro Xaa Xaa Xaa Xaa Xaa Xaa Asp
Leu Gly Xaa Leu Asp 20 25 30 Thr Xaa Xaa Xaa Leu Xaa Xaa Xaa Xaa
Xaa Xaa Xaa Xaa Val Xaa Xaa 35 40 45 Xaa Xaa Leu Pro Xaa Xaa Xaa
Xaa Xaa Phe Lys Xaa Xaa Xaa Xaa Xaa 50 55 60 Gly Xaa Xaa Xaa Xaa
Xaa Asp Xaa Glu Xaa Xaa Asn Ala Xaa Lys Pro 65 70 75 80 Xaa Leu Ile
Ile Ile Xaa Xaa Arg Xaa Xaa Lys Xaa Xaa Asp Lys Leu 85 90 95 162 96
PRT Artificial Sequence Description of Artificial Sequence Lipo 162
Glu Gly Asp Ser Phe Leu Val Lys Asp Ser Leu Gly Glu Asn Lys Thr 1 5
10 15 Pro Lys Asn Pro Ser Lys Val Val Ile Leu Asp Leu Gly Ile Leu
Asp 20 25 30 Thr Phe Asp Ala Leu Lys Leu Asn Asp Lys Val Ala Gly
Val Pro Ala 35 40 45 Lys Asn Leu Pro Lys Tyr Leu Gln Gln Phe Lys
Asn Lys Pro Ser Val 50 55 60 Gly Gly Val Gln Gln Val Asp Phe Glu
Ala Ile Asn Ala Leu Lys Pro 65 70 75 80 Asp Leu Ile Ile Ile Ser Gly
Arg Gln Ser Lys Phe Tyr Asp Lys Leu 85 90 95 163 91 PRT Artificial
Sequence Description of Artificial Sequence ORF44 163 Thr Val Ser
Tyr Val Cys Gln Gln Gly Lys Lys Val Lys Val Thr Tyr 1 5 10 15 Gly
Phe Asn Lys Gln Gly Leu Thr Thr Tyr Ala Ser Ala Val Ile Asn 20 25
30 Gly Lys Arg Val Gln Met Pro Val Asn Leu Asp Lys Ser Asp Asn Val
35 40 45 Glu Thr Phe Tyr Gly Lys Glu Gly Gly Tyr Val Leu Gly Thr
Gly Val 50 55 60 Met Asp Gly Lys Ser Tyr Arg Lys Gln Pro Ile Met
Ile Thr Ala Pro 65 70 75 80 Asp Asn Gln Ile Val Phe Lys Asp Cys Ser
Pro 85 90 164 91 PRT Artificial Sequence Description of Artificial
Sequence overlap identity 164 Xaa Val Xaa Tyr Val Cys Gln Gln Gly
Xaa Xaa Xaa Xaa Val Xaa Tyr 1 5 10 15 Xaa Phe Asn Xaa Xaa Gly Xaa
Xaa Thr Xaa Ala Xaa Xaa Xaa Xaa Asn 20 25 30 Xaa Xaa Xaa Xaa Xaa
Xaa Pro Xaa Asn Leu Xaa Xaa Ser Asp Asn Val 35 40 45 Xaa Thr Xaa
Xaa Xaa Xaa Xaa Xaa Gly Tyr Xaa Leu Xaa Thr Xaa Xaa 50 55 60 Met
Asp Xaa Xaa Xaa Tyr Arg Xaa Gln Xaa Ile Xaa Xaa Xaa Ala Pro 65 70
75 80 Xaa Xaa Gln Xaa Xaa Xaa Lys Asp Cys Ser Pro 85 90 165 90 PRT
Artificial Sequence Description of Artificial Sequence LecA 165 Ser
Val Ala Tyr Val Cys Gln Gln Gly Arg Arg Leu Asn Val Asn Tyr 1 5 10
15 Arg Phe Asn Ser Ala Gly Val Pro Thr Ser Ala Glu Leu Arg Val Asn
20 25 30 Asn Arg Asn Leu Arg Leu Pro Tyr Asn Leu Ser Ala Ser Asp
Asn Val 35 40 45 Asp Thr Val Phe Ser Ala Asn Gly Tyr Arg Leu Thr
Thr Asn Ala Met 50 55 60 Asp Ser Ala Asn Tyr Arg Ser Gln Asp Ile
Ile Val Ser Ala Pro Asn 65 70 75 80 Gly Gln Met Leu Tyr Lys Asp Cys
Ser Pro 85 90 166 240 PRT Artificial Sequence Description of
Artificial Sequence ORF49a 166 Ser Lys Asn Glu Leu Asn Glu Thr Lys
Leu Pro Val Arg Val Val Ala 1 5 10 15 Gln Xaa Ala Ala Thr Arg Ser
Gly Trp Asp Thr Val Leu Glu Gly Thr 20 25 30 Glu Phe Lys Thr Thr
Leu Ala Gly Ala Asp Ile Gln Ala Gly Val Xaa 35 40 45 Glu Lys Ala
Arg Val Asp Ala Lys Ile Ile Leu Lys Gly Ile Val Asn 50 55 60 Arg
Ile Gln Ser Glu Glu Lys Leu Glu Thr Asn Ser Thr Val Trp Gln 65 70
75 80 Lys Gln Ala Gly Arg Gly Ser Thr Ile Glu Thr Leu Lys Leu Pro
Ser 85 90 95 Phe Glu Ser Pro Thr Pro Pro Lys Leu Ser Ala Pro Gly
Gly Tyr Ile 100 105 110 Val Asp Ile Pro Lys Gly Asn Leu Lys Thr Glu
Ile Glu Lys Leu Ser 115 120 125 Lys Gln Pro Glu Tyr Ala Tyr Leu Lys
Gln Leu Gln Val Ala Lys Asn 130 135 140 Ile Asn Trp Asn Gln Val Gln
Leu Ala Tyr Asp Arg Trp Asp Tyr Lys 145 150 155 160 Gln Glu Gly Leu
Thr Glu Ala Gly Ala Ala Ile Ile Ala Leu Ala Val 165 170 175 Thr Val
Val Thr Ser Gly Ala Gly Thr Gly Ala Val Leu Gly Leu Asn 180 185 190
Gly Ala Xaa Ala Ala Ala Thr Asp Ala Ala Phe Ala Ser Leu Ala Ser 195
200 205 Gln Ala Ser Val Ser Phe Ile Asn Asn Lys Gly Asp Val Gly Lys
Thr 210 215 220 Leu Lys Glu Leu Gly Arg Ser Ser Thr Val Lys Asn Leu
Val Val Ala 225 230 235 240 167 540 PRT Artificial Sequence
Description of Artificial Sequence ORF49a 167 Xaa Gln Leu Leu Ala
Glu Glu Gly Ile His Lys His Glu Leu Asp Val 1 5 10 15 Gln Lys Ser
Arg Arg Phe Ile Gly Ile Lys Val Gly Xaa Ser Asn Tyr 20 25 30 Ser
Lys Asn Glu Leu Asn Glu Thr Lys Leu Pro Val Arg Val Val Ala 35 40
45 Gln Xaa Ala Ala Thr Arg Ser Gly Trp Asp Thr Val Leu Glu Gly Thr
50 55 60 Glu Phe Lys Thr Thr Leu Ala Gly Ala Asp Ile Gln Ala Gly
Val Xaa 65 70 75 80 Glu Lys Ala Arg Val Asp Ala Lys Ile Ile Leu Lys
Gly Ile Val Asn 85 90 95 Arg Ile Gln Ser Glu Glu Lys Leu Glu Thr
Asn Ser Thr Val Trp Gln 100 105 110 Lys Gln Ala Gly Arg Gly Ser Thr
Ile Glu Thr Leu Lys Leu Pro Ser 115 120 125 Phe Glu Ser Pro Thr Pro
Pro Lys Leu Ser Ala Pro Gly Gly Tyr Ile 130 135 140 Val Asp Ile Pro
Lys Gly Asn Leu Lys Thr Glu Ile Glu Lys Leu Ser 145 150 155 160 Lys
Gln Pro Glu Tyr Ala Tyr Leu Lys Gln Leu Gln Val Ala Lys Asn 165 170
175 Ile Asn Trp Asn Gln Val Gln Leu Ala Tyr Asp Arg Trp Asp Tyr Lys
180 185 190 Gln Glu Gly Leu Thr Glu Ala Gly Ala Ala Ile Ile Ala Leu
Ala Val 195 200 205 Thr Val Val Thr Ser Gly Ala Gly Thr Gly Ala Val
Leu Gly Leu Asn 210 215 220 Gly Ala Xaa Ala Ala Ala Thr Asp Ala Ala
Phe Ala Ser Leu Ala Ser 225 230 235 240 Gln Ala Ser Val Ser Phe Ile
Asn Asn Lys Gly Asp Val Gly Lys Thr 245 250 255 Leu Lys Glu Leu Gly
Arg Ser Ser Thr Val Lys Asn Leu Val Val Ala 260 265 270 Ala Ala Thr
Ala Gly Val Ala Asp Lys Ile Gly Ala Ser Ala Leu Xaa 275 280 285 Asn
Val Ser Asp Lys Gln Trp Ile Asn Asn Leu Thr Val Asn Leu Ala 290 295
300 Asn Ala Gly Ser Ala Ala Leu Ile Asn Thr Ala Val Asn Gly Gly Ser
305 310 315 320 Leu Lys Asp Xaa Leu Glu Ala Asn Ile Leu Ala Ala Leu
Val Asn Thr 325 330 335 Ala His Gly Glu Ala Ala Ser Lys Ile Lys Gln
Leu Asp Gln His Tyr 340 345 350 Ile Val His Lys Ile Ala His Ala Ile
Ala Gly Cys Ala Ala Ala Ala 355 360 365 Ala Asn Lys Gly Lys Cys Gln
Asp Gly Ala Ile Gly Ala Ala Val Gly 370 375 380 Glu Ile Val Gly Glu
Ala Leu Thr Asn Gly Lys Asn Pro Asp Thr Leu 385 390 395 400 Thr Ala
Lys Glu Arg Glu Gln Ile Leu Ala Tyr Ser Lys Leu Val Ala 405 410 415
Gly Thr Val Ser Gly Val Val Gly Gly Asp Val Asn Ala Ala Ala Asn 420
425 430 Ala Ala Glu Val Ala Val Lys Asn Asn Gln Leu Ser Asp Xaa Glu
Gly 435 440 445 Arg Glu Phe Asp Asn Glu Met Thr Ala Cys Ala Lys Gln
Asn Xaa Pro 450 455 460 Gln Leu Cys Arg Lys Asn Thr Val Lys Lys Tyr
Gln Asn Val Ala Asp 465 470 475 480 Lys Arg Leu Ala Ala Ser Ile Ala
Ile Cys Thr Asp Ile Ser Arg Ser 485 490 495 Thr Glu Cys Arg Thr Ile
Arg Lys Gln His Leu Ile Asp Ser Arg Ser 500 505 510 Leu His Ser Ser
Trp Glu Ala Gly Leu Ile Gly Lys Asp Asp Glu Trp 515 520 525 Tyr Lys
Leu Phe Ser Lys Ser Tyr Thr Gln Ala Asp 530 535 540 168 540 PRT
Artificial Sequence Description of Artificial Sequence ORF49-1 168
Met Gln Leu Leu Ala Ala Glu Gly Ile His Gln His Gln Leu Asn Val 1 5
10 15 Gln Lys Ser Thr Arg Phe Ile Gly Ile Lys Val Gly Lys Ser Asn
Tyr 20 25 30 Ser Lys Asn Glu Leu Asn Glu Thr Lys Leu Pro Val Arg
Val Ile Ala 35 40 45 Gln Thr Ala Lys Thr Arg Ser Gly Trp Asp Thr
Val Leu Glu Gly Thr 50 55 60 Glu Phe Lys Thr Thr Leu Ser Gly Ala
Asp Ile Gln Ala Gly Val Gly 65 70 75 80 Glu Lys Ala Arg Ala Asp Ala
Lys Ile Ile Leu Lys Gly Ile Val Asn 85 90 95 Arg Ile Gln Thr Glu
Glu Lys Leu Glu Ser Asn Ser Thr Val Trp Gln 100 105 110 Lys Gln Ala
Gly Ser Gly Ser Thr Val Glu Thr Leu Lys Leu Pro Ser 115 120 125 Phe
Glu Gly Pro Ala Leu Pro Lys Leu Thr Ala Pro Gly Gly Tyr Ile 130 135
140 Ala Asp Ile Pro Lys Gly Asn Leu Lys Thr Glu Ile Glu Lys Leu Ala
145 150 155 160 Lys Gln Pro Glu Tyr Ala Tyr Leu Lys Gln Leu Gln Thr
Val Lys Asp 165 170 175 Val Asn Trp Asn Gln Val Gln Leu Ala Tyr Asp
Lys Trp Asp Tyr Lys 180 185 190 Gln Glu Gly Leu Thr Gly Ala Gly Ala
Ala Ile Ile Ala Leu Ala Val 195 200 205 Thr Val Val Thr Ser Gly Ala
Gly Thr Gly Ala Val Leu Gly Leu Asn 210 215 220 Gly Ala Ala Ala Ala
Ala Thr Asp Ala Ala Phe Ala Ser Leu Ala Ser 225 230 235 240 Gln Ala
Ser Val Ser Phe Ile Asn Asn Lys Gly Asn Ile Gly Asn Thr 245 250 255
Leu Lys Glu Leu Gly Arg Ser Ser Thr Val Lys Asn Leu Met Val Ala 260
265 270 Val Ala Thr Ala Gly Val Ala Asp Lys Ile Gly Ala Ser Ala Leu
Asn 275 280 285 Asn Val Ser Asp Lys Gln Trp Ile Asn Asn Leu Thr Val
Asn Leu Ala 290 295 300 Asn Ala Gly Ser Ala Ala Leu Ile Asn Thr Ala
Val Asn Gly Gly Ser 305 310 315 320 Leu Lys Asp Asn Leu Glu Ala Asn
Ile Leu Ala Ala Leu Val Asn Thr 325 330 335 Ala His Gly Glu Ala Ala
Ser Lys Ile Lys Gln Leu Asp Gln His Tyr 340 345 350 Ile Ala His Lys
Ile Ala His Ala Ile Ala Gly Cys Ala Ala Ala Ala 355 360 365 Ala Asn
Lys Gly Lys Cys Gln Asp Gly Ala Ile Gly Ala Ala Val Gly 370 375 380
Glu Ile Leu Gly Glu Thr Leu Leu Asp Gly Arg Asp Pro Gly Ser Leu 385
390 395 400 Asn Val Lys Asp Arg Ala Lys Ile Ile Ala Lys Ala Lys Leu
Ala Ala 405 410 415 Gly Ala Val Ala Ala Leu Ser Lys Gly Asp Val Ser
Thr Ala Ala Asn 420 425 430 Ala Ala Ala Val Ala Val Glu Asn Asn Ser
Leu Asn Asp Ile Gln Asp 435 440 445 Arg Leu Leu Ser Gly Asn Tyr Ala
Leu Cys Met Ser Ala Gly Gly Ala 450 455 460 Glu Ser Phe Cys Glu Ser
Tyr Arg Pro Leu Gly Leu Pro His Phe Val 465 470 475 480 Ser Val Ser
Gly Glu Met Lys Leu Pro Asn Lys Phe Gly Asn Arg Met 485 490 495 Val
Asn Gly Lys Leu Ile Ile Asn Thr Arg Asn Gly Asn Val Tyr Phe 500 505
510 Ser Val Gly Lys Ile Trp Ser Thr Val Lys Ser Thr Lys Ser Asn Ile
515 520 525 Ser Gly Val Ser Val Gly Trp Val Leu Asn Val Ser 530 535
540 169 210 PRT Artificial Sequence Description of Artificial
Sequence ORF39 169 Lys Phe Asp Phe Thr Trp Phe Ile Pro Ala Val Ile
Lys Tyr Arg Arg 1 5 10 15 Leu Phe Phe Glu Val Leu Val Val Ser Val
Val Leu Gln Leu Phe Ala 20 25 30 Leu Ile Thr Pro Leu Phe Phe Gln
Val Val Met Asp Lys Val Leu Val 35 40 45 His Arg Gly Phe Ser Thr
Leu Asp Val Val Ser Val Ala Leu Leu Val 50 55 60 Val Ser Leu Phe
Glu Ile Val Leu Gly Gly Leu Arg Thr Tyr Leu Phe 65 70 75 80 Ala His
Thr Thr Ser Arg Ile Asp Val Glu Leu Gly Ala Arg Leu Phe 85 90 95
Arg His Leu Leu Ser Leu Pro Leu Ser Tyr Phe Glu His Arg Arg Val 100
105 110 Gly Asp Thr Val Ala Arg Val Arg Glu Leu Glu Gln Ile Arg Asn
Phe 115 120 125 Leu Thr Gly Gln Ala Leu Thr Ser Val Leu Asp Leu Ala
Phe Ser Phe 130 135 140 Ile Phe Leu Ala Val Met Trp Tyr Tyr Ser Ser
Thr Leu Thr Trp Val 145 150 155 160 Val Leu Ala Ser Leu Xaa Xaa Xaa
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 165 170 175 Xaa Xaa Xaa Xaa
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 180 185 190 Xaa Ile
Cys Ala Asn Arg Thr Val Leu Ile Ile Ala His Arg Leu Ser 195 200 205
Thr Val 210 170 240 PRT Artificial Sequence Description of
Artificial Sequence ORF39a 170 Ala Val Leu Ser Phe Ala Glu Phe Ser
Asn Arg Tyr Ser Gly Lys Leu 1 5 10 15 Ile Leu Val Ala Ser Arg Ala
Ser Val Leu Gly Ser Leu Ala Lys Phe 20 25 30 Asp Phe Thr Trp Phe
Ile Pro Ala Val Ile Lys Tyr Arg Arg Leu Phe 35 40 45 Phe Glu Val
Leu Val Val Ser Val Val Leu Gln Leu Phe Ala Leu Ile 50 55 60 Thr
Pro Leu Phe Phe Gln Val Val Met Asp Lys Val Leu Val His Arg 65 70
75 80 Gly Phe Ser Thr Leu Asp Val Val Ser Val Ala Leu Leu Val Val
Ser 85 90 95 Leu Phe Glu Ile Val Leu Gly Gly Leu Arg Thr Tyr Leu
Phe Ala His 100 105 110 Thr Thr Ser Arg Ile Asp Val Glu Leu Gly Ala
Arg Leu Phe Arg His 115 120 125 Leu Leu Ser Leu Pro Leu Ser Tyr Phe
Glu His Arg Arg Val Gly Asp 130 135 140 Thr Val Ala Arg Val Arg Glu
Leu Glu Gln Ile Arg Asn Phe Leu Thr 145 150 155 160 Gly Gln Ala Leu
Thr Ser Val Leu Asp Leu Ala Phe Ser Phe Ile Phe 165 170 175 Leu Ala
Val Met Trp Tyr Tyr Ser Ser Thr Leu Thr Trp Val Val Leu 180 185 190
Ala Ser Leu Pro Ala Tyr Ala Phe Trp Ser Ala Phe Ile Ser Pro Ile 195
200 205 Leu Arg Thr Arg Leu Asn Asp Lys Phe Ala Arg Asn Ala Asp Asn
Gln 210 215 220 Ser Phe Leu Val Glu Ser Ile Thr Ala Val Gly Thr Val
Lys Ala Met 225 230 235 240 171 690 PRT Artificial Sequence
Description of Artificial Sequence ORF39a 171 Tyr His Gly Ile Ala
Ala Asn Pro Ala Asp Ile Gln His Glu Phe Cys 1 5 10 15 Thr Ser Ala
Gln Ser Asp Leu Asn Glu Thr Gln Trp Xaa Xaa Xaa Xaa 20 25 30 Xaa
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Val Val Arg Gln Pro Ile Lys Arg 35 40
45 Leu Ala Met Ala Thr Leu Pro Ala Leu Val Trp Cys Asp Asp Gly Asn
50 55 60 His Phe Ile Leu Ala Lys Thr Asp Gly Gly Gly Glu His Ala
Gln Tyr 65 70 75 80 Leu Ile Gln Asp Leu Thr Thr Asn Lys Ser Ala Val
Leu Ser Phe Ala 85 90 95 Glu Phe Ser Asn Arg Tyr Ser Gly Lys Leu
Ile Leu Val Ala Ser Arg 100 105 110 Ala Ser Val Leu Gly Ser Leu Ala
Lys Phe Asp Phe Thr Trp Phe Ile 115 120 125 Pro Ala Val Ile Lys Tyr
Arg Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 130 135 140 Xaa Xaa Xaa Xaa
Xaa Xaa Xaa Xaa Xaa Ile Thr Pro Leu Phe Phe Gln 145 150 155 160 Val
Val Met Asp Lys Val Leu Val His Arg Gly Phe Xaa Xaa Xaa Xaa 165 170
175 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Phe Glu Ile Val Leu
180 185 190 Gly Gly Leu Arg Thr Tyr Leu Phe Ala His Thr Thr Ser Arg
Ile Asp 195 200 205 Val Glu Leu Gly Ala Arg Leu Phe Arg His Leu Leu
Ser Leu Pro Leu 210 215 220 Ser Tyr Phe Glu His Arg Arg Val Gly Asp
Thr Val Ala Arg Val Arg 225 230 235 240 Glu Leu Glu Gln Ile Arg Asn
Phe Leu Thr Gly Gln Ala Leu Thr Ser 245 250 255 Val Leu Asp Leu Ala
Phe Ser Phe Ile Phe Leu Ala Val Met Trp Tyr 260 265 270 Tyr Ser Ser
Thr Leu Thr Trp Val Val Leu Ala Ser Leu Pro Ala Tyr 275 280 285 Ala
Phe Trp Ser Ala Phe Ile Ser Pro Ile Leu Arg Thr Arg Leu Asn 290 295
300 Asp Lys Phe Ala Arg Asn Ala Asp Asn Gln Ser Phe Leu Val Glu Ser
305 310 315 320 Ile Thr Ala Val Gly Thr Val Lys Ala Met Ala Val Glu
Pro Gln Met 325 330 335 Thr Gln Arg Trp Asp Asn Gln Leu Ala Ala Tyr
Val Ala Ser Gly Phe 340 345 350 Arg Val Thr Lys Leu Ala Val Val Gly
Gln Gln Gly Val Gln Leu Ile 355 360 365 Gln Lys Leu Val Thr Val Ala
Thr Leu Trp Ile Gly Ala Arg Leu Val 370 375 380 Ile Glu Ser Lys Leu
Thr Val Gly Gln Leu Ile Ala Phe Asn Met Leu 385 390 395 400 Ser Gly
Gln Val Ala Ala Pro Val Ile Arg Leu Ala Gln Leu Trp Gln 405 410 415
Asp Phe Gln Gln Val Gly Ile Ser Val Ala Arg Leu Gly Asp Ile Leu 420
425 430 Asn Ala Pro Thr Glu Asn Ala Ser Ser His Leu Ala Leu Pro Asp
Ile 435 440 445 Arg Gly Glu Ile Thr Phe Glu His Val Asp Phe Arg Tyr
Lys Ala Asp 450 455 460 Gly Arg Leu Ile Leu Gln Asp Leu Asn Leu Arg
Ile Arg Ala Gly Glu 465 470 475 480 Val Leu Gly Ile Val Gly Arg Ser
Gly Ser Gly Lys Ser Thr Leu Thr 485 490 495 Lys Leu Val Gln Arg Leu
Tyr Val Pro Ala Gln Gly Arg Val Leu Val 500 505 510 Asp Gly Asn Asp
Leu Ala Leu Ala Ala Pro Ala Trp Leu Arg Arg Gln 515 520 525 Val Gly
Val Val Leu Gln Glu Asn Val Leu Leu Asn Arg Ser Ile Arg 530 535 540
Asp Asn Ile Ala Leu Thr Asp Thr Gly Met Pro Leu Glu Arg Ile Ile 545
550 555 560 Glu Ala Ala Lys Leu Ala Gly Ala His Glu Phe Ile Met Glu
Leu Pro 565 570 575 Glu Gly Tyr Gly Thr Val Val Gly Glu Gln Gly Ala
Gly Leu Ser Gly 580 585 590 Gly Gln Arg Gln Arg Ile Ala Ile Ala Arg
Ala Leu Ile Thr Asn Pro 595 600 605 Arg Ile Leu Ile Phe Asp Glu Ala
Thr Ser Ala Leu Asp Tyr Glu Ser 610 615 620 Glu Arg Ala Ile Met Gln
Asn Met Gln Ala Ile Cys Ala Asn Arg Thr 625 630 635 640 Val Leu Ile
Ile Ala His Arg Leu Ser Thr Val Lys Thr Ala His Arg 645 650 655 Ile
Ile Ala Met Asp Lys Gly Arg Ile Val Glu Ala Gly Thr Gln Gln 660 665
670 Glu Leu Leu Ala Lys Pro Asn Gly Tyr Tyr Arg Tyr Leu Tyr Asp Leu
675 680 685 Gln Asn 690 172 690 PRT Artificial Sequence Description
of Artificial Sequence homology 172 Tyr His Xaa Ile Ala Xaa Asn Pro
Xaa Xaa Xaa Xaa His Xaa Phe Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa
Leu Xaa Xaa Thr Xaa Trp Xaa Xaa Xaa Xaa 20 25 30 Xaa Xaa Xaa Xaa
Xaa Xaa Xaa Xaa Xaa Val Xaa Xaa Xaa Ile Xaa Arg 35 40 45 Leu Ala
Xaa Xaa Xaa Leu Pro Ala Leu Val Trp Xaa Xaa Asp Gly Xaa 50 55 60
His Phe Ile Leu Xaa Lys Xaa Asp Xaa Xaa Xaa Glu Xaa Xaa Xaa Tyr 65
70 75 80 Leu Ile Xaa Asp Leu Xaa Thr Xaa Xaa Xaa Xaa Xaa Leu Xaa
Xaa Ala 85 90 95 Glu Phe Xaa Xaa Xaa Tyr Xaa Gly Lys Leu Ile Leu
Val Ala Ser Arg 100 105 110 Ala Ser Xaa Xaa Gly Xaa Leu Ala Lys Phe
Asp Phe Thr Trp Phe Ile 115 120 125 Pro Ala Val Ile Lys Tyr Arg Xaa
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 130 135 140 Xaa Xaa Xaa Xaa Xaa Xaa
Xaa Xaa Xaa Ile Thr Pro Leu Phe Phe Gln 145 150 155 160 Val Val Met
Asp Lys Val Leu Val His Arg Gly Phe Xaa Xaa Xaa Xaa 165 170 175 Xaa
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Phe Glu Ile Val Leu 180 185
190 Xaa Gly Leu Arg Thr Tyr Xaa Phe Ala His Xaa Thr Ser Arg Ile Asp
195 200 205 Val Glu Leu Gly Ala Arg Leu Phe Arg His Leu Leu Xaa Leu
Pro Xaa 210 215 220 Ser Tyr Phe Glu Xaa Arg Arg Val Gly Asp Thr Val
Ala Arg Val Arg 225 230 235 240 Glu Leu Xaa Gln Ile Arg Asn Phe Leu
Thr Gly Gln Ala Leu Thr Ser 245 250 255 Val Leu Asp Leu Xaa Phe Ser
Phe Ile Phe Xaa Ala Val Met Trp Tyr 260 265 270 Tyr Ser Xaa Xaa Leu
Thr Xaa Val Xaa Leu Xaa Ser Leu Pro Xaa Tyr 275 280 285 Xaa Xaa Trp
Ser Xaa Phe Ile Ser Pro Ile Leu Arg Xaa Arg Leu Xaa 290 295 300 Xaa
Lys Phe Ala Arg Xaa Ala Asp Asn Gln Ser Phe Leu Val Glu Ser 305 310
315 320 Xaa Thr Ala Xaa Xaa Thr Xaa Lys Ala Xaa Ala Val Xaa Pro Gln
Met 325 330 335 Thr Xaa Xaa Trp Asp Xaa Gln Leu Ala Xaa Tyr Val Xaa
Xaa Gly Phe 340 345 350 Arg Val Thr Xaa Leu Ala Xaa Xaa Gly Gln Gln
Gly Val Gln Xaa Ile 355 360 365 Gln Lys Xaa Val Xaa Val Xaa Thr Leu
Trp Xaa Gly Ala Xaa Leu Val 370 375 380 Ile Xaa Xaa Xaa Leu Xaa Xaa
Gly Gln Leu Ile Ala Phe Asn Met Leu 385 390 395 400 Ser Gly Gln Val
Xaa Ala Pro Val Ile Arg Leu Ala Gln Leu Trp Gln 405 410 415 Asp Phe
Gln Gln Val Gly Ile Ser Val Xaa Arg Leu Gly Asp Xaa Leu 420 425 430
Asn Xaa Pro Thr Glu Xaa Xaa Xaa Xaa Xaa Leu Ala Leu Pro Xaa Ile 435
440 445 Xaa Gly Xaa Ile Thr Phe Xaa Xaa Xaa Xaa Phe Arg Tyr Lys Xaa
Asp 450 455 460 Xaa Xaa Xaa Ile Leu Xaa Asp Xaa Asn Leu Xaa Ile Xaa
Xaa Gly Glu 465 470 475 480 Val Xaa Gly Ile Val Gly Arg Ser Gly Ser
Gly Lys Ser Thr Leu Thr 485 490 495 Lys Leu Xaa Gln Arg Xaa Tyr Xaa
Pro Xaa Xaa Gly Xaa Val Leu Xaa 500 505 510 Asp Gly Xaa Asp Leu Ala
Leu Ala Xaa Pro Xaa Trp Leu Arg Arg Gln 515 520 525 Val Gly Val Val
Leu Gln Xaa Asn Val Leu Leu Asn Arg Ser Ile Arg 530 535 540 Asp Asn
Ile Ala Leu Xaa Asp Xaa Gly Met Pro Xaa Glu Xaa Ile Xaa 545 550 555
560 Xaa Ala Ala Lys Leu Ala Gly Ala His Glu Phe Ile Xaa Glu Leu Xaa
565 570 575 Glu Gly Tyr Xaa Thr Xaa Val Gly Glu Gln Gly Ala Gly Leu
Ser Gly 580 585 590 Gly Gln Arg Gln Arg Ile Ala Ile Ala Arg Ala Leu
Xaa Xaa Asn Pro 595 600 605 Xaa Ile Leu Ile Phe Asp Glu Ala Thr Ser
Ala Leu Asp Tyr Glu Ser 610 615 620 Glu Xaa Xaa Ile Met Xaa Asn Met
Xaa Xaa Ile Cys Xaa Xaa Arg Thr 625 630 635 640 Val Xaa Ile Ile Ala
His Arg Leu Ser Thr Val Lys Xaa Ala Xaa Arg 645 650 655 Ile Ile Xaa
Met Xaa Lys Gly Xaa Ile Val Glu Xaa Gly Xaa Xaa Xaa 660 665 670 Glu
Leu Leu Ala Xaa Pro Asn Gly Xaa Tyr Xaa Tyr Leu Xaa Xaa Leu 675 680
685 Gln Xaa 690 173 687 PRT Artificial Sequence Description of
Artificial Sequence cytolysin from A. pleuropneumoniae 173 Tyr His
Asn Ile Ala Val Asn Pro Glu Glu Leu Lys His Lys Phe Asp 1 5 10 15
Leu Glu Gly Lys Gly Leu Asp Leu Thr Ala Trp Leu Leu Ala Ala Lys 20
25 30 Ser Leu Glu Leu Lys Ala Lys Gln Val Lys Lys Ala Ile Asp Arg
Leu 35 40 45 Ala Phe Ile Ala Leu Pro Ala Leu Val Trp Arg Glu Asp
Gly Lys His 50 55 60 Phe Ile Leu Thr Lys Ile Asp Asn Glu Ala Lys
Lys Tyr Leu Ile Phe 65 70 75 80 Asp Leu Glu Thr His Asn Pro Arg Ile
Leu Glu Gln Ala Glu Phe Glu 85 90 95 Ser Leu Tyr Gln Gly Lys Leu
Ile Leu Val Ala Ser Arg Ala Ser Ile 100 105 110 Val Gly Lys Leu Ala
Lys Phe Asp Phe Thr Trp Phe Ile Pro Ala Val 115 120 125 Ile Lys Tyr
Arg Lys Ile Phe Ile Glu Thr Leu Ile Val Ser Ile Phe 130 135 140 Leu
Gln Ile Phe Ala Leu Ile Thr Pro Leu Phe Phe Gln Val Val Met 145 150
155 160 Asp Lys Val Leu Val His Arg Gly Phe Ser Thr Leu Asn Val Ile
Thr 165 170 175 Val Ala Leu Ala Ile Val Val Leu Phe Glu Ile Val Leu
Asn Gly Leu 180 185 190 Arg Thr Tyr Ile Phe Ala His Ser Thr Ser Arg
Ile Asp Val Glu Leu 195 200 205 Gly Ala Arg Leu Phe Arg His Leu Leu
Ala Leu Pro Ile Ser Tyr Phe 210 215 220 Glu Asn Arg Arg Val Gly Asp
Thr Val Ala Arg Val Arg Glu Leu Asp 225 230 235 240 Gln Ile Arg Asn
Phe Leu Thr Gly Gln Ala Leu Thr Ser Val Leu Asp 245 250 255 Leu Met
Phe Ser Phe Ile Phe Phe Ala Val Met Trp Tyr Tyr Ser Pro 260 265 270
Lys Leu Thr Leu Val Ile Leu Gly Ser Leu Pro Phe Tyr Met Gly Trp 275
280 285 Ser Ile Phe Ile Ser Pro Ile Leu Arg Arg Arg Leu Asp Glu Lys
Phe 290 295 300 Ala Arg Gly Ala Asp Asn Gln Ser Phe Leu Val Glu Ser
Val Thr Ala 305 310 315 320 Ile Asn Thr Ile Lys Ala Leu Ala Val Thr
Pro Gln Met Thr Asn Thr 325 330 335 Trp Asp Lys Gln Leu Ala Ser Tyr
Val Ser Ala Gly Phe Arg Val Thr 340 345 350 Thr Leu Ala Thr Ile Gly
Gln Gln Gly Val Gln Phe Ile Gln Lys Val 355 360 365 Val Met Val Ile
Thr Leu Trp Leu Gly Ala His Leu Val Ile Ser Gly 370 375 380 Asp Leu
Ser Ile Gly Gln Leu Ile Ala Phe Asn Met Leu Ser Gly Gln 385 390 395
400 Val Ile Ala Pro Val Ile Arg Leu Ala Gln Leu Trp Gln Asp Phe Gln
405 410 415 Gln Val Gly Ile Ser Val Thr Arg Leu Gly Asp Val Leu Asn
Ser Pro 420 425 430 Thr Glu Ser Tyr Gln Gly Lys Leu Ala Leu Pro Glu
Ile Lys Gly Asp 435 440 445 Ile Thr Phe Arg Asn Ile Arg Phe Arg Tyr
Lys Pro Asp Ala Pro Val 450 455 460 Ile Leu Asn Asp Val Asn Leu Ser
Ile Gln Gln Gly Glu Val Ile Gly 465 470 475 480 Ile Val Gly Arg Ser
Gly Ser Gly Lys Ser Thr Leu Thr Lys Leu Ile 485 490 495 Gln Arg Phe
Tyr Ile Pro Glu Asn Gly Gln Val Leu Ile Asp Gly His 500 505 510 Asp
Leu Ala Leu Ala Asp Pro Asn Trp Leu Arg Arg Gln Val Gly Val 515 520
525 Val Leu Gln Asp Asn Val Leu Leu Asn Arg Ser Ile Arg Asp Asn Ile
530 535 540 Ala Leu Ala Asp Pro Gly Met Pro Met Glu Lys Ile Val His
Ala Ala 545 550 555 560 Lys Leu Ala Gly Ala His Glu Phe Ile Ser Glu
Leu Arg Glu Gly Tyr 565 570 575 Asn Thr Ile Val Gly Glu Gln Gly Ala
Gly Leu Ser Gly Gly Gln Arg 580 585 590 Gln Arg Ile Ala Ile Ala Arg
Ala Leu Val Asn Asn Pro Lys Ile Leu 595 600 605 Ile Phe Asp Glu Ala
Thr Ser Ala Leu Asp Tyr Glu Ser Glu His Ile 610 615 620 Ile Met Arg
Asn Met His Gln Ile Cys Lys Gly Arg Thr Val Ile Ile 625 630 635 640
Ile Ala His Arg Leu Ser Thr Val Lys Asn Ala Asp Arg Ile Ile Val 645
650 655 Met Glu Lys Gly Gln Ile Val Glu Gln Gly Lys His Lys Glu Leu
Leu 660 665 670 Ala Asp Pro Asn Gly Leu Tyr His Tyr Leu His Gln Leu
Gln Ser 675 680 685 174 222 PRT Artificial Sequence Description of
Artificial Sequence ORF39 174 Lys Phe Asp Phe Thr Trp Phe Ile Pro
Ala Val Ile Lys Tyr Arg Arg 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 30 Xaa Ile Thr Pro Leu
Phe Phe Gln Val Val Met Asp Lys Val Leu Val 35 40 45 His Arg Gly
Phe Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
Xaa Xaa Xaa Xaa 50 55 60 Xaa Xaa Xaa Phe Glu Ile Val Leu Gly Gly
Leu Arg Thr Tyr Leu Phe 65 70 75 80 Ala His Thr Thr Ser Arg Ile Asp
Val Glu Leu Gly Ala Arg Leu Phe 85 90 95 Arg His Leu Leu Ser Leu
Pro Leu Ser Tyr Phe Glu His Arg Arg Val 100 105 110 Gly Asp Thr Val
Ala Arg Val Arg Glu Leu Glu Gln Ile Arg Asn Phe 115 120 125 Leu Thr
Gly Gln Ala Leu Thr Ser Val Leu Asp Leu Ala Phe Ser Phe 130 135 140
Ile Phe Leu Ala Val Met Trp Tyr Tyr Ser Ser Thr Leu Thr Trp Val 145
150 155 160 Val Leu Ala Ser Leu Ile Cys Ile Cys Ala Asn Arg Thr Val
Leu Ile 165 170 175 Ile Ala His Arg Leu Ser Thr Val Lys Thr Ala His
Arg Ile Ile Ala 180 185 190 Met Asp Lys Gly Arg Ile Val Glu Ala Gly
Thr Gln Gln Glu Leu Leu 195 200 205 Ala Asn Xaa Asn Gly Tyr Tyr Arg
Tyr Leu Tyr Asp Leu Gln 210 215 220 175 222 PRT Artificial Sequence
Description of Artificial Sequence overlap identity 175 Lys Phe Asp
Phe Thr Trp Phe Ile Pro Ala Val Ile Lys Tyr Arg Xaa 1 5 10 15 Xaa
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25
30 Xaa Ile Thr Pro Leu Phe Phe Gln Val Val Met Asp Lys Val Leu Val
35 40 45 His Arg Gly Phe Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
Xaa Xaa 50 55 60 Xaa Xaa Xaa Phe Glu Ile Xaa Leu Gly Gly Leu Arg
Thr Tyr Xaa Phe 65 70 75 80 Ala His Xaa Thr Ser Arg Ile Asp Val Glu
Leu Gly Ala Arg Leu Phe 85 90 95 Arg His Leu Leu Xaa Leu Pro Xaa
Ser Tyr Phe Glu Xaa Arg Arg Val 100 105 110 Gly Asp Thr Val Ala Arg
Val Arg Glu Leu Xaa Gln Ile Arg Asn Phe 115 120 125 Leu Thr Gly Gln
Ala Leu Thr Ser Xaa Leu Asp Leu Xaa Phe Ser Phe 130 135 140 Ile Phe
Xaa Ala Val Met Trp Tyr Tyr Ser Xaa Xaa Leu Thr Xaa Val 145 150 155
160 Val Leu Xaa Ser Leu Xaa Cys Ile Cys Xaa Asn Arg Thr Val Leu Ile
165 170 175 Ile Ala His Arg Leu Ser Thr Val Lys Xaa Ala Xaa Arg Ile
Ile Xaa 180 185 190 Met Asp Lys Gly Xaa Ile Xaa Glu Xaa Gly Xaa Xaa
Gln Glu Leu Leu 195 200 205 Xaa Xaa Xaa Xaa Gly Xaa Tyr Xaa Tyr Leu
Xaa Xaa Leu Gln 210 215 220 176 222 PRT Artificial Sequence
Description of Artificial Sequence HlyB 176 Lys Phe Asp Phe Thr Trp
Phe Ile Pro Ala Val Ile Lys Tyr Arg Lys 1 5 10 15 Ile Phe Ile Glu
Thr Leu Ile Val Ser Ile Phe Leu Gln Ile Phe Ala 20 25 30 Leu Ile
Thr Pro Leu Phe Phe Gln Val Val Met Asp Lys Val Leu Val 35 40 45
His Arg Gly Phe Ser Thr Leu Asn Val Ile Thr Val Ala Leu Ala Ile 50
55 60 Val Val Leu Phe Glu Ile Ile Leu Gly Gly Leu Arg Thr Tyr Val
Phe 65 70 75 80 Ala His Ser Thr Ser Arg Ile Asp Val Glu Leu Gly Ala
Arg Leu Phe 85 90 95 Arg His Leu Leu Ala Leu Pro Ile Ser Tyr Phe
Glu Ala Arg Arg Val 100 105 110 Gly Asp Thr Val Ala Arg Val Arg Glu
Leu Asp Gln Ile Arg Asn Phe 115 120 125 Leu Thr Gly Gln Ala Leu Thr
Ser Ile Leu Asp Leu Leu Phe Ser Phe 130 135 140 Ile Phe Phe Ala Val
Met Trp Tyr Tyr Ser Pro Lys Leu Thr Leu Val 145 150 155 160 Val Leu
Gly Ser Leu Pro Cys Ile Cys Gln Asn Arg Thr Val Leu Ile 165 170 175
Ile Ala His Arg Leu Ser Thr Val Lys Asn Ala Asp Arg Ile Ile Val 180
185 190 Met Asp Lys Gly Glu Ile Ile Glu Gln Gly Lys His Gln Glu Leu
Leu 195 200 205 Lys Asp Glu Lys Gly Leu Tyr Ser Tyr Leu His Gln Leu
Gln 210 215 220 177 240 PRT Artificial Sequence Description of
Artificial Sequence ORF112a 177 Met Asn Leu Ile Ser Arg Tyr Ile Ile
Arg Gln Met Ala Val Met Ala 1 5 10 15 Val Tyr Ala Leu Leu Ala Phe
Leu Ala Leu Tyr Ser Phe Phe Glu Ile 20 25 30 Leu Tyr Glu Thr Gly
Asn Leu Gly Lys Gly Ser Tyr Gly Ile Trp Glu 35 40 45 Met Xaa Gly
Tyr Thr Ala Leu Lys Met Xaa Ala Arg Ala Tyr Glu Leu 50 55 60 Met
Pro Leu Ala Val Leu Ile Gly Gly Leu Val Ser Xaa Ser Gln Leu 65 70
75 80 Ala Ala Gly Ser Glu Leu Xaa Val Ile Lys Ala Ser Gly Met Ser
Thr 85 90 95 Lys Lys Leu Leu Leu Ile Leu Ser Gln Phe Gly Phe Ile
Phe Ala Ile 100 105 110 Ala Thr Val Ala Leu Gly Glu Trp Val Ala Pro
Thr Leu Ser Gln Lys 115 120 125 Ala Glu Asn Ile Lys Ala Ala Ala Ile
Asn Gly Lys Ile Ser Thr Gly 130 135 140 Asn Thr Gly Leu Trp Leu Lys
Glu Lys Asn Ser Ile Ile Asn Val Arg 145 150 155 160 Glu Met Leu Pro
Asp His Thr Leu Leu Gly Ile Lys Ile Trp Ala Arg 165 170 175 Asn Asp
Lys Asn Glu Leu Ala Glu Ala Val Glu Ala Asp Ser Ala Val 180 185 190
Leu Asn Ser Asp Gly Ser Trp Gln Leu Lys Asn Ile Arg Arg Ser Thr 195
200 205 Leu Gly Glu Asp Lys Val Glu Val Ser Ile Ala Ala Glu Glu Xaa
Trp 210 215 220 Pro Ile Ser Val Lys Arg Asn Leu Met Asp Val Leu Leu
Val Lys Pro 225 230 235 240 178 360 PRT Artificial Sequence
Description of Artificial Sequence ORF114a 178 Met Asn Lys Gly Leu
His Arg Ile Ile Phe Ser Lys Lys His Ser Thr 1 5 10 15 Met Val Ala
Val Ala Glu Thr Ala Asn Ser Gln Gly Lys Gly Lys Gln 20 25 30 Ala
Gly Ser Ser Val Ser Val Ser Leu Lys Thr Ser Gly Asp Leu Cys 35 40
45 Gly Lys Leu Lys Thr Thr Leu Lys Thr Leu Val Cys Ser Leu Val Ser
50 55 60 Leu Ser Met Xaa Xaa Xaa Xaa Xaa Xaa Gln Ile Thr Thr Asp
Lys Ser 65 70 75 80 Ala Pro Lys Asn Xaa Gln Val Val Ile Leu Lys Thr
Asn Thr Gly Ala 85 90 95 Pro Leu Val Asn Ile Gln Thr Pro Asn Gly
Arg Gly Leu Ser His Asn 100 105 110 Arg Tyr Thr Gln Phe Asp Val Asp
Asn Lys Gly Ala Val Leu Asn Asn 115 120 125 Asp Arg Asn Asn Asn Pro
Phe Leu Val Lys Gly Ser Ala Gln Leu Ile 130 135 140 Leu Asn Glu Val
Arg Gly Thr Ala Ser Lys Leu Asn Gly Ile Val Thr 145 150 155 160 Val
Gly Gly Gln Lys Ala Asp Val Ile Ile Ala Asn Pro Asn Gly Ile 165 170
175 Thr Val Asn Gly Gly Gly Phe Lys Asn Val Gly Arg Gly Ile Leu Thr
180 185 190 Ile Gly Ala Pro Gln Ile Gly Lys Asp Gly Ala Leu Thr Gly
Phe Asp 195 200 205 Val Arg Gln Gly Thr Leu Thr Val Gly Ala Ala Gly
Trp Asn Asp Lys 210 215 220 Gly Gly Ala Asp Tyr Thr Gly Val Leu Ala
Arg Ala Val Ala Leu Gln 225 230 235 240 Gly Lys Leu Gln Gly Lys Asn
Leu Ala Val Ser Thr Gly Pro Gln Lys 245 250 255 Val Asp Tyr Ala Ser
Gly Glu Ile Ser Ala Gly Thr Ala Ala Gly Thr 260 265 270 Lys Pro Thr
Ile Ala Leu Asp Thr Ala Ala Leu Gly Gly Met Tyr Ala 275 280 285 Asp
Ser Ile Thr Leu Ile Ala Xaa Glu Lys Gly Val Gly Val Lys Asn 290 295
300 Ala Gly Thr Leu Glu Ala Ala Lys Gln Leu Ile Val Thr Ser Ser Gly
305 310 315 320 Arg Ile Glu Asn Ser Gly Arg Ile Ala Thr Thr Ala Asp
Gly Thr Glu 325 330 335 Ala Ser Pro Thr Tyr Leu Xaa Ile Glu Thr Thr
Glu Lys Gly Ala Xaa 340 345 350 Gly Thr Phe Ile Ser Asn Gly Gly 355
360 179 1574 PRT Artificial Sequence Description of Artificial
Sequence ORF114-1 179 Met Asn Lys Gly Leu His Arg Ile Ile Phe Ser
Lys Lys His Ser Thr 1 5 10 15 Met Val Ala Val Ala Glu Thr Ala Asn
Ser Gln Gly Lys Gly Lys Gln 20 25 30 Ala Gly Ser Ser Val Ser Val
Ser Leu Lys Thr Ser Gly Asp Leu Cys 35 40 45 Gly Lys Leu Lys Thr
Thr Leu Lys Thr Leu Val Cys Ser Leu Val Ser 50 55 60 Leu Ser Met
Val Leu Pro Ala His Ala Gln Ile Thr Thr Asp Lys Ser 65 70 75 80 Ala
Pro Lys Asn Gln Gln Val Val Ile Leu Lys Thr Asn Thr Gly Ala 85 90
95 Pro Leu Val Asn Ile Gln Thr Pro Asn Gly Arg Gly Leu Ser His Asn
100 105 110 Arg Tyr Thr Gln Phe Asp Val Asp Asn Lys Gly Ala Val Leu
Asn Asn 115 120 125 Asp Arg Asn Asn Asn Pro Phe Val Val Lys Gly Ser
Ala Gln Leu Ile 130 135 140 Leu Asn Glu Val Arg Gly Thr Ala Ser Lys
Leu Asn Gly Ile Val Thr 145 150 155 160 Val Gly Gly Gln Lys Ala Asp
Val Ile Ile Ala Asn Pro Asn Gly Ile 165 170 175 Thr Val Asn Gly Gly
Gly Phe Lys Asn Val Gly Arg Gly Ile Leu Thr 180 185 190 Thr Gly Ala
Pro Gln Ile Gly Lys Asp Gly Ala Leu Thr Gly Phe Asp 195 200 205 Val
Arg Gln Gly Thr Leu Thr Val Gly Ala Ala Gly Trp Asn Asp Lys 210 215
220 Gly Gly Ala Asp Tyr Thr Gly Val Leu Ala Arg Ala Val Ala Leu Gln
225 230 235 240 Gly Lys Leu Gln Gly Lys Asn Leu Ala Val Ser Thr Gly
Pro Gln Lys 245 250 255 Val Asp Tyr Ala Ser Gly Glu Ile Ser Ala Gly
Thr Ala Ala Gly Thr 260 265 270 Lys Pro Thr Ile Ala Leu Asp Thr Ala
Ala Leu Gly Gly Met Tyr Ala 275 280 285 Asp Ser Ile Thr Leu Ile Ala
Asn Glu Lys Gly Val Gly Val Lys Asn 290 295 300 Ala Gly Thr Leu Glu
Ala Ala Lys Gln Leu Ile Val Thr Ser Ser Gly 305 310 315 320 Arg Ile
Glu Asn Ser Gly Arg Ile Ala Thr Thr Ala Asp Gly Thr Glu 325 330 335
Ala Ser Pro Thr Tyr Leu Ser Ile Glu Thr Thr Glu Lys Gly Ala Ala 340
345 350 Gly Thr Phe Ile Ser Asn Gly Gly Arg Ile Glu Ser Lys Gly Leu
Leu 355 360 365 Val Ile Glu Thr Gly Glu Asp Ile Ser Leu Arg Asn Gly
Ala Val Val 370 375 380 Gln Asn Asn Gly Ser Arg Pro Ala Thr Thr Val
Leu Asn Ala Gly His 385 390 395 400 Asn Leu Val Ile Glu Ser Lys Thr
Asn Val Asn Asn Ala Lys Gly Pro 405 410 415 Ala Thr Leu Ser Ala Asp
Gly Arg Thr Val Ile Lys Glu Ala Ser Ile 420 425 430 Gln Thr Gly Thr
Thr Val Tyr Ser Ser Ser Lys Gly Asn Ala Glu Leu 435 440 445 Gly Asn
Asn Thr Arg Ile Thr Gly Ala Asp Val Thr Val Leu Ser Asn 450 455 460
Gly Thr Ile Ser Ser Ser Ala Val Ile Asp Ala Lys Asp Thr Ala His 465
470 475 480 Ile Glu Ala Gly Lys Pro Leu Ser Leu Glu Ala Ser Thr Val
Thr Ser 485 490 495 Asp Ile Arg Leu Asn Gly Gly Ser Ile Lys Gly Gly
Lys Gln Leu Ala 500 505 510 Leu Leu Ala Asp Asp Asn Ile Thr Ala Lys
Thr Thr Asn Leu Asn Thr 515 520 525 Pro Gly Asn Leu Tyr Val His Thr
Gly Lys Asp Leu Asn Leu Asn Val 530 535 540 Asp Lys Asp Leu Ser Ala
Ala Ser Ile His Leu Lys Ser Asp Asn Ala 545 550 555 560 Ala His Ile
Thr Gly Thr Ser Lys Thr Leu Thr Ala Ser Lys Asp Met 565 570 575 Gly
Val Glu Ala Gly Ser Leu Asn Val Thr Asn Thr Asn Leu Arg Thr 580 585
590 Asn Ser Gly Asn Leu His Ile Gln Ala Ala Lys Gly Asn Ile Gln Leu
595 600 605 Arg Asn Thr Lys Leu Asn Ala Ala Lys Ala Leu Glu Thr Thr
Ala Leu 610 615 620 Gln Gly Asn Ile Val Ser Asp Gly Leu His Ala Val
Ser Ala Asp Gly 625 630 635 640 His Val Ser Leu Leu Ala Asn Gly Asn
Ala Asp Phe Thr Gly His Asn 645 650 655 Thr Leu Thr Ala Lys Ala Asp
Val Asn Ala Gly Ser Val Gly Lys Gly 660 665 670 Arg Leu Lys Ala Asp
Asn Thr Asn Ile Thr Ser Ser Ser Gly Asp Ile 675 680 685 Thr Leu Val
Ala Gly Asn Gly Ile Gln Leu Gly Asp Gly Lys Gln Arg 690 695 700 Asn
Ser Ile Asn Gly Lys His Ile Ser Ile Lys Asn Asn Gly Gly Asn 705 710
715 720 Ala Asp Leu Lys Asn Leu Asn Val His Ala Lys Ser Gly Ala Leu
Asn 725 730 735 Ile His Ser Asp Arg Ala Leu Ser Ile Glu Asn Thr Lys
Leu Glu Ser 740 745 750 Thr His Asn Thr His Leu Asn Ala Gln His Glu
Arg Val Thr Leu Asn 755 760 765 Gln Val Asp Ala Tyr Ala His Arg His
Leu Ser Ile Thr Gly Ser Gln 770 775 780 Ile Trp Gln Asn Asp Lys Leu
Pro Ser Ala Asn Lys Leu Val Ala Asn 785 790 795 800 Gly Val Leu Ala
Leu Asn Ala Arg Tyr Ser Gln Ile Ala Asp Asn Thr 805 810 815 Thr Leu
Arg Ala Gly Ala Ile Asn Leu Thr Ala Gly Thr Ala Leu Val 820 825 830
Lys Arg Gly Asn Ile Asn Trp Ser Thr Val Ser Thr Lys Thr Leu Glu 835
840 845 Asp Asn Ala Glu Leu Lys Pro Leu Ala Gly Arg Leu Asn Ile Glu
Ala 850 855 860 Gly Ser Gly Thr Leu Thr Ile Glu Pro Ala Asn Arg Ile
Ser Ala His 865 870 875 880 Thr Asp Leu Ser Ile Lys Thr Gly Gly Lys
Leu Leu Leu Ser Ala Lys 885 890 895 Gly Gly Asn Ala Gly Ala Pro Ser
Ala Gln Val Ser Ser Leu Glu Ala 900 905 910 Lys Gly Asn Ile Arg Leu
Val Thr Gly Glu Thr Asp Leu Arg Gly Ser 915 920 925 Lys Ile Thr Ala
Gly Lys Asn Leu Val Val Ala Thr Thr Lys Gly Lys 930 935 940 Leu Asn
Ile Glu Ala Val Asn Asn Ser Phe Ser Asn Tyr Phe Pro Thr 945 950 955
960 Gln Lys Ala Ala Glu Leu Asn Gln Lys Ser Lys Glu Leu Glu Gln Gln
965 970 975 Ile Ala Gln Leu Lys Lys Ser Ser Pro Lys Ser Lys Leu Ile
Pro Thr 980 985 990 Leu Gln Glu Glu Arg Asp Arg Leu Ala Phe Tyr Ile
Gln Ala Ile Asn 995 1000 1005 Lys Glu Val Lys Gly Lys Lys Pro Lys
Gly Lys Glu Tyr Leu Gln Ala 1010 1015 1020 Lys Leu Ser Ala Gln Asn
Ile Asp Leu Ile Ser Ala Gln Gly Ile Glu 1025 1030 1035 1040 Ile Ser
Gly Ser Asp Ile Thr Ala Ser Lys Lys Leu Asn Leu His Ala 1045 1050
1055 Ala Gly Val Leu Pro Lys Ala Ala Asp Ser Glu Ala Ala Ala Ile
Leu 1060 1065 1070 Ile Asp Gly Ile Thr Asp Gln Tyr Glu Ile Gly Lys
Pro Thr Tyr Lys 1075 1080 1085 Ser His Tyr Asp Lys Ala Ala Leu Asn
Lys Pro Ser Arg Leu Thr Gly 1090 1095 1100 Arg Thr Gly Val Ser Ile
His Ala Ala Ala Ala Leu Asp Asp Ala Arg 1105 1110 1115 1120 Ile Ile
Ile Gly Ala Ser Glu Ile Lys Ala Pro Ser Gly Ser Ile Asp 1125 1130
1135 Ile Lys Ala His Ser Asp Ile Val Leu Glu Ala Gly Gln Asn Asp
Ala 1140 1145 1150 Tyr Thr Phe Leu Lys Thr Lys Gly Lys Ser Gly Lys
Ile Ile Arg Lys 1155 1160 1165 Thr Lys Phe Thr Ser Thr Arg Asp His
Leu Ile Met Pro Ala Pro Val 1170
1175 1180 Glu Leu Thr Ala Asn Gly Ile Thr Leu Gln Ala Gly Gly Asn
Ile Glu 1185 1190 1195 1200 Ala Asn Thr Thr Arg Phe Asn Ala Pro Ala
Gly Lys Val Thr Leu Val 1205 1210 1215 Ala Gly Glu Glu Leu Gln Leu
Leu Ala Glu Glu Gly Ile His Lys His 1220 1225 1230 Glu Leu Asp Val
Gln Lys Ser Arg Arg Phe Ile Gly Ile Lys Val Gly 1235 1240 1245 Lys
Ser Asn Tyr Ser Lys Asn Glu Leu Asn Glu Thr Lys Leu Pro Val 1250
1255 1260 Arg Val Val Ala Gln Thr Ala Ala Thr Arg Ser Gly Trp Asp
Thr Val 1265 1270 1275 1280 Leu Glu Gly Thr Glu Phe Lys Thr Thr Leu
Ala Gly Ala Asp Ile Gln 1285 1290 1295 Ala Gly Val Gly Glu Lys Ala
Arg Ala Asp Ala Lys Ile Ile Leu Lys 1300 1305 1310 Gly Ile Val Asn
Arg Ile Gln Ser Glu Glu Lys Leu Glu Thr Asn Ser 1315 1320 1325 Thr
Val Trp Gln Lys Gln Ala Gly Arg Gly Ser Thr Ile Glu Thr Leu 1330
1335 1340 Lys Leu Pro Ser Phe Glu Ser Pro Thr Pro Pro Lys Leu Thr
Ala Pro 1345 1350 1355 1360 Gly Gly Tyr Ile Val Asp Ile Pro Lys Gly
Asn Leu Lys Thr Glu Ile 1365 1370 1375 Glu Lys Leu Ala Lys Gln Pro
Glu Tyr Ala Tyr Leu Lys Gln Leu Gln 1380 1385 1390 Val Ala Lys Asn
Val Asn Trp Asn Gln Val Gln Leu Ala Tyr Asp Lys 1395 1400 1405 Trp
Asp Tyr Lys Gln Glu Gly Leu Thr Arg Ala Gly Ala Ala Ile Val 1410
1415 1420 Thr Ile Ile Val Thr Ala Leu Thr Tyr Gly Tyr Gly Ala Thr
Ala Ala 1425 1430 1435 1440 Gly Gly Val Ala Ala Ser Gly Ser Ser Thr
Ala Ala Ala Ala Gly Thr 1445 1450 1455 Ala Ala Thr Thr Thr Ala Ala
Ala Thr Thr Val Ser Thr Ala Thr Ala 1460 1465 1470 Met Gln Thr Ala
Ala Leu Ala Ser Leu Tyr Ser Gln Ala Ala Val Ser 1475 1480 1485 Ile
Ile Asn Asn Lys Gly Asp Val Gly Lys Ala Leu Lys Asp Leu Gly 1490
1495 1500 Thr Ser Asp Thr Val Lys Gln Ile Val Thr Ser Ala Leu Thr
Ala Gly 1505 1510 1515 1520 Ala Leu Asn Gln Met Gly Ala Asp Ile Ala
Gln Leu Asn Ser Lys Val 1525 1530 1535 Arg Thr Glu Leu Phe Ser Ser
Thr Gly Asn Gln Thr Ile Ala Asn Leu 1540 1545 1550 Gly Gly Arg Leu
Ala Thr Asn Leu Ser Asn Ala Gly Ile Ser Ala Gly 1555 1560 1565 Ile
Asn Thr Ala Val Asn 1570 180 281 PRT Artificial Sequence
Description of Artificial Sequence ORF114 180 Ala Val Ala Glu Thr
Ala Asn Ser Gln Gly Lys Gly Lys Gln Ala Gly 1 5 10 15 Ser Ser Val
Ser Val Ser Leu Lys Thr Ser Gly Asp Xaa Xaa Xaa Xaa 20 25 30 Xaa
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 35 40
45 Xaa Xaa Xaa Pro Ala His Ala Gln Ile Thr Thr Asp Lys Ser Ala Pro
50 55 60 Lys Asn Gln Gln Val Val Ile Leu Lys Thr Asn Thr Gly Ala
Pro Leu 65 70 75 80 Val Asn Ile Gln Thr Pro Asn Gly Arg Gly Leu Ser
His Asn Arg Xaa 85 90 95 Tyr Ala Phe Asp Val Asp Asn Lys Gly Ala
Val Leu Asn Asn Asp Arg 100 105 110 Asn Asn Asn Pro Phe Val Val Lys
Gly Ser Ala Gln Leu Ile Leu Asn 115 120 125 Glu Val Arg Gly Thr Ala
Ser Lys Leu Asn Gly Ile Val Thr Val Gly 130 135 140 Gly Gln Lys Ala
Asp Val Ile Ile Ala Asn Pro Asn Gly Ile Thr Val 145 150 155 160 Asn
Gly Gly Gly Phe Lys Asn Val Gly Arg Gly Ile Leu Thr Thr Gly 165 170
175 Ala Pro Gln Ile Gly Lys Asp Gly Ala Leu Thr Gly Phe Asp Val Val
180 185 190 Lys Ala His Trp Thr Val Xaa Ala Ala Gly Trp Asn Asp Lys
Gly Gly 195 200 205 Ala Xaa Tyr Thr Gly Val Leu Ala Arg Ala Val Ala
Leu Gln Gly Lys 210 215 220 Xaa Xaa Gly Lys Xaa Leu Ala Val Ser Thr
Gly Pro Gln Lys Val Asp 225 230 235 240 Tyr Ala Ser Gly Glu Ile Ser
Ala Gly Thr Ala Ala Gly Thr Lys Pro 245 250 255 Thr Ile Ala Leu Asp
Thr Ala Ala Leu Gly Gly Met Tyr Ala Asp Ser 260 265 270 Ile Thr Leu
Ile Ala Asn Glu Lys Gly 275 280 181 302 PRT Artificial Sequence
Description of Artificial Sequence overlap identity 181 Ala Val Ala
Glu Xaa Xaa Xaa Xaa Xaa Gly Lys Xaa Xaa Gln Xaa Xaa 1 5 10 15 Xaa
Xaa Xaa Ser Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Ser Xaa Xaa 20 25
30 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
35 40 45 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Pro Ala Xaa Ala Xaa Xaa Ile
Xaa Xaa 50 55 60 Asp Lys Ser Ala Pro Lys Asn Gln Gln Xaa Val Ile
Leu Xaa Thr Xaa 65 70 75 80 Xaa Gly Xaa Pro Xaa Val Asn Ile Gln Thr
Pro Xaa Xaa Xaa Gly Xaa 85 90 95 Ser Xaa Asn Arg Xaa Xaa Xaa Phe
Asp Val Asp Xaa Lys Gly Xaa Xaa 100 105 110 Leu Asn Asn Xaa Arg Xaa
Asn Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 115 120 125 Xaa Xaa Asn Pro
Xaa Xaa Xaa Xaa Gly Xaa Ala Xaa Xaa Ile Xaa Asn 130 135 140 Xaa Xaa
Xaa Xaa Xaa Xaa Xaa Ser Xaa Leu Asn Gly Xaa Xaa Xaa Val 145 150 155
160 Gly Gly Xaa Xaa Ala Xaa Val Xaa Xaa Ala Asn Pro Xaa Gly Ile Xaa
165 170 175 Val Asn Gly Gly Gly Xaa Xaa Asn Xaa Xaa Xaa Xaa Xaa Leu
Thr Xaa 180 185 190 Gly Xaa Pro Xaa Xaa Xaa Xaa Xaa Gly Xaa Leu Thr
Gly Phe Asp Val 195 200 205 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
Gly Xaa Xaa Asp Xaa Xaa 210 215 220 Xaa Ala Xaa Tyr Thr Xaa Xaa Leu
Xaa Arg Ala Xaa Xaa Xaa Xaa Xaa 225 230 235 240 Xaa Xaa Xaa Gly Lys
Xaa Xaa Xaa Val Xaa Xaa Gly Xaa Xaa Lys Xaa 245 250 255 Asp Xaa Xaa
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Ala Xaa Xaa Xaa Xaa 260 265 270 Xaa
Xaa Xaa Xaa Pro Thr Xaa Ala Xaa Asp Thr Ala Xaa Leu Gly Gly 275 280
285 Met Tyr Ala Asp Xaa Ile Thr Leu Ile Xaa Xaa Xaa Xaa Gly 290 295
300 182 300 PRT Artificial Sequence Description of Artificial
Sequence pspA 182 Ala Val Ala Glu Asn Val His Arg Asp Gly Lys Ser
Met Gln Asp Ser 1 5 10 15 Glu Ala Ala Ser Val Arg Val Thr Gly Ala
Ala Ser Val Ser Ser Ala 20 25 30 Arg Ala Ala Phe Gly Phe Arg Met
Ala Ala Phe Ser Val Met Leu Ala 35 40 45 Leu Gly Val Ala Ala Phe
Ser Pro Ala Pro Ala Ser Gly Ile Ile Ala 50 55 60 Asp Lys Ser Ala
Pro Lys Asn Gln Gln Ala Val Ile Leu Gln Thr Ala 65 70 75 80 Asn Gly
Leu Pro Gln Val Asn Ile Gln Thr Pro Ser Ser Gln Gly Val 85 90 95
Ser Val Asn Arg Phe Lys Gln Phe Asp Val Asp Glu Lys Gly Val Ile 100
105 110 Leu Asn Asn Ser Arg Ser Asn Thr Gln Thr Gln Leu Gly Gly Trp
Ile 115 120 125 Gln Gly Asn Pro His Leu Ala Arg Gly Glu Ala Arg Val
Ile Val Asn 130 135 140 Gln Ile Asp Ser Ser Asn Pro Ser Leu Leu Asn
Gly Tyr Ile Glu Val 145 150 155 160 Gly Gly Lys Arg Ala Glu Val Val
Val Ala Asn Pro Ser Gly Ile Arg 165 170 175 Val Asn Gly Gly Gly Leu
Ile Asn Ala Ala Ser Val Thr Leu Thr Ser 180 185 190 Gly Val Pro Val
Leu Asn Asn Gly Asn Leu Thr Gly Phe Asp Val Ser 195 200 205 Ser Gly
Lys Val Val Ile Gly Gly Lys Gly Leu Asp Thr Ser Asp Ala 210 215 220
Asp Tyr Thr Arg Ile Leu Ser Arg Ala Ala Glu Ile Asn Ala Gly Val 225
230 235 240 Trp Gly Lys Asp Val Lys Val Val Ser Gly Lys Asn Lys Leu
Asp Phe 245 250 255 Asp Gly Ser Leu Ala Lys Thr Ala Ser Ala Pro Ser
Ser Ser Asp Ser 260 265 270 Val Thr Pro Thr Val Ala Ile Asp Thr Ala
Thr Leu Gly Gly Met Tyr 275 280 285 Ala Asp Lys Ile Thr Leu Ile Ser
Thr Asp Asn Gly 290 295 300 183 628 PRT Artificial Sequence
Description of Artificial Sequence ORF114a 183 Met Asn Lys Gly Leu
His Arg Ile Ile Phe Ser Lys Lys His Ser Thr 1 5 10 15 Met Val Ala
Val Ala Glu Thr Ala Asn Ser Gln Gly Lys Gly Lys Gln 20 25 30 Ala
Gly Ser Ser Val Ser Val Ser Leu Lys Thr Ser Gly Asp Xaa Xaa 35 40
45 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
50 55 60 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gln Ile Thr Thr Asp
Lys Ser 65 70 75 80 Ala Pro Lys Asn Xaa Gln Val Val Ile Leu Lys Thr
Asn Thr Gly Ala 85 90 95 Pro Leu Val Asn Ile Gln Thr Pro Asn Gly
Arg Gly Leu Ser His Asn 100 105 110 Arg Tyr Thr Gln Phe Asp Val Asp
Asn Lys Gly Ala Val Leu Asn Asn 115 120 125 Asp Arg Asn Asn Asn Pro
Phe Leu Val Lys Gly Ser Ala Gln Leu Ile 130 135 140 Leu Asn Glu Val
Arg Gly Thr Ala Ser Lys Leu Asn Gly Ile Val Thr 145 150 155 160 Val
Gly Gly Gln Lys Ala Asp Val Ile Ile Ala Asn Pro Asn Gly Ile 165 170
175 Thr Val Asn Gly Gly Gly Phe Lys Asn Val Gly Arg Gly Ile Leu Thr
180 185 190 Ile Gly Ala Pro Gln Ile Gly Lys Asp Gly Ala Leu Thr Gly
Phe Asp 195 200 205 Val Arg Gln Gly Thr Leu Thr Val Gly Ala Ala Gly
Trp Asn Asp Lys 210 215 220 Gly Gly Ala Asp Tyr Thr Gly Val Leu Ala
Arg Ala Val Ala Leu Gln 225 230 235 240 Gly Lys Leu Gln Gly Lys Asn
Leu Ala Val Ser Thr Gly Pro Gln Lys 245 250 255 Val Asp Tyr Ala Ser
Gly Glu Ile Ser Ala Gly Thr Ala Ala Gly Thr 260 265 270 Lys Pro Thr
Ile Ala Leu Asp Thr Ala Ala Leu Gly Gly Met Tyr Ala 275 280 285 Asp
Ser Ile Thr Leu Ile Ala Xaa Glu Lys Gly Val Gly Val Lys Asn 290 295
300 Ala Gly Thr Leu Glu Ala Ala Lys Gln Leu Ile Val Thr Ser Ser Gly
305 310 315 320 Arg Ile Glu Asn Ser Gly Arg Ile Ala Thr Thr Ala Asp
Gly Thr Glu 325 330 335 Ala Ser Pro Thr Tyr Leu Xaa Ile Glu Thr Thr
Glu Lys Gly Ala Xaa 340 345 350 Gly Thr Phe Ile Ser Asn Gly Gly Arg
Ile Glu Ser Lys Gly Leu Leu 355 360 365 Val Ile Glu Thr Gly Glu Asp
Ile Xaa Leu Arg Asn Gly Ala Val Val 370 375 380 Gln Asn Asn Gly Ser
Arg Pro Ala Thr Thr Val Leu Asn Ala Gly His 385 390 395 400 Asn Leu
Val Ile Glu Ser Lys Thr Asn Val Asn Asn Ala Lys Gly Ser 405 410 415
Xaa Asn Leu Ser Ala Gly Gly Arg Thr Thr Ile Asn Asp Ala Thr Ile 420
425 430 Gln Ala Gly Ser Ser Val Tyr Ser Ser Thr Lys Gly Asp Thr Xaa
Leu 435 440 445 Gly Glu Asn Thr Arg Ile Ile Ala Glu Asn Val Thr Val
Leu Ser Asn 450 455 460 Gly Ser Ile Gly Ser Ala Ala Val Ile Glu Ala
Lys Asp Thr Ala His 465 470 475 480 Ile Glu Ser Gly Lys Pro Leu Ser
Leu Glu Thr Ser Thr Val Ala Ser 485 490 495 Asn Ile Arg Leu Asn Asn
Gly Asn Ile Lys Gly Gly Lys Gln Leu Ala 500 505 510 Leu Leu Ala Asp
Asp Asn Ile Thr Ala Lys Thr Thr Asn Leu Asn Thr 515 520 525 Pro Gly
Asn Leu Tyr Val His Thr Gly Lys Asp Leu Asn Leu Asn Val 530 535 540
Asp Lys Asp Leu Ser Ala Ala Ser Ile His Leu Lys Ser Asp Asn Ala 545
550 555 560 Ala His Ile Thr Gly Thr Ser Lys Thr Leu Thr Ala Ser Lys
Asp Met 565 570 575 Gly Val Glu Ala Gly Xaa Xaa Xaa Xaa Xaa Xaa Xaa
Xaa Xaa Xaa Xaa 580 585 590 Xaa Ser Gly Asn Leu His Ile Gln Ala Ala
Lys Gly Asn Ile Gln Leu 595 600 605 Arg Asn Thr Lys Leu Asn Ala Ala
Lys Ala Leu Glu Thr Thr Ala Leu 610 615 620 Gln Gly Asn Ile 625 184
663 PRT Artificial Sequence Description of Artificial Sequence
homology 184 Met Asn Lys Xaa Xaa Xaa Xaa Xaa Ile Phe Xaa Lys Lys
Xaa Ser Xaa 1 5 10 15 Met Xaa Ala Val Ala Glu Xaa Xaa Xaa Xaa Xaa
Gly Lys Xaa Xaa Gln 20 25 30 Xaa Xaa Xaa Xaa Xaa Ser Val Xaa Xaa
Xaa Xaa Xaa Xaa Xaa Xaa Xaa 35 40 45 Ser Xaa Xaa Xaa Xaa Xaa Xaa
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 50 55 60 Xaa Xaa Xaa Xaa Xaa
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Ile 65 70 75 80 Xaa Xaa Asp
Lys Ser Ala Pro Lys Asn Xaa Gln Xaa Val Ile Leu Xaa 85 90 95 Thr
Xaa Xaa Gly Xaa Pro Xaa Val Asn Ile Gln Thr Pro Xaa Xaa Xaa 100 105
110 Gly Xaa Ser Xaa Asn Arg Xaa Xaa Gln Phe Asp Val Asp Xaa Lys Gly
115 120 125 Xaa Xaa Leu Asn Asn Xaa Arg Xaa Asn Xaa Xaa Xaa Xaa Xaa
Xaa Xaa 130 135 140 Xaa Xaa Xaa Xaa Asn Pro Xaa Leu Xaa Xaa Gly Xaa
Ala Xaa Xaa Ile 145 150 155 160 Xaa Asn Xaa Xaa Xaa Xaa Xaa Xaa Xaa
Ser Xaa Leu Asn Gly Xaa Xaa 165 170 175 Xaa Val Gly Gly Xaa Xaa Ala
Xaa Val Xaa Xaa Ala Asn Pro Xaa Gly 180 185 190 Ile Xaa Val Asn Gly
Gly Gly Xaa Xaa Asn Xaa Xaa Xaa Xaa Xaa Leu 195 200 205 Thr Xaa Gly
Xaa Pro Xaa Xaa Xaa Xaa Xaa Gly Xaa Leu Thr Gly Phe 210 215 220 Asp
Val Xaa Xaa Gly Xaa Xaa Xaa Xaa Gly Xaa Xaa Gly Xaa Xaa Asp 225 230
235 240 Xaa Xaa Xaa Ala Asp Tyr Thr Xaa Xaa Leu Xaa Arg Ala Xaa Xaa
Xaa 245 250 255 Xaa Xaa Xaa Xaa Xaa Gly Lys Xaa Xaa Xaa Val Xaa Xaa
Gly Xaa Xaa 260 265 270 Lys Xaa Asp Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
Xaa Xaa Ala Xaa Xaa 275 280 285 Xaa Xaa Xaa Xaa Xaa Xaa Pro Thr Xaa
Ala Xaa Asp Thr Ala Xaa Leu 290 295 300 Gly Gly Met Tyr Ala Asp Xaa
Ile Thr Leu Ile Xaa Xaa Xaa Xaa Gly 305 310 315 320 Xaa Xaa Xaa Xaa
Asn Xaa Gly Xaa Xaa Xaa Ala Ala Xaa Xaa Xaa Xaa 325 330 335 Xaa Xaa
Xaa Xaa Xaa Gly Xaa Xaa Xaa Asn Ser Gly Xaa Ile Xaa Xaa 340 345 350
Xaa Xaa Xaa Xaa Xaa Xaa Ala Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Thr 355
360 365 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly Xaa
Ile 370 375 380 Xaa Ser Xaa Xaa Xaa Xaa Val Xaa Xaa Xaa Xaa Xaa Xaa
Ile Xaa Xaa 385 390 395 400 Xaa Xaa Gly Xaa Xaa Xaa Xaa Xaa Xaa Gly
Ser Xaa Xaa Xaa Xaa Xaa 405 410 415 Xaa Xaa Xaa Xaa Gly Xaa Xaa Xaa
Xaa Xaa Xaa Ser Xaa Xaa Xaa Xaa 420 425 430 Asn Asn Xaa Xaa Gly Xaa
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Ser Xaa Xaa 435 440 445 Xaa Xaa Xaa Xaa
Xaa Asn Asp Xaa Xaa Xaa Xaa Ala Xaa Xaa Xaa Val 450 455 460 Xaa Ser
Xaa Xaa Xaa Xaa Asp Xaa Xaa Xaa Gly Xaa Xaa Xaa Xaa Xaa 465 470 475
480 Xaa Xaa Xaa Xaa Xaa Thr Xaa Xaa Xaa Xaa Gly Xaa Xaa Xaa Xaa
Xaa
485 490 495 Xaa Xaa Ile Xaa Ala Xaa Asp Thr Xaa Xaa Xaa Xaa Xaa Xaa
Xaa Xaa 500 505 510 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Ser Xaa Xaa
Arg Xaa Xaa Xaa 515 520 525 Xaa Xaa Xaa Xaa Gly Xaa Xaa Xaa Xaa Xaa
Leu Xaa Xaa Xaa Xaa Xaa 530 535 540 Ile Thr Xaa Xaa Xaa Xaa Xaa Ala
Lys Xaa Xaa Asn Xaa Xaa Thr Xaa 545 550 555 560 Gly Xaa Xaa Tyr Xaa
Xaa Xaa Gly Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asp 565 570 575 Xaa Xaa Leu
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Ala Ala 580 585 590 Xaa
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Ala Xaa Xaa Xaa Xaa Xaa 595 600
605 Xaa Xaa Ala Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
610 615 620 Ser Gly Xaa Leu His Ile Xaa Xaa Ala Xaa Xaa Xaa Xaa Xaa
Xaa Xaa 625 630 635 640 Gln Xaa Xaa Asn Thr Xaa Leu Xaa Asn Xaa Xaa
Xaa Ala Xaa Glu Xaa 645 650 655 Xaa Xaa Xaa Xaa Gly Asn Ile 660 185
622 PRT Artificial Sequence Description of Artificial Sequence pspA
185 Met Asn Lys Arg Cys Tyr Lys Val Ile Phe Asn Lys Lys Arg Ser Cys
1 5 10 15 Met Met Ala Val Ala Glu Asn Val His Arg Asp Gly Lys Ser
Met Gln 20 25 30 Asp Ser Glu Ala Ala Ser Val Arg Val Thr Gly Ala
Ala Ser Val Ser 35 40 45 Ser Ala Arg Ala Ala Phe Gly Phe Arg Met
Ala Ala Phe Ser Val Met 50 55 60 Leu Ala Leu Gly Val Ala Ala Phe
Ser Pro Ala Pro Ala Ser Gly Ile 65 70 75 80 Ile Ala Asp Lys Ser Ala
Pro Lys Asn Gln Gln Ala Val Ile Leu Gln 85 90 95 Thr Ala Asn Gly
Leu Pro Gln Val Asn Ile Gln Thr Pro Ser Ser Gln 100 105 110 Gly Val
Ser Val Asn Arg Phe Lys Gln Phe Asp Val Asp Glu Lys Gly 115 120 125
Val Ile Leu Asn Asn Ser Arg Ser Asn Thr Gln Thr Gln Leu Gly Gly 130
135 140 Trp Ile Gln Gly Asn Pro His Leu Ala Arg Gly Glu Ala Arg Val
Ile 145 150 155 160 Val Asn Gln Ile Asp Ser Ser Asn Pro Ser Leu Leu
Asn Gly Tyr Ile 165 170 175 Glu Val Gly Gly Lys Arg Ala Glu Val Val
Val Ala Asn Pro Ser Gly 180 185 190 Ile Arg Val Asn Gly Gly Gly Leu
Ile Asn Ala Ala Ser Val Thr Leu 195 200 205 Thr Ser Gly Val Pro Val
Leu Asn Asn Gly Asn Leu Thr Gly Phe Asp 210 215 220 Val Ser Ser Gly
Lys Val Val Ile Gly Gly Lys Gly Leu Asp Thr Ser 225 230 235 240 Asp
Ala Asp Tyr Thr Arg Ile Leu Ser Arg Ala Ala Glu Ile Asn Ala 245 250
255 Gly Val Trp Gly Lys Asp Val Lys Val Val Ser Gly Lys Asn Lys Leu
260 265 270 Asp Phe Asp Gly Ser Leu Ala Lys Thr Ala Ser Ala Pro Ser
Ser Ser 275 280 285 Asp Ser Val Thr Pro Thr Val Ala Ile Asp Thr Ala
Thr Leu Gly Gly 290 295 300 Met Tyr Ala Asp Lys Ile Thr Leu Ile Ser
Thr Asp Asn Gly Ala Val 305 310 315 320 Ile Arg Asn Lys Gly Arg Ile
Phe Ala Ala Thr Gly Gly Val Thr Leu 325 330 335 Ser Ala Asp Gly Lys
Leu Ser Asn Ser Gly Ser Ile Asp Ala Ala Glu 340 345 350 Ile Thr Ile
Ser Ala Gln Thr Val Asp Asn Arg Gln Gly Phe Ile Arg 355 360 365 Ser
Gly Lys Gly Ser Val Leu Lys Val Ser Asp Gly Ile Asn Asn Gln 370 375
380 Ala Gly Leu Ile Gly Ser Ala Gly Leu Leu Asp Ile Arg Asp Thr Gly
385 390 395 400 Lys Ser Ser Leu His Ile Asn Asn Thr Asp Gly Thr Ile
Ile Ala Gly 405 410 415 Lys Asp Val Ser Leu Gln Ala Lys Ser Leu Asp
Asn Asp Gly Ile Leu 420 425 430 Thr Ala Ala Arg Asp Val Ser Val Ser
Leu His Asp Asp Phe Ala Gly 435 440 445 Lys Arg Asp Ile Glu Ala Gly
Arg Thr Leu Thr Phe Ser Thr Gln Gly 450 455 460 Arg Leu Lys Asn Thr
Arg Ile Ile Gln Ala Gly Asp Thr Val Ser Leu 465 470 475 480 Thr Ala
Ala Gln Ile Asp Asn Thr Val Ser Gly Lys Ile Gln Ser Gly 485 490 495
Asn Arg Thr Gly Leu Asn Gly Lys Asn Gly Ile Thr Asn Arg Gly Leu 500
505 510 Ile Asn Ser Asn Gly Ile Thr Leu Leu Gln Thr Glu Ala Lys Ser
Asp 515 520 525 Asn Ala Gly Thr Gly Arg Ile Tyr Gly Ser Arg Val Ala
Val Glu Ala 530 535 540 Asp Thr Leu Leu Asn Arg Glu Glu Thr Val Asn
Gly Glu Thr Lys Ala 545 550 555 560 Ala Val Ile Ala Ala Arg Glu Arg
Leu Asp Ile Gly Ala Arg Glu Ile 565 570 575 Glu Asn Arg Glu Ala Ala
Leu Leu Ser Ser Ser Gly Asp Leu His Ile 580 585 590 Gly Ser Ala Leu
Asn Gly Ser Arg Gln Val Gln Gly Ala Asn Thr Ser 595 600 605 Leu His
Asn Arg Ser Ala Ala Ile Glu Ser Ser Gly Asn Ile 610 615 620 186 400
PRT Artificial Sequence Description of Artificial Sequence ORF114a
186 Leu Gln Gly Lys Leu Gln Gly Lys Asn Leu Ala Val Ser Thr Gly Pro
1 5 10 15 Gln Lys Val Asp Tyr Ala Ser Gly Glu Ile Ser Ala Gly Thr
Ala Ala 20 25 30 Gly Thr Lys Pro Thr Ile Ala Leu Asp Thr Ala Ala
Leu Gly Gly Met 35 40 45 Tyr Ala Asp Ser Ile Thr Leu Ile Ala Xaa
Glu Lys Gly Val Gly Val 50 55 60 Lys Asn Ala Gly Thr Leu Glu Ala
Ala Lys Gln Leu Ile Val Thr Ser 65 70 75 80 Ser Gly Arg Ile Glu Asn
Ser Gly Arg Ile Ala Thr Thr Ala Asp Gly 85 90 95 Thr Glu Ala Ser
Pro Thr Tyr Leu Xaa Ile Glu Thr Thr Glu Lys Gly 100 105 110 Ala Xaa
Gly Thr Phe Ile Ser Asn Gly Gly Arg Ile Glu Ser Lys Gly 115 120 125
Leu Leu Val Ile Glu Thr Gly Glu Asp Ile Xaa Leu Arg Asn Gly Ala 130
135 140 Val Val Gln Asn Asn Gly Ser Arg Pro Ala Thr Thr Val Leu Asn
Ala 145 150 155 160 Gly His Asn Leu Val Ile Glu Ser Lys Thr Asn Val
Asn Asn Ala Lys 165 170 175 Gly Ser Xaa Asn Leu Ser Ala Gly Gly Arg
Thr Thr Ile Asn Asp Ala 180 185 190 Thr Ile Gln Ala Gly Ser Ser Val
Tyr Ser Ser Thr Lys Gly Asp Thr 195 200 205 Xaa Leu Gly Glu Asn Thr
Arg Ile Ile Ala Glu Asn Val Thr Val Leu 210 215 220 Ser Asn Gly Ser
Ile Gly Ser Ala Ala Val Ile Glu Ala Lys Asp Thr 225 230 235 240 Ala
His Ile Glu Ser Gly Lys Pro Leu Ser Leu Glu Thr Ser Thr Val 245 250
255 Ala Ser Asn Ile Arg Leu Asn Asn Gly Asn Ile Lys Gly Gly Lys Gln
260 265 270 Leu Ala Leu Leu Ala Asp Asp Asn Ile Thr Ala Lys Thr Thr
Asn Leu 275 280 285 Asn Thr Pro Gly Asn Leu Tyr Val His Thr Gly Lys
Asp Leu Asn Leu 290 295 300 Asn Val Asp Lys Asp Leu Ser Ala Ala Ser
Ile His Leu Lys Ser Asp 305 310 315 320 Asn Ala Ala His Ile Thr Gly
Thr Ser Lys Thr Leu Thr Ala Ser Lys 325 330 335 Asp Met Gly Val Glu
Ala Gly Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 340 345 350 Xaa Xaa Xaa
Ser Gly Asn Leu His Ile Gln Ala Ala Lys Gly Asn Ile 355 360 365 Gln
Leu Arg Asn Thr Lys Leu Asn Ala Ala Lys Ala Leu Glu Thr Thr 370 375
380 Ala Leu Gln Gly Asn Ile Val Ser Asp Gly Leu His Ala Val Ser Ala
385 390 395 400 187 432 PRT Artificial Sequence Description of
Artificial Sequence homology 187 Leu Gln Gly Xaa Leu Gln Gly Lys
Asn Xaa Xaa Xaa Xaa Xaa Gly Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa
Xaa Gly Xaa Ile Xaa Ala Xaa Xaa Ala Xaa 20 25 30 Xaa Xaa Lys Xaa
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Ala Xaa Xaa Xaa Xaa 35 40 45 Xaa Xaa
Xaa Ser Xaa Thr Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Val 50 55 60
Xaa Asn Xaa Gly Xaa Xaa Xaa Ala Xaa Xaa Xaa Leu Xaa Xaa Xaa Xaa 65
70 75 80 Xaa Gly Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Ile Xaa Xaa
Thr Ala 85 90 95 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
Glu Xaa Thr Xaa 100 105 110 Xaa Xaa Xaa Xaa Gly Xaa Thr Xaa Xaa Xaa
Xaa Gly Gly Xaa Ile Xaa 115 120 125 Ser Xaa Xaa Xaa Xaa Xaa Xaa Xaa
Xaa Xaa Xaa Xaa Ile Xaa Xaa Xaa 130 135 140 Xaa Xaa Xaa Val Xaa Xaa
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Thr Xaa 145 150 155 160 Xaa Xaa Xaa
Gly Xaa Asn Leu Xaa Xaa Xaa Xaa Lys Xaa Xaa Xaa Xaa 165 170 175 Xaa
Xaa Xaa Xaa Xaa Val Xaa Xaa Xaa Xaa Gly Xaa Xaa Xaa Leu Xaa 180 185
190 Ala Gly Xaa Xaa Xaa Xaa Xaa Xaa Asp Xaa Xaa Xaa Xaa Ala Gly Xaa
195 200 205 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Tyr Xaa Xaa Xaa
Xaa Gly 210 215 220 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Thr Arg Xaa Xaa Xaa
Xaa Xaa Xaa Xaa 225 230 235 240 Xaa Xaa Xaa Xaa Gly Xaa Xaa Xaa Xaa
Xaa Xaa Xaa Ile Xaa Xaa Xaa 245 250 255 Xaa Xaa Xaa Xaa Xaa Xaa Xaa
Gly Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 260 265 270 Thr Xaa Xaa Ser Xaa
Xaa Xaa Xaa Asn Asn Xaa Xaa Xaa Lys Xaa Xaa 275 280 285 Xaa Xaa Xaa
Xaa Xaa Xaa Ala Xaa Xaa Asn Xaa Xaa Xaa Lys Xaa Xaa 290 295 300 Xaa
Xaa Xaa Xaa Xaa Gly Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Lys Asp 305 310
315 320 Xaa Xaa Xaa Asn Xaa Xaa Xaa Xaa Xaa Ser Xaa Xaa Xaa Xaa Xaa
Xaa 325 330 335 Xaa Ser Xaa Asn Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
His Xaa Thr 340 345 350 Xaa Thr Xaa Xaa Thr Xaa Xaa Xaa Xaa Xaa Xaa
Asp Xaa Gly Xaa Xaa 355 360 365 Xaa Gly Xaa Xaa Xaa Xaa Xaa Xaa Xaa
Xaa Xaa Xaa Xaa Xaa Xaa Xaa 370 375 380 Xaa Xaa Xaa Xaa Xaa Xaa Xaa
Lys Gly Xaa Xaa Xaa Xaa Xaa Xaa Xaa 385 390 395 400 Xaa Xaa Xaa Asn
Thr Xaa Xaa Xaa Ala Xaa Xaa Ala Xaa Xaa Xaa Xaa 405 410 415 Xaa Xaa
Xaa Gly Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Ala Xaa Xaa Ala 420 425 430
188 402 PRT Artificial Sequence Description of Artificial Sequence
pspA 188 Leu Gln Gly Asp Leu Gln Gly Lys Asn Ile Phe Ala Ala Ala
Gly Ser 1 5 10 15 Asp Ile Thr Asn Thr Gly Ser Ile Gly Ala Glu Asn
Ala Leu Leu Leu 20 25 30 Lys Ala Ser Asn Asn Ile Glu Ser Arg Ser
Glu Thr Arg Ser Asn Gln 35 40 45 Asn Glu Gln Gly Ser Val Arg Asn
Ile Gly Arg Val Ala Gly Ile Tyr 50 55 60 Leu Thr Gly Arg Gln Asn
Gly Ser Val Leu Leu Asp Ala Gly Asn Asn 65 70 75 80 Ile Val Leu Thr
Ala Ser Glu Leu Thr Asn Gln Ser Glu Asp Gly Gln 85 90 95 Thr Val
Leu Asn Ala Gly Gly Asp Ile Arg Ser Asp Thr Thr Gly Ile 100 105 110
Ser Arg Asn Gln Asn Thr Ile Phe Asp Ser Asp Asn Tyr Val Ile Arg 115
120 125 Lys Glu Gln Asn Glu Val Gly Ser Thr Ile Arg Thr Arg Gly Asn
Leu 130 135 140 Ser Leu Asn Ala Lys Gly Asp Ile Arg Ile Arg Ala Ala
Glu Val Gly 145 150 155 160 Ser Glu Gln Gly Arg Leu Lys Leu Ala Ala
Gly Arg Asp Ile Lys Val 165 170 175 Glu Ala Gly Lys Ala His Thr Glu
Thr Glu Asp Ala Leu Lys Tyr Thr 180 185 190 Gly Arg Ser Gly Gly Gly
Ile Lys Gln Lys Met Thr Arg His Leu Lys 195 200 205 Asn Gln Asn Gly
Gln Ala Val Ser Gly Thr Leu Asp Gly Lys Glu Ile 210 215 220 Ile Leu
Val Ser Gly Arg Asp Ile Thr Val Thr Gly Ser Asn Ile Ile 225 230 235
240 Ala Asp Asn His Thr Ile Leu Ser Ala Lys Asn Asn Ile Val Leu Lys
245 250 255 Ala Ala Glu Thr Arg Ser Arg Ser Ala Glu Met Asn Lys Lys
Glu Lys 260 265 270 Ser Gly Leu Met Gly Ser Gly Gly Ile Gly Phe Thr
Ala Gly Ser Lys 275 280 285 Lys Asp Thr Gln Thr Asn Arg Ser Glu Thr
Val Ser His Thr Glu Ser 290 295 300 Val Val Gly Ser Leu Asn Gly Asn
Thr Leu Ile Ser Ala Gly Lys His 305 310 315 320 Tyr Thr Gln Thr Gly
Ser Thr Ile Ser Ser Pro Gln Gly Asp Val Gly 325 330 335 Ile Ser Ser
Gly Lys Ile Ser Ile Asp Ala Ala Gln Asn Arg Tyr Ser 340 345 350 Gln
Glu Ser Lys Gln Val Tyr Glu Gln Lys Gly Val Thr Val Ala Ile 355 360
365 Ser Val Pro Val Val Asn Thr Val Met Gly Ala Val Asp Ala Val Lys
370 375 380 Ala Val Gln Thr Val Gly Lys Ser Lys Asn Ser Arg Val Asn
Ala Met 385 390 395 400 Ala Ala 189 497 PRT Artificial Sequence
Description of Artificial Sequence ORF116 189 Glu Ala Val Gly Ser
Asn Ile Gly Gly Gly Lys Met Ile Val Ala Ala 1 5 10 15 Gly Gln Asp
Ile Asn Val Arg Gly Xaa Ser Leu Ile Ser Asp Lys Gly 20 25 30 Ile
Val Leu Lys Ala Gly His Asp Ile Asp Ile Ser Thr Ala His Asn 35 40
45 Arg Tyr Thr Gly Asn Glu Tyr His Glu Ser Xaa Xaa Xaa Xaa Xaa Xaa
50 55 60 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn Arg Lys Xaa
Xaa Xaa 65 70 75 80 Xaa Xaa Xaa Arg Thr Asn Ile Val His Thr Gly Ser
Ile Ile Gly Ser 85 90 95 Leu Asn Gly Asp Thr Val Thr Val Ala Gly
Asn Arg Tyr Arg Gln Thr 100 105 110 Gly Ser Thr Val Ser Ser Pro Glu
Gly Arg Asn Thr Val Thr Ala Lys 115 120 125 Xaa Ile Asp Val Glu Phe
Ala Asn Asn Arg Tyr Ala Thr Asp Tyr Ala 130 135 140 His Thr Gln Glu
Gln Lys Gly Leu Thr Val Ala Leu Asn Val Pro Xaa 145 150 155 160 Xaa
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly Lys 165 170
175 Ser Lys Asn Lys Arg Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Trp
180 185 190 Gln Ser Tyr Gln Ala Thr Gln Gln Met Gln Gln Phe Ala Pro
Ser Ser 195 200 205 Ser Ala Gly Gln Gly Gln Asn Tyr Asn Gln Ser Pro
Ser Ile Ser Val 210 215 220 Ser Ile Xaa Tyr Gly Glu Gln Lys Ser Arg
Asn Glu Gln Lys Arg His 225 230 235 240 Tyr Thr Glu Ala Ala Ala Ser
Gln Ile Ile Gly Lys Gly Gln Thr Thr 245 250 255 Leu Ala Ala Thr Gly
Ser Gly Glu Gln Ser Asn Ile Asn Ile Thr Gly 260 265 270 Ser Asp Val
Ile Gly His Ala Gly Thr Xaa Leu Ile Ala Asp Asn His 275 280 285 Ile
Arg Leu Gln Ser Ala Lys Gln Asp Gly Ser Glu Gln Ser Lys Asn 290 295
300 Lys Ser Ser Gly Trp Asn Ala Gly Val Arg Xaa Lys Ile Gly Asn Gly
305 310 315 320 Ile Arg Phe Gly Ile Thr Ala Xaa Xaa Xaa Xaa Xaa Xaa
Xaa Xaa Xaa 325 330 335 Xaa Xaa Xaa Ser Thr Thr His Arg His Thr His
Val Gly Ser Thr Thr 340 345 350 Gly Lys Thr Thr Ile Arg Ser Gly Gly
Asp Thr Thr Leu Lys Gly Val 355 360 365 Gln Leu Ile
Gly Lys Gly Ile Gln Ala Asp Thr Arg Asn Leu His Ile 370 375 380 Glu
Ser Val Gln Asp Thr Glu Thr Tyr Gln Ser Lys Gln Gln Asn Gly 385 390
395 400 Asn Val Gln Val Thr Val Gly Tyr Gly Phe Ser Ala Ser Gly Ser
Tyr 405 410 415 Arg Gln Ser Lys Val Lys Ala Asp His Ala Ser Val Thr
Gly Gln Ser 420 425 430 Gly Ile Tyr Ala Gly Glu Asp Gly Tyr Gln Ile
Lys Val Arg Asp Asn 435 440 445 Thr Asp Leu Lys Gly Gly Ile Ile Thr
Ser Ser Gln Ser Ala Glu Asp 450 455 460 Lys Gly Lys Asn Leu Phe Gln
Thr Ala Thr Leu Thr Ala Ser Asp Ile 465 470 475 480 Gln Asn His Ser
Arg Tyr Glu Gly Arg Ser Phe Gly Ile Gly Gly Ser 485 490 495 Phe 190
502 PRT Artificial Sequence Description of Artificial Sequence
overlap identity 190 Xaa Ala Val Xaa Xaa Xaa Xaa Xaa Gly Xaa Xaa
Xaa Ile Xaa Xaa Xaa 1 5 10 15 Gly Xaa Asp Ile Xaa Val Xaa Gly Xaa
Xaa Xaa Ile Xaa Asp Xaa Xaa 20 25 30 Xaa Xaa Leu Xaa Ala Xaa Xaa
Xaa Ile Xaa Xaa Xaa Xaa Ala Xaa Xaa 35 40 45 Arg Xaa Xaa Xaa Xaa
Glu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 50 55 60 Xaa Xaa Xaa
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Lys Xaa Xaa Xaa 65 70 75 80 Xaa
Xaa Xaa Xaa Xaa Xaa Xaa Xaa His Thr Xaa Ser Xaa Xaa Gly Ser 85 90
95 Leu Asn Gly Xaa Thr Xaa Xaa Xaa Ala Gly Xaa Xaa Tyr Xaa Gln Thr
100 105 110 Gly Ser Thr Xaa Ser Ser Pro Xaa Gly Xaa Xaa Xaa Xaa Xaa
Xaa Xaa 115 120 125 Xaa Ile Xaa Xaa Xaa Xaa Ala Xaa Asn Arg Tyr Xaa
Xaa Xaa Xaa Xaa 130 135 140 Xaa Xaa Xaa Glu Gln Lys Gly Xaa Thr Val
Ala Xaa Xaa Val Pro Xaa 145 150 155 160 Xaa Xaa Xaa Xaa Xaa Xaa Xaa
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 165 170 175 Xaa Gly Lys Ser Lys
Asn Xaa Arg Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa 180 185 190 Xaa Xaa Xaa
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Ala 195 200 205 Xaa
Xaa Pro Xaa Xaa Xaa Ala Gly Gln Gly Xaa Xaa Xaa Xaa Xaa Xaa 210 215
220 Xaa Xaa Ile Ser Val Ser Xaa Xaa Tyr Gly Glu Gln Lys Xaa Xaa Xaa
225 230 235 240 Glu Xaa Xaa Xaa Xaa Xaa Thr Xaa Xaa Xaa Xaa Xaa Xaa
Ile Xaa Gly 245 250 255 Xaa Gly Xaa Xaa Xaa Leu Xaa Ala Xaa Gly Xaa
Gly Xaa Xaa Ser Xaa 260 265 270 Ile Xaa Ile Thr Gly Ser Asp Val Xaa
Gly Xaa Xaa Gly Thr Xaa Leu 275 280 285 Xaa Ala Xaa Asn Xaa Xaa Xaa
Xaa Xaa Xaa Ala Xaa Gln Xaa Xaa Xaa 290 295 300 Glu Xaa Ser Xaa Asn
Lys Ser Xaa Gly Xaa Asn Ala Gly Val Xaa Xaa 305 310 315 320 Xaa Ile
Xaa Xaa Gly Ile Xaa Phe Gly Xaa Thr Ala Xaa Xaa Xaa Xaa 325 330 335
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Thr Xaa Xaa Arg Xaa Xaa His 340
345 350 Xaa Gly Ser Xaa Xaa Xaa Xaa Thr Xaa Ile Xaa Ser Gly Gly Asp
Thr 355 360 365 Xaa Xaa Lys Gly Xaa Gln Leu Xaa Gly Lys Gly Xaa Xaa
Xaa Xaa Xaa 370 375 380 Xaa Xaa Leu His Ile Glu Ser Xaa Gln Asp Thr
Xaa Xaa Xaa Xaa Xaa 385 390 395 400 Lys Gln Xaa Asn Xaa Xaa Xaa Gln
Val Thr Val Gly Tyr Gly Phe Ser 405 410 415 Xaa Xaa Gly Ser Tyr Xaa
Xaa Ser Lys Xaa Xaa Xaa Asp Xaa Ala Ser 420 425 430 Val Xaa Xaa Gln
Ser Gly Ile Xaa Ala Gly Xaa Asp Gly Tyr Xaa Ile 435 440 445 Xaa Val
Xaa Xaa Xaa Thr Xaa Leu Xaa Gly Xaa Xaa Xaa Xaa Ser Xaa 450 455 460
Xaa Xaa Xaa Xaa Asp Lys Xaa Lys Asn Leu Xaa Xaa Thr Xaa Xaa Xaa 465
470 475 480 Xaa Xaa Xaa Asp Ile Gln Asn His Xaa Xaa Xaa Xaa Xaa Xaa
Xaa Xaa 485 490 495 Gly Xaa Xaa Gly Xaa Phe 500 191 491 PRT
Artificial Sequence Description of Artificial Sequence pspA 191 Gln
Ala Val Ser Gly Thr Leu Asp Gly Lys Glu Ile Ile Leu Val Ser 1 5 10
15 Gly Arg Asp Ile Thr Val Thr Gly Ser Asn Ile Ile Ala Asp Asn His
20 25 30 Thr Ile Leu Ser Ala Lys Asn Asn Ile Val Leu Lys Ala Ala
Glu Thr 35 40 45 Arg Ser Arg Ser Ala Glu Met Asn Lys Lys Glu Lys
Ser Gly Leu Met 50 55 60 Gly Ser Gly Gly Ile Gly Phe Thr Ala Gly
Ser Lys Lys Asp Thr Gln 65 70 75 80 Thr Asn Arg Ser Glu Thr Val Ser
His Thr Glu Ser Val Val Gly Ser 85 90 95 Leu Asn Gly Asn Thr Leu
Ile Ser Ala Gly Lys His Tyr Thr Gln Thr 100 105 110 Gly Ser Thr Ile
Ser Ser Pro Gln Gly Asp Val Gly Ile Ser Ser Gly 115 120 125 Lys Ile
Ser Ile Asp Ala Ala Gln Asn Arg Tyr Ser Gln Glu Ser Lys 130 135 140
Gln Val Tyr Glu Gln Lys Gly Val Thr Val Ala Ile Ser Val Pro Val 145
150 155 160 Val Asn Thr Val Met Gly Ala Val Asp Ala Val Lys Ala Val
Gln Thr 165 170 175 Val Gly Lys Ser Lys Asn Ser Arg Val Asn Ala Met
Ala Ala Ala Asn 180 185 190 Ala Leu Asn Lys Gly Val Asp Ser Gly Val
Ala Leu Tyr Asn Ala Ala 195 200 205 Arg Asn Pro Lys Lys Ala Ala Gly
Gln Gly Ile Ser Val Ser Val Thr 210 215 220 Tyr Gly Glu Gln Lys Asn
Thr Ser Glu Ser Arg Ile Lys Gly Thr Gln 225 230 235 240 Val Gln Glu
Gly Lys Ile Thr Gly Gly Gly Lys Val Ser Leu Thr Ala 245 250 255 Ser
Gly Ala Gly Lys Asp Ser Arg Ile Thr Ile Thr Gly Ser Asp Val 260 265
270 Tyr Gly Gly Lys Gly Thr Arg Leu Lys Ala Glu Asn Ala Val Gln Ile
275 280 285 Glu Ala Ala Arg Gln Thr His Gln Glu Arg Ser Glu Asn Lys
Ser Ala 290 295 300 Gly Phe Asn Ala Gly Val Ala Ile Ala Ile Asn Lys
Gly Ile Ser Phe 305 310 315 320 Gly Phe Thr Ala Gly Ala Asn Tyr Gly
Lys Gly Tyr Gly Asn Gly Asp 325 330 335 Glu Thr Ala Tyr Arg Asn Ser
His Ile Gly Ser Lys Asp Ser Gln Thr 340 345 350 Ala Ile Glu Ser Gly
Gly Asp Thr Val Ile Lys Gly Gly Gln Leu Lys 355 360 365 Gly Lys Gly
Val Gly Val Thr Ala Glu Ser Leu His Ile Glu Ser Leu 370 375 380 Gln
Asp Thr Ala Val Phe Lys Gly Lys Gln Glu Asn Val Ser Ala Gln 385 390
395 400 Val Thr Val Gly Tyr Gly Phe Ser Val Gly Gly Ser Tyr Asn Arg
Ser 405 410 415 Lys Ser Ser Ser Asp Tyr Ala Ser Val Asn Glu Gln Ser
Gly Ile Phe 420 425 430 Ala Gly Gly Asp Gly Tyr Arg Ile Arg Val Asn
Gly Lys Thr Gly Leu 435 440 445 Val Gly Ala Ala Val Val Ser Asp Ala
Asp Lys Ser Lys Asn Leu Leu 450 455 460 Lys Thr Ser Glu Ile Trp His
Lys Asp Ile Gln Asn His Ala Ser Ala 465 470 475 480 Ala Ala Ser Ala
Leu Gly Leu Ser Gly Gly Phe 485 490 192 310 PRT Artificial Sequence
Description of Artificial Sequence ORF41 192 Tyr Arg Arg His Leu
Leu Cys Lys Tyr Ile Tyr Arg Phe Pro Ile Tyr 1 5 10 15 Cys Pro Xaa
Ala Cys Val Ala Glu Asp Thr Pro Tyr Ala Cys Tyr Leu 20 25 30 Xaa
Gln Leu Gln Val Thr Lys Asp Val Asn Trp Asn Gln Val Xaa Leu 35 40
45 Ala Tyr Asp Lys Trp Asp Tyr Lys Gln Glu Gly Leu Thr Gly Ala Gly
50 55 60 Ala Ala Ile Ile Ala Leu Ala Val Thr Val Val Thr Ala Gly
Ala Gly 65 70 75 80 Ala Gly Ala Ala Leu Gly Leu Asn Gly Ala Ala Ala
Ala Ala Thr Asp 85 90 95 Ala Ala Phe Ala Ser Leu Ala Ser Gln Ala
Ser Val Ser Leu Ile Asn 100 105 110 Asn Lys Gly Asn Ile Gly Asn Thr
Leu Lys Glu Leu Gly Arg Ser Ser 115 120 125 Thr Val Lys Asn Leu Met
Val Ala Val Ala Thr Ala Gly Val Ala Asp 130 135 140 Lys Ile Gly Ala
Ser Ala Leu Asn Asn Val Ser Asp Lys Gln Trp Ile 145 150 155 160 Asn
Asn Leu Thr Val Asn Leu Ala Asn Ala Gly Ser Ala Ala Leu Ile 165 170
175 Asn Thr Ala Val Asn Gly Gly Ser Leu Lys Asp Asn Leu Glu Ala Asn
180 185 190 Ile Leu Ala Ala Leu Val Asn Thr Ala His Gly Glu Ala Ala
Ser Lys 195 200 205 Ile Lys Gln Leu Asp Gln His Tyr Ile Thr His Lys
Ile Ala His Ala 210 215 220 Ile Ala Gly Cys Ala Ala Ala Ala Ala Asn
Lys Gly Lys Cys Gln Asp 225 230 235 240 Gly Ala Ile Gly Ala Ala Val
Gly Glu Ile Val Gly Glu Ala Leu Thr 245 250 255 Asn Gly Lys Asn Pro
Asp Thr Leu Thr Ala Lys Glu Arg Glu Gln Ile 260 265 270 Leu Ala Tyr
Ser Lys Leu Val Ala Gly Thr Val Ser Gly Val Val Gly 275 280 285 Gly
Asp Val Asn Ala Ala Ala Asn Ala Ala Glu Val Ala Val Lys Asn 290 295
300 Asn Gln Leu Ser Asp Lys 305 310 193 330 PRT Artificial Sequence
Description of Artificial Sequence ORF41a 193 Tyr Leu Lys Gln Leu
Gln Val Ala Lys Asn Ile Asn Trp Asn Gln Val 1 5 10 15 Gln Leu Ala
Tyr Asp Arg Trp Asp Tyr Lys Gln Glu Gly Leu Thr Glu 20 25 30 Ala
Gly Ala Ala Ile Ile Ala Leu Ala Val Thr Val Val Thr Ser Gly 35 40
45 Ala Gly Thr Gly Ala Val Leu Gly Leu Asn Gly Ala Xaa Ala Ala Ala
50 55 60 Thr Asp Ala Ala Phe Ala Ser Leu Ala Ser Gln Ala Ser Val
Ser Phe 65 70 75 80 Ile Asn Asn Lys Gly Asp Val Gly Lys Thr Leu Lys
Glu Leu Gly Arg 85 90 95 Ser Ser Thr Val Lys Asn Leu Val Val Ala
Ala Ala Thr Ala Gly Val 100 105 110 Ala Asp Lys Ile Gly Ala Ser Ala
Leu Xaa Asn Val Ser Asp Lys Gln 115 120 125 Trp Ile Asn Asn Leu Thr
Val Asn Leu Ala Asn Ala Gly Ser Ala Ala 130 135 140 Leu Ile Asn Thr
Ala Val Asn Gly Gly Ser Leu Lys Asp Xaa Leu Glu 145 150 155 160 Ala
Asn Ile Leu Ala Ala Leu Val Asn Thr Ala His Gly Glu Ala Ala 165 170
175 Ser Lys Ile Lys Gln Leu Asp Gln His Tyr Ile Val His Lys Ile Ala
180 185 190 His Ala Ile Ala Gly Cys Ala Ala Ala Ala Ala Asn Lys Gly
Lys Cys 195 200 205 Gln Asp Gly Ala Ile Gly Ala Ala Val Gly Glu Ile
Val Gly Glu Ala 210 215 220 Leu Thr Asn Gly Lys Asn Pro Asp Thr Leu
Thr Ala Lys Glu Arg Glu 225 230 235 240 Gln Ile Leu Ala Tyr Ser Lys
Leu Val Ala Gly Thr Val Ser Gly Val 245 250 255 Val Gly Gly Asp Val
Asn Ala Ala Ala Asn Ala Ala Glu Val Ala Val 260 265 270 Lys Asn Asn
Gln Leu Ser Asp Xaa Glu Gly Arg Glu Phe Asp Asn Glu 275 280 285 Met
Thr Ala Cys Ala Lys Gln Asn Xaa Pro Gln Leu Cys Arg Lys Asn 290 295
300 Thr Val Lys Lys Tyr Gln Asn Val Ala Asp Lys Arg Leu Ala Ala Ser
305 310 315 320 Ile Ala Ile Cys Thr Asp Ile Ser Arg Ser 325 330 194
180 PRT Artificial Sequence Description of Artificial Sequence
ORF51a 194 Tyr Lys Leu Leu Ala Ile Gly Ser Val Val Gly Ser Ile Leu
Gly Val 1 5 10 15 Lys Leu Leu Leu Ile Leu Pro Val Ser Trp Leu Leu
Leu Leu Met Ala 20 25 30 Ile Ile Thr Leu Tyr Tyr Ser Val Asn Gly
Ile Leu Asn Val Cys Ala 35 40 45 Lys Ala Lys Asn Ile Gln Val Val
Ala Asn Asn Lys Asn Met Val Leu 50 55 60 Phe Gly Phe Leu Ala Gly
Ile Ile Gly Gly Ser Thr Asn Ala Met Ser 65 70 75 80 Pro Ile Leu Leu
Ile Phe Leu Leu Ser Glu Thr Glu Asn Lys Asn Arg 85 90 95 Ile Ala
Lys Ser Ser Asn Leu Cys Tyr Leu Leu Ala Lys Ile Val Gln 100 105 110
Ile Tyr Met Leu Arg Asp Gln Tyr Trp Leu Leu Asn Lys Ser Glu Tyr 115
120 125 Gly Leu Ile Phe Leu Leu Ser Val Leu Ser Val Ile Gly Leu Tyr
Val 130 135 140 Gly Ile Arg Leu Arg Thr Lys Ile Ser Pro Asn Phe Phe
Lys Met Leu 145 150 155 160 Ile Phe Ile Val Leu Leu Val Leu Ala Leu
Lys Ile Gly Tyr Ser Gly 165 170 175 Leu Ile Lys Leu 180 195 180 PRT
Artificial Sequence Description of Artificial Sequence ORF82a 195
Met Arg His Met Lys Asn Lys Asn Tyr Leu Leu Val Phe Ile Val Leu 1 5
10 15 His Ile Thr Leu Ile Val Ile Asn Ile Val Phe Gly Tyr Phe Val
Phe 20 25 30 Leu Phe Asp Phe Phe Ala Phe Leu Phe Phe Ala Asn Val
Phe Leu Ala 35 40 45 Val Asn Leu Leu Phe Leu Glu Lys Asn Ile Lys
Asn Lys Leu Leu Phe 50 55 60 Leu Leu Pro Ile Ser Ile Ile Ile Trp
Met Val Ile His Ile Ser Met 65 70 75 80 Ile Asn Ile Lys Phe Tyr Lys
Phe Glu His Gln Ile Lys Glu Gln Asn 85 90 95 Ile Ser Ser Ile Thr
Gly Val Ile Lys Pro His Asp Ser Tyr Asn Tyr 100 105 110 Val Tyr Asp
Ser Asn Gly Tyr Ala Lys Leu Lys Asp Asn His Arg Tyr 115 120 125 Gly
Arg Val Ile Arg Glu Thr Pro Tyr Ile Asp Val Val Ala Ser Asp 130 135
140 Val Lys Asn Lys Ser Ile Arg Leu Ser Leu Val Cys Gly Ile His Ser
145 150 155 160 Tyr Ala Pro Cys Ala Asn Phe Ile Lys Phe Ala Lys Lys
Pro Val Lys 165 170 175 Ile Tyr Phe Tyr 180
* * * * *
References